FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Hall, DE AF Hall, Daniel E. TI The Guild of Surgeons as a Tradition of Moral Enquiry SO JOURNAL OF MEDICINE AND PHILOSOPHY LA English DT Article DE apprenticeship; phronesis; practical wisdom; surgery; surgical training AB Alisdair MacIntyre argues that the virtues necessary for good work are everywhere and always embodied by particular communities of practice. As a general surgeon, MacIntyre's work has deeply influenced my own understanding of the practice of good surgery. The task of this essay is to describe how the guild of surgeons functions as a more-or-less coherent tradition of moral enquiry, embodying and transmitting the virtues necessary for the practice of good surgery. Beginning with an example of surgeons engaged in a process of moral discernment, I describe how the practice of surgery depends on the cultivation of a certain kind of practical wisdom (phronesis) that effectively orders the techniques of surgery toward particular notions of human flourishing within the limits of what is possible with the particular body on which the surgeon operates. I then argue that one reason why surgeons train in an apprenticeship model of "residency" is to cultivate not only the technical skill but also the practical wisdom to perform good surgery. I conclude by noting that the surgical profession is enduring necessary, but unprecedented, changes in the way it practices and transmits its art; and without deliberate and sustained attention to the character formation of surgeons, the profession runs the risk of creating excellent technicians who are nonetheless ill-equipped to practice wise and good surgery. C1 [Hall, Daniel E.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA 15213 USA. [Hall, Daniel E.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Hall, DE (reprint author), Univ Pittsburgh, Med Ctr, Dept Surg, 200 Lothrop St,Suite F1200, Pittsburgh, PA 15213 USA. EM hallde@upmc.edu RI Hall, Daniel/H-4843-2013; OI Hall, Daniel/0000-0001-6382-0522 NR 13 TC 4 Z9 4 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0360-5310 J9 J MED PHILOS JI J. Med. Philos. PD APR PY 2011 VL 36 IS 2 BP 114 EP 132 DI 10.1093/jmp/jhr005 PG 19 WC Ethics; Social Sciences, Biomedical SC Social Sciences - Other Topics; Biomedical Social Sciences GA 766UJ UT WOS:000290811700002 PM 21576372 ER PT J AU Kim, JH Muder, RR AF Kim, J. H. Muder, R. R. TI Clostridium difficile enteritis: A review and pooled analysis of the cases SO ANAEROBE LA English DT Review DE Clostridium difficile; Enteritis ID INFLAMMATORY-BOWEL-DISEASE; PSEUDOMEMBRANOUS ENTERITIS; TOTAL PROCTOCOLECTOMY; TOTAL COLECTOMY; CROHNS-DISEASE; INFECTION; TOXIN; COLITIS; MANIFESTATIONS; POUCHITIS AB Introduction: Clostridium difficile is the most common cause of healthcare-associated infection diarrhea and usually restricted to infection of the colon. However, small bowel involvement of C difficile infection has been reported. We performed a literature review and pooled analysis of the reported cases of C. difficile enteritis Method: A Pubmed literature database search and pooled analysis of the reported cases of C. difficile enteritis. Results: 56 cases of C. difficile enteritis have been reported from 1980 to 2010; 48 cases were published since 2001. Median age was 55 years. 27 patients (48.2%) were female. 29 patients (51.8%) had inflammatory bowel disease (IBD) - Crohn's disease or ulcerative colitis and 20 patients (35.7%) had predisposing medical condition(s) that might lead to an immunoincompetent state. 33 patients (58.9%) had colectomy with ileostomy and 13 patients (23.2%) had other small and/or large bowel surgery. Thirty four patients (60.7%) received ICU management and 18 patients (32.1%) died. We categorized the patients into two groups, 38 survivors (67.9%) 18 non-survivors (32.1%). Significantly older age was noted in non-survivors. Median age was 48 years and 66 years, respectively for survivors and non-survivors, P < 0.001. There were more patients with predisposing medical condition(s) among non-survivors, (13/18, 72.2%) than among survivors (7/38, 18.4%), P < 0.001. Conclusions: C. difficile enteritis is still rare, however it seems to be increasingly reported in recent years. Surgically altered intestinal anatomies, advanced age, predisposing medical condition(s) that might lead to immunoincompetence appear to be at risk for developing C. difficile enteritis. Recognition of C. difficile infection not only in the colon but also in the small bowel may lead to improved outcomes. Published by Elsevier Ltd. C1 [Muder, R. R.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA 15240 USA. [Kim, J. H.; Muder, R. R.] Univ Pittsburgh, Med Ctr, Div Infect Dis, Pittsburgh, PA 15213 USA. RP Muder, RR (reprint author), VA Pittsburgh Healthcare Syst, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM robert.muder@va.gov NR 41 TC 20 Z9 23 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1075-9964 J9 ANAEROBE JI Anaerobe PD APR PY 2011 VL 17 IS 2 BP 52 EP 55 DI 10.1016/j.anaerobe.2011.02.002 PG 4 WC Microbiology SC Microbiology GA 781CI UT WOS:000291907800002 PM 21334446 ER PT J AU Schultz, AP Zou, Y Marwan, N Turvey, MT AF Schultz, Aaron P. Zou, Yong Marwan, Norbert Turvey, Michael T. TI LOCAL MINIMA-BASED RECURRENCE PLOTS FOR CONTINUOUS DYNAMICAL SYSTEMS SO INTERNATIONAL JOURNAL OF BIFURCATION AND CHAOS LA English DT Article DE Distance function; local minima thresholding; recurrence quantification analysis; continuous dynamical system ID TIME-SERIES; QUANTIFICATION AB A major issue in using recurrence plots (RPs) to study dynamical systems is the choice of neighborhood size for thresholding the distance matrix that creates the plot. This is particularly important for continuous dynamical systems as temporal correlations of the trajectory might provide redundant information for recurrence analysis. We suggest an alternative procedure for creating RPs using the local minima provided by the distance profile, which approximately corresponds to the recurrence information in the orthogonal direction. The local minima-based thresholding yields a clean RP of minimized line thickness, that is compared to the plot obtained by the standard radius bases thresholding. New definitions of line segments arising from the local minima-based method are outlined, which yield consistent results with those derived from standard methods. Our preliminary comparison suggests that the newly introduced thresholding technique is more sensitive to small changes in a system's dynamics. We demonstrate our method via the chaotic Lorenz system without the loss of generality. C1 [Schultz, Aaron P.; Turvey, Michael T.] Haskins Labs Inc, New Haven, CT 06511 USA. [Schultz, Aaron P.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Zou, Yong; Marwan, Norbert] Potsdam Inst Climate Impact Res, D-14412 Potsdam, Germany. RP Schultz, AP (reprint author), Haskins Labs Inc, 300 George St,Suite 900, New Haven, CT 06511 USA. EM aschultz@nmr.mgh.harvard.edu; yong.zou@pik-potsdam.de RI Marwan, Norbert/D-9576-2011; Zou, Yong/G-1139-2012 OI Marwan, Norbert/0000-0003-1437-7039; Zou, Yong/0000-0002-3241-3139 FU NIH [HD-01994]; German Research Foundation [SFB 555]; Potsdam Research Cluster for Georisk Analysis, Environmental Change and Sustainability (PROGRESS); Leibniz association [ECONS] FX This work was supported in part by NIH Grant HD-01994, the German Research Foundation (SFB 555), the Potsdam Research Cluster for Georisk Analysis, Environmental Change and Sustainability (PROGRESS), and the Leibniz association (project ECONS). NR 20 TC 5 Z9 5 U1 0 U2 4 PU WORLD SCIENTIFIC PUBL CO PTE LTD PI SINGAPORE PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE SN 0218-1274 J9 INT J BIFURCAT CHAOS JI Int. J. Bifurcation Chaos PD APR PY 2011 VL 21 IS 4 BP 1065 EP 1075 DI 10.1142/S0218127411029045 PG 11 WC Mathematics, Interdisciplinary Applications; Multidisciplinary Sciences SC Mathematics; Science & Technology - Other Topics GA 779OL UT WOS:000291788200005 ER PT J AU Crowley, PM Schultz, A AF Crowley, Patrick M. Schultz, Aaron TI MEASURING THE INTERMITTENT SYNCHRONICITY OF MACROECONOMIC GROWTH IN EUROPE SO INTERNATIONAL JOURNAL OF BIFURCATION AND CHAOS LA English DT Article DE Euro area; business cycles; growth cycles; recurrence plots; synchronicity; convergence ID INTERNATIONAL-BUSINESS CYCLE; CROSS RECURRENCE PLOTS; TIME-SERIES; CONVERGENCE; ERM; EMU AB Synchronization of growth rates are an important feature of international business cycles, particularly in relation to regional integration projects such as the single currency in Europe. Synchronization of growth rates clearly enhances the effectiveness of European Central Bank monetary policy, ensuring that policy changes are attuned to the dynamics of growth and business cycles in the majority of member states. In this paper, a dissimilarity metric is constructed by measuring the topological differences between the GDP growth patterns in recurrence plots for individual countries. The results show that synchronization of growth rates were higher among the euro area member states during the second half of the 1980s and from 1997 to roughly 2002. Apart from these two time periods, euro area member states do not appear to be more synchronized than a group of major international countries, suggesting that apart from specific times when European integration initiatives were being implemented, globalization was likely the dominant factor behind international business cycle synchronization. C1 [Crowley, Patrick M.] Texas A&M Univ, Corpus Christi, TX 78412 USA. [Schultz, Aaron] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Schultz, Aaron] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Crowley, PM (reprint author), Texas A&M Univ, 6300 Ocean Dr, Corpus Christi, TX 78412 USA. EM patrick.crowley@tamucc.edu; aschultz@nmr.mgh.harvard.edu NR 30 TC 5 Z9 5 U1 1 U2 4 PU WORLD SCIENTIFIC PUBL CO PTE LTD PI SINGAPORE PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE SN 0218-1274 J9 INT J BIFURCAT CHAOS JI Int. J. Bifurcation Chaos PD APR PY 2011 VL 21 IS 4 BP 1215 EP 1231 DI 10.1142/S0218127411028957 PG 17 WC Mathematics, Interdisciplinary Applications; Multidisciplinary Sciences SC Mathematics; Science & Technology - Other Topics GA 779OL UT WOS:000291788200017 ER PT J AU Sakhuja, R Yeh, RW Bhatt, DL AF Sakhuja, Rahul Yeh, Robert W. Bhatt, Deepak L. TI Anticoagulant Agents in Acute Coronary Syndromes SO CURRENT PROBLEMS IN CARDIOLOGY LA English DT Review ID ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; LOW-MOLECULAR-WEIGHT; FACTOR-XA INHIBITOR; HIGH-RISK PATIENTS; INTRAVENOUS UNFRACTIONATED HEPARIN; GLYCOPROTEIN-IIB/IIIA INHIBITORS; TRIPLE ANTITHROMBOTIC THERAPY; RECOMBINANT HIRUDIN LEPIRUDIN; ACUITY ACUTE CATHETERIZATION AB There has been substantial interest in novel antiplatelet therapies; yet, despite a growing number of studies with novel anticoagulants, there have been few comprehensive reviews summarizing the data for anticoagulants in acute coronary syndromes. Large-scale trials have demonstrated the efficacy of novel procedural anticoagulants, such as selective Factor-Xa inhibitors and direct thrombin inhibitors. Moreover, with as many as 10% of patients with non-ST-segment elevation acute coronary syndrome experiencing recurrent ischemia or death in the first 30 days, there is continued interest in oral anticoagulants. The purpose of this review is to synthesize the evidence for current anticoagulants, including heparins and more recent Factor Xa inhibitors and direct thrombin inhibitors, as well as oral anticoagulants and newer agents in later phases of clinical testing. (Curr Probl Cardiol 2011;36:127-168.) C1 [Sakhuja, Rahul; Yeh, Robert W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Integrated Intervent Cardiovasc Program, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Sakhuja, R (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. FU AstraZeneca, Bristol-Myers Squibb, Eisai, Sanofi Aventis; Medicines Company; Research Grant Schering Plough FX Dr Bhatt discloses the following relationships: Research Grants-AstraZeneca, Bristol-Myers Squibb, Eisai, Sanofi Aventis, the Medicines Company. Dr Yeh discloses the following relationship: Research Grant Schering Plough. Dr Sakhuja does not have any relevant disclosures. NR 110 TC 3 Z9 5 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0146-2806 J9 CURR PROB CARDIOLOGY JI Curr. Probl. Cardiol. PD APR PY 2011 VL 36 IS 4 BP 127 EP 168 DI 10.1016/j.cpcardiol.2011.03.003 PG 42 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 774JF UT WOS:000291380800001 PM 21586352 ER PT J AU Peterson, CL Kautz, SA Neptune, RR AF Peterson, Carrie L. Kautz, Steven A. Neptune, Richard R. TI Braking and propulsive impulses increase with speed during accelerated and decelerated walking SO GAIT & POSTURE LA English DT Article DE Non-steady-state; Ground reaction forces; Step length; Step frequency; Joint moments ID GROUND REACTION FORCES; HUMAN LOCOMOTION; MUSCLE-ACTIVITY; CHANGING SPEED; JOINT MOMENTS; LEVEL WALKING; PROGRESSION; SUPPORT; TRANSITION; FREQUENCY AB The ability to accelerate and decelerate is important for daily activities and likely more demanding than maintaining a steady-state walking speed. Walking speed is modulated by anterior-posterior (AP) ground reaction force (GRF) impulses. The purpose of this study was to investigate AP impulses across a wide range of speeds during accelerated and decelerated walking. Kinematic and GRF data were collected from 10 healthy subjects walking on an instrumented treadmill. Subjects completed trials at steady-state speeds and at four rates of acceleration and deceleration across a speed range of 0-1.8 m/s. Mixed regression models were generated to predict AP impulses, step length and frequency from speed, and joint moment impulses from AP impulses during non-steady-state walking. Braking and propulsive impulses were positively related to speed. The braking impulse had a greater relationship with speed than the propulsive impulse, suggesting that subjects modulate the braking impulse more than the propulsive impulse to change speed. Hip and knee extensor, and ankle plantarflexor moment impulses were positively related to the braking impulse, and knee flexor and ankle plantarflexor moment impulses were positively related to the propulsive impulse. Step length and frequency increased with speed and were near the subjects' preferred combination at steady-state speeds, at which metabolic cost is minimized in nondisabled walking. Thus, these variables may be modulated to minimize metabolic cost while accelerating and decelerating. The outcomes of this work provide the foundation to investigate motor coordination in pathological subjects in response to the increased task demands of non-steady-state walking. (C) 2011 Elsevier B.V. All rights reserved. C1 [Peterson, Carrie L.; Neptune, Richard R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Kautz, Steven A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kautz, Steven A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. RP Neptune, RR (reprint author), Univ Texas Austin, Dept Mech Engn, 1 Univ Stn,C2200, Austin, TX 78712 USA. EM rneptune@mail.utexas.edu RI Peterson, Carrie/C-6007-2016; OI Peterson, Carrie/0000-0002-7169-2089; Kautz, Steven/0000-0003-3151-8235 FU NIH [R01 HD46820]; Rehabilitation Research and Development Service of the Department of Veteran Affairs; National Science Foundation FX This work was supported by NIH Grant R01 HD46820, the Rehabilitation Research and Development Service of the Department of Veteran Affairs and the National Science Foundation Graduate Research Fellowship Program. The authors are grateful to members of the Brain Rehabilitation Research Center for their help with subject recruitment and data collection. NR 22 TC 16 Z9 17 U1 0 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 J9 GAIT POSTURE JI Gait Posture PD APR PY 2011 VL 33 IS 4 BP 562 EP 567 DI 10.1016/gaitpost.2011.01.010 PG 6 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 771EI UT WOS:000291139600008 PM 21356590 ER PT J AU Whittaker, EC Aubin, PM Ledoux, WR AF Whittaker, Eric C. Aubin, Patrick M. Ledoux, William R. TI Foot bone kinematics as measured in a cadaveric robotic gait simulator SO GAIT & POSTURE LA English DT Article DE Robotics; Gait simulation; Cadaveric simulations; Kinematics; Foot and ankle ID 1ST METATARSOPHALANGEAL JOINT; STANCE PHASE; IN-VITRO; MOTION; MODEL; WALKING; VIVO AB The bony motion of the foot during the stance phase of gait is useful to further our understanding of joint function, disease etiology, injury prevention and surgical intervention. In this study, we used a 10-segment in vitro foot model with anatomical coordinate systems and a robotic gait simulator (RGS) to measure the kinematics of the tibia, talus, calcaneus, cuboid, navicular, medial cuneiform, first metatarsal, hallux, third metatarsal, and fifth metatarsal from six cadaveric feet. The RGS accurately reproduced in vivo vertical ground reaction force (5.9% body weight RMS error) and tibia to ground kinematics. The kinematic data from the foot model generally agree with invasive in vivo descriptions of bony motion and provides the most realistic description of bony motion currently available for an in vitro model. These data help to clarify the function of several joints that are difficult to study in vivo; for example, the combined range of motion of the talonavicular, naviculocuneiform, metatarsocuneiform joints provided more sagittal plane mobility (27.4 degrees) than the talotibial joint alone (23.2 degrees). Additionally, the anatomical coordinate systems made it easier to meaningfully determine bone-to-bone motion, describing uniplanar motion as rotation about a single axis rather than about three. The data provided in this study allow for many kinematic interpretations to be made about dynamic foot bone motion, and the methodology presents a means to explore many invasive foot biomechanics questions under near-physiologic conditions. Published by Elsevier B.V. C1 [Whittaker, Eric C.; Aubin, Patrick M.; Ledoux, William R.] VA RR&D Ctr Excellence Limb Loss Prevent & Prosth, Seattle, WA USA. [Aubin, Patrick M.] Univ Washington, Dept Elect Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Ledoux, WR (reprint author), VA Puget Sound, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714 FU Department of Veterans Affairs Rehabilitation Research and Development Service [A3923R, A6669R] FX This work was funded in part by the Department of Veterans Affairs Rehabilitation Research and Development Service grants A3923R and A6669R. NR 22 TC 21 Z9 21 U1 1 U2 19 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 J9 GAIT POSTURE JI Gait Posture PD APR PY 2011 VL 33 IS 4 BP 645 EP 650 DI 10.1016/j.gaitpost.2011.02.011 PG 6 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 771EI UT WOS:000291139600023 PM 21458991 ER PT J AU Weierich, MR Kensinger, EA Munnell, AH Sass, SA Dickerson, BC Wright, CI Barrett, LF AF Weierich, Mariann R. Kensinger, Elizabeth A. Munnell, Alicia H. Sass, Steven A. Dickerson, Brad C. Wright, Christopher I. Barrett, Lisa Feldman TI Older and wiser? An affective science perspective on age-related challenges in financial decision making SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE LA English DT Article DE affect; neuroscience; retirement; decision-making; aging ID SOCIOEMOTIONAL SELECTIVITY THEORY; MEDIAL TEMPORAL-LOBE; HUMAN LIFE-SPAN; RISK-TAKING; COGNITIVE CONTROL; YOUNGER ADULTS; MEMORY DYSFUNCTION; EMOTIONAL MEMORY; DURABILITY BIAS; EPISODIC MEMORY AB Financial planning decisionss are fundamentally affective in nature; they are decisions related to money, longevity and quality of life. Over the next several decades people will be increasingly responsible for managing their own assets and investments, and they will be subject to the affective influences on active, personal decision-making. Many of these crucial decisions are made and revised across the lifespan, including when to buy or sell a home, how to save for childrens' education, how to manage healthcare costs, when to retire, how much to save for retirement and how to allocate retirement funds. As average life expectancy increases, many retirees will be faced with inadequate savings to live comfortably until the end of their lives. In the current article, we examine the problems of and potential solutions to inadequate financial planning through the lens of affective science, with an emphasis on how brain-based changes in affective processing with age might contribute to the challenge of financial planning. C1 [Weierich, Mariann R.] CUNY Hunter Coll, Dept Psychol, New York, NY 10065 USA. [Weierich, Mariann R.; Kensinger, Elizabeth A.; Dickerson, Brad C.; Wright, Christopher I.; Barrett, Lisa Feldman] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Weierich, Mariann R.; Kensinger, Elizabeth A.; Dickerson, Brad C.; Wright, Christopher I.; Barrett, Lisa Feldman] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Kensinger, Elizabeth A.; Barrett, Lisa Feldman] Boston Coll, Dept Psychol, Chestnut Hill, MA 02467 USA. [Munnell, Alicia H.; Sass, Steven A.] Boston Coll, Ctr Retirement Res, Chestnut Hill, MA 02467 USA. RP Weierich, MR (reprint author), CUNY Hunter Coll, Dept Psychol, N Bldg Room 627B,695 Pk Ave, New York, NY 10065 USA. EM weierich@nmr.mgh.harvard.edu RI Wright, Nicole/A-2824-2012 FU National Institute on Aging [R01AG030311]; National Institutes of Health Director's Pioneer [DP10D003312] FX This research was funded by the National Institute on Aging R01AG030311 (to L.F.B) and the National Institutes of Health Director's Pioneer Award DP10D003312 (to L.F.B). NR 122 TC 15 Z9 15 U1 3 U2 17 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1749-5016 EI 1749-5024 J9 SOC COGN AFFECT NEUR JI Soc. Cogn. Affect. Neurosci. PD APR PY 2011 VL 6 IS 2 SI SI BP 195 EP 206 DI 10.1093/scan/nsq056 PG 12 WC Neurosciences; Psychology; Psychology, Experimental SC Neurosciences & Neurology; Psychology GA 776NT UT WOS:000291543100005 PM 20587596 ER PT J AU Puzanov, I Burnett, P Flaherty, KT AF Puzanov, Igor Burnett, Patrick Flaherty, Keith T. TI Biological challenges of BRAF inhibitor therapy SO MOLECULAR ONCOLOGY LA English DT Review DE BRAF inhibitors; Targeted therapies; Cancer; Oncogenic BRAF signaling ID N-RAS MUTATIONS; B-RAF; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; MALIGNANT-MELANOMA; TUMOR PROGRESSION; DRUG-RESISTANCE; CELL-LINES; CANCER; KINASE AB Activating mutations in BRAF, a constituent of the map kinase pathway, were first discovered as being most prevalent in melanoma in 2002. Only recently have potent and selective, orally available inhibitors of BRAF emerged for clinical testing and demonstrated clear evidence of tumor regression in the majority of patients whose tumors harbor a BRAF mutation. While these early observations suggest that the BRAF targeted therapy will become part of the standard treatment paradigm for patients with advanced melanoma, it is also clear that a majority of these responses are incomplete and temporary. Therefore, the focus of the melanoma field has shifted to understanding the limits of the first generation of selective BRAF inhibitors with regard to safety and efficacy, the context of somatic genetic changes that accompany BRAF, and the combination regimens that target distinct elements of melanoma pathophysiology. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. C1 [Flaherty, Keith T.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Puzanov, Igor; Burnett, Patrick] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN USA. RP Flaherty, KT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. EM KFLAHERTY@PARTNERS.ORG NR 54 TC 20 Z9 20 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1574-7891 J9 MOL ONCOL JI Mol. Oncol. PD APR PY 2011 VL 5 IS 2 BP 116 EP 123 DI 10.1016/j.molonc.2011.01.005 PG 8 WC Oncology SC Oncology GA 771SV UT WOS:000291181900002 PM 21393075 ER PT J AU Soulieres, I Zeffiro, TA Girard, ML Mottron, L AF Soulieres, I. Zeffiro, T. A. Girard, M. L. Mottron, L. TI Enhanced mental image mapping in autism SO NEUROPSYCHOLOGIA LA English DT Article DE Mental rotation; Visual imagery; Discrimination; Perception; Enhanced perceptual functioning model; Autism ID HIGH-FUNCTIONING AUTISM; VISUAL-SEARCH; SPECTRUM DISORDERS; NEURAL MECHANISMS; ROTATION; PERCEPTION; INDIVIDUALS; IMITATION; PATTERNS; CHILDREN AB The formation and manipulation of mental images represents a key ability for successfully solving visuospatial tasks like Wechsler's Block Design or visual reasoning problems, tasks where autistics perform at higher levels than predicted by their Wechsler IQ. Visual imagery can be used to compare two mental images, allowing judgment of their relative properties. To examine higher visual processes in autism, and their possible role in explaining autistic visuospatial peaks, we carried out two mental imagery experiments in 23 autistic and 14 age and IQ matched, non-autistic adolescents and adults. Among autistics, 11 had significantly higher Block Design scores than predicted by their IQ. Experiment 1 involved imagining a letter inside a circle, followed by a decision concerning which of two highlighted portions of the circle would contain the greater proportion of the letter. Experiment 2 involved four classic mental rotation tasks utilizing two- and three-dimensional geometric figures, hands and letters. Autistics were more accurate in the formation and comparison of mental images than non-autistics. Autistics with a Block Design peak outperformed other participants in both speed and accuracy of mental rotation. Also, Performance IQ and Block Design scores were better predictors of mental rotation accuracy in autistic compared to non-autistic participants. The ability to form, access and manipulate visual mental representations may be more developed in autistics. We propose two complementary mechanisms to explain these processing advantages: (1) a global advantage in perceptual processing, discussed in the framework of the enhanced perceptual functioning model, and (2) particular strengths in veridical mapping, the ability to efficiently detect isomorphisms among entities and then to use these mappings to process stimulus characteristics, thereby facilitating judgments about their differences. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Soulieres, I.; Girard, M. L.; Mottron, L.] CETEDUM, Hop Riviere des Prairies, Montreal, PQ H1E 1A4, Canada. [Soulieres, I.; Zeffiro, T. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neural Syst Grp, Boston, MA USA. [Mottron, L.] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada. RP Soulieres, I (reprint author), CETEDUM, Hop Riviere des Prairies, 7070 Blvd Perras, Montreal, PQ H1E 1A4, Canada. EM isabelle@nmr.mgh.harvard.edu FU Autism Speaks [2706]; Canadian Institutes of Health Research (CIHR); FRSQ FX We thank Dr Stephen Kosslyn for access to some of the stimuli, Dr Jean-Philippe Lafrance for help with statistical analyses and Elise B. Barbeau, Isabelle Simard and Jennifer Lepage-Hamel for data collection. We also thank the participants and their family for their time and commitment. This work was supported by grant 2706 from Autism Speaks to L. Mottron, T. Zeffiro and I. Soulieres, a post-doctoral award from the Canadian Institutes of Health Research (CIHR) to I. Soulieres, and a National FRSQ fellowship to L. Mottron. NR 61 TC 32 Z9 32 U1 3 U2 27 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD APR PY 2011 VL 49 IS 5 BP 848 EP 857 DI 10.1016/j.neuropsychologia.2011.01.027 PG 10 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 764RE UT WOS:000290649200010 PM 21256856 ER PT J AU Hyde, DC Winkler-Rhoades, N Lee, SA Izard, V Shapiro, KA Spelke, ES AF Hyde, Daniel C. Winkler-Rhoades, Nathan Lee, Sang-Ah Izard, Veronique Shapiro, Kevin A. Spelke, Elizabeth S. TI Spatial and numerical abilities without a complete natural language SO NEUROPSYCHOLOGIA LA English DT Article DE Symbol use; Reorientation; Geometry; Counting; Deaf ID AMAZONIAN INDIGENE GROUP; CORE KNOWLEDGE; YOUNG-CHILDREN; COUNTING PRINCIPLES; STATISTICAL POWER; GEOMETRIC MODULE; ENCLOSED SPACES; 2 SYSTEMS; NUMBER; COGNITION AB We studied the cognitive abilities of a 13-year-old deaf child, deprived of most linguistic input from late infancy, in a battery of tests designed to reveal the nature of numerical and geometrical abilities in the absence of a full linguistic system. Tests revealed widespread proficiency in basic symbolic and non-symbolic numerical computations involving the use of both exact and approximate numbers. Tests of spatial and geometrical abilities revealed an interesting patchwork of age-typical strengths and localized deficits. In particular, the child performed extremely well on navigation tasks involving geometrical or landmark information presented in isolation, but very poorly on otherwise similar tasks that required the combination of the two types of spatial information. Tests of number- and space-specific language revealed proficiency in the use of number words and deficits in the use of spatial terms. This case suggests that a full linguistic system is not necessary to reap the benefits of linguistic vocabulary on basic numerical tasks. Furthermore, it suggests that language plays an important role in the combination of mental representations of space. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Hyde, Daniel C.; Winkler-Rhoades, Nathan; Lee, Sang-Ah; Izard, Veronique; Shapiro, Kevin A.; Spelke, Elizabeth S.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA. [Shapiro, Kevin A.] Massachusetts Gen Hosp, Dept Neurol, Pediat Neurol Unit, Boston, MA 02114 USA. [Shapiro, Kevin A.] Childrens Hosp, Div Dev Med, Boston, MA 02115 USA. RP Hyde, DC (reprint author), Harvard Univ, Dept Psychol, 1118 WJH,33 Kirkland St, Cambridge, MA 02138 USA. EM dchyde@fas.harvard.edu FU NIH [HD23103]; NSF [DRL-0633955] FX We would like to thank Alison Schonwald, MD and Katherine Engel, LICSW, MPH in the Division of Developmental Medicine at Children's Hospital Boston for referring IC for testing. Psychological assessment was conducted by Amy Szarkowski, PhD and Terrell Clark, PhD through the Deaf and Hard of Hearing Program at Children's Hospital Boston. Support for this research was generously provided by grants from NIH (HD23103) and NSF (DRL-0633955) to E.S. Spelke. NR 62 TC 7 Z9 7 U1 1 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD APR PY 2011 VL 49 IS 5 BP 924 EP 936 DI 10.1016/j.neuropsychologia.2010.12.017 PG 13 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 764RE UT WOS:000290649200018 PM 21168425 ER PT J AU Kret, ME Denollet, J Grezes, J de Gelder, B AF Kret, Mariska Esther Denollet, Johan Grezes, Julie de Gelder, Beatrice TI The role of negative affectivity and social inhibition in perceiving social threat: An fMRI study SO NEUROPSYCHOLOGIA LA English DT Article DE Emotion; fMRI; Individual differences; Social inhibition; Negative affectivity; Personality ID DYNAMIC FACIAL EXPRESSIONS; MAJOR DEPRESSIVE DISORDER; D PERSONALITY; INDIVIDUAL-DIFFERENCES; ORBITOFRONTAL CORTEX; AMYGDALA REACTIVITY; BODY EXPRESSIONS; NEURAL SYSTEMS; HEART-DISEASE; EMOTION AB Personality is associated with specific emotion regulation styles presumably linked with unique brain activity patterns. By using functional magnetic resonance imaging (fMRI) in 26 individuals, the neural responses to threatening (fearful and angry) facial and bodily expressions were investigated in relation to negative affectivity and social inhibition. A negative correlation was observed between negative affectivity and activation of the amygdala, fusiform gyrus, insula and hippocampus. Increased activation following threatening stimuli was observed in the left temporo-parietal junction and right extrastriate body area correlating with more social inhibition traits. Interestingly, the orbitofrontal cortex, superior temporal sulcus, inferior frontal gyrus (Brodmann area 45) and temporal pole correlated negatively with negative affectivity and positively with social inhibition. Whereas individuals with increased negative affectivity tend to de-activate the core emotion system, socially inhibited people tend to over-activate a broad cortical network. Our findings demonstrate effects of personality traits on the neural coding of threatening signals. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Kret, Mariska Esther; de Gelder, Beatrice] Tilburg Univ, Cognit & Affect Neurosci Lab, NL-5000 LE Tilburg, Netherlands. [Kret, Mariska Esther; Denollet, Johan] Tilburg Univ, CoRPS Ctr Res Psychol Somat Dis, NL-5000 LE Tilburg, Netherlands. [Grezes, Julie] Ecole Normale Super, Dept Etud Cognit, F-75231 Paris, France. [Grezes, Julie] INSERM, Lab Neurosci Cognit, U960, Paris, France. [de Gelder, Beatrice] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA USA. RP de Gelder, B (reprint author), Room P 511,Postbus 90153, NL-5000 LE Tilburg, Netherlands. EM b.degelder@uvt.nl RI Kret, Mariska/B-4798-2010; Grezes, Julie/E-5060-2016 FU Human Frontiers Science Program [RGP54/2004]; NWO Nederlandse Organisatie voor Wetenschappelijk Onderzoek [400.04081]; VICI [453.04004]; EU [FP6-NEST-COBOL043403] FX This study was partly supported by Human Frontiers Science Program RGP54/2004, NWO Nederlandse Organisatie voor Wetenschappelijk Onderzoek 400.04081 to BdG, VICI grant 453.04004 (to JD) and EU FP6-NEST-COBOL043403 and FP7 TANGO to BdG. We thank three reviewers for their helpful and insightful comments and suggestions. NR 65 TC 37 Z9 37 U1 1 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0028-3932 J9 NEUROPSYCHOLOGIA JI Neuropsychologia PD APR PY 2011 VL 49 IS 5 BP 1187 EP 1193 DI 10.1016/j.neuropsychologia.2011.02.007 PG 7 WC Behavioral Sciences; Neurosciences; Psychology, Experimental SC Behavioral Sciences; Neurosciences & Neurology; Psychology GA 764RE UT WOS:000290649200043 PM 21315749 ER PT J AU Eliott, D Hauch, A Kim, RW Fawzi, A AF Eliott, Dean Hauch, Adam Kim, Rubin W. Fawzi, Amani TI Retinal dialysis and detachment in a child after airbag deployment SO JOURNAL OF AAPOS LA English DT Article ID BAG INJURY AB A variety of airbag-associated ocular injuries have been reported in children sitting in the front passenger seat during automobile collisions. These injuries range from corneal abrasions to traumatic hyphema with secondary glaucoma and cataract. We report the case of a 5-year-old boy who experienced retinal dialysis and detachment associated with airbag deployment. The patient recovered 20/20 visual acuity after cryopexy and placement of a radial sponge. C1 [Eliott, Dean] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02163 USA. [Hauch, Adam; Fawzi, Amani] Univ So Calif, Keck Sch Med, Doheny Retina Inst, Los Angeles, CA 90033 USA. [Kim, Rubin W.] Kaiser Permanente No Calif, Santa Clara, CA USA. RP Eliott, D (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02163 USA. EM dean_eliott@meei.harvard.edu OI fawzi, amani/0000-0002-9568-3558 NR 7 TC 3 Z9 3 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1091-8531 J9 J AAPOS JI J. AAPOS PD APR PY 2011 VL 15 IS 2 BP 203 EP 204 DI 10.1016/j.jaapos.2010.11.021 PG 2 WC Ophthalmology; Pediatrics SC Ophthalmology; Pediatrics GA 770JP UT WOS:000291083100023 PM 21420338 ER PT J AU Zhu, CW Livote, EE Kahle-Wrobleski, K Scarmeas, N Albert, M Brandt, J Blacker, D Sano, M Stern, Y AF Zhu, Carolyn W. Livote, Elayne E. Kahle-Wrobleski, Kristin Scarmeas, Nikolaos Albert, Marilyn Brandt, Jason Blacker, Deborah Sano, Mary Stern, Yaakov TI Utilization of Antihypertensives, Antidepressants, Antipsychotics, and Hormones in Alzheimer Disease SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE Alzheimer disease; antihypertensive; antidepressant; antipsychotic; hormone; longitudinal studies ID HEALTH INITIATIVE MEMORY; CONJUGATED EQUINE ESTROGENS; GLOBAL COGNITIVE FUNCTION; PLACEBO-CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; MEDICARE BENEFICIARIES; DOUBLE-BLIND; DEMENTIA; HYPERTENSION; SYMPTOMS AB This study explores the longitudinal relationship between patient characteristics and use of 4 drug classes (antihypertensives, antidepressants, antipsychotics, and hormones) that showed significant changes in use rates over time in patients with Alzheimer disease. Patient/caregiver-reported prescription medication usage was categorized by drug class for 201 patients from the Predictors Study. Patient characteristics included use of cholinesterase inhibitors and/or memantine, function, cognition, living situation, baseline age, and sex. Assessment interval, year of study entry, and site were controlled for. Before adjusting for covariates, useage increased for antihypertensives (47.8% to 62.2%), antipsychotics (3.5% to 27.0%), and antidepressants (32.3% to 40.5%); use of hormones decreased (19.4% to 5.4%). After controlling for patient characteristics, effects of time on the use of antidepressants were no longer significant. Antihypertensive use was associated with poorer functioning, concurrent use of memantine, and older age. Antipsychotic use was associated with poorer functioning and poorer cognition. Antidepressant use was associated with younger age, poorer functioning, and concurrent use of cholinesterase inhibitors and memantine. Hormone use was associated with being female and younger age. Findings suggest accurate modeling of the Alzheimer disease treatment paradigm for certain subgroups of patients should include antihypertensives and antipsychotics in addition to cholinesterase inhibitors and memantine. C1 [Zhu, Carolyn W.; Livote, Elayne E.; Sano, Mary] James J Peters VA Med Ctr, GRECC, Bronx, NY 10468 USA. [Zhu, Carolyn W.; Livote, Elayne E.; Sano, Mary] James J Peters VA Med Ctr, Hlth Serv Res & Dev HSR & D Ctr Study Hlth Care S, Bronx, NY 10468 USA. [Zhu, Carolyn W.; Livote, Elayne E.; Sano, Mary] Mt Sinai Sch Med, Brookdale Dept Geriatr, New York, NY USA. [Sano, Mary] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Gertrude H Sergievsky Ctr, Med Ctr, New York, NY 10027 USA. [Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Dept Neurol, Med Ctr, New York, NY 10027 USA. [Kahle-Wrobleski, Kristin] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Scarmeas, Nikolaos; Stern, Yaakov] Columbia Univ, Med Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, Cognit Neurosci Div, New York, NY USA. [Albert, Marilyn; Brandt, Jason] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Blacker, Deborah] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Zhu, CW (reprint author), James J Peters VA Med Ctr, GRECC, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM carolyn.zhu@mssm.edu OI Brandt, Jason/0000-0001-7381-6244 FU Federal [AG07370, RR00645, U01AG010483]; Eli Lilly and Company; US Department of Veterans Affairs, Veterans Health Administration FX The Predictors Study is supported by Federal grants AG07370, RR00645, and U01AG010483. Funding for this analysis was also partially provided by Eli Lilly and Company. Drs Zhu and Sano and Ms Livote are also supported by the US Department of Veterans Affairs, Veterans Health Administration. The views expressed in this article are those of the authors and do not necessarily represent the views of the US Department of Veterans Affairs. NR 28 TC 3 Z9 3 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD APR-JUN PY 2011 VL 25 IS 2 BP 144 EP 148 DI 10.1097/WAD.0b013e3181fcba68 PG 5 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 766MR UT WOS:000290787700007 PM 20975515 ER PT J AU Skoglund, L Matsui, T Freeman, SH Wallin, A Blom, ES Frosch, MP Growdon, JH Hyman, BT Lannfelt, L Ingelsson, M Glaser, A AF Skoglund, Lena Matsui, Toshifumi Freeman, Stefanie H. Wallin, Anders Blom, Elin S. Frosch, Matthew P. Growdon, John H. Hyman, Bradley T. Lannfelt, Lars Ingelsson, Martin Glaser, Anna TI Novel Progranulin Mutation Detected in 2 Patients With FTLD SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE frontotemporal lobar degeneration; frontotemporal dementia; progranulin; ubiquitin; TDP-43 ID FRONTOTEMPORAL LOBAR DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; DEMENTIA; TAU; DISEASE; GENE; PREVALENCE; PROTEIN; CHROMOSOME-17; EXPRESSION AB Frontotemporal lobar degeneration (FTLD) with ubiquitin- positive, tau-negative inclusions, and linkage to chromosome 17 was recently found to be caused by mutations in the progranulin (PGRN) gene. In this study, we screened a group of 51 FTLD patients for PGRN mutations and identified a novel exon 6 splice donor site deletion (IVS6 + 5_8delGTGA) in 2 unrelated patients. This mutation displayed an altered splicing pattern generating 2 aberrant transcripts and causing frameshifts of the coding sequence, premature termination codons, and a near absence of PGRN mRNA from the mutated alleles most likely through nonsense-mediated decay. The subsequent PGRN haploin-sufficiency is consistent with previously described PGRN mutations. We present a molecular characterization of the IVS6 + 5_8delGTGA mutation and also describe clinical and neuropathologic features from the 2 patients carrying this PGRN mutation. From the screening of these 51 FTLD patients, we could also identify the earlier reported mutation Gln130fs, and several coding sequence variants that are most likely nonpathogenic. C1 [Skoglund, Lena; Blom, Elin S.; Lannfelt, Lars; Ingelsson, Martin; Glaser, Anna] Uppsala Univ, Dept Publ Hlth & Caring Sci, S-75185 Uppsala, Sweden. [Wallin, Anders] Univ Goteborg, Sahlgrenska Univ Hosp, Dept Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden. [Matsui, Toshifumi; Freeman, Stefanie H.; Frosch, Matthew P.; Growdon, John H.; Hyman, Bradley T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA. RP Glaser, A (reprint author), Uppsala Univ, Dept Publ Hlth & Caring Sci, Dag Hammarskjolds Vag 20, S-75185 Uppsala, Sweden. EM Anna.Glaser@pubcare.uu.se FU Swedish Research Council; Swedish Brain Foundation; Stohne's Foundation; Swedish Alzheimer Foundation; Swedish Dementia Association; Swedish Society of Medicine FX This work was supported by the Swedish Research Council, the Swedish Brain Foundation, Stohne's Foundation, the Swedish Alzheimer Foundation, the Swedish Dementia Association, and the Swedish Society of Medicine. NR 29 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD APR-JUN PY 2011 VL 25 IS 2 BP 173 EP 178 DI 10.1097/WAD.0b013e3181fbc22c PG 6 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA 766MR UT WOS:000290787700012 PM 20975516 ER PT J AU Gewirtz, H AF Gewirtz, Henry TI Quantitative PET Measurements of Myocardial Blood Flow in Young, Healthy Volunteers What Should We Expect? SO JACC-CARDIOVASCULAR IMAGING LA English DT Editorial Material DE healthy controls; myocardial blood flow; PET; quantitative ID ADENOSINE; RESERVE; HYPERTENSION; EXERCISE; HUMANS C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Cardiol Div,Cardiac Yawkey 5E, Boston, MA 02114 USA. RP Gewirtz, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Cardiol Div,Cardiac Yawkey 5E, Boston, MA 02114 USA. EM hgewirtz@partners.org NR 14 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD APR PY 2011 VL 4 IS 4 BP 413 EP 415 DI 10.1016/j.jcmg.2011.02.010 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 764WY UT WOS:000290666500012 PM 21492817 ER PT J AU Cho, JM Sohn, IS Kim, CJ Jang, IK AF Cho, Jin-Man Sohn, Il-Suk Kim, Chong-Jin Jang, Ik-Kyung TI Vulnerable Plaque Inside Stent SO JACC-CARDIOVASCULAR IMAGING LA English DT Editorial Material C1 [Jang, Ik-Kyung] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Cho, Jin-Man; Sohn, Il-Suk; Kim, Chong-Jin] Kyung Hee Univ Hosp Gangdong, Dept Cardiol, Seoul, South Korea. RP Jang, IK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Bigelow 800,55 Fruit St, Boston, MA 02114 USA. EM ijang@partners.org NR 2 TC 2 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-878X J9 JACC-CARDIOVASC IMAG JI JACC-Cardiovasc. Imag. PD APR PY 2011 VL 4 IS 4 BP 430 EP 431 DI 10.1016/j.jcmg.2010.09.026 PG 2 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 764WY UT WOS:000290666500014 PM 21492819 ER PT J AU Copeland, LA Zeber, JE Bingham, MO Pugh, MJ Noel, PH Schmacker, ER Lawrence, VA AF Copeland, Laurel A. Zeber, John E. Bingham, Mona O. Pugh, Mary Jo Noel, Polly Hitchcock Schmacker, Eric R. Lawrence, Valerie A. TI Transition from military to VHA care: Psychiatric health services for Iraq/Afghanistan combat-wounded SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Combat disorders; Health services; Iraq War 2003-; Mental health services; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; IRAQ; VETERANS; AFGHANISTAN; DEPRESSION; DEPLOYMENT; DIAGNOSES AB Objective: Veterans from the wars in Afghanistan and Iraq (OEF/OIF) report high rates of mental distress especially affective disorders. Ensuring continuity of care across institutions is a priority for both the Department of Defense (DOD) and the Veterans Health Administration (VHA), yet this process is not monitored nor are medical records integrated. This study assessed transition from DoD to VHA and subsequent psychiatric care of service members traumatically injured in OEF/OIF. Methods: Inpatients at a DoD trauma treatment facility discharged in FY02-FY06 (n = 994) were tracked into the VHA via archival data (n = 216 OEF/OIF veterans). Mental health utilization in both systems was analyzed. Results: VHA users were 9% female, 15% Hispanic; mean age 32 (SD= 10; range 19-59). No DoD inpatients received diagnoses of post-traumatic stress disorder (PTSD); 21% had other mental health diagnoses, primarily drug abuse. In the VHA, 38% sought care within 6 months of DoD discharge; 75% within 1 year. VHA utilization increased over time, with 88-89% of the transition cohort seeking care in FY07-FY09. Most accessed VHA mental health services (81%) and had VHA psychiatric diagnoses (71%); half met criteria for depression (27%) or PTSD (38%). Treatment retention through FY09 was significantly greater for those receiving psychiatric care: 98% vs 62% of those not receiving psychiatric care (chi(2)=53.3; p <.001). Limitations: DoD outpatient data were not available. The study relied on administrative data. Conclusions: Although physical trauma led to hospitalization in the DoD, high rates of psychiatric disorders were identified in subsequent VHA care, suggesting delay in development or recognition of psychiatric problems. Published by Elsevier B.V. C1 [Copeland, Laurel A.; Zeber, John E.] Scott & White Healthcare, Ctr Appl Hlth Res, Temple, TX 76502 USA. [Copeland, Laurel A.; Zeber, John E.] Vet Affairs, Cent Texaas Vet Hlth Care Syst, Temple, TX USA. [Bingham, Mona O.; Pugh, Mary Jo; Noel, Polly Hitchcock; Lawrence, Valerie A.] Vet Affairs, VERDICT Res, S Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pugh, Mary Jo; Noel, Polly Hitchcock; Lawrence, Valerie A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Schmacker, Eric R.] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA. RP Copeland, LA (reprint author), Scott & White Healthcare, Ctr Appl Hlth Res, 2102 Birdcreek Dr, Temple, TX 76502 USA. EM LaurelACopeland@gmail.com RI Schueter, nicos/A-3625-2014; OI Copeland, Laurel/0000-0002-9478-0209 FU Department of Veterans Affairs HSRD [SHP-08-0140]; VHA; DoD; Department of Veterans Affairs; VERDICT Research Center at South Texas Veterans Health Care System; Central Texas Veterans Health Care System; Scott & White Healthcare System; University of Texas Health Science Center at San Antonio; Brooke Army Medical Center at Fort Sam Houston; Nursing Research Services and the Department of Health Care Operations FX Funding for this study was provided by the Department of Veterans Affairs HSR&D Grant # SHP-08-0140. The funding agency had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.; The authors are employed as researchers by the Department of Veterans Affairs (VHA) or Department of Defense (DoD). The DoD researchers are stationed at the DoD hospital studied. The VHA researchers are supported by grants from non-profit agencies including VHA and DoD. The authors report no conflicts of interest.; This research was supported by the Department of Veterans Affairs with additional support from VERDICT Research Center at South Texas Veterans Health Care System, Central Texas Veterans Health Care System, Scott & White Healthcare System, and the University of Texas Health Science Center at San Antonio. The work was also supported by Brooke Army Medical Center at Fort Sam Houston, Nursing Research Services and the Department of Health Care Operations. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or the Department of Defense. NR 21 TC 13 Z9 13 U1 2 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2011 VL 130 IS 1-2 BP 226 EP 230 DI 10.1016/j.jad.2010.10.017 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 759KO UT WOS:000290241600033 PM 21051088 ER PT J AU Lemaire, CM Graham, DP AF Lemaire, Chad M. Graham, David P. TI Factors associated with suicidal ideation in OEF/OIF veterans SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Veterans; Suicide; Posttraumatic Stress; Disorder; Depression ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM COMBAT VETERANS; MILITARY-PERSONNEL; RISK-FACTOR; DEPRESSION; SYMPTOMS; COMORBIDITY; IMPAIRMENT; AFFAIRS; PATIENT AB Background: The purpose of this project was to examine factors associated with suicidal ideation in returning Iraq and Afghanistan war veterans. Methods: A cross-sectional review of 1740 veterans' initial mental health screening evaluations. One-hundred and thirteen (6.5%) OEF/OIF veterans reported active suicidal ideation at the time of the interview. Results: Prior exposures of physical or sexual abuse and having a history of a prior suicide attempt(s) were associated with the presence of current suicidal ideation, as were having a diagnosis of a psychotic disorder, a depressive disorder, or posttraumatic stress disorder (PTSD). Deployment concerns related to training (protective), the deployment environment, family concerns, deployment concerns, post-deployment support (protective), and postdeployment stressors were also associated with current suicidal ideation. Logistic regression analysis revealed the major risk factors were having a prior suicide attempt, female gender, and a depressive disorder diagnosis; while more perceived current social support was a protective factor. Logistic regression analysis also revealed having comorbid PTSD and depression carried a higher odds ratio for risk than did having either PTSD or depression alone; and that the PTSD avoidance symptom-cluster was associated with more risk than either the re-experiencing or hyper-arousal symptom clusters for current suicidal ideation. Limitations: As a cross-sectional retrospective medical chart review, limitations include limited generalizability and causal relationships cannot be evaluated. Conclusions: Further investigation of these risk factors is warranted to aid in suicide risk assessment and in the development of targeted interventions to mitigate the identified risk factors and bolster the identified protective factor. Published by Elsevier B.V. C1 [Lemaire, Chad M.; Graham, David P.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Lemaire, Chad M.] Legacy Community Hlth Serv, Houston, TX USA. [Graham, David P.] Michael E DeBakey Dept Vet Affairs Med Ctr, Rehabil Res & Dev Serv, Neurorehabil Neurons Networks TBI Ctr Excellence, Houston, TX USA. [Graham, David P.] Michael E DeBakey Dept Vet Affairs Med Ctr, Res & Dev Serv, Hlth Serv, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA. RP Graham, DP (reprint author), Michael E DeBakey VA Med Ctr 116A, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM david.graham@va.gov RI Schueter, nicos/A-3625-2014; Graham, David /J-1158-2014 FU Veterans' Affairs Administration's Substance Use Disorders Quality Enhancement Research initiative (SUD-QUERI) FX We would like to thank all the helpers and assistants whose hard work helped to perform the chart reviews and data extraction, and particularly all the veterans who, through their time and efforts to become familiar with VA services, underwent a Mental Health evaluation, without which this project could not have been done. This project was funded by a grant from the Veterans' Affairs Administration's Substance Use Disorders Quality Enhancement Research initiative (SUD-QUERI) Program. The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. NR 44 TC 53 Z9 54 U1 2 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2011 VL 130 IS 1-2 BP 231 EP 238 DI 10.1016/j.jad.2010.10.021 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 759KO UT WOS:000290241600034 PM 21055828 ER PT J AU Yeung, AS Ameral, VE Chuzi, SE Fava, M Mischoulon, D AF Yeung, Albert S. Ameral, Victoria E. Chuzi, Sarah E. Fava, Maurizio Mischoulon, David TI A pilot study of acupuncture augmentation therapy in antidepressant partial and non-responders with major depressive disorder SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Acupuncture; Antidepressant; Augmentation; Depression ID CONTROLLED-TRIAL; CLINICAL-TRIALS AB Background: Acupuncture is widely used for treating major depressive disorder (MDD). There is evidence supporting acupuncture as an antidepressant monotherapy, but its efficacy as augmentation in antidepressant partial and non-responders has not been well-investigated. Methods: Thirty subjects (47% female, mean age 48 +/- 11 years) with a history of SCID-diagnosed MDD and partial or non-response after 8 weeks of antidepressant therapy were assigned 8 weeks of standardized 30-min open acupuncture augmentation sessions on a weekly (n = 24) or twice-weekly (n = 6) basis. Change in the Hamilton-D-17 score was the primary outcome measure, and response rates (based on HAM-D-17 score improvement of >= 50%) the secondary outcome. Results: Twenty subjects (40% female: 18 in weekly and 2 in twice-weekly treatment) completed the study. In the intent-to-treat (ITT) sample (N = 30), HAM-D-17 scores decreased from 18.5 +/- 3.8 to 11.2 +/- 5.3 in the weekly group (p < 0.001), and from 18.5 +/- 3.3 to 11.8 +/- 4.8 in the twice-weekly group (p = 0.03). Improvement did not differ significantly between treatment arms (p = 0.76). Response rates were 47% for all ITT subjects, 50% for the weekly group and 33% for the twice-weekly group (p =0.66). The most common side effects included soreness/pain (n = 7), bruising (n = 4), and mild bleeding (n = 1) at the needle site. One subject discontinued because of side effects (pain). Limitations: Open design, small sample, polypharmacy with antidepressants. Conclusions: Once or twice-weekly acupuncture augmentation was safe, well-tolerated and effective in antidepressant partial and non-responders, suggesting good feasibility in outpatient settings. Replication in controlled trials is warranted. (C) 2010 Elsevier B.V. All rights reserved. C1 [Yeung, Albert S.; Ameral, Victoria E.; Chuzi, Sarah E.; Fava, Maurizio; Mischoulon, David] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. RP Mischoulon, D (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM dmischoulon@partners.org FU MGH Depression Clinical and Research Program; Abbott Laboratories; Alkermes; Aspect Medical Systems; Astra-Zeneca; BioResearch; BrainCells, Inc.; Bristol-Myers-Squibb Company; Cephalon; Clinical Trial Solutions,LLC; Eli Lilly Company; EnVivo Pharmaceuticals, Inc.; Forest Pharmaceuticals Inc.; Ganeden; GlaxoSmithKline; J & J Pharmaceuticals; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; NARSAD; NCCAM; NIDA; NIMH; Novartis; Organon Inc.; PamLab, LLC; Pfizer Inc; Synthelabo; Wyeth-Ayerst Laboratories; Laxdale (Arnarin); Nordic Naturals; SwissMedica FX This study was supported by the MGH Depression Clinical and Research Program's clinical practice revenues. Only the authors of the manuscript were involved in the study design, collection, analysis and interpretation of data, writing of the report, and the decision to submit the paper for publication.; Dr. Fava has received research support from Abbott Laboratories, Alkermes, Aspect Medical Systems, Astra-Zeneca, BioResearch, BrainCells, Inc., Bristol-Myers-Squibb Company, Cephalon, Clinical Trial Solutions,LLC, Eli Lilly & Company, EnVivo Pharmaceuticals, Inc., Forest Pharmaceuticals Inc., Ganeden, GlaxoSmithKline, J & J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, NARSAD, NCCAM, NIDA, NIMH, Novartis, Organon Inc., PamLab, LLC, Pfizer Inc, Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay Pharmaceuticals, Inc., Synthelabo, and Wyeth-Ayerst Laboratories. He has served as an advisor and consultant to Abbott Laboratories, Affectis Pharmaceuticals AG, Amarin, Aspect Medical Systems, Astra-Zeneca, Auspex Pharmaceuticals, Bayer AG, Best Practice Project Management, Inc, BioMarin Pharmaceuticals, Inc., Biovail Pharmaceuticals, Inc., BrainCells, Inc, Bristol-Myers-Squibb Company, Cephalon, Clinical Trials Solutions, LLC, CNS Response, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eisai, Inc., Eli Lilly & Company, EPIX Pharmaceuticals, Euthymics Bioscience, Inc., Fabre-Kramer, Pharmaceuticals, Inc., Forest Pharmaceuticals Inc., GlaxoSmithKline, Grunenthal GmBH, Janssen Pharmaceutica, Jazz Pharmaceuticals, J & J Pharmaceuticals, Knoll Pharmaceutical Company, Labopharm, Lorex Pharmaceuticals, Lundbeck, MedAvante Inc., Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab, LLC, Pfizer Inc. PharmaStar, Pharmavite, Precision Human Biolaboratory, Prexa Pharmaceuticals, Inc., PsychoGenics, Psylin Neurosciences, Inc., Ridge Diagnostics, Inc., Roche, Sanofi-Aventis, Sepracor, Schering-Plough, Solvay Pharmaceuticals, Inc., Somaxon, Somerset Pharmaceuticals, Synthelabo, Takeda, Tetragenex, TransForm Pharmaceuticals, Inc., Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc., and Wyeth-Ayerst Laboratories. He has received speaking and publishing honoraria from Adamed, Co., Advanced Meeting Partners, American Psychiatric Association, American Society of Clinical Psychopharmacology, Astra-Zeneca, Belvoir, Boehringer-lngelheim, Bristol-Myers-Squibb Company, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, lmedex, Novartis, Organon Inc., Pfizer Inc, PharmaStar, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed-Elsevier, UBC, and Wyeth-Ayerst Laboratories. He holds equity in Compellis. He currently holds a patent for SPCD and a patent application for a combination of azapirones and bupropion in MDD, and has received copyright royalties for the MGH CPFQ SFI, ATRQ DESS, and SAFER diagnostic instruments.; Dr. Mischoulon has received research support from Laxdale (Arnarin), Nordic Naturals, Ganeden, and SwissMedica. He has served as a consultant to Bristol-Meyers-Squibb Company. He has received speaking honoraria from Pamlab, Virbac, and Nordic Naturals. He has received writing honoraria from Pamlab. He has received royalties from Back Bay Scientific for PMS Escape, and royalties from Lippincott Williams & Wilkins, for textbook "Natural Medications for Psychiatric Disorders: Considering the Alternatives" (David Mischoulon and Jerrold F Rosenbaum, Eds.). He has received honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the Mal Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supporting programs along with participant tuition. Commercial entities currently supporting the MGH Psychiatry Academy are listed on the Academy's website http://www.mghcme.org. NR 23 TC 17 Z9 19 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD APR PY 2011 VL 130 IS 1-2 BP 285 EP 289 DI 10.1016/j.jad.2010.07.025 PG 5 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 759KO UT WOS:000290241600042 PM 20692042 ER PT J AU Misra, M Klibanski, A AF Misra, M. Klibanski, A. TI Bone metabolism in adolescents with anorexia nervosa SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION LA English DT Review DE Adolescents; anorexia nervosa; bone microarchitecture; bone density; bone tumover; cortisol; estrogen; ghrelin; GH; leptin; peptide YY; testosterone ID TRABECULAR STRUCTURE-ANALYSIS; MAPK SIGNALING PATHWAY; PANEL VOLUME CT; MINERAL DENSITY; HEALTHY ADOLESCENTS; SECRETORY DYNAMICS; GROWTH-HORMONE; YOUNG-WOMEN; HYPOTHALAMIC AMENORRHEA; HUMAN OSTEOBLASTS AB Adolescents with anorexia nervosa (AN) are at risk for low bone mass at multiple sites, associated with decreased bone turnover. Bone microarchitecture is also affected, with a decrease in bone trabecular volume and trabecular thickness, and an increase in trabecular separation. The adolescent years are typically the time when marked increases occur in bone mass accrual towards the attainment of peak bone mass, an important determinant of bone health and fracture risk in later life. AN often begins in the adolescent years, and decreased rates of bone mass accrual at this critical time are therefore also concerning for deficits in peak bone mass. Factors contributing to low bone density and decreased rates of bone accrual include alterations in body composition such as low body mass index and lean body mass, and hormonal alterations such as hypogonadism, a nutritionally acquired resistance to GH and low levels of IGF-I, relative hypercortisolemia, low levels of leptin, and increased adiponectin (for fat mass) and peptide YY. Therapeutic strategies include optimizing Weight and menstrual recovery, and adequate calcium and vitamin D replacement. Oral estrogen-progesterone combination pills are not effective in increasing bone density in adolescents with AN. Recombinant human IGF-I increases levels of bone formation markers in the short term, while long-term effects remain to be determined. Bisphosphonates act by decreasing bone resorption, and are not optimal for use in adolescents with AN, in whom the primary defect is low bone formation. (J. Endocrinol. Invest. 34: 324-332, 2011) (C) 2011, Editrice Kurtis C1 [Misra, M.] Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457, Boston, MA 02114 USA. [Misra, M.; Klibanski, A.] Harvard Univ, Sch Med, Boston, MA USA. [Misra, M.] Mass Gen Hosp Children, Pediat Endocrine Unit, Boston, MA USA. RP Misra, M (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457, 55 Fruit St, Boston, MA 02114 USA. EM mmisra@partners.org FU National Institutes of Health [R01 DK 062249, K23 RR018851, 1 UL1 RR025758-01] FX This work was supported by National Institutes of Health Grants R01 DK 062249, K23 RR018851, and 1 UL1 RR025758-01. NR 69 TC 14 Z9 14 U1 2 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0391-4097 EI 1720-8386 J9 J ENDOCRINOL INVEST JI J. Endocrinol. Invest. PD APR PY 2011 VL 34 IS 4 BP 324 EP 332 DI 10.3275/7505 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 767UN UT WOS:000290883900014 PM 21301203 ER PT J AU Huang, HC Yang, Y Nanda, A Koria, P Rege, K AF Huang, Huang-Chiao Yang, Yoonsun Nanda, Alisha Koria, Piyush Rege, Kaushal TI Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices SO NANOMEDICINE LA English DT Article DE 17-AAG; cancer; combination treatment; gold nanorod; heat-shock inhibitor; hyperthermia; photothermal ablation; plasmonic matrix; prostate cancer ID PROTEIN-BASED POLYMERS; PHASE-II TRIAL; PROSTATE-CANCER; GOLD NANORODS; ABLATION; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; NANOPARTICLES; HYPERTHERMIA; INJURY; ENERGY AB Aim: Resistance of cancer cells to hyperthermic temperatures and spatial limitations of nanoparticle-induced hyperthermia necessitates the identification of effective combination treatments that can enhance the efficacy of this treatment. Here we show that novel polypeptide-based degradable plasmonic matrices can be employed for simultaneous administration of hyperthermia and chemotherapeutic drugs as an effective combination treatment that can overcome cancer cell resistance to hyperthermia. Method: Novel gold nanorod elastin-like polypeptide matrices were generated and characterized. The matrices were also loaded with the heat-shock protein (HSP)90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), currently in clinical trials for different malignancies, in order to deliver a combination of hyperthermia and chemotherapy. Results: Laser irradiation of cells cultured over the plasmonic matrices (without 17-AAG) resulted in the death of cells directly in the path of the laser, while cells outside the laser path did not show any loss of viability. Such spatial limitations, in concert with expression of prosurvival HSPs, reduce the efficacy of hyperthermia treatment. 17-AAG gold nanorod polypeptide matrices demonstrated minimal leaching of the drug to surrounding media. The combination of hyperthermic temperatures and the release of 17-AAG from the matrix, both induced by laser irradiation, resulted in significant (>90%) death of cancer cells, while 'single treatments' (i.e., hyperthermia alone and 17-AAG alone) demonstrated minimal loss of cancer cell viability (<10%). Conclusion: Simultaneous administration of hyperthermia and HSP inhibitor release from plasmonic matrices is a powerful approach for the ablation of malignant cells and can be extended to different combinations of nanoparticles and chemotherapeutic drugs for a variety of malignancies. C1 [Yang, Yoonsun; Rege, Kaushal] Arizona State Univ, Biol Design Program, Tempe, AZ 85287 USA. [Koria, Piyush] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. RP Rege, K (reprint author), Arizona State Univ, Biol Design Program, Tempe, AZ 85287 USA. EM Kaushal.rege@asu.edu FU National Science Foundation [CBET 0829128]; NIH [5R21 CA 133618-02]; Defense Threat Reduction Agency [HDTRA 1-10-1-019]; state of Arizona; ASU FX This work was supported by the National Science Foundation (CBET 0829128), NIH (5R21 CA 133618-02) and the Defense Threat Reduction Agency (HDTRA 1-10-1-019), as well as start-up finds from the state of Arizona to Kaushal Rege, and a Fulton Undergraduate Research Initiative (FURI) Award at ASU to Alisha Nanda. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 31 TC 24 Z9 24 U1 3 U2 36 PU FUTURE MEDICINE LTD PI LONDON PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND SN 1743-5889 J9 NANOMEDICINE-UK JI Nanomedicine PD APR PY 2011 VL 6 IS 3 BP 459 EP 473 DI 10.2217/NNM.10.133 PG 15 WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology SC Biotechnology & Applied Microbiology; Science & Technology - Other Topics GA 764AW UT WOS:000290601800015 PM 21542685 ER PT J AU Conboy, LA Macklin, E Kelley, J Kokkotou, E Lembo, A Davis, R Kaptchuk, T AF Conboy, Lisa Ann Macklin, Eric Kelley, John Kokkotou, Efi Lembo, Anthony Davis, Roger Kaptchuk, Ted TI Which patients improve: Characteristics increasing sensitivity to a supportive patient-practitioner relationship (vol 70, pg 479, 2010) SO SOCIAL SCIENCE & MEDICINE LA English DT Correction C1 [Conboy, Lisa Ann; Davis, Roger; Kaptchuk, Ted] Harvard Univ, Sch Med, Osher Res Ctr, Boston, MA 02115 USA. [Macklin, Eric] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. [Kelley, John] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Kokkotou, Efi; Lembo, Anthony] Beth Israel Hosp, Dept Gastroenterol, Boston, MA USA. RP Conboy, LA (reprint author), Harvard Univ, Sch Med, Osher Res Ctr, 401 Pk Dr,Suite 22A, Boston, MA 02115 USA. EM lisa_conboy@hms.harvard.edu RI Macklin, Eric/E-2955-2013 OI Macklin, Eric/0000-0003-1618-3502 NR 1 TC 1 Z9 1 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD APR PY 2011 VL 72 IS 8 BP 1409 EP 1409 DI 10.1016/j.socscimed.2011.03.001 PG 1 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 765IU UT WOS:000290699700023 ER PT J AU Benitez, A Horner, MD Bachman, D AF Benitez, Andreana Horner, Michael David Bachman, David TI Intact Cognition in Depressed Elderly Veterans Providing Adequate Effort SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Depression; Elderly/geriatrics/aging; Suboptimal effort; Cognition; Repeatable Battery for the Assessment of Neuropsychological Status; Geriatric Depression Scale ID MEMORY MALINGERING TOMM; SYMPTOM VALIDITY TESTS; DWELLING OLDER-ADULTS; GERIATRIC DEPRESSION; LATE-LIFE; EXECUTIVE DYSFUNCTION; MOOD DISORDERS; DEMENTIA; ASSOCIATION; PERFORMANCE AB Geriatric depression has been associated with cognitive impairments, but whether suboptimal effort contributes to these deficits is unknown. This study investigated differences in cognitive functioning between depressed and nondepressed elderly veterans, before and after excluding patients who provided suboptimal effort on testing at a memory disorders clinic. Patients diagnosed with a depressive disorder performed more poorly than nondepressed patients on almost all Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) indices, but these differences became nonstatistically significant after excluding patients who provided suboptimal effort. However, when patients were classified as normal, mildly, or severely depressed based on Geriatric Depression Scale scores, these groups were not significantly different on RBANS indices, regardless of whether patients who provided suboptimal effort were included or excluded from analyses. The findings suggest that cognitive deficits in depression reported in previous research may be attributable to suboptimal effort and that identifying depression via clinical diagnosis or psychometric data may affect this trend. C1 [Benitez, Andreana] Kent State Univ, Dept Psychol, Kent, OH 44242 USA. [Horner, Michael David; Bachman, David] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Benitez, Andreana; Horner, Michael David; Bachman, David] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Bachman, David] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. RP Benitez, A (reprint author), 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90095 USA. EM abenitez@mednet.ucla.edu NR 50 TC 11 Z9 11 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD APR PY 2011 VL 26 IS 3 BP 184 EP 193 DI 10.1093/arclin/acr001 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA 756WV UT WOS:000290046400003 PM 21278197 ER PT J AU Gallardo, G Guardia, J Villasenor, T McNeil, MR AF Gallardo, Geisa Guardia, Joan Villasenor, Teresita McNeil, Malcolm R. TI Psychometric Data for the Revised Token Test in Normally Developing Mexican Children Ages 4-12 Years SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Auditory language comprehension; Pediatric population; Psychometric study; Spanish-speaking population; Revised Token Test ID NORMATIVE DATA; PERFORMANCE; LANGUAGE; INTELLIGENCE; MODELS AB Language comprehension is vital to social and educational development but few pediatric tests are available for its assessment. To approach this problem, two versions of the Token Test (TT), "TT short form" (DeRenzi & Faglioni, 1978) and "Revised Token Test" (RTT), were first compared. Using a sample of 88 normally developing Spanish-speaking children, the tests were compared on their: (a) established psychometric development and (b) internal consistency. The RTT was judged to be superior and was selected for additional experimentation. The RTT was compared with a developmental measure of lexical knowledge on a cross-sectional sample of 250 4-12-year-old normally developing Spanish-speaking children. A significant positive and high correlation supports its concurrent validity. Significant differences across the age groups, along with a principal component analysis that yielded a three-factor structure, support its construct validity. Preliminary normative data across the nine age groups are provided. C1 [Guardia, Joan] Univ Barcelona, Dept Metodol Ciencias Comportamiento, Fac Psicol, Inst Recerca Cervell Cognicio & Conducta, Barcelona, Spain. [Gallardo, Geisa; Villasenor, Teresita] Univ Guadalajara, Dept Neurociencias, Ctr Univ Ciencias Salud, Guadalajara, Jalisco, Mexico. [McNeil, Malcolm R.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA USA. [McNeil, Malcolm R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Guardia, J (reprint author), Fac Psicol, Dept Ciencies Comportament, Passeig Vall dHebron 171, Barcelona 08035, Spain. EM jguardia@ub.edu FU MINISTERIO DE CIENCIA E INNOVACION [PSI2010 - 21214 - C02 - 01] FX Funding received from MINISTERIO DE CIENCIA E INNOVACION grant number PSI2010 - 21214 - C02 - 01. NR 41 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD APR PY 2011 VL 26 IS 3 BP 225 EP 234 DI 10.1093/arclin/acr018 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA 756WV UT WOS:000290046400007 PM 21441259 ER PT J AU Kelly, JF Stout, RL Magill, M Tonigan, JS AF Kelly, John F. Stout, Robert L. Magill, Molly Tonigan, J. Scott TI The role of Alcoholics Anonymous in mobilizing adaptive social network changes: A prospective lagged mediational analysis SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Alcoholics Anonymous; Social networks; Self help groups; Alcoholism; Alcohol dependence ID SELF-HELP GROUPS; SUBSTANCE-ABUSE PATIENTS; USE DISORDERS; BEHAVIOR-CHANGE; PROJECT MATCH; REDUCE DEMAND; OUTCOMES; SUPPORT; MECHANISMS; ABSTINENCE AB Objective: Many individuals entering treatment are involved in social networks and activities that heighten relapse risk. Consequently, treatment programs facilitate engagement in social recovery resources, such as Alcoholics Anonymous (AA), to provide a low risk network. While it is assumed that AA works partially through this social mechanism, research has been limited in rigor and scope. This study used lagged mediational methods to examine changes in pro-abstinent and pro-drinking network ties and activities. Method: Adults (N = 1726) participating ill a randomized controlled trial of alcohol use disorder treatment were assessed at intake, and 3, 9, and 15 months. Generalized linear modeling (Generalized linear modeling) tested whether changes in pro-abstinent and pro-drinking network ties and drinking and abstinent activities helped to explain AA's effects. Results: Greater AA attendance facilitated substantial decreases in pro-drinking social ties and significant, but less substantial increases in pro-abstinent ties. Also, AA attendance reduced engagement in drinking-related activities and increased engagement in abstinent activities. Lagged mediational analyses revealed that it was through reductions in pro-drinking network ties and, to a lesser degree, increases in pro-abstinent ties that AA exerted its salutary effect on abstinence, and to a lesser extent, on drinking intensity. Conclusions: AA appears to facilitate recovery by mobilizing adaptive changes in the social networks of individuals exhibiting a broad range of impairment. Specifically by reducing involvement with pro-drinking ties and increasing involvement with pro-abstinent ties. These changes may aid recovery by decreasing exposure to alcohol-related cues thereby reducing craving, while simultaneously increasing rewarding social relationships. (c) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Kelly, John F.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. [Kelly, John F.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Stout, Robert L.] Decis Sci Inst PIRE, Pawtucket, RI 02860 USA. [Magill, Molly] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Tonigan, J. Scott] CASAA, Albuquerque, NM 87106 USA. RP Kelly, JF (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, 60 Staniford St,Suite 120, Boston, MA 02114 USA. EM jkelly11@partners.org FU National Institute of Alcohol Abuse and Alcoholism (NIAAA) [R21 AA016762] FX Funding for this study was provided by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) grant R21 AA016762. The NIAAA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Opinions are those solely of the authors and do not reflect those of the funding agency. NR 61 TC 38 Z9 38 U1 4 U2 17 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD APR 1 PY 2011 VL 114 IS 2-3 BP 119 EP 126 DI 10.1016/j.drugalcdep.2010.09.009 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 759XO UT WOS:000290283000004 PM 21035276 ER PT J AU Janssens, ACJW Ioannidis, JPA Bedrosian, S Boffetta, P Dolan, SM Dowling, N Fortier, I Freedman, AN Grimshaw, JM Gulcher, J Gwinn, M Hlatky, MA Janes, H Kraft, P Melillo, S O'Donnell, CJ Pencina, MJ Ransohoff, D Schully, SD Seminara, D Winn, DM Wright, CF van Duijn, CM Little, J Khoury, MJ AF Janssens, A. Cecile J. W. Ioannidis, John P. A. Bedrosian, Sara Boffetta, Paolo Dolan, Siobhan M. Dowling, Nicole Fortier, Isabel Freedman, Andrew N. Grimshaw, Jeremy M. Gulcher, Jeffrey Gwinn, Marta Hlatky, Mark A. Janes, Holly Kraft, Peter Melillo, Stephanie O'Donnell, Christopher J. Pencina, Michael J. Ransohoff, David Schully, Sheri D. Seminara, Daniela Winn, Deborah M. Wright, Caroline F. van Duijn, Cornelia M. Little, Julian Khoury, Muin J. TI Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration SO EUROPEAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Genetic; Risk prediction; Methodology; Guidelines; Reporting ID GENOME-WIDE ASSOCIATION; HEART-DISEASE RISK; OPERATING CHARACTERISTIC CURVE; TYPE-2 DIABETES RISK; RECLASSIFICATION MEASURES; MACULAR DEGENERATION; DIAGNOSTIC-ACCURACY; CARDIOVASCULAR RISK; CONTROLLED-TRIALS; PROSTATE-CANCER AB The rapid and continuing progress in gene discovery for complex diseases is fuelling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but they vary widely in completeness of reporting and apparent quality. Transparent reporting of the strengths and weaknesses of these studies is important to facilitate the accumulation of evidence on genetic risk prediction. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency, quality and completeness of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct or analysis. C1 [Janssens, A. Cecile J. W.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands. [Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece. [Ioannidis, John P. A.] Fdn Res & Technol, Biomed Res Inst, Ioannina, Greece. [Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Ioannidis, John P. A.] Tufts Med Ctr, Ctr Genet Epidemiol & Modeling, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Ioannidis, John P. A.] Tufts Med Ctr, Tufts CTSI, Inst Clin Res & Hlth Policy Studies, Boston, MA USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA. [Bedrosian, Sara; Dowling, Nicole; Gwinn, Marta; Melillo, Stephanie; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA. [Boffetta, Paolo] Int Prevent Res Inst, Lyon, France. [Dolan, Siobhan M.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY 10467 USA. [Fortier, Isabel] Publ Populat Project Genom P3G, Montreal, PQ, Canada. [Freedman, Andrew N.; Schully, Sheri D.; Seminara, Daniela; Winn, Deborah M.] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA. [Grimshaw, Jeremy M.] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada. [Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada. [Gulcher, Jeffrey] DeCODE Genet, Reykjavik, Iceland. [Hlatky, Mark A.] Stanford Univ, Dept Hlth Res & Policy, Palo Alto, CA 94304 USA. [Janes, Holly] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, Seattle, WA 98104 USA. [Janes, Holly] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [O'Donnell, Christopher J.] NHLBI, Framingham, MA USA. [O'Donnell, Christopher J.] NHLBIs Framingham Heart Study, Framingham, MA USA. [O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [Pencina, Michael J.] Boston Univ, Dept Biostat, Boston, MA 02215 USA. [Pencina, Michael J.] Harvard Clin Res Inst, Boston, MA USA. [Ransohoff, David] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Wright, Caroline F.] PHG Fdn, Cambridge, England. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Janssens, ACJW (reprint author), Erasmus MC, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM a.janssens@erasmusmc.nl RI Ioannidis, John/G-9836-2011; janssens, cecile/L-1075-2015; OI Janssens, A Cecile/0000-0002-6153-4976; Wright, Caroline/0000-0003-2958-5076 FU NCI NIH HHS [U24 CA086368, U24 CA086368-11] NR 93 TC 10 Z9 10 U1 0 U2 4 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0393-2990 J9 EUR J EPIDEMIOL JI Eur. J. Epidemiol. PD APR PY 2011 VL 26 IS 4 BP 313 EP 337 DI 10.1007/s10654-011-9551-z PG 25 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 760ON UT WOS:000290333700009 PM 21424820 ER PT J AU Gunzler, D Eberly, S Oakes, D Ascherio, A Schwarzschild, MA AF Gunzler, D. Eberly, S. Oakes, D. Ascherio, A. Schwarzschild, M. A. TI Urate as a Predictor of the Rate of Cognitive Decline in the DATATOP Trial SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 25th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinsons Disease and Other Movement Disorders CY MAY 13, 2011 CL Irving, TX C1 [Ascherio, A.; Schwarzschild, M. A.] Harvard Univ, Sch Med, Boston, MA USA. [Ascherio, A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Gunzler, D.; Eberly, S.; Oakes, D.] Univ Rochester, Rochester, NY USA. [Schwarzschild, M. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2011 VL 26 IS 5 BP III EP IV PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 762AT UT WOS:000290445400008 ER PT J AU Lieberman, DA Eberly, S Biglan, K Shoulson, I Oakes, D Ascherio, A Schwarzschild, MA AF Lieberman, D. A. Eberly, S. Biglan, K. Shoulson, I. Oakes, D. Ascherio, A. Schwarzschild, M. A. TI Serum urate and changes in the Unified Parkinson's Disease Rating Scale score in the CALM-PD trial SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 25th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinsons Disease and Other Movement Disorders CY MAY 13, 2011 CL Irving, TX C1 [Lieberman, D. A.; Ascherio, A.; Schwarzschild, M. A.] Harvard Univ, Sch Med, Boston, MA USA. [Eberly, S.; Biglan, K.; Shoulson, I.; Oakes, D.] Univ Rochester, Rochester, NY USA. [Ascherio, A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Schwarzschild, M. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2011 VL 26 IS 5 BP III EP III PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 762AT UT WOS:000290445400007 ER PT J AU Weintraub, D Mamikonyan, E Papay, K Shea, J Xie, S Siderowf, A AF Weintraub, D. Mamikonyan, E. Papay, K. Shea, J. Xie, S. Siderowf, A. TI Validity and reliability of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 25th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinsons Disease and Other Movement Disorders CY MAY 13, 2011 CL Irving, TX C1 [Weintraub, D.; Mamikonyan, E.; Papay, K.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, D.; Siderowf, A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, D.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr PADRECC, Philadelphia, PA USA. [Weintraub, D.] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. [Shea, J.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Shea, J.] Philadelphia Vet Affairs Med Ctr, CHERP, Philadelphia, PA USA. [Xie, S.] Univ Penn, Dept Biostat & Epidemiol, Sch Med Philadelphia, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2011 VL 26 IS 5 BP III EP III PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA 762AT UT WOS:000290445400006 ER PT J AU Peterson, A Quinn, J Woltjer, R AF Peterson, A. Quinn, J. Woltjer, R. TI Gluten Ataxia - Pathological Results of a Case of Rapidly Progressive Ataxia with Positive Anti-gliadin antibodies SO MOVEMENT DISORDERS LA English DT Meeting Abstract CT 25th Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinsons Disease and Other Movement Disorders CY MAY 13, 2011 CL Irving, TX C1 [Peterson, A.; Quinn, J.; Woltjer, R.] Oregon Hlth & Sci Univ OHSU Portland, Portland, OR USA. [Peterson, A.; Quinn, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2011 VL 26 IS 5 BP VIII EP IX PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 762AT UT WOS:000290445400024 ER PT J AU Mata, IF Yearout, D Alvarez, V Coto, E de Mena, L Ribacoba, R Lorenzo-Betancor, O Samaranch, L Pastor, P Cervantes, S Infante, J Garcia-Gorostiaga, I Sierra, M Combarros, O Snapinn, KW Edwards, KL Zabetian, CP AF Mata, Ignacio F. Yearout, Dora Alvarez, Victoria Coto, Eliecer de Mena, Lorena Ribacoba, Renee Lorenzo-Betancor, Oswaldo Samaranch, Lluis Pastor, Pau Cervantes, Sebastian Infante, Jon Garcia-Gorostiaga, Ines Sierra, Maria Combarros, Onofre Snapinn, Katherine W. Edwards, Karen L. Zabetian, Cyrus P. TI Replication of MAPT and SNCA, but not PARK16-18, as Susceptibility Genes for Parkinson's Disease SO MOVEMENT DISORDERS LA English DT Article DE Parkinson's disease; genome-wide; replication ID GENOME-WIDE ASSOCIATION; ALPHA-SYNUCLEIN; POPULATION STRATIFICATION; RISK-FACTORS; HLA REGION; VARIANTS; SNPS; LOCI; TAU AB Recent genome-wide association studies of Parkinson's disease have nominated 3 new susceptibility loci (PARK16-18) and confirmed 2 known risk genes (MAPT and SNCA) in populations of European ancestry. We sought to replicate these findings. We genotyped single-nucleotide polymorphisms in each of these genes/loci in 1445 Parkinson's disease patients and 1161 controls from northern Spain. Logistic regression was used to test for association between genotype and Parkinson's disease under an additive model, adjusting for sex, age, and site. We also performed analyses stratified by age at onset. Single-nucleotide polymorphisms in MAPT (rs1800547; P = 3.1 x 10(-4)) and SNCA (rs356219; P = 5.5 x 10(-4)) were significantly associated with Parkinson's disease. However, none of the markers in PARK16-18 associated with Parkin-son's disease in the overall sample, or in any age stratum, with P values ranging from .09 to .88. Although our data further validate MAPT and SNCA as Parkinson's disease susceptibility genes, we failed to replicate PARK16, PARK17, and PARK18. Potential reasons for the discordance between our study and previous genome-wide association studies include effects of population structure, power, and population-specific environmental interactions. Our findings suggest that additional studies of PARK16-18 are necessary to establish the role of these loci in modifying risk for Parkinson's disease in European-derived populations. (C) 2011 Movement Disorder Society C1 [Zabetian, Cyrus P.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, Seattle, WA 98108 USA. [Mata, Ignacio F.; Yearout, Dora; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Alvarez, Victoria; Coto, Eliecer; de Mena, Lorena] Hosp Univ Cent de Asturias, Lab Genet Mol, Inst Invest Nefrol IRSINFRIAT, Oviedo, Spain. [Ribacoba, Renee] Hosp Alvarez Buylla, Dept Neurol, Mieres, Spain. [Lorenzo-Betancor, Oswaldo; Samaranch, Lluis; Pastor, Pau; Cervantes, Sebastian] Univ Navarra, Ctr Appl Med Res, Div Neurosci, Neurogenet Lab, E-31080 Pamplona, Spain. [Lorenzo-Betancor, Oswaldo; Pastor, Pau; Cervantes, Sebastian] Univ Navarra, Sch Med, Clin Univ Navarra, Dept Neurol, E-31080 Pamplona, Spain. [Pastor, Pau] Inst Salud Carlos III, CIBERNED, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain. [Infante, Jon; Sierra, Maria; Combarros, Onofre] Marques de Valdecilla Univ Hosp, Dept Neurol, Santander, Spain. [Infante, Jon; Sierra, Maria; Combarros, Onofre] Marques de Valdecilla Univ Hosp, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Santander, Spain. [Garcia-Gorostiaga, Ines] Hosp Galdakao, Neurol Serv, Vizcaya, Spain. [Snapinn, Katherine W.; Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr S 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu RI Pastor, Pau/C-9834-2009; OI Pastor, Pau/0000-0002-7493-8777; Fernandez Mata, Ignacio/0000-0003-1198-0633; Zabetian, Cyrus/0000-0002-7739-4306 FU Department of Veterans Affairs [1I01BX000531]; National Institutes of Health [P50 NS062684, R01 NS065070]; Spanish Ministry of Education and Science [SAF2006-10126: 2006-2009]; Fondo de Investigacion Sanitaria (FIS) [PI070014]; Spanish Ministry of Science and Technology; European Social Fund; Asociacion Parkinson Asturias FX This work was supported by funding from the Department of Veterans Affairs (1I01BX000531), National Institutes of Health (P50 NS062684 and R01 NS065070), Spanish Ministry of Education and Science (SAF2006-10126: 2006-2009), Fondo de Investigacion Sanitaria (FIS, PI070014), Spanish Ministry of Science and Technology, European Social Fund, and the Asociacion Parkinson Asturias. NR 22 TC 41 Z9 43 U1 0 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0885-3185 J9 MOVEMENT DISORD JI Mov. Disord. PD APR PY 2011 VL 26 IS 5 BP 819 EP 823 DI 10.1002/mds.23642 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 762AT UT WOS:000290445400035 PM 21425343 ER PT J AU Cenik, C Chua, HN Zhang, H Tarnawsky, SP Akef, A Derti, A Tasan, M Moore, MJ Palazzo, AF Roth, FP AF Cenik, Can Chua, Hon Nian Zhang, Hui Tarnawsky, Stefan P. Akef, Abdalla Derti, Adnan Tasan, Murat Moore, Melissa J. Palazzo, Alexander F. Roth, Frederick P. TI Genome Analysis Reveals Interplay between 5 ' UTR Introns and Nuclear mRNA Export for Secretory and Mitochondrial Genes SO PLOS GENETICS LA English DT Article ID EXON JUNCTION COMPLEX; UNTRANSLATED REGIONS; PROTEIN; SEQUENCE; DATABASE; TRANSCRIPTION; LOCALIZATION; TRANSLATION; EXPRESSION; DECAY AB In higher eukaryotes, messenger RNAs (mRNAs) are exported from the nucleus to the cytoplasm via factors deposited near the 59 end of the transcript during splicing. The signal sequence coding region (SSCR) can support an alternative mRNA export (ALREX) pathway that does not require splicing. However, most SSCR-containing genes also have introns, so the interplay between these export mechanisms remains unclear. Here we support a model in which the furthest upstream element in a given transcript, be it an intron or an ALREX-promoting SSCR, dictates the mRNA export pathway used. We also experimentally demonstrate that nuclear-encoded mitochondrial genes can use the ALREX pathway. Thus, ALREX can also be supported by nucleotide signals within mitochondrial-targeting sequence coding regions (MSCRs). Finally, we identified and experimentally verified novel motifs associated with the ALREX pathway that are shared by both SSCRs and MSCRs. Our results show strong correlation between 5' untranslated region (5'UTR) intron presence/absence and sequence features at the beginning of the coding region. They also suggest that genes encoding secretory and mitochondrial proteins share a common regulatory mechanism at the level of mRNA export. C1 [Cenik, Can; Chua, Hon Nian; Derti, Adnan; Tasan, Murat; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Zhang, Hui; Tarnawsky, Stefan P.; Akef, Abdalla; Palazzo, Alexander F.] Univ Toronto, Dept Biochem, Toronto, ON, Canada. [Moore, Melissa J.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA. [Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. [Roth, Frederick P.] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada. [Roth, Frederick P.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. RP Cenik, C (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. EM alex.palazzo@utoronto.ca; fritz_roth@hms.harvard.edu RI Palazzo, Alexander/B-1270-2013; Roth, Frederick/H-6308-2011; OI Palazzo, Alexander/0000-0002-9700-1995; Cenik, Can/0000-0001-6370-0889; Roth, Frederick/0000-0002-6628-649X FU Canadian Institute for Health Research [FRN 102725]; National Institutes of Health [HG003224, HG001715, HL081341, NS035611, MH087394, HG004233]; Canada Excellence Research Chairs program; Canadian Institute for Advanced Research FX MJM is an HHMI Investigator. AFP was supported by a grant from the Canadian Institute for Health Research (FRN 102725). FPR was supported in part by the National Institutes of Health (grants HG003224, HG001715, HL081341, NS035611, MH087394, and HG004233), by the Canada Excellence Research Chairs program, and by the Canadian Institute for Advanced Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 29 Z9 30 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1001366 DI 10.1371/journal.pgen.1001366 PG 14 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000021 PM 21533221 ER PT J AU Fogelgren, B Lin, SY Zuo, XF Jaffe, KM Park, KM Reichert, RJ Bell, PD Burdine, RD Lipschutz, JH AF Fogelgren, Ben Lin, Shin-Yi Zuo, Xiaofeng Jaffe, Kimberly M. Park, Kwon Moo Reichert, Ryan J. Bell, P. Darwin Burdine, Rebecca D. Lipschutz, Joshua H. TI The Exocyst Protein Sec10 Interacts with Polycystin-2 and Knockdown Causes PKD-Phenotypes SO PLOS GENETICS LA English DT Article ID LEFT-RIGHT AXIS; REGULATED KINASE PATHWAY; CYST EPITHELIAL-CELLS; KIDNEY-DISEASE; INTRAFLAGELLAR TRANSPORT; PRIMARY CILIUM; KUPFFERS VESICLE; COLLECTING DUCT; CATION CHANNEL; MDCK CELLS AB Autosomal dominant polycystic kidney disease (ADPKD) is characterized by formation of renal cysts that destroy the kidney. Mutations in PKD1 and PKD2, encoding polycystins-1 and -2, cause ADPKD. Polycystins are thought to function in primary cilia, but it is not well understood how these and other proteins are targeted to cilia. Here, we provide the first genetic and biochemical link between polycystins and the exocyst, a highly-conserved eight-protein membrane trafficking complex. We show that knockdown of exocyst component Sec10 yields cellular phenotypes associated with ADPKD, including loss of flow-generated calcium increases, hyperproliferation, and abnormal activation of MAPK. Sec10 knockdown in zebrafish phenocopies many aspects of polycystin-2 knockdown-including curly tail up, left-right patterning defects, glomerular expansion, and MAPK activation-suggesting that the exocyst is required for pkd2 function in vivo. We observe a synergistic genetic interaction between zebrafish sec10 and pkd2 for many of these cilia-related phenotypes. Importantly, we demonstrate a biochemical interaction between Sec10 and the ciliary proteins polycystin-2, IFT88, and IFT20 and co-localization of the exocyst and polycystin-2 at the primary cilium. Our work supports a model in which the exocyst is required for the ciliary localization of polycystin-2, thus allowing for polycystin-2 function in cellular processes. C1 [Fogelgren, Ben; Zuo, Xiaofeng; Park, Kwon Moo; Lipschutz, Joshua H.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Lin, Shin-Yi; Jaffe, Kimberly M.; Burdine, Rebecca D.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA. [Park, Kwon Moo] Kyungpook Natl Univ, Dept Anat, Taegu, South Korea. [Park, Kwon Moo] Kyungpook Natl Univ, Project BK 21, Taegu, South Korea. [Reichert, Ryan J.; Bell, P. Darwin] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. RP Fogelgren, B (reprint author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA. EM jhlipsch@mail.med.upenn.edu OI Burdine, Rebecca/0000-0001-6620-5015 FU National Institutes of Health [DK069909, DK070980, 1RO1HD048584, KO1 DK087852]; Satellite Healthcare FX The authors and this work were supported by the National Institutes of Health (DK069909 and DK070980 to JHL, 1RO1HD048584 to RDB, and KO1 DK087852 to BF) and Satellite Healthcare (Norman S. Coplon Extramural Research Grant to JHL, URL: http://www.satellitehealth.com/pdf/Coplon_Grant_2011.pdf The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 70 TC 28 Z9 29 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1001361 DI 10.1371/journal.pgen.1001361 PG 17 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000043 PM 21490950 ER PT J AU Maruyama, R Choudhury, S Kowalczyk, A Bessarabova, M Beresford-Smith, B Conway, T Kaspi, A Wu, ZH Nikolskaya, T Merino, VF Lo, PK Liu, XS Nikolsky, Y Sukumar, S Haviv, I Polyak, K AF Maruyama, Reo Choudhury, Sibgat Kowalczyk, Adam Bessarabova, Marina Beresford-Smith, Bryan Conway, Thomas Kaspi, Antony Wu, Zhenhua Nikolskaya, Tatiana Merino, Vanessa F. Lo, Pang-Kuo Liu, X. Shirley Nikolsky, Yuri Sukumar, Saraswati Haviv, Izhak Polyak, Kornelia TI Epigenetic Regulation of Cell Type-Specific Expression Patterns in the Human Mammary Epithelium SO PLOS GENETICS LA English DT Article ID STEM-CELLS; DNA METHYLATION; HUMAN BREAST; FUNCTIONAL-ANALYSIS; DIFFERENTIATION; GLAND; PROGENITORS; PLURIPOTENT; ACQUISITION; POPULATION AB Differentiation is an epigenetic program that involves the gradual loss of pluripotency and acquisition of cell type-specific features. Understanding these processes requires genome-wide analysis of epigenetic and gene expression profiles, which have been challenging in primary tissue samples due to limited numbers of cells available. Here we describe the application of high-throughput sequencing technology for profiling histone and DNA methylation, as well as gene expression patterns of normal human mammary progenitor-enriched and luminal lineage-committed cells. We observed significant differences in histone H3 lysine 27 tri-methylation (H3K27me3) enrichment and DNA methylation of genes expressed in a cell type-specific manner, suggesting their regulation by epigenetic mechanisms and a dynamic interplay between the two processes that together define developmental potential. The technologies we developed and the epigenetically regulated genes we identified will accelerate the characterization of primary cell epigenomes and the dissection of human mammary epithelial lineage-commitment and luminal differentiation. C1 [Maruyama, Reo; Choudhury, Sibgat; Polyak, Kornelia] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Maruyama, Reo; Choudhury, Sibgat; Polyak, Kornelia] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Maruyama, Reo; Choudhury, Sibgat; Polyak, Kornelia] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Kowalczyk, Adam; Beresford-Smith, Bryan] Univ Melbourne, NICTA Victoria Res Lab, Melbourne, Vic, Australia. [Kowalczyk, Adam; Beresford-Smith, Bryan; Conway, Thomas] Univ Melbourne, Dept Elect & Elect Engn, Melbourne, Vic, Australia. [Bessarabova, Marina; Nikolskaya, Tatiana; Nikolsky, Yuri] Thomson Reuters, Healthcare & Sci, Encinitas, CA USA. [Conway, Thomas] Univ Melbourne, Dept Comp Sci & Software Engn, Melbourne, Vic, Australia. [Kaspi, Antony; Haviv, Izhak] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia. [Wu, Zhenhua] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Wu, Zhenhua; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Merino, Vanessa F.; Lo, Pang-Kuo; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA. [Haviv, Izhak] Univ Melbourne, Dept Biochem, Melbourne, Vic, Australia. [Haviv, Izhak] Peter MacCallum Canc Ctr, Metastasis Res Lab, Melbourne, Vic, Australia. [Polyak, Kornelia] Harvard Stem Cell Inst, Cambridge, MA USA. RP Maruyama, R (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM Kornelia_Polyak@dfci.harvard.edu RI Nikolskaya, Tatiana/M-5008-2013 FU National Cancer Institute [P50-CA89393, P01-CA080111]; US Army [W81XWH-07-1-0294]; Breast Cancer Research Foundation; Susan G. Komen Foundation; Terri Brodeur Breast Cancer Foundation; Avon Research Foundation FX This work was supported by the National Cancer Institute (P50-CA89393 and P01-CA080111), US Army (W81XWH-07-1-0294), and Breast Cancer Research Foundation grants awarded to KP; Susan G. Komen Foundation Fellowships awarded to RM; Terri Brodeur Breast Cancer Foundation Fellowship awarded to SC; and Avon Research Foundation grant awarded to KP and SS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 38 TC 48 Z9 49 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1001369 DI 10.1371/journal.pgen.1001369 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000016 PM 21533021 ER PT J AU Myre, MA Lumsden, AL Thompson, MN Wasco, W MacDonald, ME Gusella, JF AF Myre, Michael A. Lumsden, Amanda L. Thompson, Morgan N. Wasco, Wilma MacDonald, Marcy E. Gusella, James F. TI Deficiency of Huntingtin Has Pleiotropic Effects in the Social Amoeba Dictyostelium discoideum SO PLOS GENETICS LA English DT Article ID DISEASE GENE HOMOLOG; CELL-CELL ADHESION; ADENYLYL-CYCLASE-G; CONTRACTILE VACUOLE; EMBRYONIC LETHALITY; SIGNAL-TRANSDUCTION; MOLECULAR-GENETICS; CONTACT SITES; PSI-BLAST; PROTEIN AB Huntingtin is a large HEAT repeat protein first identified in humans, where a polyglutamine tract expansion near the amino terminus causes a gain-of-function mechanism that leads to selective neuronal loss in Huntington's disease (HD). Genetic evidence in humans and knock-in mouse models suggests that this gain-of-function involves an increase or deregulation of some aspect of huntingtin's normal function(s), which remains poorly understood. As huntingtin shows evolutionary conservation, a powerful approach to discovering its normal biochemical role(s) is to study the effects caused by its deficiency in a model organism with a short life-cycle that comprises both cellular and multicellular developmental stages. To facilitate studies aimed at detailed knowledge of huntingtin's normal function(s), we generated a null mutant of hd, the HD ortholog in Dictyostelium discoideum. Dictyostelium cells lacking endogenous huntingtin were viable but during development did not exhibit the typical polarized morphology of Dictyostelium cells, streamed poorly to form aggregates by accretion rather than chemotaxis, showed disorganized F-actin staining, exhibited extreme sensitivity to hypoosmotic stress, and failed to form EDTA-resistant cell-cell contacts. Surprisingly, chemotactic streaming could be rescued in the presence of the bivalent cations Ca(2+) or Mg(2+) but not pulses of cAMP. Although hd(-) cells completed development, it was delayed and proceeded asynchronously, producing small fruiting bodies with round, defective spores that germinated spontaneously within a glassy sorus. When developed as chimeras with wild-type cells, hd(-) cells failed to populate the prespore region of the slug. In Dictyostelium, huntingtin deficiency is compatible with survival of the organism but renders cells sensitive to low osmolarity, which produces pleiotropic cell autonomous defects that affect cAMP signaling and as a consequence development. Thus, Dictyostelium provides a novel haploid organism model for genetic, cell biological, and biochemical studies to delineate the functions of the HD protein. C1 [Myre, Michael A.; Lumsden, Amanda L.; Thompson, Morgan N.; MacDonald, Marcy E.; Gusella, James F.] Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [Wasco, Wilma] Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Genet & Aging Res Unit, Charlestown, MA USA. RP Myre, MA (reprint author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. EM myre@chgr.mgh.harvard.edu FU Massachusetts HD Center Without Walls [NINDS NS032765, NS016367]; Huntington's Disease Society of America Coalition for the Cure; CHDI Foundation; Hereditary Disease Foundation FX This study was funded by grants NINDS NS032765, Massachusetts HD Center Without Walls NS016367, Huntington's Disease Society of America Coalition for the Cure, and the CHDI Foundation. ALL received a fellowship from the Hereditary Disease Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 72 TC 20 Z9 20 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7390 J9 PLOS GENET JI PLoS Genet. PD APR PY 2011 VL 7 IS 4 AR e1002052 DI 10.1371/journal.pgen.1002052 PG 17 WC Genetics & Heredity SC Genetics & Heredity GA 755YI UT WOS:000289977000010 PM 21552328 ER PT J AU Schoenfeld, AJ Harris, MB McGuire, KJ Warholic, N Wood, KB Bono, CM AF Schoenfeld, Andrew J. Harris, Mitchel B. McGuire, Kevin J. Warholic, Natalie Wood, Kirkham B. Bono, Christopher M. TI Mortality in elderly patients with hyperostotic disease of the cervical spine after fracture: an age- and sex-matched study SO SPINE JOURNAL LA English DT Article DE Ankylosing spondylitis; Diffuse idiopathic skeletal hyperostosis; Cervical spine trauma; Elderly; Mortality ID IDIOPATHIC SKELETAL HYPEROSTOSIS; ANKYLOSING-SPONDYLITIS; CORD-INJURY; COMPLICATIONS; MANAGEMENT; TRAUMA AB BACKGROUND CONTEXT: Several reports indicate that patients with ankylosing spondylitis (AS) and diffuse idiopathic skeletal hyperostosis (DISH) have increased mortality after cervical spine fractures. However, outcomes of the fractured hyperostotic cervical spine are incompletely described, and there are limited data regarding the covariable effects of patient age and medical comorbidities on mortality. PURPOSE: To determine mortality associated with cervical fractures in patients with hyperostotic disease. STUDY DESIGN: Retrospective case-control study. PATIENT SAMPLE: Forty-three patients identified through a registry as having fractures of the cervical spine in the setting of hyperostotic disease. These patients were matched to 43 controls who did not carry the diagnosis of hyperostotic disease. OUTCOME MEASURES: Mortality at 3 months and 1, 2, and 3 years after fracture. METHODS: An institutional database was used to identify all cervical fractures sustained by patients aged 65 years and older from 1991 to 2006. Demographic information, date of injury, associated injuries, treatment type, presence of AS or DISH, and comorbidities were abstracted from medical records and radiographs. Mortality was ascertained using the National Death Index. Patients with AS or DISH were matched to controls who did not carry the diagnosis of hyperostotic disease. Risks of mortality were calculated at 3 months, 1 year, 2 years, and 3 years. Kaplan-Meier methods, logistic regression analysis, the two independent sample t test, and the Fisher exact test were used to compare mortalities between the two groups. Statistical significance was determined as p values <.05. RESULTS: Forty-three patients were identified as having fractures in the setting of hyperostotic disease of the cervical spine. Twenty-seven individuals had DISH, and 16 had AS. The average age of both the study group and controls was 80 years, with an age range of 68 to 94. There was no significantly increased risk of mortality between the overall study group and control group at 3 months (p=.20), 1 (p=.22), 2 (p=.15), or 3 years (p=.50) after injury. Compared with controls, subgroup analysis of patients with AS showed a statistically increased risk of mortality at 3 months (p<.01) and at 1 and 2 years (p<.01 at both time points). When compared with individuals with DISH, those with AS had an increased risk of mortality at time points up to 2 years after fracture. Patients with DISH did not have an increased mortality risk at any time point when compared with controls. CONCLUSIONS: The effect of fracture on mortality appears to be greatest in those with AS. Patients with DISH did not demonstrate an increased risk of mortality compared with age- and sex-matched controls. Future studies of patients with hyperostotic disease should analyze patients with DISH and AS separately instead of as a single homogenous group. LEVEL OF EVIDENCE: Level IV. Published by Elsevier Inc. C1 [Schoenfeld, Andrew J.] Texas Tech Univ, Hlth Sci Ctr, William Beaumont Army Med Ctr, Dept Orthopaed Surg, El Paso, TX 79920 USA. [Harris, Mitchel B.; Bono, Christopher M.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Brigham & Womens Hosp, Boston, MA 02115 USA. [McGuire, Kevin J.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Wood, Kirkham B.] Harvard Univ, Sch Med, Dept Orthopaed Surg, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Schoenfeld, AJ (reprint author), Texas Tech Univ, Hlth Sci Ctr, William Beaumont Army Med Ctr, Dept Orthopaed Surg, 5005 N Piedras St, El Paso, TX 79920 USA. EM ajschoen@neoucom.edu OI Schoenfeld, Andrew/0000-0002-3691-1215 FU Archus Orthopedics; Synthes Spine; Stryker Spine; DePuy Spine; EBI; NASS; Medtronic; Scoliosis Research Society FX Author disclosures: CMB (royalties, Life Spine; consulting, DePuy Spine, Medtronic Sofamor Danek; speaking/teaching arrangements, DePuy Spine, Stryker Spine; board of directors, North American Spine Society; other office, Applied Spine; research support: staff/materials, Archus Orthopedics, Synthes Spine; grants, Stryker Spine; fellowship support, DePuy Spine); KJM (consulting, Globus Medical; fellowship support, EBI); KBW (stock ownership, including options and warrants, TranS1; scientific advisory board, United HealthCare; research support: investigator salary, NASS; research support: staff/materials, Medtronic; grants, Scoliosis Research Society; fellowship support, DePuy Spine); MBH (speaking/teaching arrangements, AO Spine; research support: staff/materials, Synthes Spine; fellowship support, Synthes Spine). NR 23 TC 10 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1529-9430 J9 SPINE J JI Spine Journal PD APR PY 2011 VL 11 IS 4 BP 257 EP 264 DI 10.1016/j.spinee.2011.01.018 PG 8 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA 761KI UT WOS:000290396300004 PM 21377938 ER PT J AU Elnahal, SM Joynt, KE Bristol, SJ Jha, AK AF Elnahal, Shereef M. Joynt, Karen E. Bristol, Steffanie J. Jha, Ashish K. TI Electronic Health Record Functions Differ Between Best and Worst Hospitals SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID PHYSICIAN ORDER ENTRY; INFORMATION-TECHNOLOGY; COSTS; INTERVENTION; EFFICIENCY; QUALITY; CARE AB Objective: To determine whether patterns of electronic health record (EHR) adoption and "meaningful use" vary between high-, intermediate-, and low-quality US hospitals. Study Design: We used data from the Hospital Quality Alliance program to designate hospitals as high quality (performance in the top decile nationally), low quality (bottom decile), and intermediate quality (all others). We examined EHR adoption and meaningful use using national survey data. Methods: We used logistic regression models to determine the frequency with which hospitals in each group adopted individual EHR functions and met meaningful use criteria, and factor analyses to examine adoption patterns in high-and low-quality hospitals. Results: High-quality hospitals were more likely to have all clinical decision support functions. High-quality hospitals were also more likely to have computerized physician order entry for medications compared with intermediate-and low-quality hospitals. Among those who had not yet implemented components of clinical decision support, two-thirds of low-quality hospitals reported no concrete plans for adoption. Finally, high-quality hospitals were more likely to meet many of the meaningful use criteria such as reporting quality measures, implementing at least 1 clinical decision support rule, and exchanging key clinical data. Conclusions: We found higher rates of adoption of key EHR functions among high-quality hospitals, suggesting that high quality and EHR adoption may be linked. Most low-quality hospitals without EHR functions reported no plans to implement them, pointing to challenges faced by policy makers in achieving widespread EHR adoption while simultaneously improving quality of care. (Am J Manag Care. 2011;17(4):e121-e147) C1 [Joynt, Karen E.; Bristol, Steffanie J.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Elnahal, Shereef M.] Harvard Univ, Sch Med, Boston, MA USA. [Joynt, Karen E.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [Jha, Ashish K.] VA Boston Healthcare Syst, Boston, MA USA. RP Jha, AK (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA. EM ajha@hsph.harvard.edu FU NIH [T32HL007604-24]; Brigham and Women's Hospital, Division of Cardiovascular Medicine FX Funding Source: Dr Joynt was supported by NIH Training Grant T32HL007604-24, Brigham and Women's Hospital, Division of Cardiovascular Medicine. NR 12 TC 11 Z9 11 U1 0 U2 7 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 2011 VL 17 IS 4 BP E121 EP 147 PG 27 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 755XS UT WOS:000289974300004 PM 21774097 ER PT J AU Magid, DJ Ho, PM Olson, KL Brand, DW Welch, LK Snow, KE Lambert-Kerzner, AC Plomondon, ME Havranek, EP AF Magid, David J. Ho, P. Michael Olson, Kari L. Brand, David W. Welch, Lesley K. Snow, Karen E. Lambert-Kerzner, Anne C. Plomondon, Mary E. Havranek, Edward P. TI A Multimodal Blood Pressure Control Intervention in 3 Healthcare Systems SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RANDOMIZED-TRIAL; HYPERTENSION CONTROL; MANAGEMENT; PREVENTION; PHARMACIST; DISEASE AB Objective: To determine if a multimodal intervention composed of patient education, home blood pressure (BP) monitoring, BP measurement reporting to an interactive voice response (IVR) phone system, and clinical pharmacist follow-up improves BP control compared with usual care. Study Design: Prospective study with patient enrollment, medication consultation and adjustment, remote BP monitoring, and follow-up at 6 months. Methods: This randomized controlled trial was conducted at 3 healthcare systems in Denver, Colorado, including a large health maintenance organization, a Veterans Affairs medical center, and a county hospital. At each site, patients with uncontrolled BP were randomized to the multimodal intervention vs usual care for 6 months, with the primary end point of BP reduction. Results: Of 338 patients randomized, 283 (84%) completed the study, including 138 intervention patients and 145 usual care patients. Baseline BP was higher in the intervention group vs the usual care group (150.5/89.4 vs 143.8/85.3 mm Hg). At 6 months, BPs were similar in the intervention group vs the usual care group (137.4 vs 136.7 mm Hg, P = .85 for systolic; 82.9 vs 81.1 mm Hg, P = .14 for diastolic). However, BP reductions were greater in the intervention group vs the usual care group (-13.1 vs -7.1 mm Hg, P = .006 for systolic; -6.5 vs -4.2 mm Hg, P = .07 for diastolic). Adherence to medications was similar between the 2 groups, but intervention patients had a greater increase in medication regimen intensity. Conclusions: A multimodal intervention of patient education, home BP monitoring, BP measurement reporting to an IVR system, and clinical pharmacist follow-up achieved greater reductions in BP compared with usual care. (Am J Manag Care. 2011;17(4):e96-e103) C1 [Magid, David J.; Brand, David W.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO 80231 USA. [Ho, P. Michael; Lambert-Kerzner, Anne C.; Plomondon, Mary E.] Denver Vet Affairs Med Ctr, Div Cardiol, Denver, CO USA. [Olson, Kari L.] Kaiser Permanente Colorado, Dept Pharm, Denver, CO 80231 USA. [Welch, Lesley K.] Denver Vet Affairs Med Ctr, Dept Pharm, Denver, CO USA. [Snow, Karen E.] Denver Hlth Med Ctr, Dept Pharm, Denver, CO USA. [Magid, David J.; Ho, P. Michael; Olson, Kari L.; Havranek, Edward P.] Univ Colorado Denver, Aurora, CO USA. [Havranek, Edward P.] Denver Hlth Med Ctr, Div Cardiol, Denver, CO USA. RP Magid, DJ (reprint author), Kaiser Permanente Colorado, Inst Hlth Res, 10065 E Harvard Ave,Ste 300, Denver, CO 80231 USA. EM david.j.magid@kp.org FU American Heart Association [0535086N]; Colorado Department of Public Health and Environment [99]; Veterans Affairs Research and Development Career Development Award [05-026-2] FX Funding Source: This work was funded in part by grant 0535086N from the American Heart Association and by grant CCPD#99 from the Colorado Department of Public Health and Environment. Dr Ho is supported by Veterans Affairs Research and Development Career Development Award 05-026-2. The funders had no involvement in the design or conduct of the study or in the collection, management, analysis, or interpretation of the data. NR 16 TC 33 Z9 35 U1 0 U2 2 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD APR PY 2011 VL 17 IS 4 BP E96 EP E103 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 755XS UT WOS:000289974300002 PM 21774100 ER PT J AU Jayadev, S Nochlin, D Poorkaj, P Steinbart, EJ Mastrianni, JA Montine, TJ Ghetti, B Schellenberg, GD Bird, TD Leverenz, JB AF Jayadev, Suman Nochlin, David Poorkaj, Parvoneh Steinbart, Ellen J. Mastrianni, James A. Montine, Thomas J. Ghetti, Bernardino Schellenberg, Gerard D. Bird, Thomas D. Leverenz, James B. TI Familial Prion Disease with Alzheimer Disease-Like Tau Pathology and Clinical Phenotype SO ANNALS OF NEUROLOGY LA English DT Article ID STRAUSSLER-SCHEINKER-DISEASE; CREUTZFELDT-JAKOB-DISEASE; NEUROFIBRILLARY TANGLES; AMYLOID DEPOSITS; PROTEIN; DEMENTIA; PRNP; MUTATIONS; COMPONENT; INDIANA AB Objective: To describe the Alzheimer disease (AD)-like clinical and pathological features, including marked neurofibrillary tangle (NFT) pathology, of a familial prion disease due to a rare nonsense mutation of the prion gene (PRNP). Methods: Longitudinal clinical assessments were available for the proband and her mother. After death, both underwent neuropathological evaluation. PRNP was sequenced after failure to find immunopositive A beta deposits in the proband and the documentation of prion protein (PrP) immunopositive pathology. Results: The proband presented at age 42 years with a 3-year history of progressive short-term memory impairment and depression. Neuropsychological testing found impaired memory performance, with relatively preserved attention and construction. She was diagnosed with AD and died at age 47 years. Neuropathologic evaluation revealed extensive limbic and neocortical NFT formation and neuritic plaques consistent with a Braak stage of VI. The NFTs were immunopositive, with multiple tau antibodies, and electron microscopy revealed paired helical filaments. However, the neuritic plaques were immunonegative for A beta, whereas immunostaining for PrP was positive. The mother of the proband had a similar presentation, including depression, and had been diagnosed clinically and pathologically as AD. Reevaluation of her brain tissue confirmed similar tau and PrP immunostaining findings. Genetic analysis revealed that both the proband and her mother had a rare PRNP mutation (Q160X) that resulted in the production of truncated PrP. Interpretation: We suggest that PRNP mutations that result in a truncation of PrP lead to a prolonged clinical course consistent with a clinical diagnosis of AD and severe AD-like NFTs. ANN NEUROL 2011; 69: 712-720 C1 [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Mental Illness Clin & Educ Ctr, Seattle Div, Seattle, WA 98108 USA. [Leverenz, James B.] VA Puget Sound Hlth Care Syst, Parkinsons Dis Clin & Educ Ctr, Seattle Div, Seattle, WA 98108 USA. [Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Jayadev, Suman; Bird, Thomas D.; Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Nochlin, David] JFK Med Ctr, New Jersey Neurosci Inst, Edison, NJ USA. [Poorkaj, Parvoneh; Steinbart, Ellen J.; Bird, Thomas D.] VA Puget Sound Hlth Care Syst, Geriatr Res Clin & Educ Ctr, Seattle Div, Seattle, WA 98108 USA. [Mastrianni, James A.] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA. [Montine, Thomas J.] Univ Washington, Dept Pathol Neuropathol, Seattle, WA 98195 USA. [Ghetti, Bernardino] Indiana Univ Sch Med, Indiana Alzheimer Dis Ctr, Indianapolis, IN USA. [Ghetti, Bernardino] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA. [Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Bird, Thomas D.] Univ Washington, Dept Med, Seattle, WA USA. RP Leverenz, JB (reprint author), VA Puget Sound Hlth Care Syst, Mental Illness Clin & Educ Ctr, Seattle Div, GRECC 182,1660 S Columbian Way, Seattle, WA 98108 USA. EM leverenz@u.washington.edu FU US Department of Veterans Affairs, Office of Research and Development; National Institutes of Health (NIH)/National Institute on Aging (NIA) [2P50AG005136-27, 5P50NS062684-02, 5R01NS051480-05, 5P30AG010133-20]; Athena Diagnostics FX This work supported in part by the US Department of Veterans Affairs, Office of Research and Development Clinical R&D Program, and National Institutes of Health (NIH)/National Institute on Aging (NIA) 2P50AG005136-27, 5P50NS062684-02, 5R01NS051480-05, 5P30AG010133-20. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIA or the NIH.; T.D.B. has received speaking fees and royalties from Athena Diagnostics. NR 23 TC 36 Z9 37 U1 1 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 2011 VL 69 IS 4 BP 712 EP 720 DI 10.1002/ana.22264 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 758HV UT WOS:000290155800017 PM 21416485 ER PT J AU Yang, C Choy, E Hornicek, FJ Wood, KB Schwab, JH Liu, XZ Mankin, H Duan, ZF AF Yang, Cao Choy, Edwin Hornicek, Francis J. Wood, Kirkham B. Schwab, Joseph H. Liu, Xianzhe Mankin, Henry Duan, Zhenfeng TI Histone Deacetylase Inhibitor PCI-24781 Enhances Chemotherapy-induced Apoptosis in Multidrug-resistant Sarcoma Cell Lines SO ANTICANCER RESEARCH LA English DT Article DE Histone deacetylase inhibitor; chemotherapy; multidrug resistant; sarcoma; PCI-24781 ID SUBEROYLANILIDE HYDROXAMIC ACID; SOFT-TISSUE SARCOMA; HUMAN RAD51 PROTEIN; HDAC INHIBITORS; CANCER-CELLS; IN-VITRO; EXPRESSION; OSTEOSARCOMA; ACTIVATION; MECHANISMS AB The antitumor activity of histone deacetylase inhibitors (HDACI) on multidrug-resistant sarcoma cell lines has not been previously described. Treatment of multidrug-resistant sarcoma cell lines with HDACI PCI-24781 resulted in dose-dependent accumulation of acetylated histone, p21 and poly(ADP-ribose)polymerase (PARP) cleavage products. Growth of these cell lines was inhibited by PCI-24781 at IC(50) of 0.43 to 2.7. When we looked for synergy of PCI-24781 with chemotherapeutic agents, we found that PCI-24781 reverses drug resistance in all four multidrug-resistant sarcoma cell lines and synergizes with chemotherapeutic agents to enhance caspase-3/-7 activity. Expression of RAD51 (a marker for DNA double-strand break repair) was inhibited and the expression of GADD45 alpha (a marker for growth arrest and DNA-damage) was induced by PCI-24781 in multidrug-resistant sarcoma cell lines. In conclusion, HDACI PCI-24781 synergizes with chemotherapeutic drugs to induce apoptosis and reverses drug resistance in multidrug-resistant sarcoma cell lines. C1 [Yang, Cao; Liu, Xianzhe] Huazhong Univ Sci & Technol, Dept Orthopaed Surg, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China. [Yang, Cao; Hornicek, Francis J.; Wood, Kirkham B.; Schwab, Joseph H.; Liu, Xianzhe; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Yang, Cao; Choy, Edwin; Hornicek, Francis J.; Schwab, Joseph H.; Liu, Xianzhe; Mankin, Henry; Duan, Zhenfeng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA. [Choy, Edwin] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Choy, Edwin] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Yang, C (reprint author), Huazhong Univ Sci & Technol, Dept Orthopaed Surg, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China. EM yangcaom@gmail.com FU Gattegno and Wechsler Funds; Kenneth Stanton Fund; Sarcoma Foundation of America; National Cancer Institute, NIH [R01-CA119617]; Harvard Catalyst, The Harvard Clinical and Translational Science Center [UL1 RR 025758]; Jennifer Hunter Yates Sarcoma Foundation FX This project was supported by a grant from the Gattegno and Wechsler Funds. Support has also been provided by the Kenneth Stanton Fund. Dr. Duan is supported, in part, through a grant from Sarcoma Foundation of America, and a grant from the National Cancer Institute, NIH (Nanotechnology Platform Partnership), R01-CA119617. Dr. Choy is supported by the Harvard Catalyst, The Harvard Clinical and Translational Science Center (award #UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic heatlh care centers) and the Jennifer Hunter Yates Sarcoma Foundation. NR 42 TC 15 Z9 17 U1 0 U2 3 PU INT INST ANTICANCER RESEARCH PI ATHENS PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE SN 0250-7005 J9 ANTICANCER RES JI Anticancer Res. PD APR PY 2011 VL 31 IS 4 BP 1115 EP 1123 PG 9 WC Oncology SC Oncology GA 760AC UT WOS:000290292000003 PM 21508354 ER PT J AU Polley, KH Navarro, R Avery, DH George, MS Holtzheimer, PE AF Polley, Kurt H. Navarro, Rita Avery, David H. George, Mark S. Holtzheimer, Paul E. TI 2010 Updated Avery-George-Holtzheimer Database of rTMS depression studies SO BRAIN STIMULATION LA English DT Editorial Material C1 [Polley, Kurt H.; George, Mark S.] Med Univ S Carolina, Brain Stimulat Lab, Charleston, SC 29425 USA. [Navarro, Rita; Avery, David H.] Univ Washington, Harborview Med Ctr, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Holtzheimer, Paul E.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA. RP George, MS (reprint author), Med Univ S Carolina, Brain Stimulat Lab, 67 President St, Charleston, SC 29425 USA. EM georgem@musc.edu RI Holtzheimer, Paul/B-6212-2015 OI Holtzheimer, Paul/0000-0002-3552-3296 NR 0 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X J9 BRAIN STIMUL JI Brain Stimul. PD APR PY 2011 VL 4 IS 2 BP 115 EP 116 DI 10.1016/j.brs.2010.09.001 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 758TZ UT WOS:000290191100009 PM 21511213 ER PT J AU Harford, JB Otero, IV Anderson, BO Cazap, E Gradishar, WJ Gralow, JR Kane, GM Niens, LM Porter, PL Reeler, AV Rieger, PT Shockney, LD Shulman, LN Soldak, T Thomas, DB Thompson, B Winchester, DP Zelle, SG Badwe, RA AF Harford, Joe B. Otero, Isabel V. Anderson, Benjamin O. Cazap, Eduardo Gradishar, William J. Gralow, Julie R. Kane, Gabrielle M. Niens, Laurens M. Porter, Peggy L. Reeler, Anne V. Rieger, Paula T. Shockney, Lillie D. Shulman, Lawrence N. Soldak, Tanya Thomas, David B. Thompson, Beti Winchester, David P. Zelle, Sten G. Badwe, Rajendra A. TI Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative SO BREAST LA English DT Article DE Implementation science; Cost-effectiveness research; Situational analysis; Mortality-to-incidence ratio; Patient navigation; Advocacy ID REDUCE CANCER DISPARITIES; INCOME COUNTRIES; GUIDELINE IMPLEMENTATION; 5 CONTINENTS; MORTALITY; ERADICATION; ALLOCATION; POLICIES; SCIENCE; DISEASE AB International collaborations like the Breast Health Global Initiative (BHGI) can help low and middle income countries (LMCs) to establish or improve breast cancer control programs by providing evidence-based, resource-stratified guidelines for the management and control of breast cancer. The Problem Solving Working Group of the BHGI 2010 Global Summit met to develop a consensus statement on problem-solving strategies addressing breast cancer in LMCs. To better assess breast cancer burden in poorly studied populations, countries require accurate statistics regarding breast cancer incidence and mortality. To better identify health care system strengths and weaknesses, countries require reasonable indicators of true health system quality and capacity. Using qualitative and quantitative research methods, countries should formulate cancer control strategies to identify both system inefficiencies and patient barriers. Patient navigation programs linked to public advocacy efforts feed and strengthen functional early detection and treatment programs. Cost-effectiveness research and implementation science are tools that can guide and expand successful pilot programs. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Anderson, Benjamin O.] Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Seattle, WA 98195 USA. [Harford, Joe B.; Otero, Isabel V.] NCI, Off Int Affairs, NIH, Bethesda, MD 20892 USA. [Cazap, Eduardo] SLACOM Soc Latinoamer & Caribe Oncol Med, Buenos Aires, DF, Argentina. [Gradishar, William J.] Northwestern Univ, Feinberg Sch Med, NW Mem Hosp, Evanston, IL USA. [Gralow, Julie R.] Seattle Canc Care Alliance, Seattle, WA USA. [Anderson, Benjamin O.; Gralow, Julie R.; Kane, Gabrielle M.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Niens, Laurens M.] Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands. [Reeler, Anne V.] Axios Int, Paris, France. [Rieger, Paula T.] Oncol Nursing Soc, Pittsburgh, PA USA. [Shockney, Lillie D.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA. [Shulman, Lawrence N.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Soldak, Tanya] Resource & Policy Exchange, Delhi, NY USA. [Thomas, David B.] Amer Coll Surg, Natl Accreditat Program Breast Ctr, Chicago, IL USA. [Zelle, Sten G.] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands. [Badwe, Rajendra A.] Tata Mem Hosp, Dept Surg, Bombay 400012, Maharashtra, India. RP Anderson, BO (reprint author), Univ Washington, Fred Hutchinson Canc Res Ctr, Breast Hlth Global Initiat, Box 356410, Seattle, WA 98195 USA. EM banderso@u.washington.edu FU Breast Health Global Initiative (BHGI); Bayer Schering Pharma; Breast Cancer Research Foundation (BCRF); ASCO; UICC; ESMO; BCRF; Genetech; Amgen; Norvartis; Roche; Susan G. Komen for the CureRegistered; Fogarty International FX BOA received funding from Breast Health Global Initiative (BHGI); EC received consultancy funding from Bayer Schering Pharma, grants from the Breast Cancer Research Foundation (BCRF) and Poniard Pharmaceuticals, was on the speakers bureaus for Bayer and Bristol Meyers Squibb, and received travel expenses from ASCO, UICC, ESMO, and BCRF; DBT and PP have received funding from BHGI for travel; JRG received funding from Genetech, Amgen, Norvartis, and Roche; LMN and SGZ received funding from BHGI and Susan G. Komen for the Cure (R); BT received travel funding or other support from Fogarty International. All other authors and working group members reported no conflict of interest. NR 70 TC 17 Z9 17 U1 0 U2 8 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0960-9776 J9 BREAST JI Breast PD APR PY 2011 VL 20 SU 2 BP S20 EP S29 DI 10.1016/j.breast.2011.02.007 PG 10 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 758VB UT WOS:000290194000004 PM 21376593 ER PT J AU Sadrai, Z Hajrasouliha, AR Chauhan, S Saban, DR Dastjerdi, MH Dana, R AF Sadrai, Zahra Hajrasouliha, Amir Reza Chauhan, Sunil Saban, Daniel R. Dastjerdi, Mohammad H. Dana, Reza TI Effect of Topical Azithromycin on Corneal Innate Immune Responses SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID HERPETIC STROMAL KERATITIS; ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; IN-VIVO; NEOVASCULARIZATION; PHARMACOKINETICS; INTERLEUKIN-8; ANGIOGENESIS; INVOLVEMENT; POPULATION AB PURPOSE. To determine the effect of azithromycin (AZM) in a murine model of corneal inflammation. METHODS. The effect of topical AZM was studied in murine corneal inflammation. Corneal inflammation was induced by thermal cautery in BALB/c mice. Leukocyte infiltration at different time points was analyzed by flow cytometry. At set time points, real-time polymerase chain reaction was performed to quantify the expression of different inflammatory cytokine transcript in the cornea. Corneal samples were analyzed immunohistochemically for the expression of intercellular adhesion molecule-1 (ICAM-1). Corneal neovascularization (CNV) was induced by micropellet (VEGF-A) placement. Mice were then treated topically with either AZM or vehicle. CNV was evaluated morphometrically. RESULTS. Eyes receiving AZM showed a significant decrease in corneal infiltration compared with the vehicle-treated group. AZM also significantly decreased messenger RNA expression levels of interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha) and ICAM-1 in the cornea. There was no significant difference in CNV between the AZM- and vehicle-treated groups. CONCLUSIONS. After an inflammatory insult, topical AZM significantly reduced leukocyte infiltration into the cornea. This was further supported by an associated decrease in expression of IL-1 beta, TNF-alpha, and ICAM-1 in the cornea, indicating AZM may have a potential anti-inflammatory effect on corneal inflammation. (Invest Ophthalmol Vis Sci. 2011;52:2525-2531) DOI:10.1167/iovs.10-5658 C1 [Sadrai, Zahra; Hajrasouliha, Amir Reza; Chauhan, Sunil; Saban, Daniel R.; Dastjerdi, Mohammad H.; Dana, Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA. [Sadrai, Zahra; Hajrasouliha, Amir Reza; Chauhan, Sunil; Saban, Daniel R.; Dastjerdi, Mohammad H.; Dana, Reza] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. [Dastjerdi, Mohammad H.; Dana, Reza] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Dana, R (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM reza.dana@schepens.harvard.edu FU Inspire Pharmaceuticals FX Supported in part by Inspire Pharmaceuticals. NR 35 TC 15 Z9 15 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2011 VL 52 IS 5 BP 2525 EP 2531 DI 10.1167/iovs.10-5658 PG 7 WC Ophthalmology SC Ophthalmology GA 757TQ UT WOS:000290111000003 PM 21296809 ER PT J AU Ferrari, G Chauhan, SK Ueno, H Nallasamy, N Gandolfi, S Borges, L Dana, R AF Ferrari, Giulio Chauhan, Sunil K. Ueno, Hiroki Nallasamy, Nambi Gandolfi, Stefano Borges, Lawrence Dana, Reza TI A Novel Mouse Model for Neurotrophic Keratopathy: Trigeminal Nerve Stereotactic Electrolysis through the Brain SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID SUBSTANCE-P; DRY EYE; SENSORY DENERVATION; CORNEAL EPITHELIUM; ANTERIOR SEGMENT; OCULAR SURFACE; RABBIT CORNEA; RAT MODEL; APOPTOSIS; MICE AB PURPOSE. To develop a mouse model of neurotrophic keratopathy by approaching the trigeminal nerve through the brain and to evaluate changes in corneal cell apoptosis and proliferation. METHODS. Six-to 8-week-old male C57BL/6 mice underwent trigeminal stereotactic electrolysis (TSE) to destroy the ophthalmic branch of the trigeminal nerve. Clinical follow-up using biomicroscopy of the cornea was performed at days 2, 4, 5, and 7. To confirm the effectiveness of the procedure, we examined the gross nerve pathology, blink reflex, and immunohistochemistry of the corneal nerves. TUNEL-positive apoptotic and Ki-67-positive proliferating corneal cells were evaluated to detect changes from the contralateral normal eye. RESULTS. TSE was confirmed by gross histology of the trigeminal nerve and was considered effective if the corneal blink reflex was completely abolished. TSE totally abolished the blink reflex in 70% of mice and significantly reduced it in the remaining 30%. Animals with absent blink reflex were used for subsequent experiments. In these mice, a progressive corneal degeneration developed, with thinning of the corneal epithelium and eventually perforation after 7 days. In all mice, 48 hours after TSE, corneal nerves were not recognizable histologically. Seven days after TSE, an increase in cellular apoptosis in all the corneal layers and a reduction in proliferation in basal epithelial cells were detected consistently in all mice. CONCLUSIONS. TSE was able, in most cases, to induce a disease state that reflected clinical neurotrophic keratitis without damaging the periocular structures. Moreover, corneal denervation led to increased apoptosis and reduced proliferation of epithelial cells, formally implicating intact nerve function in regulating epithelial survival and turnover. (Invest Ophthalmol Vis Sci. 2011;52:2532-2539) DOI:10.1167/iovs.10-5688 C1 [Ferrari, Giulio; Chauhan, Sunil K.; Ueno, Hiroki; Nallasamy, Nambi; Dana, Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ferrari, Giulio; Chauhan, Sunil K.; Dana, Reza] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm,Massachusetts Gen, Boston, MA 02114 USA. [Ferrari, Giulio] IRCCS, GB Bietti Eye Fdn, Rome, Italy. [Gandolfi, Stefano] Univ Hosp Parma, Dept Ophthalmol, Parma, Italy. [Borges, Lawrence] Harvard Univ, Sch Med, Neurosurg Spine Ctr, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Dana, R (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Gen Hosp, 20 Staniford St, Boston, MA 02114 USA. EM reza.dana@schepens.harvard.edu RI ferrari, giulio/J-9260-2016 OI ferrari, giulio/0000-0001-6474-9908 FU National Institutes of Health/National Eye Institute [K24 EY019098]; Department of Defense (Schepens Eye Research Institute) [W81XWH-09-2-0091]; Bietti Eye Foundation, Rome, Italy FX Supported in part by National Institutes of Health/National Eye Institute Grant K24 EY019098, Department of Defense Grant W81XWH-09-2-0091 (Schepens Eye Research Institute), and the Bietti Eye Foundation, Rome, Italy. NR 48 TC 25 Z9 25 U1 1 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2011 VL 52 IS 5 BP 2532 EP 2539 DI 10.1167/iovs.10-5688 PG 8 WC Ophthalmology SC Ophthalmology GA 757TQ UT WOS:000290111000004 PM 21071731 ER PT J AU Liu, SH Richards, SM Lo, K Hatton, M Fay, A Sullivan, DA AF Liu, Shaohui Richards, Stephen M. Lo, Kristine Hatton, Mark Fay, Aaron Sullivan, David A. TI Changes in Gene Expression in Human Meibomian Gland Dysfunction SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID ELDERLY CHINESE POPULATION; EVAPORATIVE DRY EYE; OCULAR SURFACE; CHRONIC BLEPHARITIS; EPIDERMAL DIFFERENTIATION; CONFOCAL MICROSCOPY; ANDROGEN DEFICIENCY; PROTEIN EXPRESSION; S100 CALGRANULINS; SJOGRENS-SYNDROME AB PURPOSE. Meibomian gland dysfunction (MGD) may be the leading cause of dry eye syndrome throughout the world. However, the precise mechanism(s) underlying the pathogenesis of this disease is unclear. This study was conducted to identify meibomian gland genes that may promote the development and/or progression of human MGD. METHODS. Lid tissues were obtained from male and female MGD patients and age-matched controls after eyelid surgeries (e. g., to correct entropion or ectropion). Meibomian glands were isolated and processed for RNA extraction and the analysis of gene expression. RESULTS. The results show that MGD is associated with significant alterations in the expression of almost 400 genes in the human meibomian gland. The levels of 197 transcripts, including those encoding various small proline-rich proteins and S100 calcium-binding proteins, are significantly increased, whereas the expression of 194 genes, such as claudin 3 and cell adhesion molecule 1, is significantly decreased. These changes, which cannot be accounted for by sex differences, are accompanied by alterations in many gene ontologies (e. g., keratinization, cell cycle, and DNA repair). The findings also show that the human meibomian gland contains several highly expressed genes that are distinct from those in an adjacent tissue (i.e., conjunctival epithelium). CONCLUSIONS. The results demonstrate that MGD is accompanied by multiple changes in gene expression in the meibomian gland. The nature of these alterations, including the upregulation of genes encoding small proline-rich proteins and S100 calcium-binding proteins, suggest that keratinization plays an important role in the pathogenesis of MGD. (Invest Ophthalmol Vis Sci. 2011;52:2727-2740) DOI:10.1167/iovs.10-6482 C1 [Liu, Shaohui; Richards, Stephen M.; Hatton, Mark; Sullivan, David A.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA. [Liu, Shaohui; Richards, Stephen M.; Lo, Kristine; Hatton, Mark; Fay, Aaron; Sullivan, David A.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. [Lo, Kristine; Fay, Aaron] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA. [Hatton, Mark] Ophthalm Consultants Boston, Boston, MA USA. RP Sullivan, DA (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM david.sullivan@schepens.harvard.edu FU National Institutes of Health [EY05612]; Alcon Research, Ltd. FX Supported by Grant EY05612 from the National Institutes of Health and by Alcon Research, Ltd. NR 111 TC 20 Z9 22 U1 0 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2011 VL 52 IS 5 BP 2727 EP 2740 DI 10.1167/iovs.10-6482 PG 14 WC Ophthalmology SC Ophthalmology GA 757TQ UT WOS:000290111000029 PM 21372006 ER PT J AU Ramirez, JA Anzueto, AR AF Ramirez, Julio Alberto Anzueto, Antonio R. TI Changing needs of community-acquired pneumonia SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE antimicrobial therapy; PSI/CURB-65 score; clinical outcomes ID RESISTANT STAPHYLOCOCCUS-AUREUS; PANTON-VALENTINE LEUKOCIDIN; STREPTOCOCCUS-PNEUMONIAE; HOSPITALIZED-PATIENTS; UNITED-STATES; EARLY SWITCH; ANTIMICROBIAL RESISTANCE; SEVERITY CRITERIA; PREDICTION RULE; STRAIN USA300 AB Community-acquired pneumonia (CAP) is a serious condition associated with significant morbidity and potential long-term mortality. Although the majority of patients with CAP are treated as outpatients, the greatest proportion of pneumonia-related mortality and healthcare expenditure occurs among the patients who are hospitalized. There has been considerable interest in determining risk factors and severity criteria assessments to assist with site-of-care decisions. For both inpatients and outpatients, the most common pathogens associated with CAP include Streptococcus pneumoniae, Haemophilus influenzae, group A streptococci and Moraxella catarrhalis. Atypical pathogens, Gram-negative bacilli, methicillin-resistant Staphylococcus aureus (MRSA) and viruses are also recognized aetiological agents of CAP. Despite the availability of antimicrobial therapies, the recent emergence of drug-resistant pneumococcal and staphylococcal isolates has limited the effectiveness of currently available agents. Because early and rapid initiation of empirical antimicrobial treatment is critical for achieving a favourable outcome in CAP, newer agents with activity against drug-resistant strains of S. pneumoniae and MRSA are needed for the management of patients with CAP. C1 [Ramirez, Julio Alberto] Univ Louisville, Louisville, KY 40202 USA. [Anzueto, Antonio R.] Univ Texas Hlth Sci Ctr San Antonio, Audie L Murphy Mem Vet Hosp, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Ramirez, JA (reprint author), Univ Louisville, Louisville, KY 40202 USA. EM j.ramirez@louisville.edu FU Forest Laboratories, Inc.; Astra-Zeneca; Bayer-Schering Pharma; Pfizer; GlaxoSmithKline; Cubist Pharmaceuticals; Merck; Boehringer Ingelheim; BARD; Lilly; NIH FX Funding for editorial assistance was provided by Forest Laboratories, Inc.; J. A. R. has participated as a speaker in scientific meetings or courses organized and financed by various pharmaceutical companies, including Astra-Zeneca, Bayer-Schering Pharma, Pfizer, GlaxoSmithKline and Cubist Pharmaceuticals. J. A. R. has been a consultant for Pfizer. J. A. R. has been the principal investigator for research grants sponsored by Bayer-Schering Pharma, Pfizer, Cubist Pharmaceuticals and Merck. A. R. A. has participated as a speaker in scientific meetings or courses organized and financed by various pharmaceutical companies, including Astra-Zeneca, Boehringer Ingelheim, Bayer-Schering Pharma, Pfizer, GlaxoSmithKline and Forest Laboratories, Inc. A. R. A. has been a consultant for Astra-Zeneca, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Forest Laboratories, Inc. and Bayer-Schering Pharma. A. R. A. has been the principal investigator for research grants and the University of Texas Health Science Center at San Antonio was paid for participating in multicentre clinical trials sponsored by GlaxoSmithKline, Bayer-Schering Pharma, BARD, Lilly and NIH. NR 61 TC 5 Z9 6 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD APR PY 2011 VL 66 SU 3 BP III3 EP III9 DI 10.1093/jac/dkr094 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 758HA UT WOS:000290153500002 ER PT J AU Fava, M Schaefer, K Huang, H Wilson, A Iosifescu, DV Mischoulon, D Wessel, TC AF Fava, Maurizio Schaefer, Kendyl Huang, Holly Wilson, Amy Iosifescu, Dan V. Mischoulon, David Wessel, Thomas C. TI A Post Hoc Analysis of the Effect of Nightly Administration of Eszopiclone and a Selective Serotonin Reuptake Inhibitor in Patients With Insomnia and Anxious Depression SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID GAMMA-AMINOBUTYRIC-ACID; GENERALIZED ANXIETY DISORDER; STAR-ASTERISK-D; MAJOR DEPRESSION; GABA(A) RECEPTOR; NONANXIOUS DEPRESSION; FLUOXETINE; OUTPATIENTS; FEATURES; SCALE AB Objective: Patients with major depressive disorder (MDD) and significant anxiety are less responsive to antidepressants than those without anxiety. In this post hoc analysis of patients with insomnia and comorbid anxious depression, eszopiclone cotherapy with a selective serotonin re-uptake inhibitor (SSRI) was compared with placebo cotherapy. Method: Data were pooled from 2 randomized, double-blind, 8-week trials. One trial (conducted from January 2004 to October 2004) included patients with DSM-IV insomnia and comorbid MDD treated with fluoxetine concurrently with eszopiclone 3 mg/d or placebo. The other trial (conducted from July 2005 to April 2006) included patients with DSM-IV-TR insomnia and comorbid generalized anxiety disorder treated with escitalopram concurrently with eszopiclone 3 mg/d or placebo. Anxious depression was defined as a baseline 17-item Hamilton Depression Rating Scale (HDRS-17) score >= 14 (excluding insomnia items) and an anxiety/somatization factor score >= 7. Treatment group differences were determined for mean changes in HDRS-17 scores (with and without insomnia items), HDRS anxiety/somatization scores, and response and remission rates. Severity of insomnia was assessed by the Insomnia Severity Index (ISI). Results: In the combined dataset, 347 of 1,136 patients (30.5%) had insomnia and comorbid anxious depression. Significant improvements in insomnia were observed for eszopiclone cotherapy relative to placebo cotherapy (mean change from baseline on the ISI: -11.0 vs -7.8, respectively; P<.001). There were greater reductions in HDRS-17 scores at week 8 following cotherapy with eszopiclone compared with placebo when the insomnia items were included (mean change: -14.1 vs -11.2, respectively; P<.01) or excluded (-10.6 vs -8.9; P<.01), but not for anxiety/somatization (-4.3 vs -4.1; P=.23). Response rates were greater for eszopiclone cotherapy than for placebo cotherapy (55.6% vs 42.0%, respectively; P=.01; 50.0% vs 44.4% when insomnia items were removed; P=.3). Remission rates were not significantly different (32.6% vs 27.2%, respectively; P=.28). Conclusions: In this post hoc analysis of patients with insomnia and comorbid anxious depression derived from 2 trials, 8 weeks of eszopiclone therapy coadministered with an SSRI resulted in significantly greater improvements in insomnia, significantly greater reductions in HDRS-17 total score, and significantly greater HDRS-17 response rates compared with placebo coadministration. There were no significant differences in response rates (when insomnia items were excluded) and remission rates, as well as in anxiety/somatization scores. Further research is warranted to determine whether these modest antidepressant effects can be replicated, and anxiolytic effects demonstrated, when evaluated in a prospective manner. J Clin Psychiatry 2011;72(4):473-479 (C) Copyright 2010 Physicians Postgraduate Press, Inc. C1 [Fava, Maurizio; Iosifescu, Dan V.; Mischoulon, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, Boston, MA 02114 USA. [Schaefer, Kendyl; Huang, Holly; Wilson, Amy; Wessel, Thomas C.] Sepracor Inc, Marlborough, MA USA. RP Fava, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program, 55 Fruit St,Bulfinch 351, Boston, MA 02114 USA. EM mfava@partners.org FU Abbott; Alkermes; Aspect Medical Systems; AstraZeneca; Bristol-Myers Squibb; Cephalon; Eli Lilly; Forest; Ganeden; GlaxoSmithKline; Johnson Johnson; Lichtwer Pharma; Lorex; NARSAD; National Center for Complementary and Alternative Medicine; National Institute of Mental Health; National Institute on Drug Abuse; Novartis; Organon; PamLab; Pfizer; Pharmavite; Roche; Sanofi-Aventis; Shire; Solvay; Synthelabo; Wyeth-Ayerst; Janssen; Amarin (Laxdale); Nordic Naturals; Bristol-Myers Squibb, Cederroth; Swiss Medica; Wyeth; AstraZeneca, Cephalon; Sepracor Inc, Marlborough, Massachusetts FX Dr Fava has received research support from Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, Ganeden, GlaxoSmithKline; Johnson & Johnson, Lichtwer Pharma, Lorex, NARSAD, National Center for Complementary and Alternative Medicine, National Institute of Mental Health, National Institute on Drug Abuse, Novartis, Organon, PamLab, Pfizer, Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay, Synthelabo, and Wyeth-Ayerst; has served in an advisory or consulting capacity with Abbott, Amarin, Aspect Medical Systems, AstraZeneca, Auspex, Bayer, Best Practice Project Management, Biovail, BrainCells, Bristol-Myers Squibb, Cephalon, Clinical Trials Solutions, CNS Response, Compellis, Cypress, DOV, Eli Lilly, EPIX, Fabre-Kramer, Forest, GlaxoSmithKline, Grunenthal, Janssen, Jazz, Johnson & Johnson, Knoll, Labopharm, Lorex, Lundbeck, MedAvante, Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon, PamLab, Pfizer, PharmaStar, Pharmavite, Precision Human Biolaboratory, Roche, Sanofi-Aventis, Sepracor, Solvay, Somaxon, Somerset, Synthelabo, Takeda, Tetragenex, Transcept, Vanda, and Wyeth-Ayerst; has been a speaker for Advanced Meeting Partners, American Psychiatric Association, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Cephalon, Eli Lilly, Forest, GlaxoSmithKline, Imedex, Novartis, Organon, Pfizer, PharmaStar, Massachusetts General Hospital (MGH) Psychiatry Academy/PRIMEDIA Healthcare, MGH Psychiatry Academy/Reed Elsevier, UBC, and Wyeth-Ayerst; has equity holdings in Compellis; and receives royalty/patent income (patent applications for Sequential Parallel Comparison Design [SPCD] and for a combination of azapirones and bupropion in major depressive disorder; copyright royalties for the MGH Cognitive and Physical Functioning Questionnaire [CPFQ], Sexual Functioning Inventory [SFI], Antidepressant Treatment Response Questionnaire [ATRQ], Discontinuation-Emergent Signs and Symptoms scale [DESS], and SAFER Criteria Interview). Dr Iosifescu has received research support from Aspect Medical Systems, Forest, and Janssen; has been a consultant for Forest, Gerson Lehrman Group, and Pfizer; and has been a speaker for Eli Lilly, Forest, Pfizer, and Reed Medical Education (a logistics collaborator for the MGH Psychiatry Academy). Dr Mischoulon has received research support for other clinical trials in the form of donated medications from Amarin (Laxdale), Nordic Naturals, Lichtwer Pharma, Bristol-Myers Squibb, Cederroth, and Swiss Medica; has received consulting and writing honoraria from PamLab; has received speaking honoraria from Bristol-Myers Squibb, Pfizer, PamLab, Virbac, Nordic Naturals, and the MGH Psychiatry Academy (which has been supported by several pharmaceutical companies including Pfizer, Bristol-Myers Squibb, Wyeth, AstraZeneca, Cephalon, Janssen, and Eli Lilly; commercial entities supporting the MGH Psychiatry Academy are listed on the Academy's Web site at http://www.mghcme.org/ organization/supporters); and has received royalty income from Back Bay Scientific for PMS Escape (patent application pending). Mss Schaefer and Huang are employees of Sepracor, and Ms Schaefer is also a stock shareholder of Sepracor. Drs Wilson and Wessel were employees of Sepracor at the time of the study.; Sponsored by Sepracor Inc, Marlborough, Massachusetts. NR 38 TC 16 Z9 17 U1 0 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD APR PY 2011 VL 72 IS 4 BP 473 EP 479 DI 10.4088/JCP.09m05131gry PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 756LK UT WOS:000290012500006 PM 21208574 ER PT J AU Levkovitz, Y Tedeschini, E Papakostas, GI AF Levkovitz, Yeciel Tedeschini, Enrico Papakostas, George I. TI Efficacy of Antidepressants for Dysthymia: A Meta-Analysis of Placebo-Controlled Randomized Trials SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID DOUBLE-BLIND; CHRONIC DEPRESSION; DIAGNOSTIC CRITERIA; MAJOR DEPRESSION; DISORDER; FLUOXETINE; IMIPRAMINE; PHARMACOTHERAPY; COMORBIDITY; RITANSERIN AB Objective: The authors sought to determine the efficacy of antidepressants in dysthymic disorder and to compare antidepressant and placebo response rates between major depressive disorder (MDD) and dysthymic disorder. Data Sources: PubMed/MEDLINE databases were searched for double-blind, randomized, placebo-controlled trials of antidepressants used as monotherapy for treatment of MDD or dysthymic disorder. We defined antidepressants as those with a letter of approval by the US, Canadian, or European Union drug regulatory agencies for treatment of MDD or dysthymic disorder, which included the following: amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, trimipramine, protriptyline, dothiepin, doxepin, lofepramine, amoxapine, maprotiline, amineptine, nomifensine, bupropion, phenelzine, tranylcypromine, isocarboxazid, moclobemide, brofaromine, fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, zimelidine, tianeptine, ritanserin, trazodone, nefazodone, agomelatine, venlafaxine, desvenlafaxine, duloxetine, milnacipran, reboxetine, mirtazapine, and mianserin. Eligible studies were identified by cross-referencing the search term placebo with each of the above-mentioned agents. The search was limited to articles published between January 1, 1980, and November 20, 2009 (inclusive). To expand our database, we also reviewed the reference lists of the identified studies. Study Selection: We selected randomized, double-blind, placebo-controlled trials of antidepressants for either MDD or dysthymic disorder according to preset criteria relating to comorbidities, patient age, drug formulation, study duration, diagnostic criteria, choice of assessment scales, and whether or not the study reported original data. Final selection of articles was determined by consensus among the authors. Results: A total of 194 studies were found that were eligible for inclusion in our analysis. Of these, 177 focused on the treatment of MDD and 17 on the treatment of dysthymic disorder. We found that antidepressant therapy was significantly more effective than placebo in dysthymic disorder (risk ratio = 1.75; 95% CI, 1.49-2.04; P<.0001), while placebo response rates in dysthymic disorder trials were significantly lower compared to MDD trials (29.9% vs 37.9%, respectively; P=.042). Meta-regression suggested a statistically significant difference in the risk ratio of responding to antidepressants versus placebo when comparing studies either on dysthymic disorder or on MDD, suggesting a greater risk ratio for response in favor of antidepressant therapy versus placebo in patients with dysthymic disorder versus MDD (coefficient of -0.113; P=.007). Conclusions: These results support the utility of antidepressants for dysthymic disorder. In fact, the margin of efficacy of antidepressants for dysthymic disorder was larger than for MDD. Future studies providing longer-term data on the treatment of dysthymic disorder with antidepressants are essential. J Clin Psychiatry 2011;72(4):509-514 (C) Copyright 2011 Physicians Postgraduate Press, Inc. C1 [Tedeschini, Enrico] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA 02114 USA. [Levkovitz, Yeciel] Tel Aviv Univ, Emot Cognit Res Ctr, Shalvata Mental Hlth Ctr, Hod & Sackler Fac Med, IL-69978 Tel Aviv, Israel. [Levkovitz, Yeciel; Tedeschini, Enrico; Papakostas, George I.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Tedeschini, Enrico] Univ Modena & Reggio Emilia, Reggio Emilia, Italy. RP Tedeschini, E (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, 50 Staniford St,Suite 401, Boston, MA 02114 USA. EM etedeschini@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 FU Bristol-Myers Squibb; Forest; National Institute of Mental Health; Pamlab; Pfizer; Ridge Diagnostics FX Dr Levkovitz has been a consultant for Brainsway and NeuroDerm and has been a member of the speakers or advisory board for AstraZeneca. Dr Papakostas has served as a consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Evotec, GlaxoSmithKline, Inflabloc, Jazz, Otsuka, Pamlab, Pfizer, Pierre Fabre, Shire, and Wyeth; has received honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Evotec, GlaxoSmithKline, Inflabloc, Jazz, Lundbeck, Otsuka, Pamlab, Pfizer, Pierre Fabre, Shire, Titan, and Wyeth; has received research support from Bristol-Myers Squibb, Forest, the National Institute of Mental Health, Pamlab, Pfizer, and Ridge Diagnostics (formerly Precision Human Biolaboratories); and has been a member of the speakers bureaus for Bristol-Myers Squibb and Pfizer. Dr Tedeschini has no personal affiliations or financial relationships with any commercial interest to disclose relative to the article. NR 40 TC 21 Z9 21 U1 1 U2 9 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD APR PY 2011 VL 72 IS 4 BP 509 EP 514 DI 10.4088/JCP.09m05949blu PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 756LK UT WOS:000290012500011 PM 21527126 ER PT J AU Ring, D AF Ring, David TI The Role of Science and Psychology in Optimizing Care of Hand Illness SO JOURNAL OF HAND THERAPY LA English DT Editorial Material C1 [Ring, David] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Ring, David] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Yawkey 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 3 TC 3 Z9 3 U1 0 U2 0 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0894-1130 J9 J HAND THER JI J. Hand Ther. PD APR-JUN PY 2011 VL 24 IS 2 SI SI BP 82 EP 83 DI 10.1016/j.jht.2010.11.004 PG 2 WC Orthopedics; Rehabilitation; Surgery SC Orthopedics; Rehabilitation; Surgery GA 760YS UT WOS:000290361800002 PM 21306872 ER PT J AU Vranceanu, AM Elbon, M Ring, D AF Vranceanu, Ana-Maria Elbon, Megan Ring, David TI The Emotive Impact of Orthopedic Words SO JOURNAL OF HAND THERAPY LA English DT Article ID SHARED DECISION-MAKING; COMMUNICATION-SKILLS; ANXIETY; PAIN AB Research has shown that effective communication skills are paramount for delivering efficient and quality health care. More recently, research has started to show that in addition to how the medical information is delivered, the words used by health care providers are important factors in how patients cope with illness and their reports of pain intensity and disability. In this article, we discuss the emotional impact of words used by hand specialists, the impact of the nomenclature chosen to describe orthopedic diagnosis and procedures, and provide recommendations consistent with evidence-based practice. J HAND THER. 2011;24:112-7. C1 [Vranceanu, Ana-Maria] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Behav Med Serv,Wang Ambulatory Care Ctr,Dept Psyc, Boston, MA 02114 USA. [Elbon, Megan] Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. [Ring, David] Massachusetts Gen Hosp, Yawkey Ctr, Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Vranceanu, AM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Behav Med Serv,Wang Ambulatory Care Ctr,Dept Psyc, 15 Parkman St, Boston, MA 02114 USA. EM avranceanu@partners.org NR 25 TC 8 Z9 8 U1 0 U2 1 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0894-1130 J9 J HAND THER JI J. Hand Ther. PD APR-JUN PY 2011 VL 24 IS 2 SI SI BP 112 EP 116 DI 10.1016/j.jht.2010.10.010 PG 5 WC Orthopedics; Rehabilitation; Surgery SC Orthopedics; Rehabilitation; Surgery GA 760YS UT WOS:000290361800007 PM 21277166 ER PT J AU Vranceanu, AM Barsky, A Ring, D AF Vranceanu, Ana-Maria Barsky, Arthur Ring, David TI Less Specific Arm Illnesses SO JOURNAL OF HAND THERAPY LA English DT Article ID PRONATOR SYNDROME; PAIN; SOMATIZATION; DISORDERS; FIBROMYALGIA; WORKPLACE; SYMPTOMS; SPECTRUM AB Unexplained symptoms are among the most common complaints addressed by health providers. Nonspecific (or less specific) arm pain, in particular, is characterized by vague, diffuse, uncharacteristic symptoms, and disproportionate pain and disability. Many of the conditions diagnosed and treated by hand specialists as specific abnormalities might be better considered nonspecific because no distinct, unique, characteristic pathology or pathophysiology can be identified. An approach that assumes that symptoms are directly related to underlying pathophysiology and ignores the important psychological and sociological contributions to illness risks hindering recovery. J HAND THER. 2011;24:118-23. C1 [Ring, David] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. [Vranceanu, Ana-Maria] Massachusetts Gen Hosp, Behav Med Serv, Boston, MA 02114 USA. [Barsky, Arthur] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 47 TC 5 Z9 5 U1 0 U2 1 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0894-1130 J9 J HAND THER JI J. Hand Ther. PD APR-JUN PY 2011 VL 24 IS 2 SI SI BP 118 EP 122 DI 10.1016/j.jht.2010.12.002 PG 5 WC Orthopedics; Rehabilitation; Surgery SC Orthopedics; Rehabilitation; Surgery GA 760YS UT WOS:000290361800008 PM 21392938 ER PT J AU Vranceanu, AM Safren, S AF Vranceanu, Ana-Maria Safren, Steve TI Cognitive-Behavioral Therapy for Hand and Arm Pain SO JOURNAL OF HAND THERAPY LA English DT Article ID BACK-PAIN; INTERVENTIONS; MANAGEMENT AB Cognitive-behavioral therapy (CBT) is a psychological treatment that emphasizes the interrelation among thoughts, behaviors, feelings, and sensations. CBT has been proved effective not only for treatment of psychological illness but also for teaching adaptive coping strategies in the context of chronic illnesses, including chronic pain. The present article provides general information on CBT, specific information on CBT for pain, as well as guidelines and strategies for using CBT for hand and arm pain patients, as part of multidisciplinary care models. J HAND THER. 2011;24:124-31. C1 [Vranceanu, Ana-Maria; Safren, Steve] Massachusetts Gen Hosp, Dept Psychiat, Behav Med Serv, Cambridge, MA 02138 USA. RP Vranceanu, AM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Behav Med Serv, 1 Bowdoin Sq, Cambridge, MA 02138 USA. EM avranceanu@partners.org FU NIMH NIH HHS [K24 MH094214] NR 32 TC 5 Z9 5 U1 0 U2 1 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0894-1130 J9 J HAND THER JI J. Hand Ther. PD APR-JUN PY 2011 VL 24 IS 2 SI SI BP 124 EP 130 DI 10.1016/j.jht.2010.08.005 PG 7 WC Orthopedics; Rehabilitation; Surgery SC Orthopedics; Rehabilitation; Surgery GA 760YS UT WOS:000290361800009 PM 21051204 ER PT J AU Ruperto, N Hanrahan, LM Alarcon, GS Belmont, HM Brey, RL Brunetta, P Buyon, JP Costner, MI Cronin, ME Dooley, MA Filocamo, G Fiorentino, D Fortin, PR Franks, AG Gilkeson, G Ginzler, E Gordon, C Grossman, J Hahn, B Isenberg, DA Kalunian, KC Petri, M Sammaritano, L Sanchez-Guerrero, J Sontheimer, RD Strand, V Urowitz, M von Feldt, JM Werth, VP Merrill, JT AF Ruperto, N. Hanrahan, L. M. Alarcon, G. S. Belmont, H. M. Brey, R. L. Brunetta, P. Buyon, J. P. Costner, M. I. Cronin, M. E. Dooley, M. A. Filocamo, G. Fiorentino, D. Fortin, P. R. Franks, A. G., Jr. Gilkeson, G. Ginzler, E. Gordon, C. Grossman, J. Hahn, B. Isenberg, D. A. Kalunian, K. C. Petri, M. Sammaritano, L. Sanchez-Guerrero, J. Sontheimer, R. D. Strand, V. Urowitz, M. von Feldt, J. M. Werth, V. P. Merrill, J. T. CA Lupus Fdn Amer Inc TI International consensus for a definition of disease flare in lupus SO LUPUS LA English DT Article DE autoimmune disease; flare; systemic lupus erythematosus AB The Lupus Foundation of America (LFA) convened an international working group to obtain a consensus definition of disease flare in lupus. With help from the Paediatric Rheumatology International Trials Organization (PRINTO), two web-based Delphi surveys of physicians were conducted. Subsequently, the LFA held a second consensus conference followed by a third Delphi survey to reach a community-wide agreement for flare definition. Sixty-nine of the 120 (57.5%) polled physicians responded to the first survey. Fifty-nine of the responses were available to draft 12 preliminary statements, which were circulated in the second survey. Eighty-seven of 118 (74%) physicians completed the second survey, with an agreement of 70% for 9/12 (75%) statements. During the second conference, three alternative flare definitions were consolidated and sent back to the international community. One hundred and sixteen of 146 (79.5%) responded, with agreement by 71/116 (61%) for the following definition: "A flare is a measurable increase in disease activity in one or more organ systems involving new or worse clinical signs and symptoms and/or laboratory measurements. It must be considered clinically significant by the assessor and usually there would be at least consideration of a change or an increase in treatment.'' The LFA proposes this definition for lupus flare on the basis of its high face validity. Lupus (2011) 20, 453-462. C1 [Merrill, J. T.] Oklahoma Med Res Fdn, Res Program, Oklahoma City, OK 73104 USA. [Ruperto, N.; Filocamo, G.] PRINTO, Genoa, Italy. [Hanrahan, L. M.] Lupus Fdn Amer Inc, Washington, DC USA. [Alarcon, G. S.] Univ Alabama, Birmingham, AL USA. [Belmont, H. M.] NYU, Hosp Joint Dis, New York, NY USA. [Brey, R. L.] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA. [Brunetta, P.] Genentech Inc, San Francisco, CA USA. [Buyon, J. P.; Franks, A. G., Jr.] NYU, Sch Med, New York, NY USA. [Costner, M. I.] UT SW Med Ctr, Dallas, TX USA. [Cronin, M. E.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Dooley, M. A.] Univ N Carolina, Chapel Hill, NC USA. [Fiorentino, D.; Strand, V.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Fortin, P. R.; Urowitz, M.] Univ Toronto, Toronto Western Hosp, Toronto, ON M5T 2S8, Canada. [Gilkeson, G.] Med Univ S Carolina, Charleston, SC 29425 USA. [Ginzler, E.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Gordon, C.] Univ Birmingham, Sch Med, Birmingham, W Midlands, England. [Grossman, J.; Hahn, B.] Univ Calif Los Angeles, Los Angeles, CA USA. [Isenberg, D. A.] UCL, London, England. [Kalunian, K. C.] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA. [Petri, M.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Sammaritano, L.] Hosp Special Surg, New York, NY 10021 USA. [Sanchez-Guerrero, J.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Salvador Zubiran Mexico, Mexico. [Sontheimer, R. D.] Univ Utah, Sch Med, Salt Lake City, UT USA. [von Feldt, J. M.; Werth, V. P.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Werth, V. P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Merrill, JT (reprint author), Oklahoma Med Res Fdn, Res Program, 825 NE 13th St, Oklahoma City, OK 73104 USA. EM Joan-Merrill@omrf.org OI Hough, Douglas/0000-0001-7728-816X; Fiorentino, David/0000-0001-7951-3674; Isenberg, David/0000-0001-9514-2455; Belmont, Howard/0000-0003-3389-2976; Franks, Andrew/0000-0001-5427-6369 FU Lupus Foundation of America, Inc. FX This work was supported by the Lupus Foundation of America, Inc. NR 28 TC 40 Z9 41 U1 1 U2 8 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 J9 LUPUS JI Lupus PD APR PY 2011 VL 20 IS 5 BP 453 EP 462 DI 10.1177/0961203310388445 PG 10 WC Rheumatology SC Rheumatology GA 759BC UT WOS:000290213800003 PM 21148601 ER PT J AU Ju, SL Tardiff, DF Han, HS Divya, K Zhong, Q Maquat, LE Bosco, DA Hayward, LJ Brown, RH Lindquist, S Ringe, D Petsko, GA AF Ju, Shulin Tardiff, Daniel F. Han, Haesun Divya, Kanneganti Zhong, Quan Maquat, Lynne E. Bosco, Daryl A. Hayward, Lawrence J. Brown, Robert H., Jr. Lindquist, Susan Ringe, Dagmar Petsko, Gregory A. TI A Yeast Model of FUS/TLS-Dependent Cytotoxicity SO PLOS BIOLOGY LA English DT Article ID AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; SPINAL MUSCULAR-ATROPHY; ALPHA-SYNUCLEIN; SACCHAROMYCES-CEREVISIAE; GENE-MUTATIONS; FUS; PROTEIN; TDP-43; ALS AB FUS/TLS is a nucleic acid binding protein that, when mutated, can cause a subset of familial amyotrophic lateral sclerosis (fALS). Although FUS/TLS is normally located predominantly in the nucleus, the pathogenic mutant forms of FUS/TLS traffic to, and form inclusions in, the cytoplasm of affected spinal motor neurons or glia. Here we report a yeast model of human FUS/TLS expression that recapitulates multiple salient features of the pathology of the disease-causing mutant proteins, including nuclear to cytoplasmic translocation, inclusion formation, and cytotoxicity. Protein domain analysis indicates that the carboxyl-terminus of FUS/TLS, where most of the ALS-associated mutations are clustered, is required but not sufficient for the toxicity of the protein. A genome-wide genetic screen using a yeast over-expression library identified five yeast DNA/RNA binding proteins, encoded by the yeast genes ECM32, NAM8, SBP1, SKO1, and VHR1, that rescue the toxicity of human FUS/TLS without changing its expression level, cytoplasmic translocation, or inclusion formation. Furthermore, hUPF1, a human homologue of ECM32, also rescues the toxicity of FUS/TLS in this model, validating the yeast model and implicating a possible insufficiency in RNA processing or the RNA quality control machinery in the mechanism of FUS/TLS mediated toxicity. Examination of the effect of FUS/TLS expression on the decay of selected mRNAs in yeast indicates that the nonsense-mediated decay pathway is probably not the major determinant of either toxicity or suppression. C1 [Ju, Shulin; Divya, Kanneganti; Ringe, Dagmar; Petsko, Gregory A.] Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biochem & Chem, Waltham, MA 02254 USA. [Ju, Shulin; Ringe, Dagmar; Petsko, Gregory A.] Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA. [Ju, Shulin; Ringe, Dagmar; Petsko, Gregory A.] Harvard Univ, Sch Med, Ctr Neurol Dis, Cambridge, MA 02138 USA. [Ju, Shulin; Ringe, Dagmar; Petsko, Gregory A.] Brigham & Womens Hosp, Cambridge, MA USA. [Tardiff, Daniel F.; Han, Haesun; Lindquist, Susan] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Tardiff, Daniel F.; Han, Haesun; Lindquist, Susan] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA USA. [Zhong, Quan] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Zhong, Quan] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Maquat, Lynne E.] Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY USA. [Maquat, Lynne E.] Univ Rochester, Sch Med & Dent, Ctr RNA Biol, Rochester, NY USA. [Bosco, Daryl A.; Hayward, Lawrence J.; Brown, Robert H., Jr.] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA. RP Ju, SL (reprint author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biochem & Chem, Waltham, MA 02254 USA. EM ringe@brandeis.edu; petsko@brandeis.edu FU Fidelity Biosciences Research Initiative; ALS Therapy Alliance; NIH [1RC1NS06839, U01NS05225-03, R01NS050557-05, 1RC2NS070342-01]; Angel Fund; Project ALS; Pierre L. de Bourgknecht ALS Research Foundation; National Research Service [NS614192] FX This work is supported by grants from the Fidelity Biosciences Research Initiative (GAP and DR), the ALS Therapy Alliance (GAP, DR, DAB and RHB), and NIH 1RC1NS06839 (LJH and RHB). RHB also receives funding from NIH U01NS05225-03, R01NS050557-05, and 1RC2NS070342-01 as well as the Angel Fund, the ALS Association, Project ALS, and the Pierre L. de Bourgknecht ALS Research Foundation. Susan Lindquist is an investigator of the Howard Hughes Medical Institute. DFT was supported by National Research Service Award fellowship number NS614192. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 59 Z9 62 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1544-9173 J9 PLOS BIOL JI PLoS. Biol. PD APR PY 2011 VL 9 IS 4 AR e1001052 DI 10.1371/journal.pbio.1001052 PG 17 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 755NM UT WOS:000289938900019 PM 21541368 ER PT J AU Myers, RM Stamatoyannopoulos, J Snyder, M Dunham, I Hardison, RC Bernstein, BE Gingeras, TR Kent, WJ Birney, E Wold, B Crawford, GE Bernstein, BE Epstein, CB Shoresh, N Ernst, J Mikkelsen, TS Kheradpour, P Zhang, XL Wang, L Issner, R Coyne, MJ Durham, T Ku, MC Truong, T Ward, LD Altshuler, RC Lin, MF Kellis, M Gingeras, TR Davis, CA Kapranov, P Dobin, A Zaleski, C Schlesinger, F Batut, P Chakrabortty, S Jha, S Lin, W Drenkow, J Wang, HE Bell, K Gao, H Bell, I Dumais, E Dumais, J Antonarakis, SE Ucla, C Borel, C Guigo, R Djebali, S Lagarde, J Kingswood, C Ribeca, P Sammeth, M Alioto, T Merkel, A Tilgner, H Carninci, P Hayashizaki, Y Lassmann, T Takahashi, H Abdelhamid, RF Hannon, G Fejes-Toth, K Preall, J Gordon, A Sotirova, V Reymond, A Howald, C Graison, EAY Chrast, J Ruan, YJ Ruan, XA Shahab, A Poh, WT Wei, CL Crawford, GE Furey, TS Boyle, AP Sheffield, NC Song, LY Shibata, Y Vales, T Winter, D Zhang, ZC London, D Wang, TY Birney, E Keefe, D Iyer, VR Lee, BK McDaniell, RM Liu, Z Battenhouse, A Bhinge, AA Lieb, JD Grasfeder, LL Showers, KA Giresi, PG Kim, SKC Shestak, C Myers, RM Pauli, F Reddy, TE Gertz, J Partridge, EC Jain, P Sprouse, RO Bansal, A Pusey, B Muratet, MA Varley, KE Bowling, KM Newberry, KM Nesmith, AS Dilocker, JA Parker, SL Waite, LL Thibeault, K Roberts, K Absher, DM Wold, B Mortazavi, A Williams, B Marinov, G Trout, D Pepke, S King, B McCue, K Kirilusha, A DeSalvo, G Fisher-Aylor, K Amrhein, H Vielmetter, J Sherlock, G Sidow, A Batzoglou, S Rauch, R Kundaje, A Libbrecht, M Margulies, EH Parker, SCJ Elnitski, L Green, ED Hubbard, T Harrow, J Searle, S Kokocinski, F Aken, B Frankish, A Hunt, T Despacio-Reyes, G Kay, M Mukherjee, G Bignell, A Saunders, G Boychenko, V Brent, M Van Baren, MJ Brown, RH Gerstein, M Khurana, E Balasubramanian, S Zhang, ZD Lam, H Cayting, P Robilotto, R Lu, Z Guigo, R Derrien, T Tanzer, A Knowles, DG Mariotti, M Kent, WJ Haussler, D Harte, R Diekhans, M Kellis, M Lin, M Kheradpour, P Ernst, J Reymond, A Howald, C Graison, EAY Chrast, J Valencia, A Tress, M Rodriguez, JM Snyder, M Landt, SG Raha, D Shi, MY Euskirchen, G Grubert, F Kasowski, M Lian, J Cayting, P Lacroute, P Xu, YH Monahan, H Patacsil, D Slifer, T Yang, XQ Charos, A Reed, B Wu, LF Auerbach, RK Habegger, L Hariharan, M Rozowsky, J Abyzov, A Weissman, SM Gerstein, M Struhl, K Lamarre-Vincent, N Lindahl-Allen, M Miotto, B Moqtaderi, Z Fleming, JD Newburger, P Farnham, PJ Frietze, S O'Geen, H Xu, XQ Blahnik, KR Cao, AR Iyengar, S Stamatoyannopoulos, JA Kaul, R Thurman, RE Wang, H Navas, PA Sandstrom, R Sabo, PJ Weaver, M Canfield, T Lee, K Neph, S Roach, V Reynolds, A Johnson, A Rynes, E Giste, E Vong, S Neri, J Frum, T Johnson, EM Nguyen, ED Ebersol, AK Sanchez, ME Sheffer, HH Lotakis, D Haugen, E Humbert, R Kutyavin, T Shafer, T Dekker, J Lajoie, BR Sanyal, A Kent, WJ Rosenbloom, KR Dreszer, TR Raney, BJ Barber, GP Meyer, LR Sloan, CA Malladi, VS Cline, MS Learned, K Swing, VK Zweig, AS Rhead, B Fujita, PA Roskin, K Karolchik, D Kuhn, RM Haussler, D Birney, E Dunham, I Wilder, SP Keefe, D Sobral, D Herrero, J Beal, K Lukk, M Brazma, A Vaquerizas, JM Luscombe, NM Bickel, PJ Boley, N Brown, JB Li, QH Huang, HY Gerstein, M Habegger, L Sboner, A Rozowsky, J Auerbach, RK Yip, KY Cheng, C Yan, KK Bhardwaj, N Wang, J Lochovsky, L Jee, J Gibson, T Leng, J Du, J Hardison, RC Harris, RS Song, G Miller, W Haussler, D Roskin, K Suh, B Wang, T Paten, B Noble, WS Hoffman, MM Buske, OJ Weng, ZP Dong, XJ Wang, J Xi, HL Tenenbaum, SA Doyle, F Penalva, LO Chittur, S Tullius, TD Parker, SCJ White, KP Karmakar, S Victorsen, A Jameel, N Bild, N Grossman, RL Snyder, M Landt, SG Yang, XQ Patacsil, D Slifer, T Dekker, J Lajoie, BR Sanyal, A Weng, ZP Whitfield, TW Wang, J Collins, PJ Trinklein, ND Partridge, EC Myers, RM Giddings, MC Chen, X Khatun, J Maier, C Yu, YB Gunawardena, H Risk, B Feingold, EA Lowdon, RF Dillon, LAL Good, PJ AF Myers, Richard M. Stamatoyannopoulos, John Snyder, Michael Dunham, Ian Hardison, Ross C. Bernstein, Bradley E. Gingeras, Thomas R. Kent, W. James Birney, Ewan Wold, Barbara Crawford, Gregory E. Bernstein, Bradley E. Epstein, Charles B. Shoresh, Noam Ernst, Jason Mikkelsen, Tarjei S. Kheradpour, Pouya Zhang, Xiaolan Wang, Li Issner, Robbyn Coyne, Michael J. Durham, Timothy Ku, Manching Thanh Truong Ward, Lucas D. Altshuler, Robert C. Lin, Michael F. Kellis, Manolis Gingeras, Thomas R. Davis, Carrie A. Kapranov, Philipp Dobin, Alexander Zaleski, Christopher Schlesinger, Felix Batut, Philippe Chakrabortty, Sudipto Jha, Sonali Lin, Wei Drenkow, Jorg Wang, Huaien Bell, Kim Gao, Hui Bell, Ian Dumais, Erica Dumais, Jacqueline Antonarakis, Stylianos E. Ucla, Catherine Borel, Christelle Guigo, Roderic Djebali, Sarah Lagarde, Julien Kingswood, Colin Ribeca, Paolo Sammeth, Micha Alioto, Tyler Merkel, Angelika Tilgner, Hagen Carninci, Piero Hayashizaki, Yoshihide Lassmann, Timo Takahashi, Hazuki Abdelhamid, Rehab F. Hannon, Gregory Fejes-Toth, Katalin Preall, Jonathan Gordon, Assaf Sotirova, Vihra Reymond, Alexandre Howald, Cedric Graison, Emilie Ait Yahya Chrast, Jacqueline Ruan, Yijun Ruan, Xiaoan Shahab, Atif Poh, Wan Ting Wei, Chia-Lin Crawford, Gregory E. Furey, Terrence S. Boyle, Alan P. Sheffield, Nathan C. Song, Lingyun Shibata, Yoichiro Vales, Teresa Winter, Deborah Zhang, Zhancheng London, Darin Wang, Tianyuan Birney, Ewan Keefe, Damian Iyer, Vishwanath R. Lee, Bum-Kyu McDaniell, Ryan M. Liu, Zheng Battenhouse, Anna Bhinge, Akshay A. Lieb, Jason D. Grasfeder, Linda L. Showers, Kimberly A. Giresi, Paul G. Kim, Seul K. C. Shestak, Christopher Myers, Richard M. Pauli, Florencia Reddy, Timothy E. Gertz, Jason Partridge, E. Christopher Jain, Preti Sprouse, Rebekka O. Bansal, Anita Pusey, Barbara Muratet, Michael A. Varley, Katherine E. Bowling, Kevin M. Newberry, Kimberly M. Nesmith, Amy S. Dilocker, Jason A. Parker, Stephanie L. Waite, Lindsay L. Thibeault, Krista Roberts, Kevin Absher, Devin M. Wold, Barbara Mortazavi, Ali Williams, Brian Marinov, Georgi Trout, Diane Pepke, Shirley King, Brandon McCue, Kenneth Kirilusha, Anthony DeSalvo, Gilberto Fisher-Aylor, Katherine Amrhein, Henry Vielmetter, Jost Sherlock, Gavin Sidow, Arend Batzoglou, Serafim Rauch, Rami Kundaje, Anshul Libbrecht, Max Margulies, Elliott H. Parker, Stephen C. J. Elnitski, Laura Green, Eric D. Hubbard, Tim Harrow, Jennifer Searle, Stephen Kokocinski, Felix Aken, Browen Frankish, Adam Hunt, Toby Despacio-Reyes, Gloria Kay, Mike Mukherjee, Gaurab Bignell, Alexandra Saunders, Gary Boychenko, Veronika Brent, Michael Van Baren, M. J. Brown, Randall H. Gerstein, Mark Khurana, Ekta Balasubramanian, Suganthi Zhang, Zhengdong Lam, Hugo Cayting, Philip Robilotto, Rebecca Lu, Zhi Guigo, Roderic Derrien, Thomas Tanzer, Andrea Knowles, David G. Mariotti, Marco Kent, W. James Haussler, David Harte, Rachel Diekhans, Mark Kellis, Manolis Lin, Mike Kheradpour, Pouya Ernst, Jason Reymond, Alexandre Howald, Cedric Graison, Emilie Ait Yahya Chrast, Jacqueline Valencia, Alfonso Tress, Michael Manuel Rodriguez, Jose Snyder, Michael Landt, Stephen G. Raha, Debasish Shi, Minyi Euskirchen, Ghia Grubert, Fabian Kasowski, Maya Lian, Jin Cayting, Philip Lacroute, Phil Xu, Youhan Monahan, Hannah Patacsil, Dorrelyn Slifer, Teri Yang, Xinqiong Charos, Alexandra Reed, Brian Wu, Linfeng Auerbach, Raymond K. Habegger, Lukas Hariharan, Manoj Rozowsky, Joel Abyzov, Alexej Weissman, Sherman M. Gerstein, Mark Struhl, Kevin Lamarre-Vincent, Nathan Lindahl-Allen, Marianne Miotto, Benoit Moqtaderi, Zarmik Fleming, Joseph D. Newburger, Peter Farnham, Peggy J. Frietze, Seth O'Geen, Henriette Xu, Xiaoqin Blahnik, Kim R. Cao, Alina R. Iyengar, Sushma Stamatoyannopoulos, John A. Kaul, Rajinder Thurman, Robert E. Wang, Hao Navas, Patrick A. Sandstrom, Richard Sabo, Peter J. Weaver, Molly Canfield, Theresa Lee, Kristen Neph, Shane Roach, Vaughan Reynolds, Alex Johnson, Audra Rynes, Eric Giste, Erika Vong, Shinny Neri, Jun Frum, Tristan Johnson, Ericka M. Nguyen, Eric D. Ebersol, Abigail K. Sanchez, Minerva E. Sheffer, Hadar H. Lotakis, Dimitra Haugen, Eric Humbert, Richard Kutyavin, Tanya Shafer, Tony Dekker, Job Lajoie, Bryan R. Sanyal, Amartya Kent, W. James Rosenbloom, Kate R. Dreszer, Timothy R. Raney, Brian J. Barber, Galt P. Meyer, Laurence R. Sloan, Cricket A. Malladi, Venkat S. Cline, Melissa S. Learned, Katrina Swing, Vanessa K. Zweig, Ann S. Rhead, Brooke Fujita, Pauline A. Roskin, Krishna Karolchik, Donna Kuhn, Robert M. Haussler, David Birney, Ewan Dunham, Ian Wilder, Steven P. Keefe, Damian Sobral, Daniel Herrero, Javier Beal, Kathryn Lukk, Margus Brazma, Alvis Vaquerizas, Juan M. Luscombe, Nicholas M. Bickel, Peter J. Boley, Nathan Brown, James B. Li, Qunhua Huang, Haiyan Gerstein, Mark Habegger, Lukas Sboner, Andrea Rozowsky, Joel Auerbach, Raymond K. Yip, Kevin Y. Cheng, Chao Yan, Koon-Kiu Bhardwaj, Nitin Wang, Jing Lochovsky, Lucas Jee, Justin Gibson, Theodore Leng, Jing Du, Jiang Hardison, Ross C. Harris, Robert S. Song, Giltae Miller, Webb Haussler, David Roskin, Krishna Suh, Bernard Wang, Ting Paten, Benedict Noble, William S. Hoffman, Michael M. Buske, Orion J. Weng, Zhiping Dong, Xianjun Wang, Jie Xi, Hualin Tenenbaum, Scott A. Doyle, Frank Penalva, Luiz O. Chittur, Sridar Tullius, Thomas D. Parker, Stephen C. J. White, Kevin P. Karmakar, Subhradip Victorsen, Alec Jameel, Nader Bild, Nick Grossman, Robert L. Snyder, Michael Landt, Stephen G. Yang, Xinqiong Patacsil, Dorrelyn Slifer, Teri Dekker, Job Lajoie, Bryan R. Sanyal, Amartya Weng, Zhiping Whitfield, Troy W. Wang, Jie Collins, Patrick J. Trinklein, Nathan D. Partridge, E. Christopher Myers, Richard M. Giddings, Morgan C. Chen, Xian Khatun, Jainab Maier, Chris Yu, Yanbao Gunawardena, Harsha Risk, Brian Feingold, Elise A. Lowdon, Rebecca F. Dillon, Laura A. L. Good, Peter J. CA ENCODE Project Consortium TI A User's Guide to the Encyclopedia of DNA Elements (ENCODE) SO PLOS BIOLOGY LA English DT Article ID EMBRYONIC STEM-CELLS; CHROMOSOME CONFORMATION CAPTURE; TRANSCRIPTION FACTOR-BINDING; MESSENGER-RNA SUBSETS; UCSC GENOME BROWSER; COLORECTAL-CANCER; IN-VIVO; COPY-NUMBER; RIBONUCLEOPROTEIN COMPLEXES; DEVELOPMENTAL REGULATORS AB The mission of the Encyclopedia of DNA Elements (ENCODE) Project is to enable the scientific and medical communities to interpret the human genome sequence and apply it to understand human biology and improve health. The ENCODE Consortium is integrating multiple technologies and approaches in a collective effort to discover and define the functional elements encoded in the human genome, including genes, transcripts, and transcriptional regulatory regions, together with their attendant chromatin states and DNA methylation patterns. In the process, standards to ensure high-quality data have been implemented, and novel algorithms have been developed to facilitate analysis. Data and derived results are made available through a freely accessible database. Here we provide an overview of the project and the resources it is generating and illustrate the application of ENCODE data to interpret the human genome. C1 [Pauli, Florencia; Partridge, E. Christopher; Bansal, Anita; Pusey, Barbara; Nesmith, Amy S.; Dilocker, Jason A.; Absher, Devin M.] HudsonAlpha Inst Biotechnol, Huntsville, AL USA. [Stamatoyannopoulos, John; Stamatoyannopoulos, John A.; Kaul, Rajinder; Thurman, Robert E.; Wang, Hao; Navas, Patrick A.; Sandstrom, Richard; Sabo, Peter J.; Weaver, Molly; Canfield, Theresa; Lee, Kristen; Neph, Shane; Roach, Vaughan; Reynolds, Alex; Johnson, Audra; Rynes, Eric; Giste, Erika; Vong, Shinny; Neri, Jun; Frum, Tristan; Johnson, Ericka M.; Nguyen, Eric D.; Ebersol, Abigail K.; Sanchez, Minerva E.; Sheffer, Hadar H.; Lotakis, Dimitra; Haugen, Eric; Humbert, Richard; Kutyavin, Tanya; Shafer, Tony; Noble, William S.; Hoffman, Michael M.; Buske, Orion J.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Snyder, Michael; Sherlock, Gavin; Sidow, Arend; Rauch, Rami; Cayting, Philip; Landt, Stephen G.; Shi, Minyi; Euskirchen, Ghia; Grubert, Fabian; Lacroute, Phil; Patacsil, Dorrelyn; Slifer, Teri; Yang, Xinqiong; Wu, Linfeng; Hariharan, Manoj] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA. [Dunham, Ian; Birney, Ewan; Keefe, Damian; Wilder, Steven P.; Sobral, Daniel; Herrero, Javier; Beal, Kathryn; Lukk, Margus; Brazma, Alvis; Vaquerizas, Juan M.; Luscombe, Nicholas M.] European Bioinformat Inst EBI, Cambridge, England. [Hardison, Ross C.; Harris, Robert S.; Song, Giltae; Miller, Webb] Penn State Univ, Dept Biochem & Mol Biol, Ctr Comparat Genom & Bioinformat, University Pk, PA 16802 USA. [Bernstein, Bradley E.; Epstein, Charles B.; Shoresh, Noam; Ernst, Jason; Mikkelsen, Tarjei S.; Kheradpour, Pouya; Zhang, Xiaolan; Wang, Li; Issner, Robbyn; Coyne, Michael J.; Durham, Timothy; Ku, Manching; Ward, Lucas D.; Lin, Michael F.; Kellis, Manolis; Sidow, Arend; Lin, Mike] Broad Inst MT & Harvard, Cambridge, MA USA. Howard Hughes Med Inst, Boston, MA 02115 USA. Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Lian, Jin; Weissman, Sherman M.] Harvard Univ, Sch Med, Boston, MA USA. [Gingeras, Thomas R.; Davis, Carrie A.; Dobin, Alexander; Zaleski, Christopher; Schlesinger, Felix; Batut, Philippe; Chakrabortty, Sudipto; Jha, Sonali; Lin, Wei; Drenkow, Jorg; Wang, Huaien; Bell, Kim; Fejes-Toth, Katalin; Preall, Jonathan; Gordon, Assaf; Sotirova, Vihra] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA. [Haussler, David; Rosenbloom, Kate R.; Raney, Brian J.; Barber, Galt P.; Sloan, Cricket A.; Zweig, Ann S.; Rhead, Brooke; Suh, Bernard; Paten, Benedict] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA. [Wold, Barbara; Mortazavi, Ali; Kirilusha, Anthony; Reynolds, Alex; Ebersol, Abigail K.] CALTECH, Div Biol, Pasadena, CA 91125 USA. [Mortazavi, Ali] CALTECH, Beckman Inst, Pasadena, CA 91125 USA. [Crawford, Gregory E.; Boyle, Alan P.; Winter, Deborah; London, Darin] Duke Univ, Inst Genome Sci & Policy, Durham, NC USA. Duke Univ, Dept Pediat, Durham, NC 27706 USA. MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA. [Kapranov, Philipp; Bell, Ian; Dumais, Erica; Dumais, Jacqueline] Affymetrix, Santa Clara, CA USA. [Gao, Hui] Karolinska Inst, Huddinge, Sweden. [Antonarakis, Stylianos E.; Ucla, Catherine; Borel, Christelle] Univ Geneva, Geneva, Switzerland. [Guigo, Roderic; Lagarde, Julien; Kingswood, Colin; Ribeca, Paolo; Sammeth, Micha; Merkel, Angelika; Tilgner, Hagen; Tanzer, Andrea; Knowles, David G.; Mariotti, Marco] Ctr Regulacio Genom, Barcelona, Spain. [Carninci, Piero; Hayashizaki, Yoshihide; Lassmann, Timo; Takahashi, Hazuki; Abdelhamid, Rehab F.] RIKEN Yokohama Inst, Omics Sci Ctr, Kanagawa, Japan. [Hannon, Gregory] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA. [Reymond, Alexandre] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland. [Iyer, Vishwanath R.; Lee, Bum-Kyu; McDaniell, Ryan M.; Liu, Zheng; Battenhouse, Anna; Bhinge, Akshay A.] Univ Texas Austin, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Ctr Syst & Synthet Biol, Austin, TX 78712 USA. [Lieb, Jason D.; Grasfeder, Linda L.; Showers, Kimberly A.; Giresi, Paul G.; Kim, Seul K. C.; Shestak, Christopher] Univ N Carolina, Carolina Ctr Genome Sci, Dept Biol, Chapel Hill, NC USA. [Lieb, Jason D.; Grasfeder, Linda L.; Showers, Kimberly A.; Giresi, Paul G.; Kim, Seul K. C.; Shestak, Christopher] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Pepke, Shirley] CALTECH, Ctr Adv Comp Res, Pasadena, CA 91125 USA. [Sidow, Arend; Kundaje, Anshul] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA. [Batzoglou, Serafim; Kundaje, Anshul; Libbrecht, Max] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA. [Margulies, Elliott H.; Parker, Stephen C. J.; Parker, Stephen C. J.] NHGRI, Div Intramural Res, NIH, Bethesda, MD 20892 USA. [Elnitski, Laura] NHGRI, Genome Technol Branch, NIH, Rockville, MD USA. [Green, Eric D.] NHGRI, NIH Intramural Sequencing Ctr, NIH, Bethesda, MD 20892 USA. [Hubbard, Tim; Harrow, Jennifer; Searle, Stephen; Kokocinski, Felix; Aken, Browen; Frankish, Adam; Hunt, Toby; Despacio-Reyes, Gloria; Kay, Mike; Mukherjee, Gaurab; Bignell, Alexandra; Saunders, Gary; Boychenko, Veronika] Wellcome Trust Sanger Inst, Hinxton, Cambs, England. [Boyle, Alan P.; Bhinge, Akshay A.; Frankish, Adam; Bignell, Alexandra; Khurana, Ekta; Lam, Hugo; Valencia, Alfonso; Charos, Alexandra; Rozowsky, Joel; Abyzov, Alexej; Ebersol, Abigail K.; Brown, James B.; Sboner, Andrea; Cheng, Chao; Wang, Jing; Leng, Jing] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA. [Khurana, Ekta; Lam, Hugo; Abyzov, Alexej; Sboner, Andrea; Cheng, Chao; Wang, Jing; Leng, Jing] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT USA. [Gerstein, Mark; Du, Jiang] Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA. Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA. [Valencia, Alfonso; Tress, Michael; Manuel Rodriguez, Jose] Ctr Nacl Invest Oncol, Madrid, Spain. [Raha, Debasish; Kasowski, Maya; Xu, Youhan; Monahan, Hannah; Charos, Alexandra; Reed, Brian] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA. [Lian, Jin; Weissman, Sherman M.] Yale Univ, Dept Genet, New Haven, CT USA. [Newburger, Peter; Farnham, Peggy J.] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA USA. [Frietze, Seth; O'Geen, Henriette] Univ So Calif, Norris Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA. [Frietze, Seth; O'Geen, Henriette; Xu, Xiaoqin; Blahnik, Kim R.; Cao, Alina R.; Iyengar, Sushma] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA. [Sanyal, Amartya] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Gene Funct & Express, Worcester, MA USA. [Bickel, Peter J.; Li, Qunhua; Huang, Haiyan] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA. [Wang, Ting] Washington Univ, Dept Genet, St Louis, MO 63110 USA. [Noble, William S.] Univ Washington, Dept Comp Sci & Engn, Seattle, WA 98195 USA. [Wang, Jie] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Program Bioinformat & Integrat Biol, Worcester, MA USA. [Xi, Hualin] Boston Univ, Bioinformat Program, Boston, MA 02215 USA. [Tenenbaum, Scott A.; Doyle, Frank; Chittur, Sridar] SUNY Albany, Coll Nanoscale Sci & Engn, Albany, NY 12222 USA. [Penalva, Luiz O.] Childrens Canc Res Inst, Dept Cellular & Struct Biol, San Antonio, TX USA. [Tullius, Thomas D.; Parker, Stephen C. J.] Boston Univ, Dept Chem, Boston, MA 02215 USA. [Tullius, Thomas D.; Parker, Stephen C. J.] Boston Univ, Program Bioinformat, Boston, MA 02215 USA. [White, Kevin P.; Karmakar, Subhradip; Victorsen, Alec; Jameel, Nader; Bild, Nick; Grossman, Robert L.] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA. [Collins, Patrick J.; Trinklein, Nathan D.] SwitchGear Genom, Menlo Pk, CA USA. [Giddings, Morgan C.; Khatun, Jainab; Maier, Chris] Boise State Univ, Biomol Res Ctr, Boise, ID 83725 USA. [Giddings, Morgan C.; Risk, Brian] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA. [Giddings, Morgan C.; Yu, Yanbao; Gunawardena, Harsha] Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA. [Chen, Xian; Feingold, Elise A.; Lowdon, Rebecca F.; Dillon, Laura A. L.; Good, Peter J.] NHGRI, NIH, Bethesda, MD 20892 USA. RP Myers, RM (reprint author), HudsonAlpha Inst Biotechnol, Huntsville, AL USA. RI Hardison, Ross/G-1142-2010; Alioto, Tyler/K-7267-2015; Hubbard, Tim/C-2567-2008; Tanzer, Andrea/L-3147-2015; Valencia, Alfonso/I-3127-2015; Hariharan, Manoj/N-2855-2015; Boyle, Alan/I-1848-2014; Lassmann, Timo/A-8271-2008; Tullius, Thomas/A-9685-2008; Abyzov, Alexej/M-4284-2013; Sobral, Daniel/B-4786-2014; Sammeth, Michael/C-1157-2014; Carninci, Piero/K-1568-2014; Dong, Xianjun/N-3867-2014; Antonarakis, Stylianos/N-8866-2014; Djebali, Sarah/O-9817-2014; SANYAL, AMARTYA/D-7240-2015; Brown, James/H-2971-2015; cheng, yong/I-4270-2012; Guigo, Roderic/D-1303-2010; Yu, Yanbao/G-3035-2010; Schlesinger, Felix/E-2143-2011; Vaquerizas, Juan/F-2676-2011; Wang, Jie/F-9747-2011; Frankish, Adam/G-6545-2011; Liu, Zheng/G-2612-2011; Sboner, Andrea/C-6487-2008; Sincan, Murat /A-3794-2010; Dong, Xianjun/B-5334-2012; Mikkelsen, Tarjei/A-1306-2007; Sherlock, Gavin/E-9110-2012; Hoffman, Michael/I-1924-2012; Khurana, Ekta/C-4933-2013; Yan, Koon-Kiu/A-5940-2009 OI Brazma, Alvis/0000-0001-5988-7409; Hardison, Ross/0000-0003-4084-7516; Herrero, Javier/0000-0001-7313-717X; Haugen, Eric/0000-0001-7444-8981; Wilder, Steven/0000-0001-8049-2559; Newburger, Peter/0000-0002-8615-673X; Winter, Deborah/0000-0003-1806-673X; Birney, Ewan/0000-0001-8314-8497; Sherlock, Gavin/0000-0002-1692-4983; Rozowsky, Joel/0000-0002-3565-0762; Farnham, Peggy/0000-0003-4469-7914; Saunders, Gary/0000-0002-7468-0008; Furey, Terry/0000-0001-5546-9672; Merkel, Angelika/0000-0001-5164-6803; Ward, Lucas/0000-0002-8017-809X; Dunham, Ian/0000-0003-2525-5598; Aken, Bronwen/0000-0002-3032-4095; Grossman, Robert/0000-0003-3741-5739; Alioto, Tyler/0000-0002-2960-5420; Hubbard, Tim/0000-0002-1767-9318; Tanzer, Andrea/0000-0003-2873-4236; Valencia, Alfonso/0000-0002-8937-6789; Hariharan, Manoj/0000-0002-1006-5372; Boyle, Alan/0000-0002-2081-1105; Marinov, Georgi/0000-0003-1822-7273; Gingeras, Thomas/0000-0001-9106-3573; Hunt, Toby/0000-0001-8377-0841; Song, Giltae/0000-0001-8796-4678; Sheffield, Nathan/0000-0001-5643-4068; Lassmann, Timo/0000-0002-0138-2691; Tullius, Thomas/0000-0003-4425-796X; Sobral, Daniel/0000-0003-3955-0117; Sammeth, Michael/0000-0002-6528-9883; Carninci, Piero/0000-0001-7202-7243; Dong, Xianjun/0000-0002-8052-9320; Antonarakis, Stylianos/0000-0001-8907-5823; Djebali, Sarah/0000-0002-0599-1267; SANYAL, AMARTYA/0000-0002-2109-4478; Guigo, Roderic/0000-0002-5738-4477; Yu, Yanbao/0000-0003-2994-1974; Vaquerizas, Juan/0000-0002-6583-6541; Sboner, Andrea/0000-0001-6915-3070; Mikkelsen, Tarjei/0000-0002-8133-3135; Hoffman, Michael/0000-0002-4517-1562; FU National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA FX Funded by the National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. The role of the NIH Project Management Group in the preparation of this paper was limited to coordination and scientific management of the ENCODE Consortium. NR 121 TC 156 Z9 161 U1 11 U2 96 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1544-9173 J9 PLOS BIOL JI PLoS. Biol. PD APR PY 2011 VL 9 IS 4 AR e1001046 DI 10.1371/journal.pbio.1001046 PG 21 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 755NM UT WOS:000289938900014 ER PT J AU Rajimehr, R Devaney, KJ Bilenko, NY Young, JC Tootell, RBH AF Rajimehr, Reza Devaney, Kathryn J. Bilenko, Natalia Y. Young, Jeremy C. Tootell, Roger B. H. TI The "Parahippocampal Place Area" Responds Preferentially to High Spatial Frequencies in Humans and Monkeys SO PLOS BIOLOGY LA English DT Article ID INFERIOR TEMPORAL NEURONS; HUMAN EXTRASTRIATE CORTEX; MACAQUE CEREBRAL-CORTEX; VENTRAL VISUAL PATHWAY; INFEROTEMPORAL CORTEX; OCCIPITAL CORTEX; OBJECT AREAS; SELECTIVITY; GRATINGS; REPRESENTATION AB Defining the exact mechanisms by which the brain processes visual objects and scenes remains an unresolved challenge. Valuable clues to this process have emerged from the demonstration that clusters of neurons ("modules") in inferior temporal cortex apparently respond selectively to specific categories of visual stimuli, such as places/scenes. However, the higher-order "category-selective" response could also reflect specific lower-level spatial factors. Here we tested this idea in multiple functional MRI experiments, in humans and macaque monkeys, by systematically manipulating the spatial content of geometrical shapes and natural images. These tests revealed that visual spatial discontinuities (as reflected by an increased response to high spatial frequencies) selectively activate a well-known place-selective region of visual cortex (the "parahippocampal place area") in humans. In macaques, we demonstrate a homologous cortical area, and show that it also responds selectively to higher spatial frequencies. The parahippocampal place area may use such information for detecting object borders and scene details during spatial perception and navigation. C1 [Rajimehr, Reza; Devaney, Kathryn J.; Bilenko, Natalia Y.; Young, Jeremy C.; Tootell, Roger B. H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02138 USA. [Rajimehr, Reza] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA. RP Rajimehr, R (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02138 USA. EM reza@nmr.mgh.harvard.edu FU US National Institutes of Health (NIH) [R01 MH67529, R01 EY017081]; Martinos Center for Biomedical Imaging; NCRR; MIND Institute FX This research was supported by the US National Institutes of Health (NIH Grants R01 MH67529 and R01 EY017081 to RBHT), the Martinos Center for Biomedical Imaging, the NCRR, and the MIND Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 66 Z9 66 U1 2 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1544-9173 J9 PLOS BIOL JI PLoS. Biol. PD APR PY 2011 VL 9 IS 4 AR e1000608 DI 10.1371/journal.pbio.1000608 PG 11 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA 755NM UT WOS:000289938900003 PM 21483719 ER PT J AU Moitra, E Sperry, JA Mongold, D Kyle, BN Selby, J AF Moitra, Ethan Sperry, Jeannie A. Mongold, Derek Kyle, Brandon N. Selby, Joseph TI A Group Medical Visit Program for Primary Care Patients With Chronic Pain SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE LA English DT Article DE integrated care; chronic pain; primary care; group medical visit ID RANDOMIZED-TRIAL; HEALTH-CARE; DEPRESSION; ANXIETY; METAANALYSIS; PREVALENCE; DISORDERS; QUESTIONNAIRE; MANAGEMENT; SERVICES AB Chronic pain is a significant public health problem, which leads to physical disability, psychological distress, and reduced quality of life. Furthermore, patients with chronic pain conditions place a high burden on the healthcare system because of the nature of their disease and their ongoing treatment needs. The treatment of chronic pain lends itself well to the primary care setting, where an integrated care approach involving physicians and behavioral health specialists can play a significant role in patient outcomes. One such integrated care model, Group Medical Visits (GMVs), was used to provide medical and behavioral interventions for primary care patients with chronic pain problems. The primary objective of this report is to discuss the GMV model and its feasibility. Additionally, notable baseline data are discussed. A program description is provided, as well as practical considerations for the future use of GMVs in the treatment of patients with chronic conditions. C1 [Moitra, Ethan] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA. [Sperry, Jeannie A.; Mongold, Derek; Selby, Joseph] W Virginia Univ, Dept Family Med, Morgantown, WV 26506 USA. [Sperry, Jeannie A.; Mongold, Derek] W Virginia Univ, Dept Behav Med & Psychiat, Morgantown, WV 26506 USA. [Mongold, Derek; Selby, Joseph] W Virginia Univ, Sch Med, Morgantown, WV 26506 USA. S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. RP Moitra, E (reprint author), Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Box G BH, Providence, RI 02912 USA. EM ethan_moitra@brown.edu NR 40 TC 1 Z9 2 U1 1 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0735-7028 J9 PROF PSYCHOL-RES PR JI Prof. Psychol.-Res. Pract. PD APR PY 2011 VL 42 IS 2 BP 153 EP 159 DI 10.1037/a0022240 PG 7 WC Psychology, Multidisciplinary SC Psychology GA 755JW UT WOS:000289927300008 ER PT J AU Park, JH MacLaughlin, DT Teixeira, JM AF Park, Joo Hyun MacLaughlin, David T. Teixeira, Jose M. TI The Rate of In Vitro Maturation of Primary Follicles From Adult Mice and the Quality of Oocytes is Improved in the Absence of Anti-Mullerian Hormone SO REPRODUCTIVE SCIENCES LA English DT Article DE oocytes; folliculogenesis; metaphase II; Mullerian inhibiting substance ID OVARIAN-FOLLICLE; MOUSE OOCYTES; PRIMORDIAL FOLLICLES; INHIBITING SUBSTANCE; STIMULATING-HORMONE; PREANTRAL FOLLICLES; GENE-EXPRESSION; GROWTH; FERTILIZATION; TEMPERATURE AB Anti-Mullerian hormone (AMH) inhibits the recruitment of primordial follicles into the growing pool, but its role in primary and secondary follicles is not clear. We isolated primary follicles from the ovaries of 9- to 10-week old mice and examined whether AMH affected follicular development. Follicles were matured in media that was prepared using unsexed fetal bovine serum (FBS) or female FBS (FFBS) with or without added AMH for approximately 2 weeks and maturation rates to secondary follicles and metaphase II (MII) oocytes were measured by standard morphological criteria. Rates of parthenogenetic activation and in vitro fertilization (IVF) were assessed by cleavage and blastocyst development, respectively. Whereas addition of AMH blocked primary to secondary follicle transition, the primary to secondary and secondary to MII follicle maturation rates was significantly improved with FFBS. Folliculogenesis resumed once AMH was removed from the media of the arrested primary follicles. The rates of IVF and parthenogenesis of oocytes after in vitro maturation (IVM) without AMH were also improved compared to controls. The results indicate that removal of AMH from culture conditions during IVM from primary follicular stages should be considered to improve outcome. C1 [Park, Joo Hyun; Teixeira, Jose M.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Park, Joo Hyun; MacLaughlin, David T.; Teixeira, Jose M.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [MacLaughlin, David T.] Massachusetts Gen Hosp, Pediat Surg Res Lab, Dept Surg, Boston, MA 02114 USA. RP Teixeira, JM (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Thier 931,55 Fruit St, Boston, MA 02114 USA. EM teixeira@helix.mgh.harvard.edu OI Teixeira, Jose/0000-0002-6438-5064 FU Stem Cell Research Foundation; Vincent Memorial Research Fund FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article: Grant from the Stem Cell Research Foundation and by the Vincent Memorial Research Fund to JMT. NR 41 TC 4 Z9 6 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 J9 REPROD SCI JI Reprod. Sci. PD APR PY 2011 VL 18 IS 4 BP 334 EP 341 DI 10.1177/1933719110388294 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 758KW UT WOS:000290164600003 PM 21098214 ER PT J AU Kamat, A Nijland, MJ McDonald, TJ Cox, LA Nathanielsz, PW Li, C AF Kamat, Amrita Nijland, Mark J. McDonald, Thomas J. Cox, Laura A. Nathanielsz, Peter W. Li, Cun TI Moderate Global Reduction in Maternal Nutrition Has Differential Stage of Gestation Specific Effects on beta(1)- and beta(2)-Adrenergic Receptors in the Fetal Baboon Liver SO REPRODUCTIVE SCIENCES LA English DT Article DE beta-adrenergic receptor; immunolocalization; gene expression; protein expression; baboon ID ADRENERGIC-RECEPTORS; MESSENGER-RNA; BETA(1)-ADRENERGIC RECEPTORS; RAT; GENE; EXPRESSION; GLYCOGENOLYSIS; OVEREXPRESSION; IDENTIFICATION; CYCLASE AB Hepatic beta-adrenergic receptors (beta-ARs) play a pivotal role in mobilization of reserves via gluconeogenesis and glycogenolysis to supply the animal with its energy needs during decreased nutrient availability. Using a unique nutrient-deprived baboon model, we have demonstrated for the first time that immunoreactive hepatic beta(1)- and beta(2)-AR subtypes are regionally distributed and localized on cells around the central lobular vein in 0.5 and 0.9 gestation (G) fetuses of ad libitum fed control (CTR) and maternal nutrient restricted (MNR) mothers. Furthermore, MNR decreased fetal liver immunoreactive beta(1)-AR and increased immunoreactive beta(2)-AR at 0.5G. However, at 0.9G, immunohistochemistry and Western blot analysis revealed a decrease in beta(1)-AR and no change in beta(2)-AR levels. Thus, MNR in a nonhuman primate species has effects on hepatic beta(1)- and beta(2)-ARs that are receptor- and gestation stage-specific and may represent compensatory systems whose effects would increase glucose availability in the presence of nutrient deprivation. C1 [Kamat, Amrita] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Kamat, Amrita] S Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX USA. [Nijland, Mark J.; McDonald, Thomas J.; Nathanielsz, Peter W.; Li, Cun] Univ Texas Hlth Sci Ctr San Antonio, Ctr Pregnancy & Newborn Res, San Antonio, TX 78229 USA. [McDonald, Thomas J.; Cox, Laura A.; Nathanielsz, Peter W.; Li, Cun] SW Fdn Biomed Res, Dept Genet, San Antonio, TX USA. [Nijland, Mark J.; Cox, Laura A.] SW Fdn Biomed Res, SW Natl Primate Res Ctr, San Antonio, TX 78284 USA. RP Kamat, A (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr,MC 7875, San Antonio, TX 78229 USA. EM kamat@uthscsa.edu OI Nathanielsz, Peter/0000-0001-8410-6280 FU NIH [HD 21350]; Department of Veterans Affairs [17]; American Heart Association FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article: Grant support from NIH grant HD 21350, Department of Veterans Affairs VISN 17 Award (AK) and Grant-in-Aid American Heart Association Award (AK). NR 40 TC 4 Z9 4 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 J9 REPROD SCI JI Reprod. Sci. PD APR PY 2011 VL 18 IS 4 BP 398 EP 405 DI 10.1177/1933719110386496 PG 8 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 758KW UT WOS:000290164600010 PM 21079239 ER PT J AU Valero-Cabre, A Pascual-Leone, A Coubard, OA AF Valero-Cabre, A. Pascual-Leone, A. Coubard, O. A. TI Transcranial magnetic stimulation (TMS) in basic and clinical neuroscience research SO REVUE NEUROLOGIQUE LA French DT Review DE Transcranial magnetic stimulation (TMS); Neuromodulation; Neuroscience; Connectivity; Neural networks; Brain plasticity; Neurology; Therapy ID HUMAN MOTOR CORTEX; THETA-BURST STIMULATION; CEREBRAL-BLOOD-FLOW; DORSOLATERAL PREFRONTAL CORTEX; POSITRON-EMISSION-TOMOGRAPHY; VISUAL CORTICAL EXCITABILITY; UNILATERAL SPATIAL NEGLECT; POSTERIOR PARIETAL CORTEX; DORSAL PREMOTOR CORTEX; ADULT SQUIRREL-MONKEYS AB Introduction. - Non-invasive brain stimulation methods such as transcranial magnetic stimulation (TMS) are starting to be widely used to make causality-based inferences about brain-behavior interactions. Moreover, TMS-based clinical applications are under development to treat specific neurological or psychiatric conditions, such as depression, dystonia, pain, tinnitus and the sequels of stroke, among others. Background. - TMS works by inducing non-invasively electric currents in localized cortical regions thus modulating their activity levels according to settings, such as frequency, number of pulses, train and regime duration and intertrain intervals. For instance, it is known for the motor cortex that low frequency or continuous patterns of TMS pulses tend to depress local activity whereas high frequency and discontinuous TMS patterns tend to enhance it. Additionally, local cortical effects of TMS can result in dramatic patterns in distant brain regions. These distant effects are mediated via anatomical connectivity in a magnitude that depends on the efficiency and sign of such connections. Perspectives. - An efficient use of TMS in both fields requires however, a deep understanding of its operational principles, its risks, its potential and limitations. In this article, we will briefly present the principles through which non-invasive brain stimulation methods, and in particular TMS, operate. Conclusion. - Readers will be provided with fundamental information needed to critically discuss TMS studies and design hypothesis-driven TMS applications for cognitive and clinical neuroscience research. (C) 2011 Elsevier Masson SAS. All rights reserved. C1 [Valero-Cabre, A.] CNRS UMR 7225 Inserm S975 UPMC, Grp Dynam Cerebrales Plast & Reeduc, Ctr Rech, Inst Cerveau & Moelle, F-75013 Paris, France. [Valero-Cabre, A.] Univ Pierre Mendes, UMR CNRS 5105, Lab Psychol & Neurocognit, F-38040 Grenoble, France. [Valero-Cabre, A.] Univ Pierre Mendes, CNRS UMR CRICM 7225, Lab Psychol & Neurocognit, F-38040 Grenoble, France. [Valero-Cabre, A.] Boston Univ, Sch Med, Lab Cerebral Dynam Plast & Rehabil, Boston, MA 02118 USA. [Valero-Cabre, A.; Pascual-Leone, A.] Harvard Univ, Berenson Allen Ctr Non Invas Magnet Stimulat, Sch Med, BIDMC, Boston, MA 02215 USA. [Coubard, O. A.] CNS Fed, Neuropsychol Lab, F-75019 Paris, France. RP Valero-Cabre, A (reprint author), CNRS UMR 7225 Inserm S975 UPMC, Grp Dynam Cerebrales Plast & Reeduc, Ctr Rech, Inst Cerveau & Moelle, 47 Blvd Hop, F-75013 Paris, France. EM avalerocabre@gmail.com OI Valero-Cabre, Antoni/0000-0002-5033-2279 FU NINDS NIH HHS [R21 NS062317-01A2] NR 248 TC 6 Z9 9 U1 3 U2 32 PU MASSON EDITEUR PI MOULINEAUX CEDEX 9 PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE SN 0035-3787 J9 REV NEUROL-FRANCE JI Rev. Neurol. PD APR PY 2011 VL 167 IS 4 BP 291 EP 316 DI 10.1016/j.neurol.2010.10.013 PG 26 WC Clinical Neurology SC Neurosciences & Neurology GA 759XD UT WOS:000290281100003 PM 21420698 ER PT J AU Wang, BX Losina, E Stark, R Munro, A Walensky, RP Wilke, M Martin, D Lu, ZG Freedberg, KA Wood, R AF Wang, Bingxia Losina, Elena Stark, Ruth Munro, Alison Walensky, Rochelle P. Wilke, Marisa Martin, Des Lu, Zhigang Freedberg, Kenneth A. Wood, Robin TI Loss to follow-up in a community clinic in South Africa - roles of gender, pregnancy and CD4 count SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL LA English DT Article ID ANTIRETROVIRAL TREATMENT; PROGRAMS; OUTCOMES; THERAPY; HIV AB Background. Faith-based organisations have expanded antiretroviral therapy (ART) in community clinics across South Africa. Loss to follow-up (LIEU), however, limits the potential individual and population treatment benefits and optimal care. Objective. To identify patient characteristics associated with LTFU 6 months after starting ART in a large community clinic. Methods. Patients initiating ART between April 2004 and October 2006 in one South African Catholic Bishops' Conference HIV treatment clinic who had at least one follow-up visit were included and routinely monitored every 6 months after ART initiation. Standardised instruments were used to collect data. Rates of LTFU over time were estimated by the Kaplan-Meier method. The Cox proportional hazard regression examined the impact of age, baseline CD4 count, baseline HIV RNA, gender and pregnancy status on LTFU. Results. Data front 925 patients (age > 14 years, median age 36 years, 70% female, of whom 16% were pregnant) were included: 51 (6%) were lost to follow-up 6 months after ART initiation. Younger age (<= 30 years) (hazard ratio (HR) 2.14, 95% confidence interval (Cl) 1.05 - 4.38) and pregnancy for women (HR 3.75, 95% CI 1.53 - 9.16) were significantly associated with higher LTFU rates. When stratified by baseline CD4 count, gender and pregnancy status, pregnant women with lower baseline CD4 counts (<= 200 cells/mu l) had 6.06 times the hazard (95% CI 2.20 - 16.71) of LTFU at 6 months compared with men. Conclusions. HIV-infected pregnant women initiating ART were significantly more likely to be lost to follow-up in a community clinic in South Africa. Urgent interventions to successfully retain pregnant women in care are needed. S Afr Med J 2011;101:253-257. C1 [Wang, Bingxia; Losina, Elena; Walensky, Rochelle P.; Freedberg, Kenneth A.] Harvard Univ, Sch Med, CFAR, Boston, MA 02115 USA. [Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA. [Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Wang, Bingxia; Walensky, Rochelle P.; Lu, Zhigang; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA. [Walensky, Rochelle P.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA. [Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Martin, Des] Univ Pretoria, Dept Clin Virol, ZA-0002 Pretoria, South Africa. [Wood, Robin] Univ Cape Town, Desmond Turu HIV Ctr, Inst Infect Dis & Mol Med, ZA-7700 Rondebosch, South Africa. [Wood, Robin] Univ Cape Town, Dept Med, ZA-7700 Rondebosch, South Africa. RP Losina, E (reprint author), Harvard Univ, Sch Med, CFAR, Boston, MA 02115 USA. EM elosina@partners.org RI Wood, Robin/G-8509-2011; OI Walensky, Rochelle P./0000-0002-8795-379X FU NIAID NIH HHS [R01 AI058736] NR 22 TC 26 Z9 26 U1 0 U2 4 PU SA MEDICAL ASSOC PI PRETORIA PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3, PRETORIA, 0002, SOUTH AFRICA SN 0256-9574 J9 SAMJ S AFR MED J JI SAMJ S. Afr. Med. J. PD APR PY 2011 VL 101 IS 4 BP 253 EP 257 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 757ZS UT WOS:000290129200021 PM 21786730 ER PT J AU Wang, HX Li, QL Sharma, C Knoblich, K Hemler, ME AF Wang, Hong-Xing Li, Qinglin Sharma, Chandan Knoblich, Konstantin Hemler, Martin E. TI Tetraspanin protein contributions to cancer SO BIOCHEMICAL SOCIETY TRANSACTIONS LA English DT Article; Proceedings Paper CT 4th European Conference on Tetraspanins CY SEP 08-10, 2010 CL Univ Birmingham, Birmingham, ENGLAND HO Univ Birmingham DE a disintegrin and metalloproteinase 10 (ADAM10); CD9; CD151; EWI-2; EWI-F; beta 4 integrin; tetraspanin; Tspan12 ID FAMILIAL EXUDATIVE VITREORETINOPATHY; RETINAL VASCULAR DEVELOPMENT; HUMAN BREAST-CARCINOMA; ALPHA-6-BETA-4 INTEGRIN; BETA-4 INTEGRIN; GROWTH-FACTOR; MICE LACKING; TUMOR-CELLS; IN-VIVO; HEPATOCELLULAR-CARCINOMA AB Among the 33 human tetraspanin proteins, CD151, CD9 and Tspan12 play particularly important roles in cancer. Tetraspanin CD151, in partnership with integrins alpha 6 beta 1 and alpha 6 beta 4, modulates tumour cell growth, invasion, migration, metastasis, signalling and drug sensitivity. Tetraspanin CD9 has suppressor functions in multiple tumour cell types. Major CD9 partner proteins, such as EWI-2 and EWI-F, may modulate these tumour-suppressor functions. Tetraspanin Tspan12 mutations are linked to a human disease called familial exudative vitreoretinopathy. In addition, as a regulator of the metalloprotease ADAM10 (a disintegrin and metalloprotease 10) maturation and function, Tspan12 probably contributes to the pro-tumorigenic functions of ADAM10. C1 [Wang, Hong-Xing; Li, Qinglin; Sharma, Chandan; Knoblich, Konstantin; Hemler, Martin E.] Dana Farber Canc Inst, Dept Canc Biol & AIDS, Boston, MA 02115 USA. RP Hemler, ME (reprint author), Dana Farber Canc Inst, Dept Canc Biol & AIDS, 44 Binney St, Boston, MA 02115 USA. EM Martin_Hemler@DFCI.Harvard.edu RI Knoblich, Konstantin/B-5980-2009; Li, Qinglin/K-2570-2015 OI Knoblich, Konstantin/0000-0002-5646-837X; Li, Qinglin/0000-0002-4125-1944 FU NCI NIH HHS [CA42368]; NIGMS NIH HHS [GM38903] NR 79 TC 34 Z9 36 U1 0 U2 9 PU PORTLAND PRESS LTD PI LONDON PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND SN 0300-5127 J9 BIOCHEM SOC T JI Biochem. Soc. Trans. PD APR PY 2011 VL 39 BP 547 EP 552 DI 10.1042/BST0390547 PN 2 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 755SY UT WOS:000289958200026 PM 21428937 ER PT J AU Robinson, A Fien, S Grassi, MA AF Robinson, Amanda Fien, Sari Grassi, Marcelle A. TI Nonhealing Scalp Wound Infected With Aspergillus niger in an Elderly Patient SO CUTIS LA English DT Article ID PRIMARY CUTANEOUS ASPERGILLOSIS; SOLID-ORGAN TRANSPLANT; FUNGAL-INFECTIONS; IMMUNOCOMPETENT PATIENT; INVASIVE ASPERGILLOSIS; VORICONAZOLE; HOST; EPIDEMIOLOGY; SINUSITIS; OUTBREAK AB Cutaneous aspergillosis is a rare infection most often seen in immunocompromised patients. We report a case of primary cutaneous aspergillosis infection in a nonhealing scalp wound of an immunocompetent elderly patient. The patient had a cutaneous malignancy of the scalp,treated with surgical excision but complicated by poor wound healing. Fungal culture of the nonhealing wound revealed Aspergillus niger. The nonhealing wound subsequently resolved with retapamulin ointment 1% and ketoconazole gel 2%. Cutis. 2011;87:197-200. C1 [Robinson, Amanda; Fien, Sari; Grassi, Marcelle A.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Dermatol, New York, NY USA. [Fien, Sari; Grassi, Marcelle A.] Roswell Pk Canc Inst, Dept Dermatol, Buffalo, NY 14263 USA. RP Robinson, A (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 50 Staniford St, Boston, MA 02114 USA. EM robinsonama@gmail.com NR 39 TC 2 Z9 2 U1 0 U2 1 PU QUADRANT HEALTHCOM INC PI PARSIPPANY PA 7 CENTURY DRIVE, STE 302, PARSIPPANY, NJ 07054-4603 USA SN 0011-4162 J9 CUTIS JI Cutis PD APR PY 2011 VL 87 IS 4 BP 197 EP 200 PG 4 WC Dermatology SC Dermatology GA 754TM UT WOS:000289880200012 PM 21644495 ER PT J AU Morrell, J Zeymer, U Baumgartner, I Limbourg, T Rother, J Bhatt, DL Steg, PG AF Morrell, Jonathan Zeymer, Uwe Baumgartner, Iris Limbourg, Tobias Roether, Joachim Bhatt, Deepak L. Steg, Ph Gabriel CA REACH Registry Investigators TI Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe SO EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION LA English DT Article DE Cardiovascular agents; cardiovascular disease; cardiovascular surgical procedures; sex ID CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; PERIPHERAL ARTERIAL-DISEASE; GENDER-DIFFERENCES; PRIMARY-CARE; EVENT RATES; SECONDARY PREVENTION; CARDIOVASCULAR RISK; SEX-DIFFERENCES AB Background: Although guidelines recommend similar evaluation and treatment for both sexes, differences in approach and outcomes have been reported. Design: Prospective, observational registry. Methods: Consecutive patients at high cardiovascular risk were assessed for risk factors and management at baseline, and followed-up for 2 years. Results: Twenty-two thousand and twenty-eight patients with documented arterial disease (symptomatic) or three or more atherothrombotic risk factors (asymptomatic) completed the 2-year follow-up of the REduction of Atherothrombosis for Continued Health Registry in Europe (women, 31.5%; men, 68.4%). Women patients were 3.3 years (mean) older than men. Few differences were observed between asymptomatic men and women in risk factor profile or management at baseline. Higher proportions of symptomatic women than men had diabetes (P < 0.001), hypertension (P < 0.0001), elevated total cholesterol levels (P < 0.0001) or elevated triglycerides (P < 0.01). A much lower proportion of women than men were current smokers (asymptomatic, 14.6 vs. 29.3%; symptomatic, 11.9 vs. 19.5%, both P < 0.0001). Within the symptomatic population, women received antithrombotic agents (91.8 vs. 94.9%, P < 0.0001) and lipid-lowering agents (68.2 vs. 73.1%, P < 0.0001) less frequently than men. After multivariate adjustment, fewer symptomatic women than men had undergone coronary revascularizations at 2 years (odds ratio, 0.72; 95% confidence interval, 0.61-0.85). There were no differences in primary outcomes, including cardiovascular death/myocardial infarction/stroke (odds ratio, 1.01, 95% confidence interval, 0.93-1.11, P = 0.78), between the sexes. Discussion: Although no differences were found in cardiovascular event rates at 2-year follow-up, secondary prevention could be improved in women, which might further reduce event rates. C1 [Morrell, Jonathan] Conquest Hosp, St Leonards On Sea, E Sussex, England. [Zeymer, Uwe; Limbourg, Tobias] Heidelberg Univ, Inst Herzinfarktforsch Ludwigshafen, Ludwigshafen, Germany. [Baumgartner, Iris] Univ Hosp Bern, Swiss Cardiovasc Ctr, Bern, Switzerland. [Baumgartner, Iris] Univ Bern, CH-3012 Bern, Switzerland. [Roether, Joachim] Johannes Wesling Klinikum Minden, Hannover Med Sch, Hannover, Germany. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Steg, Ph Gabriel] Univ Paris, INSERM, U698, F-75252 Paris, France. [Steg, Ph Gabriel] AP HP, Paris, France. RP Morrell, J (reprint author), Conquest Hosp, St Leonards On Sea, E Sussex, England. EM Drjmmorrell@aol.com FU sanofi-aventis; Bristol-Myers Squibb; Waksman Foundation (Tokyo, Japan); Bristol-Myers-Squibb; sanofi aventis; Lundbeck; Boehringer Ingelheim; AstraZeneca; Eisai; Ethicon; Heartscape; Medicines Company FX The REACH Registry is sponsored by sanofi-aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan).; J.M. has received honoraria from Astra Zeneca, Bristol Myers Squibb, Genzyme, MSD, Novartis, sanofi aventis, Schering Plough, Servier, Solvay Healthcare, Takeda, Pfizer and Unilever. U.Z. has received research grants and speaker honoraria from Bristol-Myers-Squibb and sanofi aventis. I.B.: none. T.L.: none. J.R. has received honoraria and consulting fees from sanofi-aventis, Bristol-Myers Squibb, Lundbeck and Boehringer Ingelheim. D. L. B. has received research grants (to the institution) from: AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, and The Medicines Company. D. L. B. has served as a consultant (honoraria waived or donated for past 3 years) for: Arena, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Car-dax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, McNeil, Medtronic, Millennium, Molecular Insights, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Scios, Takeda, The Medicines Company, and Vertex. P. G. S. has received research grant from sanofi-aventis (1999-2008); is on the Speaker's Bureau for Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Menarini, Medtronic, Nycomed, Pierre Fabre, sanofi-aventis, Servier, and The Medicines Company; is on the consulting/advisory boards for Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, Endotis, GlaxoSmithKline, Medtronic, MSD, Nycomed, sanofi-aventis, Servier, and The Medicines Company; and is a stockholder for Aterovax. NR 39 TC 17 Z9 17 U1 0 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1741-8267 J9 EUR J CARDIOV PREV R JI Eur. J. Cardiovasc. Prev. Rehabil. PD APR PY 2011 VL 18 IS 2 BP 270 EP 277 DI 10.1097/HJR.0b013e32833cca34 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 754ZG UT WOS:000289895800018 PM 20606595 ER PT J AU Liguori, M Healy, BC Glanz, BI Khoury, SJ Moscufo, N Weiner, HL De Jager, PL Guttmann, CR AF Liguori, M. Healy, B. C. Glanz, B. I. Khoury, S. J. Moscufo, N. Weiner, H. L. De Jager, P. L. Guttmann, C. R. TI HLA (A-B-C and-DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study SO GENES AND IMMUNITY LA English DT Article DE multiple sclerosis; HLA alleles; brain MRI; genotype-phenotype correlation; brain parenchymal fraction; T2-weighted lesion volume ID DISEASE SEVERITY; DIAGNOSTIC-CRITERIA; SUSCEPTIBILITY; HLA-DRB1-ASTERISK-1501; GENES; RISK; ASSOCIATION; DISABILITY; ANTIBODIES; EPISTASIS AB Several major histocompatibility complex (MHC) alleles have been postulated to influence the susceptibility to multiple sclerosis (MS), as well as its clinical/radiological course. In this longitudinal observation, we further explored the impact of human leukocyte antigen (HLA) class I/II alleles on MS outcomes, and we tested the hypothesis that HLA DRB1* 1501 might uncover different strata of MS subjects harboring distinct MHC allele associations with magnetic resonance imaging (MRI) measures. Five hundred eighteen MS patients with two-digit HLA typing and at least one brain MRI were recruited for the study. T2-weighted hyperintense lesion volume (T2LV) and brain parenchymal fraction (BPF) were acquired at each time point. The association between allele count and MRI values was determined using linear regression modeling controlling for age, disease duration and gender. Analyses were also stratified by the presence/absence of HLA DRB1*1501. HLA DRB1* 04 was associated with higher T2LV (P=0.006); after stratification, its significance remained only in the presence of HLA DRB1*1501 (P=0.012). The negative effect of HLA DRB1*14 on T2LV was exerted in DRB1*1501-negative group (P=0.012). Longitudinal analysis showed that HLA DRB1*10 was significantly protective on T2LV accrual in the presence of HLA DRB1*1501 (P=0.002). Although the majority of our results did not withstand multiple comparison correction, the differential impact of several HLA alleles in the presence/absence of HLA DRB1* 1501 suggests that they may interact in determining the different phenotypic expressions of MS. Genes and Immunity (2011) 12, 183-190; doi:10.1038/gene.2010.58; published online 23 December 2010 C1 [Liguori, M.; Moscufo, N.; Guttmann, C. R.] Harvard Univ, Ctr Neurol Imaging, Dept Radiol, Brigham & Womens Hosp,Med Sch, Boston, MA 02115 USA. [Liguori, M.] CNR, Inst Neurol Sci, Mangone, Italy. [Healy, B. C.; Glanz, B. I.; Khoury, S. J.; Weiner, H. L.; De Jager, P. L.] Brigham & Womens Hosp, Partners MS Ctr, Dept Neurol, Boston, MA 02115 USA. [Healy, B. C.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [De Jager, P. L.] Brigham & Womens Hosp, Program Translat NeuroPsychiat Genom, Dept Neurol, Boston, MA 02115 USA. [De Jager, P. L.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. RP Guttmann, CR (reprint author), Harvard Univ, Ctr Neurol Imaging, Dept Radiol, Brigham & Womens Hosp,Med Sch, 221 Longwood Ave,RF394, Boston, MA 02115 USA. EM guttmann@bwh.harvard.edu RI Liguori, Maria/D-4390-2016; OI Liguori, Maria/0000-0003-4338-0392; khoury, samia/0000-0003-3198-6063 NR 39 TC 6 Z9 6 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1466-4879 J9 GENES IMMUN JI Genes Immun. PD APR PY 2011 VL 12 IS 3 BP 183 EP 190 DI 10.1038/gene.2010.58 PG 8 WC Genetics & Heredity; Immunology SC Genetics & Heredity; Immunology GA 754DO UT WOS:000289832900004 PM 21179117 ER PT J AU Chu-Shore, CJ Kramer, MA Bianchi, MT Caviness, VS Cash, SS AF Chu-Shore, Catherine J. Kramer, Mark A. Bianchi, Matt T. Caviness, Verne S. Cash, Sydney S. TI Network Analysis: Applications for the Developing Brain SO JOURNAL OF CHILD NEUROLOGY LA English DT Article DE development; connectivity; network; neocortex ID GRAPH-THEORETICAL ANALYSIS; DEVELOPING RHESUS-MONKEY; WHITE-MATTER MATURATION; DIFFUSION-WEIGHTED MRI; RESTING-STATE NETWORKS; FUNCTIONAL CONNECTIVITY; DEFAULT NETWORK; CEREBRAL-CORTEX; SMALL-WORLD; AXON OVERPRODUCTION AB Development of the human brain follows a complex trajectory of age-specific anatomical and physiological changes. The application of network analysis provides an illuminating perspective on the dynamic interregional and global properties of this intricate and complex system. Here, we provide a critical synopsis of methods of network analysis with a focus on developing brain networks. After discussing basic concepts and approaches to network analysis, we explore the primary events of anatomical cortical development from gestation through adolescence. Upon this framework, we describe early work revealing the evolution of age-specific functional brain networks in normal neurodevelopment. Finally, we review how these relationships can be altered in disease and perhaps even rectified with treatment. While this method of description and inquiry remains in early form, there is already substantial evidence that the application of network models and analysis to understanding normal and abnormal human neural development holds tremendous promise for future discovery. C1 [Chu-Shore, Catherine J.; Bianchi, Matt T.; Caviness, Verne S.; Cash, Sydney S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA. [Kramer, Mark A.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. RP Chu-Shore, CJ (reprint author), 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM cchushore@partners.org RI Kramer, Mark/A-1291-2014 FU Burroughs Wellcome Fund; Department of Neurology, Massachusetts General Hospital; Harvard/MIT Health Sciences and Technology-Beth Israel Deaconess Medical Center; Pfizer, Inc.; Merck Co.; NINDS [NS062092] FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article: Mark A. Kramer holds a Career Award at the Scientific Interface from the Burroughs Wellcome Fund. Matt T. Bianchi receives funding from the Department of Neurology, Massachusetts General Hospital, and the Clinical Investigator Training Program: Harvard/MIT Health Sciences and Technology-Beth Israel Deaconess Medical Center, in collaboration with Pfizer, Inc., and Merck &Co. Sydney S. Cash is supported by NINDS-NS062092. NR 102 TC 13 Z9 13 U1 1 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0883-0738 J9 J CHILD NEUROL JI J. Child Neurol. PD APR PY 2011 VL 26 IS 4 BP 488 EP 500 DI 10.1177/0883073810385345 PG 13 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 751OO UT WOS:000289627600012 PM 21303762 ER PT J AU Chaiwat, O Vavilala, MS Philip, S Malakouti, A Neff, MJ Deem, S Treggiari, MM Wang, J Lang, JD AF Chaiwat, Onuma Vavilala, Monica S. Philip, Shaji Malakouti, Amin Neff, Margaret J. Deem, Steven Treggiari, Miriam M. Wang, Jin Lang, John D. TI Intraoperative adherence to a low tidal volume ventilation strategy in critically ill patients with preexisting acute lung injury SO JOURNAL OF CRITICAL CARE LA English DT Article DE Lung injury; ALI; ARDS; Low tidal volume; Mechanical ventilation; Intraoperative; Anesthesia ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CLINICAL-TRIAL; MECHANICAL VENTILATION; PROTECTIVE-VENTILATION; INFLAMMATORY RESPONSES; CARDIOPULMONARY BYPASS; PULMONARY-FUNCTION; CARDIAC-SURGERY; THERAPY; RELEASE AB Purpose: Low tidal volume (LTV) ventilation reduces mortality in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). This study investigates adherence of intraoperative LTV and whether patient outcomes were different with or without continued intraoperative LTV ventilation in patients with previously established ALI or ARDS. Materials and Methods: A retrospective analysis was performed of adults with ALI/ARDS over a 2-year period who underwent surgery between 24 hours and 14 days after the diagnosis of ALI/ARDS. The main outcome was intraoperative LTV use. Secondary outcomes included perioperative respiratory and clinical outcomes. Results: Of the 249 patients who underwent surgery between 24 hours and 14 days after ALI/ARDS diagnosis, 101 (41%) received preoperative LTV ventilation. Fifty-four (53%) received intraoperative LTV ventilation, whereas 47 (47%) did not. Use of preoperative LTV ventilation was associated with use of intraoperative LTV ventilation (P < .01). No differences in respiratory or clinical outcomes between patients with or without intraoperative LTV ventilation were observed. Conclusions: Adherence to intraoperative LTV in surgical patients was low. Adherence of LTV intraoperatively was not associated with improved oxygenation, reductions in hospital length of stay, or in-hospital mortality. The importance of adhering to an intraoperative LTV strategy remains unclear. Published by Elsevier Inc. C1 [Lang, John D.] Univ Washington, Sch Med, Dept Anesthesiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Lang, John D.] Univ Washington, Sch Med, Dept Pulm & Crit Care Med, Seattle, WA USA. [Neff, Margaret J.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Deem, Steven] Univ Washington, Sch Med, Dept Anesthesiol & Med Pulm & Crit Care Med, Seattle, WA USA. [Treggiari, Miriam M.] Univ Washington, Sch Med, Dept Anesthesiol & Neurol Surg, Seattle, WA USA. [Wang, Jin] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA USA. RP Lang, JD (reprint author), Univ Washington, Sch Med, Dept Anesthesiol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM jdlang@u.washington.edu FU Harborview Anesthesiology Research Center; National Institutes of Health [HL067982] FX Funded by Harborview Anesthesiology Research Center and National Institutes of Health HL067982. NR 25 TC 10 Z9 11 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0883-9441 J9 J CRIT CARE JI J. Crit. Care PD APR PY 2011 VL 26 IS 2 BP 144 EP 151 DI 10.1016/j.jcrc.2010.08.002 PG 8 WC Critical Care Medicine SC General & Internal Medicine GA 754WG UT WOS:000289887800008 PM 20869200 ER PT J AU Denisenko, O Lin, B Louey, S Thornburg, K Bomsztyk, K Bagby, S AF Denisenko, O. Lin, B. Louey, S. Thornburg, K. Bomsztyk, K. Bagby, S. TI Maternal malnutrition and placental insufficiency induce global downregulation of gene expression in fetal kidneys SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE LA English DT Article DE epigenetics; gene expression; histone modifications; intrauterine growth restriction; transcription ID GESTATIONAL-AGE FETUSES; DEVELOPMENTAL ORIGINS; CHROMATIN-STRUCTURE; GROWTH RESTRICTION; RNA-POLYMERASE; POSTNATAL-GROWTH; DNA METHYLATION; ADULT DISEASE; BIRTH-WEIGHT; RAT-KIDNEY AB Malnutrition during pregnancy causes intrauterine growth restriction and long-term changes in the offspring's physiology and metabolism. To explore molecular mechanisms by which the intrauterine environment conveys programming in fetal kidneys, an organ known to undergo substantial changes in many animal models of late gestational undernutrition, we used a microswine model of maternal protein restriction (MPR) in which sows were exposed to isocaloric low protein (LP) diet during late gestation/early lactation to encompass the bulk of nephrogenesis. To define general v. model-specific effects, we also used a sheep model of placental insufficiency. In kidneys from near-term fetal and neonatal microswine LP offspring, per cell levels of total RNA, poly(A)+ mRNA and transcripts of several randomly chosen housekeeping genes were significantly reduced compared to controls. Microarray analysis revealed only a few MPR-resistant genes that escape such downregulation. The ratio of histone modifications H3K4m3/H3K9m3 (active/silenced) was reduced at promoters of downregulated but not MPR-resistant genes suggesting that transcriptional suppression is the point of control. In juvenile offspring, on a normal diet from weaning, cellular RNA levels and histone mark patterns were recovered to near control levels, indicating that global repression of transcription is dependent on ongoing MPR. Importantly, cellular RNA content was also reduced in ovine fetal kidneys during placental insufficiency. These studies show that global repression of transcription may be a universal consequence of a poor intrauterine environment that contributes to fetal restriction. C1 [Denisenko, O.; Bomsztyk, K.] Univ Washington, Dept Med, Seattle, WA 98109 USA. [Louey, S.; Thornburg, K.; Bagby, S.] Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97201 USA. [Louey, S.; Thornburg, K.] Oregon Hlth & Sci Univ, Div Cardiovasc Med, Portland, OR 97201 USA. [Lin, B.; Bagby, S.] Oregon Hlth & Sci Univ, Div Nephrol, Portland, OR 97201 USA. [Lin, B.; Bagby, S.] Portland VA Med Ctr, Res Serv, Portland, OR USA. RP Denisenko, O (reprint author), Univ Washington, Dept Med, 815 Mercer St,Room 244, Seattle, WA 98109 USA. EM odenis@uw.edu FU NIH/NICHD [P01HD34430, RO1 HD042570]; Medical Research Foundation of Oregon; M. Lowell Edwards Endowment; NIH [R37 DK45978]; Gates Foundation FX This study was supported by grants P01HD34430 and RO1 HD042570 (SB) from NIH/NICHD, the Medical Research Foundation of Oregon (SB), M. Lowell Edwards Endowment (KT), NIH grant R37 DK45978 (KB) and a grant from Gates Foundation (OD). Microarray assays were performed in the OHSU Gene Microarray Shared Resource. The authors are grateful to Dr Chris Harrington for microarray assistance and Dr G. Bagby for discussions and critical reading of the manuscript. NR 64 TC 8 Z9 8 U1 0 U2 6 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 2040-1744 J9 J DEV ORIG HLTH DIS JI J. Dev. Orig. Health Dis. PD APR PY 2011 VL 2 IS 2 BP 124 EP 133 DI 10.1017/S2040174410000632 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 755MC UT WOS:000289934700006 PM 25140926 ER PT J AU Milne, LW AF Milne, Leslie W. TI THORACIC TRAUMA IN POLO: TWO CASES AND A REVIEW OF THE LITERATURE SO JOURNAL OF EMERGENCY MEDICINE LA English DT Review DE polo; equestrian injury; chest trauma; horseback riding; horses ID RIDING ACCIDENTS; SPINAL-INJURIES; SPORTS AB Background: The traditional sport of polo has been played for centuries and has been deemed one of the most dangerous sports due to its high speed and the uncertainty of what might happen as directions change and contact occurs between horses and riders as well as with balls and mallets. Despite its longevity, there is very little in the medical literature about the sport of polo. Objectives: Two cases of thoracic trauma after falls from horses while playing polo are presented. Both falls resulted in similar injury patterns to the riders. A discussion follows that reviews the medical literature on equestrian injuries in general and polo injuries in particular. Discussion: Both cases show a similar injury pattern of clavicle fracture, multiple rib fractures, and lung injury (pulmonary contusion and pneumothorax). Literature review reveals severe injury including head and spinal trauma to be disproportionately represented in the equestrian sports. Conclusion: Emergency physicians should look for significant injuries when evaluating victims of polo accidents, as the forces generated can be quite high. Protective equipment, although potentially helpful, has not been studied and may not prevent these high-velocity injuries. (C) 2011 Elsevier Inc. C1 [Milne, Leslie W.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Milne, LW (reprint author), Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. NR 11 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD APR PY 2011 VL 40 IS 4 BP 410 EP 414 DI 10.1016/j.jemermed.2010.07.006 PG 5 WC Emergency Medicine SC Emergency Medicine GA 754CD UT WOS:000289828600010 PM 20947282 ER PT J AU Hariharan, P Kabrhel, C AF Hariharan, Praveen Kabrhel, Christopher TI SENSITIVITY OF ERYTHROCYTE SEDIMENTATION RATE AND C-REACTIVE PROTEIN FOR THE EXCLUSION OF SEPTIC ARTHRITIS IN EMERGENCY DEPARTMENT PATIENTS SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article; Proceedings Paper CT Conference on Mediterranean Emergency Medicine CY 2009 CL Valencia, SPAIN DE septic arthritis; erythrocyte sedimentation rate; C-reactive protein; joint infection AB Background: Previous studies in postoperative orthopedic and pediatric patients suggest that erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) testing may be helpful in ruling out septic arthritis. However, these tests have not been evaluated in a population of adult Emergency Department (ED) patients. Study Objective: Determine the sensitivity of ESR and CRP in patients with septic arthritis. Methods: Retrospective analysis of ED patients with septic arthritis from 2003 to 2008. Eligible patients had an International Classification of Diseases - Ninth Revision diagnosis of pyogenic arthritis (711.0x) plus: positive synovial fluid culture, positive synovial Gram stain, or operative irrigation. Patients were excluded if no ESR or CRP was performed within 24 h. Sensitivity of ESR and CRP at various cutoffs was calculated with 95% confidence intervals (CI). Results: We identified 167 patients with septic arthritis. We included 143 (86%) who had ESR (n = 140, 84%) or CRP (n = 96, 57%) performed. Mean age was 49 (+/- 22) years, and 85 (59%) were male. Race was: 125 (87%) white, 4 (3%) black, and 12 (8%) Hispanic. Thirty-five (24%) had infection of prosthetic joints. Synovial cultures were positive in 102 (71%). Sensitivity of ESR was: 98% (95% CI 94-100%) using a cutoff of >= 10 mm/h (n=134) and 94% (95% CI 88-97%) using a cutoff of >= 15 mm/h (n = 131). The sensitivity of CRP was 92% (95% CI 84-96%) using a cutoff of >= 20 mg/L (n = 88). Conclusion: ESR and CRP have sensitivities of > 90% for septic arthritis, but only when low thresholds are used. Further study is required to determine the clinical usefulness of ESR and CRP testing. (C) 2011 Elsevier Inc. C1 [Kabrhel, Christopher] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02114 USA. [Hariharan, Praveen] Boston Univ, Med Ctr, Dept Med, Internal Med Residency Program, Boston, MA USA. RP Kabrhel, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. OI Kabrhel, Christopher/0000-0002-8699-7176 NR 9 TC 11 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD APR PY 2011 VL 40 IS 4 BP 428 EP 431 DI 10.1016/j.jemermed.2010.05.029 PG 4 WC Emergency Medicine SC Emergency Medicine GA 754CD UT WOS:000289828600013 PM 20655163 ER PT J AU Elmer, J Tiamfook-Morgan, T Brown, DFM Nadel, ES AF Elmer, Jonathan Tiamfook-Morgan, Tami Brown, David F. M. Nadel, Eric S. TI A 25-YEAR-OLD WOMAN WITH PROGRESSIVE NEUROLOGICAL DECLINE SO JOURNAL OF EMERGENCY MEDICINE LA English DT Editorial Material ID ANOREXIA-NERVOSA; WERNICKES ENCEPHALOPATHY; EATING-DISORDER; DEFICIENCY; COMPLICATIONS; PATIENT C1 [Nadel, Eric S.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. [Elmer, Jonathan] Massachusetts Gen Hosp Harvard Affiliated Emergen, Brigham & Womens Hosp, Boston, MA USA. [Tiamfook-Morgan, Tami] Mt Auburn Hosp, Dept Emergency Med, Cambridge, MA USA. [Brown, David F. M.; Nadel, Eric S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Nadel, ES (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. NR 18 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD APR PY 2011 VL 40 IS 4 BP 432 EP 435 DI 10.1016/j.jemermed.2010.10.016 PG 4 WC Emergency Medicine SC Emergency Medicine GA 754CD UT WOS:000289828600014 PM 21123018 ER PT J AU Walls, RM AF Walls, Ron M. TI FACILITATING SMOOTH INSERTION OF AN ENDOTRACHEAL TUBE INTO THE TRACHEA UNDER GLIDESCOPE (R) VIDEO LARYNGOSCOPE REPLY SO JOURNAL OF EMERGENCY MEDICINE LA English DT Letter C1 Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. RP Walls, RM (reprint author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD APR PY 2011 VL 40 IS 4 BP 444 EP 445 DI 10.1016/j.jemermed.2011.03.002 PG 2 WC Emergency Medicine SC Emergency Medicine GA 754CD UT WOS:000289828600020 ER PT J AU Jamshidi, S Kandiah, PA Singhal, AB Resnick, JB Furie, KL Borczuk, P Parry, BA Lev, M Koroshetz, WJ Chang, YC Nagurney, JT AF Jamshidi, Soheil Kandiah, Prem A. Singhal, Aneesh B. Resnick, Joshua B. Furie, Karen L. Borczuk, Pierre Parry, Blair A. Lev, Michael Koroshetz, Walter J. Chang, Yuchiao Nagurney, John T. TI CLINICAL PREDICTORS OF SIGNIFICANT FINDINGS ON HEAD COMPUTED TOMOGRAPHIC ANGIOGRAPHY SO JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE neurology; stroke; imaging; CT; CTA; angiography ID ACUTE ISCHEMIC-STROKE; CT-ANGIOGRAPHY; INTRACEREBRAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE; HEMATOMA EXPANSION; BRAIN; ANEURYSMS; INJURIES; QUALITY AB Background: Although head computed tomographic angiography (CTA) is a sensitive tool for the evaluation of neurological symptoms in the emergency department (ED), little is known about which clinical signs predict significant CTA findings. Objectives: To identify clinical factors that predict significant findings on head CTA in patients presenting to the ED with neurological complaints. Methods: Retrospective chart review of consecutive adult patients undergoing head CTA over a 6-month period in an urban, tertiary care ED with an annual volume of 76,000. Significant head CTA findings were defined as clinically significant neurological abnormalities undetected by previous imaging studies. Demographics, chief complaint, results of the neurological examinations (NE), and head non-contrast computed tomography (CT) results were used as predictors of significant head CTA. All predictors with a univariate p < 0.2 using Pearson's chi-squared were entered stepwise into a multivariable logistic regression including odds ratios (OR), with inclusion restricted to p < 0.05. Results: Chart review yielded 456 cases; 215 (47%) were male. Mean age was 62 (SD 20) years. There were 189 patients (41%) with abnormal CTAs. Multivariable logistic regression indicated five variables that predicted a clinically significant CTA: abnormal CT (OR 3.72), chief complaint of subarachnoid hemorrhage-type headache (OR 2.30), and motor deficit (OR 2.23), visual deficit (OR 2.23), and other focal deficit (OR 2.18) on NE. A chief complaint of trauma (OR 0.23) predicted a normal CTA. Conclusions: Specific historical and focal neurological findings are useful for predicting clinically significant findings on head CTA. (C) 2011 Published by Elsevier Inc. C1 [Jamshidi, Soheil; Resnick, Joshua B.; Borczuk, Pierre; Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Singhal, Aneesh B.; Furie, Karen L.; Koroshetz, Walter J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Jamshidi, S (reprint author), 100 Lowinger Ave, Ancaster, ON L9K 1P9, Canada. NR 20 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0736-4679 J9 J EMERG MED JI J. Emerg. Med. PD APR PY 2011 VL 40 IS 4 BP 469 EP 474 DI 10.1016/j.jemermed.2009.08.021 PG 6 WC Emergency Medicine SC Emergency Medicine GA 754CD UT WOS:000289828600026 PM 19854018 ER PT J AU Rodriguez-Garcia, M Porichis, F de Jong, OG Levi, K Diefenbach, TJ Lifson, JD Freeman, GJ Walker, BD Kaufmann, DE Kavanagh, DG AF Rodriguez-Garcia, Marta Porichis, Filippos de Jong, Olivier G. Levi, Karen Diefenbach, Thomas J. Lifson, Jeffrey D. Freeman, Gordon J. Walker, Bruce D. Kaufmann, Daniel E. Kavanagh, Daniel G. TI Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10 SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE B7-H1; B7-DC ID T-CELL-ACTIVATION; PROGRAMMED DEATH-1; DENDRITIC CELLS; DISEASE PROGRESSION; INFECTION; MONOCYTES; IMMUNITY; LIGANDS; B7-H1; B7-DC AB PD-1 plays an important role in T cell exhaustion during HIV infection. PD-1 has two ligands: PD-L1, expressed on hematopoietic and nonhematopoietic cells, and PD-L2, limited to DCs and macrophages. Little is known about PD-L1 expression and regulation in human macrophages. Previous reports have found few immediate effects of macrophage exposure to HIV, suggesting that macrophages lack PRRs for this virus. Using quantitative confocal microscopy and a multiplexed cytokine bead array, we measured induction of PD-L1, PD-L2, and innate response cytokines in human MDMs in response to chemically inactivated HIV virions. Consistent with previous reports, no cytokines were induced by HIV virion exposure. Whereas PD-L1 and PD-L2 had low baseline expression, TLR ligands (LPS and CL097) up-regulated PD-L1 but not PD-L2. Unlike what we found for cytokine expression, PD-L1 and PD-L2 were up-regulated in response to exposure with inactivated HIV virions or with replication-competent HIV. Expression of PD-L1 was differentially modulated by IL-10, which induced up-regulation of PD-L1 but not of PD-L2, and IL-10 blockade enhanced only PD-L2 expression. We discuss implications for innate recognition of HIV by macrophages and potential, different roles for PD-L1 and PD-L2 in immunity and pathogenesis. J. Leukoc. Biol. 89: 507-515; 2011. C1 [Rodriguez-Garcia, Marta; Porichis, Filippos; de Jong, Olivier G.; Levi, Karen; Diefenbach, Thomas J.; Walker, Bruce D.; Kaufmann, Daniel E.; Kavanagh, Daniel G.] MIT, Ragon Inst MGH, Charlestown, MA 02129 USA. [Rodriguez-Garcia, Marta; Porichis, Filippos; de Jong, Olivier G.; Levi, Karen; Diefenbach, Thomas J.; Walker, Bruce D.; Kaufmann, Daniel E.; Kavanagh, Daniel G.] Harvard Univ, Charlestown, MA 02129 USA. [Walker, Bruce D.] Howard Hughes Med Inst, Charlestown, MA USA. [Lifson, Jeffrey D.] SAIC Frederick Inc, AIDS & Canc Virus Program, Natl Canc Inst Frederick, Frederick, MD USA. [Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med,Dept Med Oncol, Boston, MA 02115 USA. [Kaufmann, Daniel E.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Kavanagh, DG (reprint author), MIT, Ragon Inst MGH, 149 13th St, Charlestown, MA 02129 USA. EM dkavanagh@partners.org FU National Institutes of Health [1U19A1082630, A108080192, HL92565]; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; [1P01AI080192-0] FX This work was supported by grant 1P01AI080192-0 and grants 1U19A1082630, A108080192, and HL92565 from the National Institutes of Health. The work was supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. We thank Marcus Altfeld, Judy Chang, and Angela Meier for their comments and suggestions. NR 40 TC 43 Z9 43 U1 0 U2 6 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD APR PY 2011 VL 89 IS 4 BP 507 EP 515 DI 10.1189/jlb.0610327 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 757OZ UT WOS:000290098900004 PM 21097698 ER PT J AU Perez, RA Ginebra, MP Spector, M AF Perez, R. A. Ginebra, M. P. Spector, M. TI Cell response to collagen-calcium phosphate cement scaffolds investigated for nonviral gene delivery SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE LA English DT Article; Proceedings Paper CT 23rd European Conference on Biomaterials CY SEP, 2010 CL Tampere, FINLAND ID BONE MORPHOGENETIC PROTEIN; HYDROXYAPATITE SCAFFOLDS; NANOPARTICLES; TRANSFECTION; ADSORPTION; VECTORS; GELATIN; SPONGE; REPAIR; BMP-7 AB Collagen-hydroxyapatite (HA) scaffolds for the non-viral delivery of a plasmid encoding the osteoinductive protein bone morphogenetic protein (BMP)-7 were developed. The collagen-HA was obtained by the combination of calcium phosphate cement in a collagen template. The effect on cell behavior of increasing amounts of HA in the scaffolds was evaluated. Collagen-HA scaffolds containing 13, 23 or 83 wt% HA were prepared. Cell proliferation was reduced in the 83% HA scaffold after 1 day compared to 13 and 23% HA, but by 14 days the number of cells in 83% HA considerably increased. Alkaline phosphatase (ALP) activity was 8 times higher for the 83% HA scaffolds. BMP-7 plasmid was incorporated into the 83% HA scaffold. The transfection was low, although significant levels of BMP7 were expressed, associated with an increase in cell proliferation. C1 [Spector, M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Orthoped Res Lab, Boston, MA 02115 USA. [Perez, R. A.; Ginebra, M. P.] Tech Univ Catalonia UPC, Dept Mat Sci & Met, Biomat Biomech & Tissue Engn Grp, Barcelona 08028, Spain. [Perez, R. A.; Ginebra, M. P.] Biomed Res Networking Ctr Bioengn, Biomat & Nanomed CIBER BBN, Zaragoza 50118, Spain. [Perez, R. A.; Spector, M.] VA Boston Healthcare Syst, Tissue Engn, Boston, MA 02130 USA. RP Spector, M (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Orthoped Res Lab, Boston, MA 02115 USA. EM mspector@rics.bwh.harvard.edu RI Perez, Roman/E-9445-2012 NR 37 TC 14 Z9 15 U1 0 U2 11 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-4530 EI 1573-4838 J9 J MATER SCI-MATER M JI J. Mater. Sci.-Mater. Med. PD APR PY 2011 VL 22 IS 4 BP 887 EP 897 DI 10.1007/s10856-011-4308-5 PG 11 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA 756VY UT WOS:000290044000015 PM 21461916 ER PT J AU Ohta, K Kajiya, M Zhu, T Nishi, H Mawardi, H Shin, J Elbadawi, L Kamata, N Komatsuzawa, H Kawai, T AF Ohta, Kouji Kajiya, Mikihiko Zhu, Tongbo Nishi, Hiromi Mawardi, Hani Shin, Jane Elbadawi, Leena Kamata, Nobuyuki Komatsuzawa, Hitoshi Kawai, Toshihisa TI Additive effects of orexin B and vasoactive intestinal polypeptide on LL-37-mediated antimicrobial activities SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE Neuropeptide; Orexin B; Vasoactive intestinal polypeptide; LL-37; Antimicrobial activity AB The present study examined the bactericidal effects of orexin B (ORXB) and vasoactive intestinal peptide (VIP) alone or combined with cationic antimicrobial peptides, such as LL-37, on Escherichia coli, Pseudomonas aeruginosa, Streptococcus mutans and Staphylococcus aureus. The bactericidal effect of ORXB or VIP alone was detected in low NaCl concentration, but attenuated in physiological NaCl concentration (150 mM). However, such attenuated bactericidal activities of ORXB and VIP in 150 mM NaCl were regained by adding LL-37. Therefore, our results indicate that VIP and ORXB appear to mediate bactericidal effects in concert with LL-37 in the physiological context of mucosal tissue. (C) 2010 Elsevier B.V. All rights reserved. C1 [Ohta, Kouji; Kajiya, Mikihiko; Zhu, Tongbo; Nishi, Hiromi; Mawardi, Hani; Shin, Jane; Elbadawi, Leena; Kawai, Toshihisa] Forsyth Inst, Dept Immunol, Cambridge, MA USA. [Ohta, Kouji; Kajiya, Mikihiko; Zhu, Tongbo; Mawardi, Hani; Shin, Jane; Kawai, Toshihisa] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. [Elbadawi, Leena] Tufts Univ, Sch Dent Med, Dept Periodontol, Boston, MA 02111 USA. [Kamata, Nobuyuki] Hiroshima Univ, Dept Oral & Maxillofacial Surg, Programs Appl Biomed, Div Cervicognathostmatol,Grad Sch Biomed Sci, Hiroshima, Japan. [Komatsuzawa, Hitoshi] Kagoshima Univ Grad, Sch Med & Dent Sci, Dept Oral Microbiol, Kagoshima, Japan. RP Kawai, T (reprint author), Forsyth Inst, Dept Immunol, Cambridge, MA USA. EM tkawai@forsyth.org FU National Institute of Dental and Craniofacial Research, NIH [DE-018310]; Harvard Catalyst FX This study was supported by NIH grant DE-018310 from the National Institute of Dental and Craniofacial Research and Pilot Grant from Harvard Catalyst. NR 1 TC 8 Z9 8 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 EI 1872-8421 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD APR PY 2011 VL 233 IS 1-2 BP 37 EP 45 DI 10.1016/j.jneuroim.2010.11.009 PG 9 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 757FD UT WOS:000290070000006 PM 21176972 ER PT J AU Gross, R Healy, BC Cepok, S Chitnis, T Khoury, SJ Hemmer, B Weiner, HL Hafler, DA De Jager, PL AF Gross, Robert Healy, Brian C. Cepok, Sabine Chitnis, Tanuja Khoury, Samia J. Hemmer, Bernard Weiner, Howard L. Hafler, David A. De Jager, Philip L. TI Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE Multiple sclerosis; Disease modifying treatment; Genetic ID PLACEBO-CONTROLLED TRIAL; GLATIRAMER ACETATE; DOUBLE-BLIND; INTERFERON BETA-1B; RELAPSING MS; MULTICENTER; THERAPY; DISEASE; MRI AB Using retrospectively collected outcome data for treatment naive subjects treated with either glatiramer acetate (GA) (n=332) or interferon beta (IFN beta) (n=424), we replicated the lack of a significant difference in efficacy between? these treatments. Further, for both treatments, we observed a decline in the hazard of a relapse over time, which may suggest the existence of subsets of subjects with differential responses to each treatment. The HLA DRB1*1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN beta treated subjects. (C) 2010 Elsevier B.V. All rights reserved. C1 [Gross, Robert; De Jager, Philip L.] Brigham & Womens Hosp, Program Translat NeuroPsychiat Gen, Dept Neurol, Boston, MA 02115 USA. [Gross, Robert; Healy, Brian C.; Chitnis, Tanuja; Khoury, Samia J.; Weiner, Howard L.; Hafler, David A.; De Jager, Philip L.] Harvard Univ, Sch Med, Boston, MA USA. [Healy, Brian C.; Chitnis, Tanuja; Khoury, Samia J.; Weiner, Howard L.; Hafler, David A.; De Jager, Philip L.] Brigham & Womens Hosp, Dept Neurol, Partners Multiple Sclerosis Ctr, Boston, MA 02115 USA. [Healy, Brian C.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. [Cepok, Sabine; Hemmer, Bernard] Tech Univ Munich, Klinikum Rechts Isar, Dept Neurol, D-8000 Munich, Germany. [Hafler, David A.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA. [Hafler, David A.; De Jager, Philip L.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. RP De Jager, PL (reprint author), Brigham & Womens Hosp, Program Translat NeuroPsychiat Gen, Dept Neurol, 77 Ave Louis Pasteur,NRB 168C, Boston, MA 02115 USA. EM pdejager@rics.bwh.harvard.edu OI khoury, samia/0000-0003-3198-6063 FU National MS Society (NMSS) FX P.L.D. is a Harry Weaver Neuroscience Scholar Award Recipient of the National MS Society (NMSS). DAH is a Jacob Javits Scholar of the NIH. NR 27 TC 16 Z9 16 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD APR PY 2011 VL 233 IS 1-2 BP 168 EP 174 DI 10.1016/j.jneuroim.2010.10.038 PG 7 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 757FD UT WOS:000290070000021 PM 21115201 ER PT J AU Bassig, BA Inskip, PD Burdette, L Shapiro, WR Selker, RG Fine, HA Loeffler, JS Black, PM Dubrow, R Brenner, AV AF Bassig, Bryan A. Inskip, Peter D. Burdette, Laurie Shapiro, William R. Selker, Robert G. Fine, Howard A. Loeffler, Jay S. Black, Peter M. Dubrow, Robert Brenner, Alina V. TI Selected human leukocyte antigen class II polymorphisms and risk of adult glioma SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE Glioma; Brain tumors; HLA polymorphisms; DQB1; DRB1 AB Few studies have examined the relationship between human leukocyte antigen (HLA) polymorphisms and adult glioma, particularly at class II loci. We evaluated the association between selected HLA class II polymorphisms and adult glioma in a large, hospital-based case-control study, using unconditional logistic regression. DQB1*06 (OR=1.67, 95% CI=1.17-2.39) and DRB1*13 (OR=1.69, 95% CI=1.08-2.64) alleles were associated with an increased risk of glioma, while the DQB1*05 allele showed an inverse association (OR=0.63, 95% CI=0.43-0.93). These results, which were of borderline significance once controlled for the false discovery rate, suggest a potential role for the DQB1*06, DQB1*05, and DRB1*13 alleles in glioma susceptibility. (C) 2010 Published by Elsevier B.V. C1 [Inskip, Peter D.; Brenner, Alina V.] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Bassig, Bryan A.; Dubrow, Robert] Yale Univ, Sch Med, Yale Sch Publ Hlth, New Haven, CT 06510 USA. [Burdette, Laurie] NCI Frederick, Core Genotyping Facil, Adv Technol Program, SAIC Frederick Inc, Ft Detrick, MD 21702 USA. [Shapiro, William R.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA. [Selker, Robert G.] Western Penn Hosp, Div Neurosurg, Pittsburgh, PA 15224 USA. [Fine, Howard A.] NCI, Neurooncol Branch, Bethesda, MD 20892 USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Black, Peter M.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Brenner, AV (reprint author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,MSC 7362, Bethesda, MD 20892 USA. EM brennera@mail.nih.gov FU National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics) FX This study was supported by Intramural Research program of the National Institutes of Health (National Cancer Institute, Division of Cancer Epidemiology and Genetics). NR 1 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD APR PY 2011 VL 233 IS 1-2 BP 185 EP 191 DI 10.1016/j.jneuroim.2010.11.005 PG 7 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 757FD UT WOS:000290070000024 PM 21195488 ER PT J AU Hilsabeck, RC Anstead, GM Webb, AL Stern, SL Hoyumpa, A AF Hilsabeck, Robin C. Anstead, Gregory M. Webb, Amy L. Stern, Stephen L. Hoyumpa, Anastasio TI Impact of Helicobacter pylori on chronic hepatitis C-related cognitive dysfunction Response SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Letter ID CENTRAL-NERVOUS-SYSTEM; VIRUS; EFFICIENCY; LIVER C1 [Hilsabeck, Robin C.; Anstead, Gregory M.; Webb, Amy L.; Stern, Stephen L.] S Texas Vet Hlth Care Syst, Psychol Serv 116B, San Antonio, TX 78229 USA. [Anstead, Gregory M.; Webb, Amy L.; Stern, Stephen L.; Hoyumpa, Anastasio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. RP Hilsabeck, RC (reprint author), S Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Hilsabeck@uthscsa.edu NR 11 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD APR PY 2011 VL 233 IS 1-2 BP 257 EP 258 DI 10.1016/j.jneuroim.2010.10.003 PG 2 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 757FD UT WOS:000290070000036 ER PT J AU Codman, EA AF Codman, E. A. (mory) TI Complete rupture of the supraspinatus tendon. Operative treatment with report of two successful cases SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Codman, EA (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 7 Z9 8 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD APR PY 2011 VL 20 IS 3 BP 347 EP 349 DI 10.1016/j.jse.2010.10.031 PG 3 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 754WL UT WOS:000289888400009 PM 21288744 ER PT J AU Morman, M Fowler, RL Sanosky, B Higgins, LD AF Morman, Monica Fowler, Rachel L. Sanosky, Ben Higgins, Laurence D. TI Arthroscopic tissue biopsy for evaluation of infection before revision arthroplasty SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article ID ERYTHROCYTE SEDIMENTATION-RATE; INTRAOPERATIVE FROZEN-SECTIONS; ROTATOR CUFF REPAIR; SHOULDER ARTHROPLASTY; PROPIONIBACTERIUM-ACNES; REIMPLANTATION; DIAGNOSIS; HIP; COMPONENT C1 [Higgins, Laurence D.] Brigham & Womens Hosp, Sports Med & Shoulder Serv, Harvard Shoulder Serv, Boston, MA 02115 USA. [Morman, Monica] Massachusetts Gen Hosp, Harvard Shoulder Serv, Boston, MA 02114 USA. RP Higgins, LD (reprint author), Brigham & Womens Hosp, Sports Med & Shoulder Serv, Harvard Shoulder Serv, 75 Francis St, Boston, MA 02115 USA. EM ldhiggins@partners.org NR 32 TC 11 Z9 11 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD APR PY 2011 VL 20 IS 3 BP E15 EP E22 DI 10.1016/j.jse.2010.11.015 PG 8 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 754WL UT WOS:000289888400004 PM 21330156 ER PT J AU Nazarian, RM Mandal, RV Kagan, A Kay, J Duncan, LM AF Nazarian, Rosalynn M. Mandal, Rajni V. Kagan, Anna Kay, Jonathan Duncan, Lyn M. TI Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: A diagnostic aid SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE cellularity; fibroblast; gadolinium contrast; nephrogenic systemic fibrosis ID RENAL-FAILURE; DERMOPATHY; GADOLINIUM; INVOLVEMENT; SKIN; GROWTH; SCLEROMYXEDEMA; EXPRESSION; APOPTOSIS; WOMAN AB Background: Nephrogenic systemic fibrosis (NSF) affects patients with impaired renal function who have received gadolinium-containing contrast agents (GCCAs). Increased dermal cellularity is a key diagnostic feature of NSF, however, the histologic findings can be subtle. Objective: We sought to determine whether dermal cellularity in skin biopsy specimens from NSF cases: (1) differs significantly from that of controls; and (2) correlates with duration of the skin lesions, level of plasma creatinine, GCCA close, or a combination of these. Methods: Seventeen NSF skin biopsy specimens and age-, sex-, and site-matched controls were retrieved from the dermatopathology files of the Massachusetts General Hospital in Boston. Dermal cellularity was manually quantified on hematoxylin-eosin stained sections and patient medical records were reviewed for demographic and clinical data. Results: NSF cases showed a mean dermal cellularity of 70.8/high-power field (control mean: 14.4/high-power field, P < .001) and a cut-off range of 19 to 26/high-power field was established. No significant correlation was identified between dermal cellularity and demographic and clinical data. Limitations: In this retrospective analysis, duration of skin lesion was defined as the interval from most recent prior GCCA study, rather than the actual clinical onset, to time of skin biopsy, and the cumulative GCCA dose may reflect a minimum if GCCA was received at an outside institution. Conclusion: Enumeration of dermal cellularity on hemwatoxylin-eosin-stained sections can aid in the histologic diagnosis of NSF in the setting of chronic kidney disease and GCCA exposure and is independent of patient age, sex, plasma creatinine, time. from last GCCA exposure, and GCCA close. (J Am Acad Dermatol 2011;64:741-7.) C1 [Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Dept Pathol, Dermatopathol Unit, Pathol Serv, Boston, MA 02114 USA. [Mandal, Rajni V.] NYU Med Ctr, Dept Dermatol, Dermatopathol Sect, New York, NY 10016 USA. [Kagan, Anna] Baylor Univ, Methodist Hosp, Dept Med, Serv Nephrol, Houston, TX 77030 USA. [Kay, Jonathan] Univ Massachusetts, Ctr Rheumatol, Worcester, MA 01605 USA. [Kay, Jonathan] Univ Massachusetts, Sch Med, Dept Med, Div Rheumatol, Worcester, MA USA. RP Nazarian, RM (reprint author), Massachusetts Gen Hosp, Dept Pathol, Dermatopathol Unit, Pathol Serv, WRN 831B, Boston, MA 02114 USA. EM rmnazarian@partners.org OI Nazarian, Rosalynn/0000-0003-4003-7193; Kay, Jonathan/0000-0002-8970-4260 NR 25 TC 8 Z9 8 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 2011 VL 64 IS 4 BP 741 EP 747 DI 10.1016/j.jaad.2010.05.034 PG 7 WC Dermatology SC Dermatology GA 740XL UT WOS:000288827600013 PM 21414498 ER PT J AU Cardenas, VA Chao, LL Studholme, C Yaffe, K Miller, BL Madison, C Buckley, ST Mungas, D Schuff, N Weiner, MW AF Cardenas, V. A. Chao, L. L. Studholme, C. Yaffe, K. Miller, B. L. Madison, C. Buckley, S. T. Mungas, D. Schuff, N. Weiner, M. W. TI Brain atrophy associated with baseline and longitudinal measures of cognition SO NEUROBIOLOGY OF AGING LA English DT Article DE Deformation morphometry; Longitudinal; Brain; MRI; Cognition; Memory; Executive function ID VOXEL-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTION; QUANTITATIVE VALIDATION; INDIVIDUAL-DIFFERENCES; SEMANTIC KNOWLEDGE; OLDER PERSONS; IMPAIRMENT; DEMENTIA; MRI AB The overall goal was to identify patterns of brain atrophy associated with cognitive impairment and future cognitive decline in non-demented elders. Seventy-one participants were studied with structural MRI and neuropsychological testing at baseline and 1-year follow-up. Deformation-based morphometry was used to examine the relationship between regional baseline brain tissue volume with baseline and longitudinal measures of delayed verbal memory, semantic memory, and executive function. Smaller right hippocampal and entorhinal cortex (ERC) volumes at baseline were associated with worse delayed verbal memory performance at baseline while smaller left ERC volume was associated with greater longitudinal decline. Smaller left superior temporal cortex at baseline was associated with worse semantic memory at baseline, while smaller left temporal white and gray matter volumes were associated with greater semantic memory decline. Increased CSF and smaller frontal lobe volumes were associated with impaired executive function at baseline and greater longitudinal executive decline. These findings suggest that baseline volumes of prefrontal and temporal regions may underlie continuing cognitive decline due to aging, pathology, or both in non-demented elderly individuals. (C) 2009 Elsevier Inc. All rights reserved. C1 [Cardenas, V. A.; Chao, L. L.; Studholme, C.; Yaffe, K.; Miller, B. L.; Schuff, N.; Weiner, M. W.] Univ Calif San Francisco, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Cardenas, V. A.; Chao, L. L.; Studholme, C.; Yaffe, K.; Buckley, S. T.; Schuff, N.; Weiner, M. W.] San Francisco VA Med Ctr, San Francisco, CA USA. [Madison, C.] Calif Pacific Med Ctr, San Francisco, CA 94115 USA. [Mungas, D.] Univ Calif Davis, Davis, CA 95616 USA. RP Cardenas, VA (reprint author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, 4150 Clement St,114M, San Francisco, CA 94121 USA. EM valerie.cardenas-nicolson@ucsf.edu RI Mungas, Dan/E-6810-2011 FU NIH [R01 AG10897, R01 MH65392, R03 EB008136]; Department of Veterans Affairs FX This work was supported in part by NIH grants R01 AG10897, R01 MH65392 and R03 EB008136, and the Department of Veterans Affairs. We thank Diana Truran and her staff for MRI scanning, image quality control, and data organization. NR 44 TC 46 Z9 47 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD APR PY 2011 VL 32 IS 4 BP 572 EP 580 DI 10.1016/j.neurobiolaging.2009.04.011 PG 9 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 755SL UT WOS:000289956600002 PM 19446370 ER PT J AU Smith, EE Salat, DH Jeng, J McCreary, CR Fischl, B Schmahmann, JD Dickerson, BC Viswanathan, A Albert, MS Blacker, D Greenberg, SM AF Smith, E. E. Salat, D. H. Jeng, J. McCreary, C. R. Fischl, B. Schmahmann, J. D. Dickerson, B. C. Viswanathan, A. Albert, M. S. Blacker, D. Greenberg, S. M. TI Correlations between MRI white matter lesion location and executive function and episodic memory SO NEUROLOGY LA English DT Article ID MILD COGNITIVE IMPAIRMENT; CEREBRAL AMYLOID ANGIOPATHY; SURFACE-BASED ANALYSIS; ALZHEIMER-DISEASE; OLDER PERSONS; DEMENTIA; HYPERINTENSITIES; BRAIN; DECLINE; SEGMENTATION AB Objectives: MRI white matter hyperintensity (WMH) volume is associated with cognitive impairment. We hypothesized that specific loci of WMH would correlate with cognition even after accounting for total WMH volume. Methods: Subjects were identified from a prospective community-based study: 40 had normal cognition, 94 had mild impairment (defined here as a Clinical Dementia Rating [CDR] score of 0.5 without dementia), and 11 had mild Alzheimer's dementia. Factor analysis of a 22-item neuropsychological battery yielded 4 factors (episodic memory, executive function, spatial skills, and general knowledge). MRI WMH segmentation and analysis was performed using FreeSurfer software. Results: Higher WMH volume was independently associated with lower executive function and episodic memory factor scores. Voxel-based general linear models showed loci where WMH was strongly inversely associated with specific cognitive factor scores (p < 0.001), controlling for age, education, sex, APOE genotype, and total WMH volume. For episodic memory, clusters were observed in bilateral temporal-occipital and right parietal periventricular white matter, and the left anterior limb of the internal capsule. For executive function, clusters were observed in bilateral inferior frontal white matter, bilateral temporal-occipital and right parietal periventricular white matter, and the anterior limb of the internal capsule bilaterally. Conclusions: Specific WMH loci are closely associated with executive function and episodic memory, independent of total WMH volume. The anatomic locations suggest that WMH may cause cognitive impairment by affecting connections between cortex and subcortical structures, including the thalamus and striatum, or connections between the occipital lobe and frontal or parietal lobes. Neurology (R) 2011;76:1492-1499 C1 [Smith, E. E.] Univ Calgary, Dept Clin Neurosci, Foothills Med Ctr, Calgary, AB T2N 2T9, Canada. [Smith, E. E.; McCreary, C. R.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 2T9, Canada. [Smith, E. E.; McCreary, C. R.] Univ Calgary, Dept Radiol, Calgary, AB T2N 2T9, Canada. [Salat, D. H.; Jeng, J.; Fischl, B.; Dickerson, B. C.] Massachusetts Gen Hosp, Martinos Biomed Imaging Ctr, Boston, MA 02114 USA. [Schmahmann, J. D.; Dickerson, B. C.; Viswanathan, A.; Greenberg, S. M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Blacker, D.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Blacker, D.] Massachusetts Gen Hosp, Gerontol Res Unit, Boston, MA 02114 USA. [Albert, M. S.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA. RP Smith, EE (reprint author), Univ Calgary, Dept Clin Neurosci, Foothills Med Ctr, Room C1212, Calgary, AB T2N 2T9, Canada. EM eesmith@ucalgary.ca RI Yue, Chunlin/B-3554-2014; OI Yue, Chunlin/0000-0002-2261-6725; Smith, Eric/0000-0003-3956-1668 FU National Institute on Aging [P01 AG04953, R01 AG26484]; National Institute of Neurological Disorders and Stroke [R01 NS062028]; NIH; Alberta Heritage Foundation for Medical Research; Canadian Institutes for Health Research; Heart and Stroke Foundation of Canada; Canadian Stroke Network; Hotchkiss Brain Institute; NIH/NINR; NIH (NCRR/NIBIB/NIA/NINDS); Ellison Medical Foundation; Birmingham Foundation; MINDlink Foundation; Sidney R. Baer, Jr. Foundation; NIH/NIA; Alzheimer's Association; Pfizer Inc; GE Healthcare; NIH (NIA/NHLBI); NIH (NINDS/NIA); Cure Alzheimer's Foundation FX Supported by the National Institute on Aging (P01 AG04953, R01 AG26484) and the National Institute of Neurological Disorders and Stroke (R01 NS062028).; Dr. Smith has received speaker honoraria from the BMJ Group and QuantiaMD; has received an honorarium from the Canadian Conference on Dementia; has served on a scientific advisory board for Genentech, Inc.; serves as an Assistant Editor for Stroke; and receives research support from the NIH, the Alberta Heritage Foundation for Medical Research, Canadian Institutes for Health Research, Heart and Stroke Foundation of Canada, Canadian Stroke Network, and the Hotchkiss Brain Institute. Dr. Salat receives research support from the NIH/NINR. J. Jeng and Dr. McCreary report no disclosures. Dr. Fischl serves on the editorial board of NeuroImage; has served as a consultant for Cephalon, Inc.; and receives research support from the NIH (NCRR/NIBIB/NIA/NINDS) and the Ellison Medical Foundation. Dr. Schmahmann serves on the editorial board of The Cerebellum; is listed as author on a pending patent re: Transcranial magnetic stimulation applied to the cerebellum; receives publishing royalties for The Cerebellum and Cognition (Academic Press, 1997), MRI Atlas of the Human Cerebellum (Academic Press, 2000), and Fiber Pathways of the Brain (Oxford University Press, 2006); and receives research support from the NIH, the Birmingham Foundation, MINDlink Foundation, and the Sidney R. Baer, Jr. Foundation; and his sibling serves as legal counsel to Johnson & Johnson. Dr. Dickerson serves on the editorial board of Hippocampus; and receives research support from the NIH/NIA and the Alzheimer's Association. Dr. Viswanathan has served as a consultant for Athena Diagnostics, Inc.; and receives research support from the NIH/NIA. Dr. Albert serves as a consultant for Genentech, Inc., Eli Lilly and Company, and the Dana Foundation; and receives research support from Pfizer Inc, GE Healthcare, the NIH (NIA/NHLBI), and the Alzheimer's Association. Dr. Blacker serves on the editorial board of Experimental Gerontology; serves as a consultant for ClinicalTrials.gov; and receives research support from the NIH (NINDS/NIA), the Alzheimer's Association, Cure Alzheimer's Foundation, and Anonymous Foundation. Dr. Greenberg serves on a data safety monitoring board for the NIH/NINDS; has received speaker honoraria from Esteve, Medtronics, Inc., and Pfizer Inc; serves on the editorial boards of Neurology (R), Stroke, Cerebrovascular Disease, and the Journal of Alzheimer's Disease and Other Dementias; has served as a consultant for Roche, Janssen Alzheimer Immunotherapy, and Bristol-Myers Squibb; and has received/receives research support from the NIH (NIA/NINDS) and the Alzheimer's Association. NR 40 TC 66 Z9 69 U1 2 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2011 VL 76 IS 17 BP 1492 EP 1499 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 754VB UT WOS:000289884700013 PM 21518999 ER PT J AU Heath, RJW Leong, JM Visegrady, B Machesky, LM Xavier, RJ AF Heath, Robert J. W. Leong, John M. Visegrady, Balazs Machesky, Laura M. Xavier, Ramnik J. TI Bacterial and Host Determinants of MAL Activation upon EPEC Infection: The Roles of Tir, ABRA, and FLRT3 SO PLOS PATHOGENS LA English DT Article ID SERUM RESPONSE FACTOR; ACTIN PEDESTAL FORMATION; ESCHERICHIA-COLI TIR; RHO GTPASES; EFFECTORS TIR; SRF ACTIVITY; PROTEIN; RECEPTOR; NCK; PHOSPHORYLATION AB Infection of host cells by pathogenic microbes triggers signal transduction pathways leading to a multitude of host cell responses including actin cytoskeletal re-arrangements and transcriptional programs. The diarrheagenic pathogens Enteropathogenic E. coli (EPEC) and the related Enterohemorrhagic E. coli (EHEC) subvert the host-cell actin cytoskeleton to form attaching and effacing lesions on the surface of intestinal epithelial cells by injecting effector proteins via a type III secretion system. Here we use a MAL translocation assay to establish the effect of bacterial pathogens on host cell signaling to transcription factor activation. MAL is a cofactor of Serum response factor (SRF), a transcription factor with important roles in the regulation of the actin cytoskeleton. We show that EPEC induces nuclear accumulation of MAL-GFP. The translocated intimin receptor is essential for this process and phosphorylation of Tyrosine residues 454 and 474 is important. Using an expression screen we identify FLRT3, C22orf28 and TESK1 as novel activators of SRF. Importantly we demonstrate that ABRA (actin-binding Rho-activating protein, also known as STARS) is necessary for EPEC-induced nuclear accumulation of MAL and the novel SRF activator FLRT3, is a component of this pathway. We further demonstrate that ABRA is important for structural maintenance of EPEC pedestals. Our results uncover novel components in pathogen-activated cytoskeleton signalling to MAL activation. C1 [Heath, Robert J. W.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02115 USA. [Heath, Robert J. W.; Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Ctr Inflammatory Bowel Dis, Boston, MA USA. [Leong, John M.] UMass Med Sch, Dept Mol Genet & Microbiol, Worcester, MA USA. [Visegrady, Balazs; Machesky, Laura M.] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland. [Xavier, Ramnik J.] Broad Inst MIT & Harvard, Cambridge, MA USA. RP Heath, RJW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02115 USA. EM Xavier@molbiol.mgh.harvard.edu FU CCIB development fund; NIH [R01-AI46454]; [AI062773]; [DK83756]; [DK 043351] FX RJWH was supported by the CCIB development fund and AI062773. JML is supported by the NIH grant R01-AI46454. RJX is supported by grants AI062773, DK83756 and DK 043351. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 2 Z9 2 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD APR PY 2011 VL 7 IS 4 AR e1001332 DI 10.1371/journal.ppat.1001332 PG 15 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 755ZE UT WOS:000289979900004 PM 21490959 ER PT J AU Liu, SW Singer, SJ Sun, BC Camargo, CA AF Liu, Shan W. Singer, Sara J. Sun, Benjamin C. Camargo, Carlos A., Jr. TI A Conceptual Model for Assessing Quality of Care for Patients Boarding in the Emergency Department: Structure-Process-Outcome SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID HEALTH-CARE; MYOCARDIAL-INFARCTION; AMBULANCE DIVERSION; ADMITTED PATIENTS; IMPACT; SATISFACTION; CAPACITY; MEDICINE; ASSOCIATION; ADMISSIONS AB Many believe that the "boarding'' of emergency department (ED) patients awaiting inpatient beds compromises quality of care. To better study the quality of care of boarded patients, one should identify and understand the mechanisms accounting for any potential differences in care. This paper presents a conceptual boarding "structure-process-outcome'' model to help assess quality of care provided to boarded patients and to aid in recognizing potential solutions to improve that quality, if it is deficient. The goal of the conceptual model is to create a practical framework on which a research and policy agenda can be based to measure and improve quality of care for boarded patients. C1 [Liu, Shan W.; Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA. [Liu, Shan W.; Singer, Sara J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Sun, Benjamin C.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Sun, Benjamin C.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. RP Liu, SW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA. EM sliu1@partners.org FU UCLA Older Americans Independence Center, NIH/NIA [P30-AG028748] FX Dr. Sun received support from the UCLA Older Americans Independence Center, NIH/NIA Grant P30-AG028748. The content does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health. NR 46 TC 7 Z9 10 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1069-6563 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD APR PY 2011 VL 18 IS 4 BP 430 EP 435 DI 10.1111/j.1553-2712.2011.01033.x PG 6 WC Emergency Medicine SC Emergency Medicine GA 751SE UT WOS:000289637100017 PM 21496148 ER PT J AU Haun, JB Devaraj, NK Marinelli, BS Lee, H Weissleder, R AF Haun, Jered B. Devaraj, Neal K. Marinelli, Brett S. Lee, Hakho Weissleder, Ralph TI Probing Intracellular Biomarkers and Mediators of Cell Activation Using Nanosensors and Bioorthogonal Chemistry SO ACS NANO LA English DT Article DE nanoparticles; intracellular; targeting; bioorthogonal chemistry; tetrazine; diagnostic magnetic resonance; cancer ID SEMICONDUCTOR QUANTUM DOTS; CIRCULATING TUMOR-CELLS; IN-VIVO; CANCER-CELLS; MAGNETIC NANOPARTICLES; BREAST-CANCER; TAT PEPTIDE; LIVE CELLS; UP-CONVERSION; LIVING CELLS AB Nanomaterials offer unique physical properties that make them ideal biosensors for scant cell populations. However, specific targeting of nanoparticles to intracellular proteins has been challenging. Here, we describe a technique to improve intracellular biomarker sensing using nanoparticles that is based on bioorthogonal chemistry. Using trans-cyclooctene-modified affinity ligands that are administered to semipermeabilized cells and revealed by cycloaddition reaction with tetrazine-conjugated nanoparticles, we demonstrate site-specific amplification of nanomaterial binding. We also show that this technique Is capable of sensing protein biomarkers and phosho-protein signal mediators, both within the cytosol and nucleus, via magnetic or fluorescent modalities. We expect the described method will have broad applications in nanomaterial-based diagnostics and therapeutics. C1 [Haun, Jered B.; Devaraj, Neal K.; Marinelli, Brett S.; Lee, Hakho; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA. RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA. EM rweissleder@mgh.harvard.edu RI Devaraj, Neal/B-4712-2014 FU NCI [P50CA86355, F32CA144139]; NIBIB [K01EB010078]; NIH [U54 11934, U54 CA 151884, R01 EB 004626, R01 EB 010011, HHSN268201000044C] FX The authors thank N. Sergeyev for synthesizing CLIO, S. Hilderbrand for synthesizing the tetrazine precursor, and V. Peterson for assistance with cell culture. We also thank M. Pittet, F. Swirski, and Y. Fisher-Jeffes for many helpful discussions and critical review of the manuscript. This work was funded in part by NCI Grant P50CA86355. J.B.H. was supported in part by NCI fellowship F32CA144139, and N.K.D. was supported in part by NIBIB Grant K01EB010078. The following NIH funding sources are also acknowledged: U54 11934, U54 CA 151884, R01 EB 004626, R01 EB 010011 and HHSN268201000044C. NR 54 TC 38 Z9 38 U1 7 U2 63 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1936-0851 J9 ACS NANO JI ACS Nano PD APR PY 2011 VL 5 IS 4 BP 3204 EP 3213 DI 10.1021/nn200333m PG 10 WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary SC Chemistry; Science & Technology - Other Topics; Materials Science GA 753CJ UT WOS:000289742100092 PM 21351804 ER PT J AU Yu, LY Quinn, DA Garg, HG Hales, CA AF Yu, Lunyin Quinn, Deborah A. Garg, Hari G. Hales, Charles A. TI Heparin Inhibits Pulmonary Artery Smooth Muscle Cell Proliferation through Guanine Nucleotide Exchange Factor-H1/RhoA/Rho Kinase/p27 SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY LA English DT Article DE Rho kinase; guanine nucleotide exchange factor-H1; pulmonary artery smooth muscle cell; proliferation; heparin ID LONG-TERM INHIBITION; RHO-KINASE; GUINEA-PIG; HYPERTENSION; HYPOXIA; GEF-H1; MICE; P27(KIP1); GTPASES; RAT AB Ras homolog gene family member A (RhoA) through Rho kinase kinase (ROCK), one of its downstream effectors, regulates a wide range of cell physiological functions, including vascular smooth muscle cell (SMC) proliferation, by degrading cyclin-dependent kinase inhibitor, p27. Our previous studies found that heparin inhibition of pulmonary artery SMC (PASMC) proliferation and pulmonary hypertension was dependent on p27 up-regulation. To investigate whether ROCK, a regulator of p27, is involved in regulation of heparin inhibition of PASMC proliferation, we analyzed ROCK expression in the lungs from mice and from human PASMCs exposed to hypoxia, and investigated the effect of ROCK expression in vitro by RhoAcDNA transfection. We also investigated the effect of guanine nucleotide exchange factor (GEF)-H1, an upstream regulator of RhoA, on heparin inhibition of PASMC proliferation by GEF-H1 cDNA transfection. We found that: (1) hypoxia increased ROCK expression in mice and PASMCs; (2) overexpression of RhoA diminished the inhibitory effect of heparin on PASMC proliferation and down-regulated p27 expression; and (3) overexpression of GEF-H1 negated heparin inhibition of PASMC proliferation, which was accompanied by increased GTP-RhoA and decreased p27. This study demonstrates that the RhoA/ROCK pathway plays an important role in heparin inhibition on PASMC proliferation, and reveals that heparin inhibits PASMC proliferation through GEF-H1/RhoA/ROCK/p27 signaling pathway, by down-regulating GEF-H1, RhoA, and ROCK, and then up-regulating p27. C1 [Yu, Lunyin; Quinn, Deborah A.; Garg, Hari G.; Hales, Charles A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, Boston, MA 02114 USA. RP Yu, LY (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, 55 Fruit St,Bulfinch 148, Boston, MA 02114 USA. EM lyu3@partners.org FU National Institutes of Health [HL39150]; American Thoracic Society/Pulmonary Hypertension Research [PH-08-010]; Susannah Wald Wood Foundation FX This work was supported by National Institutes of Health grants HL39150 (C.A.H.) and American Thoracic Society/Pulmonary Hypertension Research grant PH-08-010 (L.Y.) and by the Susannah Wald Wood Foundation. NR 47 TC 15 Z9 16 U1 0 U2 4 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1044-1549 J9 AM J RESP CELL MOL JI Am. J. Respir. Cell Mol. Biol. PD APR PY 2011 VL 44 IS 4 BP 524 EP 530 DI 10.1165/rcmb.2010-0145OC PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System GA 753KX UT WOS:000289773400012 PM 20558775 ER PT J AU Hirohashi, S Chase, CM Alessandrini, A Della Pelle, P Sebastian, D Madsen, JC Russell, PS Colvin, RB AF Hirohashi, S. Chase, C. M. Alessandrini, A. Della Pelle, P. Sebastian, D. Madsen, J. C. Russell, P. S. Colvin, R. B. TI A Novel Pathway of Chronic Allograft Rejection Mediated by NK Cells and Alloantibody. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Chase, C. M.; Alessandrini, A.; Della Pelle, P.; Sebastian, D.; Madsen, J. C.; Russell, P. S.; Colvin, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 41 BP 41 EP 41 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400041 ER PT J AU Daly, K Seifert, M Stack, M Chandraker, A Zurakowski, D Nohria, A Givertz, M Karumanchi, A Briscoe, D AF Daly, K. Seifert, M. Stack, M. Chandraker, A. Zurakowski, D. Nohria, A. Givertz, M. Karumanchi, A. Briscoe, D. TI Identification of a Highly Sensitive and Specific Biomarker Panel for the Diagnosis of Chronic Rejection/Allograft Vasculopathy Following Human Cardiac Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Daly, K.; Seifert, M.; Stack, M.; Zurakowski, D.; Briscoe, D.] Childrens Hosp, Boston, MA 02115 USA. [Chandraker, A.; Nohria, A.; Givertz, M.] BWH, Boston, MA USA. [Karumanchi, A.] BIDMC, Boston, MA USA. [Daly, K.; Seifert, M.; Stack, M.; Chandraker, A.; Zurakowski, D.; Nohria, A.; Givertz, M.; Karumanchi, A.; Briscoe, D.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 126 BP 68 EP 69 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400126 ER PT J AU Kawai, T Sachs, DH Spitzer, T Nina, TR Wong, W Smith, RN Ko, D Williams, W Saidman, S Sykes, M Colvin, RB Cosimi, AB AF Kawai, T. Sachs, D. H. Spitzer, T. Nina, T. -R. Wong, W. Smith, R. -N. Ko, D. Williams, W. Saidman, S. Sykes, M. Colvin, R. B. Cosimi, A. B. TI Follow-Up of HLA Mismatched Kidney Transplantation after Discontinuing Maintenance Immunosuppression SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Kawai, T.; Spitzer, T.; Nina, T. -R.; Wong, W.; Smith, R. -N.; Ko, D.; Williams, W.; Saidman, S.; Colvin, R. B.; Cosimi, A. B.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. [Sachs, D. H.] Massachusetts Gen Hosp, Transplant Biol Res Ctr, Charlestown, MA USA. [Sykes, M.] Columbia Univ, New York, NY USA. Immune Tolerance Network, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 155 BP 77 EP 77 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400155 ER PT J AU Gabardi, S Asipenko, N Fleming, J Lor, K McDevitt, L Mohammed, A Rogers, C Tichy, E Weng, R Lee, RA AF Gabardi, S. Asipenko, N. Fleming, J. Lor, K. McDevitt, L. Mohammed, A. Rogers, C. Tichy, E. Weng, R. Lee, R. -A. TI Efficacy and Safety of Six Months of Low- vs. High-Dose Valganciclovir for Cytomegalovirus Disease Prevention in High-Risk Renal Transplant Recipients SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Gabardi, S.; Mohammed, A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Asipenko, N.; Rogers, C.] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Fleming, J.] Henry Ford Hosp, Detroit, MI USA. [Lor, K.] Univ Calif, San Diego Med Ctr, San Diego, CA USA. [McDevitt, L.] Tufts Med Ctr, Boston, MA USA. [Tichy, E.] Yale New Haven Med Ctr, New Haven, CT USA. [Weng, R.] Univ Calif Irvine, Irvine Med Ctr, Irvine, CA USA. [Lee, R. -A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 161 BP 79 EP 79 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400161 ER PT J AU Tocco, G Kim, P Kant, CD Lin, C Yun, SY Benichou, G AF Tocco, G. Kim, P. Kant, C. D. Lin, C. Yun, S. -Y. Benichou, G. TI Allorecognition after Non-Primarily Vascularized Skin Transplantation: Direct or Semi-Direct Pathway? SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Tocco, G.; Kant, C. D.; Benichou, G.] Massachusetts Gen Hosp, Surg Transplant Ctr, Boston, MA 02114 USA. [Kim, P.; Lin, C.; Yun, S. -Y.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 173 BP 82 EP 82 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400173 ER PT J AU Davies, JK Barbon, CM Voskertchian, A Nadler, LM Guinan, EC AF Davies, J. K. Barbon, C. M. Voskertchian, A. Nadler, L. M. Guinan, E. C. TI Es Vivo Costimulatory Blockade with Belatacept Provides a Strategy To Control Alloresponses after Allogeneic Transplantation SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Davies, J. K.; Barbon, C. M.; Voskertchian, A.; Nadler, L. M.; Guinan, E. C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 209 BP 93 EP 93 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400209 ER PT J AU Buhler, LH Cooper, DKC Benichou, G AF Buhler, L. H. Cooper, D. K. C. Benichou, G. TI Persistence of Indirect but Not Direct Xenoresponse by T Cells in Immunosuppressed Baboons Transplanted with Pig Xenografts SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Buhler, L. H.; Cooper, D. K. C.; Benichou, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 258 BP 108 EP 109 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400258 ER PT J AU Machaidze, Z Wei, L Schuetz, C Carvello, M Peng, Q Lei, J Deng, S Yeh, H Markmann, J Buhler, L AF Machaidze, Z. Wei, L. Schuetz, C. Carvello, M. Peng, Q. Lei, J. Deng, S. Yeh, H. Markmann, J. Buhler, L. TI Transplantation of Encapsulated Porcine Hepatocytes Improves Metabolic Function and Survival in Baboons with Acute Liver Failure SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Machaidze, Z.; Wei, L.; Schuetz, C.; Carvello, M.; Peng, Q.; Lei, J.; Deng, S.; Yeh, H.; Markmann, J.; Buhler, L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg, Boston, MA USA. [Buhler, L.] Univ Hosp Geneva, Dept Surg, Geneva, Switzerland. RI Schuetz, Christian/K-5234-2013 OI Schuetz, Christian/0000-0002-6828-4543 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 256 BP 108 EP 108 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400256 ER PT J AU Farkash, E Masahiro, M Alessandrini, A Chase, C Delle Pelle, P Connolly, S Russell, P Colvin, R AF Farkash, E. Masahiro, M. Alessandrini, A. Chase, C. Delle Pelle, P. Connolly, S. Russell, P. Colvin, R. TI Intragraft Treg-Rich Organized Lymphoid Structures in Stably Accepted Renal Allografts in Mice. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Farkash, E.; Masahiro, M.; Alessandrini, A.; Chase, C.; Delle Pelle, P.; Connolly, S.; Russell, P.; Colvin, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 418 BP 156 EP 156 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400418 ER PT J AU Yamada, Y Aoyama, A Boskovic, S Nadazdin, O Murakami, T Putheti, P Bhasin, MK Smith, NR Colvin, RB Madsen, JC Strom, TB Sachs, DH Benichou, G Cosimi, AB Kawai, T AF Yamada, Y. Aoyama, A. Boskovic, S. Nadazdin, O. Murakami, T. Putheti, P. Bhasin, M. K. Smith, N. R. Colvin, R. B. Madsen, J. C. Strom, T. B. Sachs, D. H. Benichou, G. Cosimi, A. B. Kawai, T. TI Post-Transplant Memory T Cell and Inflammtory Responses Inhibit Delayed Tolerance Induction. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Yamada, Y.; Aoyama, A.; Boskovic, S.; Nadazdin, O.; Murakami, T.; Smith, N. R.; Colvin, R. B.; Madsen, J. C.; Sachs, D. H.; Benichou, G.; Cosimi, A. B.; Kawai, T.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. [Putheti, P.; Bhasin, M. K.; Strom, T. B.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA. [Putheti, P.; Bhasin, M. K.; Strom, T. B.] Beth Israel Deaconess Med Ctr, Transplant Inst, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 439 BP 162 EP 162 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400439 ER PT J AU Porcheray, F Ferdman, J DeVito, J Helou, Y Nobecourt, P Kawai, T Wong, W Zorn, E AF Porcheray, F. Ferdman, J. DeVito, J. Helou, Y. Nobecourt, P. Kawai, T. Wong, W. Zorn, E. TI In Situ Expansion of Memory B Cell Clones in a Rejected Human Kidney Graft. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Porcheray, F.; Ferdman, J.; DeVito, J.; Helou, Y.; Nobecourt, P.; Kawai, T.; Wong, W.; Zorn, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI porcheray, fabrice/B-9505-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 469 BP 170 EP 170 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400468 ER PT J AU Scalea, JR Nishimura, H Okumi, M Moran, SG Gillon, BC Cormack, T Sachs, DH Yamada, K AF Scalea, J. R. Nishimura, H. Okumi, M. Moran, S. G. Gillon, B. C. Cormack, T. Sachs, D. H. Yamada, K. TI Evidence for a Balance between Peripheral Alloreactive and Regulatory T-Cells in the Maintenance of Tolerance. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Scalea, J. R.; Nishimura, H.; Okumi, M.; Moran, S. G.; Gillon, B. C.; Cormack, T.; Sachs, D. H.; Yamada, K.] Harvard Univ, Massachusetts Gen Hosp, TBRC, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 472 BP 171 EP 171 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400471 ER PT J AU Zhao, G Kim, JI Lee, KM O'Connor, MR Yang, M Lei, J Schuetz, C Markmann, JF Deng, S AF Zhao, G. Kim, J. I. Lee, K. M. O'Connor, M. R. Yang, M. Lei, J. Schuetz, C. Markmann, J. F. Deng, S. TI Anti-CD45RB mAb Induces Tolerance in Human-to-Mouse Islet Xenograft Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Zhao, G.; Kim, J. I.; Lee, K. M.; O'Connor, M. R.; Yang, M.; Lei, J.; Schuetz, C.; Markmann, J. F.; Deng, S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Zhao, G.; Yang, M.; Deng, S.] Sichuan Prov Peoples Hosp, Dept Surg, Chengdu, Sichuan, Peoples R China. RI Schuetz, Christian/K-5234-2013 OI Schuetz, Christian/0000-0002-6828-4543 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 718 BP 245 EP 245 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318400722 ER PT J AU Varma, MC Tolkoff-Rubin, N Cosimi, AB Elias, N Malik, F Goes, NB Pratt, DS Thiim, M Andersson, K Markmann, JF Hertl, M AF Varma, M. C. Tolkoff-Rubin, N. Cosimi, A. B. Elias, N. Malik, F. Goes, N. B. Pratt, D. S. Thiim, M. Andersson, K. Markmann, J. F. Hertl, M. TI Plasmapheresis in Treatment of Fibrosing Cholestatic Hepatitis Due to Recurrent Hepatitis C after Liver Transplant SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Varma, M. C.; Tolkoff-Rubin, N.; Cosimi, A. B.; Elias, N.; Malik, F.; Goes, N. B.; Pratt, D. S.; Thiim, M.; Andersson, K.; Markmann, J. F.; Hertl, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 831 BP 278 EP 278 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401037 ER PT J AU LeGuern, C Germana, S Martins, P AF LeGuern, C. Germana, S. Martins, P. TI MHC Class II Self-Presentation: A Central Driver of Immune Tolerance. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [LeGuern, C.; Germana, S.; Martins, P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1056 BP 341 EP 341 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401267 ER PT J AU Demirci, G Spoerl, S Li, XC AF Demirci, G. Spoerl, S. Li, X. C. TI Role of OX40 for CD4 Deficient Tregs. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Demirci, G.; Spoerl, S.; Li, X. C.] Beth Israel Deac Med Ctr, Transplant Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1062 BP 343 EP 343 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401273 ER PT J AU Kim, JI Zhao, G O'Connor, MR Lee, KM Eliades, P Deng, S Markmann, JF AF Kim, J. I. Zhao, G. O'Connor, M. R. Lee, K. M. Eliades, P. Deng, S. Markmann, J. F. TI Transplant Tolerance Induced by Anti-CD45RB Antibody Is B Cell-Dependent SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Kim, J. I.; O'Connor, M. R.; Lee, K. M.; Eliades, P.; Deng, S.; Markmann, J. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zhao, G.] Sichuan Acad Med Sci, Chengdu, Sichuan, Peoples R China. [Zhao, G.] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1154 BP 369 EP 369 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401369 ER PT J AU Magee, CN De Serres, SA Mfarrej, BG Singh, MK Taheri, D Smith, RN Colvin, RB Najafian, N Murphy, B AF Magee, C. N. De Serres, S. A. Mfarrej, B. G. Singh, M. K. Taheri, D. Smith, R. N. Colvin, R. B. Najafian, N. Murphy, B. TI Development of De Novo Alloantibodies Post Transplantation Is Associated with Poorer Allograft Function and Adverse Histological Features. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Magee, C. N.; De Serres, S. A.; Mfarrej, B. G.; Najafian, N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Transplantat Res Ctr, Boston, MA 02115 USA. [Singh, M. K.; Murphy, B.] Mt Sinai Sch Med, New York, NY USA. [Taheri, D.; Smith, R. N.; Colvin, R. B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1217 BP 385 EP 385 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401432 ER PT J AU Baid-Agrawal, S Farris, AB Pascual, M Mauiyyedi, S Farrell, ML Tolkoff-Rubin, N Collins, AB Colvin, RB AF Baid-Agrawal, S. Farris, A. B. Pascual, M. Mauiyyedi, S. Farrell, M. L. Tolkoff-Rubin, N. Collins, A. B. Colvin, R. B. TI Overlapping Pathways to Transplant Glomerulopathy: Chronic Humoral Rejection, Hepatitis C Infection and Thrombotic Microangiopathy SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Baid-Agrawal, S.] Charite, Campus Virchow Klinikum, Dept Nephrol & Med Intens Care, D-13353 Berlin, Germany. [Farris, A. B.] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA. [Pascual, M.] CHUV, Transplantat Ctr, Lausanne, Switzerland. [Mauiyyedi, S.] Univ Texas Houston, Dept Pathol & Lab Med, Houston, TX USA. [Farrell, M. L.; Tolkoff-Rubin, N.] Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA. [Farrell, M. L.; Tolkoff-Rubin, N.] Massachusetts Gen Hosp, Transplantat Unit, Boston, MA 02114 USA. [Collins, A. B.; Colvin, R. B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1273 BP 401 EP 401 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401486 ER PT J AU Varrna, MC Elias, N Yeh, H Martins, PN Markmann, JF AF Varrna, M. C. Elias, N. Yeh, H. Martins, P. N. Markmann, J. F. TI Death on Liver Transplant Waitlist: Can Broader Sharing Have an Impact on Cost of Patient Care? SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Varrna, M. C.; Elias, N.; Yeh, H.; Martins, P. N.; Markmann, J. F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1357 BP 424 EP 425 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401570 ER PT J AU Zhao, G Moore, DJ Kim, JI Lee, KM Duff, PE O'Connor, MR Yang, M Lei, J Markmann, JF Deng, S AF Zhao, G. Moore, D. J. Kim, J. I. Lee, K. M. Duff, P. E. O'Connor, M. R. Yang, M. Lei, J. Markmann, J. F. Deng, S. TI Endocrine Modulation Reverses Immune Senescence and Restores Susceptibility to Antigen-Specific Tolerance Induction SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Zhao, G.; Kim, J. I.; Lee, K. M.; Duff, P. E.; O'Connor, M. R.; Yang, M.; Lei, J.; Markmann, J. F.; Deng, S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Zhao, G.; Yang, M.; Deng, S.] Sichuan Prov Peoples Hosp, Dept Surg, Chengdu, Sichuan, Peoples R China. [Zhao, G.; Yang, M.; Deng, S.] Sichuan Acad Med Sci, Chengdu, Sichuan, Peoples R China. [Moore, D. J.] Vanderbilt Childrens Hosp, Dept Pediat, Nashville, TN USA. RI Moore, Daniel/A-4924-2008 OI Moore, Daniel/0000-0002-6889-9345 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1399 BP 437 EP 437 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401615 ER PT J AU AkhavanHeidari, M Akoad, M Wagener, M Karuman, P Cacciarelli, TV AF AkhavanHeidari, M. Akoad, M. Wagener, M. Karuman, P. Cacciarelli, T. V. TI Pretransplant Ablative Therapy (PAT) Improves Short-Term Outcome in Liver Transplantation for Hepatocellular Carcinoma (HCC). SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [AkhavanHeidari, M.; Wagener, M.; Karuman, P.; Cacciarelli, T. V.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [AkhavanHeidari, M.; Wagener, M.; Cacciarelli, T. V.] Univ Pittsburgh, Pittsburgh, PA USA. [Akoad, M.] Lahey Clin Fdn, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1509 BP 468 EP 469 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401727 ER PT J AU AkhavanHeidari, M Akoad, M Wagener, M Karuman, P Frye, R Cacciarelli, TV AF AkhavanHeidari, M. Akoad, M. Wagener, M. Karuman, P. Frye, R. Cacciarelli, T. V. TI A Comparison of the Milan Pathologic vs the American Joint Committee on Cancer (AJCC) Staging for Hepatocellular Carcinoma (HCC) and Liver Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [AkhavanHeidari, M.; Wagener, M.; Karuman, P.; Frye, R.; Cacciarelli, T. V.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [AkhavanHeidari, M.; Wagener, M.; Cacciarelli, T. V.] Univ Pittsburgh, Pittsburgh, PA USA. [Akoad, M.] Lahey Clin Fdn, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1508 BP 468 EP 468 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401726 ER PT J AU AkhavanHeidari, M Akoad, M Wagener, M Karuman, P Cacciarelli, TV AF AkhavanHeidari, M. Akoad, M. Wagener, M. Karuman, P. Cacciarelli, T. V. TI Predictors of Outcome in Patients with Hepatocellular Carcinoma (HCC) Treated with Liver Transplantation. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [AkhavanHeidari, M.; Wagener, M.; Karuman, P.; Cacciarelli, T. V.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [AkhavanHeidari, M.; Wagener, M.; Cacciarelli, T. V.] Univ Pittsburgh, Pittsburgh, PA USA. [Akoad, M.] Lahey Clin Fdn, Burlington, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1510 BP 469 EP 469 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401728 ER PT J AU Porcheray, F DeVito, J Helou, Y Nobecourt, P Ferdman, J Girouard, TC Kawai, T Saidman, SL Wong, W Zorn, E AF Porcheray, F. DeVito, J. Helou, Y. Nobecourt, P. Ferdman, J. Girouard, T. C. Kawai, T. Saidman, S. L. Wong, W. Zorn, E. TI High Frequency Polyreactive B Cells Contribute to Serum Reactivity to Donor Specific and Non Donor Specific Antigens during Human Kidney Graft Rejection. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Porcheray, F.; DeVito, J.; Helou, Y.; Nobecourt, P.; Ferdman, J.; Girouard, T. C.; Kawai, T.; Saidman, S. L.; Wong, W.; Zorn, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI porcheray, fabrice/B-9505-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1515 BP 470 EP 470 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401733 ER PT J AU Yamada, K Torabi, R Scalea, JR Barone, AAL Gillon, BC Cormack, TA Randolph, MA Sachs, DH Cetrulo, CL AF Yamada, K. Torabi, R. Scalea, J. R. Barone, A. A. Leto Gillon, B. C. Cormack, T. A. Randolph, M. A. Sachs, D. H. Cetrulo, C. L., Jr. TI Tolerance of Class I-Mismatched Composite Tissue Allografts in Swine Tolerant of Renal Allografts. SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Yamada, K.; Torabi, R.; Scalea, J. R.; Barone, A. A. Leto; Gillon, B. C.; Cormack, T. A.; Sachs, D. H.; Cetrulo, C. L., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA. [Torabi, R.; Barone, A. A. Leto; Randolph, M. A.; Cetrulo, C. L., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1518 BP 471 EP 471 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401736 ER PT J AU Buhler, LH Sondermeijer, H McMurchy, A Hu, Z Boskovic, S Kawai, T Benichou, G Wekerle, T Yang, YG Levings, M Sykes, M AF Buhler, L. H. Sondermeijer, H. McMurchy, A. Hu, Z. Boskovic, S. Kawai, T. Benichou, G. Wekerle, T. Yang, Y. -G. Levings, M. Sykes, M. TI Regulatory T Cells for Promotion of Durable Mixed Hematopoietic Chimerism and Immune Tolerance in a Nonhuman Primate Model SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Buhler, L. H.; Boskovic, S.; Kawai, T.; Benichou, G.] Massachussetts Gen Hosp, Boston, MA USA. [Sondermeijer, H.; Hu, Z.; Yang, Y. -G.; Sykes, M.] Columbia Univ, Med Ctr, New York, NY USA. [McMurchy, A.; Levings, M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Wekerle, T.] Univ Hosp Vienna, Vienna, Austria. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1681 BP 520 EP 520 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401911 ER PT J AU Lee, KM Zhao, G Carvello, M Wei, L Kim, J Deng, S Markmann, J AF Lee, K. M. Zhao, G. Carvello, M. Wei, L. Kim, J. Deng, S. Markmann, J. TI Enhancement of Tolerance Induction with Anti-CD45RB Treatment in Islet Allograft by B Cell Depletion SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Lee, K. M.; Zhao, G.; Carvello, M.; Wei, L.; Kim, J.; Deng, S.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1692 BP 523 EP 523 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401922 ER PT J AU Peng, Q Yeh, H Enjoji, K Machaidze, Z Wei, L Csizmad, E Schuetz, C Deng, S Markmann, J Robson, S Buhler, L AF Peng, Q. Yeh, H. Enjoji, K. Machaidze, Z. Wei, L. Csizmad, E. Schuetz, C. Deng, S. Markmann, J. Robson, S. Buhler, L. TI Integrin Dependent Baboon Platelet Activation and Phagocytosis by Porcine Hepatocytes and Endothelial Cells SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY 2011 CL Philadelphia, PA C1 [Peng, Q.; Yeh, H.; Machaidze, Z.; Wei, L.; Schuetz, C.; Deng, S.; Markmann, J.; Buhler, L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Enjoji, K.; Csizmad, E.; Robson, S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Liver, Boston, MA 02215 USA. RI Schuetz, Christian/K-5234-2013 OI Schuetz, Christian/0000-0002-6828-4543 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD APR PY 2011 VL 11 SU 2 MA 1701 BP 525 EP 526 PG 2 WC Surgery; Transplantation SC Surgery; Transplantation GA 747KJ UT WOS:000289318401931 ER PT J AU Ahnen, D AF Ahnen, Dennis TI LYNCH SYNDROME SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ahnen, Dennis] Denver VA Med Ctr, Denver, CO USA. [Ahnen, Dennis] Univ Colorado, Sch Med, Denver, CO 80202 USA. EM ssg19@columbia.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S128 EP S128 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700503 ER PT J AU Bailey, K Ruderman, A Diviak, K Mermelstein, R AF Bailey, Katherine Ruderman, Audrey Diviak, Kathi Mermelstein, Robin TI WEIGHT-RELATED CONSTRUCTS AND TRAJECTORIES OF ADOLESCENT CIGARETTE SMOKING OVER TIME SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Bailey, Katherine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Ruderman, Audrey; Diviak, Kathi; Mermelstein, Robin] Univ Illinois, Chicago, IL USA. EM kcbailey@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S118 EP S118 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700465 ER PT J AU Barinas, J Bedoya, A Psaros, C Safren, SA AF Barinas, Jennifer Bedoya, Andres Psaros, Christina Safren, Steven A. TI ACTIVE SUBSTANCE USE AND SATISFACTION WITH RELATIONSHIPS, SOCIAL SUPPORT AMONG HIV-INFECTED MINORITY WOMEN IN SUBSTANCE USE TREATMENT SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Barinas, Jennifer; Bedoya, Andres; Psaros, Christina; Safren, Steven A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bedoya, Andres; Safren, Steven A.] Fenway Community Hlth, Boston, MA USA. EM Jennifer.Barinas@Gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S19 EP S19 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700070 ER PT J AU Bauer-Wu, S Carmody, J Cooley, M Reed, G Rosenbaum, E Whitworth, R LaCasce, A Flowers, C AF Bauer-Wu, Susan Carmody, James Cooley, Mary Reed, George Rosenbaum, Elana Whitworth, Rachael LaCasce, Ann Flowers, Christopher TI A RANDOMIZED CONTROLLED TRIAL OF MINDFULNESS TRAINING FOR CANCER PATIENTS UNDERGOING STEM CELL TRANSPLANT SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Bauer-Wu, Susan; Whitworth, Rachael] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA. [Carmody, James; Reed, George; Rosenbaum, Elana] Univ Massachusetts, Sch Med, Worcester, MA USA. [Cooley, Mary; LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bauer-Wu, Susan; Flowers, Christopher] Winship Canc Inst, Atlanta, GA USA. EM sbauerw@emory.edu RI Flowers, Christopher/F-1953-2010 OI Flowers, Christopher/0000-0002-9524-3990 NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S241 EP S241 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701432 ER PT J AU Beverly, EA Bishop, JS Lee, Y Brooks, KM Hultgren, BA Ritholz, MD Ganda, OP Caballero, AE Munshi, M Weinger, K AF Beverly, Elizabeth A. Bishop, Jonathan S. Lee, Yishan Brooks, Kelly M. Hultgren, Brittney A. Ritholz, Marilyn D. Ganda, Om P. Caballero, A. E. Munshi, Medha Weinger, Katie TI THE PROTECTIVE EFFECT OF SOCIAL SUPPORT ON DIABETES SELF-CARE IN ADULTS WITH TYPE 1 AND TYPE 2 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Beverly, Elizabeth A.; Bishop, Jonathan S.; Lee, Yishan; Brooks, Kelly M.; Hultgren, Brittney A.; Ritholz, Marilyn D.; Ganda, Om P.; Caballero, A. E.; Munshi, Medha; Weinger, Katie] Joslin Diabet Ctr, Boston, MA 02215 USA. [Beverly, Elizabeth A.; Ritholz, Marilyn D.; Ganda, Om P.; Caballero, A. E.; Munshi, Medha; Weinger, Katie] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S164 EP S164 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701127 ER PT J AU Beverly, EA Brooks, KM Bishop, JS Ritholz, MD Ganda, OP Munshi, M Caballero, AE Weinger, K AF Beverly, Elizabeth A. Brooks, Kelly M. Bishop, Jonathan S. Ritholz, Marilyn D. Ganda, Om P. Munshi, Medha Caballero, A. E. Weinger, Katie TI "I'M MY OWN WORST ENEMY:" SELF AS A BARRIER IN DIABETES MANAGEMENT SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Beverly, Elizabeth A.; Brooks, Kelly M.; Bishop, Jonathan S.; Ritholz, Marilyn D.; Ganda, Om P.; Munshi, Medha; Caballero, A. E.; Weinger, Katie] Joslin Diabet Ctr, Boston, MA 02215 USA. [Beverly, Elizabeth A.; Ritholz, Marilyn D.; Ganda, Om P.; Munshi, Medha; Caballero, A. E.; Weinger, Katie] Harvard Univ, Sch Med, Boston, MA USA. EM katie.weinger@joslin.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S91 EP S91 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700357 ER PT J AU Beverly, EA LaCoe, CL Scanze, MA Gabbay, RA Wray, LA AF Beverly, Elizabeth A. LaCoe, Cynthia L. Scanze, Michele A. Gabbay, Robert A. Wray, Linda A. TI OLDER ADULTS' TREATMENT PREFERENCES FOR TYPE 2 DIABETES CARE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Beverly, Elizabeth A.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Beverly, Elizabeth A.] Harvard Univ, Sch Med, Boston, MA USA. [LaCoe, Cynthia L.; Scanze, Michele A.; Gabbay, Robert A.; Wray, Linda A.] Penn State Univ, University Pk, PA 16802 USA. [Gabbay, Robert A.] Penn State Coll Med, Hershey, PA USA. EM Elizabeth.Beverly@Joslin.Harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S91 EP S91 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700356 ER PT J AU Blashill, AJ O'Cleirigh, C Safren, SA Mayer, KH AF Blashill, Aaron J. O'Cleirigh, Conall Safren, Steven A. Mayer, Kenneth H. TI THE MODERATING ROLE OF BMI ON THE RELATIONSHIP BETWEEN DEPRESSION AND TRANSMISSION RISK BEHAVIORS AMONG HIV-INFECTED MSM SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Blashill, Aaron J.; O'Cleirigh, Conall; Safren, Steven A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [O'Cleirigh, Conall; Safren, Steven A.; Mayer, Kenneth H.] Fenway Hlth, Boston, MA USA. [Mayer, Kenneth H.] Brown Med Sch, Providence, RI USA. EM ablashill@partners.org NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S94 EP S94 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700366 ER PT J AU Busby, AK Emery, CF AF Busby, Andrea K. Emery, Charles F. TI RELATIONSHIP OF SYSTEMIC INFLAMMATION WITH LUNG FUNCTIONING, PSYCHOLOGICAL DISTRESS, QUALITY OF LIFE, AND PHYSICAL ENDURANCE AMONG COPD PATIENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Busby, Andrea K.] VA Boston Healthcare Syst, Boston, MA 02130 USA. [Busby, Andrea K.; Emery, Charles F.] Ohio State Univ, Columbus, OH 43210 USA. EM busby.22@osu.edu NR 0 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S104 EP S104 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700408 ER PT J AU Caccavale, LJ Nansel, T Haynie, D Laffel, L Mehta, S AF Caccavale, Laura J. Nansel, Tonja Haynie, Denise Laffel, Lori Mehta, Sanjeev TI DISORDERED EATING AMONG ADOLESCENTS WITH TYPE 1 DIABETES: RELATIONS WITH FAMILY ENVIRONMENT AND QUALITY OF LIFE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Caccavale, Laura J.; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA. EM caccavalel@mail.nih.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S206 EP S206 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701294 ER PT J AU Collins, A Niles, B Mori, DL Silberbogen, AK AF Collins, Allison Niles, Barbara Mori, DeAnna L. Silberbogen, Amy K. TI USING TELEHEALTH TO PROMOTE DIABETES MANAGEMENT IN VETERANS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Collins, Allison; Niles, Barbara; Mori, DeAnna L.; Silberbogen, Amy K.] VA Boston Healthcare Syst, Boston, MA USA. [Collins, Allison; Niles, Barbara; Mori, DeAnna L.; Silberbogen, Amy K.] Boston Univ, Sch Med, Boston, MA 02118 USA. EM allison_collins@hotmail.com NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S15 EP S15 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700057 ER PT J AU Collins, BN Nair, US Shwarz, M Jaffe, K Winickoff, J AF Collins, Bradley N. Nair, Uma S. Shwarz, Michelle Jaffe, Karen Winickoff, Johnathan TI MATERNAL DEPRESSION AMONG UNDERSERVED AFRICAN AMERICAN SMOKERS: OPPORTUNITY FOR INTERVENTION DURING PEDIATRIC SICK VISITS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Collins, Bradley N.; Nair, Uma S.; Shwarz, Michelle; Jaffe, Karen] Temple Univ, Philadelphia, PA 19122 USA. [Winickoff, Johnathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. EM uma.nair@temple.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S259 EP S259 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701504 ER PT J AU Cooley, ME Rosenberg, S Emmons, KM Johnson, BE Wang, Q Bueno, R Haddad, R AF Cooley, Mary E. Rosenberg, Shoshana Emmons, Karen M. Johnson, Bruce E. Wang, Qian Bueno, Raphael Haddad, Robert TI CHARACTERISTICS ASSOCIATED WITH MEMBERSHIP IN SMOKING CESSATION SUBGROUPS AFTER THE DIAGNOSIS OF CANCER SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Cooley, Mary E.; Emmons, Karen M.; Johnson, Bruce E.; Wang, Qian; Haddad, Robert] Dana Farber Canc Inst, Boston, MA 02015 USA. [Cooley, Mary E.] Univ Massachusetts, Boston, MA 02125 USA. [Rosenberg, Shoshana; Emmons, Karen M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Bueno, Raphael] Brigham & Womens Hosp, Boston, MA 02115 USA. [Johnson, Bruce E.; Bueno, Raphael; Haddad, Robert] Harvard Univ, Sch Med, Boston, MA USA. EM mary_cooley@dfci.harvard.edu NR 0 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S192 EP S192 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701238 ER PT J AU Ferguson, MJ Russell, SW Knight, S Spring, B AF Ferguson, Molly J. Russell, Stephanie W. Knight, Sara Spring, Bonnie TI A DELPHI POLL ON CLOSING THE RESEARCH TO PRACTICE GAP IN EVIDENCE-BASED PRACTICE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ferguson, Molly J.; Russell, Stephanie W.; Spring, Bonnie] Northwestern Univ, Chicago, IL 60611 USA. [Knight, Sara] San Francisco VA Med Ctr, San Francisco, CA USA. EM m-ferguson@northwestern.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S171 EP S171 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701154 ER PT J AU Galarce, EM Viswanath, K AF Galarce, Ezequiel M. Viswanath, K. TI SOCIODEMOGRAPHIC FACTORS, BELIEFS AND CHILDREN'S A(H1N1) VACCINE UPTAKE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Galarce, Ezequiel M.; Viswanath, K.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Galarce, Ezequiel M.; Viswanath, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. EM ezequiel_galarce@dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S221 EP S221 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701355 ER PT J AU Geyer, EJ Hawkins, LC Piper, HA Knisley, EA Elliot, BA Lovejoy, TI AF Geyer, Eric J. Hawkins, Liana C. Piper, Heather A. Knisley, Elisabeth A. Elliot, Blake A. Lovejoy, Travis I. TI BRIEF MOTIVATIONAL INTERVIEWING ENHANCES ATTITUDES AND SELF-EFFICACY FOR CONDOM USE IN HIV+ OLDER ADULTS: A RANDOMIZED CONTROLLED TRIAL SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Geyer, Eric J.; Hawkins, Liana C.; Piper, Heather A.; Knisley, Elisabeth A.; Elliot, Blake A.; Lovejoy, Travis I.] Ohio Univ, Athens, OH 45701 USA. [Lovejoy, Travis I.] Portland VA Med Ctr, Portland, OR USA. EM tl399805@ohio.edu NR 0 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S94 EP S94 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700367 ER PT J AU Gonzalez, JS Psaros, C Delahanty, L Carper, M Cagliero, E Safren, S AF Gonzalez, Jeffrey S. Psaros, Christina Delahanty, Linda Carper, Matthew Cagliero, Enrico Safren, Steven TI DEPRESSION, DIABETES DISTRESS AND MEDICATION ADHERENCE IN TYPE 2 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Gonzalez, Jeffrey S.] Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA. [Psaros, Christina; Delahanty, Linda; Carper, Matthew; Cagliero, Enrico; Safren, Steven] Harvard Univ, Sch Med, Mass Gen Hosp, Boston, MA 02115 USA. EM jeffrey.gonzalez@einstein.yu.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S14 EP S14 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700053 ER PT J AU Goodrich, DE Kilbourne, A Burghardt, A Post, E Schumacher, K Bramlet, P Lai, ZS Bauer, M AF Goodrich, David E. Kilbourne, Amy Burghardt, Amy Post, Edward Schumacher, Karen Bramlet, Peggy Lai, Zongshan Bauer, Mark TI A RANDOMIZED TRIAL TESTING A CHRONIC CARE MODEL TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH BIPOLAR DISORDER SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Goodrich, David E.; Kilbourne, Amy; Burghardt, Amy; Post, Edward; Schumacher, Karen; Bramlet, Peggy; Lai, Zongshan] Natl Serious Mental Illness Treatment Res & Evalu, Ann Arbor, MI USA. [Goodrich, David E.; Kilbourne, Amy; Burghardt, Amy; Post, Edward; Schumacher, Karen; Bramlet, Peggy; Lai, Zongshan] Ctr Clin Management Res, HSR&D Ctr Excellence, Ann Arbor, MI 48113 USA. [Goodrich, David E.; Kilbourne, Amy; Burghardt, Amy; Lai, Zongshan] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Post, Edward] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA. [Bauer, Mark] Boston VAMC, VA Boston Healthcare Syst, Boston, MA USA. EM david.goodrich2@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S19 EP S19 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700073 ER PT J AU Greaney, M Puleo, E Geller, A Hu, SW Werchniak, A DeCristofaro, S Emmons, K AF Greaney, M. Puleo, E. Geller, A. Hu, S. W. Werchniak, A. DeCristofaro, S. Emmons, K. TI FOLLOW-UP AFTER ABNORMAL FINDINGS IN A BEACH-BASED SKIN CANCER EXAM SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Greaney, M.; DeCristofaro, S.; Emmons, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Puleo, E.] Univ Massachusetts, Amherst, MA 01003 USA. [Geller, A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Hu, S. W.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Werchniak, A.] Brigham & Womens Hosp, Boston, MA 02115 USA. EM mary_greaney@dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S200 EP S200 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701269 ER PT J AU Greaney, M Sprunck, K Bennett, G Haines, J Puleo, E Viswanath, K Emmons, K AF Greaney, M. Sprunck, K. Bennett, G. Haines, J. Puleo, E. Viswanath, K. Emmons, K. TI USE OF PROMPTS TO INCREASE TRACKING IN A WEB-BASED INTERVENTION SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Greaney, M.; Sprunck, K.; Viswanath, K.; Emmons, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bennett, G.] Duke Univ, Durham, NC USA. [Puleo, E.] Univ Massachusetts, Amherst, MA 01003 USA. [Haines, J.] Univ Guelph, Guelph, ON N1G 2W1, Canada. EM mary_greaney@dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S178 EP S178 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701183 ER PT J AU Greer, J Bemis, H Traeger, L Hendriksen, E Pirl, W Temel, J Safren, S AF Greer, Joseph Bemis, Heather Traeger, Lara Hendriksen, Ellen Pirl, William Temel, Jennifer Safren, Steven TI COGNITIVE-BEHAVIORAL THERAPY FOR ANXIETY IN PATIENTS WITH TERMINAL CANCER SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Greer, Joseph; Bemis, Heather; Traeger, Lara; Hendriksen, Ellen; Pirl, William; Temel, Jennifer; Safren, Steven] Massachusetts Gen Hosp, Boston, MA 02114 USA. EM jgreer2@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S81 EP S81 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700314 ER PT J AU Groessl, EJ Weingart, K Johnson, N Gifford, A Asch, S Ho, S AF Groessl, Erik J. Weingart, Kim Johnson, Neil Gifford, Allen Asch, Steve Ho, Samuel TI EFFECTS OF THE HEPATITIS C SELF-MANAGEMENT PROGRAM AT 1-YEAR SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Groessl, Erik J.; Weingart, Kim; Johnson, Neil; Ho, Samuel] VA San Diego, HSR&D, San Diego, CA 92161 USA. [Groessl, Erik J.; Ho, Samuel] UCSD, La Jolla, CA USA. [Gifford, Allen] Bedford VA, Bedford, MA USA. [Asch, Steve] VA Greater Los Angeles, Los Angeles, CA USA. EM egroessl@ucsd.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S105 EP S105 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700410 ER PT J AU Hultgren, BA Beverly, EA Brooks, KM Ritholz, MD Weinger, K AF Hultgren, Brittney A. Beverly, Elizabeth A. Brooks, Kelly M. Ritholz, Marilyn D. Weinger, Katie TI TYPE 2 DIABETES PATIENTS' PERCEPTIONS OF THEIR PHYSICIANS RESPONSES TO PSYCHOSOCIAL ISSUES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Hultgren, Brittney A.; Beverly, Elizabeth A.; Brooks, Kelly M.; Ritholz, Marilyn D.; Weinger, Katie] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA. EM katie.weinger@joslin.harvard.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S206 EP S206 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701292 ER PT J AU Johnson, E Mori, D Niles, B Collins, A Bailey, K AF Johnson, Elizabeth Mori, DeAnna Niles, Barbara Collins, Allison Bailey, Kelley TI PARTICIPANT RECRUITMENT AND RETENTION IN AN AUTOMATED TELEPHONE INTERVENTION TO ENHANCE EXERCISE ADOPTION IN VETERANS WITH TYPE 2 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Johnson, Elizabeth; Mori, DeAnna; Niles, Barbara; Collins, Allison; Bailey, Kelley] VA Boston Healthcare Syst, Boston, MA 02130 USA. [Johnson, Elizabeth; Mori, DeAnna; Niles, Barbara; Collins, Allison] Boston Univ, Sch Med, Boston, MA 02118 USA. EM ejohns05@vt.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S90 EP S90 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700353 ER PT J AU LaCoe, CL Beverly, EA Scanze, MA Gabbay, RA Wray, LA AF LaCoe, Cynthia L. Beverly, Elizabeth A. Scanze, Michele A. Gabbay, Robert A. Wray, Linda A. TI THE IMPORTANCE OF PATIENTS' VALUES IN TYPE 2 DIABETES CARE SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [LaCoe, Cynthia L.; Scanze, Michele A.; Gabbay, Robert A.; Wray, Linda A.] Penn State Univ, University Pk, PA 16802 USA. [Beverly, Elizabeth A.] Harvard Univ, Joslin Diabet Ctr, Boston, PA USA. EM cll222@psu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S165 EP S165 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701129 ER PT J AU Lipsky, L Nansel, T Haynie, D Laffel, L Mehta, S AF Lipsky, Leah Nansel, Tonja Haynie, Denise Laffel, Lori Mehta, Sanjeev TI CONCORDANCE OF DIETARY INTAKE AND QUALITY BETWEEN CHILDREN WITH TYPE-1 DIABETES (T1D) AND THEIR PARENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Lipsky, Leah; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA. EM lipskylm@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S22 EP S22 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700084 ER PT J AU Merport, A Mahler, HI Werchniak, AE Recklitis, CJ AF Merport, Anna Mahler, Heike I. Werchniak, Andrew E. Recklitis, Christopher J. TI USING ULTRAVIOLET-LIGHT PHOTOGRAPHY TO PROMOTE SUN PROTECTION: WILL CANCER SURVIVORS "GET THE PICTURE?" SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Merport, Anna; Recklitis, Christopher J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mahler, Heike I.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Werchniak, Andrew E.] Brigham & Womens Hosp, Boston, MA 02115 USA. EM anna_merport@dfci.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S85 EP S85 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700333 ER PT J AU Mysore, SS Gonzalez, JS Traeger, L Delahanty, L Psaros, C Safren, SA AF Mysore, Sony S. Gonzalez, Jeffrey S. Traeger, Lara Delahanty, Linda Psaros, Christina Safren, Steven A. TI THE ROLE OF SELF-EFFICACY RELATED TO DEPRESSION AND SELF-MANAGEMENT IN TYPE 2 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Mysore, Sony S.; Traeger, Lara; Delahanty, Linda; Psaros, Christina; Safren, Steven A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gonzalez, Jeffrey S.] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY USA. EM smysore@partners.org NR 0 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S164 EP S164 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701125 ER PT J AU Nansel, TR Lipsky, L Haynie, D Mehta, S Laffel, L AF Nansel, Tonja R. Lipsky, Leah Haynie, Denise Mehta, Sanjeev Laffel, Lori TI RELATIONS AMONG PARENT AND YOUTH SOCIAL COGNITIVE CONSTRUCTS AND DIETARY INTAKE IN YOUTH WITH TYPE 1 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Nansel, Tonja R.; Lipsky, Leah; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, Bethesda, MD USA. [Mehta, Sanjeev; Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA. EM nanselt@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S213 EP S213 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701322 ER PT J AU Norton, WE Glanz, K Collins, CB Mittman, BS Glasgow, RE AF Norton, Wynne E. Glanz, Karen Collins, Charles B. Mittman, Brian S. Glasgow, Russell E. TI SCALING-UP EVIDENCE-BASED HEALTH PROMOTION/DISEASE PREVENTION INTERVENTIONS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Norton, Wynne E.] Univ Alabama, Birmingham, AL 35293 USA. [Glanz, Karen] Univ Penn, Philadelphia, PA 19104 USA. [Collins, Charles B.] Ctr Dis Control & Prevent, Capac Bldg Branch, Atlanta, GA USA. [Mittman, Brian S.] VA Greater Los Angeles Healthcare Syst, Ctr Implementat Practice & Res Support, Los Angeles, CA USA. [Glasgow, Russell E.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. EM wenorton@uab.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S152 EP S152 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701080 ER PT J AU Park, ER Kirchhoff, AC Pandiscio, J Armstrong, G Robison, L Mertens, A Recklitis, C Diller, L Kuhlthau, K AF Park, Elyse R. Kirchhoff, Anne C. Pandiscio, Jennifer Armstrong, Gregory Robison, Leslie Mertens, Ann Recklitis, Christopher Diller, Lisa Kuhlthau, Karen TI CHILDHOOD CANCER SURVIVOR STUDY PARTICIPANTS' PERCEPTIONS & KNOWLEDGE OF HEALTH INSURANCE COVERAGE: IMPLICATIONS FOR THE 2010 HEALTH CARE REFORM LAW SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Park, Elyse R.; Pandiscio, Jennifer; Kuhlthau, Karen] MGH, Boston, MA 02114 USA. [Kirchhoff, Anne C.] Fred Hutchinson CRC, Seattle, WA USA. [Armstrong, Gregory; Robison, Leslie] St Jude Childrens, Memphis, TN USA. [Mertens, Ann] Emory, Atlanta, GA USA. [Recklitis, Christopher; Diller, Lisa] Dana Farber, Boston, MA USA. EM epark@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S253 EP S253 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701479 ER PT J AU Park, ER Traeger, L Lee, J Gerade, B Willett, J Webster, A Rastegar, S Fricchione, G Benson, H AF Park, Elyse R. Traeger, Lara Lee, Janie Gerade, Beverly Willett, Jessica Webster, Ann Rastegar, Sarah Fricchione, Greg Benson, Herbert TI A BRIEF MIND-BODY INTERVENTION FOR WOMEN UNDERGOING BREAST BIOPSY: A PILOT STUDY SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Park, Elyse R.; Traeger, Lara; Willett, Jessica; Webster, Ann; Rastegar, Sarah; Fricchione, Greg; Benson, Herbert] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. [Lee, Janie; Gerade, Beverly] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. EM epark@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S241 EP S241 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701433 ER PT J AU Park, ER Smith, KB Muzikansky, A Wang, DL Plotkin, SR AF Park, Elyse R. Smith, Kelly B. Muzikansky, Alona Wang, Daphne L. Plotkin, Scott R. TI EXAMINING CANCER RISK PERCEPTIONS AMONG PATIENTS WITH NEUROFIBROMATOSIS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Park, Elyse R.; Smith, Kelly B.; Muzikansky, Alona; Wang, Daphne L.; Plotkin, Scott R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. EM epark@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S154 EP S154 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701086 ER PT J AU Psaros, C Alert, MD Willett, J Stagg, A Fricchione, G Benson, H Park, ER AF Psaros, Christina Alert, Marissa D. Willett, Jessica Stagg, Amy Fricchione, Gregory Benson, Herbert Park, Elyse R. TI BREASTFEEDING PREPAREDNESS AND CURRENT BREASTFEEDING STATUS: WOMEN'S PERCEPTIONS OF BREASTFEEDING SUPPORT DURING THE IMMEDIATE POSTPARTUM PERIOD SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Psaros, Christina; Alert, Marissa D.; Willett, Jessica; Stagg, Amy; Fricchione, Gregory; Benson, Herbert; Park, Elyse R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. EM malert@partners.org NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S187 EP S187 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701220 ER PT J AU Psaros, C Willett, J Alert, M Stagg, A Fricchione, G Benson, H Park, E AF Psaros, Christina Willett, Jessica Alert, Marissa Stagg, Amy Fricchione, Gregory Benson, Herbert Park, Elyse TI PREGNANT WOMEN'S PREFERENCES FOR MENTAL HEALTH TREATMENT SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Psaros, Christina; Willett, Jessica; Alert, Marissa; Stagg, Amy; Fricchione, Gregory; Benson, Herbert; Park, Elyse] Massachusets Gen Hosp, Boston, MA 02144 USA. EM jwillett1@partners.org NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S188 EP S188 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701221 ER PT J AU Psaros, C Barinas, J Park, ER Robbins, G Bedoya, CA Safren, SA AF Psaros, Christina Barinas, Jennifer Park, Elyse R. Robbins, Gregory Bedoya, C. Andres Safren, Steven A. TI PSYCHOSOCIAL CONCERNS OF OLDER HIV-INFECTED WOMEN SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Psaros, Christina; Barinas, Jennifer; Park, Elyse R.; Robbins, Gregory; Bedoya, C. Andres; Safren, Steven A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. EM cpsaros@partners.org NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S93 EP S93 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700365 ER PT J AU Ritholz, MD Beverly, EA Bishop, JS Brooks, KM Ganda, OP Caballero, AE Munshi, M Weinger, K AF Ritholz, Marilyn D. Beverly, Elizabeth A. Bishop, Jonathan S. Brooks, Kelly M. Ganda, Om P. Caballero, A. E. Munshi, Medha Weinger, Katie TI PATIENTS' PERCEPTIONS OF FACTORS IMPACTING THEIR HBA1C LEVELS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ritholz, Marilyn D.; Beverly, Elizabeth A.; Bishop, Jonathan S.; Brooks, Kelly M.; Ganda, Om P.; Caballero, A. E.; Munshi, Medha; Weinger, Katie] Joslin Diabet Ctr, Boston, MA 02215 USA. [Ritholz, Marilyn D.; Beverly, Elizabeth A.; Ganda, Om P.; Caballero, A. E.; Munshi, Medha; Weinger, Katie] Harvard Univ, Sch Med, Boston, MA USA. EM katie.weinger@joslin.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S165 EP S165 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297701130 ER PT J AU Ryan, B Theodore, M Mehta, S Butler, D Haynie, D Nansel, T Laffel, L AF Ryan, Brittany Theodore, Miranda Mehta, Sanjeev Butler, Deborah Haynie, Denise Nansel, Tonja Laffel, Lori TI DIABETES-SPECIFIC FAMILY CONFLICT, ADHERENCE AND GLYCEMIC CONTROL IN YOUTH WITH TYPE 1 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ryan, Brittany; Theodore, Miranda; Mehta, Sanjeev; Butler, Deborah; Laffel, Lori] Joslin Diabet Ctr, Boston, MA 02215 USA. [Haynie, Denise; Nansel, Tonja] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. EM brittany.ryan@joslin.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S92 EP S92 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700358 ER PT J AU Schneider, H Gonzalez, J Psaros, C Mysore, S Delahanty, L Cagliero, E Safren, S AF Schneider, Havah Gonzalez, Jeffrey Psaros, Christina Mysore, Sony Delahanty, Linda Cagliero, Enrico Safren, Steven TI VALIDATING SELF-REPORTED MEDICATION ADHERENCE IN TYPE 2 DIABETES SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Schneider, Havah; Gonzalez, Jeffrey] Yeshiva Univ, New York, NY 10040 USA. [Gonzalez, Jeffrey] Albert Einstein Coll Med, New York, NY USA. [Psaros, Christina; Mysore, Sony; Delahanty, Linda; Cagliero, Enrico; Safren, Steven] Harvard Univ, Sch Med, Mass Gen Hosp, Boston, MA USA. EM havahesther@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S90 EP S90 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700352 ER PT J AU Traeger, L Greer, J Bemis, H Temel, J Park, E Pirl, W AF Traeger, Lara Greer, Joseph Bemis, Heather Temel, Jennifer Park, Elyse Pirl, William TI DYSPNEA AND PANIC AMONG NEWLY DIAGNOSED NON-SMALL CELL LUNG CANCER PATIENTS SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Traeger, Lara; Greer, Joseph; Bemis, Heather; Temel, Jennifer; Park, Elyse; Pirl, William] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. EM ltraeger@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S75 EP S75 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700293 ER PT J AU Tse, J Nansel, T Haynie, D Laffel, L Mehta, S AF Tse, Julia Nansel, Tonja Haynie, Denise Laffel, Lori Mehta, Sanjeev TI THE RELATIONSHIP OF DIET QUALITY AND DISORDERED EATING BEHAVIORS IN ADOLESCENTS WITH TYPE 1 DIABETES (T1D) SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Tse, Julia; Nansel, Tonja; Haynie, Denise] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Laffel, Lori; Mehta, Sanjeev] Joslin Diabet Ctr, Boston, MA 02215 USA. EM tsej2@mail.nih.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S60 EP S60 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700235 ER PT J AU Tucker-Seeley, R Stoddard, A Sorensen, G AF Tucker-Seeley, Reginald Stoddard, Anne Sorensen, Glorian TI A CROSS-SECTIONAL ANALYSIS OF THE ASSOCIATION BETWEEN FINANCIAL HARDSHIP AND SELF-RATED HEALTH SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Tucker-Seeley, Reginald; Sorensen, Glorian] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. [Stoddard, Anne] New England Res Inst, Stat Anal & Res Ctr, Watertown, MA 02172 USA. EM retuck-er@hsph.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S67 EP S67 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700261 ER PT J AU Ulloa, EW Silberbogen, AK AF Ulloa, Erin W. Silberbogen, Amy K. TI BARRIERS TO PROSTATE CANCER SCREENING IN AN AT-RISK POPULATION SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Meeting Abstract C1 [Ulloa, Erin W.; Silberbogen, Amy K.] VA Boston Healthcare Syst, Jamaica Plain, MA 02130 USA. [Ulloa, Erin W.; Silberbogen, Amy K.] Boston Univ, Sch Med, Boston, MA 02118 USA. EM erin.ulloa@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD APR PY 2011 VL 41 SU 1 BP S4 EP S4 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 747CK UT WOS:000289297700013 ER PT J AU Fiorentino, D Werth, VP AF Fiorentino, David Werth, Victoria P. TI Dermatomyositis Autoantibodies Clinical Markers of Patients Past, Present, and Future SO ARCHIVES OF DERMATOLOGY LA English DT Editorial Material ID INTERSTITIAL LUNG-DISEASE; IDIOPATHIC INFLAMMATORY MYOPATHY; MYOSITIS-SPECIFIC AUTOANTIBODIES; AMYOPATHIC DERMATOMYOSITIS; MYCOPHENOLATE-MOFETIL; JAPANESE PATIENTS; CLASSIFICATION; EXPRESSION C1 [Fiorentino, David] Stanford Univ, Dept Dermatol & Med Immunol & Rheumatol, Redwood City, CA USA. [Werth, Victoria P.] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Werth, Victoria P.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA. RP Werth, VP (reprint author), Perelman Ctr Adv Med, Dept Dermatol, 3400 Civ Ctr Blvd,Ste 1-330A, Philadelphia, PA 19104 USA. EM werth@mail.med.upenn.edu OI Fiorentino, David/0000-0001-7951-3674 FU NIAMS NIH HHS [K24-AR 02207] NR 24 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 2011 VL 147 IS 4 BP 492 EP 494 PG 3 WC Dermatology SC Dermatology GA 752FY UT WOS:000289677800020 PM 21482900 ER PT J AU Lee, LN Shin, JJ Kunst, MM Hsu, M Holbrook, EH Keamy, DG AF Lee, Linda N. Shin, Jennifer J. Kunst, Mara M. Hsu, Maylee Holbrook, Eric H. Keamy, Donald G., Jr. TI Radiology Quiz Case 3 Organizing hematoma of maxillary sinus (OHMS) SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Editorial Material ID MASS C1 [Lee, Linda N.; Shin, Jennifer J.; Holbrook, Eric H.; Keamy, Donald G., Jr.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Kunst, Mara M.; Hsu, Maylee] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Lee, LN (reprint author), Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RI Shin, Jennifer/A-3169-2016 NR 7 TC 2 Z9 2 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD APR PY 2011 VL 137 IS 4 BP 406 EP + PG 2 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 751VZ UT WOS:000289647100019 PM 21502484 ER PT J AU Jung, D Hasserjian, RP Faquin, WC Deschler, DG AF Jung, David Hasserjian, Robert P. Faquin, William C. Deschler, Daniel G. TI Pathology Quiz Case 2 Myeloid sarcoma (MS) of the submandibular gland SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Editorial Material ID GRANULOCYTIC-SARCOMA C1 [Jung, David; Deschler, Daniel G.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Jung, David; Hasserjian, Robert P.; Faquin, William C.; Deschler, Daniel G.] Harvard Univ, Sch Med, Boston, MA USA. [Hasserjian, Robert P.; Faquin, William C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jung, D (reprint author), Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD APR PY 2011 VL 137 IS 4 BP 411 EP + PG 3 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 751VZ UT WOS:000289647100021 PM 21502486 ER PT J AU Bramos, A Velmahos, GC Butt, UM Fikry, K Smith, RM Chang, YC AF Bramos, Athanasios Velmahos, George C. Butt, Umar M. Fikry, Karim Smith, R. Malcolm Chang, Yuchiao TI Predictors of Bleeding From Stable Pelvic Fractures SO ARCHIVES OF SURGERY LA English DT Article ID ANGIOGRAPHIC EMBOLIZATION; RING DISRUPTIONS; BLUNT TRAUMA; INJURIES; HEMORRHAGE; MORTALITY; CLASSIFICATION AB Hypothesis: Stable pelvic fractures (SPFs) that do not need operative fixation are only infrequently associated with significant bleeding (SigBleed). Our hypothesis is that simple indicators, easily detectable at the bedside, can alert the clinician about the likelihood of bleeding and the need for closer monitoring or early intervention in patients with SPFs. Design: Retrospective review of medical records. Setting: Academic level 1 trauma center. Patients: The medical records of patients with SPFs admitted to our academic level 1 trauma center from January 1, 2002, to June 30, 2007, were reviewed. Stable pelvic fractures were defined as fractures not requiring external or internal fixation. SigBleed was defined as the need for blood transfusion and/or intervention for bleeding control within the first 24 hours after admission. The patients were divided into group A, which included patients without SigBleed; group B, which included patients with SigBleed of a nonpelvic cause; and group C, which included patients with SigBleed caused by the SPF. The 3 groups were compared by univariate and multivariate analysis. Main Outcome Measure: Significant bleeding from SPFs. Results: Of 391 patients with SPFs, 280 (72%) were in group A, 90 (23%) were in group B, and 21 (5%) were in group C. Compared with group A patients, those in group C were older and had a lower hematocrit and systolic blood pressure on admission. They also had longer hospital stays and a higher mortality. The following independent predictors of SigBleed from SPF were identified: hematocrit of 30% or lower (odds ratio [OR], 43.93; 95% confidence interval [CI], 9.78-197.32; P <.001); presence of pelvic hematoma on computed tomographic scan (OR, 39.37; 95% CI, 4.58-338.41; P <.001); and systolic blood pressure of 90 mm Hg or lower (OR, 18.352; 95% CI, 1.98-169.87; P=.01). When all independent predictors were present, 100% of the patients had SigBleed; when all were absent, no one had SigBleed. Conclusions: The incidence of SigBleed due to SPFs is low (5% in this study) and independently predicted by an admission hematocrit of 30% or lower, the presence of a pelvic hematoma on computed tomographic scan, and systolic blood pressure of 90 mm Hg or lower. C1 [Bramos, Athanasios; Velmahos, George C.; Butt, Umar M.; Fikry, Karim] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Smith, R. Malcolm] Massachusetts Gen Hosp, Div Orthoped Trauma, Boston, MA 02114 USA. [Chang, Yuchiao] Massachusetts Gen Hosp, Div Clin Epidemiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Velmahos, GC (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Ste 810, Boston, MA 02114 USA. EM gvelmahos@partners.org NR 18 TC 3 Z9 3 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD APR PY 2011 VL 146 IS 4 BP 407 EP 411 DI 10.1001/archsurg.2010.277 PG 5 WC Surgery SC Surgery GA 751VX UT WOS:000289646900009 PM 21173284 ER PT J AU Gordon, PE Miller, DL Rattner, DW Conrad, C AF Gordon, Paul E. Miller, Diane L. Rattner, David W. Conrad, Claudius TI Image of the Month Cholecystocutaneous Fistula (Jean-Louis Petit Phlegmon) SO ARCHIVES OF SURGERY LA English DT Editorial Material C1 [Conrad, Claudius] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA. [Miller, Diane L.] Tufts Univ, Sch Med, Boston, MA 02111 USA. RP Conrad, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, 55 Fruit St,GRB 425, Boston, MA 02114 USA. EM cconrad1@partners.org NR 6 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0004-0010 J9 ARCH SURG-CHICAGO JI Arch. Surg. PD APR PY 2011 VL 146 IS 4 BP 487 EP 488 PG 2 WC Surgery SC Surgery GA 751VX UT WOS:000289646900026 PM 21502463 ER PT J AU Hinton, DE Hofmann, SG Rivera, E Otto, MW Pollack, MH AF Hinton, Devon E. Hofmann, Stefan G. Rivera, Edwin Otto, Michael W. Pollack, Mark H. TI Culturally adapted CBT (CA-CBT) for Latino women with treatment-resistant PTSD: A pilot study comparing CA-CBT to applied muscle relaxation SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE Posttraumatic stress disorder; Cognitive-behavior therapy; Emotion regulation; Latino; Nervios; Ataque de nervios ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY; EVIDENCE-BASED INTERVENTIONS; RANDOMIZED CONTROLLED-TRIAL; ATAQUES-DE-NERVIOS; CAMBODIAN REFUGEES; PANIC DISORDER; EXPOSURE THERAPY; ATTACKS; METAANALYSIS AB We examined the therapeutic efficacy of a culturally adapted form of CBT (CA-CBT) for PTSD as compared to applied muscle relaxation (AMR) for female Latino patients with treatment-resistant PTSD. Participants were randomized to receive either CA-CBT (n = 12) or AMR (n = 12), and were assessed before treatment, after treatment, and at a 12-week follow-up. The treatments were manualized and delivered in the form of group therapy across 14 weekly sessions. Assessments included a measure of PTSD, anxiety, culturally relevant idioms of distress (nervios and ataque de nervios), and emotion regulation ability. Patients receiving CA-CBT improved significantly more than in the AMR condition. Effect size estimates showed very large reductions in PTSD symptoms from pretreatment to posttreatment in the CA-CBT group (Cohen's d = 2.6) but only modest improvements in the AMR group (0.8). These results suggest that CA-CBT can be beneficial for previously treatment-resistant PTSD in Latino women. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Hinton, Devon E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hinton, Devon E.; Pollack, Mark H.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Hinton, Devon E.; Rivera, Edwin] Arbour Counseling Serv, Lowell, MA USA. [Hofmann, Stefan G.; Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. RP Hinton, DE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM devon_hinton@hms.harvard.edu RI Hofmann, Stefan/B-8769-2014 OI Hofmann, Stefan/0000-0002-3548-9681 FU NIMH NIH HHS [K23MH066253, R01MH079032] NR 56 TC 36 Z9 38 U1 3 U2 23 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 J9 BEHAV RES THER JI Behav. Res. Ther. PD APR PY 2011 VL 49 IS 4 BP 275 EP 280 DI 10.1016/j.brat.2011.01.005 PG 6 WC Psychology, Clinical SC Psychology GA 749HD UT WOS:000289454000008 PM 21333272 ER PT J AU Sloan, DM Marx, BP Greenberg, EM AF Sloan, Denise M. Marx, Brian P. Greenberg, Eva M. TI A test of written emotional disclosure as an intervention for posttraumatic stress disorder SO BEHAVIOUR RESEARCH AND THERAPY LA English DT Article DE PTSD; Trauma; Depression; Written disclosure; Exposure therapy ID COGNITIVE PROCESSING THERAPY; RANDOMIZED CONTROLLED-TRIAL; NARRATIVE EXPOSURE THERAPY; PSYCHOTHERAPY; DEPRESSION; CLOSER AB This study examined the efficacy of the written emotional disclosure (WED) procedure with a sample of young adults who met diagnostic criteria for posttraumatic stress disorder (PTSD). Participants were randomly assigned to either WED or a control writing condition and were assessed at baseline and one month following the writing sessions. During each writing session, participants' heart rate was recorded; participants also provided self-report ratings of emotional responding. Findings indicated no significant group differences for PTSD and depression symptom severity at follow-up assessment. Relative to control participants, WED participants displayed significantly greater heart rate activity and reported greater emotional responding during the first writing session; however, no reduction in emotional responding occurred for either condition from the first to the last writing session. Taken together, these findings indicate that WED may not be an efficacious intervention for PTSD. Suggestions are made for future work in this area. Published by Elsevier Ltd. C1 [Sloan, Denise M.; Marx, Brian P.] VA Boston Healthcare Syst, Natl Ctr PTSD 116B2, Boston, MA 02130 USA. [Sloan, Denise M.; Marx, Brian P.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Greenberg, Eva M.] Drexel Univ, Sch Med, Philadelphia, PA 19104 USA. RP Sloan, DM (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B2, 150 S Huntington Ave, Boston, MA 02130 USA. EM denise.sloan@va.gov OI Sloan, Denise/0000-0002-0962-478X FU NIMH NIH HHS [R34 MH077658] NR 32 TC 15 Z9 15 U1 0 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0005-7967 J9 BEHAV RES THER JI Behav. Res. Ther. PD APR PY 2011 VL 49 IS 4 BP 299 EP 304 DI 10.1016/j.brat.2011.02.001 PG 6 WC Psychology, Clinical SC Psychology GA 749HD UT WOS:000289454000012 PM 21367400 ER PT J AU Peacock, WF Varon, J Ebrahimi, R Dunbar, L Pollack, CV AF Peacock, W. Frank Varon, Joseph Ebrahimi, Ramin Dunbar, Lala Pollack, Charles V., Jr. TI Clevidipine for severe hypertension in patients with renal dysfunction: A VELOCITY trial analysis SO BLOOD PRESSURE LA English DT Article DE Calcium-channel blocker; clevidipine; hypertension; intravenous antihypertensive agent; renal insufficiency ID ACTING CALCIUM-ANTAGONIST; CARDIAC-SURGERY PATIENTS; HEALTHY-VOLUNTEERS; NITROPRUSSIDE; EFFICACY; CYANIDE AB Introduction. Acute and severe hypertension is common, especially in patients with renal dysfunction (RD). Clevidipine is a rapidly acting (t(1/2)similar to 1 mm) intravenous (IV) dihydropyridine calcium-channel blocker metabolized by blood and tissue esterases and may be useful in patients with RD. The purpose of this analysis was to assess the safety and efficacy of clevidipine in patients with RD. Methods. VELOCITY, a multicenter open-label study of severe hypertension, enrolled 126 patients with persistent systolic blood pressure (SBP) >180 mmHg. Investigators pre-specified a SBP initial target range (ITR) for each patient to be achieved within 30 min. Blood pressure monitoring was by cuff. Clevidipine was infused via peripheral IV at 2 mg/h for at least 3 min, then doubled every 3 min as needed to a maximum of 32 mg/h (non-weight-based treat-to-target protocol). Per protocol, clevidipine was continued for at least 18 h (96 h maximum). RD was diagnosed and reported as an end-organ injury by the investigator and was defined as requiring dialysis or an initial creatinine >2.0 mg/dl. Primary endpoints were the percentage of patients within the ITR by 30 min and the percentage below the ITR after 3 min of clevidipine infusion. Results. Of the 24 patients with moderate to severe RD, most (13/24) were dialysis dependent. Forty-six percent were male, with mean age 51 +/- 14 years; 63% were black and 96% had a hypertension history. Median time to achieve the ITR was 8.5 min. Almost 90% of patients reached the ITR in 30 min without evidence of overshoot and were maintained on clevidipine through 18 h. Most patients (88%) transitioned to oral antihypertensive therapy within 6 h of clevidipine termination. Conclusions. This report is the first demonstrating that clevidipine is safe and effective in RD complicated by severe hypertension. Prolonged infusion maintained blood pressure within a target range and allowed successful transition to oral therapy. C1 [Peacock, W. Frank] Cleveland Clin, Dept Emergency Med, Cleveland, OH 44195 USA. [Varon, Joseph] Univ Texas Hlth Sci Ctr, Houston, TX USA. [Ebrahimi, Ramin] Univ Calif Los Angeles, Los Angeles, CA USA. [Ebrahimi, Ramin] VA Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Dunbar, Lala] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [Pollack, Charles V., Jr.] Univ Penn, Philadelphia, PA 19104 USA. RP Peacock, WF (reprint author), Cleveland Clin, Dept Emergency Med, Desk E19,9500 Euclid Ave, Cleveland, OH 44195 USA. EM Peacocw@ccf.org OI Varon, Joseph/0000-0002-7622-9974 FU Abbott; BAS; Biosite; Brahms; PCT; CHF Solutions; Heartscape Technologies, Inc.; Inovise Medical; Inverness Medical Innovations, Inc.; PDL Pharmaceuticals; Medicines Company FX W.F.P. has received honoraria for lectures from Abbott, Biosite, Otsuka Pharmaceuticals, Ortho Clinical Diagnostics, PDL Pharmaceuticals, Scios, Inc. and The Medicines Company. He has served as a consultant for Abbott, Beckman-Coulter, Inc., Biosite, Inovise Medical, Inc., Inverness Medical Innovations, Inc., Otsuka Pharmaceuticals, Ortho Clinical Diagnostics and The Medicines Company, Heartscape Technologies, Inc.; and he has received support in the form of research grants from Abbott, BAS, Biosite, Brahms, PCT, CHF Solutions, Heartscape Technologies, Inc., Inovise Medical, Inverness Medical Innovations, Inc., PDL Pharmaceuticals, and The Medicines Company. NR 21 TC 3 Z9 3 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0803-7051 J9 BLOOD PRESSURE JI Blood Pressure PD APR PY 2011 VL 20 SU 1 BP 20 EP 25 DI 10.3109/08037051.2010.539317 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 752NU UT WOS:000289699700003 ER PT J AU Lankshear, A Lowson, K Weingart, SN AF Lankshear, Annette Lowson, Karin Weingart, Saul N. TI An assessment of the quality and impact of NPSA medication safety outputs issued to the NHS in England and Wales SO BMJ QUALITY & SAFETY LA English DT Article ID PATIENT SAFETY; PRESCRIBING ERRORS; DOCTORS; EPIDEMIOLOGY; ALERTS AB Objectives: To assess the quality and impact of medication safety outputs issued by the National Patient Safety Agency (NPSA) to the NHS in England and Wales. Methods: A multi-method study comprising (1) focus groups and interviews with NHS Chief Pharmacists and (2) an electronic survey of medical, nursing and clinical governance directors. Results: Acute sector respondents agreed that the medication outputs had a major impact on patient safety. Pharmacists welcomed national support for medication safety improvement, despite the resulting workload. Medical Directors were much less likely to be aware of alerts and Rapid Response Reports (RRRs) than their nursing and clinical governance colleagues. One key finding was the inability of around half of NHS trusts to communicate effectively and reliably with their junior doctors. Conclusion: Medication alerts issued by the NPSA have stimulated significant work to improve medication safety and are believed to have had an important impact on patient safety. C1 [Lankshear, Annette] Cardiff Univ, Cardiff Sch Nursing Midwifery Studies, Cardiff CF24 0AB, S Glam, Wales. [Lowson, Karin] Univ York, York Hlth Econ Consortium, York YO10 5DD, N Yorkshire, England. [Weingart, Saul N.] Harvard Univ, Sch Med, Boston, MA USA. [Weingart, Saul N.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Lankshear, A (reprint author), Cardiff Univ, Cardiff Sch Nursing Midwifery Studies, Eastgate House,City Rd, Cardiff CF24 0AB, S Glam, Wales. EM lankshearaj@cardiff.ac.uk RI Lankshear, Annette/C-9953-2010 FU National Patient Safety Agency, 4-8 Maple Street, London W1T 5HD, UK; National Patient Safety Agency FX National Patient Safety Agency, 4-8 Maple Street, London W1T 5HD, UK. Other Funders: National Patient Safety Agency. NR 20 TC 7 Z9 7 U1 1 U2 5 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD APR PY 2011 VL 20 IS 4 BP 360 EP 365 DI 10.1136/bmjqs.2010.040287 PG 6 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 752XL UT WOS:000289728700012 PM 21303768 ER PT J AU Hainz, U Stevenson, K Ho, V Alonso, A Sievers, Q Zhang, W Lokko, N Goldstein, N Koreth, J Cutler, C Armand, P Antin, J Ritz, J Dranoff, G Soiffer, R Wu, C AF Hainz, U. Stevenson, K. Ho, V. Alonso, A. Sievers, Q. Zhang, W. Lokko, N. Goldstein, N. Koreth, J. Cutler, C. Armand, P. Antin, J. Ritz, J. Dranoff, G. Soiffer, R. Wu, C. TI Early post-transplant whole tumour cell vaccination elicits anti-tumour T-cell immunity in patients with chronic lymphocytic leukaemia SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Hainz, U.; Stevenson, K.; Ho, V.; Alonso, A.; Sievers, Q.; Zhang, W.; Lokko, N.; Goldstein, N.; Koreth, J.; Cutler, C.; Armand, P.; Antin, J.; Ritz, J.; Dranoff, G.; Soiffer, R.; Wu, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S55 EP S55 PG 1 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195400126 ER PT J AU Jacobsohn, D Danner-Koptik, K Brazauskas, R Wang, Z Duncan, C Sorror, M Majhail, N AF Jacobsohn, D. Danner-Koptik, K. Brazauskas, R. Wang, Z. Duncan, C. Sorror, M. Majhail, N. TI Second malignancies after autologous haematopoietic stem cell transplantation in children SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Jacobsohn, D.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Danner-Koptik, K.] Childrens Mem Med Ctr, Chicago, IL USA. [Brazauskas, R.] Ctr Blood & Marrow Transplant Res, Milwaukee, WI USA. [Wang, Z.] Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA. [Duncan, C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sorror, M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Majhail, N.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S20 EP S20 PG 1 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195400042 ER PT J AU Lehmann, L Chirnomas, D AF Lehmann, L. Chirnomas, D. TI Successful use of reduced-intensity conditioning for unrelated donor bone transplantation in children with dyskeratosis congenita associated bone marrow failure SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Lehmann, L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chirnomas, D.] Yale Univ, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S141 EP S141 PG 1 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195401134 ER PT J AU Levine, JE Logan, B Wu, J Alousi, AM Bolanos-Meade, J Ho, V Weisdorf, DJ Paczesny, S AF Levine, J. E. Logan, B. Wu, J. Alousi, A. M. Bolanos-Meade, J. Ho, V. Weisdorf, D. J. Paczesny, S. TI GvHD biomarkers measured during treatment independently predict response to therapy and survival: A Blood and Marrow Transplant Clinical Trials Network Study SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Levine, J. E.; Paczesny, S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Logan, B.] Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA. [Wu, J.] EMMES Corp, Rockville, MD USA. [Alousi, A. M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Bolanos-Meade, J.] Johns Hopkins Univ, Baltimore, MD USA. [Ho, V.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Weisdorf, D. J.] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S8 EP S9 PG 2 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195400017 ER PT J AU Norde, WJ Maas, F Korman, A Quigley, M Kester, M Hebeda, K Falkenburg, JHF de Witte, T Schaap, N van der Voort, R Dolstra, H AF Norde, W. J. Maas, F. Korman, A. Quigley, M. Kester, M. Hebeda, K. Falkenburg, J. H. F. de Witte, T. Schaap, N. van der Voort, R. Dolstra, H. TI PD-1/PD-L1 interactions contribute to functional impairment of minor histocompatibility antigen-specific CD8+T-cells targeting PD-L1-expressing leukaemic cells SO BONE MARROW TRANSPLANTATION LA English DT Meeting Abstract CT 37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group CY APR 03-06, 2011 CL Paris, FRANCE SP European Grp Bone & Marrow Transplantat, European Grp Bone & Marrow Transplantat Nurses Grp, European Grp Bone & Marrow Transplantat Management Grp C1 [Norde, W. J.; Maas, F.; Hebeda, K.; de Witte, T.; Schaap, N.; van der Voort, R.; Dolstra, H.] Radboud Univ Nijmegen, NL-6525 ED Nijmegen, Netherlands. [Korman, A.] Bristol Myers Squibb Co, Milpitas, CA USA. [Quigley, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kester, M.; Falkenburg, J. H. F.] Leiden Univ, Leiden, Netherlands. RI Dolstra, H./L-4276-2015; Witte, T.J.M./L-4762-2015; Hebeda, K.M./L-4354-2015; Schaap, N.P.M./L-4625-2015 NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0268-3369 J9 BONE MARROW TRANSPL JI Bone Marrow Transplant. PD APR PY 2011 VL 46 SU 1 BP S310 EP S310 PG 1 WC Biophysics; Oncology; Hematology; Immunology; Transplantation SC Biophysics; Oncology; Hematology; Immunology; Transplantation GA 745VC UT WOS:000289195402177 ER PT J AU Hamshere, ML O'Donovan, MC Jones, IR Jones, L Kirov, G Green, EK Moskvina, V Grozeva, D Bass, N McQuillin, A Gurling, H St Clair, D Young, AH Ferrier, IN Farmer, A McGuffin, P Sklar, P Purcell, S Holmans, PA Owen, MJ Craddock, N AF Hamshere, M. L. O'Donovan, M. C. Jones, I. R. Jones, L. Kirov, G. Green, E. K. Moskvina, V. Grozeva, D. Bass, N. McQuillin, A. Gurling, H. St Clair, D. Young, A. H. Ferrier, I. N. Farmer, A. McGuffin, P. Sklar, P. Purcell, S. Holmans, P. A. Owen, M. J. Craddock, N. TI Polygenic dissection of the bipolar phenotype SO BRITISH JOURNAL OF PSYCHIATRY LA English DT Article ID GENOME-WIDE ASSOCIATION; AFFECTIVE PSYCHOSES; SCHIZOPHRENIA; DISORDER; IDENTIFICATION; CLASSIFICATION; RELIABILITY; RATIONALE; CRITERIA; ILLNESS AB Background Recent data provide strong support for a substantial common polygenic contribution (i.e. many alleles each of small effect) to genetic susceptibility for schizophrenia and overlapping susceptibility for bipolar disorder. Aims To test hypotheses about the relationship between schizophrenia and psychotic types of bipolar disorder. Method Using a polygenic score analysis to test whether schizophrenia polygenic risk alleles, en masse, significantly discriminate between individuals with bipolar disorder with and without psychotic features. The primary sample included 1829 participants with bipolar disorder and the replication sample comprised 506 people with bipolar disorder. Results The subset of participants with Research Diagnostic Criteria schizoaffective bipolar disorder (n=277) were significantly discriminated from the remaining participants with bipolar disorder (n=1552) in both the primary (P=0.00059) and the replication data-sets (P=0.0070). In contrast, those with psychotic bipolar disorder as a whole were not significantly different from those with non-psychotic bipolar disorder in either data-set. Conclusions Genetic susceptibility influences at least two major domains of psychopathological variation in the schizophrenia-bipolar disorder clinical spectrum: one that relates to expression of a 'bipolar disorder-like' phenotype and one that is associated with expression of 'schizophrenia-like' psychotic symptoms. C1 [Craddock, N.] Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Sch Med, Cardiff CF14 4XN, S Glam, Wales. [Jones, L.] Univ Birmingham, Dept Psychiat, Natl Ctr Mental Hlth, Birmingham, W Midlands, England. [Bass, N.; McQuillin, A.; Gurling, H.] UCL, Dept Mental Hlth Sci, London WC1E 6BT, England. [St Clair, D.] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland. [Young, A. H.; Ferrier, I. N.] Royal Victoria Infirm, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England. [Young, A. H.] Univ Blvd Vancouver, UBC Inst Mental Hlth, Vancouver, BC, Canada. [McGuffin, P.] Kings Coll London, Inst Psychiat, London, England. [Sklar, P.; Purcell, S.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [Sklar, P.; Purcell, S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Sklar, P.; Purcell, S.] Broad Inst, Stanley Ctr Psychiat Genet, Cambridge, MA USA. RP Craddock, N (reprint author), Cardiff Univ, MRC Ctr Neuropsychiat Genet & Genom, Sch Med, Heath Pk, Cardiff CF14 4XN, S Glam, Wales. EM craddockn@cardiff.ac.uk RI turton, miranda/F-4682-2011; Gurling, Hugh/A-5029-2010; McGuffin, Peter/A-1565-2012; McQuillin, Andrew/C-1623-2008; OI McGuffin, Peter/0000-0002-9888-2907; McQuillin, Andrew/0000-0003-1567-2240; O'Donovan, Michael/0000-0001-7073-2379; Holmans, Peter/0000-0003-0870-9412; Escott-Price, Valentina/0000-0003-1784-5483 FU Wellcome Trust [076113]; Medical Research Council FX Funding for recruitment and phenotype assessment has been provided by the Wellcome Trust and the Medical Research Council. This study makes use of data generated by the Wellcome Trust Case-Control Consortium. Funding for the project was provided by the Wellcome Trust under award 076113. NR 40 TC 28 Z9 28 U1 0 U2 11 PU ROYAL COLLEGE OF PSYCHIATRISTS PI LONDON PA BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND SN 0007-1250 J9 BRIT J PSYCHIAT JI Br. J. Psychiatry PD APR PY 2011 VL 198 IS 4 BP 284 EP 288 DI 10.1192/bjp.bp.110.087866 PG 5 WC Psychiatry SC Psychiatry GA 751IH UT WOS:000289610200010 PM 21972277 ER PT J AU Perna, F Heist, EK Danik, SB Barrett, CD Ruskin, JN Mansour, M AF Perna, Francesco Heist, E. Kevin Danik, Stephan B. Barrett, Conor D. Ruskin, Jeremy N. Mansour, Moussa TI Assessment of Catheter Tip Contact Force Resulting in Cardiac Perforation in Swine Atria Using Force Sensing Technology SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY LA English DT Article DE contact force; force sensing; cardiac perforation; catheter ablation; cardiac tamponade ID ACCESSORY ATRIOVENTRICULAR PATHWAYS; PARKINSON-WHITE SYNDROME; RADIOFREQUENCY ABLATION; SUPRAVENTRICULAR ARRHYTHMIAS; NODAL REENTRY; LESION SIZE; STEAM POP; ELECTRODE; TACHYCARDIA; COMPLICATIONS AB Background-Force sensing is a recently developed technology that allows the determination of the contact force (CF) at the tip of the catheter during electrophysiology procedures. Previous studies suggested that the optimal CF for adequate catheter contact ranges between 10 and 40 g. The aim of this study was to determine the CF needed to cause perforation in the swine atria. Methods and Results-Pericardial access was obtained at the beginning of the study in a swine model to drain pericardial effusions. Electroanatomic maps of the right atrium (RA) and left atrium (LA) were constructed. Ablation was performed using an irrigated-tip radiofrequency catheter equipped with force-sensing technology (30 W, 30 mL/min, for 30 seconds). Perforations of the LA and RA wall were intentionally performed in different locations with and without radiofrequency ablation. CF values preceding each perforation were recorded. A total of 111 cardiac perforations were achieved in 7 pigs. The overall average CF resulting in perforation was 175.8 +/- 60.4 g (range, 77 to 376 g). This was significantly lower after 30 seconds of radiofrequency delivery: 151.8 +/- 49.9 g versus 197 +/- 61.3 g (P = 0.00005). The average value of CF resulting in perforation was not statistically different between the RA and the LA (169.6 +/- 61.6 g versus 181.7 +/- 59.3 g) (P = 0.29). Conclusions-Perforation of the atrial wall in a swine model can occur over a wide range of CF values. Perforation can occur with a CF as low as 77 g. Ablation reduces the perforating force by 23%. (Circ Arrhythm Electrophysiol. 2011;4:218-224.) C1 [Perna, Francesco] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Ctr Heart, Boston, MA 02114 USA. RP Mansour, M (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Ctr Heart, GRB 109,55 Fruit St, Boston, MA 02114 USA. EM mmansour@partners.org OI Perna, Francesco/0000-0002-9019-9492 FU Deane Institute for Integrative Research in Atrial Fibrillation and Stroke; Biosense Webster; Biotronik; St Jude Medical; Boston Scientific; Medtronic FX The study was partially funded by the Deane Institute for Integrative Research in Atrial Fibrillation and Stroke and a research grant from Biosense Webster. The authors used an electroanatomic system owned by Biosense Webster with force sensing ability to perform the experiments.; Dr Heist received research grants from Biotronik and St Jude Medical, honoraria from Biotronik, Boston Scientific, Sorin, and St Jude Medical, and serves as consultant to Biotronik, Boston Scientific, and St Jude Medical. Dr Ruskin received fellowship support from Biosense Webster, Boston Scientific, Medtronic, and St Jude Medical; he serves on the Scientific Advisory Board of CardioInsight, the Clinical Oversight Committee for CardioFocus, and the Scientific Steering Committee for CryoCath and as a consultant for Biosense Webster and Medtronic. Dr Mansour received research grant support from Biosense Webster and St Jude Medical and serves as consultant for both companies. NR 27 TC 57 Z9 58 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3149 J9 CIRC-ARRHYTHMIA ELEC JI Circ.-Arrhythmia Electrophysiol. PD APR PY 2011 VL 4 IS 2 BP 218 EP 224 DI 10.1161/CIRCEP.110.959429 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 752EQ UT WOS:000289672800019 PM 21248244 ER PT J AU Anderson, CD Nalls, MA Biffi, A Rost, NS Greenberg, SM Singleton, AB Meschia, JF Rosand, J AF Anderson, Christopher D. Nalls, Michael A. Biffi, Alessandro Rost, Natalia S. Greenberg, Steven M. Singleton, Andrew B. Meschia, James F. Rosand, Jonathan TI The Effect of Survival Bias on Case-Control Genetic Association Studies of Highly Lethal Diseases SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Article DE stroke; hemorrhage; myocardial infarction; genetics; epidemiology ID UNRECOGNIZED MYOCARDIAL-INFARCTION; CASE-FATALITY; STROKE INCIDENCE; GENOMEWIDE ASSOCIATION; POPULATION; EPIDEMIOLOGY; REGISTRY; RISK; PREVALENCE; ROTTERDAM AB Background-Survival bias is the phenomenon by which individuals are excluded from analysis of a trait because of mortality related to the expression of that trait. In genetic association studies, variants increasing risk for disease onset as well as risk of disease-related mortality (lethality) could be difficult to detect in genetic association case-control designs, possibly leading to underestimation of a variant's effect on disease risk. Methods and Results-We modeled cohorts for 3 diseases of high lethality (intracerebral hemorrhage, ischemic stroke, and myocardial infarction) using existing longitudinal data. Based on these models, we simulated case-control genetic association studies for genetic risk factors of varying effect sizes, lethality, and minor allele frequencies. For each disease, erosion of detected effect size was larger for case-control studies of individuals of advanced age (age >75 years) and/or variants with very high event-associated lethality (genotype relative risk for event-related death >2.0). We found that survival bias results in no more than 20% effect size erosion for cohorts with mean age <75 years, even for variants that double lethality risk. Furthermore, we found that increasing effect size erosion was accompanied by depletion of minor allele frequencies in the case population, yielding a "signature" of the presence of survival bias. Conclusions-Our simulation provides formulas to allow estimation of effect size erosion given a variant's odds ratio of disease, odds ratio of lethality, and minor allele frequencies. These formulas will add precision to power calculation and replication efforts for case-control genetic studies. Our approach requires validation using prospective data. (Circ Cardiovasc Genet. 2011;4:188-196.) C1 [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Greenberg, Steven M.; Rosand, Jonathan] Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Dept Neurol, Boston, MA 02114 USA. [Anderson, Christopher D.; Biffi, Alessandro; Rost, Natalia S.; Rosand, Jonathan] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Nalls, Michael A.; Singleton, Andrew B.] NIA, Neurogenet Lab, Intramural Res Program, Bethesda, MD 20892 USA. [Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA. RP Rosand, J (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA. EM jrosand@partners.org RI Singleton, Andrew/C-3010-2009; OI Anderson, Christopher/0000-0002-0053-2002 FU American Heart Association/Bugher Foundation Centers for Stroke Prevention Research [0775011N, 0755984T]; Deane Institute for Integrative Study of Atrial Fibrillation and Stroke; National Institute for Neurologic Disorders and Stroke [R01 NS063925, R01 NS059727, P50 NS051343, K23NS064052-01A1]; National Institute of Health, National Institute on Aging [Z01-AG000954-06:2007] FX This work was supported by funding from the American Heart Association/Bugher Foundation Centers for Stroke Prevention Research (0775011N, 0755984T), Deane Institute for Integrative Study of Atrial Fibrillation and Stroke, and the National Institute for Neurologic Disorders and Stroke (R01 NS063925, R01 NS059727, P50 NS051343, K23NS064052-01A1). This research was also supported in part by the Intramural Research Program of the National Institute of Health, National Institute on Aging, under Annual Report No. Z01-AG000954-06:2007. NR 33 TC 15 Z9 18 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD APR PY 2011 VL 4 IS 2 BP 188 EP U265 DI 10.1161/CIRCGENETICS.110.957928 PG 19 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 752SA UT WOS:000289712700015 PM 21292865 ER PT J AU Poon, K Bell, B Raffel, OC Walters, DL Jang, IK AF Poon, Karl Bell, Brendan Raffel, Owen Christopher Walters, Darren L. Jang, Ik-Kyung TI Spontaneous Coronary Artery Dissection Utility of Intravascular Ultrasound and Optical Coherence Tomography During Percutaneous Coronary Intervention SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS LA English DT Editorial Material DE ultrasonography; tomography optical tomography C1 [Poon, Karl; Bell, Brendan; Raffel, Owen Christopher; Walters, Darren L.] Prince Charles Hosp, Chermside, Qld 4032, Australia. [Jang, Ik-Kyung] Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Poon, K (reprint author), Prince Charles Hosp, Rode Rd, Chermside, Qld 4032, Australia. EM karlkpoon@gmail.com RI Walters, Darren/A-7069-2011 NR 2 TC 11 Z9 12 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7640 J9 CIRC-CARDIOVASC INTE JI Circ.-Cardiovasc. Interv. PD APR PY 2011 VL 4 IS 2 BP E5 EP E7 DI 10.1161/CIRCINTERVENTIONS.110.959593 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 752EW UT WOS:000289673600001 PM 21505162 ER PT J AU Mortazavi, F Dubinett, S Rettig, M AF Mortazavi, Fariborz Dubinett, Steven Rettig, Matthew TI c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells SO CLINICAL & EXPERIMENTAL METASTASIS LA English DT Article DE Cell adhesion; c-Crk; Lung cancer; Metastasis; p120 catenin; Signal transduction; Transcription factors ID P120 CATENIN; CADHERIN EXPRESSION; GENE-EXPRESSION; LOCALIZATION; TURNOVER; PROTEINS; INVASION; BINDING AB As a member of adherens junction, p120-catenin (p120ctn) plays a major role in cell adhesions through stabilization of E-cadherin. p120ctn is transcriptionally down-regulated in non-small cell lung cancer (NSCLC), although the molecular mechanisms underlying p120ctn repression are incompletely defined. Here we further investigated transcriptional regulation of p120ctn in NSCLC. We prepared a promoter reporter plasmid construct that contained p120ctn promoter region from position -1082 to +320 relative to transcription start site. Through serial deletion mutation analysis of the p120ctn promoter, we pinpointed cis-acting elements involved in regulation of p120ctn. We identified transcription factor SP1 as a transcriptional repressor of p120ctn that directly binds to segment (-9 to +36) of the p120ctn promoter. SP1 can receive multiple signals from several intracellular signaling pathways. Through examination of SP1 binding partners, we identified proto-oncogene c-Crk to be involved in transcriptional down-regulation of p120ctn. RNAi mediated silencing of CRK in A549, H157 and H358 cells increased p120ctn protein levels. On the other hand, over-expression of CRK-I and CRK-II in NSCLC cells down-regulated p120ctn, an effect that was abrogated by simultaneous silencing of SP1. In summary, our data provide evidence for the role of c-Crk proto-oncogene in transcriptional repression of p120ctn that further clarifies the mechanism by which this biochemical signal promotes metastasis in NSCLC. C1 [Mortazavi, Fariborz; Dubinett, Steven; Rettig, Matthew] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Mortazavi, Fariborz; Rettig, Matthew] W Los Angeles VA, Div Hematol & Oncol, Los Angeles, CA USA. [Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Lung Canc Res Program, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Dubinett, Steven] Div Pulm & Crit Care Med, Los Angeles, CA USA. [Dubinett, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. [Rettig, Matthew] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. RP Mortazavi, F (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. EM fredmortazavi@ucla.edu NR 30 TC 7 Z9 12 U1 0 U2 5 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0262-0898 J9 CLIN EXP METASTAS JI Clin. Exp. Metastasis PD APR PY 2011 VL 28 IS 4 BP 391 EP 404 DI 10.1007/s10585-011-9378-8 PG 14 WC Oncology SC Oncology GA 753RN UT WOS:000289797400006 PM 21336985 ER PT J AU Pritchett, Y Jemiai, Y Chang, YC Bhan, I Agarwal, R Zoccali, C Wanner, C Lloyd-Jones, D Cannata-Andia, JB Thompson, T Appelbaum, E Audhya, P Andress, D Zhang, WY Solomon, S Manning, WJ Thadhani, R AF Pritchett, Yili Jemiai, Yannis Chang, Yuchiao Bhan, Ishir Agarwal, Rajiv Zoccali, Carmine Wanner, Christoph Lloyd-Jones, Donald Cannata-Andia, Jorge B. Thompson, Taylor Appelbaum, Evan Audhya, Paul Andress, Dennis Zhang, Wuyan Solomon, Scott Manning, Warren J. Thadhani, Ravi TI The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease SO CLINICAL TRIALS LA English DT Article ID LEFT-VENTRICULAR MASS; CARDIOVASCULAR MAGNETIC-RESONANCE; VITAMIN-D; CLINICAL-TRIALS; HEMODIALYSIS-PATIENTS; NOCTURNAL HEMODIALYSIS; MYOCARDIAL-INFARCTION; IMPROVED SURVIVAL; ANEMIA CORRECTION; HYPERTROPHY AB Background Chronic kidney disease is associated with a marked increase in risk for left ventricular hypertrophy and cardiovascular mortality compared with the general population. Therapy with vitamin D receptor activators has been linked with reduced mortality in chronic kidney disease and an improvement in left ventricular hypertrophy in animal studies. Purpose PRIMO (Paricalcitol capsules benefits in Renal failure Induced cardia MOrbidity) is a multinational, multicenter randomized controlled trial to assess the effects of paricalcitol (a selective vitamin D receptor activator) on mild to moderate left ventricular hypertrophy in patients with chronic kidney disease. Methods Subjects with mild-moderate chronic kidney disease are randomized to paricalcitol or placebo after confirming left ventricular hypertrophy using a cardiac echocardiogram. Cardiac magnetic resonance imaging is then used to assess left ventricular mass index at baseline, 24 and 48 weeks, which is the primary efficacy endpoint of the study. Because of limited prior data to estimate sample size, a maximum information group sequential design with sample size re-estimation is implemented to allow sample size adjustment based on the nuisance parameter estimated using the interim data. An interim efficacy analysis is planned at a pre-specified time point conditioned on the status of enrollment. The decision to increase sample size depends on the observed treatment effect. A repeated measures analysis model, using available data at Week 24 and 48 with a backup model of an ANCOVA analyzing change from baseline to the final nonmissing observation, are pre-specified to evaluate the treatment effect. Gamma-family of spending function is employed to control family-wise Type I error rate as stopping for success is planned in the interim efficacy analysis. Limitations If enrollment is slower than anticipated, the smaller sample size used in the interim efficacy analysis and the greater percent of missing week 48 data might decrease the parameter estimation accuracy, either for the nuisance parameter or for the treatment effect, which might in turn affect the interim decision-making. Conclusions The application of combining a group sequential design with a sample-size re-estimation in clinical trial design has the potential to improve efficiency and to increase the probability of trial success while ensuring integrity of the study. Clinical Trials 2011; 8: 165-174. http://ctj.sagepub.com C1 [Pritchett, Yili; Audhya, Paul; Andress, Dennis; Zhang, Wuyan] Abbott Labs, Abbott Pk, IL 60064 USA. [Jemiai, Yannis] Cytel Inc, Cambridge, MA USA. [Chang, Yuchiao; Bhan, Ishir; Thadhani, Ravi] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA. [Chang, Yuchiao; Bhan, Ishir; Thompson, Taylor; Thadhani, Ravi] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol, Boston, MA USA. [Agarwal, Rajiv] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA. [Zoccali, Carmine] Nephrol Dialysis & Transplantat Unit, Reggio Di Calabria, Italy. [Zoccali, Carmine] CNR IBIM Clin Epidemiol & Pathophysiol Renal Dis, Reggio Di Calabria, Italy. [Wanner, Christoph] Univ Wurzburg, Dept Med, Div Nephrol, Univ Hosp, Wurzburg, Germany. [Lloyd-Jones, Donald] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Cannata-Andia, Jorge B.] Univ Oviedo, Serv Metab Oseo & Mineral, Inst Reina Sofia Invest, REDinREN ISCIII,Hosp Univ Cent Asturias, Oviedo, Spain. [Appelbaum, Evan; Manning, Warren J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, CMR Core Lab PERFUSE, Boston, MA 02215 USA. [Appelbaum, Evan; Manning, Warren J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA. [Appelbaum, Evan; Manning, Warren J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiol WJM, Boston, MA 02215 USA. [Manning, Warren J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA. RP Pritchett, Y (reprint author), Abbott Labs, 100 Abbott Pk Rd, Abbott Pk, IL 60064 USA. EM yili.pritchett@aboott.com RI Lloyd-Jones, Donald/C-5899-2009; Cannata-Andia, Jorge/L-2260-2013; OI Zoccali, Carmine/0000-0002-6616-1996 FU Abbott Laboratories; Abbott FX RT is supported by a research grant from Abbott Laboratories. RA has received honoraria for serving on the speaker's bureau and steering committees of Abbott Laboratories. CW serves on an advisory board for Abbott and has received research support, speakers' fees and travel support from Abbott. YP, PA, DA, and WZ are employed by Abbott. NR 53 TC 10 Z9 10 U1 0 U2 4 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 J9 CLIN TRIALS JI Clin. Trials PD APR PY 2011 VL 8 IS 2 BP 165 EP 174 DI 10.1177/1740774511399128 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 754YA UT WOS:000289892600005 PM 21478328 ER PT J AU Fiore, LD Brophy, M Ferguson, RE D'Avolio, L Hermos, JA Lew, RA Doros, G Conrad, CH O'Neil, JA Sabin, TP Kaufman, J Swartz, SL Lawler, E Liang, MH Gaziano, JM Lavori, PW AF Fiore, Louis D. Brophy, Mary Ferguson, Ryan E. D'Avolio, Leonard Hermos, John A. Lew, Robert A. Doros, Gheorghe Conrad, Chester H. O'Neil, Joseph A. (Gus), Jr. Sabin, Thomas P. Kaufman, James Swartz, Stephen L. Lawler, Elizabeth Liang, Matthew H. Gaziano, J. Michael Lavori, Philip W. TI A point-of-care clinical trial comparing insulin administered using a sliding scale versus a weight-based regimen SO CLINICAL TRIALS LA English DT Article ID RANDOMIZED CONTROLLED TRIALS; INFORMED-CONSENT; NEED AB Background Clinical trials are widely considered the gold standard in comparative effectiveness research (CER) but the high cost and complexity of traditional trials and concerns about generalizability to broad patient populations and general clinical practice limit their appeal. Unsuccessful implementation of CER results limits the value of even the highest quality trials. Planning for a trial comparing two standard strategies of insulin administration for hospitalized patients led us to develop a new method for a clinical trial designed to be embedded directly into the clinical care setting thereby lowering the cost, increasing the pragmatic nature of the overall trial, strengthening implementation, and creating an integrated environment of research-based care. Purpose We describe a novel randomized clinical trial that uses the informatics and statistics infrastructure of the Veterans Affairs Healthcare System (VA) to illustrate one key component (called the point-of-care clinical trial - POC-CT) of a 'learning healthcare system,' and settles a clinical question of interest to the VA. Methods This study is an open-label, randomized trial comparing sliding scale regular insulin to a weight-based regimen for control of hyperglycemia, using the primary outcome length of stay, in non-ICU inpatients within the northeast region of the VA. All non-ICU patients who require in-hospital insulin therapy are eligible for the trial, and the VA's automated systems will be used to assess eligibility and present the possibility of randomization to the clinician at the point of care. Clinicians will indicate their approval for informed consent to be obtained by study staff. Adaptive randomization will assign up to 3000 patients, preferentially to the currently 'winning' strategy, and all care will proceed according to usual practices. Based on a Bayesian stopping rule, the study has acceptable frequentist operating characteristics (Type I error 6%, power 86%) against a 12% reduction of median length of stay from 5 to 4.4 days. The adaptive stopping rule promotes implementation of a successful treatment strategy. Limitations Despite clinical equipoise, individual healthcare providers may have strong treatment preferences that jeopardize the success and implementation of the trial design, leading to low rates of randomization. Unblinded treatment assignment may bias results. In addition, generalization of clinical results to other healthcare systems may be limited by differences in patient population. Generalizability of the POC-CT method depends on the level of informatics and statistics infrastructure available to a healthcare system. Conclusions The methods proposed will demonstrate outcome-based evaluation of control of hyperglycemia in hospitalized veterans. By institutionalizing a process of statistically sound and efficient learning, and by integrating that learning with automatic implementation of best practice, the participating VA Healthcare Systems will accelerate improvements in the effectiveness of care. Clinical Trials 2011; 8: 183-195. http://ctj.sagepub.com C1 [Fiore, Louis D.; Brophy, Mary; Ferguson, Ryan E.; D'Avolio, Leonard; Hermos, John A.; Lew, Robert A.; Doros, Gheorghe; Conrad, Chester H.; O'Neil, Joseph A. (Gus), Jr.; Sabin, Thomas P.; Kaufman, James; Swartz, Stephen L.; Lawler, Elizabeth; Liang, Matthew H.; Gaziano, J. Michael] VA Healthcare Syst, VA Cooperat Studies Program, MAVERIC, Boston, MA 02130 USA. [Fiore, Louis D.; Ferguson, Ryan E.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Fiore, Louis D.; Brophy, Mary; Hermos, John A.; Conrad, Chester H.; Kaufman, James] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [D'Avolio, Leonard] Harvard Univ, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA. [Hermos, John A.] Boston Med Ctr, Gen Internal Med Sect, Boston, MA USA. [Lew, Robert A.; Doros, Gheorghe] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Lawler, Elizabeth; Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Lawler, Elizabeth; Gaziano, J. Michael] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Liang, Matthew H.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. [Lavori, Philip W.] Stanford Univ, Dept Stat, Palo Alto, CA 94304 USA. RP Fiore, LD (reprint author), VA Healthcare Syst, VA Cooperat Studies Program, MAVERIC, 150 S Huntington Ave, Boston, MA 02130 USA. EM louis.fiore@va.gov FU Department of Veterans Affairs; [UL1 RR025744]; [R01 MH051481] FX This study was supported by the Department of Veterans Affairs Cooperative Studies Program. Dr Lavori's efforts have been supported by grants UL1 RR025744 and R01 MH051481 to Stanford University. NR 20 TC 36 Z9 36 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1740-7745 J9 CLIN TRIALS JI Clin. Trials PD APR PY 2011 VL 8 IS 2 BP 183 EP 195 DI 10.1177/1740774511398368 PG 13 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 754YA UT WOS:000289892600007 PM 21478329 ER PT J AU McCarthy, JC Lee, JA AF McCarthy, Joseph C. Lee, Jo-Ann TI History of Hip Arthroscopy: Challenges and Opportunities SO CLINICS IN SPORTS MEDICINE LA English DT Article DE Hip arthroscopy; Hip anatomy; Chondral lesion; Labral injury; Chondral injury ID 10-YEAR FOLLOW-UP; FEMOROACETABULAR IMPINGEMENT; ACETABULAR LABRUM; PORTAL PLACEMENT; PAINFUL HIP; DISEASE; REPAIR; DIAGNOSIS; ARTHRITIS; TEARS AB Hip arthroscopy began with resection of pathologies and later progressed to repair of different tissues. There is an increasing impetus for reconstruction of biologic joints; although this has occurred with other joints, hip arthroscopic procedures are now headed in this direction. Thus, despite considerable initial challenges, multiple opportunities are now available in this fertile field. C1 [McCarthy, Joseph C.; Lee, Jo-Ann] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. [McCarthy, Joseph C.; Lee, Jo-Ann] Newton Wellesley Hosp, Kaplan Ctr Joint Reconstruct Surg, Newton, MA 02462 USA. RP McCarthy, JC (reprint author), Massachusetts Gen Hosp, Dept Orthopaed, 55 Fruit St, Boston, MA 02114 USA. EM jcmccarthy1@partners.org NR 52 TC 6 Z9 6 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-5919 J9 CLIN SPORT MED JI Clin. Sports Med. PD APR PY 2011 VL 30 IS 2 BP 217 EP + DI 10.1016/j.csm.2010.12.001 PG 9 WC Sport Sciences SC Sport Sciences GA 753WS UT WOS:000289811500003 PM 21419953 ER PT J AU Yusufzai, T Kadonaga, JT AF Yusufzai, Timur Kadonaga, James T. TI Branching out with DNA helicases SO CURRENT OPINION IN GENETICS & DEVELOPMENT LA English DT Review ID SIMPLE REPETITIVE SEQUENCES; STALLED REPLICATION FORKS; COMPLEMENTATION GROUP-M; HOLLIDAY JUNCTIONS; ANNEALING HELICASE; SYNDROME PROTEINS; STRANDED-DNA; REPAIR; RECG; FANCM AB The proper resolution of branched DNA molecules, which arise during processes such as DNA replication, DNA repair, and transcription, is critical for the maintenance of the genome. Disruption of this process can lead to genome instability and cancer progression. In this review, we describe recent progress on several interesting and biologically important enzymes that act upon different types of branched DNA substrates. C1 [Yusufzai, Timur] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Yusufzai, Timur] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02215 USA. [Kadonaga, James T.] Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA. RP Yusufzai, T (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 250 Longwood Ave, Boston, MA 02115 USA. EM timur_yusufzai@dfci.harvard.edu FU National Institutes of Health [GM058272] FX We are grateful to Alan D'Andrea, Barbara Rattner, George Kassavetis, Yuan-Liang Wang, James Gucwa, and Mai Khuong for critical reading of this manuscript. This work was supported by a grant from the National Institutes of Health (GM058272) to J.T.K. NR 39 TC 4 Z9 4 U1 0 U2 3 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0959-437X J9 CURR OPIN GENET DEV JI Curr. Opin. Genet. Dev. PD APR PY 2011 VL 21 IS 2 BP 214 EP 218 DI 10.1016/j.gde.2011.01.019 PG 5 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA 754AR UT WOS:000289823700014 PM 21324673 ER PT J AU Lee, AI Okam, MM AF Lee, Alfred Ian Okam, Maureen M. TI Anemia in Pregnancy SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Anemia; Pregnancy; Iron deficiency; Folate; B(12) deficiency ID SICKLE-CELL-DISEASE; IRON-DEFICIENCY ANEMIA; HOMOZYGOUS ALPHA-THALASSEMIA; RANDOMIZED CONTROLLED-TRIAL; HEMOGLOBIN-H DISEASE; BETA-THALASSEMIA; APLASTIC-ANEMIA; FOLIC-ACID; INEFFECTIVE ERYTHROPOIESIS; SULFADOXINE-PYRIMETHAMINE AB Anemia in pregnancy is a global health problem affecting nearly half of all pregnant women worldwide. High fetal demands for iron render iron deficiency the most common cause of anemia of pregnancy, with other micronutrient deficiencies contributing less frequently. In certain geographical populations, human pathogens such as hookworm, malarial parasite and human immunodeficiency virus are important factors in anemia of pregnancy. The hemoglobinopathies, sickle cell disease and thalassemia, represent diverse causes of anemia of pregnancy, requiring specialized care. Aplastic anemia is a rare, morbid cause of anemia of pregnancy and is managed with transfusions until the completion of pregnancy. C1 [Okam, Maureen M.] Harvard Univ, Div Hematol, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Lee, Alfred Ian] Harvard Univ, Dana Farber Canc Inst, Sch Med, Dept Med Oncol, Boston, MA 02118 USA. RP Okam, MM (reprint author), Harvard Univ, Div Hematol, Brigham & Womens Hosp, Sch Med, 75 Francis St,Midcampus 3, Boston, MA 02115 USA. EM mokam@partners.org NR 101 TC 22 Z9 23 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD APR PY 2011 VL 25 IS 2 BP 241 EP + DI 10.1016/j.hoc.2011.02.001 PG 20 WC Oncology; Hematology SC Oncology; Hematology GA 754OQ UT WOS:000289865400002 PM 21444028 ER PT J AU Battinelli, EM Bauer, KA AF Battinelli, E. M. Bauer, K. A. TI Thrombophilias in Pregnancy SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Thrombophilias; Venous thromboembolic events; Pregnancy; Hypercoagulable; Anticoagulation ID FACTOR-V-LEIDEN; MOLECULAR-WEIGHT HEPARIN; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; UNITED-STATES POPULATION; DEEP-VEIN THROMBOSIS; LOW-DOSE ASPIRIN; VENOUS THROMBOEMBOLISM; FETAL LOSS; RISK-FACTORS; ANTIPHOSPHOLIPID ANTIBODIES AB Thrombophilic conditions are associated with an increased risk of venous thromboembolic events (VTE) during pregnancy. Thrombophilic disorders are either acquired, as in antiphospholipid syndrome, or inherited, as in factor V Leiden. Both are associated with VTE but acquired disorders can also increase the risk of arterial events. However, there is controversy as to whether they may adversely affect other pregnancy outcomes including pregnancy loss, placental abruption, severe preeclampsia, and stillbirth. This article discusses the effect of thrombophilias on pregnancy. C1 [Battinelli, E. M.] Harvard Univ, Brigham & Womens Hosp, Div Hematol, Sch Med, Boston, MA 02115 USA. [Bauer, K. A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Sch Med, Boston, MA 02215 USA. [Bauer, K. A.] Harvard Univ, Dept Hematol Oncol, VA Boston Healthcare Syst, Sch Med, Boston, MA 02215 USA. RP Battinelli, EM (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Hematol, Sch Med, 1 Blackfan Circle,Karp 5, Boston, MA 02115 USA. EM ebattinelli@partners.org NR 62 TC 7 Z9 8 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD APR PY 2011 VL 25 IS 2 BP 323 EP + DI 10.1016/j.hoc.2011.02.003 PG 12 WC Oncology; Hematology SC Oncology; Hematology GA 754OQ UT WOS:000289865400007 PM 21444033 ER PT J AU Fogerty, AE Connors, JM AF Fogerty, Annemarie E. Connors, Jean M. TI Treating Venous Thromboembolism in Pregnancy SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Venous thromboembolism; Pregnancy; Diagnostic testing; Heparin ID MOLECULAR-WEIGHT HEPARIN; SUSPECTED PULMONARY-EMBOLISM; FETAL RADIATION-EXPOSURE; BONE-MINERAL DENSITY; RADIOLOGICAL PROCEDURES; UNFRACTIONATED HEPARIN; THROMBOLYTIC THERAPY; POSTPARTUM PERIOD; CONTROLLED-TRIAL; RISK-FACTORS AB This review summarizes the currently available data concerning risk, diagnosis, and management of venous thromboembolism (VTE) in pregnant women. While the actual incidence of VTE in pregnancy remains low, the hypercoagulable state and increased risk requires clinicians to be aware of the specific aspects of presentation, diagnosis, and treatment in this population. The authors outline the strategies, efficacy, and safety of the diagnostic approach, as well as the available data concerning treatment. Considerations in treatment include maternal and fetal bleeding risk, as well as management of labor and delivery. The optimal approach to treatment requires collaboration between obstetrics, hematology, and anesthesia. C1 [Connors, Jean M.] Brigham & Womens Hosp, Div Hematol, Dept Med, Boston, MA 02115 USA. [Connors, Jean M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Fogerty, Annemarie E.] Massachusetts Gen Hosp, Dept Hematol Oncol, Ctr Canc, Boston, MA 02114 USA. [Fogerty, Annemarie E.; Connors, Jean M.] Harvard Univ, Sch Med, Boston, MA USA. RP Connors, JM (reprint author), Brigham & Womens Hosp, Div Hematol, Dept Med, 75 Francis St, Boston, MA 02115 USA. EM jconnors@partners.org NR 50 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD APR PY 2011 VL 25 IS 2 BP 379 EP + DI 10.1016/j.hoc.2011.02.004 PG 14 WC Oncology; Hematology SC Oncology; Hematology GA 754OQ UT WOS:000289865400010 PM 21444036 ER PT J AU Lee, AI Kaufman, RM AF Lee, Alfred Ian Kaufman, Richard M. TI Transfusion Medicine and the Pregnant Patient SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article DE Hemolytic disease of the fetus and newborn; Fetomaternal hemorrhage; Fetal and neonatal alloimmune thrombocytopenia; Postpartum hemorrhage; Obstetric hemorrhage; Disseminated intravascular coagulation; Recombinant factor VIIa; Parvovirus B19 ID NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; ACTIVATED FACTOR-VII; RECOMBINANT-FACTOR-VIIA; DISSEMINATED INTRAVASCULAR COAGULATION; THREATENING POSTPARTUM HEMORRHAGE; BLOOD-CELL ALLOIMMUNIZATION; INJURED TRAUMA PATIENTS; ANTI-D IMMUNOGLOBULIN; RH HEMOLYTIC-DISEASE; PLATELET ANTIGENS AB Alloimmunity in pregnancy is the basis for two of the major complications of pregnancy in transfusion medicine: hemolytic disease of the fetus and newborn (HDFN), and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Use of Rh(D) immune globulin has dramatically reduced the incidence of HDFN in Rh(D)-mismatched pregnancies. Treatment of HDFN may involve intrauterine transfusion, with fetal and neonatal survival rates of 70% to 90%. Treatments for FNAIT include immune globulin, steroids, or in severe cases, intrauterine platelet transfusions. Transfusion medicine is central to the management of pregnancy-associated complications such as postpartum hemorrhage, parvovirus B19 infection, hemoglobinopathies, and aplastic anemia. C1 [Kaufman, Richard M.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Lee, Alfred Ian] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02118 USA. RP Kaufman, RM (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM rmkaufman@partners.org NR 146 TC 2 Z9 2 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD APR PY 2011 VL 25 IS 2 BP 393 EP + DI 10.1016/j.hoc.2011.02.002 PG 22 WC Oncology; Hematology SC Oncology; Hematology GA 754OQ UT WOS:000289865400011 PM 21444037 ER PT J AU Meslin, F Hamai, A Mlecnik, B Rosselli, F Richon, C Jalil, A Wemhoff, G Thiery, J Galon, J Chouaib, S AF Meslin, Franck Hamai, Ahmed Mlecnik, Bernhard Rosselli, Filippo Richon, Catherine Jalil, Abdelali Wemhoff, Gregory Thiery, Jerome Galon, Jerome Chouaib, Salem TI hSMG-1 is a granzyme B-associated stress-responsive protein kinase SO JOURNAL OF MOLECULAR MEDICINE-JMM LA English DT Article DE Granzyme B; p53; Tumor cell; DNA damage; hSMG-1 ID TUMOR-CELL SUSCEPTIBILITY; DNA-DAMAGE; INDUCED APOPTOSIS; IN-VIVO; P53; DEATH; PATHWAYS; ATM; CTL; PHOSPHORYLATION AB Granzyme B plays a key role in cell-mediated programmed cell death. We previously demonstrated that p53 is a functional determinant in the granzyme B-induced cytotoxic T-lymphocyte response. However, the pathways leading to activation of p53 by granzyme B remain incompletely understood. We now demonstrate that granzyme B-induced DNA damage signaling as revealed by histone H2AX phosphorylation and subsequent activation of the stress kinase CHK2. Confocal microscopy analysis indicates that granzyme B treatment of tumor cells induced an early translocation of endonuclease caspase-activated DNase. DNA microarray-based global transcriptional profiling and RT-PCR indeed revealed genes related to DNA damage. Among these genes, hSMG-1, a genotoxic stress-activated protein, was constantly upregulated in tumor cells following granzyme B treatment. Knockdown of the hSMG-1 gene in T1 tumor target cell line resulted in a significant inhibition of granzyme B-and CTL-induced killing. Our data suggest that granzyme B may exert cell death through DNA damage signaling and uncover a novel molecular link between the DNA damage pathway and granzyme B-induced cell death. C1 [Meslin, Franck; Hamai, Ahmed; Jalil, Abdelali; Thiery, Jerome; Chouaib, Salem] Inst Gustave Roussy PR1 & IFR 54, INSERM, Lab Immunol Tumeurs Humaines Interact Effecteurs, U753, F-94805 Villejuif, France. [Mlecnik, Bernhard; Galon, Jerome] Ctr Rech Cordeliers, INSERM, U872, F-75006 Paris, France. [Rosselli, Filippo] Inst Gustave Roussy PR2 & IFR 54, CNRS, Lab Stabilite Genet & Oncogenese, FRE2939, F-94805 Villejuif, France. [Richon, Catherine] Inst Gustave Roussy PR2 & IFR 54, Funct Genom Unit, F-94805 Villejuif, France. [Wemhoff, Gregory] Sigma Aldrich, Funct Genom, St Louis, MO 63103 USA. [Thiery, Jerome] Harvard Univ, Immune Dis Inst, Sch Med, Boston, MA 02115 USA. RP Chouaib, S (reprint author), Inst Gustave Roussy PR1 & IFR 54, INSERM, Lab Immunol Tumeurs Humaines Interact Effecteurs, U753, F-94805 Villejuif, France. EM chouaib@igr.fr RI Chouaib, Salem/F-7939-2016 FU INSERM; "Association pour la Recherche contre le Cancer" (ARC) [3922]; Ligue contre le Cancer [SR2005-430]; Agence Nationale de la Recherche FX We thank Florence Faure for T1 cells and Lisa Bain for editing the manuscript. This work was supported by grants from the INSERM, the "Association pour la Recherche contre le Cancer" (ARC, grant 3922) and the "Ligue contre le Cancer" (SR2005-430, comite des Hauts de Seine), and the "Agence Nationale de la Recherche". NR 38 TC 6 Z9 6 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0946-2716 J9 J MOL MED JI J. Mol. Med. PD APR PY 2011 VL 89 IS 4 BP 411 EP 421 DI 10.1007/s00109-010-0708-0 PG 11 WC Genetics & Heredity; Medicine, Research & Experimental SC Genetics & Heredity; Research & Experimental Medicine GA 752KD UT WOS:000289689200009 PM 21301799 ER PT J AU Steinman, MA Lund, BC Miao, YH Boscardin, WJ Kaboli, PJ AF Steinman, Michael A. Lund, Brian C. Miao, Yinghui Boscardin, W. John Kaboli, Peter J. TI Geriatric Conditions, Medication Use, and Risk of Adverse Drug Events in a Predominantly Male, Older Veteran Population SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE drug therapy; adverse effects; frail elderly; polypharmacy ID HOSPITALIZED-PATIENTS; EMERGENCY-DEPARTMENT; DEPRESSIVE SYMPTOMS; COGNITIVE FUNCTION; ELDERLY-PATIENTS; ADULTS; COMMUNITY; MORTALITY; FRAILTY; DISCHARGE AB OBJECTIVES To determine whether geriatric conditions and functional impairment are independent risk factors for adverse drug events (ADEs). DESIGN Prospective cohort study. SETTING Veterans Affairs Medical Center. PARTICIPANTS Three hundred seventy-seven veterans aged 65 and older and taking five or more medications. MEASUREMENTS Geriatric conditions and functional status were assessed using participant interviews and structured assessments at study baseline. ADEs were elicited during participant interviews 3 and 12 months after study enrollment using validated methods. RESULTS The strong majority (97%) of participants were male, with a mean age of 74 +/- 5; 123 (33%) had one or more dependencies in instrumental activities of daily living (IADLs). Over the 1-year study period, 126 participants (33%) developed 167 ADEs. Upon multivariable analysis, risk of ADEs was not associated with any of the geriatric conditions that there was sufficient power to evaluate, including IADL function, cognitive impairment, depression, visual impairment, incontinence, constipation, and a summative measure of geriatric burden comprising the above and history of falls or gait instability. In exploratory analyses, the strongest factor associated with ADEs was the number of drugs added to a participant's medication regimen during the 1-year study period (incidence rate ratio 1.11 per each added drug, 95% confidence interval=1.03-1.19). CONCLUSION Common geriatric conditions and IADL function were not associated with ADEs in a predominantly male, older veteran population. Although it is important to consider the unique circumstances of each participant, excessive caution in prescribing to older adults with these geriatric conditions may not be warranted. C1 [Steinman, Michael A.; Miao, Yinghui; Boscardin, W. John] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Steinman, Michael A.; Miao, Yinghui] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Lund, Brian C.; Kaboli, Peter J.] Iowa City Vet Affairs Med Ctr, Ctr Res Implementat Innovat Strategies Practice, Iowa City, IA USA. [Lund, Brian C.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Kaboli, Peter J.] Univ Iowa, Dept Internal Med, Div Gen Internal Med, Iowa City, IA 52242 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU National Institute on Aging; American Federation for Aging Research [1K23-AG030999]; Health Services Research and Development Service, Department of Veterans Affairs [SAF98-152]; Research Career Development award [RCD 03-033-1]; Center for Research in the Implementation of Innovative Strategies in Practice at the Iowa City Veterans Affairs Medical Center [HFP 04-149] FX Supported by the National Institute on Aging and the American Federation for Aging Research (1K23-AG030999), by the Health Services Research and Development Service, Department of Veterans Affairs, through an investigator-initiated research award (SAF98-152); by a Research Career Development award (RCD 03-033-1); and by the Center for Research in the Implementation of Innovative Strategies in Practice (HFP 04-149) at the Iowa City Veterans Affairs Medical Center (Kaboli and Lund). NR 39 TC 11 Z9 12 U1 4 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 IS 4 BP 615 EP 621 DI 10.1111/j.1532-5415.2011.03331.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DS UT WOS:000289525500006 PM 21410446 ER PT J AU Lee, SJ Boscardin, WJ Cenzer, IS Huang, ES Rice-Trumble, K Eng, C AF Lee, Sei J. Boscardin, W. John Cenzer, Irena Stijacic Huang, Elbert S. Rice-Trumble, Kathy Eng, Catherine TI The Risks and Benefits of Implementing Glycemic Control Guidelines in Frail Older Adults with Diabetes Mellitus SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE glycemic control; guideline; hypoglycemia; PACE; diabetes mellitus ID LONG-TERM-CARE; BLOOD-GLUCOSE CONTROL; ELDERLY-PEOPLE; FOLLOW-UP; TYPE-2; INSULIN; QUALITY; COMPLICATIONS; HYPOGLYCEMIA; INTERVENTIONS AB OBJECTIVES To determine the hypo- and hyperglycemic outcomes associated with implementing the American Geriatrics Society (AGS) guideline for a glycosylated hemoglobin (HbA1c) level of less than 8% in frail older adults with diabetes mellitus (DM). DESIGN Guideline implementation. SETTING Program of All-Inclusive Care for the Elderly. PARTICIPANTS All participants in the before (October 2002-December 2004, n=338), early (January 2005-June 2006, n=289) and late (July 2006-December 2008, n=385) periods of guideline implementation with a diagnosis of DM and at least one HbA1c measurement. INTERVENTION Clinician education in 2005 with annual monitoring of the proportion of each clinician's patients with DM with HbA1c less than 8%. MEASUREMENTS Hypoglycemia (blood glucose < 50 mg/dL), hyperglycemia (blood glucose > 400 mg/dL), and severe hypoglycemia (emergency department (ED) visit for hypoglycemia). RESULTS Participants in the before, early, and late periods were similar in age, race and ethnicity, comorbidities, and functional dependence. Antihyperglycemic medication use was greater in the late period, with more participants using metformin (28% before, 42% late, P <.001) and insulin (23% before, 34% late, P <.001) and achieving the AGS glycemic target of HbA1c of less than 8% (74% before, 84% late, P <.001). Episodes of hyperglycemia (per 100 person-years) were dramatically lower in the late period (159 before, 46 late, P <.001), and episodes of hypoglycemia were similar (10.1 before, 9.3 late, P=.50). There were more episodes of severe hypoglycemia in the early period (1.1 before, 2.9 early, P=.03). CONCLUSION Implementing the AGS glycemic control guideline for frail older adults led to fewer hyperglycemic episodes but more severe hypoglycemic episodes requiring ED visits in the early implementation period. Future glycemic control guideline implementation efforts should be coupled with close monitoring for severe hypoglycemia in the early guideline implementation period. C1 [Lee, Sei J.; Boscardin, W. John; Cenzer, Irena Stijacic] San Francisco VA Med Ctr, Div Geriatr, San Francisco, CA USA. [Lee, Sei J.; Boscardin, W. John; Cenzer, Irena Stijacic] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Huang, Elbert S.] Univ Chicago, Med Ctr, Gen Internal Med Sect, Chicago, IL 60637 USA. [Rice-Trumble, Kathy; Eng, Catherine] On Lok Lifeways, San Francisco, CA USA. RP Lee, SJ (reprint author), SFVAMC UCSF Geriatr, 4150 Clement St,Bldg 1,Rm 211A, San Francisco, CA 94121 USA. EM sei.lee@ucsf.edu FU Hartford Geriatrics Health Outcomes Research Scholars Award; University of California at San Francisco; National Center for Research Resources, a component of the National Institutes of Health [KL2RR024130] FX Conflict of Interest: The editor in chief has reviewed the conflict of interest checklist provided by the authors and has determined that the authors have no financial or any other kind of personal conflicts with this paper.; Dr. Sei Lee was funded by a Hartford Geriatrics Health Outcomes Research Scholars Award, the Hellman Family Award for Early Career Faculty at the University of California at San Francisco and the KL2RR024130 from the National Center for Research Resources, a component of the National Institutes of Health. NR 44 TC 26 Z9 26 U1 1 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 IS 4 BP 666 EP 672 DI 10.1111/j.1532-5415.2011.03362.x PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DS UT WOS:000289525500012 PM 21480838 ER PT J AU Allman, RM Sawyer, P Bowling, CB Ritchie, CS Ahmed, A AF Allman, R. M. Sawyer, P. Bowling, C. B. Ritchie, C. S. Ahmed, A. TI Pulse Irregularity Predicts Functional Decline in Older Adults with Hypertension SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Allman, R. M.; Bowling, C. B.; Ritchie, C. S.; Ahmed, A.] Birmingham VA Med Ctr, Birmingham Atlanta GRECC, Birmingham, AL USA. [Allman, R. M.; Sawyer, P.; Bowling, C. B.; Ritchie, C. S.; Ahmed, A.] Univ Alabama, Ctr Aging, Birmingham, AL USA. [Allman, R. M.; Sawyer, P.; Bowling, C. B.; Ritchie, C. S.; Ahmed, A.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S72 EP S72 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600209 ER PT J AU Aye, L Chen, BH Hahn, TJ Seeman, T Lee, CC AF Aye, L. Chen, B. H. Hahn, T. J. Seeman, T. Lee, C. C. TI Gender Difference in Association of Testosterone Levels with the Metabolic Syndrome in Healthy Older Adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Hahn, T. J.; Seeman, T.; Lee, C. C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Aye, L.] Univ Med & Dent New Jersey, Stratford, NJ USA. [Chen, B. H.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Program Genom & Nutr, Los Angeles, CA 90024 USA. [Chen, B. H.] Univ Calif Los Angeles, Sch Publ Hlth, Ctr Metab Dis Prevent, Los Angeles, CA 90024 USA. [Hahn, T. J.; Lee, C. C.] VA Greater Angeles Healthcare Syst, GRECC, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S107 EP S108 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600310 ER PT J AU Berry, S Mittleman, M Zhang, Y Solomon, D Lipsitz, L Kiel, D AF Berry, S. Mittleman, M. Zhang, Y. Solomon, D. Lipsitz, L. Kiel, D. TI Diuretics and the Acute Risk of Falls in the Nursing Home SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Berry, S.; Lipsitz, L.; Kiel, D.] Heb SenLife, Boston, MA USA. [Berry, S.; Mittleman, M.; Lipsitz, L.; Kiel, D.] BIDMC, Boston, MA USA. [Zhang, Y.] BU SOM, Boston, MA USA. [Solomon, D.] Brig & Wom, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S13 EP S13 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600038 ER PT J AU Boockvar, KS Hung, W Liu, S Siegel, J Kwak, J Singleton, J Signor, D AF Boockvar, K. S. Hung, W. Liu, S. Siegel, J. Kwak, J. Singleton, J. Signor, D. TI Delirium during Acute Illness (AI) in Nursing Home Residents SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Boockvar, K. S.; Hung, W.; Kwak, J.; Signor, D.] James J Peters VA Med Ctr, Bronx, NY USA. [Boockvar, K. S.; Singleton, J.] Jewish Home Lifecare, New York, NY USA. [Hung, W.; Singleton, J.] Mt Sinai Sch Med, New York, NY USA. [Liu, S.] New York Presbyterian Hosp, New York, NY USA. [Siegel, J.] Virginia Commonwealth Univ, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S16 EP S16 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600045 ER PT J AU Bowling, C Feller, MA Mujib, M Zhang, Y Ekundayo, O Sanders, PW Fonarow, GC Allman, RM Ahmed, A AF Bowling, C. Feller, M. A. Mujib, M. Zhang, Y. Ekundayo, O. Sanders, P. W. Fonarow, G. C. Allman, R. M. Ahmed, A. TI Chronic Kidney Disease and Incident Heart Failure in Older Adults: Predictor but Not a Risk Factor? SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Bowling, C.] Birmingham VA Med Ctr, Birmingham Atlanta VA GRECC, Birmingham, AL USA. [Bowling, C.; Allman, R. M.; Ahmed, A.] Univ Alabama, Div Gerontol Geriatr & Palliat Care, Birmingham, AL USA. [Ekundayo, O.; Fonarow, G. C.] Univ Calif Los Angeles, Los Angeles, CA USA. RI Mujib, Marjan/J-2709-2013 OI Mujib, Marjan/0000-0002-3261-8599 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S107 EP S107 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600308 ER PT J AU Chongkrairatanakul, N Hesse, K AF Chongkrairatanakul, N. Hesse, K. TI "Painful Vulva Lesions in a Geriatric Bedridden Nursing Home Resident". SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Chongkrairatanakul, N.; Hesse, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S28 EP S28 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600080 ER PT J AU Chongkrairatanakul, N Bauman, J Hesse, K AF Chongkrairatanakul, N. Bauman, J. Hesse, K. TI "We Can Fix the Hip but Nothing Else." SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Chongkrairatanakul, N.; Bauman, J.; Hesse, K.] Massachusetts Gen Hosp, Dept Med, Geriatr Med Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S20 EP S20 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600055 ER PT J AU Edes, T Skupien, M Finke, B Greene, R AF Edes, T. Skupien, M. Finke, B. Greene, R. TI Expanding Comprehensive Home Care to Rural Indian Country. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Edes, T.; Skupien, M.; Greene, R.] US Dept Vet Affairs, Washington, DC USA. [Finke, B.] Indian Hlth Serv, Hlth & Human Serv, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S149 EP S149 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600432 ER PT J AU Espinoza, S Jung, I Hazuda, H AF Espinoza, S. Jung, I. Hazuda, H. TI Predictors of Dependence in Activities of Daily Living and Instrumental Activities of Daily Living in Mexican American and European American Older Adults SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Espinoza, S.; Hazuda, H.] S Texas Vet Healthcare Syst, San Antonio, TX USA. [Espinoza, S.; Hazuda, H.] UT Hlth Sci Ctr San Antonio, San Antonio, TX USA. [Jung, I.] Yonsei Univ, Coll Med, Seoul, South Korea. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S72 EP S72 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600210 ER PT J AU Fischer, BL Gleason, CE Gangnon, RE Mahoney, JE AF Fischer, B. L. Gleason, C. E. Gangnon, R. E. Mahoney, J. E. TI Cognitive Impairment Predisposes Older Adults to Risky Behaviors and Falls. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Fischer, B. L.] Wm S Middleton Mem Vet Hosp, Madison, WI USA. [Gleason, C. E.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Mahoney, J. E.] Univ Wisconsin, Dept Med, Sect Geriatr & Gerontol, Madison, WI USA. [Gleason, C. E.] Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Gangnon, R. E.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA. [Gangnon, R. E.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S90 EP S90 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600260 ER PT J AU Fong, TG Jones, RN Marcantonio, E Rudolph, JL Inouye, SK AF Fong, T. G. Jones, R. N. Marcantonio, E. Rudolph, J. L. Inouye, S. K. TI Negative Impact of Hospitalization and Delirium in Alzheimer's Disease SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Fong, T. G.; Jones, R. N.; Inouye, S. K.] Hebrew SeniorLife, Aging Brain Ctr, Boston, MA USA. [Fong, T. G.; Marcantonio, E.; Inouye, S. K.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Rudolph, J. L.] VA Boston Healthcare Syst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S11 EP S11 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600032 ER PT J AU France, A Andrews, C Garza, M Lee, S Ross, J Sanchez-Reilly, S AF France, A. Andrews, C. Garza, M. Lee, S. Ross, J. Sanchez-Reilly, S. TI Comparison of Advance Directive Completion Rates and Pain Assessment and Management between Geriatric Oncology and Non-Oncology Clinics. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [France, A.; Andrews, C.; Ross, J.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Garza, M.; Lee, S.; Ross, J.; Sanchez-Reilly, S.] S Texas Vet Hlth Care Syst, Geriatr, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S201 EP S202 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600588 ER PT J AU Gangavati, AS Lipsitz, L AF Gangavati, A. S. Lipsitz, L. TI Characteristics & challenges in management of elderly patients on warfarin in a Geriatric Outpatient Practice. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Gangavati, A. S.; Lipsitz, L.] BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S32 EP S32 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600091 ER PT J AU Garcia, CH Espinoza, SE Hazuda, HP AF Garcia, C. H. Espinoza, S. E. Hazuda, H. P. TI Ethnic Differences in Perceived Caregiver Burden between Mexican American and European Older Caregivers. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Garcia, C. H.; Espinoza, S. E.; Hazuda, H. P.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Espinoza, S. E.; Hazuda, H. P.] S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S92 EP S92 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600266 ER PT J AU Goldstein, MK Martins, SB Tu, SW Heidenreich, P Massie, B Furmaga, E AF Goldstein, M. K. Martins, S. B. Tu, S. W. Heidenreich, P. Massie, B. Furmaga, E. TI Developing Heart Failure (HF) Clinical Decision Support for Patients with Comorbidities. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Goldstein, M. K.; Martins, S. B.; Tu, S. W.; Heidenreich, P.] VA Palo Alto Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Palo Alto, CA USA. [Goldstein, M. K.; Tu, S. W.; Heidenreich, P.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Massie, B.] San Francisco VA Med Ctr, San Francisco, CA USA. [Massie, B.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Furmaga, E.] VA Cent Off, Pharm Benefits Management Serv, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S146 EP S146 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600424 ER PT J AU Greenberg, E Silver, S Shen, J Le, H Bradner, JE AF Greenberg, E. Silver, S. Shen, J. Le, H. Bradner, J. E. TI Autophagy and Aging: A Novel High-Content, Image-based RNAi screen SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Greenberg, E.] Univ Rochester, Sch Med & Dent, Rochester, NY USA. [Greenberg, E.; Silver, S.; Shen, J.; Le, H.; Bradner, J. E.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Bradner, J. E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Shen, J.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S77 EP S77 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600223 ER PT J AU Healy, JM Patel, T Lee, S Sanchez-Reilly, S AF Healy, J. M. Patel, T. Lee, S. Sanchez-Reilly, S. TI Do Symptoms Matter When Considering Patients For Phase I Clinical Trials? A Pilot Study Of Older Adults With Advanced Cancer SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Healy, J. M.; Sanchez-Reilly, S.] Univ Texas Hlth Sci Ctr San Antonio, Div Geriatr Gerontol & Palliat Med, Dept Med, San Antonio, TX USA. [Patel, T.; Lee, S.; Sanchez-Reilly, S.] S Texas Vet Healthcare Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S60 EP S61 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600176 ER PT J AU Hung, WW Ross, JS Siu, AL AF Hung, W. W. Ross, J. S. Siu, A. L. TI Evaluation of a Mobile Acute Care for the Elderly Team for hospitalized older adults: a prospective outcomes study. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Hung, W. W.; Siu, A. L.] Mt Sinai Sch Med, New York, NY USA. [Hung, W. W.; Siu, A. L.] James J Peters VA Med Ctr, Bronx, NY USA. [Ross, J. S.] Yale Univ, Sch Med, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S100 EP S101 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600290 ER PT J AU Kashif, F Tubbesing, S Bluen, H Schwartz, M Sohn, L AF Kashif, F. Tubbesing, S. Bluen, H. Schwartz, M. Sohn, L. TI Purple Urine Bag Syndrome in an Elderly Male Nursing Home Resident. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Kashif, F.] Univ Calif Los Angeles, Kern Med Ctr, Bakersfield, CA USA. [Tubbesing, S.; Bluen, H.; Schwartz, M.; Sohn, L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sohn, L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Geriatr, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S119 EP S119 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600345 ER PT J AU Kelley, AS Ettner, SL Morrison, R Du, Q Wenger, NS Sarkisian, CA AF Kelley, A. S. Ettner, S. L. Morrison, R. Du, Q. Wenger, N. S. Sarkisian, C. A. TI Determinants of Treatment Intensity in Last 6 Months of Life: The Importance of Patient Characteristics. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Kelley, A. S.; Morrison, R.; Du, Q.] Mt Sinai Sch Med, New York, NY USA. [Ettner, S. L.; Wenger, N. S.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Morrison, R.] James J Peters VA Med Ctr, Bronx, NY USA. [Sarkisian, C. A.] Univ Calif Los Angeles, Dept Med, Div Geriatr, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Sarkisian, C. A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S2 EP S3 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600008 ER PT J AU Kinosian, B Edes, T Becker, P Klepac, L AF Kinosian, B. Edes, T. Becker, P. Klepac, L. TI Reduction in 30-day Readmissions with VA's Home Based Primary Care. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Kinosian, B.] Univ Penn, Philadelphia, PA 19104 USA. [Edes, T.; Becker, P.; Klepac, L.] Dept Vet Affairs, Washington, DC USA. [Kinosian, B.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S98 EP S99 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600284 ER PT J AU Kinosian, B Edes, T Hossain, M Klepac, L AF Kinosian, B. Edes, T. Hossain, M. Klepac, L. TI Predicted and Observed Costs of Veterans receiving Home Based Primary Care Among 23 Veteran Integrated Service Networks (VISN). SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Kinosian, B.] Univ Penn, Philadelphia, PA 19104 USA. [Edes, T.; Hossain, M.; Klepac, L.] Dept Vet Affairs, Washington, DC USA. [Kinosian, B.] Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S6 EP S7 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600020 ER PT J AU Lo, S Hirano, L Matsumoto, AM AF Lo, S. Hirano, L. Matsumoto, A. M. TI Evaluation and treatment of low vitamin D levels in veterans over 70 years old. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Lo, S.; Hirano, L.; Matsumoto, A. M.] VA Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. [Lo, S.; Hirano, L.; Matsumoto, A. M.] Univ Washington, Dept Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S35 EP S35 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600100 ER PT J AU Marcum, ZA Amuan, ME Hanlon, JT Aspinall, SL Handler, SM Ruby, CM Pugh, MV AF Marcum, Z. A. Amuan, M. E. Hanlon, J. T. Aspinall, S. L. Handler, S. M. Ruby, C. M. Pugh, M. V. TI Adverse Drug Reactions Leading to Hospitalization among Older Outpatient Veterans. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Marcum, Z. A.; Hanlon, J. T.; Handler, S. M.; Ruby, C. M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Marcum, Z. A.; Hanlon, J. T.; Handler, S. M.] VAPHS, GRECC, Pittsburgh, PA USA. [Amuan, M. E.] Bedford VA Hosp, Bedford, MA USA. [Aspinall, S. L.] VA Ctr Medicat Safety, Hines, IL USA. [Aspinall, S. L.] VAPHS, CHERP, Pittsburgh, PA USA. [Ruby, C. M.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Pugh, M. V.] S Texas Vet Hlth Care Syst, Vet Evidence Based Res Disseminat & Implementat C, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S97 EP S97 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600279 ER PT J AU Paquin, AM Rudolph, JL AF Paquin, A. M. Rudolph, J. L. TI Delirium and Discharge Drugs. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Paquin, A. M.; Rudolph, J. L.] VA Boston Healthcare Syst, GRECC, Boston, MA USA. [Paquin, A. M.] VA Boston Healthcare Syst, Dept Pharm, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S92 EP S92 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600265 ER PT J AU Rahman, A Nakashima, B Mortensen, E AF Rahman, A. Nakashima, B. Mortensen, E. TI Impact of Prior Antibiotic Use on Outcomes for Patients Hospitalized with Pneumonia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Mortensen, E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Rahman, A.; Nakashima, B.; Mortensen, E.] S Texas Vet Healthcare Syst, VERDICT Res Program, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S73 EP S74 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600213 ER PT J AU Ramakrishna, Y Berger, DL Hamann, C AF Ramakrishna, Y. Berger, D. L. Hamann, C. TI Uncommon Etiology of Acute Abdomen in an Older Patient SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Ramakrishna, Y.; Berger, D. L.; Hamann, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S20 EP S21 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600057 ER PT J AU Ramaswamy, R Clark, EM AF Ramaswamy, R. Clark, E. M. TI Shooting in the Dark - Use of Donepezil in Non-Alzheimer's Dementia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Ramaswamy, R.; Clark, E. M.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Ramaswamy, R.; Clark, E. M.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S21 EP S21 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600059 ER PT J AU Simone, M Roberts, DH Irish, JT Neeman, N Schulze, JE Lipsitz, LA Schwartzstein, R Aronson, MD Tan, ZS AF Simone, M. Roberts, D. H. Irish, J. T. Neeman, N. Schulze, J. E. Lipsitz, L. A. Schwartzstein, R. Aronson, M. D. Tan, Z. S. TI An Educational Intervention for Providers to Promote Bone Health in High-Risk Older Patients. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Simone, M.; Roberts, D. H.; Irish, J. T.; Lipsitz, L. A.; Schwartzstein, R.; Aronson, M. D.; Tan, Z. S.] Harvard Univ, Sch Med, Boston, MA USA. [Simone, M.] Mt Auburn Hosp, Cambridge, MA USA. [Roberts, D. H.; Irish, J. T.; Neeman, N.; Schulze, J. E.; Lipsitz, L. A.; Schwartzstein, R.; Aronson, M. D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Tan, Z. S.] VA Boston Healthcare Syst, GRECC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S86 EP S86 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600249 ER PT J AU Stephens, LA Foley, KT Lowman, JD McGwin, G Jones, LS Brown, C AF Stephens, L. A. Foley, K. T. Lowman, J. D. McGwin, G. Jones, L. S. Brown, C. TI Frequency and Duration of Out of Bed Mobility Episodes During Hospitalization. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [McGwin, G.; Brown, C.] Birmighma Atlanta VA GRECC, Birmingham, AL USA. [Jones, L. S.] Birmingham VAMC, Birmingham, AL USA. [Stephens, L. A.; Foley, K. T.; Lowman, J. D.; McGwin, G.; Brown, C.] Univ Alabama, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S111 EP S111 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600320 ER PT J AU Wang, L Sarkisian, C Kelley, AS AF Wang, L. Sarkisian, C. Kelley, A. S. TI Religion, Spirituality, and Culture-Based Preferences in End-of-Life Medical Decision-Making SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Wang, L.; Kelley, A. S.] Mt Sinai Sch Med, New York, NY USA. [Sarkisian, C.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sarkisian, C.] GRECC, Los Angeles, CA USA. [Sarkisian, C.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S179 EP S179 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600521 ER PT J AU Wilson, BZ Nakashima, B Restrepo, MI Anzueto, A Mortensen, EM AF Wilson, B. Z. Nakashima, B. Restrepo, M. I. Anzueto, A. Mortensen, E. M. TI Comparative Efficacy of Two Antimicrobial Combinations in Elderly Patients Hospitalized with Severe Pneumonia SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Wilson, B. Z.; Restrepo, M. I.; Anzueto, A.; Mortensen, E. M.] UTHSCSA, San Antonio, TX USA. [Nakashima, B.; Restrepo, M. I.; Mortensen, E. M.] S Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S66 EP S66 PG 1 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600192 ER PT J AU Womack, JA Goulet, J Gibert, C Brandt, C Gulanski, B Rimland, D Rodriguez-Barradas, M Yin, M Justice, AC AF Womack, J. A. Goulet, J. Gibert, C. Brandt, C. Gulanski, B. Rimland, D. Rodriguez-Barradas, M. Yin, M. Justice, A. C. TI HIV Infection, Fragility Fractures and Age SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Womack, J. A.; Goulet, J.; Brandt, C.; Gulanski, B.; Justice, A. C.] VHA Connecticut, West Haven, CT USA. [Gibert, C.] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Gibert, C.] George Washington Univ, Washington, DC USA. [Brandt, C.] Yale Univ, Yale Ctr Med Informat, New Haven, CT USA. [Gulanski, B.; Justice, A. C.] Yale Univ, Sch Med, New Haven, CT USA. [Rimland, D.] Vet Affairs Med Ctr, Atlanta, GA 30033 USA. [Rimland, D.] Emory Univ, Sch Med, Atlanta, GA USA. [Rodriguez-Barradas, M.] Michael E De Bakey Vet Affairs Med Ctr, Houston, TX USA. [Rodriguez-Barradas, M.] Baylor Coll Med, Houston, TX 77030 USA. [Yin, M.] Columbia Univ, Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S70 EP S71 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600205 ER PT J AU Yourman, L Lee, S Schonberg, M Smith, AK AF Yourman, L. Lee, S. Schonberg, M. Smith, A. K. TI Systematic Review of Non-disease Specific Prognostic Indices for Older Adults. SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Meeting Abstract CT Annual Scientific Meeting on the American-Geriatrics-Society CY MAY 11-14, 2011 CL National Harbor, MD SP Amer Geriatr Soc C1 [Yourman, L.; Lee, S.; Smith, A. K.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Schonberg, M.] Beth Israel Deaconness Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2011 VL 59 SU 1 BP S97 EP S98 PG 2 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 750DJ UT WOS:000289524600281 ER PT J AU Wen, PY Schiff, D Cloughesy, TF Raizer, JJ Laterra, J Smitt, M Wolf, M Oliner, KS Anderson, A Zhu, M Loh, E Reardon, DA AF Wen, Patrick Y. Schiff, David Cloughesy, Timothy F. Raizer, Jeffrey J. Laterra, John Smitt, Melanie Wolf, Michael Oliner, Kelly S. Anderson, Abraham Zhu, Min Loh, Elwyn Reardon, David A. TI A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma SO NEURO-ONCOLOGY LA English DT Article DE Rilotumumab; AMG 102; hepatocyte growth factor; c-Met; glioblastoma; phase II clinical trial ID HEPATOCYTE GROWTH-FACTOR; ADVANCED SOLID TUMORS; C-MET; MALIGNANT GLIOMAS; MONOCLONAL-ANTIBODIES; FACTOR RECEPTOR; TEMOZOLOMIDE; BEVACIZUMAB; EGFRVIII; XENOGRAFTS AB This phase II study evaluated the efficacy and safety of AMG 102 (rilotumumab), a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in patients with recurrent glioblastoma (GBM). Patients with histologically confirmed, measurable recurrent GBM or gliosarcoma (World Health Organization grade 4) and <= 3 relapses or prior systemic therapies received AMG 102 (10 or 20 mg/kg) by infusion every 2 weeks. The primary endpoint was best confirmed objective response rate (central assessment) per Macdonald criteria. Of the 61 patients who enrolled, 60 received AMG 102. Twenty-nine patients (48%) had previously received bevacizumab. There were no objective responses per central assessment, but 1 patient had an objective response per investigator assessment. Median overall survival (95% CI) in the 10- and 20-mg/kg cohorts was 6.5 months (4.1-9.8) and 5.4 months (3.4-11.4), respectively, and progression-free survival (PFS) per central assessment was 4.1 weeks (4.0-4.1) and 4.3 weeks (4.1-8.1), respectively. PFS was similar among patients who had previously received bevacizumab compared with bevacizumab-naive patients. The most common adverse events were fatigue (38%), headache (33%), and peripheral edema (23%). AMG 102 serum concentrations increased approximately dose-proportionally with 2-fold accumulation at steady state. Plasma total HGF/SF and soluble c-Met concentrations increased 12.05- and 1.12-fold, respectively, from baseline during AMG 102 treatment. AMG 102 monotherapy at doses up to 20 mg/kg was not associated with significant antitumor activity in heavily pretreated patients with recurrent GBM. C1 [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02115 USA. [Schiff, David] Univ Virginia Hlth Syst, Div Neurooncol, Charlottesville, VA USA. [Cloughesy, Timothy F.] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Raizer, Jeffrey J.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. [Laterra, John] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA. [Smitt, Melanie; Loh, Elwyn] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA. [Wolf, Michael] Amgen Inc, Dept Global Biostat & Epidemiol, Thousand Oaks, CA 91320 USA. [Oliner, Kelly S.; Anderson, Abraham] Amgen Inc, Dept Mol Sci, Thousand Oaks, CA 91320 USA. [Zhu, Min] Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA. [Reardon, David A.] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC USA. RP Wen, PY (reprint author), Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, 44 Binney St,Shields Warren 430 D, Boston, MA 02115 USA. EM patrick_wen@dfci.harvard.edu FU Genentech/Roche; Excelixis; Genentech; Novartis; Amgen Inc. FX T.F.C. has served as a consultant/adviser for and has received research funding from Genentech/Roche and Excelixis and has provided expert testimony on behalf of Genentech/Roche. J.J.R. has received research funding from Genentech and Novartis and has served as a consultant/advisor/speaker for and received honoraria from Genentech and Merck. J.L. has served as a consultant for Amgen Inc. M.S., M.W., K.S.O., A.A., M.Z., and E.L. are employees of and shareholders in Amgen Inc. D.A.R. has served as a consultant/advisor for and has received honoraria from Schering-Plough/Merck, Genentech/Roche, and EMD Serono. P.Y.W. has received research support from Amgen Inc. D.S. declares no conflicts of interest. NR 40 TC 74 Z9 76 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD APR PY 2011 VL 13 IS 4 BP 437 EP 446 DI 10.1093/neuonc/noq198 PG 10 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 749TE UT WOS:000289492000010 PM 21297127 ER PT J AU Dickerson, BC Stoub, TR Shah, RC Sperling, RA Killiany, RJ Albert, MS Hyman, BT Blacker, D deToledo-Morrell, L AF Dickerson, B. C. Stoub, T. R. Shah, R. C. Sperling, R. A. Killiany, R. J. Albert, M. S. Hyman, B. T. Blacker, D. deToledo-Morrell, L. TI Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults SO NEUROLOGY LA English DT Article ID AMYLOID DEPOSITION; MEMORY COMPLAINTS; SENILE PLAQUES; AMNESTIC MCI; OLDER-ADULTS; DISEASE; DECLINE; BRAIN; ONSET; ATROPHY AB Objective: Since Alzheimer disease (AD) neuropathology is thought to develop years before dementia, it may be possible to detect subtle AD-related atrophy in preclinical AD. Here we hypothesized that the "disease signature" of AD-related cortical thinning, previously identified in patients with mild AD dementia, would be useful as a biomarker to detect anatomic abnormalities consistent with AD in cognitively normal (CN) adults who develop AD dementia after longitudinal follow-up. Methods: We studied 2 independent samples of adults who were CN when scanned. In sample 1, 8 individuals developing AD dementia (CN-AD converters) after an average of 11.1 years were compared to 25 individuals who remained CN (CN-stable). In sample 2, 7 CN-AD converters (average follow-up 7.1 years) were compared to 25 CN-stable individuals. Results: AD-signature cortical thinning in CN-AD converters in both samples was remarkably similar, about 0.2 mm (p < 0.05). Despite this small absolute difference, Cohen d effect sizes for these differences were very large (> 1). Of the 11 CN individuals with baseline low AD-signature thickness (>= 1 SD below cohort mean), 55% developed AD dementia over nearly the next decade, while none of the 9 high AD-signature thickness individuals (>= 1 SD above mean) developed dementia. This marker predicted time to diagnosis of dementia (hazard ratio = 3.4, p < 0.0005); 1 SD of thinning increased dementia risk by 3.4. Conclusions: By focusing on cortical regions known to be affected in AD dementia, subtle but reliable atrophy is identifiable in asymptomatic individuals nearly a decade before dementia, making this measure a potentially important imaging biomarker of early neurodegeneration. Neurology (R) 2011; 76: 1395-1402 C1 [Dickerson, B. C.; Sperling, R. A.; Hyman, B. T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Blacker, D.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Dickerson, B. C.; Sperling, R. A.; Hyman, B. T.; Blacker, D.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA. [Dickerson, B. C.; Sperling, R. A.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA. [Stoub, T. R.; deToledo-Morrell, L.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Shah, R. C.] Rush Univ, Med Ctr, Dept Family Med, Rush Alzheimers Dis Ctr, Chicago, IL 60612 USA. [Sperling, R. A.] Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA. [Killiany, R. J.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA. [Albert, M. S.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Dickerson, BC (reprint author), MGH, Frontotemporal Dementia Unit, 149 13th St,Suite 2691, Charlestown, MA 02129 USA. EM bradd@nmr.mgh.harvard.edu FU NIH [NIA R01-AG29411, R21-AG29840, P50-AG005134, P01-AG09466, P01-AG14449, P30-AG10161, R01-AG17917, R01-AG10688, NCRR P41-RR14075, U24-RR021382]; Alzheimer's Association; Mental Illness and Neuroscience Discovery (MIND) Institute; Illinois Department of Public Health; Ceregene; Danone Research B.V.; Eisai Inc.; Elan Corporation; Merck Serono; Pamlab, L.L.C.; Orasi, Inc.; Pfizer Inc; Illinois Department of Public Aid Alzheimer's Disease Assistance Center; Janssen; Bristol-Myers-Squibb; NIH/NIA; Anonymous Foundation; American Health Assistance Foundation; Fidelity Biosciences FX Supported by the NIH (NIA R01-AG29411, R21-AG29840, P50-AG005134, P01-AG09466, P01-AG14449, P30-AG10161, R01-AG17917, and R01-AG10688, and NCRR P41-RR14075 and U24-RR021382), the Alzheimer's Association, the Mental Illness and Neuroscience Discovery (MIND) Institute, and the Illinois Department of Public Health.; Dr. Dickerson serves on the editorial board of Hippocampus and receives research support from the NIH and the Alzheimer's Association. Dr. Stoub reports no disclosures. Dr. Shah receives research support from Ceregene, Danone Research B.V., Eisai Inc., Elan Corporation, Merck Serono, Pamlab, L.L.C., Orasi, Inc., Pfizer Inc, the NIH, and the Illinois Department of Public Aid Alzheimer's Disease Assistance Center. Dr. Sperling served on the editorial board of Alzheimer's Disease and Associated Disorders; has served as a consultant for Elan Corporation, Wyeth, Bristol-Myers Squibb, Pfizer Inc, and Bayer Schering Pharma; and receives research support from Elan Corporation, Janssen, Bristol-Myers-Squibb, NIH/NIA, the Alzheimer's Association, the Anonymous Foundation, and the American Health Assistance Foundation. Dr. Killiany receives research support from the NIH. Dr. Albert serves as a consultant for Genentech Inc. and Eli Lilly and Company and receives research support from the NIH/NIA. Dr. Hyman serves on a scientific advisory board for NeuroPhage; serves as a consultant for FoldRx Pharmaceuticals, Pfizer Inc, EMD Serono, Inc., Janssen, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, NeuroPhage, Campbell Alliance, Quanterix, VBI Belgium, and Schlesinger Associates & The Research House; receives research support from Fidelity Biosciences, the NIH and the Alzheimer's Association; and holds stock in Novartis. Dr. Blacker receives research support from the NIH and the Alzheimer's Association. Dr. de Toledo-Morrell serves on the editorial board of Neurobiology of Aging and receives research support from the NIH/NIA. NR 41 TC 100 Z9 102 U1 2 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD APR PY 2011 VL 76 IS 16 BP 1395 EP 1402 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA 752EF UT WOS:000289671400009 PM 21490323 ER PT J AU Suk, K Choi, J Suzuki, Y Ozturk, SB Mellor, JC Wong, KH MacKay, JL Gregory, RI Roth, FP AF Suk, Kyoungho Choi, Jihye Suzuki, Yo Ozturk, Sedide B. Mellor, Joseph C. Wong, Koon Ho MacKay, Joanna L. Gregory, Richard I. Roth, Frederick P. TI Reconstitution of human RNA interference in budding yeast SO NUCLEIC ACIDS RESEARCH LA English DT Article ID DOUBLE-STRANDED-RNA; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; HAIRPIN RNAS; DICER; BIOGENESIS; EXPRESSION; COMPLEX AB Although RNA-mediated interference (RNAi) is a widely conserved process among eukaryotes, including many fungi, it is absent from the budding yeast Saccharomyces cerevisiae. Three human proteins, Ago2, Dicer and TRBP, are sufficient for reconstituting the RISC complex in vitro. To examine whether the introduction of human RNAi genes can reconstitute RNAi in S. cerevisiae, genes encoding these three human proteins were introduced into S. cerevisiae. We observed both siRNA and siRNA- and RISC-dependent silencing of the target gene GFP. Thus, human Ago2, Dicer and TRBP can functionally reconstitute human RNAi in S. cerevisiae, in vivo, enabling the study and use of the human RNAi pathway in a facile genetic model organism. C1 [Suk, Kyoungho; Suzuki, Yo; Ozturk, Sedide B.; Mellor, Joseph C.; Wong, Koon Ho; MacKay, Joanna L.; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA USA. [Suk, Kyoungho; Choi, Jihye] Kyungpook Natl Univ, Sch Med, Cell Matrix Res Inst, Dept Pharmacol,Brain Sci & Engn Inst, Taegu 8230, South Korea. [Gregory, Richard I.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Harvard Stem Cell Inst,Childrens Hosp Boston, Boston, MA USA. [Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA. RP Roth, FP (reprint author), Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada. EM ksuk@knu.ac.kr; fritz.roth@utoronto.ca RI Roth, Frederick/H-6308-2011; OI Roth, Frederick/0000-0002-6628-649X FU National Institutes of Health (NIH) National Human Genome Research Institute (NHGRI) [HG003224]; Canadian Institute for Advanced Research; Canada Excellence Research Chair; NIH NHGRI National Research Service [HG004825]; Children's Hospital Boston; Croucher Foundation Limited, Hong Kong; NIH the National Institute of General Medical Sciences [GM086386]; Harvard Stem Cell Institute; March of Dimes; Emerald Foundation; Ministry of Education, Science and Technology (MEST) of the Korean government; National Research Foundation (NRF) of Korea [2010-0000337, 2010-0029460] FX National Institutes of Health (NIH) National Human Genome Research Institute (NHGRI) (HG003224 to F. P. R., partial); Canadian Institute for Advanced Research (to F. P. R., partial); Canada Excellence Research Chair (to F. P. R., partial); NIH NHGRI National Research Service Award Fellowship (HG004825 to J.C.M.); lab start-up funds from the Children's Hospital Boston; The Croucher Foundation Limited, Hong Kong (to K. H. W.) and by NIH the National Institute of General Medical Sciences (GM086386 to R. I. G.); the Harvard Stem Cell Institute (to R. I. G.); the March of Dimes Basil O'Connor award (to R. I. G.); Emerald Foundation (to R. I. G.). Ministry of Education, Science and Technology (MEST) of the Korean government, and the National Research Foundation (NRF) of Korea (2010-0000337 and 2010-0029460 to K. S.). Funding for open access charge: Canada Excellence Research Chairs Program. NR 22 TC 13 Z9 14 U1 0 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-1048 EI 1362-4962 J9 NUCLEIC ACIDS RES JI Nucleic Acids Res. PD APR PY 2011 VL 39 IS 7 BP E43 EP U59 DI 10.1093/nar/gkq1321 PG 5 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 751OW UT WOS:000289628400003 PM 21252293 ER PT J AU Kurtz, MP Svensson, E Heimann, TM AF Kurtz, Michael P. Svensson, Erik Heimann, Tomas M. TI Use of Platelet-Derived Growth Factor for Delayed Perineal Wound Healing in Patients with Inflammatory Bowel Disease: A Case Series SO OSTOMY WOUND MANAGEMENT LA English DT Article DE rhPDGF; abdominoperineal resection; perineum; wound closure; perineal wound healing ID ABDOMINOPERINEAL RESECTION; FACTOR-BB; ULCERATIVE COLITIS; PROCTECTOMY; COMPLICATIONS; BECAPLERMIN; SURGERY; ULCERS; ADENOCARCINOMA; RECTUM AB Abdominoperineal resection (APR) is the operative procedure of choice in patients with anorectal complications of inflammatory bowel disease (IBD) where a restorative proctocolectomy is either undesirable or impossible to perform. The challenge in these patients is poor perineal wound healing. A retrospective chart review was conducted of 118 patients (average age 44 years, range 28-73) with intractable IBD who underwent APR to evaluate perineal wound healing outcomes. Forty-four (44) had Crohn's disease (CD) and 74 had ulcerative colitis (UC). Three months after surgery, the wounds of 10 patients (six with CD and four with UC) remained unhealed with a standard protocol of sterile gauze dressings, sitz baths, and irrigation as needed. In these patients, daily topical application of a small amount of platelet-derived growth factor (rhPDGF) was added to the regimen of care. Six of the 10 unhealed wounds healed following rhPDGF application (average 80 days). The four patients whose wounds did not heal after 6 to 12 months had CD and underwent surgical revision followed by topical rhPDGF application. These wounds healed after an average of 107 days. The results of this case series confirm that delayed perineal wound healing is common following APR, especially in patients with CD, and may confirm previously reported observations that the effects of rhPDGF are most encouraging in small area defects that can be filled. Studies to evaluate the safety, efficacy, and effectiveness of this treatment modality are warranted. C1 [Heimann, Tomas M.] Mt Sinai Sch Med, Dept Surg, New York, NY 10029 USA. [Kurtz, Michael P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kurtz, Michael P.] Harvard Univ, Sch Med, Boston, MA USA. [Svensson, Erik] Allegheny Gen Hosp, Dept Gen Surg, Pittsburgh, PA 15212 USA. RP Heimann, TM (reprint author), Mt Sinai Sch Med, Dept Surg, 1 Gustave L Levy Pl,Box 1259, New York, NY 10029 USA. EM tomas.heimann@mssm.edu NR 56 TC 1 Z9 1 U1 0 U2 3 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 0889-5899 J9 OSTOMY WOUND MANAG JI Ostomy Wound Manag. PD APR PY 2011 VL 57 IS 4 BP 24 EP + PG 6 WC Surgery SC Surgery GA 752QO UT WOS:000289707700011 PM 21512190 ER PT J AU Gourcerol, G Adelson, DW Million, M Wang, LX Tache, Y AF Gourcerol, Guillaume Adelson, David W. Million, Mulugeta Wang, Lixin Tache, Yvette TI Modulation of gastric motility by brain-gut peptides using a novel non-invasive miniaturized pressure transducer method in anesthetized rodents SO PEPTIDES LA English DT Article DE Cold; CRF; Ghrelin; Intragastric pressure; Surgery; TRH agonist ID CORTICOTROPIN-RELEASING-FACTOR; DORSAL MOTOR NUCLEUS; CONSCIOUS RATS; TRANSGENIC MICE; ACID-SECRETION; GASTROINTESTINAL MOTILITY; GASTRODUODENAL MOTILITY; MYOELECTRIC ACTIVITY; ABDOMINAL-SURGERY; COLONIC TRANSIT AB Acute in vivo measurements are often the initial, most practicable approach used to investigate the effects of novel compounds or genetic manipulations on the regulation of gastric motility. Such acute methods typically involve either surgical implantation of devices or require intragastric perfusion of solutions, which can substantially alter gastric activity and may require extended periods of time to allow stabilization or recovery of the preparation. We validated a simple, non-invasive novel method to measure acutely gastric contractility, using a solid-state catheter pressure transducer inserted orally into the gastric corpus, in fasted, anesthetized rats or mice. The area under the curve of the phasic component (pAUC) of intragastric pressure (IGP) was obtained from continuous manometric recordings of basal activity and in responses to central or peripheral activation of cholinergic pathways, or to abdominal surgery. In rats, intravenous ghrelin or intracisternal injection of the thyrotropin-releasing hormone agonist, RX-77368, significantly increased pAUC while coeliotomy and cacal palpation induced a rapid onset inhibition of phasic activity lasting for the 1-h recording period. In mice, RX-77368 injected into the lateral brain ventricle induced high-amplitude contractions, and carbachol injected intraperitoneally increased pAUC significantly, while coeliotomy and cecal palpation inhibited baseline contractile activity. In wild-type mice, cold exposure (15 min) increased gastric phasic activity and tone, while there was no gastric response in corticotropin releasing factor (CRF)-overexpressing mice, a model of chronic stress. Thus the novel solid-state manometric approach provides a simple, reliable means for acute pharmacological studies of gastric motility effects in rodents. Using this method we established in mice that the gastric motility response to central vagal activation is impaired under chronic expression of CRF. Published by Elsevier Inc. C1 [Tache, Yvette] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Los Angeles, CA 90073 USA. Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress, Dept Med,Div Digest Dis, Los Angeles, CA 90073 USA. RP Tache, Y (reprint author), Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, CURE, Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu OI Adelson, David/0000-0002-4623-6030 FU NIH [R01 DK-33061]; Center grant [DK-41301]; VA; French Society of Gastroenterology; French Foreign Office FX This work was supported by NIH grants R01 DK-33061 (YT), Center grant DK-41301 (Animal Core; YT), VA Career Scientist and Merit Awards (YT), the French Society of Gastroenterology (S.N.F.G.E.; GG), and the French Foreign Office (EGIDE Program, GG). We thank Dr. Serge St Pierre (University of Quebec, Montreal, Canada) for the generous supply of ghrelin, Dr Michael Fanzelow (Department of Psychology, UCLA, Los Angeles) for the supply of CRF-OE and wild type mice and Ms. Honghui Liang for technical assistance and Eugenia Hu for helping in the preparation of the manuscript. NR 74 TC 3 Z9 3 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD APR PY 2011 VL 32 IS 4 BP 737 EP 746 DI 10.1016/j.peptides.2011.01.007 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 752QK UT WOS:000289707300016 PM 21262308 ER PT J AU Villar, J Perez-Mendez, L Basaldua, S Blanco, J Aguilar, G Toral, D Zavala, E Romera, MA Gonzalez-Diaz, G del Nogal, F Santos-Bouza, A Ramos, L Macias, S Kacmarek, RM AF Villar, Jesus Perez-Mendez, Lina Basaldua, Santiago Blanco, Jesus Aguilar, Gerardo Toral, Dario Zavala, Elizabeth Romera, Miguel A. Gonzalez-Diaz, Gumersindo del Nogal, Frutos Santos-Bouza, Antonio Ramos, Luis Macias, Santiago Kacmarek, Robert M. CA Hosp Espanoles Estudio Lesion Pulm TI A Risk Tertiles Model for Predicting Mortality in Patients With Acute Respiratory Distress Syndrome: Age, Plateau Pressure, and P-aO2/F-IO2 at ARDS Onset Can Predict Mortality SO RESPIRATORY CARE LA English DT Article DE acute respiratory distress syndrome; ARDS; age; mortality; P-ao2/F-IO2; plateau airway pressure; prediction; tertiles ID ACUTE LUNG INJURY; END-EXPIRATORY PRESSURE; POPULATION-BASED COHORT; INTENSIVE-CARE UNITS; MECHANICAL VENTILATION; CLINICAL-TRIAL; SEVERITY; ICU; METAANALYSIS; DEFINITIONS AB BACKGROUND: Predicting mortality has become a necessary step for selecting patients for clinical trials and defining outcomes. We examined whether stratification by tertiles of respiratory and ventilatory variables at the onset of acute respiratory distress syndrome (ARDS) identifies patients with different risks of death in the intensive care unit. METHODS: We performed a secondary analysis of data from 220 patients included in 2 multicenter prospective independent trials of ARDS patients mechanically ventilated with a lung-protective strategy. Using demographic, pulmonary, and ventilation data collected at ARDS onset, we derived and validated a simple prediction model based on a population-based stratification of variable values into low, middle, and high tertiles. The derivation cohort included 170 patients (all from one trial) and the validation cohort included 50 patients (all from a second trial). RESULTS: Tertile distribution for age, plateau airway pressure (p(plat)), and P-aO2/F-IO2, at ARDS onset identified subgroups with different mortalities, particularly for the highest-risk tertiles: age (> 62 years), P-plat (> 29 cm H2O), and P-aO2/F-IO2, (< 112 mm Hg). Risk was defined by the number of coexisting high-risk tertiles: patients with no high-risk tertiles had a mortality of 12%, whereas patients with 3 high-risk tertiles had 90% mortality (P < .001). CONCLUSIONS: A prediction model based on tertiles of patient age, P-plat, and P-aO2/F-IO2 at the time the patient meets ARDS criteria identifies patients with the lowest and highest risk of intensive care unit death. C1 [Villar, Jesus; Perez-Mendez, Lina; Blanco, Jesus; Zavala, Elizabeth] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER Enfermed Resp, Madrid, Spain. [Villar, Jesus] Hosp Univ Dr Negrin, Multidisciplinary Organ Dysfunct Evaluat Res Netw, Res Unit, Las Palmas Gran Canaria, Spain. [Blanco, Jesus] Hosp Univ Rio Hortega, Intens Care Unit, Valladolid, Spain. [Perez-Mendez, Lina; Basaldua, Santiago] Hosp Univ Nuestra Senora Candelaria, Res Unit, Tenerife, Spain. [Aguilar, Gerardo] Hosp Clin Valencia, Dept Anesthesiol, Valencia, Spain. [Toral, Dario] Hosp Univ 12 Octubre, Intens Care Unit, Madrid, Spain. [Zavala, Elizabeth] Hosp Clin Barcelona, Dept Anesthesia, Barcelona, Spain. [Romera, Miguel A.] Hosp Univ Puerta Hierro, Intens Care Unit, Madrid, Spain. [Gonzalez-Diaz, Gumersindo] Hosp Univ Morales Meseguer, Intens Care Unit, Murcia, Spain. [del Nogal, Frutos] Hosp Univ Severo Ochoa, Intens Care Unit, Madrid, Spain. [Santos-Bouza, Antonio] Hosp Univ Santiago, Intens Care Unit, Santiago De Compostela, Spain. [Ramos, Luis] Hosp Gen La Palma, Intens Care Unit, La Palma, Canary Islands, Spain. [Macias, Santiago] Hosp Gen Segovia, Intens Care Unit, Segovia, Spain. [Kacmarek, Robert M.] Massachusetts Gen Hosp, Resp Care Dept, Boston, MA 02114 USA. [Kacmarek, Robert M.] Harvard Univ, Dept Anesthesia, Boston, MA 02115 USA. RP Villar, J (reprint author), Hosp Univ Dr Negrin Barranco Ballena, Multidisciplinary Organ Dysfunct Evaluat Res Netw, S-N 4th Floor,South Wing, Las Palmas Gran Canaria 35010, Canary Islands, Spain. EM jesus.villar54@gmail.com FU Fondo de Investigacion Sanitaria, Madrid, Spain [07/0113]; Asociacion Cientifica Pulmon y Ventilacion Mecanica, Las Palmas, Spain FX This research was partly supported in part by grant 07/0113 from Fondo de Investigacion Sanitaria, Madrid, Spain, and by the Asociacion Cientifica Pulmon y Ventilacion Mecanica, Las Palmas, Spain. NR 37 TC 29 Z9 33 U1 0 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD APR PY 2011 VL 56 IS 4 BP 420 EP 428 DI 10.4187/respcare.00811 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 753XR UT WOS:000289814400003 PM 21255500 ER PT J AU Rubin, BK Dhand, R Ruppel, GL Branson, RD Hess, DR AF Rubin, Bruce K. Dhand, Rajiv Ruppel, Gregg L. Branson, Richard D. Hess, Dean R. TI Respiratory Care Year in Review 2010: Part 1. Asthma, COPD, Pulmonary Function Testing, Ventilator-Associated Pneumonia SO RESPIRATORY CARE LA English DT Article DE asthma; beta agonist; beta blocker; COPD; corticosteroids; exhaled nitric oxide; oxygen therapy; pulmonary function testing; spirometry; ventilator-associated pneumonia; vitamin D ID COATED ENDOTRACHEAL-TUBE; EXHALED NITRIC-OXIDE; VITAMIN-D DEFICIENCY; STEP-UP THERAPY; ACUTE EXACERBATIONS; CONTROLLED-TRIAL; LUNG-FUNCTION; INTRAVENOUS MONTELUKAST; UNCONTROLLED ASTHMA; INDUCED HYPERCAPNIA AB The purpose of this paper is to review the recent literature related to asthma, COPD, pulmonary function testing, and ventilator-associated pneumonia. Topics covered related to asthma include genetics and epigenetics; exposures; viruses; diet, obesity and exercise; exhaled nitric oxide; and drug therapy (beta agonists, macrolides, tiotropium and monteleukast). Topics covered related to COPD include childhood disadvantage factors and COPD; vitamin D deficiency and COPD; beta-blockers and COPD; corticosteroid therapy during COPD exacerbations; oxygen administration during pre-hospital transport of patients with COPD exacerbation; and prognosis of patients admitted to the hospital for COPD exacerbation. Topics related to pulmonary function testing include methods and techniques; predicted values; natural history, pulmonary function in health and disease; and the COPD controversy. Finally, the paper includes the following topics related to ventilator-associated pneumonia: the tube, the intubation route, and the cuff; mechanical ventilation; the bundle; and cost. These topics were chosen and reviewed in a manner that is most likely to have interest to the readers of RESPIRATORY CARE. C1 [Hess, Dean R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hess, Dean R.] Harvard Univ, Sch Med, Boston, MA USA. [Rubin, Bruce K.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA. [Dhand, Rajiv] Univ Missouri, Columbia, MO USA. [Ruppel, Gregg L.] St Louis Univ, St Louis, MO 63103 USA. [Branson, Richard D.] Univ Cincinnati, Cincinnati, OH USA. RP Hess, DR (reprint author), Massachusetts Gen Hosp, Ellison 401,55 Fruit St, Boston, MA 02114 USA. EM dhess@partners.org NR 104 TC 8 Z9 8 U1 1 U2 6 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 J9 RESP CARE JI Respir. Care PD APR PY 2011 VL 56 IS 4 BP 488 EP 502 DI 10.4187/respcare.01286 PG 15 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 753XR UT WOS:000289814400013 PM 21496376 ER PT J AU Hill, M Shannahan, K Jasinski, S Macklin, EA Raeke, L Roffman, JL Goff, DC AF Hill, Michele Shannahan, Kelsey Jasinski, Sarah Macklin, Eric A. Raeke, Lisa Roffman, Joshua L. Goff, Donald C. TI Folate supplementation in schizophrenia: A possible role for MTHFR genotype SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Folate; Schizophrenia; Negative symptoms; MTHFR ID METHYLENETETRAHYDROFOLATE REDUCTASE; NEGATIVE SYMPTOMS; PSYCHIATRIC-ILLNESS; COMMON MUTATION; HOMOCYSTEINE; SCALE; DEPRESSION; RISK AB Background: Folate deficiency and the methylenetetrahydrofolate reductase (MTHFR) 677C > T polymorphism have been linked to negative symptoms in schizophrenia both independently and synergistically. This study examined the effect of folate supplementation on negative symptoms overall and in relation to MTHFR 677C > T genotype. Method: Forty-six stable adult schizophrenia outpatients were enrolled and 32 were randomised, double-blind, in a parallel-group, twelve week add-on trial of folate 2 mg/d or matching placebo. The primary outcome measure was change from baseline to week 12 on the modified SANS total score using a mixed-model analysis. In addition, we measured the effect of MTHFR genotype on treatment effects and on changes in serum folate by grouping participants with T/T genotype together with C/T genotype and comparing their interactions to patients with C/C genotype. Results: Twenty-eight participants completed the trial. Folate supplementation did not significantly affect negative symptoms compared to placebo across the entire cohort. However, there was a significant genotype x treatment effect on negative symptoms (F=7.13, df=1,39, p = 0.01). In addition, MTHFR status significantly moderated the relationship between change in serum folate and change in negative symptoms: among participants with at least one copy of the T allele negative symptoms were more likely to improve with increased serum folate (p = 0.03). Conclusion: We did not detect a therapeutic benefit of folate supplementation in a sample of patients with residual negative symptoms. However, a possible association between genotypes associated with reduced MTHFR activity and benefit from folate supplementation should be investigated further. (C) 2010 Elsevier B.V. All rights reserved. C1 [Hill, Michele; Shannahan, Kelsey; Jasinski, Sarah; Raeke, Lisa; Roffman, Joshua L.; Goff, Donald C.] Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA. [Hill, Michele; Shannahan, Kelsey; Jasinski, Sarah; Macklin, Eric A.; Raeke, Lisa; Roffman, Joshua L.; Goff, Donald C.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Macklin, Eric A.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. RP Hill, M (reprint author), Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA. EM michelehill1@gmail.com RI Macklin, Eric/E-2955-2013 OI Macklin, Eric/0000-0003-1618-3502 FU NARSAD FX Funding for this study was provided by the NARSAD 2003 Investigator Award. NARSAD had no further role in study design; in the analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 25 TC 22 Z9 22 U1 1 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2011 VL 127 IS 1-3 BP 41 EP 45 DI 10.1016/j.schres.2010.12.006 PG 5 WC Psychiatry SC Psychiatry GA 748MQ UT WOS:000289395100010 PM 21334854 ER PT J AU Brent, BK Giuliano, AJ Zimmet, SV Keshavan, MS Seidman, LJ AF Brent, Benjamin K. Giuliano, Anthony J. Zimmet, Suzannah V. Keshavan, Matcheri S. Seidman, Larry J. TI Insight into illness in patients and caregivers during early psychosis: A pilot study SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Insight into illness; Early psychosis; Schizophrenia; Caregivers; Family psychoeducation ID 1ST-EPISODE PSYCHOSIS; EXPRESSED EMOTION; 1ST EPISODE; NEUROPSYCHOLOGICAL FUNCTION; SCHIZOPHRENIC-PATIENTS; MATCHING FALLACY; 3 RS; RELATIVES; FAMILY; NONADHERENCE AB Background: Impaired insight into illness is common during early psychosis and has been associated with treatment delays and poorer long-term outcomes. The relationship between patients' insight into illness and their caregivers' knowledge about psychosis is putatively associated with treatment outcome but there is limited research about this. This pilot study was designed to test the hypothesis that caregivers' levels of insight into illness is associated with patients' insight into illness in early psychosis and would be related to caregivers' levels of critical, rejecting attitudes toward patients. Methods: Patients with schizophrenia or schizoaffective disorder within 5 years of psychosis onset (n = 14) and caregivers (n = 14) of the patients' choosing were studied. Insight into illness was assessed in patients using the Scale to assess Unawareness of Mental Disorder (SUMD). Caregiver insight into illness was assessed with a modified version of the SUMD with questions rephrased to probe caregivers' understanding of the patients' illness. Caregivers' critical attitudes toward patients were assessed with the Patient Rejection Scale (PRS). Results: Significant correlations were found between patients' and caregivers' awareness of need for treatment (r = .55, p = .02), awareness of symptoms (r = .48, p = .04) and between caregivers' awareness of illness and critical attitudes toward patients (r = .65, p = .01). Conclusions: These findings suggest that caregivers' emotional characteristics and levels of insight into illness may be related to insight into illness in patients. Implications for family psychoeducational approaches to impairments of insight into illness during early psychosis are discussed. (C) 2011 Elsevier B.V. All rights reserved. C1 [Brent, Benjamin K.; Giuliano, Anthony J.; Zimmet, Suzannah V.; Keshavan, Matcheri S.; Seidman, Larry J.] Beth Israel Deaconess Med Ctr, Dept Psychiat, Massachusetts Mental Hlth Ctr, Boston, MA 02215 USA. [Brent, Benjamin K.; Giuliano, Anthony J.; Zimmet, Suzannah V.; Keshavan, Matcheri S.; Seidman, Larry J.] Harvard Univ, Sch Med, Boston, MA USA. [Seidman, Larry J.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Brent, BK (reprint author), Beth Israel Deaconess Med Ctr, Dept Psychiat, Massachusetts Mental Hlth Ctr, 401 Pk Dr,Landmark Ctr 2 E, Boston, MA 02215 USA. EM bbrent@bidmc.harvard.edu FU Harvard Medical School; Harvard Medical School DuPont-Warren Fellowship Committee FX This study was supported by the Harvard Medical School DuPont-Warren Fellowship (BKB).; We wish to thank the Harvard Medical School DuPont-Warren Fellowship Committee for its support of this research from 2008-2010. We also wish to thank the Yale Child Study Center's Psychoanalytic Research Training Program and its faculty (Peter Fonagy, PhD, Linda C. Mayes, MD, David Reiss, MD) for invaluable consultation during the planning stages of this study. NR 43 TC 9 Z9 9 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2011 VL 127 IS 1-3 BP 100 EP 106 DI 10.1016/j.schres.2010.12.024 PG 7 WC Psychiatry SC Psychiatry GA 748MQ UT WOS:000289395100017 PM 21315560 ER PT J AU Kent, BW Weinstein, ZA Passarelli, V Chen, Y Siever, LJ AF Kent, Brendon W. Weinstein, Zachary A. Passarelli, Vincent Chen, Yue Siever, Larry J. TI Deficient visual sensitivity in schizotypal personality disorder SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Vision; Perception; Contrast sensitivity; Schizophrenia; Schizotypal personality disorder; Dopamine ID WORKING-MEMORY; NEUROPSYCHOLOGICAL PERFORMANCE; SCHIZOPHRENIA SPECTRUM; DOPAMINE; CONTRAST; AMPHETAMINE; MOTION; SPECIFICITY; PERCEPTION; VISION AB Schizotypal personality disorder is a personality disorder in the schizophrenia spectrum, sharing genetic and neurobiologic characteristics with schizophrenia. Visual contrast detection, found to be abnormal in chronic schizophrenia, was investigated in schizotypal personality disorder (SPD). Since dopamine in the retina enhances visual contrast detection and SPD patients have relatively reduced dopaminergic activity in the brain compared to schizophrenia patients, it was hypothesized that SPD patients would have decreased to normal contrast sensitivity. Twenty-one subjects with DSM-IV diagnosed SPD, 18 healthy controls, and 12 subjects with a personality disorder unrelated to schizophrenia (OPD) were evaluated for contrast detection using a sinusoidal grating presented at varying temporal frequencies. Subjects also were evaluated neuropsychologically using several standardized neurocognitive tests. A significant effect of subject group was found on the contrast detection threshold (p < 0.01) with a significant difference between the SPD group and the healthy control group but not between the OPD group and the healthy control group. The SPD group had higher contrast detection thresholds at all temporal frequencies tested. Correlations were found between contrast detection and performance on the Trail-Making, N-Back, and CPT tasks in SPD patients. These results, based upon a paradigm reflecting dopamine activity in the early visual system, highlight the differences as well as similarities between SPD and schizophrenia with regard to the dopamine system in schizophrenia spectrum (Siever and Davis, 2004). Published by Elsevier B.V. C1 [Kent, Brendon W.; Weinstein, Zachary A.; Passarelli, Vincent; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Chen, Yue] Harvard Univ, Sch Med, McLean Hosp, Dept Psychiat, Belmont, MA 02178 USA. [Siever, Larry J.] VISN3 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Siever, Larry J.] James J Peters Vet Affairs Med Ctr, Psychiat Program, Bronx, NY USA. RP Siever, LJ (reprint author), James J Peters Vet Affairs Med Ctr OOMH, Mental Illness Res Educ & Clin Ctr MIRECC, 130 W Kingsbridge Rd,Room 6A-44, Bronx, NY 10468 USA. EM Larry.Siever@va.gov FU National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [MO1-RR-00071]; National Institute of Mental Health [MH56140]; Veterans Affairs Merit Review Grant [7609-028]; NCRR [MO1-RR-00071] FX This publication was made possible by grant # MO1-RR-00071 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH. This research was also supported in part by grant # MH56140 from the National Institute of Mental Health to Dr. Siever, and by a Veterans Affairs Merit Review Grant (7609-028).; Funding for this study was provided by NCRR grant MO1-RR-00071, by a Veterans Affairs Merit Review Grant (7609-028) and NIMH grant MH56140: Neither NCRR, NIMH, nor NIH had any further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 50 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2011 VL 127 IS 1-3 BP 144 EP 150 DI 10.1016/j.schres.2010.05.013 PG 7 WC Psychiatry SC Psychiatry GA 748MQ UT WOS:000289395100023 PM 20541911 ER PT J AU Harvey, PO Lee, J Horan, WP Ochsner, K Green, MF AF Harvey, Philippe-Olivier Lee, Junghee Horan, William P. Ochsner, Kevin Green, Michael F. TI Do patients with schizophrenia benefit from a self-referential memory bias? SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Self-referential processing; Recognition memory; Social cognition; Schizophrenia ID MEDIAL PREFRONTAL CORTEX; SOCIAL COGNITION; EPISODIC MEMORY; EMOTIONAL MEMORY; DEFAULT MODE; METAANALYSIS; BRAIN; FMRI; RECOGNITION; FEELINGS AB Background: Self-referential processing (i.e. linking internal and external stimuli to one's own self) has received scant attention thus far in schizophrenia. This type of processing is a key component of social cognition and thought to be important for adaptive social functioning. Memory studies in healthy subjects have shown that stimuli processed with reference to the self are better remembered than stimuli processed in other semantic forms. It is not known whether schizophrenia patients benefit from such a memory boost for self-referenced information. Methods: Twenty-five schizophrenia patients and 22 controls were assessed with a self-referential recognition memory paradigm. During an encoding phase, participants rated personality adjectives in each of three conditions: (1) structural features (uppercase or lowercase letters?); (2) social desirability (is adjective socially desirable or not?); or (3) self-referential (does adjective describe me or not?). Recognition memory for these personality adjectives was then tested during an unexpected yes-no recognition test. Results: Patients and controls were comparable in memory performance for the structural (p = 0.12) and social desirability (p = 0.30) conditions. In contrast, patients showed significantly reduced recognition sensitivity compared to controls for the self-referential condition (p = 0.03). Discussion: Compared to healthy controls, patients with schizophrenia did not benefit from a memory boost for self-referenced information. Such impaired self-referential memory may be associated with abnormal function of the medial prefrontal cortex. The inability to enhance memory for personally relevant information may partly explain poor social functioning in schizophrenia patients. (C) 2010 Elsevier By. All rights reserved. C1 [Harvey, Philippe-Olivier; Lee, Junghee; Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Harvey, Philippe-Olivier; Lee, Junghee; Horan, William P.; Green, Michael F.] Healthcare Ctr Syst, VA Greater Angeles, Los Angeles, CA USA. [Ochsner, Kevin] Columbia Univ, Dept Psychol, New York, NY 10027 USA. RP Harvey, PO (reprint author), UCLA Semel Inst, W VA Healthcare Ctr, 11301,Wilshire Blvd,210A,Room 131, Los Angeles, CA 90073 USA. EM poharvey@ucla.edu RI Lee, Junghee/C-5226-2014 OI Lee, Junghee/0000-0001-9567-8700 FU Canadian Institutes of Health Research; NIMH NIH HHS [MH043292, R01 MH043292, R01 MH043292-09, R01 MH065707, R29 MH043292] NR 56 TC 16 Z9 18 U1 2 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD APR PY 2011 VL 127 IS 1-3 BP 171 EP 177 DI 10.1016/j.schres.2010.11.011 PG 7 WC Psychiatry SC Psychiatry GA 748MQ UT WOS:000289395100027 PM 21147520 ER PT J AU Wiener-Kronish, JP Pittet, JF AF Wiener-Kronish, Jeanine P. Pittet, Jean-Francois TI Therapies against Virulence Products of Staphylococcus aureus and Pseudomonas aeruginosa SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE Methicillin-resistant S. aureus; Pseudomonas aeruginosa; virulence; antibiotic resistance; Panton-Valentine leukocidin (PVL) gene; toxins; exotoxins ID VENTILATOR-ASSOCIATED PNEUMONIA; PANTON-VALENTINE LEUKOCIDIN; COMMUNITY-ASSOCIATED MRSA; NNIS SYSTEM REPORT; ACUTE LUNG INJURY; METHICILLIN-RESISTANT; UNITED-STATES; III SECRETION; RISK-FACTORS; JANUARY 1992 AB Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are key pathogens in hospitals (particularly intensive care units), in long-term care facilities, and in outpatients with specific comorbidities and risk factors. Both MRSA and P. aeruginosa display resistance to a wide array of antibiotics. Further, both bacteria contain a variety of virulence products or systems that make it difficult to treat associated infections. Within the past several years, community-acquired MRSA containing virulence factors [particularly the Panton-Valentine leukocidin (PVL) gene] has emerged globally. Given the limited number of novel antibiotics to treat antibiotic-resistant organisms, there is growing interest in treating bacterial infections by targeting specific virulence products or systems. This article reviews potential therapeutic targets in the virulence systems of these two bacteria that are responsible for a large number of serious infections in critically ill patients. C1 [Wiener-Kronish, Jeanine P.] Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. [Pittet, Jean-Francois] Univ Alabama, Dept Anesthesiol, Crit Care Div, Birmingham, AL USA. [Pittet, Jean-Francois] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA. [Pittet, Jean-Francois] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA. RP Wiener-Kronish, JP (reprint author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, GRB 444, Boston, MA 02114 USA. EM jwiener-kronish@partners.org NR 62 TC 9 Z9 9 U1 0 U2 0 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD APR PY 2011 VL 32 IS 2 BP 228 EP 235 DI 10.1055/s-0031-1275535 PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 752SU UT WOS:000289715200012 PM 21506059 ER PT J AU Hariharan, P Takayesu, JK Kabrhel, C AF Hariharan, Praveen Takayesu, James Kimo Kabrhel, Christopher TI Association between the Pulmonary Embolism Severity Index (PESI) and short-term clinical deterioration SO THROMBOSIS AND HAEMOSTASIS LA English DT Article DE Composite outcomes; pulmonary embolism; PESI; sensitivity ID INITIAL OUTPATIENT THERAPY; RISK STRATIFICATION; SELECTING PATIENTS; PROGNOSTIC MODELS; VALIDATION; MANAGEMENT; REGISTRY; RULE AB The Pulmonary Embolism Severity Index (PESI) has been shown to predict 30 and 90 day mortality after PE. However, whether the PESI predicts patients who will be free of clinically adverse outcomes during a typical hospitalisation is not known. Retrospective analysis of Emergency Department patients with PE from May 2006 to April 2008. We compiled demographics, data to calculate the PESI and a composite outcome. Patients were considered to have a negative PESI if they were in category I or II (<= 85 points). Patients were considered to have the composite outcome if, within five days of diagnosis, they: A) had recurrent PE; B) developed a new cardiac dysrhythmia; C) required advanced cardiac life support; D) required respiratory support; E) required vasopressors; F) received thrombolysis; G) had major bleeding; H) returned to the ED; I) died. We enrolled 245 patients with PE. Of these, 115 (47%) were male, 204 (83%) were white. The mean age was 57 17 years. The PESI identified 109 (44%) as low risk and 136 (56%) as high risk. Sixty-one (26%) patients had the outcome, of whom nine (14%) were characterised as low risk by the PESI. Test characteristics were: sensitivity 86% (95% confidence interval [CI]: 75%-93%), specificity 55% (95% CI: 47%-62%), NPV 63% (95% CI: 55%-70%), PPV 40% (95% CI: 31%-49%), LR(+) 1.9 (95% CI: 1.57-2.30) and LR(-) 0.26 (95% CI: 0.14-0.48). Of the patients categorised by the PESI as safe for discharge, 14% had an adverse clinical event or required a hospital-based intervention within the first five days after PE diagnosis. Improvements in the risk stratification of patients with PE are still needed. C1 [Takayesu, James Kimo; Kabrhel, Christopher] Harvard Univ, Dept Emergency Med, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hariharan, Praveen] Boston Univ, Med Ctr, Dept Med, Internal Med Residency Program, Boston, MA USA. RP Kabrhel, C (reprint author), Harvard Univ, Dept Emergency Med, Sch Med, Massachusetts Gen Hosp, Zero Emerson Pl,Suite 3B, Boston, MA 02114 USA. EM ckabrhel@partners.org OI Kabrhel, Christopher/0000-0002-8699-7176 NR 26 TC 10 Z9 10 U1 0 U2 4 PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN PI STUTTGART PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY SN 0340-6245 J9 THROMB HAEMOSTASIS JI Thromb. Haemost. PD APR PY 2011 VL 105 IS 4 BP 706 EP 711 DI 10.1160/TH10-09-0577 PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 753FB UT WOS:000289751000018 PM 21225095 ER PT J AU Dzik, WH AF Dzik, Walter H. TI The air we breathe: three vital respiratory gases and the red blood cell: oxygen, nitric oxide, and carbon dioxide SO TRANSFUSION LA English DT Article ID HEMOGLOBIN; TRANSPORT; STORAGE; BIOAVAILABILITY; ERYTHROCYTES; SUBSTITUTES; MEMBRANE; DISEASE; STATE AB NO is a key mediator of hypoxic vasodilation, but the precise role of RBC Hb remains controversial. In addition to established theories that depend on RBC uptake, delivery, and discharge of NO or its metabolites, an alternative hypothesis based on RBC permeability is suggested. NO depletion by free Hb may account for several clinical features seen during intravascular hemolysis or during deliberate infusion of Hb solutions used as RBC substitutes. CO(2) released by tissues triggers oxygen release through a series of well-coordinated reactions centered on the Band 3 metabolon. While RBC carbonic anhydrase and the Band 3 anion exchanger are central to this process, there is surprisingly little research on the kinetics of CO(2) clearance by transfusion. The three RBC gases are directly related to the three principal gases of Earth's atmosphere. Human fossil fuel consumption dumps 90 million metric tons of carbon into the atmosphere annually. Increasing CO(2) levels are linked to global warming, melting Arctic ice, rising sea levels, and climate instability. Just as individual cells depend on balance of the three vital gases, so too will their balance determine survival of life on Earth. C1 Massachusetts Gen Hosp, Blood Transfus Serv, Boston, MA 02114 USA. RP Dzik, WH (reprint author), Massachusetts Gen Hosp, Blood Transfus Serv, 55 Fruit St, Boston, MA 02114 USA. EM sdzik@partners.org NR 31 TC 8 Z9 10 U1 2 U2 8 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0041-1132 J9 TRANSFUSION JI Transfusion PD APR PY 2011 VL 51 IS 4 BP 676 EP 685 DI 10.1111/j.1537-2995.2011.03114.x PG 10 WC Hematology SC Hematology GA 751PH UT WOS:000289629500005 PM 21496039 ER PT J AU Nappi, JJ Nagata, K AF Naeppi, Janne J. Nagata, Koichi TI Sources of false positives in computer-assisted CT colonography SO ABDOMINAL IMAGING LA English DT Article DE Computed tomographic colonography; Computer-aided detection; False-positives; Image interpretation; Colorectal neoplasms ID AIDED DETECTION; TOMOGRAPHIC COLONOGRAPHY; VIRTUAL COLONOSCOPY; COLORECTAL-CANCER; 2ND READER; POLYPS; PERFORMANCE; NEOPLASIA; DIAGNOSIS; ACCURACY AB The application of computer-aided detection (CAD) is expected to improve reader sensitivity and to reduce inter-observer variance in computed tomographic (CT) colonography. However, current CAD systems display a large number of false-positive (FP) detections. The reviewing of a large number of FP CAD detections increases interpretation time, and it may also reduce the specificity and/or sensitivity of a computer-assisted reader. Therefore, it is important to be aware of the patterns and pitfalls of FP CAD detections. This pictorial essay reviews common sources of FP CAD detections that have been observed in the literature and in our experiments in computer-assisted CT colonography. Also the recommended computer-assisted reading technique is described. C1 [Naeppi, Janne J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Nappi, JJ (reprint author), Massachusetts Gen Hosp, 25 New Chardon St,Suite 400 C, Boston, MA 02114 USA. EM jnappi@partners.org NR 44 TC 9 Z9 9 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0942-8925 EI 1432-0509 J9 ABDOM IMAGING JI Abdom. Imaging PD APR PY 2011 VL 36 IS 2 BP 153 EP 164 DI 10.1007/s00261-010-9625-5 PG 12 WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical Imaging GA 747CA UT WOS:000289296700007 PM 20473667 ER PT J AU Don, CW Roe, MT Li, SA Fraulo, E Pomerantsev, E Palacios, I Wiviott, SD AF Don, Creighton W. Roe, Matthew T. Li, Shuang Fraulo, Elizabeth Pomerantsev, Eugene Palacios, Igor Wiviott, Stephen D. TI Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry SO AMERICAN HEART JOURNAL LA English DT Article ID ACUTE CORONARY SYNDROMES; ANTIPLATELET THERAPY; BLEEDING COMPLICATIONS; INTERVENTION; TRIAL; PRETREATMENT; PREDICTORS; RISK; VARIABILITY; REACTIVITY AB Background A higher loading dose of clopidogrel achieves a more rapid and consistent degree of platelet inhibition than standard dosing, although the clinical benefit of higher doses has not been clearly established. The use of the different doses in clinical practice is not known. We evaluated the patient, procedural, and hospital characteristics associated clopidogrel loading doses given to patients with non-ST-segment elevation myocardial infarction (NSTEMI). Methods The National Cardiovascular Data Registry ACTION Get With the Guidelines Registry was queried for patients with NSTEMI admitted from 2007 to 2008. Demographic, clinical, and procedural information were collected on standardized data forms. Patients were categorized according to the clopidogrel loading dose received. Temporal trends in the use of different doses were evaluated in quarterly time intervals. Results Between January 1, 2007, and December 31, 2008, the use of a 600-mg clopidogrel loading dose increased steadily from 36.4% to 45.5%, whereas the use of 300 mg decreased slightly from 40.1% to 37.1%. Patients loaded with clopidogrel before cardiac catheterization were more likely to receive 300 mg, whereas those receiving a loading dose at the time of catheterization more often received 600 mg. The temporal increase in the use of 600 mg clopidogrel loading doses was not explained by temporal changes in periprocedural loading, use of early invasive management of patients with NSTEMI, or use of antithrombotics or glycoprotein 2b/3a inhibitors. Conclusions Higher loading dose clopidogrel increased between 2007 and 2008. Higher-dose clopidogrel was more frequently used in lower-risk patients undergoing an early invasive strategy and receiving periprocedural loading. (Am Heart J 2011; 161: 689-97.) C1 [Don, Creighton W.] Univ Washington, Med Ctr, Div Cardiol, Seattle, WA 98195 USA. [Roe, Matthew T.; Li, Shuang; Fraulo, Elizabeth] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Don, Creighton W.; Pomerantsev, Eugene; Palacios, Igor] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Wiviott, Stephen D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Wiviott, Stephen D.] Brigham & Womens Hosp, Thrombolysis Myocardial Infarct Study Grp, Boston, MA 02115 USA. RP Don, CW (reprint author), Univ Washington, Med Ctr, Div Cardiol, 1959 NE Pacific St,Box 356422, Seattle, WA 98195 USA. EM cwdon@u.washington.edu FU American College of Cardiology Foundation'sNCDR; National Center for Research Resources, a component of the National Institutes of Health [KL2 RR025015] FX None of the authors have any financial, personal, or academic conflicts of interest in the preparation of this article. This research was supported by the American College of Cardiology Foundation'sNCDR. The views expressed in this article represent those of the authors and do not necessarily represent the official views of the NCDR or its associated professional societies identified at www.ncdr.com. This publication was made possible by Grant Number KL2 RR025015 from the National Center for Research Resources, a component of the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of National Center for Research Resources or National Institutes of Health. NR 23 TC 4 Z9 4 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD APR PY 2011 VL 161 IS 4 BP 689 EP 697 DI 10.1016/j.ahj.2010.12.025 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 745TW UT WOS:000289190500011 PM 21473967 ER PT J AU Merchant, RM Becker, LB Yang, FF Groeneveld, PW AF Merchant, Raina M. Becker, Lance B. Yang, Feifei Groeneveld, Peter W. TI Hospital racial composition: A neglected factor in cardiac arrest survival disparities SO AMERICAN HEART JOURNAL LA English DT Article ID BYSTANDER CARDIOPULMONARY-RESUSCITATION; ACUTE MYOCARDIAL-INFARCTION; ARTERY-BYPASS-GRAFT; RESIDENTIAL SEGREGATION; TRANSPORT INTERVAL; MORTALITY; RACE; CARE; OUTCOMES; ACCESS AB Background Racial disparities in survival after out-of-hospital cardiac arrest have been reported, but their causes remain uncertain. We sought to determine if hospital racial composition accounted for survival differences for patients hospitalized after cardiac arrest. Methods We evaluated hospitalizations of white and black Medicare beneficiaries (2000-2007) admitted from the emergency department to the intensive care unit with a diagnosis of cardiac arrest or ventricular fibrillation. We examined unadjusted survival rates and developed a multivariable logistic regression model that included patient and hospital factors. Results We analyzed 68,115 cardiac arrest admissions. Unadjusted survival to hospital discharge was worse for blacks (n = 7,942) compared with whites (n = 60,173) (30% vs 33%, P < .001). In multivariate analyses accounting for patient and hospital factors, adjusted probability of survival was worse for black patients at hospitals with higher proportions of black patients (31%, 95% CI 29%-32%) compared with predominately white hospitals (46%, 95% CI 36%-57%; P = .003). Similarly, whites had worse risk-adjusted survival at hospitals with higher proportions of black patients (28%, 95% CI 27%-30%) compared with predominately white hospitals (32%, 95% CI 31%-33%, P = .006). Blacks were more likely to be admitted to hospitals with low survival rates (23% vs 15%, P < .001). Conclusion Hospitals with large black patient populations had worse cardiac arrest outcomes than predominantly white hospitals, and blacks were more likely to be admitted to these high-mortality hospitals. Understanding these differences in survival outcomes may uncover the causes for these disparities and lead to improved survival for all cardiac arrest victims. (Am Heart J 2011; 161: 705-11.) C1 [Merchant, Raina M.] Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, Philadelphia, PA 19104 USA. [Merchant, Raina M.; Becker, Lance B.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Yang, Feifei] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA. [Groeneveld, Peter W.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Merchant, RM (reprint author), Univ Penn, Robert Wood Johnson Fdn Clin Scholars Program, 423 Guardian St,13th Floor, Philadelphia, PA 19104 USA. EM raina.merchant@uphs.upenn.edu FU Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, Washington FX Becker: Speaker honoraria/consultant fees: Philips Healthcare, Seattle, WA. Institutional grant/research support: Philips Healthcare, Seattle, WA; Laerdal Medical, Stavanger, Norway; NIH, Bethesda, MD; Cardiac Science, Bothell, Washington. NR 42 TC 11 Z9 11 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD APR PY 2011 VL 161 IS 4 BP 705 EP 711 DI 10.1016/j.ahj.2011.01.011 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 745TW UT WOS:000289190500013 PM 21473969 ER PT J AU Rahilly-Tierney, C Sesso, HD Djousse, L Gaziano, JM AF Rahilly-Tierney, Catherine Sesso, Howard D. Djousse, Luc Gaziano, John Michael TI Lifestyle changes and 14-year change in high-density lipoprotein cholesterol in a cohort of male physicians SO AMERICAN HEART JOURNAL LA English DT Article ID HDL-CHOLESTEROL; CARDIOVASCULAR-DISEASE; ALCOHOL INTAKE; RISK; MEN; PREDICTORS; MORTALITY; EXERCISE; FAMILY AB Background Although cross-sectional studies have identified lifestyle factors associated with high-density lipoprotein cholesterol (HDL-C), no studies have examined the association between changes in lifestyle factors and long-term changes in HDL-C. Methods We examined the association between changes in lifestyle factors and changes in HDL-C over a 14-year period in a cohort of 4,168 US male physicians, followed up between 1982 and 1997 and with HDL-C measured at both time points. Using linear regression, we examined the association between HDL-C change and categorized changes in alcohol consumption, physical activity, body mass index (BMI), and smoking, adjusting for age, baseline HDL-C, and other covariates. Results Stable BMI of <25 kg/m(2) or BMI reduction from >= 25 to <25 kg/m(2) were associated with increases in HDL-C of 3.1 to 4.7 mg/dL over 14 years. Alcohol consumption of >= 1 drink daily or increase in alcohol consumption from <1 to >= 1 drink daily was associated with increases in HDL-C of 2.4 to 3.3 mg/dL over 14 years. Adopting a sedentary lifestyle was associated with decreases in 14-year decreases in HDL-C. Conclusion These findings suggest that reductions in BMI and increases in alcohol consumption are associated with 14-year increases in HDL-C, whereas decreases in physical activity are associated with 14-year decreases in HDL-C. (Am Heart J 2011; 161: 712-8.) C1 [Rahilly-Tierney, Catherine; Djousse, Luc; Gaziano, John Michael] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol & Informat Res Ctr MA, Boston, MA USA. [Rahilly-Tierney, Catherine; Sesso, Howard D.; Djousse, Luc; Gaziano, John Michael] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA. [Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA. RP Rahilly-Tierney, C (reprint author), MAVERIC, 13th Floor,150 S Huntington Ave, Jamaica Plain, MA 02130 USA. EM crahilly-tierney@partners.org RI Djousse, Luc/F-5033-2017 OI Djousse, Luc/0000-0002-9902-3047 FU NCI NIH HHS [R01 CA040360, R01 CA040360-14, R01 CA097193]; NHLBI NIH HHS [R01 HL026490, R01 HL034595] NR 21 TC 1 Z9 1 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD APR PY 2011 VL 161 IS 4 BP 712 EP 718 DI 10.1016/j.ahj.2010.12.015 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 745TW UT WOS:000289190500014 PM 21473970 ER PT J AU Ramanath, VS Eagle, KA Nienaber, CA Isselbacher, EM Froehlich, JB Montgomery, DG Cooper, JV Gu, XK Evangelista, A Voehringer, M Beckman, J Myrmel, T Pape, L Pyeritz, RE Hirsch, AT Gilon, D Bossone, E AF Ramanath, Vijay S. Eagle, Kim A. Nienaber, Christoph A. Isselbacher, Eric M. Froehlich, James B. Montgomery, Daniel G. Cooper, Jeanna V. Gu, Xiaokui Evangelista, Arturo Voehringer, Matthias Beckman, Joshua Myrmel, Truls Pape, Linda Pyeritz, Reed E. Hirsch, Alan T. Gilon, Dan Bossone, Eduardo CA Int Registry Acute Aortic Dissecti TI The role of preoperative coronary angiography in the setting of type A acute aortic dissection: Insights from the International Registry of Acute Aortic Dissection SO AMERICAN HEART JOURNAL LA English DT Article ID PREVIOUS CARDIAC-SURGERY; MANAGEMENT; SURVIVAL; ANEURYSM; DISEASE; REPAIR; IRAD AB Background Performing preoperative coronary angiography (CA) before surgical repair of a typeAacute aortic dissection (TA-AAD) remains controversial. Although the information provided by CA may be useful in planning the surgical approach, the potential delay to surgery and complications of CA may confer added risk of death before definitive repair of the aorta. Methods We analyzed 1,343 patients from January 27, 1996, to May 3, 2010, with TA-AAD from the International Registry of Acute Aortic Dissection who underwent surgical or endovascular repair during the index hospitalization, with (n = 156) or without (n = 1,187) preoperative CA. The main outcomes measured were in-hospital complications and in-hospital and long-term mortality. Results Patients who underwent preoperative CA were more likely to have a history of atherosclerosis and present with electrocardiographic signs of myocardial ischemia/infarction. In the preoperative CA group, significant delays from the onset of symptoms to the time of surgery occurred. In-hospital postoperative complications and mortality rates were largely similar between the 2 groups. On multivariable logistic regression analysis, preoperative CA had no significant effect on in-hospital risk-adjusted mortality when compared to the validated International Registry of Acute Aortic Dissection risk score. Long-term mortality was similar between patients receiving preoperative CA and those who did not; long-term rehospitalization rates were higher, although largely insignificantly, among preoperative CA recipients through 5 years of follow-up. Conclusions Preoperative CA is infrequently performed on patients with TA-AAD, except, occasionally, on patients at high risk for myocardial ischemia. When performed, preoperative CA was not associated with any significant changes in in-hospital and long-term mortality. (Am Heart J 2011; 161: 790-796.e1.) C1 [Ramanath, Vijay S.] Dartmouth Med Sch, Dartmouth Hitchcock Med Ctr, Cardiol Sect, Heart & Vasc Ctr, Lebanon, NH 03756 USA. [Eagle, Kim A.; Froehlich, James B.; Montgomery, Daniel G.; Cooper, Jeanna V.; Gu, Xiaokui] Univ Michigan, Ctr Cardiovasc, Ann Arbor, MI 48109 USA. [Nienaber, Christoph A.] Univ Rostock, Rostock, Germany. [Isselbacher, Eric M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Evangelista, Arturo] Hosp Gen Univ Vall dHebron, Barcelona, Spain. [Voehringer, Matthias] Robert Bosch Krankenhaus, Stuttgart, Germany. [Beckman, Joshua] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Myrmel, Truls] Univ Tromso Hosp, N-9012 Tromso, Norway. [Pape, Linda] Univ Massachusetts, Worcester, MA 01605 USA. [Pyeritz, Reed E.] Univ Penn, Philadelphia, PA 19104 USA. [Hirsch, Alan T.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Gilon, Dan] Hadassah Univ Hosp, Inst Heart, IL-91120 Jerusalem, Israel. [Bossone, Eduardo] Univ Hosp Scuola Med Salernitana, Dept Cardiol & Cardiac Surg, Salerno, Italy. RP Ramanath, VS (reprint author), Dartmouth Med Sch, Dartmouth Hitchcock Med Ctr, Cardiol Sect, Heart & Vasc Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA. EM vijaysr1977@gmail.com OI Beckman, Joshua/0000-0001-8332-8439 FU University of Michigan Health System; Varbedian Fund for Aortic Research; Mardigian Foundation; Hewlett Foundation; Gore, Inc. FX International Registry of Acute Aortic Dissection is supported by grants from the University of Michigan Health System, the Varbedian Fund for Aortic Research, the Mardigian Foundation, the Hewlett Foundation, and Gore, Inc. NR 12 TC 2 Z9 3 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-8703 EI 1097-5330 J9 AM HEART J JI Am. Heart J. PD APR PY 2011 VL 161 IS 4 BP 790 EP U1400 AR 796.e1 DI 10.1016/j.ahj.2011.01.010 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 745TW UT WOS:000289190500024 PM 21473980 ER PT J AU Baron, SJ Giugliano, RP AF Baron, Suzanne J. Giugliano, Robert P. TI Effectiveness and Safety of Percutaneous Coronary Intervention After Fibrinolytic Therapy for ST-Segment Elevation Acute Myocardial Infarction SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Review ID TISSUE-PLASMINOGEN-ACTIVATOR; RANDOMIZED CONTROLLED-TRIAL; IMMEDIATE ANGIOPLASTY; THROMBOLYTIC THERAPY; HEART-ASSOCIATION; MULTICENTER TRIAL; MANAGEMENT; ABCIXIMAB; STRATEGY; REGISTRY AB The goal of treatment of an acute ST-segment elevation myocardial infarction is the timely restoration of myocardial blood flow to decrease myocardial necrosis and thereby preserve cardiac tissue and overall function. Mainstays of reperfusion treatment include fibrinolytic therapy and/or primary percutaneous coronary intervention. In those patients who are treated with fibrinolysis, there is debate as to whether and when they should also undergo subsequent percutaneous coronary intervention. In conclusion, the investigators review the published reports on systematic percutaneous coronary intervention after fibrinolytic therapy in the treatment of ST-segment elevation myocardial infarction and discuss the rationale behind this treatment strategy. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1001-1009) C1 [Giugliano, Robert P.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. [Baron, Suzanne J.] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. RP Giugliano, RP (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA. EM rgiugliano@partners.org RI bashzar, salman/R-5748-2016 NR 33 TC 3 Z9 3 U1 0 U2 2 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 1 PY 2011 VL 107 IS 7 BP 1001 EP 1009 DI 10.1016/j.amjcard.2010.11.024 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 746VJ UT WOS:000289275500008 PM 21256466 ER PT J AU Kim, JH Noseworthy, PA McCarty, D Yared, K Weiner, R Wang, F Wood, MJ Hutter, AM Picard, MH Baggish, AL AF Kim, Jonathan H. Noseworthy, Peter A. McCarty, David Yared, Kibar Weiner, Rory Wang, Francis Wood, Malissa J. Hutter, Adolph M. Picard, Michael H. Baggish, Aaron L. TI Significance of Electrocardiographic Right Bundle Branch Block in Trained Athletes SO AMERICAN JOURNAL OF CARDIOLOGY LA English DT Article ID VENTRICULAR-ARRHYTHMIAS; CARDIOVASCULAR-DISEASE; CLINICAL-SIGNIFICANCE; EUROPEAN-SOCIETY; OF-CARDIOLOGY; HEART; ECHOCARDIOGRAPHY; RECOMMENDATIONS; ASSOCIATION; PARTICIPATION AB We sought to determine the clinical and physiologic significance of electrocardiographic complete right bundle branch block (CRBBB) and incomplete right bundle branch block (IRBBB) in trained athletes. The 12-lead electrocardiographic and echocardiographic data from 510 competitive athletes were analyzed. Compared to the 51 age-, sport type-, and gender-matched athletes with normal 12-lead electrocardiographic QRS complex duration, the 44 athletes with IRBBB (9%) and 13 with CRBBB (3%) had larger right ventricular (RV) dimensions, as measured by the basal RV end-diastolic diameter (CRBBB 43 +/- 3 mm, IRBBB 38 +/- 6 mm, normal QRS complex 35 +/- 4 mm, p < 0.001) and RV end-diastolic area (CRBBB 33 +/- 5, IRBBB 27 +/- 7, and normal QRS complex 23 +/- 3 cm(2); p < 0.001). Athletes with CRBBB also had a relative reduction in the RV systolic function at rest as assessed by the RV fractional area change and peak systolic tissue velocity. Finally, QRS prolongation was associated with parallel increases in interventricular dyssynchrony (basal RV to basal lateral left ventricular peak systolic tissue velocity time difference: CRBBB 112 +/- 15, IRBBB 73 +/- 33, normal QRS complex 43 +/- 39 ms, p < 0.001). Despite these findings, no athlete with CRBBB or IRBBB was found to have pathologic structural cardiac disease. In conclusion, among trained athletes, CRBBB and IRBBB appear to be markers of a structural and physiological cardiac remodeling triad characterized by RV dilation, a relative reduction in the RV systolic function at rest, and interventricular dyssynchrony. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1083-1089) C1 [Kim, Jonathan H.; Noseworthy, Peter A.; McCarty, David; Yared, Kibar; Weiner, Rory; Wood, Malissa J.; Hutter, Adolph M.; Picard, Michael H.; Baggish, Aaron L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Wang, Francis] Harvard Univ, Univ Hlth Serv, Cambridge, MA 02138 USA. RP Baggish, AL (reprint author), Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. EM abaggish@partners.org OI Picard, Michael/0000-0002-9264-3243 NR 26 TC 33 Z9 33 U1 0 U2 10 PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC PI BRIDGEWATER PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA SN 0002-9149 EI 1879-1913 J9 AM J CARDIOL JI Am. J. Cardiol. PD APR 1 PY 2011 VL 107 IS 7 BP 1083 EP 1089 DI 10.1016/j.amjcard.2010.11.037 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 746VJ UT WOS:000289275500021 PM 21296331 ER PT J AU George, MS Post, RM AF George, Mark S. Post, Robert M. TI Daily Left Prefrontal Repetitive Transcranial Magnetic Stimulation for Acute Treatment of Medication-Resistant Depression SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; COIL-CORTEX DISTANCE; DEEP BRAIN-REGIONS; HEALTHY-YOUNG MEN; MAJOR DEPRESSION; MOTOR CORTEX; ANTIDEPRESSANT RESPONSE; CORTICAL EXCITABILITY; ELECTROCONVULSIVE-THERAPY; ELECTRICAL-STIMULATION C1 George Washington Univ, Sch Med, Dept Psychiat, Washington, DC USA. Bipolar Collaborat Network, Bethesda, MD USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. [George, Mark S.] Med Univ S Carolina, Inst Psychiat, Brain Stimulat Lab, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. RP George, MS (reprint author), Med Univ S Carolina, Inst Psychiat, Brain Stimulat Lab, Dept Psychiat & Behav Sci, 67 President St,502 N, Charleston, SC 29425 USA. EM georgem@musc.edu NR 88 TC 59 Z9 62 U1 6 U2 18 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2011 VL 168 IS 4 BP 356 EP 364 DI 10.1176/appi.ajp.2010.10060864 PG 9 WC Psychiatry SC Psychiatry GA 746KM UT WOS:000289245500007 PM 21474597 ER PT J AU Poelmans, G Pauls, DL Buitelaar, JK Franke, B AF Poelmans, Geert Pauls, David L. Buitelaar, Jan K. Franke, Barbara TI Integrated Genome-Wide Association Study Findings: Identification of a Neurodevelopmental Network for Attention Deficit Hyperactivity Disorder SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Review ID DEFICIT/HYPERACTIVITY DISORDER; MOLECULAR-GENETICS; READING-DISABILITY; NEURITE OUTGROWTH; CANDIDATE GENE; ADULT ADHD; BRAIN; AMPHETAMINE; CHILDREN; RATS AB Objective: Attention deficit hyperactivity disorder (ADHD) is a highly heritable neuropsychiatric disorder. In the present study, the authors investigated the presence of genomic convergence in the top findings of the five published genome-wide association studies (GWASs) of ADHD. Method: The authors carried out bioinformatics pathway analyses, using the Ingenuity and BiNGO tools, as well as a systematic literature analysis of 85 genes from the five published GWASs containing single nucleotide polymorphisms associated with ADHD at a p value < 0.0001. Results: Findings revealed that 45 of the 85 top-ranked ADHD candidate genes encode proteins that fit into a neurodevelopmental network involved in directed neurite outgrowth. Data on copy number variations in patients with ADHD and data from animal studies provide further support for the involvement of this network in ADHD etiology. Several network proteins are also directly modulated by stimulants, the most commonly used psychopharmacological treatment for ADHD. Conclusions: The authors have identified a protein network for ADHD that contributes to our understanding of the molecular basis of the disorder. In addition, the data suggest new candidate genes for ADHD and provide clues to future research into psychopharmacological ADHD treatments. C1 Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands. Radboud Univ Nijmegen, Med Ctr, Dept Cognit Neurosci, NL-6500 HB Nijmegen, Netherlands. Radboud Univ Nijmegen, Med Ctr, Dept Psychiat, NL-6500 HB Nijmegen, Netherlands. Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, NL-6500 HB Nijmegen, Netherlands. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Psychiat & Neurodev Genet Unit,Ctr Human Genet Re, Boston, MA USA. RP Franke, B (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Human Genet 855, POB 9101, NL-6500 HB Nijmegen, Netherlands. EM b.franke@antrg.umcn.nl RI Franke, Barbara/D-4836-2009; Buitelaar, Jan/E-4584-2012 OI Franke, Barbara/0000-0003-4375-6572; Buitelaar, Jan/0000-0001-8288-7757 NR 76 TC 94 Z9 96 U1 2 U2 16 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2011 VL 168 IS 4 BP 365 EP 377 DI 10.1176/appi.ajp.2010.10070948 PG 13 WC Psychiatry SC Psychiatry GA 746KM UT WOS:000289245500008 PM 21324949 ER PT J AU Dias, RS Lafer, B Russo, C Del Debbio, A Nierenberg, AA Sachs, GS Joffe, H AF Dias, Rodrigo S. Lafer, Beny Russo, Cibele Del Debbio, Alessandro Nierenberg, Andrew A. Sachs, Gary S. Joffe, Hadine TI Longitudinal Follow-Up of Bipolar Disorder in Women With Premenstrual Exacerbation: Findings From STEP-BD SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID TREATMENT ENHANCEMENT PROGRAM; MENSTRUAL-CYCLE; DYSPHORIC DISORDER; MOOD SYMPTOMS; ILLNESS; DEPRESSION; COMORBIDITY; SEROTONIN; ESTROGEN; RECOVERY AB Objective: The impact of hormonal fluctuation during the menstrual cycle on the course of bipolar disorder is poorly understood. The authors determined the course of illness and time to relapse of bipolar disorder in prospectively followed women with premenstrual exacerbation. Method: Participants were 293 premenopause-age women with bipolar disorder who were followed prospectively for 1 year as part of the Systematic Treatment Enhancement Program for Bipolar Disorder. Frequency of mood episodes was compared between 191 women with premenstrual exacerbation (65.2%) and 102 women without. Among 129 women who were in recovered status at baseline, time to relapse was compared between 66 women with premenstrual exacerbation (51.2%) and 63 without. Results: During follow-up, the group with premenstrual exacerbation had more episodes (primarily depressive) than did the group without, but they were not more likely to meet criteria for rapid cycling during this period. In contrast, they were more likely to report rapid cycling retrospectively. Women with premenstrual exacerbation had a shorter time to relapse and were at greater risk for relapse, but this association was not significant after adjustment for retrospectively reported rapid cycling. Women with premenstrual exacerbation had more depressive and mood elevation symptoms overall. Conclusions: Women with bipolar disorder and premenstrual exacerbation have a worse course of illness, a shorter time to relapse, and greater symptom severity, but they are not more likely to meet criteria for rapid cycling. Premenstrual exacerbation may be a clinical marker predicting a more symptomatic and relapse-prone phenotype in reproductive-age women with bipolar disorder. C1 Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA. Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. Univ Sao Paulo, Sch Med, Bipolar Disorder Res Program, Dept Psychiat,Inst Psychiat, Sao Paulo, Brazil. Univ Sao Paulo, Inst Math & Stat, BR-05508 Sao Paulo, Brazil. Univ Pisa, Neurobiol & Clin Affect Disorders Postdoctoral Fe, Pisa, Italy. Harvard Univ, Massachusetts Gen Hosp, Sch Med, Perinatal & Reprod Psychiat Clin Res Program, Boston, MA USA. RP Dias, RS (reprint author), Rua Labapua 821,Cj 55, BR-04533013 Sao Paulo, Brazil. EM rdgdias@gmail.com RI Russo, Cibele/E-8462-2011; Lafer, Beny/C-1055-2012; Lafer, Beny/F-9390-2015; Dias, Rodrigo/N-8985-2013 OI Lafer, Beny/0000-0002-6132-9999; Lafer, Beny/0000-0002-6132-9999; Dias, Rodrigo/0000-0002-1315-7205 FU NIMH [01MH80001]; Thompson Motta Family; Institute of Psychiatry of the Hospital das Clinicas; University Sao Paulo Medical School; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil FX The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) project has been funded by NIMH under contract 01MH80001 (the STEP-BD core investigators and collaborators and their institutions are listed in a data supplement that accompanies the online edition of this article). This study was funded in part by a donation from the Thompson Motta Family to the Bipolar Research Program, Institute of Psychiatry of the Hospital das Clinicas, University Sao Paulo Medical School. Dr. Dias was supported by a Ph. D. scholarship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil. NR 40 TC 24 Z9 24 U1 5 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2011 VL 168 IS 4 BP 386 EP 394 DI 10.1176/appi.ajp.2010.09121816 PG 9 WC Psychiatry SC Psychiatry GA 746KM UT WOS:000289245500010 PM 21324951 ER PT J AU Hoerster, KD Mayer, JA Gabbard, S Kronick, RG Roesch, SC Malcarne, VL Zuniga, ML AF Hoerster, Katherine D. Mayer, Joni A. Gabbard, Susan Kronick, Richard G. Roesch, Scott C. Malcarne, Vanessa L. Zuniga, Maria L. TI Impact of Individual-, Environmental-, and Policy-Level Factors on Health Care Utilization Among US Farmworkers SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID OF-THE-LITERATURE; SEASONAL FARMWORKERS; UNITED-STATES; MEDICAL-CARE; CALIFORNIA FARMWORKERS; MIGRANT FARMWORKERS; BEHAVIORAL-MODEL; FARM-WORKERS; ACCESS; SERVICES AB Objectives. We examined individual-, environmental-, and policy-level correlates of US farmworker health care utilization, guided by the behavioral model for vulnerable populations and the ecological model. Methods. The 2006 and 2007 administrations of the National Agricultural Workers Survey (n=2884) provided the primary data. Geographic information systems, the 2005 Uniform Data System, and rurality and border proximity indices provided environmental variables. To identify factors associated with health care use, we performed logistic regression using weighted hierarchical linear modeling. Results. Approximately half (55.3%) of farmworkers utilized US health care in the previous 2 years. Several factors were independently associated with use at the individual level (gender, immigration and migrant status, English proficiency, transportation access, health status, and non-US health care utilization), the environmental level (proximity to US-Mexico border), and the policy level (insurance status and workplace payment structure). County Federally Qualified Health Center resources were not independently associated. Conclusions. We identified farmworkers at greatest risk for poor access. We made recommendations for change to farmworker health care access at all 3 levels of influence, emphasizing Federally Qualified Health Center service delivery. (Am J Public Health. 2011;101:685-692. doi:10.2105/AJPH.2009.190892) C1 [Hoerster, Katherine D.] Univ Calif San Diego, San Diego State Univ, San Diego Joint Doctoral Program Clin Psychol, San Diego, CA 92103 USA. [Mayer, Joni A.] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Gabbard, Susan] JBS Int, Burlingame, CA USA. [Kronick, Richard G.; Zuniga, Maria L.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA. [Roesch, Scott C.; Malcarne, Vanessa L.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA. RP Hoerster, KD (reprint author), VA Puget Sound Healthcare Syst, Seattle Div, 1660 S Columbian Way S-116, Seattle, WA 98108 USA. EM Katherine.Hoerster@va.gov FU US Department of Health and Human Services, Health Resources and Services Administration (Bureau of Primary Health Care, Office of Minority and Special Populations); US Department of Labor; JBS International FX The US Department of Health and Human Services, Health Resources and Services Administration (Bureau of Primary Health Care, Office of Minority and Special Populations) funded this work.; We are grateful to Marcia Gomez and Henry Lopez for initiating this partnership. We thank the US Department of Labor (especially Daniel Carroll) and JBS International for their support and for granting access to the National Agricultural Workers Survey (NAWS). Harry Johnson and Andre Skupin from the San Diego State University Geography Department provided guidance and access to ArcInfo software. Access to the Uniform Data System data was provided through collaboration with the National Center for Farmworker Health. We are grateful to the farmworker participants who provided their time and insights for the NAWS and for the work they do on US farms every day. NR 58 TC 12 Z9 12 U1 5 U2 20 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD APR PY 2011 VL 101 IS 4 BP 685 EP 692 DI 10.2105/AJPH.2009.190892 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 740UN UT WOS:000288820000024 PM 21330594 ER PT J AU Chen-Plotkin, AS Martinez-Lage, M Sleiman, PMA Hu, W Greene, R Wood, EM Bing, SX Grossman, M Schellenberg, GD Hatanpaa, KJ Weiner, MF White, CL Brooks, WS Halliday, GM Kril, JJ Gearing, M Beach, TG Graff-Radford, NR Dickson, DW Rademakers, R Boeve, BF Pickering-Brown, SM Snowden, J van Swieten, JC Heutink, P Seelaar, H Murrell, JR Ghetti, B Spina, S Grafman, J Kaye, JA Woltjer, RL Mesulam, M Bigio, E Llado, A Miller, BL Alzualde, A Moreno, F Rohrer, JD Mackenzie, IRA Feldman, HH Hamilton, RL Cruts, M Engelborghs, S De Deyn, PP Van Broeckhoven, C Bird, TD Cairns, NJ Goate, A Frosch, MP Riederer, PF Bogdanovic, N Lee, VMY Trojanowski, JQ Van Deerlin, VM AF Chen-Plotkin, Alice S. Martinez-Lage, Maria Sleiman, Patrick M. A. Hu, William Greene, Robert Wood, Elisabeth McCarty Bing, Shaoxu Grossman, Murray Schellenberg, Gerard D. Hatanpaa, Kimmo J. Weiner, Myron F. White, Charles L., III Brooks, William S. Halliday, Glenda M. Kril, Jillian J. Gearing, Marla Beach, Thomas G. Graff-Radford, Neill R. Dickson, Dennis W. Rademakers, Rosa Boeve, Bradley F. Pickering-Brown, Stuart M. Snowden, Julie van Swieten, John C. Heutink, Peter Seelaar, Harro Murrell, Jill R. Ghetti, Bernardino Spina, Salvatore Grafman, Jordan Kaye, Jeffrey A. Woltjer, Randall L. Mesulam, Marsel Bigio, Eileen Llado, Albert Miller, Bruce L. Alzualde, Ainhoa Moreno, Fermin Rohrer, Jonathan D. Mackenzie, Ian R. A. Feldman, Howard H. Hamilton, Ronald L. Cruts, Marc Engelborghs, Sebastiaan De Deyn, Peter P. Van Broeckhoven, Christine Bird, Thomas D. Cairns, Nigel J. Goate, Allison Frosch, Matthew P. Riederer, Peter F. Bogdanovic, Nenad Lee, Virginia M. Y. Trojanowski, John Q. Van Deerlin, Vivianna M. TI Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration SO ARCHIVES OF NEUROLOGY LA English DT Article ID UBIQUITIN-POSITIVE INCLUSIONS; AMYOTROPHIC-LATERAL-SCLEROSIS; MUTATIONS; DEMENTIA; TAU; PHENOTYPES; DISEASE; NEUROPATHOLOGY; CHROMOSOME-17; VARIABILITY AB Objective: To assess the relative frequency of unique mutations and their associated characteristics in 97 individuals with mutations in progranulin (GRN), an important cause of frontotemporal lobar degeneration (FTLD). Participants and Design: A 46-site International Frontotemporal Lobar Degeneration Collaboration was formed to collect cases of FTLD with TAR DNA-binding protein of 43-kDa (TDP-43)-positive inclusions (FTLD-TDP). We identified 97 individuals with FTLD-TDP with pathogenic GRN mutations (GRN+ FTLD-TDP), assessed their genetic and clinical characteristics, and compared them with 453 patients with FTLD-TDP in which GRN mutations were excluded (GRN- FTLD-TDP). No patients were known to be related. Neuropathologic characteristics were confirmed as FTLD-TDP in 79 of the 97 GRN+ FTLD-TDP cases and all of the GRN- FTLD-TDP cases. Results: Age at onset of FTLD was younger in patients with GRN+ FTLD-TDP vs GRN- FTLD-TDP (median, 58.0 vs 61.0 years; P < .001), as was age at death (median, 65.5 vs 69.0 years; P < .001). Concomitant motor neuron disease was much less common in GRN+ FTLD-TDP vs GRN- FTLD-TDP (5.4% vs 26.3%; P < .001). Fifty different GRN mutations were observed, including 2 novel mutations: c.139delG (p.D47TfsX7) and c.378C>A (p.C126X). The 2 most common GRN mutations were c.1477C>T (p.R493X, found in 18 patients, representing 18.6% of GRN cases) and c.26C>A (p.A9D, found in 6 patients, representing 6.2% of cases). Patients with the c.1477C>T mutation shared a haplotype on chromosome 17; clinically, they resembled patients with other GRN mutations. Patients with the c.26C>A mutation appeared to have a younger age at onset of FTLD and at death and more parkinsonian features than those with other GRN mutations. Conclusion: GRN+ FTLD-TDP differs in key features from GRN- FTLD-TDP. C1 [Chen-Plotkin, Alice S.; Grossman, Murray] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Chen-Plotkin, Alice S.; Martinez-Lage, Maria; Greene, Robert; Wood, Elisabeth McCarty; Bing, Shaoxu; Lee, Virginia M. Y.; Trojanowski, John Q.; Van Deerlin, Vivianna M.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Sleiman, Patrick M. A.] Univ Penn, Sch Med, Ctr Appl Genom, Div Human Genet,Dept Pediat, Philadelphia, PA 19104 USA. [Greene, Robert; Wood, Elisabeth McCarty; Bing, Shaoxu; Lee, Virginia M. Y.; Trojanowski, John Q.; Van Deerlin, Vivianna M.] Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA. [Martinez-Lage, Maria] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, E-08193 Barcelona, Spain. [Hu, William] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Gearing, Marla] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Hatanpaa, Kimmo J.; White, Charles L., III] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA. [Weiner, Myron F.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Weiner, Myron F.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA. [Brooks, William S.; Halliday, Glenda M.] Neurosci Res Australia, Sydney, NSW, Australia. [Brooks, William S.; Halliday, Glenda M.] Univ New S Wales, Sydney, NSW, Australia. [Kril, Jillian J.] Univ Sydney, Discipline Med, Sydney, NSW 2006, Australia. [Kril, Jillian J.] Univ Sydney, Discipline Pathol, Sydney, NSW 2006, Australia. [Beach, Thomas G.] Sun Hlth Res Inst, Sun City, AZ USA. [Graff-Radford, Neill R.] Mayo Sch Grad Med Educ, Coll Med, Dept Neurol, Jacksonville, FL USA. [Dickson, Dennis W.; Rademakers, Rosa] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA. [Boeve, Bradley F.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Pickering-Brown, Stuart M.; Snowden, Julie] Univ Manchester, Neurodegenerat & Mental Hlth Res Grp, Manchester, Lancs, England. [van Swieten, John C.; Seelaar, Harro] Erasmus MC, Dept Neurol, Rotterdam, Netherlands. [Heutink, Peter] Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet, Sect Med Genom, Amsterdam, Netherlands. [Murrell, Jill R.; Ghetti, Bernardino; Spina, Salvatore] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA. [Murrell, Jill R.; Ghetti, Bernardino; Spina, Salvatore] Indiana Univ Sch Med, Indiana Alzheimer Dis Ctr, Indianapolis, IN USA. [Spina, Salvatore] Univ Siena, Dept Neurol Neurosurg & Behav Sci, I-53100 Siena, Italy. [Grafman, Jordan] Kessler Fdn Res Ctr, Traumat Brain Injury Res Lab, W Orange, NJ USA. [Kaye, Jeffrey A.] Oregon Hlth & Sci Univ, Dept Neurol & Biomed Engn, Portland, OR 97201 USA. [Woltjer, Randall L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Mesulam, Marsel; Bigio, Eileen] Northwestern Univ, Feinberg Sch Med, Alzheimer Dis Ctr, Chicago, IL 60611 USA. [Llado, Albert] ICN Hosp Clin Barcelona, Serv Neurol, Alzheimers Dis & Cognit Disorders Unit, Barcelona, Spain. [Miller, Bruce L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Alzualde, Ainhoa] BioDonostia Inst, Ilundain Fdn, Neurosci Unit, San Sebastian, Spain. [Moreno, Fermin] BioDonostia Inst, Hosp Donostia, Neurol Serv, San Sebastian, Spain. [Rohrer, Jonathan D.] UCL Inst Neurol, Dementia Res Ctr, London, England. [Mackenzie, Ian R. A.] Univ British Columbia, Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada. [Feldman, Howard H.] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada. [Feldman, Howard H.] Bristol Myers Squibb Co, Neurosci, Wallingford, CT 06492 USA. [Hamilton, Ronald L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA. [Cruts, Marc; Van Broeckhoven, Christine] VIB, Dept Mol Genet, Neurodegenerat Brain Dis Grp, Antwerp, Belgium. [Cruts, Marc; Engelborghs, Sebastiaan; De Deyn, Peter P.; Van Broeckhoven, Christine] Univ Antwerp, Inst Born Bunge, B-2020 Antwerp, Belgium. [Engelborghs, Sebastiaan; De Deyn, Peter P.] Hosp Network Antwerp ZNA & Middelheim, Dept Neurol, Antwerp, Belgium. [Engelborghs, Sebastiaan; De Deyn, Peter P.] Memory Clin ZNA Hoge Beuken, Antwerp, Belgium. [Bird, Thomas D.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ Ctr, Seattle, WA USA. [Bird, Thomas D.] Vet Affairs Puget Sound Hlth Care Syst, Ctr Clin, Seattle, WA USA. [Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Cairns, Nigel J.] Washington Univ, Sch Med, Alzheimers Dis Res Ctr, St Louis, MO USA. [Cairns, Nigel J.; Goate, Allison] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA. [Frosch, Matthew P.] Massachusetts Gen Hosp, CS Kubik Lab Neuropathol, Boston, MA 02114 USA. [Frosch, Matthew P.] Harvard Univ, Sch Med, Boston, MA USA. [Riederer, Peter F.] Univ Wurzburg, Clin & Policlin Psychiat Psychosomat & Psychother, Wurzburg, Germany. [Bogdanovic, Nenad] Karolinska Univ Hosp, Dept Geriatr Med, Stockholm, Sweden. RP Chen-Plotkin, AS (reprint author), Univ Penn, Sch Med, Dept Neurol, 407 Johnson Pavil, Philadelphia, PA 19104 USA. EM chenplot@mail.med.upenn.edu RI Pickering-Brown, Stuart/D-4008-2009; Halliday, Glenda/E-8555-2011; Cruts, Marc/J-6161-2013; OI Pickering-Brown, Stuart/0000-0003-1561-6054; Halliday, Glenda/0000-0003-0422-8398; Cruts, Marc/0000-0002-1338-992X; Weiner, Myron/0000-0001-5682-4410; Dickson, Dennis W/0000-0001-7189-7917; Kaye, Jeffrey/0000-0002-9971-3478; Grafman, Jordan H./0000-0001-8645-4457; Snowden, Julie/0000-0002-3976-4310; Martinez-Lage, Maria/0000-0002-5859-7562; Feldman, Howard/0000-0002-9258-4538; Kril, Jillian/0000-0001-9407-8674 FU US National Institutes of Health (NIH) [AG10129, AG10124, AG17586, AG16574, AG03949, NS44266, AG15116, NS53488, AG010133, AG08671, NS044233, NS15655, NS065782, AG008017, AG13854, AG12300, AG028377, AG019724, AG13846, AG025688, AG05133, AG08702, AG05146, AG005136, AG005681, AG03991, AG010129, AG05134, NS038372]; NIH; Robert and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program; Pacific Alzheimer's Disease Research Foundation [C06-01]; Alzheimer's Research Trust; Alzheimer's Society; Medical Research Council; Stichting Dioraphte grant [07010500]; Hersenstichting grant [15F07.2.34]; Prinses Beatrix Fonds grant [006-0204]; Winspear Family Center for Research on the Neuropathology of Alzheimer Disease; McCune Foundation; Instituto Carlos III, Federal Ministry of Education and Research [01GI0505]; Basque government; Department of Innovation, Diputacion Foral de Gipuzkoa [DFG 0876/08]; ILUNDAIN Fundazioa, Centro de Investigaciones Biomedicas en Red en Enfermededades Neurodegenerativas; Wellcome Trust; Canadian Institutes of Health Research [75480]; Foundation for Alzheimer Research; Medical Foundation Queen Elisabeth; Interuniversity Attraction Poles network of the Belgian Science Policy Office [P6/43]; Flemish government; University of Antwerp; Joseph Iseman Fund; Louis and Rachel Rudin Foundation; National Health and Medical Research Council of Australia; Veterans Affairs Research Funds; Arizona Department of Health Services [211002]; Arizona Alzheimer's Research Center; Arizona Biomedical Research Commission [4001, 0011, 05-901]; Prescott Family Initiative of the Michael J. Fox Foundation for Parkinson's Research; Daljits and Elaine Sarkara Chair in Diagnostic Medicine; BrainNet Europe II; Ministerio de Ciencia y Tecnologia; Ref Saud y Farmacia [2001-4888]; Fundacion La Caxia; Burroughs Wellcome Fund; Benaroya Fund FX Many grant funding agencies provided financial support for this study, including the US National Institutes of Health (NIH) grants AG10129, AG10124, AG17586, AG16574, AG03949, NS44266, AG15116, NS53488, AG10124, AG010133, AG08671, NS044233, NS15655, NS065782, AG008017, AG13854, AG12300, AG028377, AG019724, AG13846, AG025688, AG05133, AG08702, AG05146, AG005136, AG005681, AG03991, AG010129, AG05134, NS038372, AG02219, AG05138, AG10161, AG19610, AG16570, AG05142, AG005131, AG18440, AG16582, AG16573, AG033101, and the NIH Intramural Program. Additional funds were provided by Robert and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program; the Pacific Alzheimer's Disease Research Foundation grant C06-01; the Alzheimer's Research Trust; Alzheimer's Society; Medical Research Council (Programme Grant and Returning Scientist Award); Stichting Dioraphte grant 07010500; Hersenstichting grant 15F07.2.34; Prinses Beatrix Fonds grant 006-0204; Winspear Family Center for Research on the Neuropathology of Alzheimer Disease; the McCune Foundation; Instituto Carlos III, Federal Ministry of Education and Research grant 01GI0505; SAIOTEK Program (Basque government); Department of Innovation, Diputacion Foral de Gipuzkoa grant DFG 0876/08; ILUNDAIN Fundazioa, Centro de Investigaciones Biomedicas en Red en Enfermededades Neurodegenerativas; Wellcome Trust; Canadian Institutes of Health Research grant 75480; Fund for Research Foundation Flanders, the Foundation for Alzheimer Research; Medical Foundation Queen Elisabeth; Interuniversity Attraction Poles P6/43 network of the Belgian Science Policy Office; a Methusalem excellence grant of the Flemish government and Special Research Fund of the University of Antwerp; the Joseph Iseman Fund; the Louis and Rachel Rudin Foundation; National Health and Medical Research Council of Australia; Veterans Affairs Research Funds; Arizona Department of Health Services contract 211002, Arizona Alzheimer's Research Center; the Arizona Biomedical Research Commission contracts 4001, 0011, and 05-901 to the Arizona Parkinson's Disease Consortium; the Prescott Family Initiative of the Michael J. Fox Foundation for Parkinson's Research; the Daljits and Elaine Sarkara Chair in Diagnostic Medicine; BrainNet Europe II; Ministerio de Ciencia y Tecnologia; Ref Saud y Farmacia 2001-4888; and Fundacion La Caxia.; Additional supported was provided by the Burroughs Wellcome Fund Career Award for Medical Scientists and the Benaroya Fund (Dr Chen-Plotkin). Dr Lee is the John H. Ware III Professor of Alzheimer's Disease Research, and Dr Trojanowski is the William Maul Measey-Truman G. Schnabel Jr Professor of Geriatric Medicine and Gerontology. NR 42 TC 52 Z9 53 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9942 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD APR PY 2011 VL 68 IS 4 BP 488 EP 497 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 748CY UT WOS:000289368800012 PM 21482928 ER PT J AU Weintraub, D Fraessdorf, M Potenza, MN Siderowf, AD Stacy, M Voon, V Whetteckey, J Wunderlich, GR Lang, AE AF Weintraub, Daniel Fraessdorf, Mandy Potenza, Marc N. Siderowf, Andrew D. Stacy, Mark Voon, Valerie Whetteckey, Jacqueline Wunderlich, Glen R. Lang, Anthony E. TI Dopamine Agonists vs Levodopa in Impulse Control Disorders reply SO ARCHIVES OF NEUROLOGY LA English DT Letter ID PARKINSONS-DISEASE; AMANTADINE C1 [Weintraub, Daniel] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Siderowf, Andrew D.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Fraessdorf, Mandy] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany. [Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Stacy, Mark] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA. [Voon, Valerie] Univ Cambridge, Cambridge, England. [Whetteckey, Jacqueline] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA. [Wunderlich, Glen R.] Boehringer Ingelheim Canada Ltd, Burlington, ON, Canada. [Lang, Anthony E.] Univ Toronto, Dept Neurol, Toronto, ON, Canada. RP Weintraub, D (reprint author), Univ Penn, Sch Med, Dept Psychiat, 3615 Chestnut St,Rm 330, Philadelphia, PA 19104 USA. EM daniel.weintraub@uphs.upenn.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0003-9942 EI 1538-3687 J9 ARCH NEUROL-CHICAGO JI Arch. Neurol. PD APR PY 2011 VL 68 IS 4 BP 545 EP 546 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 748CY UT WOS:000289368800031 ER PT J AU Suppiah, R Judge, A Batra, R Flossmann, O Harper, L Hoglund, P Javaid, MK Jayne, D Mukhtyar, C Westman, K Davis, JC Hoffman, GS McCune, WJ Merkel, PA St Clair, EW Seo, P Spiera, R Stone, JH Luqmani, R AF Suppiah, Ravi Judge, Andrew Batra, Rajbir Flossmann, Oliver Harper, Lorraine Hoeglund, Peter Javaid, M. Kassim Jayne, David Mukhtyar, Chetan Westman, Kerstin Davis, John C., Jr. Hoffman, Gary S. McCune, W. Joseph Merkel, Peter A. St Clair, E. William Seo, Philip Spiera, Robert Stone, John H. Luqmani, Raashid TI A Model to Predict Cardiovascular Events in Patients With Newly Diagnosed Wegener's Granulomatosis and Microscopic Polyangiitis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID ANTIBODY-ASSOCIATED VASCULITIS; ENDOTHELIAL DYSFUNCTION; RANDOMIZED-TRIAL; SYSTEMIC VASCULITIS; LOGISTIC-REGRESSION; MULTIPLE IMPUTATION; HEART-DISEASE; RISK; CYCLOPHOSPHAMIDE; ATHEROSCLEROSIS AB Objective. To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. Methods. We reviewed CV outcomes during the long-term followup of patients in the first 4 European Vasculitis Study Group (EUVAS) trials of WG and MPA. CV events were defined as CV death, stroke, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention. Logistic regression was performed to create a model to predict the absolute risk of a CV event. The model was tested using the Wegener's Granulomatosis Etanercept Trial (WGET) cohort. Results. Seventy-four (13.8%) of 535 patients with 5 years of followup from the EUVAS trials had at least 1 CV event: 33 (11.7%) of 281 WG versus 41 (16.1%) of 254 MPA. The independent determinants of CV outcomes were older age (odds ratio [OR] 1.45, 95% confidence interval [95% CI] 1.11-1.90), diastolic hypertension (OR 1.97, 95% CI 0.98-3.95), and positive proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) status (OR 0.39, 95% CI 0.20-0.74). The model was validated using the WGET cohort (area under the receiver operating characteristic curve of 0.80). Conclusion. Within 5 years of diagnosis of WG or MPA, 14% of patients will have a CV event. We have constructed and validated a tool to quantify the risk of a CV event based on age, diastolic hypertension, and PR3 ANCA status in patients without prior CV disease. In patients with vasculitis, PR3 ANCA is associated with a reduced CV risk compared to myeloperoxidase ANCA or negative ANCA status. C1 [Suppiah, Ravi; Luqmani, Raashid] Nuffield Orthopaed Ctr, Oxford Natl Inst Hlth Res, Oxford OX3 7LD, England. [Judge, Andrew; Batra, Rajbir; Javaid, M. Kassim; Luqmani, Raashid] Univ Oxford, Oxford, England. [Flossmann, Oliver; Jayne, David] Addenbrookes Hosp, Cambridge, England. [Harper, Lorraine] Univ Birmingham, Birmingham, W Midlands, England. [Hoeglund, Peter; Westman, Kerstin] Lund Univ, Lund, Sweden. [Mukhtyar, Chetan] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England. [Davis, John C., Jr.] Genentech Corp, San Francisco, CA USA. [Davis, John C., Jr.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hoffman, Gary S.] Cleveland Clin, Cleveland, OH 44106 USA. [McCune, W. Joseph] Univ Michigan, Ann Arbor, MI 48109 USA. [Merkel, Peter A.] Boston Univ, Sch Med, Boston, MA 02118 USA. [St Clair, E. William] Duke Univ, Durham, NC USA. [Seo, Philip] Johns Hopkins Univ, Baltimore, MD USA. [Spiera, Robert] Hosp Special Surg, New York, NY 10021 USA. [Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Suppiah, R (reprint author), Nuffield Orthopaed Ctr, Oxford Natl Inst Hlth Res, Windmill Rd, Oxford OX3 7LD, England. EM suppiah@gmail.com RI Batra, Rajbir/B-3049-2013; Hoglund, Peter/H-4774-2014; OI Batra, Rajbir/0000-0001-7010-8189; Hoglund, Peter/0000-0002-8395-922X; Luqmani, Raashid/0000-0002-4446-5841 FU European League Against Rheumatism; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Center for Research Resources; Office of Rare Diseases Research [1-U54RR01949, U54-AR057319, U01-AR1874]; NIH [N01AR92240]; Office of Orphan Products; Food and Drug Administration [FD-R-001652]; General Clinical Research Center [M01-RRO-00533, M01-RRO-0042, MO1-RR-30, M01-RRO-2719]; National Center for Research Resources/NIH; Rose Hellaby Medical Scholarship, New Zealand; Oxford National Institute for Health Research Biomedical Research Unit Musculoskeletal Research Group, University of Oxford; Cambridge Biomedical Research Centre; National Institute of Arthritis and Musculoskeletal and Skin Diseases [K24-AR049185-01, K24-AR2224-01A1, K24-AR02126-04]; Genentech; Human Genome Sciences FX The long-term followup study of the European Vasculitis Study Group trials was funded by a project grant from the European League Against Rheumatism. The Wegener's Granulomatosis Etanercept Trial was supported by grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Center for Research Resources, and the Office of Rare Diseases Research (1-U54RR01949, U54-AR057319, and U01-AR1874), the NIH (N01AR92240), the Office of Orphan Products, the Food and Drug Administration (FD-R-001652), the General Clinical Research Center (M01-RRO-00533 to Boston University, M01-RRO-0042 to The University of Michigan, MO1-RR-30 to Duke University, and M01-RRO-2719 to Johns Hopkins University School of Medicine), and the National Center for Research Resources/NIH. Dr. Suppiah's work was supported by the Rose Hellaby Medical Scholarship, New Zealand. Drs. Judge, Batra, Javaid, and Luqmani's work was supported by the Oxford National Institute for Health Research Biomedical Research Unit Musculoskeletal Research Group, University of Oxford. Dr. Jayne's work was supported by the Cambridge Biomedical Research Centre. Drs. Merkel, Stone, and St. Clair's work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grants K24-AR049185-01, K24-AR2224-01A1, and K24-AR02126-04).; Dr. McCune has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Genentech and has received research support from Genentech and Human Genome Sciences. NR 44 TC 46 Z9 46 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD APR PY 2011 VL 63 IS 4 BP 588 EP 596 DI 10.1002/acr.20433 PG 9 WC Rheumatology SC Rheumatology GA 748WD UT WOS:000289422700015 PM 21452269 ER PT J AU Hodi, FS AF Hodi, F. Stephen TI CTLA-4 to overcome immunological tolerance to melanoma SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY LA English DT Article; Proceedings Paper CT 7th International Congress of the Society-for-Melanoma-Research CY NOV 05, 2010 CL Sydney, AUSTRALIA SP Soc Melanoma Res DE cytotoxic T-Iymphocyte-associated antigen-4; immune regulation; immunotherapy; melanoma; monoclonal antibody ID CYTOTOXIC T-LYMPHOCYTE; TUMOR-INFILTRATING LYMPHOCYTES; STAGE-IV MELANOMA; METASTATIC MELANOMA; ANTIGEN-4 BLOCKADE; ANTIBODY BLOCKADE; MONOCLONAL-ANTIBODY; IMMUNE-RESPONSE; PHASE-I/II; AUTOIMMUNITY AB There has been much recent attention on immunotherapy for cancer due to the promising results of several randomized phase-III trials. The management of metastatic melanoma in particular is a significant clinical challenge, and it has long been a desired target of immunotherapies due to evidence of the importance of host immune responses. Cytotoxic T-Iymphocyte-associated antigen-4 (CTLA-4) serves as a negative regulator of immunity. Recent trials administering fully-human anti-CTLA-4 monoclonal antibodies to patients with melanoma have demonstrated survival benefits. However, treatment with anti-CTLA-4 antibodies is not without potential toxicities. Autoimmune side-effects, such as diarrhea, bowel inflammation and dermatitis, were the most commonly reported. To build upon the activity seen with anti-CTLA-4 antibodies, both in toxicity and efficacy profiles, there has been significant interest in investigating combinations with vaccination strategies. In recent trials, patients who were vaccinated with autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor, and were then infused with anti-CTLA-4 antibodies, demonstrated clinically-significant antitumor immunity without grade-3 or -4 toxicity in most patients. These data demonstrate how manipulation of immune regulation has produced patient benefits, and this area is a rich avenue for future investigation. C1 Dana Farber Canc Inst, Boston, MA 02115 USA. RP Hodi, FS (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM stephen_hodi@dfci.harvard.edu NR 34 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-7555 EI 1743-7563 J9 ASIA-PAC J CLIN ONCO JI Asia-Pac. J. Clin. Oncol. PD APR PY 2011 VL 7 SU 1 BP 14 EP 19 DI 10.1111/j.1743-7563.2011.01383.x PG 6 WC Oncology SC Oncology GA 749TG UT WOS:000289492200004 ER PT J AU Wang, ZC Li, Q Dai, XQ Montalbetti, N Li, S Cantiello, HF Chen, XZ AF Wang, Zuocheng Li, Q. Dai, X. -Q. Montalbetti, N. Li, S. Cantiello, H. F. Chen, X. -Z. TI Regulation of polycystin-2 by filamin SO BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE LA English DT Meeting Abstract C1 [Wang, Zuocheng; Li, Q.; Dai, X. -Q.; Li, S.; Chen, X. -Z.] Univ Alberta, Dept Physiol, Membrane Prot Res Grp, Edmonton, AB T6G 2M7, Canada. [Cantiello, H. F.] Massachusetts Gen Hosp, Dept Med, Renal Unit, Boston, MA 02114 USA. [Cantiello, H. F.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS PI OTTAWA PA 1200 MONTREAL ROAD, BUILDING M-55, OTTAWA, ON K1A 0R6, CANADA SN 0829-8211 J9 BIOCHEM CELL BIOL JI Biochem. Cell Biol. PD APR PY 2011 VL 89 IS 2 BP 273 EP 274 PG 2 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 745OF UT WOS:000289174100060 ER PT J AU Kop, WJ Seliger, SL Fink, JC Katz, R Odden, MC Fried, LF Rifkin, DE Sarnak, MJ Gottdiener, JS AF Kop, Willem J. Seliger, Stephen L. Fink, Jeffrey C. Katz, Ronit Odden, Michelle C. Fried, Linda F. Rifkin, Dena E. Sarnak, Mark J. Gottdiener, John S. TI Longitudinal Association of Depressive Symptoms with Rapid Kidney Function Decline and Adverse Clinical Renal Disease Outcomes SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID QUALITY-OF-LIFE; SERUM CYSTATIN-C; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR HEALTH; DIALYSIS PATIENTS; OLDER-ADULTS; RISK-FACTORS; HEMODIALYSIS-PATIENTS; PSYCHOLOGICAL-FACTORS; REACTIVE PROTEIN AB Background and objectives Depression is a risk indicator for adverse outcomes in dialysis patients, but its prognostic impact in individuals who are not yet on dialysis is unknown. This study examines whether depressive symptoms are longitudinally associated with renal function decline, new-onset chronic kidney disease (CKD), ESRD, or hospitalization with acute kidney injury (AKI). Design, setting, participants, & measurements Depressive symptoms were measured in a longitudinal cohort study with the 10-item Centers for Epidemiologic Studies Depression scale using a previously validated cut-off value (>= 8). CKD at study entry and during follow-up was defined as an estimated GFR (eGFR) < 60 ml/min per m(2). Outcomes were rapid decline in eGFR (> 3 ml/min per m(2) per year), new-onset CKD, ESRD (U.S. Renal Data System-based), and AKI (based on adjudicated medical record review). The median follow-up duration was 10.5 years. Results Depressed participants (21.2%) showed a higher prevalence of CKD at baseline compared with non-depressed participants in multivariable analysis. Depression was associated with a subsequent risk of rapid decline in eGFR, incident ESRD, and AKI, but not incident CKD in unadjusted models. In multivariable analyses, only associations of depressive symptoms with AKI remained significant. Conclusions Elevated depressive symptoms are associated with subsequent adverse renal disease outcomes. The depression-related elevated risk of AKI was independent of traditional renal disease risk factors and may in part be explained by the predictive value of depression for acute coronary syndromes and heart failure hospitalizations that can be complicated by AM. Clin J Am Soc Nephrol 6: 834-844, 2011. doi: 10.2215/CJN.03840510 C1 [Kop, Willem J.] Tilburg Univ, Dept Med Psychol & Neuropsychol, Ctr Res Psychol Somat Dis, NL-5000 LE Tilburg, Netherlands. [Kop, Willem J.; Seliger, Stephen L.; Fink, Jeffrey C.; Gottdiener, John S.] Univ Maryland, Dept Med, Baltimore, MD 21201 USA. [Katz, Ronit] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Odden, Michelle C.] Univ Calif Berkeley, Dept Epidemiol, Berkeley, CA 94720 USA. [Fried, Linda F.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Rifkin, Dena E.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Rifkin, Dena E.] Vet Affairs Med Ctr, San Diego, CA 92161 USA. [Sarnak, Mark J.] Tufts Med Ctr, Dept Med, Boston, MA USA. RP Kop, WJ (reprint author), Tilburg Univ, Dept Med Psychol & Neuropsychol, Ctr Res Psychol Somat Dis, POB 90153, NL-5000 LE Tilburg, Netherlands. EM w.j.kop@uvt.nl OI Fink, Jeffrey/0000-0002-5622-5052 FU National Heart, Lung, and Blood institute [N01-HC-85079, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, U01 HL080295, R0-1 HL079376]; [CHS RO1 AG 027002] FX The first author, in collaboration with the Cardiovascular Heath Study coordinating center, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. This research was supported by Contracts N01-HC-85079 through N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, Grant U01 HL080295, and Grant R0-1 HL079376 from the National Heart, Lung, and Blood institute, with additional contributions from the National Institute of Neurological Disorders and Stroke, the American Heart Association, and Grant CHS RO1 AG 027002 supporting the CHS Renal Working Group. A full list of principal CHS investigators and institutions can be found at http://www.chs-nhlbi.org/pi.htm. NR 58 TC 20 Z9 20 U1 1 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2011 VL 6 IS 4 BP 834 EP 844 DI 10.2215/CJN.03840510 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 746DU UT WOS:000289223600022 PM 21393483 ER PT J AU Bellenger, J Bellenger, S Bataille, A Massey, KA Nicolaou, A Rialland, M Tessier, C Kang, JX Narce, M AF Bellenger, Jerome Bellenger, Sandrine Bataille, Amandine Massey, Karen A. Nicolaou, Anna Rialland, Mickael Tessier, Christian Kang, Jing X. Narce, Michel TI High Pancreatic n-3 Fatty Acids Prevent STZ-Induced Diabetes in Fat-1 Mice: Inflammatory Pathway Inhibition SO DIABETES LA English DT Article ID LOW-DOSE STREPTOZOTOCIN; PRORESOLVING LIPID MEDIATORS; TUMOR NECROSIS FACTOR; NF-KAPPA-B; TRANSGENIC MICE; BETA-CELLS; INDUCED HYPERGLYCEMIA; GENE-EXPRESSION; TNF-ALPHA; OMEGA-3-FATTY-ACIDS AB OBJECTIVE-Because of confounding factors, the effects of dietary n-3 polyunsaturated fatty acids (PUFA) on type 1 diabetes remain to be clarified. We therefore evaluated whether fat-1 transgenic mice, a well-controlled experimental model endogenously synthesizing n-3 PUFA, were protected against streptozotocin (STZ)-induced diabetes. We then aimed to elucidate the in vivo response at the pancreatic level. RESEARCH DESIGN AND METHODS-beta-Cell destruction was produced by multiple low-doses STZ (MLD-STZ). Blood glucose level, plasma insulin level, and plasma lipid analysis were then performed. Pancreatic mRNA expression of cytokines, the monocyte chemoattractant protein, and GLUT2 were evaluated as well as pancreas nuclear factor (NF)-kappa B p65 and inhibitor of kappa B (I kappa B) protein expression. Insulin and cleaved caspase-3 immunostaining and lipidomic analysis were performed in the pancreas. RESULTS-STZ-induced fat-1 mice did not develop hyperglycemia compared with wild-type mice, and beta-cell destruction was prevented as evidenced by lack of histological pancreatic damage or reduced insulin level. The prevention of beta-cell destruction was associated with no proinflammatory cytokine induction (tumor necrosis factor-alpha, interleukin-1 beta, inducible nitric oxide synthase) in the pancreas, a decreased NF-kappa B, and increased I kappa B pancreatic protein expression. In the fat-1-treated mice, proinflammatory arachidonic-derived mediators as prostaglandin E-2 and 12-hydroxyeicosatetraenoic acid were decreased and the anti-inflammatory lipoxin A(4) was detected. Moreover, the 18-hydroxyeicosapentaenoic acid, precursor of the anti-inflammatory resolvin E1, was highly increased. CONCLUSIONS-Collectively, these findings indicate that fat-1 mice were protected against MLD-STZ-induced diabetes and pointed out for the first time in vivo the beneficial effects of n-3 PUFA at the pancreatic level, on each step of the development of the pathology-inflammation, beta-cell damage-through cytokine response and lipid mediator production. Diabetes 60:1090-1099, 2011 C1 [Bellenger, Jerome; Bellenger, Sandrine; Rialland, Mickael; Tessier, Christian; Narce, Michel] Univ Bourgogne, UFR Sci Vie Terre & Environm, Dijon, France. [Bellenger, Jerome; Bellenger, Sandrine; Rialland, Mickael; Tessier, Christian; Narce, Michel] Univ Bourgogne, Fac Sci Gabriel, UMR Physiopathol Dyslipidemies 866, Dijon, France. [Bataille, Amandine] Fac Med & Pharm Dijon, UMR 866, Imagerie Cellulaire Histol IFR100, Dijon, France. [Massey, Karen A.; Nicolaou, Anna] Univ Bradford, Sch Pharm, Bradford BD7 1DP, W Yorkshire, England. [Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA USA. RP Narce, M (reprint author), Univ Bourgogne, UFR Sci Vie Terre & Environm, Dijon, France. EM michel.narce@u-bourgogne.fr OI Nicolaou, Anna/0000-0002-1314-413X FU French Ministry of Education and Research, INSERM; Region Bourgogne; International Foundation for the Promotion of Nutrition Research and Nutrition Education (ISFE) FX J.B. received support from the French Ministry of Education and Research, INSERM, and from the Region Bourgogne. This work was also partially supported by a grant from the International Foundation for the Promotion of Nutrition Research and Nutrition Education (ISFE). NR 51 TC 61 Z9 62 U1 4 U2 15 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD APR PY 2011 VL 60 IS 4 BP 1090 EP 1099 DI 10.2337/db10-0901 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 749UK UT WOS:000289496100005 PM 21330635 ER PT J AU Kim, W Doyle, ME Liu, Z Lao, QZ Shin, YK Carlson, OD Kim, HS Thomas, S Napora, JK Lee, EK Moaddel, R Wang, Y Maudsley, S Martin, B Kulkarni, RN Egan, JM AF Kim, Wook Doyle, Maire E. Liu, Zhuo Lao, Qizong Shin, Yu-Kyong Carlson, Olga D. Kim, Hee Seung Thomas, Sam Napora, Joshua K. Lee, Eun Kyung Moaddel, Ruin Wang, Yan Maudsley, Stuart Martin, Bronwen Kulkarni, Rohit N. Egan, Josephine M. TI Cannabinoids Inhibit Insulin Receptor Signaling in Pancreatic beta-Cells SO DIABETES LA English DT Article ID CB1 RECEPTORS; ENDOCANNABINOID DYSREGULATION; ENERGY-BALANCE; FOOD-INTAKE; IN-VIVO; MICE; SECRETION; GLUCOSE; RATS; OBESITY AB OBJECTIVE-Optimal glucose homeostasis requires exquisitely precise adaptation of the number of insulin-secreting beta-cells in the islets of Langerhans. Insulin itself positively regulates beta-cell proliferation in an autocrine manner through the insulin receptor (IR) signaling pathway. It is now coining to light that cannabinoid 1 receptor (CB1R) agonism/antagonism influences insulin action in insulin-sensitive tissues. However, the cells on which the CB1Rs are expressed and their function in islets have not been firmly established. We undertook the current study to investigate if intraislet endogenous cannabinoids (ECs) regulate beta-cell proliferation and if they influence insulin action. RESEARCH DESIGN AND METHODS-We measured EC production in isolated human and mouse islets and beta-cell line in response to glucose and KC1. We evaluated human and mouse islets, several beta-cell lines, and CB1R-null (CB1R(-/-)) mice for the presence of a fully functioning EC system. We investigated if ECs influence beta-cell physiology through regulating insulin action and demonstrated the therapeutic potential of manipulation of the EC system in diabetic (db/db) mice. RESULTS-ECs are generated within beta-cells, which also express CB1Rs that are fully functioning when activated by ligands. Genetic and pharmacologic blockade of CB1R results in enhanced IR signaling through the insulin receptor substrate 2-AKT pathway in beta-cells and leads to increased beta-cell proliferation and mass. CB1R antagonism in db/db mice results in reduced blood glucose and increased beta-cell proliferation and mass, coupled with enhanced IR signaling in beta-cells. Furthermore, CB1R activation impedes insulin-stimulated IR autophosphorylation on beta-cells in a G alpha(i)-dependent manner. CONCLUSIONS-These findings provide direct evidence for a functional interaction between CB1R and IR signaling involved in the regulation of beta-cell proliferation and will serve as a basis for developing new therapeutic interventions to enhance beta-cell function and proliferation in diabetes. Diabetes 60:1198-1209, 2011 C1 [Kim, Wook; Liu, Zhuo; Lao, Qizong; Shin, Yu-Kyong; Carlson, Olga D.; Kim, Hee Seung; Thomas, Sam; Napora, Joshua K.; Lee, Eun Kyung; Moaddel, Ruin; Wang, Yan; Maudsley, Stuart; Martin, Bronwen; Egan, Josephine M.] NIA, NIH, Baltimore, MD 21224 USA. [Doyle, Maire E.] Johns Hopkins Med Inst, Div Endocrinol, Baltimore, MD 21205 USA. [Kulkarni, Rohit N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Islet Cell Biol & Regenerat Med, Boston, MA 02115 USA. [Kulkarni, Rohit N.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Egan, JM (reprint author), NIA, NIH, Baltimore, MD 21224 USA. EM eganj@grc.nia.nih.gov FU National Institute on Aging (NIA)/NIH; NIH [R01-DK-67536, 68721]; JDRF [26-2008-864] FX This work was supported by the Intramural Research Program of the National Institute on Aging (NIA)/NIH. R.N.K. is supported by NIH R01-DK-67536 and 68721. M.E.D. is supported by JDRF 26-2008-864. NR 47 TC 49 Z9 49 U1 0 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD APR PY 2011 VL 60 IS 4 BP 1198 EP 1209 DI 10.2337/db10-1550 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 749UK UT WOS:000289496100015 PM 21346174 ER PT J AU Hinault, C Kawamori, D Liew, CW Maier, B Hu, JA Keller, SR Mirmira, RG Scrable, H Kulkarni, RN AF Hinault, Charlotte Kawamori, Dan Liew, Chong Wee Maier, Bernhard Hu, Jiang Keller, Susanna R. Mirmira, Raghavendra G. Scrable, Heidi Kulkarni, Rohit N. TI Delta 40 Isoform of p53 Controls beta-Cell Proliferation and Glucose Homeostasis in Mice SO DIABETES LA English DT Article ID FOXO TRANSCRIPTION FACTORS; INSULIN-RESISTANCE; GROWTH-FACTOR; DIABETES-MELLITUS; CYCLE PROGRESSION; PANCREATIC-CELLS; WILD-TYPE; IN-VIVO; EXPRESSION; REGENERATION AB OBJECTIVE-Investigating the dynamics of pancreatic beta-cell mass is critical for developing strategies to treat both type 1 and type 2 diabetes. p53, a key regulator of the cell cycle and apoptosis, has mostly been a focus of investigation as a tumor suppressor. Although p53 alternative transcripts can modulate p53 activity, their functions are not fully understood. We hypothesized that beta-cell proliferation and glucose homeostasis were controlled by Delta 40p53, a p53 isoform lacking the transactivation domain of the full-length protein that modulates total p53 activity and regulates organ size and life span in mice. RESEARCH DESIGN AND METHODS-We phenotyped metabolic parameters in Delta 40p53 transgenic (p44tg) mice and used quantitative RT-PCR, Western blotting, and immunohistochemistry to examine beta-cell proliferation. RESULTS-Transgenic mice with an ectopic p,53 gene encoding Delta 40p53 developed hypoinsulinemia and glucose intolerance by 3 months of age, which worsened in older mice and led to overt diabetes and premature death from similar to 14 months of age. Consistent with a dramatic decrease in beta-cell mass and reduced beta-cell proliferation, lower expression of cyclin D2 and pancreatic duodenal homeobox-1, two key regulators of proliferation, was observed, whereas expression of the cell cycle inhibitor p21, a p53 target gene, was increased. CONCLUSIONS-These data indicate a significant and novel role for Delta 40p53 in beta-ell proliferation with implications for the development of age-dependent diabetes. Diabetes 60:1210-1222, 2011 C1 [Hinault, Charlotte; Kawamori, Dan; Liew, Chong Wee; Hu, Jiang; Kulkarni, Rohit N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Joslin Diabet Ctr,Res Div, Boston, MA 02115 USA. [Hinault, Charlotte; Kawamori, Dan; Liew, Chong Wee; Hu, Jiang; Kulkarni, Rohit N.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA. [Maier, Bernhard; Mirmira, Raghavendra G.] Indiana Univ Sch Med, Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN USA. [Keller, Susanna R.; Scrable, Heidi] Mayo Clin, Kogod Ctr Aging, Rochester, MN USA. RP Kulkarni, RN (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Joslin Diabet Ctr,Res Div, Boston, MA 02115 USA. EM rohit.kulkarni@joslin.harvard.edu OI hinault, charlotte/0000-0002-3588-039X FU National Institutes of Health (NIH) [RO1-DK-67536, R21-RR-024905, RO1-AG-026094, RO1-DK-60581, 1RL9-EB-008539-01]; Ellison Medical Research Foundation; Manpei Suzuki Diabetes Foundation, Japan; Juvenile Diabetes Research Foundation; [1-K99-DK-090210-01] FX This work was supported in part by National Institutes of Health (NIH) grants RO1-DK-67536 and R21-RR-024905 to R.N.K., RO1-AG-026094 to H.S., and RO1-DK-60581 to R.G.M. C.H. was supported by an NIH Training Grant (1RL9-EB-008539-01) (SysCODE). H.S. was also supported by a Senior Scholar in Aging award from the Ellison Medical Research Foundation. D.K. is the recipient of a Research Fellowship (Manpei Suzuki Diabetes Foundation, Japan) and a Juvenile Diabetes Research Foundation Postdoctoral Fellowship. C.W.L. is supported by 1-K99-DK-090210-01. NR 50 TC 22 Z9 22 U1 1 U2 4 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD APR PY 2011 VL 60 IS 4 BP 1210 EP 1222 DI 10.2337/db09-1379 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 749UK UT WOS:000289496100016 PM 21357466 ER PT J AU Hivert, MF Jablonski, KA Perreault, L Saxena, R McAteer, JB Franks, PW Hamman, RF Kahn, SE Haffner, S Meigs, JB Altshuler, D Knowler, WC Florez, JC AF Hivert, Marie-France Jablonski, Kathleen A. Perreault, Leigh Saxena, Richa McAteer, Jarred B. Franks, Paul W. Hamman, Richard F. Kahn, Steven E. Haffner, Steven Meigs, James B. Altshuler, David Knowler, William C. Florez, Jose C. CA DIAGRAM Consortium Diabet Prevention Program Res Grp TI Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program SO DIABETES LA English DT Article ID GENOME-WIDE ASSOCIATION; LIFE-STYLE INTERVENTION; INSULIN-RESISTANCE; COMMON VARIANTS; SUSCEPTIBILITY LOCI; RISK-FACTORS; GLUCOSE; RECLASSIFICATION; POLYMORPHISMS; MELLITUS AB OBJECTIVE Over 30 loci have been associated with risk of type 2 diabetes at genome-wide statistical significance. Genetic risk scores (GRSs) developed from these loci predict diabetes in the general population. We tested if a GRS based on an updated list of 34 type 2 diabetes-associated loci predicted progression to diabetes or regression toward normal glucose regulation (NGR) in the Diabetes Prevention Program (DPP). RESEARCH DESIGN AND METHODS We genotyped 34 type 2 diabetes-associated variants in 2,843 DPP participants at high risk of type 2 diabetes from five ethnic groups representative of the U.S. population, who had been randomized to placebo, metformin, or lifestyle intervention. We built a GRS by weighting each risk allele by its reported effect size on type 2 diabetes risk and summing these values. We tested its ability to predict diabetes incidence or regression to NGR in models adjusted for age, sex, ethnicity, waist circumference, and treatment assignment. RESULTS lit multivariate-adjusted models, the GRS was significantly associated with increased risk of progression to diabetes (hazard ratio [HR] = 1.02 per risk allele [95% CI 1.00-1.05]; P = 0.03) and a lower probability of regression to NGR (HR = 0.95 per risk allele [95% CI 0.93-0.981; P < 0.0001). At baseline, a higher GRS was associated with a lower insulinogenic index (P < 0.001), confirming an impairment in beta-cell function. We detected no significant interaction between GRS and treatment, but the lifestyle intervention was effective in the highest quartile of ORS (P < 0.0001). CONCLUSIONS A high GRS is associated with increased risk of developing diabetes and lower probability of returning to NGR in high-risk individuals, but a lifestyle intervention attenuates this risk. Diabetes 60:1340-1348, 2011 C1 [Saxena, Richa; McAteer, Jarred B.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Hivert, Marie-France] Univ Sherbrooke, Dept Med, Div Endocrinol, Sherbrooke, PQ J1K 2R1, Canada. [Jablonski, Kathleen A.] George Washington Univ, Ctr Biostat, Rockville, MD USA. [Perreault, Leigh] Univ Colorado Denver Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Aurora, CO USA. [Saxena, Richa; McAteer, Jarred B.; Florez, Jose C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. [Franks, Paul W.] Umea Univ Hosp, Dept Publ Hlth & Clin Med, Div Med, Genet Epidemiol & Clin Res Grp, S-90185 Umea, Sweden. [Franks, Paul W.] Lund Univ, Ctr Diabet, Dept Clin Sci, Malmo, Sweden. [Hamman, Richard F.] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA. [Haffner, Steven] Baylor Coll Med, Houston, TX 77030 USA. [Meigs, James B.] Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA. [Meigs, James B.; Altshuler, David; Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Altshuler, David; Florez, Jose C.] Massachusetts Gen Hosp, Dept Med, Diabet Res Ctr, Diabet Unit, Boston, MA 02114 USA. [Knowler, William C.] NIDDKD, Diabet Epidemiol & Clin Res Sect, Phoenix, AZ USA. RP Florez, JC (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. EM jcflorez@partners.org RI Altshuler, David/A-4476-2009; Boehm, Bernhard/F-8750-2015; OI Altshuler, David/0000-0002-7250-4107; Griffin, Simon/0000-0002-2157-4797; Franks, Paul/0000-0002-0520-7604; Kahn, Steven/0000-0001-7307-9002 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health; NIDDK [K24 DK080140]; Indian Health Service; National Center for Research Resources; Department of Veterans Affairs; Massachusetts General Hospital; Doris Duke Charitable Foundation; Swedish Research Council; Novo Nordisk; Swedish Diabetes Association; Swedish Heart-Lung Foundation; GlaxoSmithKline; [R01 DK072041] FX The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design and conduct of the study, and the collection, management, analysis, and interpretation of the data. The Southwestern American Indian Centers were supported directly by the NIDDK and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources, and the Department of Veterans Affairs supported data collection at many of the clinical centers. Funding for data collection and participant support was also provided by the Office of Research on Minority Health, the National Institute of Child Health and Human Development, the National Institute on Aging, the Office of Research on Women's Health, the Centers for Disease Control and Prevention, and the American Diabetes Association. This research was also supported, in part, by the intramural research program of the NIDDK.; This work was also funded by R01 DK072041 (to D.A., J.C.F., and K.A.J.). J.C.F. is also supported by Massachusetts General Hospital and a Clinical Scientist Development Award by the Doris Duke Charitable Foundation. This work was partially supported by a Doris Duke Charitable Foundation Distinguished Scientist Clinical Award to D.A. J.B.Me. is supported by NIDDK K24 DK080140. P.W.F. was supported by the Swedish Research Council, Novo Nordisk, the Swedish Diabetes Association, and the Swedish Heart-Lung Foundation. J.B.Me. currently has a research grant from GlaxoSmithKline and serves on a consultancy board for Interleukin Genetics. J.C.F. has received consulting honoraria from Daiichi-Sankyo and AstraZeneca. NR 33 TC 77 Z9 78 U1 0 U2 12 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD APR PY 2011 VL 60 IS 4 BP 1340 EP 1348 DI 10.2337/db10-1119 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 749UK UT WOS:000289496100030 PM 21378175 ER PT J AU Wilson, PWF D'Agostino, RB Fox, CS Sullivan, LM Meigs, JB AF Wilson, Peter W. F. D'Agostino, Ralph B. Fox, Caroline S. Sullivan, Lisa M. Meigs, James B. TI Type 2 diabetes risk in persons with dysglycemia: The Framingham Offspring Study SO DIABETES RESEARCH AND CLINICAL PRACTICE LA English DT Article DE Dysglycemia; Type 2 diabetes mellitus; Prospective cohort study; Risk prediction; Metabolic syndrome ID GLUCOSE-TOLERANCE TEST; INSULIN-RESISTANCE; METABOLIC SYNDROME; FASTING GLUCOSE; LIFE-STYLE; MELLITUS; PREDICTION; ATHEROSCLEROSIS; ADULTS AB Aims: Detection of risk of type 2 diabetes mellitus (T2DM) among adults with dysglycemia. Methods: We used a nested case-cohort prospective design to estimate risk of new diabetes (diabetes treatment or FPG >= 7.0 mmol/L) among 1004 Framingham Heart Study Offspring with baseline dysglycemia [ fasting plasma glucose (FPG) 5.4-6.9 mmol/L and/or 2-h post glucose load level 7.8-11.0 mmol/L]. Using clinical characteristics previously shown to predict incident T2DM, we used logistic regression to estimate odds ratios (OR), p-values for predictors, and assessment of model discrimination. Results: At the end of 7 years follow-up there were 118 incident T2DM cases. In a model that included age, sex, elevated blood pressure or blood pressure treatment, lipid-lowering treatment and elevated triglycerides, we found the following additional characteristics to be independently associated with new T2DM: parental history of diabetes (OR 2.28, p = 0.004); excess adiposity (BMI >= 30 kg/m(2) or waist circumference >= 101.6 cm) (OR 2.04, p = 0.0005), and low HDL-C [<1.0 (men) or <1.3 mmol/L (women)] (OR 2.77, p < 0.0001). The multivariable C-statistic for this model was 0.701, and with glycemic category information included, c = 0.751. Conclusions: The key non-glycemic traits that predicted later T2DM in adults with dysglycemia were parental history of diabetes, excess adiposity and low HDL-C. (C) 2010 Published by Elsevier Ireland Ltd. C1 [Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. [Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA. [Wilson, Peter W. F.] Emory Univ, Sch Med, EPICORE, Atlanta, GA 30322 USA. [Wilson, Peter W. F.] Atlanta VAMC Epidemiol & Genet Sect, Atlanta, GA 30306 USA. [D'Agostino, Ralph B.] Boston Univ, Dept Math, Boston, MA 02215 USA. [Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Sullivan, Lisa M.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. RP Meigs, JB (reprint author), Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA. EM jmeigs@partners.org RI Library, Woodruff Health/A-6096-2012; OI Sullivan, Lisa/0000-0003-0726-7149 FU NIDDK NIH HHS [K24 DK080140-03, K24 DK080140] NR 14 TC 6 Z9 6 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8227 J9 DIABETES RES CLIN PR JI Diabetes Res. Clin. Pract. PD APR PY 2011 VL 92 IS 1 BP 124 EP 127 DI 10.1016/j.diabres.2010.12.024 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 750OR UT WOS:000289558300027 PM 21242014 ER PT J AU Cavanagh, SR Urry, HL Shin, LM AF Cavanagh, Sarah R. Urry, Heather L. Shin, Lisa M. TI Mood-Induced Shifts in Attentional Bias to Emotional Information Predict Ill- and Well-Being SO EMOTION LA English DT Article DE attentional bias; emotion induction ID SELECTIVE ATTENTION; VISUAL-ATTENTION; POSITIVE MOOD; TRAIT ANXIETY; THREAT; DISENGAGEMENT; VULNERABILITY; PHYSIOLOGY; STIMULI; STATE AB Previous research has suggested that biased attention toward emotional (typically threatening) stimuli contributes to ill-being (e.g., high levels of anxiety), but its contribution to well-being is less clear. The researchers assessed naturalistic shifts in attentional bias toward threatening and pleasant schematic face cues in response to five induced mood states in college students. They also assessed state anxiety and satisfaction with life concurrently and 3 weeks later. Controlling for concurrent anxiety, a fear-induced shift in attention to threatening cues was associated with increased levels of later anxiety. Controlling for concurrent life satisfaction, a happiness-induced shift in attention to emotional cues (both threatening and pleasant) was associated with increased levels of later life satisfaction. These results suggest that mood-induced changes in deployment of attention to emotional information may accumulate in ways that impact psychological functioning, yet these effects depend on mood state and the emotional cues afforded by the context. C1 [Cavanagh, Sarah R.] Assumption Coll, Dept Psychol, Worcester, MA 01609 USA. [Cavanagh, Sarah R.; Urry, Heather L.; Shin, Lisa M.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA. [Shin, Lisa M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Shin, Lisa M.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Cavanagh, SR (reprint author), Assumption Coll, Dept Psychol, 500 Salisbury St, Worcester, MA 01609 USA. EM sarah.cavanagh@alum.bu.edu NR 30 TC 3 Z9 4 U1 3 U2 16 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1528-3542 J9 EMOTION JI Emotion PD APR PY 2011 VL 11 IS 2 BP 241 EP 248 DI 10.1037/a0022572 PG 8 WC Psychology, Experimental SC Psychology GA 746UA UT WOS:000289272000004 PM 21500893 ER PT J AU Higgins, A Zeddies, T Pearson, SD AF Higgins, Aparna Zeddies, Timothy Pearson, Steven D. TI Measuring The Performance Of Individual Physicians By Collecting Data From Multiple Health Plans: The Results Of A Two-State Test SO HEALTH AFFAIRS LA English DT Article ID UNITED-STATES; CARE; PROJECT; SAFETY AB Quality measurement and reporting have emerged as important tools that providers, health plans, and other stakeholders can use to identify gaps in quality and focus resources on improving care. Yet identifying, measuring, and evaluating the care that physicians and other health care providers deliver is complicated by limited data, privacy concerns, and the challenge of trying to compare data from diverse sources. This article describes an effort to pilot-test in Florida and Colorado a consistent approach to individual physician performance measurement using data compiled from multiple health plans. Our approach could be used as the basis for making comparable performance information available nationwide. Additional efforts are needed to address key issues, including ways to effectively engage providers in the use of performance information. C1 [Higgins, Aparna] Amer Hlth Insurance Plans, Washington, DC 20004 USA. [Zeddies, Timothy] Prior Hlth, Grand Rapids, MI USA. [Pearson, Steven D.] Massachusetts Gen Hosp, Inst Clin & Econ Review, Boston, MA 02114 USA. RP Higgins, A (reprint author), Amer Hlth Insurance Plans, Washington, DC 20004 USA. EM ahiggins@ahip.org FU Robert Wood Johnson Foundation FX The project was supported by a grant from the Robert Wood Johnson Foundation to America's Health Insurance Plans Foundation as part of the High-Value Health Care Project, an initiative of the Quality Alliance Steering Committee. NR 24 TC 7 Z9 7 U1 2 U2 7 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD APR PY 2011 VL 30 IS 4 BP 673 EP 681 DI 10.1377/hlthaff.2011.0070 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 746HE UT WOS:000289233400019 PM 21471488 ER PT J AU Werner, RM Kolstad, JT Stuart, EA Polsky, D AF Werner, Rachel M. Kolstad, Jonathan T. Stuart, Elizabeth A. Polsky, Daniel TI The Effect Of Pay-For-Performance In Hospitals: Lessons For Quality Improvement SO HEALTH AFFAIRS LA English DT Article ID OF-CARE; HEALTH-CARE; MORTALITY; OUTCOMES; STATE AB The payment approach known as "pay-for-performance" has been widely adopted with the aim of improving the quality of health care. Nonetheless, little is known about how to use the approach most effectively to improve care. We examined the effects in 260 hospitals of a pay-for-performance demonstration project carried out by the Centers for Medicare and Medicaid Services in partnership with Premier Inc., a nationwide hospital system. We compared these results to those of a control group of 780 hospitals not in the demonstration project. The performance of the hospitals in the project initially improved more than the performance of the control group: More than half of the pay-for-performance hospitals achieved high performance scores, compared to fewer than a third of the control hospitals. However, after five years, the two groups' scores were virtually identical. Improvements were largest among hospitals that were eligible for larger bonuses, were well financed, or operated in less competitive markets. These findings suggest that tailoring pay-for-performance programs to hospitals' specific situations could have the greatest effect on health care quality. C1 [Werner, Rachel M.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. [Werner, Rachel M.; Polsky, Daniel] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kolstad, Jonathan T.] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA. [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Werner, RM (reprint author), Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu OI Stuart, Elizabeth/0000-0002-9042-8611 FU Agency for Healthcare Research and Quality [R01 HS018409-01]; Department of Veterans Affairs FX This research was supported by a grant from the Agency for Healthcare Research and Quality (R01 HS018409-01). Rachel Werner is supported in part by a Department of Veterans Affairs Health Services Research and Development Career Development Award. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States government. NR 36 TC 80 Z9 81 U1 4 U2 28 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD APR PY 2011 VL 30 IS 4 BP 690 EP 698 DI 10.1377/hlthaff.2010.1277 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 746HE UT WOS:000289233400021 PM 21471490 ER PT J AU Fowler, FJ Levin, CA Sepucha, KR AF Fowler, Floyd J., Jr. Levin, Carrie A. Sepucha, Karen R. TI Informing And Involving Patients To Improve The Quality Of Medical Decisions SO HEALTH AFFAIRS LA English DT Article ID BREAST-CANCER; INSTRUMENTS AB Good-quality care requires that procedures, treatments, and tests be not only medically appropriate, but also desired by informed patients. Current evidence shows that most medical decisions are made by physicians with little input from patients. This article describes issues surrounding informed patient decision making and the steps necessary to improve the way decisions are made. Creating incentives for providers and health care organizations to inform patients and incorporate patients' goals into decisions is critical. Patient surveys are needed to monitor the quality of decision making. Health information technology can help by collecting information from patients about their symptoms, how well they understand their options, and what is important to them, and sharing that information with providers. We review public and private developments that could facilitate the development of tools and methods to improve patient-centered care. C1 [Fowler, Floyd J., Jr.; Levin, Carrie A.] Fdn Informed Med Decis Making, Boston, MA 02108 USA. [Sepucha, Karen R.] Massachusetts Gen Hosp, Hlth Decis Sci Ctr, Boston, MA 02114 USA. [Sepucha, Karen R.] Harvard Univ, Sch Med, Boston, MA USA. RP Fowler, FJ (reprint author), Fdn Informed Med Decis Making, Boston, MA 02108 USA. EM fjfowler@fimdm.org FU Foundation for Informed Medical Decision Making FX Floyd Fowler and Carrie Levin are employed by the not-for-profit Foundation for Informed Medical Decision Making. Karen Sepucha has research grants from the foundation. Through a commercial agreement with Health Dialog, a for-profit company, decision aids created jointly by Health Dialog and the foundation are distributed as part of services provided through health plans and employers to patients facing medical decisions. NR 20 TC 43 Z9 43 U1 0 U2 6 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD APR PY 2011 VL 30 IS 4 BP 699 EP 706 DI 10.1377/hlthaff.2011.0003 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 746HE UT WOS:000289233400022 PM 21471491 ER PT J AU Trivedi, AN Grebla, RC Wright, SM Washington, DL AF Trivedi, Amal N. Grebla, Regina C. Wright, Steven M. Washington, Donna L. TI Despite Improved Quality Of Care In The Veterans Affairs Health System, Racial Disparity Persists For Important Clinical Outcomes SO HEALTH AFFAIRS LA English DT Article ID ETHNIC DISPARITIES; BLOOD-PRESSURE; MANAGED CARE; RACE; TRANSFORMATION; DISEASE; TRENDS AB Both government and private health care systems have engaged in efforts to improve quality, but the effect of these initiatives on racial and ethnic disparities has not been well studied. In the decade following an organizational transformation, the Veterans Affairs (VA) health care system achieved substantial improvements in quality of care with minimal racial disparities for most process-of-care measures, such as rates of cholesterol screenings. However, in our study we observed a striking disconnect between high levels of performance on widely used process measures and modest levels of improvement in clinical outcomes, such as control of blood pressure, blood glucose, and cholesterol levels. We also observed a gap in clinical outcomes of as much as nine percentage points between African American veterans and white veterans. Almost all of the disparity in outcomes in the VA was explained by within-facility disparity, which suggests that VA medical centers need to measure and address racial gaps in care for their patient populations. Moreover, because cardiovascular disease and diabetes are major contributors to racial disparities in life expectancy, the findings of this study and others underscore the urgency of focused efforts to improve intermediate outcomes among African Americans in the VA and other settings. C1 [Trivedi, Amal N.] Brown Univ, Providence Vet Affairs VA Med Ctr, Providence, RI 02912 USA. [Trivedi, Amal N.; Grebla, Regina C.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA. [Wright, Steven M.] VA Off Qual & Performance, Washington, DC USA. [Washington, Donna L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Washington, Donna L.] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA. RP Trivedi, AN (reprint author), Brown Univ, Providence Vet Affairs VA Med Ctr, Providence, RI 02912 USA. EM Amal_Trivedi@brown.edu FU Veterans Affairs Health Services Research and Development Service [CDA-2, IIR IAA-08-087]; Robert Wood Johnson Foundation FX Early versions of this article were presented at the VA Equity Research Meeting, Boston, Massachusetts, September 13, 2010; and the VA Health Services Research and Development Annual Meeting, Washington, D. C., February 17, 2011. This research was supported by a Career Development Award (CDA-2) (Amal Trivedi) and Investigator Initiated Award (IIR IAA-08-087) (Donna Washington) from the Veterans Affairs Health Services Research and Development Service and by a Physician Faculty Scholars Award from the Robert Wood Johnson Foundation (Amal Trivedi). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. The authors thank Kenneth Kizer for helpful comments on a previous version. NR 32 TC 59 Z9 59 U1 0 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD APR PY 2011 VL 30 IS 4 BP 707 EP 715 DI 10.1377/hlthaff.2011.0074 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 746HE UT WOS:000289233400023 PM 21471492 ER PT J AU Di Bisceglie, AM Stoddard, AM Dienstag, JL Shiffman, ML Seeff, LB Bonkovsky, HL Morishima, C Wright, EC Snow, KK Lee, WM Fontana, RJ Morgan, TR Ghany, MG AF Di Bisceglie, Adrian M. Stoddard, Anne M. Dienstag, Jules L. Shiffman, Mitchell L. Seeff, Leonard B. Bonkovsky, Herbert L. Morishima, Chihiro Wright, Elizabeth C. Snow, Kristin K. Lee, William M. Fontana, Robert J. Morgan, Timothy R. Ghany, Marc G. CA HALT-C Trial Grp TI Excess Mortality in Patients with Advanced Chronic Hepatitis C Treated with Long-Term Peginterferon SO HEPATOLOGY LA English DT Article ID COMPENSATED CIRRHOSIS; CLINICAL-OUTCOMES; NATURAL-HISTORY; VIRUS-INFECTION; PLUS RIBAVIRIN; THERAPY; INTERFERON; MANAGEMENT; MORBIDITY; ALPHA-2B AB Chronic hepatitis C virus infection can cause chronic liver disease, cirrhosis and liver cancer. The Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial was a prospective, randomized controlled study of long-term, low-dose peginterferon therapy in patients with advanced chronic hepatitis C who failed to respond to a previous course of optimal antiviral therapy. The aim of this follow-up analysis is to describe the frequency and causes of death among this cohort of patients. Deaths occurring during and after the HALT-C Trial were reviewed by a committee of investigators to determine the cause of death and to categorize each death as liver-or nonliver-related and as related or not to complications of peginterferon. Rates of liver transplantation were also assessed. Over a median of 5.7 years, 122 deaths occurred among 1,050 randomized patients (12%), of which 76 were considered liver-related (62%) and 46 nonliver-related (38%); 74 patients (7%) underwent liver transplantation. At 7 years the cumulative mortality rate was higher in the treatment compared to the control group (20% versus 15%, P = 0.049); the primary difference in mortality was in patients in the fibrosis compared to the cirrhosis stratum (14% versus 7%, P = 0.01); comparable differences were observed when liver transplantation was included. Excess mortality, emerging after 3 years of treatment, was related largely to nonliver-related death; liver-related mortality was similar in the treatment and control groups. No specific cause of death accounted for the excess mortality and only one death was suspected to be a direct complication of peginterferon. Conclusion: Long-term maintenance peginterferon in patients with advanced chronic hepatitis C is associated with an excess overall mortality, which was primarily due to nonliver-related causes among patients with bridging fibrosis. (HEPATOLOGY 2011;53:1100-1108) C1 [Di Bisceglie, Adrian M.] St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, St Louis, MO 63104 USA. [Stoddard, Anne M.; Snow, Kristin K.] New England Res Inst, Watertown, MA 02172 USA. [Dienstag, Jules L.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Dienstag, Jules L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Shiffman, Mitchell L.] Bon Secours Hlth Syst, Liver Inst Virginia, Newport News, VA USA. [Seeff, Leonard B.] NIDDKD, Div Digest Dis & Nutr, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Seeff, Leonard B.; Ghany, Marc G.] NIDDKD, Liver Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Bonkovsky, Herbert L.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT USA. [Bonkovsky, Herbert L.] Carolinas Med Ctr, Charlotte, NC 28203 USA. [Morishima, Chihiro] Univ Washington, Dept Lab Med, Div Virol, Seattle, WA 98195 USA. [Wright, Elizabeth C.] NIDDKD, Off Director, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA. [Fontana, Robert J.] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI USA. [Morgan, Timothy R.] Univ Calif Irvine, Div Gastroenterol, Irvine, CA USA. [Morgan, Timothy R.] VA Long Beach Healthcare Syst, Gastroenterol Serv, Long Beach, CA USA. RP Di Bisceglie, AM (reprint author), St Louis Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, 1402 S Grand Blvd, St Louis, MO 63104 USA. EM dibiscam@slu.edu FU National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); National Cancer Institute; National Center for Minority Health and Health Disparities; National Center for Research Resources; National Institutes of Health (NIH); Genentech; Novartis; Vertex; Merck FX This study was supported by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK contract numbers are listed in the Appendix). Additional support was provided by the National Institute of Allergy and Infectious Diseases (NIAID); the National Cancer Institute; the National Center for Minority Health and Health Disparities; by General Clinical Research Center and Clinical and Translational Science Center grants from the National Center for Research Resources, National Institutes of Health (NIH grant numbers are listed in the Appendix); and by the Intramural Research Program of the NIH, NIDDK (M. G. Ghany). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Additional funding to conduct this study was supplied by Hoffmann-La Roche, Inc. (now Genentech) through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health.; Dr. Bonkovsky consults for and advises Boehringer-Ingelheim and Novartis and received grants from Novartis and Vertex.; Dr. Morgan received grants from Merck, Genentech, and Vertex. He consults for and advises Vertex. NR 23 TC 41 Z9 42 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD APR PY 2011 VL 53 IS 4 BP 1100 EP 1108 DI 10.1002/hep.24169 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 748VA UT WOS:000289419600005 PM 21480316 ER PT J AU Loftis, JM Morasco, BJ Hauser, P AF Loftis, Jennifer M. Morasco, Benjamin J. Hauser, Peter TI Depression and Antiviral Response to Interferon-Based Therapy for Hepatitis C Virus Infection SO HEPATOLOGY LA English DT Letter ID RIBAVIRIN; SYMPTOMS; ALPHA C1 [Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. [Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Loftis, Jennifer M.; Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Hauser, Peter] Long Beach Vet Affairs Med Ctr, Long Beach, CA USA. RP Loftis, JM (reprint author), Portland VA Med Ctr, Res & Dev Serv, Portland, OR USA. FU NIDA NIH HHS [K23 DA023467]; NIMH NIH HHS [F32 MH071137, F32 MH071137-03] NR 7 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD APR PY 2011 VL 53 IS 4 BP 1413 EP 1414 DI 10.1002/hep.24064 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 748VA UT WOS:000289419600051 PM 21480359 ER PT J AU Chen, Z Putrino, DF Ghosh, S Barbieri, R Brown, EN AF Chen, Zhe Putrino, David F. Ghosh, Soumya Barbieri, Riccardo Brown, Emery N. TI Statistical Inference for Assessing Functional Connectivity of Neuronal Ensembles With Sparse Spiking Data SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE Conjugate gradient; interior-point method; functional connectivity; maximum likelihood estimate (MLE); neuronal interactions; penalized maximum likelihood; point process generalized linear model; variational Bayes; l2 regularization; l1 regularization ID GENERALIZED LINEAR-MODELS; TRAIN DATA-ANALYSIS; LOGISTIC-REGRESSION; NEURAL ENSEMBLE; POINT-PROCESSES; LASSO; FRAMEWORK; SELECTION; NETWORKS; DYNAMICS AB The ability to accurately infer functional connectivity between ensemble neurons using experimentally acquired spike train data is currently an important research objective in computational neuroscience. Point process generalized linear models and maximum likelihood estimation have been proposed as effective methods for the identification of spiking dependency between neurons. However, unfavorable experimental conditions occasionally results in insufficient data collection due to factors such as low neuronal firing rates or brief recording periods, and in these cases, the standard maximum likelihood estimate becomes unreliable. The present studies compares the performance of different statistical inference procedures when applied to the estimation of functional connectivity in neuronal assemblies with sparse spiking data. Four inference methods were compared: maximum likelihood estimation, penalized maximum likelihood estimation, using either l2 or l1 regularization, and hierarchical Bayesian estimation based on a variational Bayes algorithm. Algorithmic performances were compared using well-established goodness-of-fit measures in benchmark simulation studies, and the hierarchical Bayesian approach performed favorably when compared with the other algorithms, and this approach was then successfully applied to real spiking data recorded from the cat motor cortex. The identification of spiking dependencies in physiologically acquired data was encouraging, since their sparse nature would have previously precluded them from successful analysis using traditional methods. C1 [Chen, Zhe; Putrino, David F.; Barbieri, Riccardo; Brown, Emery N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurosci Stat Res Lab, Boston, MA 02114 USA. [Chen, Zhe; Putrino, David F.; Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Brown, Emery N.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Ghosh, Soumya] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, QEII Med Ctr, Nedlands, WA 6009, Australia. RP Chen, Z (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurosci Stat Res Lab, Boston, MA 02114 USA. EM zhechen@neuro-stat.mit.edu; trinod01@neu-rostat.mit.edu; sghosh@cyllene.uwa.edu.au; barbieri@neurostat.mit.edu; enb@neurostat.mit.edu OI Barbieri, Riccardo/0000-0001-9381-3833; Putrino, David/0000-0002-2232-3324; Chen, Zhe/0000-0002-6483-6056 FU National Institutes of Health (NIH) [DP1-OD003646, R01-DA015644, R01-HL084502] FX Manuscript received March 10, 2010; revised June 01, 2010, August 13, 2010; accepted October 02, 2010. Date of publication October 11, 2010; date of current version April 08, 2011. This work was supported by the National Institutes of Health (NIH) under Grant DP1-OD003646, Grant R01-DA015644, and Grant R01-HL084502. NR 51 TC 19 Z9 19 U1 0 U2 5 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1534-4320 EI 1558-0210 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD APR PY 2011 VL 19 IS 2 BP 121 EP 135 DI 10.1109/TNSRE.2010.2086079 PG 15 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA 749OB UT WOS:000289476700002 PM 20937583 ER PT J AU Kim, SP Simeral, JD Hochberg, LR Donoghue, JP Friehs, GM Black, MJ AF Kim, Sung-Phil Simeral, John D. Hochberg, Leigh R. Donoghue, John P. Friehs, Gerhard M. Black, Michael J. TI Point-and-Click Cursor Control With an Intracortical Neural Interface System by Humans With Tetraplegia SO IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING LA English DT Article DE Amyotrophic lateral sclerosis; human motor cortex; intracortical neural interface system; multi-state decoding; point-and-click control; quadriplegia; stroke ID BRAIN-COMPUTER INTERFACE; GOAL-DIRECTED MOVEMENTS; MOTOR CORTEX; CORTICAL REPRESENTATION; SIGNALS; STATE; KINEMATICS; VELOCITY; NEURONS; DEVICES AB We present a point-and-click intracortical neural interface system (NIS) that enables humans with tetraplegia to volitionally move a 2-D computer cursor in any desired direction on a computer screen, hold it still, and click on the area of interest. This direct brain-computer interface extracts both discrete (click) and continuous (cursor velocity) signals from a single small population of neurons in human motor cortex. A key component of this system is a multi-state probabilistic decoding algorithm that simultaneously decodes neural spiking activity of a small population of neurons and outputs either a click signal or the velocity of the cursor. The algorithm combines a linear classifier, which determines whether the user is intending to click or move the cursor, with a Kalman filter that translates the neural population activity into cursor velocity. We present a paradigm for training the multi-state decoding algorithm using neural activity observed during imagined actions. Two human participants with tetraplegia (paralysis of the four limbs) performed a closed-loop radial target acquisition task using the point-and-click NIS over multiple sessions. We quantified point-and-click performance using various human-computer interaction measurements for pointing devices. We found that participants could control the cursor motion and click on specified targets with a small error rate (<3% in one participant). This study suggests that signals from a small ensemble of motor cortical neurons (similar to 40) can be used for natural point-and-click 2-D cursor control of a personal computer. C1 [Kim, Sung-Phil; Black, Michael J.] Brown Univ, Dept Comp Sci, Providence, RI 02912 USA. [Simeral, John D.; Hochberg, Leigh R.; Donoghue, John P.] Dept Vet Affairs, Rehabil Res & Dev Serv, Providence, RI 02912 USA. [Simeral, John D.; Hochberg, Leigh R.] Brown Univ, Sch Engn, Providence, RI 02912 USA. [Hochberg, Leigh R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Donoghue, John P.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Friehs, Gerhard M.] Brown Univ, Dept Clin Neurosci, Providence, RI 02912 USA. [Black, Michael J.] Max Planck Gesell, D-72012 Tubingen, Germany. RP Kim, SP (reprint author), Korea Univ, Dept Brain & Cognit Engn, Seoul, South Korea. EM spkim@cs.brown.edu; john_simeral@brown.edu; leigh_hochberg@brown.edu; john_donoghue@brown.edu; gfriehs@yahoo.com; black@cs.brown.edu OI Hochberg, Leigh/0000-0003-0261-2273 FU NIH-NINDS, NSF/NIH [R01 NS 50867-01]; NIH [R01DC009899, N01HD53403, RC1HD063931]; Office of Naval Research [N0014-04-1-082]; European Neurobotics Program [FP6-IST-001917]; Office of Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs; Doris Duke Charitable Foundation; MGH-Deane Institute; Ministry of Education, Science and Technology [R31-10008] FX Manuscript received March 27, 2010; revised September 05, 2010; accepted October 30, 2010. Date of publication January 28, 2011; date of current version April 08, 2011. This work was supported in part by NIH-NINDS R01 NS 50867-01 as part of the NSF/NIH Collaborative Research in Computational Neuroscience Program, by NIH grant, R01DC009899, N01HD53403 and RC1HD063931, and by the Office of Naval Research (award N0014-04-1-082). This work was also supported by the European Neurobotics Program FP6-IST-001917. This work was based upon work supported in part by the Office of Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs, and support from the Doris Duke Charitable Foundation and the MGH-Deane Institute for Integrated Research on Atrial Fibrillation and Stroke. This work was also in part supported by WCU (World Class University) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (R31-10008). The pilot clinical trial from which these data were derived was sponsored by Cyberkinetics Neurotechnology Systems, Inc. A preliminary version of this work appeared in the Proceedings of the 3rd IEEE International Conference on Neural Engineering. The current manuscript is significantly expanded, containing neuronal tuning analysis, additional experiments and results with a second participant. Disclosure: J. P. Donoghue was the Chief Scientific Officer and a Director of Cyberkinetics Neurotechnology Systems (CYKN). He held stock and received compensation. J. D. Simeral was a consultant for CYKN. L. R. Hochberg received research support from Massachusetts General and Spaulding Rehabilitation Hospitals, which in turn received clinical trial support from CYKN. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 34 TC 57 Z9 59 U1 0 U2 15 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1534-4320 EI 1558-0210 J9 IEEE T NEUR SYS REH JI IEEE Trans. Neural Syst. Rehabil. Eng. PD APR PY 2011 VL 19 IS 2 BP 193 EP 203 DI 10.1109/TNSRE.2011.2107750 PG 11 WC Engineering, Biomedical; Rehabilitation SC Engineering; Rehabilitation GA 749OB UT WOS:000289476700009 PM 21278024 ER PT J AU Kaewlai, R AF Kaewlai, R. TI Multidetector-row computed tomography of thoracic trauma SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE LA English DT Review ID BLUNT CHEST TRAUMA; AORTIC INJURY; RIB FRACTURES; CT; PNEUMOMEDIASTINUM; DIAGNOSIS; RUPTURE; CLASSIFICATION; DIAPHRAGM; CHILDREN AB P>Imaging in trauma patients has dramatically evolved since the advent of computed tomography (CT), particularly multidetector CT (MDCT) technology. Axial MDCT images of the body can be acquired in seconds and shown any plane, allowing immediate viewing and interpreting. These factors make CT an invaluable means to detect many injuries not previously visible by any other noninvasive imaging techniques. Potentially subtle, but significant, thoracic injuries such as pneumothorax, haemothorax, aortic injury, sternal and spinal fractures can be detected on MDCT easily. In this article, the author will discuss the use of MDCT in the diagnosis of various thoracic injuries. C1 [Kaewlai, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Kaewlai, R (reprint author), Ramathibodi Hosp, 270 Rama 6 Rd, Bangkok 10400, Thailand. EM rathachai@gmail.com OI Kaewlai, Rathachai/0000-0002-0650-9380 NR 61 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1368-5031 EI 1742-1241 J9 INT J CLIN PRACT JI Int. J. Clin. Pract. PD APR PY 2011 VL 65 SU 171 BP 3 EP 16 DI 10.1111/j.1742-1241.2010.02625.x PG 14 WC Medicine, General & Internal; Pharmacology & Pharmacy SC General & Internal Medicine; Pharmacology & Pharmacy GA 747BO UT WOS:000289295500003 ER PT J AU Fan, BJ Pasquale, LR Rhee, D Li, TS Haines, JL Wiggs, JL AF Fan, Bao Jian Pasquale, Louis R. Rhee, Douglas Li, Tiansen Haines, Jonathan L. Wiggs, Janey L. TI LOXL1 Promoter Haplotypes Are Associated with Exfoliation Syndrome in a US Caucasian Population SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID OPEN-ANGLE GLAUCOMA; UNITED-STATES POPULATION; COMMON SEQUENCE VARIANTS; PSEUDOEXFOLIATION SYNDROME; GENE POLYMORPHISMS; JAPANESE POPULATION; PREVALENCE; CHINESE; PEOPLE; SYNDROME/GLAUCOMA AB PURPOSE. LOXL1 is a major genetic risk factor for exfoliation syndrome (ES) and exfoliation glaucoma (EG). Recent evidence documenting reversal of risk alleles for the disease-associated missense variants R141L and G153D suggests that these variants are not causative and that they may be proxies for other unknown functional LOXL1 variants. The purpose of this study was to investigate the disease association of LOXL1 variants spanning the gene region, including the 5' and 3' regulatory regions, in a U.S. Caucasian case-control sample. METHODS. Twenty-five LOXL1 single-nucleotide polymorphisms (SNPs), distributed throughout the gene, were geno-typed in 196 Caucasian patients with ES/EG and 201 matched controls. Genotype data were analyzed for single SNP associations, SNP interactions, and haplotype associations. RESULTS. Promoter region haplotypes that included the risk alleles for rs12914489, a SNP located in the distal promoter region and independently associated with ES, and rs16958477, a SNP previously shown to affect gene transcription, were associated with increased disease risk (P = 0.0008; odds ratio [OR], 2.34; 95% confidence interval [CI], 1.42-3.85) and with protective effects (P = 2.3 x 10(-6); OR, 0.38; 95% CI, 0.25-0.57). Haplotypes containing rs12914489 and rs16958477 risk and protective alleles also significantly influenced the disease risk associated with missense alleles R141L and G153D. CONCLUSIONS. LOXL1 promoter haplotypes were identified that are significantly associated with ES/EG in a U.S. Caucasian population. These results suggest that promoter region SNPs can influence LOXL1 gene expression, potentially causing a reduction of enzyme activity that may predispose to disease. (Invest Ophthalmol Vis Sci. 2011;52:2372-2378) DOI: 10.1167/iovs.10-6268 C1 [Fan, Bao Jian; Pasquale, Louis R.; Rhee, Douglas; Wiggs, Janey L.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA. [Li, Tiansen] NEI, NIH, Bethesda, MD 20892 USA. [Haines, Jonathan L.] Vanderbilt Univ Sch Med, Ctr Human Genet Res, Nashville, TN USA. RP Wiggs, JL (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA. EM janey_wiggs@meei.harvard.edu RI Haines, Jonathan/C-3374-2012; OI Fan, Baojian/0000-0002-6851-2737 FU National Institutes of Health (NIH) [EY015882, P30EY014104]; Massachusetts Lions Eye Research Fund; Research to Prevent Blindness FX Supported in part by National Institutes of Health (NIH) Grants EY015882 and P30EY014104, the Massachusetts Lions Eye Research Fund, and Research to Prevent Blindness. NR 38 TC 27 Z9 29 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2011 VL 52 IS 5 BP 2372 EP 2378 DI 10.1167/iovs.10-6268 PG 7 WC Ophthalmology SC Ophthalmology GA 748SJ UT WOS:000289411300004 PM 21212179 ER PT J AU Pfab, F Athanasiadis, GI Huss-Marp, J Fuqin, J Heuser, B Cifuentes, L Brockow, K Schober, W Konstantinow, A Irnich, D Behrendt, H Ring, J Ollert, M AF Pfab, Florian Athanasiadis, Georgios I. Huss-Marp, Johannes Fuqin, Jiang Heuser, Beate Cifuentes, Liliana Brockow, Knut Schober, Wolfgang Konstantinow, Alexander Irnich, Dominik Behrendt, Heidrun Ring, Johannes Ollert, Markus TI Effect of Acupuncture on Allergen-Induced Basophil Activation in Patients with Atopic Eczema: A Pilot Trial SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article ID HISTAMINE-INDUCED ITCH; ALTERNATIVE APPROACH; CROSSOVER TRIAL; HUMAN BRAIN; DERMATITIS; ELECTROACUPUNCTURE; FMRI; PERSPECTIVES; POTENTIALS; MODULATION AB Objective and methods: The crucial symptom of atopic eczema is itch. Acupuncture has been shown to exhibit a significant effect on experimental itch; however, studies focusing on clinical itch in atopic eczema and corresponding mechanisms are lacking. The study design was a unicenter, single-blinded (observer), prospective, randomized clinical pilot trial with an additional experimental part. In 10 patients with atopic eczema, we investigated the effect of acupuncture treatment (n = 5) compared to no treatment (n = 5) on itch intensity and in vitro basophil CD63 expression upon allergen stimulation (house dust mite and timothy grass pollen) in a pilot trial. Results: Mean itch intensity in a visual analog scale was rated significantly lower in the acupuncture group (-25% +/- 26% [day 15-day 0]; -24% +/- 31% [day 33-day 0]) than in the control group (15% +/- 6% [day 15-day 0]; 29% +/- 9% [day 33-day 0]). From day 0 (before treatment) to day 15 (after 5 acupuncture treatments) as well as day 33 (after 10 acupuncture treatments), the acupuncture group showed less CD63 positive basophils than the control group regarding stimulation with house dust mite and grass pollen allergen at various concentrations (5 ng/mL, 1 ng/mL, 0.5 ng/mL, or 0.25 ng/mL). Conclusions: Our results show a reduction of itch intensity and of in vitro allergen-induced basophil activation in patients with atopic eczema after acupuncture treatment. Reducing basophil activation can be a further tool in investigating the mechanisms of action of acupuncture in immunoglobulin E-mediated allergy. Due to the limited number of patients included in our pilot trial, further studies are needed to strengthen the hypothesis. C1 [Pfab, Florian] Tech Univ Munich, Klin & Poliklin Dermatol & Allergo Biederstein, Dept Dermatol & Allergy, D-80802 Munich, Germany. [Pfab, Florian; Huss-Marp, Johannes; Cifuentes, Liliana; Brockow, Knut; Schober, Wolfgang; Behrendt, Heidrun] Helmholtz Zentrum, Div Environm Dermatol & Allergy, Munich, Germany. [Pfab, Florian; Huss-Marp, Johannes; Cifuentes, Liliana; Brockow, Knut; Schober, Wolfgang; Behrendt, Heidrun] ZAUM Ctr Allergy & Environm, TUM, Munich, Germany. [Pfab, Florian] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA. [Athanasiadis, Georgios I.; Heuser, Beate; Ollert, Markus] Tech Univ Munich, Clin Res Div Mol & Clin Allergotoxicol, Munich, Germany. [Irnich, Dominik] Univ Munich, Dept Anesthesiol, Munich, Germany. RP Pfab, F (reprint author), Tech Univ Munich, Klin & Poliklin Dermatol & Allergo Biederstein, Dept Dermatol & Allergy, Biedersteiner Str 29, D-80802 Munich, Germany. EM florian.pfab@lrz.tum.de OI Cifuentes, Liliana/0000-0002-0107-5544 FU ZAUM-Center for Allergy and Environment, Technische Universitat Munchen FX The study was financed by the ZAUM-Center for Allergy and Environment, Technische Universitat Munchen. NR 34 TC 17 Z9 18 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD APR PY 2011 VL 17 IS 4 BP 309 EP 314 DI 10.1089/acm.2009.0684 PG 6 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 751KO UT WOS:000289616600007 PM 21443446 ER PT J AU Wannomae, KK Christensen, SD Micheli, BR Rowell, SL Schroeder, DW Muratoglu, OK AF Wannomae, Keith K. Christensen, Steven D. Micheli, Brad R. Rowell, Shannon L. Schroeder, Dave W. Muratoglu, Orhun K. TI Untitled Reply SO JOURNAL OF ARTHROPLASTY LA English DT Letter ID FATIGUE RESISTANCE; UHMWPE; WEAR C1 [Wannomae, Keith K.; Christensen, Steven D.; Micheli, Brad R.; Rowell, Shannon L.; Schroeder, Dave W.; Muratoglu, Orhun K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Wannomae, KK (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 3 TC 0 Z9 0 U1 0 U2 2 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD APR PY 2011 VL 26 IS 3 BP 508 EP 509 DI 10.1016/j.arth.2010.12.009 PG 2 WC Orthopedics SC Orthopedics GA 750HP UT WOS:000289537500031 ER PT J AU Dixit, S Lavi, N Robinson, M Riley, MP Callans, DJ Marchlinski, FE Lin, D AF Dixit, Sanjay Lavi, Nimrod Robinson, Melissa Riley, Michael P. Callans, David J. Marchlinski, Francis E. Lin, David TI Noncontact Electroanatomic Mapping to Characterize Typical Atrial Flutter: Participation of Right Atrial Posterior Wall in the Reentrant Circuit SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE atrial flutter entrainment; catheter ablation; 3-dimensional mapping ID INTRACARDIAC ECHOCARDIOGRAPHY; CATHETER ABLATION; VENA-CAVA; ENTRAINMENT; CONDUCTION; ISTHMUS; FIBRILLATION; ACTIVATION; AMIODARONE; DEFINES AB Methods: Fifteen patients (pts) undergoing ablation for typical AFLT participated. Multipolar catheters were deployed in RA and coronary sinus. RA shell was created during AFLT. Entrainment was performed to confirm CTI dependence and assess participation of various RA regions (septum-Sep, PW, lateral wall-LW). Data were analyzed for (1) RA activation patterns and (2) conduction time (CT) through various RA regions. Results: Mean pt age was 70 +/- 13 years (all males; CCW = 10; CW = 5). Mean AFLT cycle length was 255 +/- 15 ms. Single activation wave front traversing sequentially CTI, Sep, and LW was seen in all pts and in 12 (80%; 9 CCW, 3 CW) this also traversed PW. Entrainment confirmed PW participation in 7 of these. Mean CT (in ms) through various RA regions was as follows: CTI = 69 +/- 27, Sep = 50 +/- 39, PW = 65 +/- 35, and LW = 76 +/- 35; P = NS. Conclusion: These observations offer new insights regarding the participation of PW in the reentrant circuit of typical AFLT in some patients. (J Cardiovasc Electrophysiol, Vol. 22, pp. 422-430). C1 [Dixit, Sanjay; Lavi, Nimrod; Robinson, Melissa; Riley, Michael P.; Callans, David J.; Marchlinski, Francis E.; Lin, David] Hosp Univ Penn, Div Cardiovasc, Philadelphia, PA 19104 USA. [Dixit, Sanjay] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Dixit, S (reprint author), Hosp Univ Penn, Div Cardiovasc, 9 Founders Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM Sanjay.Dixit@uphs.upenn.edu OI Marchlinski, Francis/0000-0001-7962-9423 NR 23 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD APR PY 2011 VL 22 IS 4 BP 422 EP 430 DI 10.1111/j.1540-8167.2010.01917.x PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 749ME UT WOS:000289470700011 PM 20958830 ER PT J AU Reust, DL Dixon, JA McKinney, RA Patel, RK Rivers, WT Mukherjee, R Stroud, RE Madden, K Groves, K Rajopadhye, M Reeves, ST Abernathy, JH Spinale, FG AF Reust, Daryl L. Dixon, Jennifer A. McKinney, Richard A. Patel, Risha K. Rivers, William T. Mukherjee, Rupak Stroud, Robert E. Madden, Karen Groves, Kevin Rajopadhye, Milind Reeves, Scott T. Abernathy, James H., III Spinale, Francis G. TI Continuous Localized Monitoring of Plasmin Activity Identifies Differential and Regional Effects of the Serine Protease Inhibitor Aprotinin: Relevance to Antifibrinolytic Therapy SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY LA English DT Article DE aprotinin; plasmin inhibition; fibrinolysis; plasma; interstitial; microdialysis probe ID EPSILON-AMINOCAPROIC ACID; PATIENTS RECEIVING APROTININ; CARDIAC-SURGERY; CARDIOPULMONARY BYPASS; RENAL-FUNCTION; TRANEXAMIC ACID; DOSE REGIMENS; DYSFUNCTION; RELEASE; INJURY AB Background: Antifibrinolytic therapy, such as the use of the serine protease inhibitor aprotinin, was a mainstay for hemostasis after cardiac surgery. However, aprotinin was empirically dosed, and although the pharmacological target was the inhibition of plasmin activity (PLact), this was never monitored, off-target effects occurred, and led to withdrawn from clinical use. The present study developed a validated fluorogenic microdialysis method to continuously measure PLact and tested the hypothesis that standardized clinical empirical aprotinin dosing would impart differential and regional effects on PLact. Methods/Results: Pigs (30 kg) were instrumented with microdialysis probes to continuously measure PLact in myocardial, kidney, and skeletal muscle compartments (deltoid) and then randomized to high-dose aprotinin administration (2 mKIU load/0.5 mKIU/hr infusion; n = 7), low-dose aprotinin administration (1 mKIU load/0.250 mKIU/hr infusion; n = 6). PLact was compared with time-matched vehicle (n = 4), and PLact was also measured in plasma by an in vitro fluorogenic method. Aprotinin suppressed PLact in the myocardium and kidney at both high and low doses, indicative that both doses exceeded a minimal concentration necessary for PLact inhibition. However, differential effects of aprotinin on PLact were observed in the skeletal muscle, indicative of different compartmentalization of aprotinin. Conclusions: Using a large animal model and a continuous method to monitor regional PLact, these unique results demonstrated that an empirical aprotinin dosing protocol causes maximal and rapid suppression in the myocardium and kidney and in turn would likely increase the probability of off-target effects and adverse events. Furthermore, this proof of principle study demonstrated that continuous monitoring of determinants of fibrinolysis might provide a novel approach for managing fibrinolytic therapy. C1 [Dixon, Jennifer A.; McKinney, Richard A.; Patel, Risha K.; Rivers, William T.; Mukherjee, Rupak; Stroud, Robert E.; Spinale, Francis G.] Med Univ S Carolina, Dept Cardiothorac Surg, Charleston, SC 29403 USA. [Reust, Daryl L.; Reeves, Scott T.; Abernathy, James H., III] Med Univ S Carolina, Dept Anesthesiol & Perioperat Med, Charleston, SC 29403 USA. [Spinale, Francis G.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Madden, Karen; Groves, Kevin; Rajopadhye, Milind] VisEn Med Inc, Bedford, MA USA. RP Spinale, FG (reprint author), Med Univ S Carolina, Dept Cardiothorac Surg, Strom Thurmond Res Bldg,114 Doughty St,Room 625, Charleston, SC 29403 USA. EM wilburnm@musc.edu FU National Institutes of Health [HL059165, HL078650]; Veterans' Affairs Health Administration FX Supported in part by National Institutes of Health grants HL059165 and HL078650 and a Merit Award form the Veterans' Affairs Health Administration. NR 37 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-2446 EI 1533-4023 J9 J CARDIOVASC PHARM JI J. Cardiovasc. Pharmacol. PD APR PY 2011 VL 57 IS 4 BP 400 EP 406 DI 10.1097/FJC.0b013e31820b7df1 PG 7 WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy GA 749YR UT WOS:000289508500005 PM 21502925 ER PT J AU Souer, JS Wiggers, J Ring, D AF Souer, J. Sebastian Wiggers, Jimme Ring, David TI Quantitative 3-Dimensional Computed Tomography Measurement of Volar Shearing Fractures of the Distal Radius SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article DE Computed tomography; fractures; morphology; quantitative; distal radius ID FIXATION; PART AB Purpose We used a method for quantitative measurement of articular surface area based on 3-dimensional computed tomography (CT) images to test the hypothesis that among volar shearing fractures of the distal radius, complete articular fractures have on average larger volar fracture fragments than partial articular fractures. Methods We analyzed 25 adult patients with a quantitative 3-dimensional CT scan of a volar shearing fracture of the distal radius. We identified 3 major fracture patterns: 10 fractures were complete articular fractures (AO C-type; complete dorsal fracture line); 8 fractures had an intact dorsal lunate facet (radial dorsal fracture line; labeled transitional type B fractures); and 7 fractures had no dorsal fracture (true AO type B partial articular fractures). Results All of the type C and transitional type B fractures, but only one of the true type B fractures had a split (fragmentation) in the dorsal articular surface (p < .001). Four of 10 type C, 6 of 8 partial type B and 2 of 7 type B fractures had fragmentation of the volar articular surface (p = .19). The articular surface area of the volar fragments in type B fractures tended to be larger (average 56%; range, 38% to 78% of the total articular surface area) compared with partial type B (average 42; range, 28% to 51%) and type C (47%; range, 25% to 68%) fractures although the differences were not statistically significant with the numbers available. Conclusions We identified 3 major volar shearing fracture patterns (complete, transitional partial, and partial articular). Although the differences in the average volar fractures surface area were not statistically significant with the numbers available, complete fractures and transitional partial fractures (intact dorsal lunate facet) were significantly more likely to have dorsal comminution. (J Hand Surg 2011;36A:599-603. Copyright (c) 2011 by the American Society for Surgery of the Hand. All rights reserved.) C1 [Ring, David] Harvard Univ, Yawkey Ctr, Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv,Med Sch, Boston, MA 02114 USA. RP Ring, D (reprint author), Harvard Univ, Yawkey Ctr, Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv,Med Sch, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 9 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD APR PY 2011 VL 36A IS 4 BP 599 EP 603 DI 10.1016/j.jhsa.2010.12.026 PG 5 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 749TN UT WOS:000289493300006 PM 21411241 ER PT J AU Lambers, K Ring, D AF Lambers, Kaj Ring, David TI Elbow Fracture-Dislocation With Triceps Avulsion: Report of 2 Cases SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Article ID RADIAL HEAD; TENDON AB We report 2 cases of elbow fracture dislocation with triceps avulsion. Despite immobilizing the elbow in neutral for 2 to 4 weeks to protect the triceps repair, good elbow motion was obtained. (J Hand Surg 2011;36A:625-627. Copyright (c) 2011 by the American Society for Surgery of the Hand. All rights reserved.) C1 [Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Boston, MA 02114 USA. RP Ring, D (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Orthopaed Hand & Upper Extrem Serv,Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM dring@partners.org NR 8 TC 3 Z9 3 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD APR PY 2011 VL 36A IS 4 BP 625 EP 627 DI 10.1016/j.jhsa.2010.12.027 PG 3 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 749TN UT WOS:000289493300011 PM 21463726 ER PT J AU Abhishek, F Heist, EK Barrett, C Danik, S Blendea, D Correnti, C Khan, Z Ruskin, JN Mansour, M AF Abhishek, Fnu Heist, Edwin Kevin Barrett, Conor Danik, Stephan Blendea, Dan Correnti, Christina Khan, Zaka Ruskin, Jeremy N. Mansour, Moussa TI Effectiveness of a strategy to reduce major vascular complications from catheter ablation of atrial fibrillation SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY LA English DT Article DE Vascular complications ID INTERNATIONAL NORMALIZED RATIO; PERIPROCEDURAL ANTICOAGULATION; RADIOFREQUENCY ABLATION; RANDOMIZED-TRIAL; FEMORAL-ARTERY; ACCESS; RISK AB Vascular access site complications are among the most frequently observed complications after catheter ablation of atrial fibrillation (AF). We sought to determine whether implementation of a three-point strategy would reduce major vascular complications resulting from catheter ablation of atrial fibrillation. Three hundred twenty-four consecutive patients undergoing catheter ablation of AF were studied: 162 in each group (with and without the test strategy). The three-point test strategy included the following: (1) performing the procedure on Warfarin with an INR from 2.0 to 3.5 (mean INR of 2.44), rather than stopping Warfarin prior to the procedure and bridging the patient back to Warfarin with low molecular heparin, (2) using a small 21 G needle to obtain femoral vein access rather than a larger 18 G needle, and (3) eliminating the use of femoral arterial access. Major vascular complications were defined as complications requiring either blood transfusion or surgical/percutaneous repair. Major vascular complications were identified in 6/162 (3.7%) of the control patients without the strategy listed above compared to 0/162 (0%) in the test patients with implementations of this strategy (p = 0.03). The frequency of other complications was comparable between the two groups (tamponade requiring drainage: 1/162 control, 1/162 test; pericardial effusion not requiring drainage: 0/162 control, 1/162 test; transient ischemic attack: 1/162 control and 1/162 test; stroke: 1/162 control, 0/162 test): (p = NS for each). A three-point strategy including performing procedures with therapeutic Warfarin, using a small gauge needle to obtain vascular access and eliminating femoral arterial access significantly reduced major vascular access complications and did not affect other major complications, during catheter ablation of AF. Implementation of this strategy may be useful to reduce groin complications resulting from AF ablation. C1 [Abhishek, Fnu; Heist, Edwin Kevin; Barrett, Conor; Danik, Stephan; Blendea, Dan; Correnti, Christina; Khan, Zaka; Ruskin, Jeremy N.; Mansour, Moussa] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Abhishek, Fnu; Heist, Edwin Kevin; Barrett, Conor; Danik, Stephan; Blendea, Dan; Correnti, Christina; Khan, Zaka; Ruskin, Jeremy N.; Mansour, Moussa] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Mansour, M (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Gray 109,55 Fruit St, Boston, MA 02114 USA. EM mmansour@partners.org FU MGH Deane Institute for Integrative Research in Atrial Fibrillation and Stroke; St. Jude Medical; Biosense Webster; Boston Scientific; CardioFocus; CardioInsight; CryoCath; Medtronic; Biosense-Webster FX This study was supported in part by MGH Deane Institute for Integrative Research in Atrial Fibrillation and Stroke.; FA: none, EKH: Boston Scientific (consultant/honoraria/research grants), St. Jude Medical (consultant/honoraria/research grant), CB: St. Jude Medical (research grants), SD: none, DB: none, CC: none, ZK: none, JNR: Biosense Webster (consultant, fellowship support), Boston Scientific (fellowship support), CardioFocus (clinical oversight committee-no compensation), CardioInsight (scientific advisory board), CryoCath (scientific steering committee-no compensation), Medtronic (consultant, fellowship support), St. Jude Medical (fellowship support), MM: St. Jude Medical (research grants), Biosense-Webster (research grants). NR 19 TC 25 Z9 25 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1383-875X J9 J INTERV CARD ELECTR JI J. Interv. Card. Electrophysiol. PD APR PY 2011 VL 30 IS 3 BP 211 EP 215 DI 10.1007/s10840-010-9539-8 PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 747EE UT WOS:000289302300002 PM 21336618 ER PT J AU Alloo, A Lin, JY Ma, J Wilson, BJ Frank, NY Zhou, J Hodi, FS Frank, MH AF Alloo, A. Lin, J. Y. Ma, J. Wilson, B. J. Frank, N. Y. Zhou, J. Hodi, F. S. Frank, M. H. TI Tumor stage-specific detection of ABCB5+circulating malignant melanoma-initiating cells SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Alloo, A.; Ma, J.; Wilson, B. J.; Frank, N. Y.; Frank, M. H.] Childrens Hosp Boston, Transplantat Res Ctr, Boston, MA USA. [Alloo, A.; Lin, J. Y.; Ma, J.; Wilson, B. J.; Frank, M. H.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Frank, N. Y.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA. [Zhou, J.; Hodi, F. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 759 BP S127 EP S127 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600756 ER PT J AU Chi, W Enshell-Seijffers, D Morgan, BA AF Chi, W. Enshell-Seijffers, D. Morgan, B. A. TI Regulation of hair morphology by the dermal papilla. SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Chi, W.; Enshell-Seijffers, D.; Morgan, B. A.] Harvard Univ, Sch Med, Cutaneous Biol Res Ctr, Boston, MA USA. [Chi, W.; Enshell-Seijffers, D.; Morgan, B. A.] Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 462 BP S77 EP S77 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600462 ER PT J AU Chren, M Linos, E Parvalaneni, R Torres, J Stuart, S Boscardin, WJ Landefeld, CS AF Chren, M. Linos, E. Parvalaneni, R. Torres, J. Stuart, S. Boscardin, W. J. Landefeld, C. S. TI Treatment for nonmelanoma skin cancer among patients with limited life expectancies SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Chren, M.; Parvalaneni, R.; Boscardin, W. J.; Landefeld, C. S.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Chren, M.; Torres, J.; Stuart, S.; Landefeld, C. S.] San Francisco VA Med Ctr, San Francisco, CA USA. [Linos, E.] Stanford Univ, Stanford, CA 94305 USA. RI Linos, Eleni/C-4392-2014 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 256 BP S43 EP S43 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600256 ER PT J AU Clark, RA Watanabe, R Tawa, M Adams, N Dorosario, A Fisher, DC Kupper, TS AF Clark, R. A. Watanabe, R. Tawa, M. Adams, N. Dorosario, A. Fisher, D. C. Kupper, T. S. TI Migration patterns of T-EM and T-CM in humans: Lessons from CTCL lesional morphology SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Clark, R. A.; Watanabe, R.; Tawa, M.; Adams, N.; Dorosario, A.; Fisher, D. C.; Kupper, T. S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 593 BP S99 EP S99 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600592 ER PT J AU Dowlatshahi, M Wang, L Teague, JE Lichtman, MK Gehad, A Watanabe, R Crisler, WJ Kupper, TS Clark, RA AF Dowlatshahi, M. Wang, L. Teague, J. E. Lichtman, M. K. Gehad, A. Watanabe, R. Crisler, W. J. Kupper, T. S. Clark, R. A. TI A role for PD-1 in suppressing T cell activity in human merkel cell carcinomas SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Dowlatshahi, M.; Wang, L.; Teague, J. E.; Lichtman, M. K.; Gehad, A.; Watanabe, R.; Crisler, W. J.; Kupper, T. S.; Clark, R. A.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 543 BP S91 EP S91 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600542 ER PT J AU Frankel, HC Frazier, L Camargo, CA Han, J Li, T Qureshi, AA AF Frankel, H. C. Frazier, L. Camargo, C. A. Han, J. Li, T. Qureshi, A. A. TI Atopic dermatitis prevalence and co-morbidities in the Growing Up Today Study II SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Frankel, H. C.; Frazier, L.; Camargo, C. A.; Han, J.; Li, T.; Qureshi, A. A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA. [Frazier, L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Camargo, C. A.; Han, J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 257 BP S43 EP S43 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600257 ER PT J AU Gamble, RG Aalborg, J Asdigian, NL Gonzalez, V Huff, LS Box, NF Crane, LA Dellavalle, RP AF Gamble, R. G. Aalborg, J. Asdigian, N. L. Gonzalez, V. Huff, L. S. Box, N. F. Crane, L. A. Dellavalle, R. P. TI Severity of sun damage in full-face ultraviolet photographs of 12 year-old children relates to phenotypic skin cancer risk factors SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Gamble, R. G.; Gonzalez, V.; Huff, L. S.; Box, N. F.; Dellavalle, R. P.] Univ Colorado, Denver, CO 80202 USA. [Aalborg, J.; Asdigian, N. L.; Crane, L. A.; Dellavalle, R. P.] Colorado Sch Publ Hlth, Aurora, CO USA. [Dellavalle, R. P.] Denver Vet Affairs Med Ctr, Denver, CO USA. RI Box, Neil/F-3591-2010 OI Box, Neil/0000-0002-3486-0346 NR 0 TC 1 Z9 1 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 240 BP S40 EP S40 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600240 ER PT J AU Gee, SN Zakhary, L Kroshinsky, D Kimball, AB AF Gee, S. N. Zakhary, L. Kroshinsky, D. Kimball, A. B. TI Treating patients with psychocutaneous disease in the outpatient dermatology setting. The results of a survey SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Gee, S. N.; Zakhary, L.; Kroshinsky, D.; Kimball, A. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 225 BP S38 EP S38 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600225 ER PT J AU Jalili, A Wagner, C Mertz, KD Pashenkov, M Stingl, G Ramaswamy, S Wagner, SN AF Jalili, A. Wagner, C. Mertz, K. D. Pashenkov, M. Stingl, G. Ramaswamy, S. Wagner, S. N. TI MAPK pathway regulates the expression of p18INK4c and p21Waf1/Cip1 cyclin-dependent kinase inhibitors through the AP-1 transcription factor SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Jalili, A.; Wagner, C.; Mertz, K. D.; Stingl, G.; Wagner, S. N.] Med Univ Vienna, DIAD, Dept Dermatol, Vienna, Austria. [Pashenkov, M.] Natl Res Ctr, Inst Immunol, Clin Immunol Lab, Moscow, Russia. [Ramaswamy, S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 726 BP S121 EP S121 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600724 ER PT J AU Jensen, JD Luo, Y Liu, W Dellavalle, RP Fujita, M AF Jensen, J. D. Luo, Y. Liu, W. Dellavalle, R. P. Fujita, M. TI Ellagic acid induces apoptosis and cell cycle arrest through upregulation of p53 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Jensen, J. D.; Luo, Y.; Liu, W.; Dellavalle, R. P.; Fujita, M.] Univ Colorado Denver, Aurora, CO USA. [Dellavalle, R. P.] Colorado Sch Publ Hlth, Aurora, CO USA. [Dellavalle, R. P.] Denver Vet Affairs Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 778 BP S130 EP S130 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600775 ER PT J AU Kardos, M Kim, G Chang, AS Kimball, AB AF Kardos, M. Kim, G. Chang, A. S. Kimball, A. B. TI Not so positive: Optimism and public self-consciousness were not associated with the placebo response in a rosacea trial. SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Kardos, M.; Kimball, A. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kim, G.; Chang, A. S.] Stanford Univ, Sch Med, Redwood City, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 222 BP S37 EP S37 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600222 ER PT J AU Katiyar, SK Singh, T AF Katiyar, S. K. Singh, T. TI Green tea catechins inhibit melanoma cell migration and invasion by inhibiting the expression of cyclooxygenase-2 and NF-kappa B activation SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Katiyar, S. K.; Singh, T.] Univ Alabama, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 713 BP S119 EP S119 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600711 ER PT J AU Piette, EW Foering, KP Chang, AY Okawa, J Werth, VP AF Piette, E. W. Foering, K. P. Chang, A. Y. Okawa, J. Werth, V. P. TI The impact of smoking in cutaneous lupus erythematosus and dermatomyositis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Piette, E. W.; Foering, K. P.; Chang, A. Y.; Okawa, J.; Werth, V. P.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Piette, E. W.; Foering, K. P.; Chang, A. Y.; Okawa, J.; Werth, V. P.] Univ PA, Sch Med, Philadelphia, PA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 514 BP S86 EP S86 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600513 ER PT J AU Reddy, VB Elmariah, SB Sun, Y Lerner, EA AF Reddy, V. B. Elmariah, S. B. Sun, Y. Lerner, E. A. TI The mechanism by which cathepsin S triggers receptor activation to cause itch SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Reddy, V. B.; Elmariah, S. B.; Sun, Y.; Lerner, E. A.] Massachusetts Gen Hosp, Dermatol Cutaneous Biol Res Ctr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 040 BP S7 EP S7 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600042 ER PT J AU Robinson, AH Kardos, M Kimball, AB AF Robinson, A. H. Kardos, M. Kimball, A. B. TI The degree of correlation between the physician's global assessment (PGA) and psoriasis area and severity index (PASI) in randomized controlled trials of biologic agents for moderate to severe plaque psoriasis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Robinson, A. H.; Kardos, M.; Kimball, A. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 524 BP S88 EP S88 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600523 ER PT J AU Ryan, C Leonardi, C Krueger, J Kimball, A Strober, B Gordon, K Langley, R Kaplan, D Menter, A AF Ryan, C. Leonardi, C. Krueger, J. Kimball, A. Strober, B. Gordon, K. Langley, R. Kaplan, D. Menter, A. TI Antagonism of p40 cytokines in psoriasis patients may promote paradoxical cardiovascular risk SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Ryan, C.; Menter, A.] Baylor Res Inst, Dallas, TX USA. [Leonardi, C.] St Louis Univ, St Louis, MO 63103 USA. [Krueger, J.] Rockefeller Univ, New York, NY 10021 USA. [Kimball, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Strober, B.] NYU, Med Ctr, New York, NY 10016 USA. [Gordon, K.] Univ Chicago, Chicago, IL 60637 USA. [Langley, R.] Dalhousie Univ, Halifax, NS, Canada. [Kaplan, D.] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 493 BP S83 EP S83 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600493 ER PT J AU Sun, Y Elmariah, SB Reddy, VB Lerner, EA AF Sun, Y. Elmariah, S. B. Reddy, V. B. Lerner, E. A. TI Up-regulation of cathepsin S by IL-23 may contribute to itching in psoriasis SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Sun, Y.; Elmariah, S. B.; Reddy, V. B.; Lerner, E. A.] Massachusetts Gen Hosp, Dermatol Cutaneous Biol Res Ctr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 038 BP S7 EP S7 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600041 ER PT J AU Vaid, M Singh, T Katiyar, SK AF Vaid, M. Singh, T. Katiyar, S. K. TI Silymarin inhibits UV-induced immunosuppression through inactivation of CD4+T cells and stimulation of CD8+effector T cells SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Vaid, M.; Singh, T.; Katiyar, S. K.] Univ Alabama, Birmingham, AL USA. [Katiyar, S. K.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 672 BP S112 EP S112 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600670 ER PT J AU Vleugels, FR Huang, SJ Collins, KM Hollman, TJ Lin, JY AF Vleugels, F. R. Huang, S. J. Collins, K. M. Hollman, T. J. Lin, J. Y. TI Chronic inflammatory demyelinating polyneuropathy (CIDP) heralding metastatic melanoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Vleugels, F. R.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Huang, S. J.; Collins, K. M.; Hollman, T. J.; Lin, J. Y.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Lin, J. Y.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 761 BP S127 EP S127 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600758 ER PT J AU Watanabe, R Tawa, M Adams, N Dorosario, A Fisher, DC Kupper, TS Clark, RA AF Watanabe, R. Tawa, M. Adams, N. Dorosario, A. Fisher, D. C. Kupper, T. S. Clark, R. A. TI T cells in the skin lesions of stage I mycosis fungoides show markedly suppressed cytokine production SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Watanabe, R.; Tawa, M.; Adams, N.; Dorosario, A.; Fisher, D. C.; Kupper, T. S.; Clark, R. A.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 534 BP S89 EP S89 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600533 ER PT J AU Yang, S Emley, A Deng, A Hoang, MP Mahalingam, M AF Yang, S. Emley, A. Deng, A. Hoang, M. P. Mahalingam, M. TI A genetic appraisal of the frequency of functional RET G691S polymorphism in the pure versus the mixed variants of desmoplastic melanoma SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the Society-for-Investigative-Dermatology CY MAY 04-07, 2011 CL Phoenix, AZ SP Soc Investigat Dermatol C1 [Yang, S.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA. [Emley, A.; Mahalingam, M.] Boston Univ, Sch Med, Dept Dermatol, Dermatopathol Sect, Boston, MA 02118 USA. [Deng, A.] UMASS Med Sch, Dept Pathol, Worcester, MA USA. [Hoang, M. P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 2011 VL 131 SU 1 MA 106 BP S18 EP S18 PG 1 WC Dermatology SC Dermatology GA 743RE UT WOS:000289035600107 ER PT J AU Han, LH Wu, SM Condit, JC Kemp, NJ Milner, TE Feldman, MD Chen, SC AF Han, Li-Hsin Wu, Shaomin Condit, J. Christopher Kemp, Nate J. Milner, Thomas E. Feldman, Marc D. Chen, Shaochen TI Light-Powered Micromotor: Design, Fabrication, and Mathematical Modeling SO JOURNAL OF MICROELECTROMECHANICAL SYSTEMS LA English DT Article DE Crookes; DSMC; light mill; microactuator; micromotor; Monte Carlo; nanoparticles AB This paper reports on the experimental and theoretical studies of a light-driven micromotor, which is a "light mill" that rotates by absorbing photon energy. This light mill has four curved blades to form an axially asymmetric geometry. Upon lateral irradiation, the shape of the light mill induces an asymmetric photon heating to the surrounding gas molecules, leading to a gas convection that forces the light mill to rotate. The light mill was applied to actuate a scanning mirror for a laser beam. Using a Direct Simulation Monte Carlo (DSMC) model, we investigated the working principle behind the operation of the light mill. The DSMC simulation yielded results consistent to our experimental data. The simulation results were used to explain the heat-induced light-mill rotation, in which the mean free path of the surrounding gas takes an important role. [2010-0149] C1 [Han, Li-Hsin] Stanford Univ, Dept Orthopaed Surg, Stanford, CA 94305 USA. [Condit, J. Christopher; Milner, Thomas E.] Univ Texas Austin, Dept Biomed Engn, Austin, TX 78712 USA. [Kemp, Nate J.] Volcano Corp, Billerica, MA 01821 USA. [Feldman, Marc D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Feldman, Marc D.] S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Chen, Shaochen] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA. RP Han, LH (reprint author), Stanford Univ, Dept Orthopaed Surg, Stanford, CA 94305 USA. EM leohan17@gmail.com; wushaomin@yahoo.com; condit.chris@gmail.com; natekemp@gmail.com; terra.laser@gmail.com; shc064@ucsd.edu RI Han, Li-Hsin/C-5440-2015 OI Han, Li-Hsin/0000-0002-0135-2863 FU Office of Naval Research [N00014-07-1-0609]; National Science Foundation [CMMI 0555275] FX The work of S. Chen was supported by grants from the Office of Naval Research (N00014-07-1-0609) and the National Science Foundation (CMMI 0555275). Subject Editor L. Lin. NR 21 TC 0 Z9 0 U1 3 U2 13 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 1057-7157 EI 1941-0158 J9 J MICROELECTROMECH S JI J. Microelectromech. Syst. PD APR PY 2011 VL 20 IS 2 BP 487 EP 496 DI 10.1109/JMEMS.2011.2105249 PG 10 WC Engineering, Electrical & Electronic; Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Applied SC Engineering; Science & Technology - Other Topics; Instruments & Instrumentation; Physics GA 745XR UT WOS:000289205400017 ER PT J AU Farrow, K Masland, RH AF Farrow, Karl Masland, Richard H. TI Physiological clustering of visual channels in the mouse retina SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE multielectrode recording; sensory encoding; ganglion cells; vision ID RECEPTIVE-FIELD PROPERTIES; SELECTIVE GANGLION-CELLS; LOCAL EDGE DETECTORS; RABBIT RETINA; QUANTITATIVE-ANALYSIS; MAMMALIAN RETINA; DATA SET; DIRECTION; CLASSIFICATION; IDENTIFICATION AB Farrow K, Masland RH. Physiological clustering of visual channels in the mouse retina. J Neurophysiol 105: 1516-1530, 2011. First published January 27, 2011; doi: 10.1152/jn.00331.2010.-Anatomy predicts that mammalian retinas should have in excess of 12 physiological channels, each encoding a specific aspect of the visual scene. Although several channels have been correlated with morphological cell types, the number of morphological types generally exceeds the known physiological types. Here, we attempted to sort the ganglion cells of the mouse retina purely on a physiological basis. The null hypothesis was that the outputs of the ganglion cells form a continuum or should be divided into only a few types. We recorded the spiking output of 471 retinal ganglion cells on a multielectrode array while presenting 4 classes of visual stimuli. Five parameters were chosen to describe each cell's response characteristics, including relative amplitude of the ON and OFF responses, response latency, response transience, direction selectivity, and the receptive field surround. We compared the results of four clustering routines and judged the results using the relevant validation indices. The optimal partition was the 12-cluster solution of the Fuzzy Gustafson-Kessel algorithm. This classification contained three visual channels that carried predominately OFF responses, six that carried ON responses, and three that carried both ON and OFF information. They differed in other parameters as well. Other evidence suggests that the true number of cell types in the mouse retina may be somewhat larger than 12, and a definitive typology will probably require broader stimulus sets and characterization of more response parameters. Nonetheless, the present results do allow us to reject the null hypothesis: it appears that in addition to well-known cell types (such as the ON-OFF direction selectivity cells) numerous other cell classes can be identified in the mouse retina based solely on their responses to a standard set of simple visual stimuli. C1 [Farrow, Karl] Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland. [Farrow, Karl; Masland, Richard H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. RP Farrow, K (reprint author), Friedrich Miescher Inst Biomed Res, WRO 1066-4-46, CH-4058 Basel, Switzerland. EM karl.farrow@fmi.ch OI Farrow, Karl/0000-0003-1409-096X NR 63 TC 36 Z9 36 U1 0 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD APR PY 2011 VL 105 IS 4 BP 1516 EP 1530 DI 10.1152/jn.00331.2010 PG 15 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 751LW UT WOS:000289620500009 PM 21273316 ER PT J AU Bansal, AK Vargas-Irwin, CE Truccolo, W Donoghue, JP AF Bansal, Arjun K. Vargas-Irwin, Carlos E. Truccolo, Wilson Donoghue, John P. TI Relationships among low-frequency local field potentials, spiking activity, and three-dimensional reach and grasp kinematics in primary motor and ventral premotor cortices SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE motor cortex; neural signals; neural coding; brain-machine interfaces; neural prosthesis ID POSTERIOR PARIETAL CORTEX; BRAIN-MACHINE INTERFACE; PRIMARY VISUAL-CORTEX; MACAQUE MONKEY; INFERIOR AREA-6; FUNCTIONAL-ORGANIZATION; MOVEMENT TRAJECTORIES; EVOKED-POTENTIALS; HAND MOVEMENTS; SIGNALS AB Bansal AK, Vargas-Irwin CE, Truccolo W, Donoghue JP. Relationships among low-frequency local field potentials, spiking activity, and three-dimensional reach and grasp kinematics in primary motor and ventral premotor cortices. J Neurophysiol 105: 1603-1619, 2011. First published January 27, 2011; doi: 10.1152/jn.00532.2010.-A prominent feature of motor cortex field potentials during movement is a distinctive low-frequency local field potential (lf-LFP) (< 4 Hz), referred to as the movement event-related potential (mEP). The lf-LFP appears to be a global signal related to regional synaptic input, but its relationship to nearby output signaled by single unit spiking activity (SUA) or to movement remains to be established. Previous studies comparing information in primary motor cortex (MI) lf-LFPs and SUA in the context of planar reaching tasks concluded that lf-LFPs have more information than spikes about movement. However, the relative performance of these signals was based on a small number of simultaneously recorded channels and units, or for data averaged across sessions, which could miss information of larger-scale spiking populations. Here, we simultaneously recorded LFPs and SUA from two 96-microelectrode arrays implanted in two major motor cortical areas, MI and ventral premotor (PMv), while monkeys freely reached for and grasped objects swinging in front of them. We compared arm end point and grip aperture kinematics' decoding accuracy for lf-LFP and SUA ensembles. The results show that lf-LFPs provide enough information to reconstruct kinematics in both areas with little difference in decoding performance between MI and PMv. Individual lf-LFP channels often provided more accurate decoding of single kinematic variables than any one single unit. However, the decoding performance of the best single unit among the large population usually exceeded that of the best single lf-LFP channel. Furthermore, ensembles of SUA outperformed the pool of lf-LFP channels, in disagreement with the previously reported superiority of lf-LFP decoding. Decoding results suggest that information in lf-LFPs recorded from intracortical arrays may allow the reconstruction of reach and grasp for real-time neuroprosthetic applications, thus potentially supplementing the ability to decode these same features from spiking populations. C1 [Bansal, Arjun K.; Vargas-Irwin, Carlos E.; Truccolo, Wilson; Donoghue, John P.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Truccolo, Wilson; Donoghue, John P.] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA. [Truccolo, Wilson] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Truccolo, Wilson; Donoghue, John P.] Vet Affairs Med Ctr, Rehabilitat Res & Dev Serv, Providence, RI USA. RP Bansal, AK (reprint author), 3 Blackfan Circle,CLS 13th Floor,13077, Boston, MA 02115 USA. EM Arjun.Bansal@childrens.havard.edu FU National Institute of Health [NIH/NINDS F32 NS061483, NIH/NINDS NS25074, RO1EB007401-01]; National Center for Research Resources [NCRR C06-16549-01A1]; National Science Foundation [IIS-0534858]; Office of Naval Research [N00014-07-1-0803, N00014-16-1-0692]; NIH-NINDS [5K01NS057389-03]; Katie Samson Foundation; Dana Foundation; Brown Brain Science Fellowship; Office of Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs FX This research project was supported by the National Institute of Health (NIH/NINDS F32 NS061483, NIH/NINDS NS25074, RO1EB007401-01), the National Center for Research Resources (NCRR C06-16549-01A1), National Science Foundation (IIS-0534858), the Office of Naval Research (N00014-07-1-0803, award N00014-16-1-0692), NIH-NINDS 5K01NS057389-03, the Katie Samson Foundation, Dana Foundation, Brown Brain Science Fellowship, and the Office of Research and Development, Rehabilitation R&D Service, Department of Veterans Affairs. NR 51 TC 64 Z9 64 U1 0 U2 10 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD APR PY 2011 VL 105 IS 4 BP 1603 EP 1619 DI 10.1152/jn.00532.2010 PG 17 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 751LW UT WOS:000289620500016 PM 21273313 ER PT J AU Barnes, TD Mao, JB Hu, D Kubota, Y Dreyer, AA Stamoulis, C Brown, EN Graybiel, AM AF Barnes, Terra D. Mao, Jian-Bin Hu, Dan Kubota, Yasuo Dreyer, Anna A. Stamoulis, Catherine Brown, Emery N. Graybiel, Ann M. TI Advance cueing produces enhanced action-boundary patterns of spike activity in the sensorimotor striatum SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE procedural learning; dorsolateral striatum; habit formation; basal ganglia; Parkinson's disease ID PRIMATE PREFRONTAL CORTEX; MEDIAL CAUDATE-NUCLEUS; TO-SAMPLE TASK; BASAL GANGLIA; PREMOTOR CORTEX; DORSAL STRIATUM; MAZE TASK; HIPPOCAMPAL; PERFORMANCE; MEMORY AB Barnes TD, Mao J-B, Hu D, Kubota Y, Dreyer AA, Stamoulis C, Brown EN, Graybiel AM. Advance cueing produces enhanced action-boundary patterns of spike activity in the sensorimotor striatum. J Neurophysiol 105: 1861-1878, 2011. First published February 9, 2011; doi:10.1152/jn.00871.2010.-One of the most characteristic features of habitual behaviors is that they can be evoked by a single cue. In the experiments reported here, we tested for the effects of such advance cueing on the firing patterns of striatal neurons in the sensorimotor striatum. Rats ran in a T-maze with instruction cues about the location of reward given at the start of the runs. This advance cueing about reward produced a highly augmented task-bracketing pattern of activity at the beginning and end of procedural task performance relative to the patterns found previously with midtask cueing. Remarkably, the largest increase in activity early during the T-maze runs was not associated with the instruction cues themselves, the earliest predictors of reward; instead, the highest peak of early activity was associated with the beginning of the motor period of the task. We suggest that the advance cueing, reducing midrun demands for decision making but adding a working-memory load, facilitated chunking of the maze runs as executable scripts anchored to sensorimotor aspects of the task and unencumbered by midtask decision-making demands. Our findings suggest that the acquisition of stronger task-bracketing patterns of striatal activity in the sensorimotor striatum could reflect this enhancement of behavioral chunking. Deficits in such representations of learned sequential behaviors could contribute to motor and cognitive problems in a range of neurological disorders affecting the basal ganglia, including Parkinson's disease. C1 [Barnes, Terra D.; Mao, Jian-Bin; Hu, Dan; Kubota, Yasuo; Graybiel, Ann M.] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA. [Barnes, Terra D.; Mao, Jian-Bin; Hu, Dan; Kubota, Yasuo; Dreyer, Anna A.; Brown, Emery N.; Graybiel, Ann M.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA. [Brown, Emery N.] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Stamoulis, Catherine] Childrens Hosp Boston, Dept Neurol & Radiol, Boston, MA USA. [Stamoulis, Catherine] Harvard Univ, Sch Med, Boston, MA USA. [Brown, Emery N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. RP Graybiel, AM (reprint author), MIT, McGovern Inst Brain Res, 46-6133,43 Vassar St, Cambridge, MA 02139 USA. EM graybiel@mit.edu FU National Institute of Health [R01 MH060379, R01 MH071847, DP1 OD003646-01, T32 NS048005]; Office of Naval Research [N000140410208]; Stanley H. and Sheila G. Sydney Fund FX This work was supported by National Institute of Health Grants R01 MH060379, Office of Naval Research Grant N000140410208, and the Stanley H. and Sheila G. Sydney Fund to A. Graybiel, and also by National Institute of Health Grants R01 MH071847 and DP1 OD003646-01 to E. Brown, and T32 NS048005 to C. Stamoulis. NR 63 TC 9 Z9 9 U1 2 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD APR PY 2011 VL 105 IS 4 BP 1861 EP 1878 DI 10.1152/jn.00871.2010 PG 18 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 751LW UT WOS:000289620500038 PM 21307317 ER PT J AU Stashenko, P Van Dyke, T Tully, P Kent, R Sonis, S Tanner, ACR AF Stashenko, Philip Van Dyke, Thomas Tully, Patrice Kent, Ralph, Jr. Sonis, Stephen Tanner, Anne C. R. TI Inflammation and Genetic Risk Indicators for Early Periodontitis in Adults SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Genotype; gingival crevicular fluid; health; periodontitis; race/ethnicity; smoking ID TUMOR-NECROSIS-FACTOR; SUBGINGIVAL MICROBIOTA; INTERLEUKIN-1 GENOTYPE; BONE DESTRUCTION; ATTACHMENT LOSS; IL-1 GENOTYPE; DISEASE; TISSUE; AGE; POLYMORPHISMS AB Background: This report is a further analysis of a study designed to determine clinical and microbial risk indicators for progressing periodontitis. Methods: One hundred ninety subjects who were periodontally healthy or had early signs of periodontitis (age range: 20 to 40 years) were monitored clinically at 6-month intervals followed by supragingival cleaning. At each visit, gingival crevicular fluid (GCF) and blood were collected for determination of interleukin (IL)-beta content (in GCF) and IL-1 genotype (in blood). Interproximal sites with a > 1.5-mm increase in clinical attachment over 18 months were considered disease active. Characteristics were compared between active and inactive subjects. Results: IL-1 beta levels in GCF increased with the severity of disease and correlated well with clinical signs of incipient disease. However, the IL-1 genotype did not show any significant associations with disease or the extent of disease. Conclusion: Indicators of inflammation may be important clinical determinants of future periodontal disease progression, but the IL-1 genotype was not a risk indictor for early (slight) periodontitis as defined in this subject population. J Periodontol 2011;82:588-596. C1 [Van Dyke, Thomas] Boston Univ, Goldman Sch Dent Med, Clin Res Ctr, Boston, MA 02118 USA. [Stashenko, Philip; Tully, Patrice] Forsyth Inst, Dept Cytokine Biol, Boston, MA USA. [Kent, Ralph, Jr.] Forsyth Inst, Dept Biostat, Boston, MA USA. [Sonis, Stephen] Brigham & Womens Hosp, Div Oral Med, Boston, MA 02115 USA. [Tanner, Anne C. R.] Forsyth Inst, Dept Mol Genet, Boston, MA USA. RP Van Dyke, T (reprint author), Boston Univ, Goldman Sch Dent Med, Clin Res Ctr, 100 E Newton St, Boston, MA 02118 USA. EM tvandyke@bu.edu FU United States Department of Health and Human Services, Washington, DC [DE09513, DE15566, DE 19938, RR00533, RR01032] FX The authors acknowledge the assistance of Lora Murray (Research Associate, The Forsyth Institute, Boston, MA), Nancy Mickels and Melissa Martins (Research Hygienists, Goldman School of Dental Medicine, Boston University, Boston, MA), and Manot Cyr and Lisa Newall (Research Hygienists, Brigham and Women's Hospital, Boston, MA) in subject recruitment and clinical measurements. We thank Dr. Kenneth Kornman, Interleukin Genetics, Waltham, Massachusetts, for the performance of the composite IL-1 genetic testing. This project was supported by grants DE09513 (to ACRT), DE15566 and DE 19938 (to TVD), RR00533 (Boston Univertsity, General Clinical Research Center), and RR01032 (Forsyth Institute, General Clinical Research Center) from the United States Department of Health and Human Services, Washington, DC. Drs. Stashenko and Van Dyke shared first authorship of this study. The authors report no conflict of interest related to this study. NR 46 TC 4 Z9 4 U1 0 U2 0 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 EI 1943-3670 J9 J PERIODONTOL JI J. Periodont. PD APR PY 2011 VL 82 IS 4 BP 588 EP 596 DI 10.1902/jop.2010.100443 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 749TD UT WOS:000289491900012 PM 21054222 ER PT J AU Singh, JA Sperling, J Buchbinder, R McMaken, K AF Singh, Jasvinder A. Sperling, John Buchbinder, Rachelle McMaken, Kelly TI Surgery for Shoulder Osteoarthritis: A Cochrane Systematic Review SO JOURNAL OF RHEUMATOLOGY LA English DT Review DE SURGERY; SHOULDER; OSTEOARTHRITIS; BENEFIT; SAFETY; COCHRANE SYSTEMATIC REVIEW ID KEELED GLENOID COMPONENTS; RANDOMIZED-TRIAL; PRIMARY-CARE; ARTHROPLASTY; PAIN; HEMIARTHROPLASTY; LIFE; INSTABILITY; PREVALENCE; DISABILITY AB Objective. To determine the benefits and harm of surgery for shoulder osteoarthritis (OA). Methods. We performed a Cochrane Systematic Review of clinical trials of adults with shoulder OA, comparing surgical techniques total shoulder arthroplasty (TSA), hemiarthroplasty, implant types, and fixation] to placebo, sham surgery, nonsurgical modalities, and no treatment. We also reviewed trials that compared various surgical techniques, reporting patient-reported outcomes (pain, function, quality of life, etc.) or revision rates. We calculated the risk ratio for categorical outcomes and mean differences for continuous outcomes with 95% CI. Results. There were no controlled trials of surgery versus placebo or nonsurgical interventions. Seven studies with 238 patients were included. Two studies compared TSA to hemiarthroplasty (n = 88). Significantly worse scores on the 0-100 American Shoulder and Elbow Surgeons scale (mean difference, -10.05 at 24-34 mo; 95% CI -18.97 to -1.13; p = 0.03) and a nonsignificant trend toward higher revision rate in hemiarthroplasty compared to TSA (relative risk 6.18; 95% CI 0.77 to 49.52; p = 0.09) were noted. With 1 study providing data (n = 41), no differences were noted between groups for pain scores (mean difference 7.8; 95% CI -5.33 to 20.93), quality of life on Medical Outcomes Study Short-Form 36 physical component summary (mean difference 0.80; 95% CI -6.63 to -8.23), and adverse events (relative risk 1.2; 95% CI 0.4 to 3.8). Conclusion. TSA was associated with better shoulder function, with no other demonstrable clinical benefits compared to hemiarthroplasty. More studies are needed to compare clinical outcomes between them and comparing shoulder surgery to sham, placebo. and other nonsurgical treatment options. (First Release Jan 15 2011; J Rheumatol 2011;38:598-605; doi:10.3899/jrheum.101008) C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham Vet Adm VA Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Hlth Sci Res, Rochester, MN USA. [Singh, Jasvinder A.] Mayo Clin, Sch Med, Dept Orthoped Surg, Rochester, MN USA. [Buchbinder, Rachelle] Cabrini Hosp, Monash Dept Clin Epidemiol, Malvern, Vic, Australia. [Buchbinder, Rachelle] Monash Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, Malvern, Vic, Australia. [McMaken, Kelly] Minneapolis VA Med Ctr, Med Serv, Minneapolis, MN USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, 510 20th St S,Fac Off Tower,Room 805B, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com RI Buchbinder, Rachelle/G-2952-2011; OI singh, jasvinder/0000-0003-3485-0006 FU National Institutes of Health [1 KL2 RR024151-01]; Australian National Health and Medical Research FX Supported by the National Institutes of Health Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) and from the resources and facilities at the Birmingham VA Medical Center. Dr. Buchbinder is supported in part by an Australian National Health and Medical Research Practitioner Fellowship. NR 52 TC 20 Z9 21 U1 0 U2 3 PU J RHEUMATOL PUBL CO PI TORONTO PA 365 BLOOR ST E, STE 901, TORONTO, ONTARIO M4W 3L4, CANADA SN 0315-162X EI 1499-2752 J9 J RHEUMATOL JI J. Rheumatol. PD APR PY 2011 VL 38 IS 4 BP 598 EP 605 DI 10.3899/jrheum.101008 PG 8 WC Rheumatology SC Rheumatology GA 747QF UT WOS:000289333800005 PM 21239751 ER PT J AU Sundt, TM Flemming, MD Oderich, GS Torres, NE Li, Z Lenoch, J Kalra, M AF Sundt, Thoralf M. Flemming, Mark D. Oderich, Gustavo S. Torres, Norman E. Li, Zhuo Lenoch, Judy Kalra, Manju TI Spinal Cord Protection During Open Repair of Thoracic and Thoracoabdominal Aortic Aneurysms Using Profound Hypothermia and Circulatory Arrest SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article; Proceedings Paper CT 122nd Annual Meeting of the Southern-Surgical-Association CY DEC, 2010 CL Palm Beach, FL SP So Surg Assoc ID OPEN SURGICAL REPAIR; ENDOVASCULAR TREATMENT; RISK; SURGERY; DEFICIT; TRIAL AB BACKGROUND: Reduced risk of paraplegia is argued as an advantage of endovascular repair of descending thoracic aortic aneurysms (DTA) and thoracoabdominal aortic aneurysms (TAAA); however, paraplegia rates with open repair vary widely. STUDY DESIGN: We identified consecutive patients undergoing open repair of TAAA or DTA with or without arch replacement using profound hypothermia and circulatory arrest as a spinal cord protection strategy on a single surgical service between June 1, 2001 and September 20, 2010. RESULTS: Ninety-nine procedures were performed in 94 patients with a mean age of 59 years (range 19 to 84 years), 56 of whom were male (60%). The extent of repair was TAAA in 37 (Crawford extent I in 6, extent II in 28, and extent III in 3), DTA in 37, and DTA plus arch in 25. Surgery was urgent or emergent in 25 patients (25%). Operative mortality (30-day) was 10% (10 of 99), including a mortality of 12% for arch DTA (3 of 26), 11% for TAAA (4 of 25), and 5% for isolated DTA (2 of 37). There were 11 (11%) strokes and 11 patients experienced renal failure (7 with dialysis). There were 15 late deaths and survival at 5 years was 74% (95% CI, 62.4-88.2%). No patients experienced paraplegia, although one had delayed paraparesis thought to be secondary to refractory hypotension postoperatively. CONCLUSIONS: Although the mortality and stroke risks for patients undergoing repair of DTA or TAAA using profound hypothermia and circulatory arrest are substantial, the risk for paraplegia is low. In appropriately selected patients, profound hypothermia and circulatory arrest should be the preferred technique for spinal cord protection for DTA and TAAA. (J Am Coll Surg 2011;212:678-685. (C) 2011 by the American College of Surgeons) C1 [Sundt, Thoralf M.; Lenoch, Judy] Mayo Clin, Div Cardiovasc Surg, Rochester, MN USA. [Flemming, Mark D.; Oderich, Gustavo S.; Kalra, Manju] Mayo Clin, Div Vasc Surg, Rochester, MN USA. [Torres, Norman E.] Mayo Clin, Div Anesthesiol, Rochester, MN USA. [Li, Zhuo] Mayo Clin, Div Biostat, Rochester, MN USA. RP Sundt, TM (reprint author), Massachusetts Gen Hosp, Div Cardiac Surg, 55 Fruit St, Boston, MA 02114 USA. EM tsundt@partners.org NR 20 TC 8 Z9 8 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD APR PY 2011 VL 212 IS 4 BP 678 EP 683 DI 10.1016/j.jamcollsurg.2010.12.022 PG 6 WC Surgery SC Surgery GA 748YU UT WOS:000289430000048 PM 21463811 ER PT J AU Niederman, R Clarkson, J Richards, D AF Niederman, Richard Clarkson, Janet Richards, Derek TI The Affordable Care Act and evidence-based care SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Editorial Material C1 [Niederman, Richard] Forsyth Inst, Ctr Evidence Based Dent, Cambridge, MA 02142 USA. [Clarkson, Janet] Univ Dundee, Effect Dent Practice Programme, Dent Hlth Serv & Res Unit, Dundee DD1 4HN, Scotland. [Clarkson, Janet] Univ Manchester, Cochrane Oral Hlth Grp, Manchester M13 9PL, Lancs, England. [Richards, Derek] Ctr Evidence Based Dent, Oxford, England. [Niederman, Richard; Richards, Derek] Evidence Based Dent, Cambridge, MA USA. RP Niederman, R (reprint author), Forsyth Inst, Ctr Evidence Based Dent, 245 1st St, Cambridge, MA 02142 USA. EM rniederman@forsyth.org NR 25 TC 9 Z9 9 U1 0 U2 2 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD APR PY 2011 VL 142 IS 4 BP 364 EP 367 PG 4 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 749EU UT WOS:000289447200001 PM 21454838 ER PT J AU Zajac, K Ruggiero, KJ Smith, DW Saunders, BE Kilpatrick, DG AF Zajac, Kristyn Ruggiero, Kenneth J. Smith, Daniel W. Saunders, Benjamin E. Kilpatrick, Dean G. TI Adolescent Distress in Traumatic Stress Research: Data From the National Survey of Adolescents-Replication SO JOURNAL OF TRAUMATIC STRESS LA English DT Article ID PARTICIPATION; VIOLENCE AB Small numbers of adults report distress in response to traumatic stress surveys. Less is known about adolescent research participants. We examined distress in response to a survey on traumatic stress using data from the National Survey of Adolescents-Replication, a nationally representative sample of 3,614 youth aged 12-17 years. Although 204 (5.7%) adolescents found some questions distressing, only 8 (0.2%) remained upset at the end of the interview, and 2 (< 0.1%) wished to speak to a counselor. Adolescents reporting traumatic experiences or mental health problems were significantly more likely to report distress compared to those not endorsing such problems. Significantly more girls (7.5%) reported distress than boys (3.9%). Findings suggest that survey questions about trauma pose minimal risk to adolescents. C1 [Zajac, Kristyn] Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Kenneth J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Zajac, K (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Natl Crime Victims Res & Treatment Ctr, 67 President St,MSC861, Charleston, SC 29425 USA. EM zajac@musc.edu FU NICHD NIH HHS [R01 HD046830, R01 HD046830-01]; NIMH NIH HHS [R01 MH81056, T32 MH018869, R01 MH081056] NR 9 TC 7 Z9 7 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-9867 EI 1573-6598 J9 J TRAUMA STRESS JI J. Trauma Stress PD APR PY 2011 VL 24 IS 2 BP 226 EP 229 DI 10.1002/jts.20621 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 750ER UT WOS:000289528300013 PM 21412852 ER PT J AU Lin, JY Warger, WC Izikson, L Anderson, RR Tannous, Z AF Lin, Jennifer Y. Warger, William C. Izikson, Leonid Anderson, R. Rox Tannous, Zeina TI A Prospective, Randomized Controlled Trial on the Efficacy of Fractional Photothermolysis on Scar Remodeling SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE clinical trial; hypertrophic scar; laser resurfacing; wound healing ID PULSED-DYE-LASER; SUPPRESSED TGF-BETA-1 EXPRESSION; HYPERTROPHIC STERNOTOMY SCARS; TREATMENT RESPONSE; SURGICAL SCARS; BURN SCARS; 5-FLUOROURACIL; MICROSCOPY; EXPERIENCE AB Background: Non-ablative fractional resurfacing (NAFR) has been reported in case studies as an effective treatment for surgical and burn scars [Behroozan et al., J Cosmet Laser Ther 2006; 8(1): 35-38; Haedersdal et al., Lasers Surg Med 2009; 41(3): 189-195; Waibel and Beer, J Drugs Dermatol 2008; 7(1): 59-61; Niwa et al., Dermatol Surg 2009; 35(5): 773-777; discussion 777-778; and Tierney et al., Dermatol Surg 2009; 35(8): 1172-1180]. We have performed a prospective, randomized controlled study with two different treatment arms to better characterize the response of hypertrophic scars to NAFR. Study Design: We conducted a prospective, controlled trial on linear, surgical hypertrophic scars 6 months or older in age. Subjects were randomized into two treatment arms of NAFR: (a) high-density treatment arm (HDTA): 40 mJ and percent coverage of 26% and (b) low-density treatment arm (LDTA): 40 mJ and percent coverage of 14%. One-half of the scar was treated every 2 weeks for a total of four treatments, with subsequent follow-up visits at 1 month and 3 months. Scar improvement was judged as compared to the untreated side by the subjects and two blinded observers using a four-point scale (0 = no improvement or worsening, 1 = minor improvement, 2 = moderate improvement, and 3 - marked improvement). Volumetric changes were also measured for a select group (n = 4) by measuring scar casts with optical frequency domain imaging. Patient satisfaction was surveyed at the end of the trial. Side effects in both treatment arms were assessed. Results: Twenty patients were enrolled, of which 17 subjects noted improvement in their scars compared to untreated side. Three subjects in the HDTA rated their scars as having a worsened appearance at the end of the study. After treatment was completed, scars continued to improve in appearance at 3 months compared to 1 month. Subjects in the LDTA rated the treated side with higher scores, than subjects in the HDTA (P = 0.001). Scars < 2 years old tended to respond better to NAFR as compared to scars > 6 years old. The side effects profile was more severe in the HDTA group. Nevertheless, all subjects were satisfied with the procedure at trial completion. Conclusions: This study demonstrates the efficacy of NAFR for treating hypertrophic scars. Low-density treatment is at least as effective as the high-density treatment and with fewer side effects. The study also suggests that younger scars respond better to NAFR. Thus, early intervention may be key in the treatment of hypertrophic scars. Lasers Surg. Med. 43: 265-272, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Lin, Jennifer Y.; Warger, William C.; Izikson, Leonid; Anderson, R. Rox; Tannous, Zeina] Wellman Ctr Photomed, Boston, MA USA. [Lin, Jennifer Y.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA. [Anderson, R. Rox; Tannous, Zeina] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA. [Tannous, Zeina] Boston Vet Affairs Hlth Care Syst, Dept Dermatol, Boston, MA USA. RP Lin, JY (reprint author), 41 Ave Louis Pasteur,Rm 319B, Boston, MA 02115 USA. EM jylin@partners.org FU USAF FX We would like to acknowledge and thank Dr. Brett Bouma and Dr. Gary Tearney for their scientific input and use of the OFDI apparatus at Wellman Center. We would like to thank Dr. Fernanda Sakamoto and Dr. Mathew Avram for serving as blinded observers. This article was presented as an abstract at the 2009 ASLMS annual meeting under the support of a USAF travel grant. NR 41 TC 17 Z9 18 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD APR PY 2011 VL 43 IS 4 BP 265 EP 272 DI 10.1002/lsm.21061 PG 8 WC Dermatology; Surgery SC Dermatology; Surgery GA 751NG UT WOS:000289624200001 PM 21500220 ER PT J AU Huang, LY Zhiyentayev, T Xuan, Y Azhibek, D Kharkwal, GB Hamblin, MR AF Huang, Liyi Zhiyentayev, Timur Xuan, Yi Azhibek, Dulat Kharkwal, Gitika B. Hamblin, Michael R. TI Photodynamic Inactivation of Bacteria Using Polyethylenimine-Chlorin(e6) Conjugates: Effect of Polymer Molecular Weight, Substitution Ratio of Chlorin(e6) and pH SO LASERS IN SURGERY AND MEDICINE LA English DT Article DE antimicrobial photodynamic therapy; polyethylenimine-chlorine(e6) conjugate; pH value; polymer molecular weight; substitution ratio; static and dynamic quenching ID GRAM-NEGATIVE BACTERIA; MESOSUBSTITUTED CATIONIC PORPHYRINS; IN-VIVO; ACINETOBACTER-BAUMANNII; PERMEABILITY BARRIERS; POSITIVE BACTERIA; WOUND INFECTIONS; CELLULAR UPTAKE; OUTER-MEMBRANE; SINGLET OXYGEN AB Background and Objectives: Antimicrobial photodynamic therapy (APDT) is a novel technique to treat local infections. Previously we reported that the attachment of chlorin(e6) to polyethylenimine (PEI) polymers to form PEI-ce6 conjugates is an effective way to improve ce6 PDT activity against bacteria. The aim of this work was to explore how the polymer molecular weight, substitution ratio (SR) of ce6 and pH value affect the PDT efficacy. Study Design/Materials and Methods: We have synthesized PEI-ce6(10) (MW 60,000, SR 1) and PEI-ce6(11) (MW 60,000, SR 5) and compared these with the previous PEI-ce6(9) (MW 10,000, SR 1). We tested the PDT efficacy of these three conjugates against Gram-negative E. coli and Gram-positive bacteria (S. aureus and E. fecalis) at three different pH values (5.0, 7.4, 10.0) that may affect the charge on both the bacterial cells and on the conjugate (that has both basic and acidic groups). Results: PEI-ce6(9) and PEI-ce6(10) were the most effective against these tested bacteria. The PDT effect of all three conjugates depended on pH values. The effective order was pH 10.0 > pH 7.4 > pH 5.0 on E. coli. For S. aureus and E. fecalis the order was pH 5.0 > pH 10.0 > pH 7.4. PEI-ce6(11) PDT activity was worse than PEI-ce6(10) activity which is probably connected to the fact that ce6 molecules are self-quenched within the PEI-ce6(11) molecule. Ce6 quenching within the PEI-ce6 molecules was proved by analyzing fluorescence spectra of PEI-ce6 conjugates at different pH values. There were no differences in bacterial uptake between different pH values in three PEI-ce6 conjugates. Conclusion: We assume high pH (rather than low pH as was hypothesized) disaggregates the conjugates, so the higher pH was more effective than the lower pH against E. coli. But for Gram-positive bacteria, low pH was more effective possibly due to more overall positive charge on the conjugate. Lasers Surg. Med. 43: 313-323, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Huang, Liyi; Zhiyentayev, Timur; Xuan, Yi; Azhibek, Dulat; Kharkwal, Gitika B.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Huang, Liyi; Kharkwal, Gitika B.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA. [Huang, Liyi] Guangxi Med Univ, Dept Infect Dis, Affiliated Coll & Hosp 1, Nanning 530021, Peoples R China. [Zhiyentayev, Timur] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA. [Xuan, Yi] Tufts Univ, Medford, MA 02155 USA. [Azhibek, Dulat] Moscow MV Lomonosov State Univ, Dept Chem, Moscow, Russia. [Hamblin, Michael R.] Harvard Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St,BAR414, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu OI Hamblin, Michael/0000-0001-6431-4605 FU NIH [R01A1050875]; US Air Force MFEL Program [FA9550-04-1-0079]; ASLMS FX This work was supported by NIH (R01A1050875 to MRH) and US Air Force MFEL Program (FA9550-04-1-0079). LH received a travel grant from ASLMS for attending the 30th ASLMS Annual Conference and presenting the preliminary data. This contribution satisfies the condition of the travel grant that a manuscript should be submitted to LSM within one year after the annual conference. NR 51 TC 19 Z9 22 U1 3 U2 33 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0196-8092 J9 LASER SURG MED JI Lasers Surg. Med. PD APR PY 2011 VL 43 IS 4 BP 313 EP 323 DI 10.1002/lsm.21056 PG 11 WC Dermatology; Surgery SC Dermatology; Surgery GA 751NG UT WOS:000289624200007 PM 21500226 ER PT J AU Calimeri, T Battista, E Conforti, F Neri, P Di Martino, MT Rossi, M Foresta, U Piro, E Ferrara, F Amorosi, A Bahlis, N Anderson, KC Munshi, N Tagliaferri, P Causa, F Tassone, P AF Calimeri, T. Battista, E. Conforti, F. Neri, P. Di Martino, M. T. Rossi, M. Foresta, U. Piro, E. Ferrara, F. Amorosi, A. Bahlis, N. Anderson, K. C. Munshi, N. Tagliaferri, P. Causa, F. Tassone, P. TI A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells SO LEUKEMIA LA English DT Letter C1 [Calimeri, T.; Neri, P.; Di Martino, M. T.; Rossi, M.; Foresta, U.; Tagliaferri, P.; Tassone, P.] Univ Magna Gracia, Dept Expt & Clin Med, Translat Med Oncol Unit, Catanzaro, Italy. [Calimeri, T.; Neri, P.; Di Martino, M. T.; Rossi, M.; Foresta, U.; Tagliaferri, P.; Tassone, P.] Tommaso Campanella Canc Ctr, Catanzaro, Italy. [Battista, E.; Causa, F.] Univ Magna Gracia, Dept Expt & Clin Med, Biomat Lab, Catanzaro, Italy. [Battista, E.; Causa, F.] Italian Inst Technol, Ctr Adv Biomat Hlth Care, Naples, Italy. [Conforti, F.; Amorosi, A.] Univ Magna Gracia, Dept Pathol, Sch Med, Catanzaro, Italy. [Neri, P.; Bahlis, N.] Univ Calgary, Dept Med, Hematol Unit, Calgary, AB, Canada. [Piro, E.] Azienda Osped Pugliese Ciaccio, Hematol Unit, Catanzaro, Italy. [Ferrara, F.] Villa Serena Hosp, Orthoped Surg Unit, Catanzaro, Italy. [Anderson, K. C.; Munshi, N.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Anderson, K. C.; Munshi, N.] Harvard Univ, Sch Med, Boston, MA USA. RP Calimeri, T (reprint author), Univ Magna Gracia, Dept Expt & Clin Med, Translat Med Oncol Unit, Catanzaro, Italy. EM tassone@unicz.it RI Battista, Edmondo/B-3104-2013; OI Battista, Edmondo/0000-0003-0915-9176; Causa, Filippo/0000-0002-5436-3857; ROSSI, Marco/0000-0002-7258-475X FU NCI NIH HHS [P01 CA155258, P01 CA078378, P50 CA100707, R01 CA124929]; Associazione Italiana per la Ricerca sul Cancro NR 8 TC 52 Z9 52 U1 2 U2 12 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0887-6924 J9 LEUKEMIA JI Leukemia PD APR PY 2011 VL 25 IS 4 BP 707 EP 711 DI 10.1038/leu.2010.300 PG 5 WC Oncology; Hematology SC Oncology; Hematology GA 749NO UT WOS:000289475300018 PM 21233838 ER PT J AU Wu, IC Zhao, Y Zhai, RH Liu, G Ter-Minassian, M Asomaning, K Su, L Liu, CY Chen, F Kulke, MH Heist, RS Christiani, DC AF Wu, I-Chen Zhao, Yang Zhai, Rihong Liu, Geoffrey Ter-Minassian, Monica Asomaning, Kofi Su, Li Liu, Chen-Yu Chen, Feng Kulke, Matthew H. Heist, Rebecca S. Christiani, David C. TI Association between Polymorphisms in Cancer-Related Genes and Early Onset of Esophageal Adenocarcinoma SO NEOPLASIA LA English DT Article ID BARRETTS-ESOPHAGUS; NITRIC-OXIDE; RISK; EXPRESSION; SEX; EPIDEMIOLOGY; DYSPEPSIA; PROGNOSIS; APOPTOSIS; SURVIVAL AB There is an increasing incidence of esophageal adenocarcinoma (EA) among younger people in the western populations. However, the association between genetic polymorphisms and the age of EA onset is unclear. In this study, 1330 functional/tagging single-nucleotide polymorphisms (SNPs) from 354 cancer-related genes were genotyped in 335 white EA patients. Twenty important SNPs that have the highest importance scores and lowest classification error rate were identified by the random forest algorithm to be associated with early onset of EA (age <= 55 years). Subsequent logistic regression analysis indicated that 10 SNPs (rs2070744 of NOS3, rs720321 of BCL2, rs17757541 of BCL2, rs11775256 of TNFRSF10A, rs1035142 of CASP8, rs2236302 of MMP14, rs4740363 of ABL1, rs696217 of GHRL, rs2445762 of CYP19A1, and rs11941492 of VEGFR2/KDR) were significantly associated with early onset of EA (<= 55 vs > 55 years, all P < .05 after adjusting for co-variates and false discovery rate). Among them, five SNPs in the NOS3, BCL2, TNFRSF10A, and CASP8 genes were known to be involved in apoptosis processes. In Kaplan-Meier analyses, rs2070744 of NOS3, rs720321 of BCL2, and rs1035142 of CASP8 were also significantly associated with early onset of EA. Moreover, there was a higher risk of developing EA at a younger age when one had more risk genotypes. In conclusion, polymorphisms in cancer-related genes, especially those in the apoptotic pathway, play an important role in the development of younger-aged EA in a dose-response manner. C1 [Wu, I-Chen; Zhao, Yang; Zhai, Rihong; Liu, Geoffrey; Ter-Minassian, Monica; Asomaning, Kofi; Su, Li; Liu, Chen-Yu; Chen, Feng; Heist, Rebecca S.; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, Boston, MA 02115 USA. [Wu, I-Chen] Kaohsiung Med Univ, Div Gastroenterol, Dept Internal Med, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan. [Liu, Geoffrey] Princess Margaret Hosp, Dept Med, Toronto, ON M4X 1K9, Canada. [Liu, Geoffrey] Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada. [Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Heist, Rebecca S.; Christiani, David C.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, 665 Huntington Ave,Bldg 1,Room 1401, Boston, MA 02115 USA. EM dchris@hsph.harvard.edu RI Liu, Geoffrey/N-4421-2016; OI LIU, CHEN-YU/0000-0002-4693-5667 FU National Institutes of Health [R01CA109193, R03CA110822, R01CA074386, ES00002]; CIHR; Kevin Jackson Memorial Fund; Alan B. Brown Chair in Molecular Genomics; PMH Foundation; Flight Attendant Medical Research Institute [062459]; National Center for Research Resources [U54 RR020278] FX This study was funded by National Institutes of Health grants R01CA109193, R03CA110822, R01CA074386, and ES00002; CIHR operating grant; the Kevin Jackson Memorial Fund; Alan B. Brown Chair in Molecular Genomics; Posluns Family Fund PMH Foundation; and the Flight Attendant Medical Research Institute Award No. 062459. The Broad Institute Center for Genotyping and Analysis is supported by grant U54 RR020278 from the National Center for Research Resources. NR 36 TC 15 Z9 15 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1522-8002 EI 1476-5586 J9 NEOPLASIA JI Neoplasia PD APR PY 2011 VL 13 IS 4 BP 386 EP U233 DI 10.1593/neo.101722 PG 10 WC Oncology SC Oncology GA 750FB UT WOS:000289529400010 PM 21472143 ER PT J AU Saleh, C Gale, JT Eskandar, E AF Saleh, Christian Gale, John T. Eskandar, Emad TI The Need for a Multifactorial Approach to Raise the Standard in Deep Brain Stimulation Reporting SO NEUROMODULATION LA English DT Letter ID SUBTHALAMIC NUCLEUS STIMULATION; PARKINSONS-DISEASE; THALAMIC NUCLEUS; ISSUES; STN C1 [Gale, John T.] Cleveland Clin, Dept Neurosci, Cleveland, OH 44106 USA. [Gale, John T.] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH 44106 USA. [Eskandar, Emad] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA. [Eskandar, Emad] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Nayef Al Rodhan Labs Cellular Neurosurg & Neurosu, Boston, MA USA. NR 20 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1094-7159 J9 NEUROMODULATION JI Neuromodulation PD APR PY 2011 VL 14 IS 2 BP 183 EP 184 DI 10.1111/j.1525-1403.2011.00341.x PG 2 WC Medicine, Research & Experimental; Clinical Neurology SC Research & Experimental Medicine; Neurosciences & Neurology GA 745FC UT WOS:000289150300050 PM 21992209 ER PT J AU Borsook, D Becerra, L AF Borsook, David Becerra, Lino TI CNS animal fMRI in pain and analgesia SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE Pain; Analgesia; Rodents; Anesthesia; Translational medicine; fMRI; BOLD; Acute pain; Chronic pain models; Pharmacology; Neuropathic pain; Visceral pain; Opioids ID NEAR-INFRARED SPECTROSCOPY; CEREBRAL-BLOOD-FLOW; SPINAL-CORD-INJURY; MAGNETIC-RESONANCE MICROSCOPY; RAT SOMATOSENSORY CORTEX; NOXIOUS ELECTRICAL-STIMULATION; POSITRON-EMISSION-TOMOGRAPHY; ISOFLURANE-ANESTHETIZED RAT; DIRECT THALAMIC-STIMULATION; VOLUME-WEIGHTED FMRI AB Animal imaging of brain systems offers exciting opportunities to better understand the neurobiology of pain and analgesia. Overall functional studies have lagged behind human studies as a result of technical issues including the use of anesthesia. Now that many of these issues have been overcome including the possibility of imaging awake animals, there are new opportunities to study whole brain systems neurobiology of acute and chronic pain as well as analgesic effects on brain systems de novo (using pharmacological MRI) or testing in animal models of pain. Understanding brain networks in these areas may provide new insights into translational science, and use neural networks as a "language of translation" between preclinical to clinical models. In this review we evaluate the role of functional and anatomical imaging in furthering our understanding in pain and analgesia. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Borsook, David; Becerra, Lino] Massachusetts Gen Hosp, Ctr Biomed Imaging, Dept Radiol, PAIN Grp, Belmont, MA 02478 USA. RP Borsook, D (reprint author), Massachusetts Gen Hosp, Ctr Biomed Imaging, Dept Radiol, PAIN Grp, 115 Mill St, Belmont, MA 02478 USA. EM dborsook@partners.org FU L Herlands Fund; [NS064050] FX Supported by (NS064050) to DB and the L Herlands Fund to the P.AI.N. Group (DB, LB). NR 165 TC 25 Z9 26 U1 1 U2 22 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 EI 1873-7528 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD APR PY 2011 VL 35 IS 5 BP 1125 EP 1143 DI 10.1016/j.neubiorev.2010.11.005 PG 19 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 747RQ UT WOS:000289337500004 PM 21126534 ER PT J AU Stufflebeam, SM AF Stufflebeam, Steven M. TI Clinical Magnetoencephalography for Neurosurgery SO NEUROSURGERY CLINICS OF NORTH AMERICA LA English DT Article DE Epilepsy; Surgery; Brain tumor; Interictal; Localization; Noninvasive; Connectivity ID EVOKED MAGNETIC-FIELDS; INTRACAROTID AMOBARBITAL PROCEDURE; SUPPLEMENTARY MOTOR AREA; LANGUAGE-SPECIFIC CORTEX; TEMPORAL-LOBE; WADA TEST; CORTICAL ACTIVITY; EPILEPSY PATIENTS; BRAIN ACTIVITY; MEG AB Noninvasive neuroimaging aids in surgical planning and in counseling patients about possible risks of surgery. Magnetoencephalography (MEG) performs the most common types of surgical planning that the neurosurgeon faces, including localization of epileptic discharges, determination of the hemispheric dominance of verbal processing, and the ability to locate eloquent cortex. MEG is most useful when it is combined with structural imaging, most commonly with structural magnetic resonance (MR) imaging and MR diffusion imaging. This article reviews the history of clinical MEG, introduces the basic concepts about the biophysics of MEG, and outlines the basic neurosurgical applications of MEG. C1 [Stufflebeam, Steven M.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA. [Stufflebeam, Steven M.] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Stufflebeam, Steven M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA. RP Stufflebeam, SM (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, 149 13th St,Mailcode 2301, Charlestown, MA 02129 USA. EM sms@nmr.mgh.harvard.edu FU NIMH NIH HHS [K08 MH067966, K08 MH067966-05]; NINDS NIH HHS [R01 NS069696-01A1, R01 NS069696, R01 NS060918] NR 90 TC 17 Z9 17 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1042-3680 J9 NEUROSURG CLIN N AM JI Neurosurg. Clin. N. Am. PD APR PY 2011 VL 22 IS 2 BP 153 EP + DI 10.1016/j.nec.2010.11.006 PG 17 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 751YQ UT WOS:000289654400005 PM 21435568 ER PT J AU Regan, S Reyen, M Lockhart, AC Richards, AE Rigotti, NA AF Regan, Susan Reyen, Michele Lockhart, Abigail C. Richards, Ann E. Rigotti, Nancy A. TI An Interactive Voice Response System to Continue a Hospital-Based Smoking Cessation Intervention After Discharge SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID DISEASE; CARE AB Hospitalized smokers benefit from tobacco counseling received in hospital only if it continues after discharge. Interactive voice response (IVR) technology may be useful in delivering this care. We conducted a randomized controlled trial testing two intensities of follow-up contact using an IVR system; 738 cigarette smokers who received inpatient counseling at an academic medical center were enrolled. Participants were randomized to receive four IVR calls during the first month postdischarge that included the offer of a call back (CB) from a smoking counselor (IVR + CB, N = 368) or 1 IVR call at 2 weeks postdischarge that assessed smoking outcomes without offering any counseling support (IVR, N = 370). All were assessed by human telephone call at 12 weeks. Postdischarge counseling and medication utilization rates and self-reported smoking cessation were assessed at 2 and 12 weeks postdischarge. Of those randomized to IVR + CB, 59% received a CB offer and 34% of those receiving offers accepted. Cessation rates did not differ between IVR + CB and IVR at 2 weeks (39% vs. 39%, rate ratio: 1.02, 95% CI: 0.85-1.22) or 12 weeks (29% vs. 26%, rate ratio: 1.11, 95% CI: 0.90-1.41). Medication use did not differ by group but was higher among those accepting versus declining CB offers (69% vs. 52%, p < .05). An IVR system is feasible for postdischarge follow-up and support for hospitalized smokers. Participants, especially pharmacotherapy users, took advantage of postdischarge counseling offers, although offers were not associated with increased smoking cessation. C1 [Regan, Susan; Reyen, Michele; Lockhart, Abigail C.; Richards, Ann E.; Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Med, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA. [Regan, Susan; Rigotti, Nancy A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. RP Regan, S (reprint author), Massachusetts Gen Hosp, Div Gen Med, Tobacco Res & Treatment Ctr, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM sregan@partners.org FU Partners Health Care System; National Heart Lung and Blood Institute [K24-HL04440]; Pfizer; Sanofi-Aventis; Nabi Biopharmaceuticals FX This project was funded by Partners Health Care System and by a grant from the National Heart Lung and Blood Institute (K24-HL04440).; Dr. Rigotti has received research grant funding from Pfizer, Sanofi-Aventis, and Nabi Biopharmaceuticals for the study of investigational and/or marketed smoking cessation products. She is an unpaid consultant for Pfizer and Free & Clear, Inc. NR 10 TC 19 Z9 19 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD APR PY 2011 VL 13 IS 4 BP 255 EP 260 DI 10.1093/ntr/ntq248 PG 6 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 745VH UT WOS:000289197400004 PM 21330278 ER PT J AU Rajpal, R Dowling, P Meiller, J Clarke, C Murphy, WG O'Connor, R Kell, M Mitsiades, C Richardson, P Anderson, KC Clynes, M O'Gorman, P AF Rajpal, Rajesh Dowling, Paul Meiller, Justine Clarke, Colin Murphy, William G. O'Connor, Robert Kell, Malcolm Mitsiades, Constantine Richardson, Paul Anderson, Kenneth C. Clynes, Martin O'Gorman, Peter TI A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients SO PROTEOMICS LA English DT Article DE Biomarkers; Biomedicine; Multiple myeloma; Thalidomide ID INTERNATIONAL STAGING SYSTEM; STEM-CELL TRANSPLANTATION; D-BINDING PROTEIN; GEL-ELECTROPHORESIS; PROTEOMIC ANALYSIS; ELDERLY-PATIENTS; HUMAN MONOCYTES; IDENTIFICATION; SERUM; CANCER AB Multiple myeloma (MM) is a heterogeneous group of disorders both genotypically and phenotypically. Response to thalidomide-based induction therapy in newly diagnosed patients varies significantly in published clinical trials. Proteomic analysis was performed on 39 newly diagnosed MM patients treated with a thalidomide-based regimen (22 responders; 17 non-responders) using immunodepletion, 2-D DIGE analysis and mass spectrometry. Zinc-alpha-2-glycoprotein (ZAG), vitamin D-binding protein (VDB), serum amyloid-A protein (SAA) and beta-2-microglobulin (B2M) had statistically significant higher concentrations in non-responders compared to responders, while haptoglobin (Hp) had a lower concentration. ELISAs were used to validate the candidate protein biomarkers using unfractionated serum from 51 newly diagnosed MM patients (29 responders; 22 non-responders). Using logistic regression, the best possible area under the curve (AUC) was 0.96 using ZAG, VDB and SAA in combination. Leave-one-out-cross-validation (LOOCV) indicated an overall predictive accuracy of 84% with associated sensitivity and specificity values of 81.8 and 86.2%, respectively. Subsequently, 16 of 22 thalidomide-refractory patients successfully achieved complete response or very good partial response using second-line treatment suggesting that the biomarker profile is specific to thalidomide response rather than identifying patients with MM refractory to all therapies. Using a novel panel of predictive biomarkers, the feasibility of predicting response to thalidomide-based therapy in previously untreated MM has been demonstrated. C1 [Rajpal, Rajesh; Dowling, Paul; Meiller, Justine; Clarke, Colin; O'Connor, Robert; Clynes, Martin; O'Gorman, Peter] Dublin City Univ, NICB, Dublin 9, Ireland. [O'Gorman, Peter] Mater Misericordiae Univ Hosp, Dept Hematol, Dublin 7, Ireland. [Rajpal, Rajesh; Murphy, William G.] Irish Blood Transfus Serv, Dublin, Ireland. [O'Connor, Robert] Dublin City Univ, Sch Nursing, Dublin 9, Ireland. [Kell, Malcolm; O'Gorman, Peter] Univ Coll Dublin, Dublin Acad Med Ctr, Dublin 2, Ireland. [Mitsiades, Constantine; Richardson, Paul; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP O'Gorman, P (reprint author), Mater Misericordiae Univ Hosp, Dept Hematol, Eccles St, Dublin 7, Ireland. EM pogorman@mater.ie RI clarke, colin/G-4453-2013; OI clarke, colin/0000-0002-1897-7472; o'connor, robert/0000-0003-4426-2507; Clarke, Colin/0000-0003-2817-9527; Dowling, Paul/0000-0002-9290-9267 FU Mater Myeloma Cancer Research Fund; Irish Blood Transfusion Services; Irish Higher Education Authority (HEA); Enterprise Ireland FX The authors thank Dr. P. Murphy and Dr. G. Crotty for providing "clinical samples.'' The Mater Myeloma Cancer Research Fund, Irish Blood Transfusion Services, Irish Higher Education Authority (HEA) PRTLI Cycle 4 and Enterprise Ireland for the funding support. NR 49 TC 12 Z9 12 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1615-9853 J9 PROTEOMICS JI Proteomics PD APR PY 2011 VL 11 IS 8 BP 1391 EP 1402 DI 10.1002/pmic.201000471 PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 750EV UT WOS:000289528800003 PM 21365752 ER PT J AU Jo, YH Kim, K Rhee, JE Suh, GJ Kwon, WY Na, SH Alam, HB AF Jo, You Hwan Kim, Kyuseok Rhee, Joong Eui Suh, Gil Joon Kwon, Woon Yong Na, Sang Hoon Alam, Hasan B. TI Therapeutic hypothermia attenuates acute lung injury in paraquat intoxication in rats SO RESUSCITATION LA English DT Article DE Paraquat; Hypothermia; Survival; Oxidative stress; Inflammation; Lung injury ID MODERATE HYPOTHERMIA; MONONUCLEAR-CELLS; NITRIC-OXIDE; TOXICITY; PREVENTION AB Aim of the study: Paraquat intoxication induces acute lung injury and numerous fatalities have been reported. The mechanism of toxic effect of paraquat is oxidative injury and inflammation. Therapeutic hypothermia has been known to have antioxidant and anti-inflammatory effects. This study was designed to evaluate the effect of therapeutic hypothermia on paraquat intoxication. Methods: Male Sprague-Dawley rats were given 50 mg/kg of paraquat intraperitoneally and divided into the normothermia (36-38 degrees C) group and the hypothermia (30-32 degrees C) group after 1 h of paraquat administration. The hypothermia group underwent 2 h of hypothermia followed by 2 h of rewarming. In the survival study, mortality was observed for 24 h after paraquat administration. An in the second experiment, lung tissues and plasma were harvested at 6 h after paraquat administration. Results: The 12 h survival rate was significantly higher in the hypothermia group than in the normothermia group (100% vs. 50%, p < 0.05), but survival rates for 24 h were not different. Acute lung injury score was lower in the hypothermia group than in the normothermia group (p < 0.05). Thmalondialdehyde contents of lung tissues, plasma interleukin-6 and nitrite/nitrate concentrations were significantly decreased in the HT group compared to the NT group (p < 0.05). Conclusion: Therapeutic hypothermia delayed early mortality and attenuated acute lung injury in paraquat intoxication. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Jo, You Hwan; Kim, Kyuseok; Rhee, Joong Eui] Seoul Natl Univ, Bundang Hosp, Dept Emergency Med, Songnam 463707, Gyeonggi Do, South Korea. [Na, Sang Hoon] Seoul Natl Univ, Coll Med, Dept Emergency Med, Dept Internal Med,Div Cardiol, Seoul 110774, South Korea. [Alam, Hasan B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care,Dept S, Boston, MA USA. RP Kim, K (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Emergency Med, 166 Gumi Ro, Songnam 463707, Gyeonggi Do, South Korea. EM dremkks@snubh.org RI Rhee, Joong Eui/J-5606-2012; Suh, Gil Joon/J-5510-2012; OI Kim, Kyuseok/0000-0002-7991-9428; Kwon, Woon Yong/0000-0002-3343-5030; Jo, You Hwan/0000-0002-9507-7603 FU SNUBH [11-2009-024] FX This study was supported by grant no. 11-2009-024 from the SNUBH Research Fund. NR 26 TC 15 Z9 21 U1 0 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-9572 J9 RESUSCITATION JI Resuscitation PD APR PY 2011 VL 82 IS 4 BP 487 EP 491 DI 10.1016/j.resuscitation.2010.11.028 PG 5 WC Critical Care Medicine; Emergency Medicine SC General & Internal Medicine; Emergency Medicine GA 750NS UT WOS:000289555800024 PM 21236547 ER PT J AU Suppiah, R Judge, A Batra, R Flossmann, O Harper, L Hoglund, P Javaid, MK Jayne, D Mukhtyar, C Westman, K Davis, JC Hoffman, GS McCune, WJ Merkel, PA St Clair, EW Seo, P Specks, U Spiera, R Stone, JH Luqmani, R AF Suppiah, Ravi Judge, Andrew Batra, Rajbir Flossmann, Oliver Harper, Lorraine Hoglund, Peter Javaid, M. Kassim Jayne, David Mukhtyar, Chetan Westman, Kerstin Davis, John C. Hoffman, Garry S. McCune, W. Joseph Merkel, Peter A. St Clair, E. William Seo, Philip Specks, Ulrich Spiera, Robert Stone, John H. Luqmani, Raashid TI A MODEL TO PREDICT CARDIOVASCULAR EVENTS IN PATIENTS WITH NEWLY DIAGNOSED WEGENER'S GRANULOMATOSIS AND MICROSCOPIC POLYANGIITIS SO RHEUMATOLOGY LA English DT Meeting Abstract CT Annual Meeting of the British-Society-for-Rheumatology 2011 CY APR 12-14, 2011 CL Brighton, ENGLAND SP British Soc Rheumatol C1 [Suppiah, Ravi] Nuffield Orthopaed Ctr, Oxford OX3 7LD, England. [Suppiah, Ravi; Judge, Andrew; Batra, Rajbir; Javaid, M. Kassim] Univ Oxford, Oxford NIHR Musculoskeletal BRU, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England. [Flossmann, Oliver; Jayne, David] Addenbrookes Hosp, Vaculitis & Lupus Clin, Cambridge, England. [Harper, Lorraine] Univ Birmingham, Birmingham, W Midlands, England. [Hoglund, Peter; Westman, Kerstin] Lund Univ, Lund, Sweden. [Mukhtyar, Chetan] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England. [Davis, John C.] Genentech Corp, San Francisco, CA USA. [Hoffman, Garry S.] Cleveland Clin, Cleveland, OH 44106 USA. [McCune, W. Joseph] Univ Michigan, Ann Arbor, MI 48109 USA. [Merkel, Peter A.] Boston Univ, Boston Univ Vasculitis Ctr, Boston, MA 02215 USA. [St Clair, E. William] Duke Univ, Durham, NC USA. [Seo, Philip; Luqmani, Raashid] Johns Hopkins Univ, Vasculitis Ctr, Baltimore, MD USA. [Specks, Ulrich] Mayo Clin, Rochester, MN USA. [Spiera, Robert] Hosp Special Surg, New York, NY 10021 USA. [Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Batra, Rajbir/B-3049-2013; Hoglund, Peter/H-4774-2014 OI Batra, Rajbir/0000-0001-7010-8189; Hoglund, Peter/0000-0002-8395-922X NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-0324 J9 RHEUMATOLOGY JI RHEUMATOLOGY PD APR PY 2011 VL 50 SU 3 BP 148 EP 148 PG 1 WC Rheumatology SC Rheumatology GA 745KH UT WOS:000289163800384 ER PT J AU Wucherpfennig, KW Sethi, D AF Wucherpfennig, Kai W. Sethi, Dhruv TI T cell receptor recognition of self and foreign antigens in the induction of autoimmunity SO SEMINARS IN IMMUNOLOGY LA English DT Review DE Autoimmune diseases; MHC; Self-antigen; T cells; Molecular mimicry ID MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS SUSCEPTIBILITY; MOLECULAR MIMICRY; CROSS-REACTIVITY; VIRAL PEPTIDE; MICROBIAL PEPTIDES; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CELIAC-DISEASE; MHC BINDING AB The major histocompatibility complex (MHC) on human chromosome 6 represents the most important genetic locus for a number of common human autoimmune diseases. Specific alleles that differ from closely related alleles by only one or a few amino acids in the peptide binding groove are frequently strongly associated with disease susceptibility, raising the important question of which peptide presentation events are critical in disease initiation and progression. This review will cover a number of topics pertinent to this fundamental question, including MHC linked disease susceptibility to autoimmune diseases, molecular mechanisms for the role of MHC molecules in autoimmune diseases as well as the recognition of self and microbial peptides by self-reactive T cell receptors (TCRs). (C) 2011 Elsevier Ltd. All rights reserved. C1 [Wucherpfennig, Kai W.; Sethi, Dhruv] Dana Farber Canc Inst, Dept Canc Immunol, Boston, MA 02115 USA. [Wucherpfennig, Kai W.; Sethi, Dhruv] Dana Farber Canc Inst, AIDS, Boston, MA 02115 USA. [Wucherpfennig, Kai W.] Harvard Univ, Sch Med, Program Immunol, Boston, MA 02115 USA. RP Wucherpfennig, KW (reprint author), Dana Farber Canc Inst, Dept Canc Immunol, 44 Binney St, Boston, MA 02115 USA. EM kai_wucherpfennig@dfci.harvard.edu FU NIH [PO1 AI045757, R01 AI054520]; National Multiple Sclerosis Society FX We would like to thank collaborators, postdoctoral fellows and students who have contributed to studies described here. This work was supported by NIH grants to K.W.W. (PO1 AI045757 and R01 AI054520). D.S. was supported by a fellowship from the National Multiple Sclerosis Society. NR 71 TC 35 Z9 35 U1 0 U2 6 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1044-5323 J9 SEMIN IMMUNOL JI Semin. Immunol. PD APR PY 2011 VL 23 IS 2 BP 84 EP 91 DI 10.1016/j.smim.2011.01.007 PG 8 WC Immunology SC Immunology GA 749US UT WOS:000289497000003 PM 21306912 ER PT J AU Stirman, SW Brown, GK Ghahramanlou-Holloway, M Fox, AJ Chohan, MZ Beck, AT AF Stirman, Shannon Wiltsey Brown, Gregory K. Ghahramanlou-Holloway, Marjan Fox, Allison J. Chohan, Mariam Zahid Beck, Aaron T. TI Participation Bias among Suicidal Adults in a Randomized Controlled Trial SO SUICIDE AND LIFE-THREATENING BEHAVIOR LA English DT Article ID DELIBERATE SELF-HARM; SUBJECT SELECTION; MAJOR DEPRESSION; FOLLOW-UP; RISK; PARASUICIDE; ATTEMPTERS; NONPARTICIPATION; SCHIZOPHRENIA; INTERVENTION AB Although individuals who attempt suicide have poor compliance rates with treatment recommendations, the nature and degree of participation bias in clinical treatment research among these individuals is virtually unknown. The purpose of this study was to examine participation bias by comparing the demographic and diagnostic characteristics of adult suicide attempters who participated in a randomized controlled trial to a sample of nonparticipants. Results indicated that males and individuals with a diagnosis of substance abuse or dependence were more likely to be participants in the randomized controlled trial. The implications of these findings for suicide intervention research are discussed. C1 [Stirman, Shannon Wiltsey] Boston Univ, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA. [Brown, Gregory K.; Fox, Allison J.; Chohan, Mariam Zahid; Beck, Aaron T.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Ghahramanlou-Holloway, Marjan] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA. RP Stirman, SW (reprint author), Boston Univ, Natl Ctr PTSD, Womens Hlth Sci Div, 150 S Huntington Ave 116B-3, Boston, MA 02130 USA. EM shannon.wiltsey-stirman@va.gov FU NICHD NIH HHS [R01 HD060915]; NIGMS NIH HHS [R01 GM060915]; NIMH NIH HHS [R25 MH080916, R01 MH060915, P20 MH71905, R00 MH080100, R01 MH60915, K99 MH080100, P20 MH071905]; PHS HHS [R37 CCR316866] NR 33 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0363-0234 EI 1943-278X J9 SUICIDE LIFE-THREAT JI Suicide Life-Threat. Behav. PD APR PY 2011 VL 41 IS 2 BP 203 EP 209 DI 10.1111/j.1943-278X.2010.00011.x PG 7 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 746LH UT WOS:000289247800009 PM 21470296 ER PT J AU Lessell, S AF Lessell, Simmons TI Nonorganic Visual Loss: What's In a Name? SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Editorial Material ID PSYCHIATRY; CONVERSION C1 [Lessell, Simmons] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Neuroophthalmol Unit, Boston, MA USA. [Lessell, Simmons] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. RP Lessell, S (reprint author), 243 Charles St, Boston, MA 02114 USA. EM simmons_lessell@meei.harvard.edu NR 13 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD APR PY 2011 VL 151 IS 4 BP 569 EP 571 DI 10.1016/j.ajo.2010.11.015 PG 3 WC Ophthalmology SC Ophthalmology GA 742VZ UT WOS:000288974700002 PM 21420520 ER PT J AU Perlis, RH Uher, R Ostacher, M Goldberg, JF Trivedi, MH Rush, AJ Fava, M AF Perlis, Roy H. Uher, Rudolf Ostacher, Michael Goldberg, Joseph F. Trivedi, Madhukar H. Rush, A. John Fava, Maurizio TI Association Between Bipolar Spectrum Features and Treatment Outcomes in Outpatients With Major Depressive Disorder SO ARCHIVES OF GENERAL PSYCHIATRY LA English DT Article ID STAR-ASTERISK-D; DIAGNOSTIC SCREENING QUESTIONNAIRE; SEQUENCED TREATMENT ALTERNATIVES; TREATMENT-RESISTANT DEPRESSION; II DISORDER; UNIPOLAR DEPRESSION; RELIEVE DEPRESSION; CLINICAL-FEATURES; DSM-IV; PSYCHOTIC FEATURES AB Context: It has been suggested that patients with major depressive disorder (MDD) who display pretreatment features suggestive of bipolar disorder or bipolar spectrum features might have poorer treatment outcomes. Objective: To assess the association between bipolar spectrum features and antidepressant treatment outcome in MDD. Design: Open treatment followed by sequential randomized controlled trials. Setting: Primary and specialty psychiatric outpatient centers in the United States. Participants: Male and female outpatients aged 18 to 75 years with a DSM-IV diagnosis of nonpsychotic MDD who participated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Interventions: Open treatment with citalopram followed by up to 3 sequential next-step treatments. Main Outcome Measures: Number of treatment levels required to reach protocol-defined remission, as well as failure to return for the postbaseline visit, loss to follow-up, and psychiatric adverse events. For this secondary analysis, putative bipolar spectrum features, including items on the mania and psychosis subscales of the Psychiatric Diagnosis Screening Questionnaire, were examined for association with treatment outcomes. Results: Of the 4041 subjects who entered the study, 1198 (30.0%) endorsed at least 1 item on the psychosis scale and 1524 (38.1%) described at least 1 recent maniclike/hypomaniclike symptom. Irritability and psychoticlike symptoms at entry were significantly associated with poorer outcomes across up to 4 treatment levels, as were shorter episodes and some neurovegetative symptoms of depression. However, other indicators of bipolar diathesis including recent maniclike symptoms and family history of bipolar disorder as well as summary measures of bipolar spectrum features were not associated with treatment resistance. Conclusion: Self-reported psychoticlike symptoms were common in a community sample of outpatients with MDD and strongly associated with poorer outcomes. Overall, the data do not support the hypothesis that unrecognized bipolar spectrum illness contributes substantially to antidepressant treatment resistance. C1 [Perlis, Roy H.; Fava, Maurizio] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Perlis, Roy H.; Fava, Maurizio] Harvard Univ, Sch Med, Boston, MA USA. [Uher, Rudolf] Kings Coll London, Social Genet & Dev Psychiat Ctr, Inst Psychiat, London WC2R 2LS, England. [Ostacher, Michael] Stanford Univ, Dept Psychiat, Sch Med, San Francisco, CA USA. [Goldberg, Joseph F.] Mt Sinai Sch Med, New York, NY USA. [Trivedi, Madhukar H.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [Rush, A. John] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore. RP Perlis, RH (reprint author), Massachusetts Gen Hosp, Simches Res Bldg,185 Cambridge St,6th Floor, Boston, MA 02114 USA. EM rperlis@partners.org RI Uher, Rudolf/A-5477-2008; OI Uher, Rudolf/0000-0002-2998-0546; Ostacher, Michael/0000-0003-0353-7535; Rush, Augustus/0000-0003-2004-2382 FU Eli Lilly Company; Elan/Eisai; AstraZeneca; Bristol-Myers Squibb; Pfizer Inc; GlaxoSmithKline; Proteus Biomedical; Abbott Laboratories; Alkermes; Aspect Medical Systems; Bristol-Myers Squibb Company; Cephalon; Forest Pharmaceuticals Inc; J & J Pharmaceuticals; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Novartis; Organon Inc; PamLab; LLC; Pharmavite; Roche; Sanofi/Synthelabo; Solvay Pharmaceuticals, Inc; Wyeth-Ayerst Laboratories; Bayer AG; Biovail Pharmaceuticals, Inc; BrainCells, Inc; Compellis; Cypress Pharmaceuticals; Dov Pharmaceuticals; EPIX Pharmaceuticals; Fabre-Kramer Pharmaceuticals, Inc; Grunenthal GmBH; Janssen Pharmaceuticals; Jazz Pharmaceuticals; Knoll Pharmaceutical Company; Lundbeck; MedAvante, Inc; Neuronetics; Nutrition 21; PharmaStar; Sepracor; Somaxon; Somerset Pharmaceuticals; Boehringer-Ingelheim; Janssen-Cilag; National Institutes of Mental Health [N01 MH-90003, MH086026] FX Dr Perlis reports receiving research support from Eli Lilly & Company and Elan/Eisai; advisory/consulting fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly & Company, and Pfizer Inc; consulting fees or honoraria from AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly & Company, GlaxoSmithKline, Pfizer Inc, and Proteus Biomedical; equity holdings and patents from Concordant Rater Systems, LLC; and royalty/patents from Concordant Rater Systems, LLC. Dr Fava reports receiving research support from Abbott Laboratories, Alkermes, Aspect Medical Systems, AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc, GlaxoSmithKline, J & J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, Novartis, Organon Inc, PamLab, LLC, Pfizer Inc, Pharmavite, Roche, Sanofi/Synthelabo, Solvay Pharmaceuticals, Inc, and Wyeth-Ayerst Laboratories; and advisory/consulting from Aspect Medical Systems, AstraZeneca, Bayer AG, Biovail Pharmaceuticals, Inc, BrainCells, Inc, Bristol-Myers Squibb Company, Cephalon, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eli Lilly & Company, EPIX Pharmaceuticals, Fabre-Kramer Pharmaceuticals, Inc, Forest Pharmaceuticals Inc, GlaxoSmithKline, Grunenthal GmBH, Janssen Pharmaceuticals, Jazz Pharmaceuticals, J & J Pharmaceuticals, Knoll Pharmaceutical Company, Lundbeck, MedAvante, Inc, Neuronetics, Novartis, Nutrition 21, Organon Inc, PamLab, LLC, Pfizer Inc, PharmaStar, Pharmavite, Roche, Sanofi/Synthelabo, Sepracor, Solvay Pharmaceuticals, Inc, Somaxon, Somerset Pharmaceuticals, and Wyeth-Ayerst Laboratories; and speaking fees from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Cephalon, Eli Lilly&Company, Forest Pharmaceuticals Inc, GlaxoSmithkline, Novartis, Organon Inc, Pfizer Inc, PharmaStar, and Wyeth-Ayerst Laboratories. Dr Goldberg reports receiving compensation for speaker's bureaus or lectures from AstraZeneca, Janssen-Cilag, GlaxoSmithKline, Eli Lilly&Co, Merck, and Pfizer; and advisory board or consultant fees from Eli Lilly & Co. Dr Rush has served as a consultant for AstraZeneca, Bristol-Myers Squibb/Otsuka, Merck, and Otsuka Pharmaceuticals and has received royalties from Guilford Publications and Healthcare Technology Systems.; The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study is supported by National Institutes of Mental Health grants N01 MH-90003 (University of Texas-Southwestern Medical Center at Dallas; A. J. Rush, principal investigator) and MH086026 (Dr Perlis). NR 66 TC 63 Z9 65 U1 6 U2 10 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-990X J9 ARCH GEN PSYCHIAT JI Arch. Gen. Psychiatry PD APR PY 2011 VL 68 IS 4 BP 351 EP 360 DI 10.1001/archgenpsychiatry.2010.179 PG 10 WC Psychiatry SC Psychiatry GA 745LC UT WOS:000289165900004 PM 21135313 ER PT J AU Younes, M Lauwers, GY Ertan, A Ergun, G Verm, R Bridges, M Woods, K Meriano, F Schmulen, C Johnson, C Barroso, A Schwartz, J McKechnie, J Lechago, J AF Younes, Mamoun Lauwers, Gregory Y. Ertan, Atilla Ergun, Gulchin Verm, Ray Bridges, Margaret Woods, Karen Meriano, Frank Schmulen, Carl Johnson, Craig Barroso, Alberto Schwartz, Jim McKechnie, John Lechago, Juan TI The Significance of "Indefinite for Dysplasia" Grading in Barrett Metaplasia SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID PHOTODYNAMIC THERAPY; ESOPHAGUS; ADENOCARCINOMA; DIAGNOSIS AB Context.-For a confident diagnosis of dysplasia in Barrett metaplasia, the epithelial atypia should also involve the surface epithelium. However, pathologists are often faced with biopsies where the crypts show dysplasia, but the surface epithelium is either uninvolved or unevaluable. We previously grouped these cases with indefinite for dysplasia (IND). Objective.-To determine the clinical significance of IND grading in Barrett metaplasia. Design.-All biopsies from 276 prospectively followed patients with Barrett metaplasia, who did not have high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) on initial biopsy, were graded as negative for dysplasia, IND, low-grade dysplasia (LGD), HGD, and EAC. Biopsies with multifocal IND or LGD were graded as INDM or LGDM, respectively. Results.-Only 3 of 193 patients (2%) with an initial diagnosis of negative for dysplasia and only 1 of 48 patients (2%) diagnosed with IND progressed to HGD or EAC. By contrast, 1 of 7 patients (14%) with INDM, 2 of 21(10%) with LGD, and 1 of 7 (14%) with LGDM progressed to HGD or EAC. There was no significant difference in progression rate between patients with an initial diagnosis of negative for dysplasia and those diagnosed IND nor were there significant differences among patients with initial diagnoses of INDM, LGD, or LGDM. Kaplan-Meier analysis showed that patients with INDM, LGD, or LGDM on initial biopsy (group 1) were more likely to progress to HGD or EAC than were those patients who were diagnosed negative for dysplasia or IND (group 2; log-rank test, P < .001). Conclusions.-Multifocal IND in an esophageal biopsy from a patient with Barrett metaplasia has the same clinical implication as LGD. (Arch Pathol Lab Med. 2011;135:430-432) C1 [Younes, Mamoun] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Younes, Mamoun; Ertan, Atilla; Ergun, Gulchin; Verm, Ray; Bridges, Margaret; Schmulen, Carl; Johnson, Craig; Schwartz, Jim] Baylor Coll Med, Gastroenterol Sect, Houston, TX 77030 USA. [Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Lauwers, Gregory Y.] Harvard Univ, Sch Med, Boston, MA USA. [Ertan, Atilla; Woods, Karen; Meriano, Frank; Schmulen, Carl; Barroso, Alberto; McKechnie, John] Methodist Hosp, Dept Med, Houston, TX USA. [Lechago, Juan] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA. RP Younes, M (reprint author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA. EM myounes@bcm.edu OI Younes, Mamoun/0000-0001-9618-3451 FU Eisai Inc (Research Triangle Park, North Carolina); Ortho-McNeil Janssen Scientific Affairs, LLC (Philadelphia, Pennsylvania); National Institutes of Health [R01 CA81570] FX This study was supported by grant R01 CA81570 from the National Institutes of Health (M.Y.) and by funding from Eisai Inc (Research Triangle Park, North Carolina) and Ortho-McNeil Janssen Scientific Affairs, LLC (Philadelphia, Pennsylvania). NR 10 TC 17 Z9 17 U1 0 U2 2 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2011 VL 135 IS 4 BP 430 EP 432 PG 3 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 746BS UT WOS:000289217200008 PM 21466357 ER PT J AU Lee-Lewandrowski, E Januzzi, JL Grisson, R Mohammed, AA Lewandrowski, G Lewandrowski, K AF Lee-Lewandrowski, Elizabeth Januzzi, James L., Jr. Grisson, Ricky Mohammed, Asim A. Lewandrowski, Grant Lewandrowski, Kent TI Evaluation of First-Draw Whole Blood, Point-of-Care Cardiac Markers in the Context of the Universal Definition of Myocardial Infarction A Comparison of a Multimarker Panel to Troponin Alone and to Testing in the Central Laboratory SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID ACUTE CORONARY SYNDROMES; EMERGENCY-DEPARTMENT; PRACTICE GUIDELINES; EARLY-DIAGNOSIS; COMMITTEE; COLLEGE AB Context.-Previous studies evaluating point-of-care testing (POCT) for cardiac biomarkers did not use current recommendations for troponin cutoff values or recognize the recent universal definition of acute myocardial infarction. Traditionally, achieving optimal sensitivity for the detection of myocardial injury on initial presentation required combining cardiac troponin and/or creatine kinase isoenzyme MB with an early marker, usually myoglobin. In recent years, the performance of central laboratory combining cardiac troponin assays has improved significantly, potentially obviating the need for a multimarker panel to achieve optimum sensitivity. Objective.-To compare 2 commonly used POCT strategies to a fourth generation, central laboratory cardiac troponin T assay on first-draw specimens from patients being evaluated for acute myocardial infarction in the emergency department. The 2 strategies included a traditional POCT multimarker panel and a newer POCT method using cardiac troponin I alone. Design.-Blood specimens from 204 patients presenting to the emergency department with signs and/or symptoms of myocardial ischemia were measured on the 2 POCT systems and by a central laboratory method. The diagnosis for each patient was determined by retrospective chart review. Results.-The cardiac troponin T assasy alone was more sensitive for acute myocardial infarction than the multimarker POCT panel with equal or better specificity. When compared with a POCT troponin I, the cardiac troponin T was also more sensitive, but this difference was not significant. The POCT troponin I alone also had the same sensitivity as the multimarker panel. Conclusions.-Testing for combining cardiac troponin alone using newer, commercially available, central laboratory or POCT assays performed with equal or greater sensitivity to acute myocardial infarction as the older, traditional, multimarker panel. In the near future, high-sensitivity, central laboratory troponins will be available for routine clinical use. As a result, the quality gap between central laboratories and older POCT methods will continue to widen, unless the performance of the POCT methods is improved. (Arch Pathol Lab Med. 2011;135:459-463) C1 [Lee-Lewandrowski, Elizabeth; Grisson, Ricky; Lewandrowski, Grant; Lewandrowski, Kent] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Januzzi, James L., Jr.; Mohammed, Asim A.] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. RP Lewandrowski, K (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Gray 5 Chem, Boston, MA 02114 USA. EM klewandrowski@partners.org FU Abbott Diagnostics, Chicago, Illinois; Roche Diagnostics, Indianapolis, Indiana; Biosite Diagnostics FX The authors have no relevant financial interest in the products or companies described in this article. This study was supported in part by a grant from Abbott Diagnostics, Chicago, Illinois. Dr Januzzi has received research grant support from Roche Diagnostics, Indianapolis, Indiana. Dr Lewandrowski has received research support from Biosite Diagnostics. NR 16 TC 13 Z9 13 U1 0 U2 8 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 2011 VL 135 IS 4 BP 459 EP 463 PG 5 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA 746BS UT WOS:000289217200013 PM 21466362 ER PT J AU Primack, BA Silk, JS DeLozier, CR Shadel, WG Carpentier, FRD Dahl, RE Switzer, GE AF Primack, Brian A. Silk, Jennifer S. DeLozier, Christian R. Shadel, William G. Carpentier, Francesca R. Dillman Dahl, Ronald E. Switzer, Galen E. TI Using Ecological Momentary Assessment to Determine Media Use by Individuals With and Without Major Depressive Disorder SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID MOOD MANAGEMENT; RISK-FACTORS; ALCOHOL-USE; SCHOOL-AGE; ADOLESCENTS; CHILDREN; TELEVISION; HEALTH; MUSIC; ADULTHOOD AB Objective: To use ecological momentary assessment techniques to measure the association of major depressive disorder (MDD) with media use. Design: Data were collected using an ecological momentary assessment protocol with cellular telephone-based brief interviews. Setting: Participants received as many as 60 telephone calls from a trained staff member during 5 extended weekends in an 8-week period. Participants: One hundred six adolescent participants who were part of a larger neurobehavioral study of depression in Pittsburgh from January 1, 2003, through December 31, 2008. Main Exposure: At each call, participants were asked whether they were using the following 5 types of media: television or movies, music, video games, Internet, and print media, such as magazines, newspapers, and books. Main Outcome Measures: We developed multivariable models to determine the independent association of each type of media use with MDD, controlling for sociodemographic variables. Results: Of the 106 participants, 46 were diagnosed as having MDD. In multivariable models controlling for age, sex, and race, each increasing quartile of audio use was associated with an 80% increase in the odds of having MDD (odds ratio, 1.8; 95% confidence interval, 1.1-2.8; P = .01 for trend). Conversely, each increasing quartile of print media use was associated with a 50% decrease in the odds of having MDD(odds ratio, 0.5; 95% confidence interval, 0.30.9; P = .009 for trend). Conclusions: Major depressive disorder is positively associated with popular music exposure and negatively associated with reading print media such as books. Further research elucidating the directionality and strength of these relationships may help advance understanding of the relationships between media use and MDD. C1 [Primack, Brian A.; DeLozier, Christian R.; Switzer, Galen E.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Sch Med, Pittsburgh, PA 15213 USA. [Primack, Brian A.] Univ Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15213 USA. [Silk, Jennifer S.] Univ Pittsburgh, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA. [Shadel, William G.] RAND Corp, Pittsburgh, PA USA. [Switzer, Galen E.] Ctr Heath Equ Res & Promot, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Carpentier, Francesca R. Dillman] Univ N Carolina, Sch Journalism & Mass Commun, Chapel Hill, NC USA. [Dahl, Ronald E.] Univ Calif Berkeley, Sch Publ Hlth, Joint Med Program, Berkeley, CA 94720 USA. RP Primack, BA (reprint author), Univ Pittsburgh, Dept Med, Div Gen Internal Med, Sch Med, 230 McKee Pl,Ste 600, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu OI Silk, Jennifer/0000-0002-8638-4337 FU National Cancer Institute [R01-CA140150, K07-CA114315]; Maurice Falk Foundation; National Institute of Mental Health [P01-MH41712]; RAND-University of Pittsburgh Health Institute FX Funding/Support: This study was supported in part by research grant R01-CA140150 from the National Cancer Institute, career development award K07-CA114315 from the National Cancer Institute, and a grant from the Maurice Falk Foundation (Dr Primack); by grant P01-MH41712 from the National Institute of Mental Health (Neal D. Ryan, MD [principal investigator], and Dr Dahl [coprincipal investigator]); and by the RAND-University of Pittsburgh Health Institute (http://www.ruphi.pitt.edu/), a formal collaboration among the RAND Corporation, RAND Health, and the University of Pittsburgh Schools of the Health Sciences. NR 52 TC 7 Z9 7 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD APR PY 2011 VL 165 IS 4 BP 360 EP 365 PG 6 WC Pediatrics SC Pediatrics GA 745LF UT WOS:000289166200012 PM 21464384 ER PT J AU Winters-Stone, KM Torgrimson, B Horak, F Eisner, A Nail, L Leo, MC Chui, S Luoh, SW AF Winters-Stone, Kerri M. Torgrimson, Britta Horak, Fay Eisner, Alvin Nail, Lillian Leo, Michael C. Chui, Steve Luoh, Shiuh-Wen TI Identifying Factors Associated With Falls in Postmenopausal Breast Cancer Survivors: A Multi-Disciplinary Approach SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Drug therapy; Muscle strength; Neoplasms; Postural balance; Rehabilitation ID VISUAL IMPAIRMENT; OLDER-ADULTS; ADJUVANT TREATMENT; RANDOMIZED-TRIAL; FRACTURE RISK; NURSING-HOME; WOMEN; TAMOXIFEN; CHEMOTHERAPY; POSTUROGRAPHY AB Winters-Stone KM, Torgrimson B, Horak F, Eisner A, Nail L, Leo MC, Chui S, Luoh S-W. Identifying factors associated with falls in postmenopausal breast cancer survivors: a multi-disciplinary approach. Arch Phys Med Rehabil 2011;92:646-52. Objective: To identify neuromuscular, balance, and vision factors that contribute to falls in recently treated breast cancer survivors (BCS) and explore links between fall risk factors and cancer treatment. Design: Case-control plus prospective observation. Setting: Comprehensive cancer center. Participants: BCS (N=59; mean age, 58y) within 2 years of chemotherapy completion and/or on adjuvant endocrine therapy. Interventions: Not applicable. Main Outcome Measures: Objective measures of postural control, vision, and neuromuscular function included: (1) a sensory organization test (SOT), (2) a visual assessment battery, (3) muscle mass by dual energy x-ray absorptiometry, and (4) neuromuscular function with strength by repetition maximum, power by timed stair climb, and gait speed by 4m walk. Falls were self-reported for the past year (retrospective) and monthly for 6 months (prospective). Results: Fifty eight percent of BCS reported falls in the past year. BCS with a history of falls had lower SOT scores with a vestibular deficit pattern in postural control (P<.01) and took longer to read letters on the contrast sensitivity chart (P<.05). Vestibular score on the SOT mediated the relationship between treatment and falls among BCS who received chemotherapy only, but not adjuvant endocrine therapy. Conclusions: Results of this project suggest that balance disturbances of vestibular origin and delays in detecting low contrast visual stimuli are associated with falls in BCS. Future studies that track falls and fall risk factors in BCS from diagnosis through treatment are warranted, as are studies that can identify treatment-related vestibular dysfunction and altered visual processing. C1 [Winters-Stone, Kerri M.; Torgrimson, Britta; Nail, Lillian; Leo, Michael C.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97239 USA. [Horak, Fay; Eisner, Alvin; Chui, Steve; Luoh, Shiuh-Wen] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA. [Luoh, Shiuh-Wen] Portland VA Med Ctr, Portland, OR USA. RP Winters-Stone, KM (reprint author), Oregon Hlth & Sci Univ, Sch Nursing, 3455 SW US Vet Hosp Rd,Mailcode SN ORD, Portland, OR 97239 USA. EM wintersk@ohsu.edu FU Oregon Clinical and Translational Research Institute (OCTRI); National Center for Research Resources (NCRR), National Institutes of Health (NIH) [UL1 RR024140]; NIH Roadmap for Medical Research FX This publication was made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NR 42 TC 25 Z9 25 U1 5 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD APR PY 2011 VL 92 IS 4 BP 646 EP 652 DI 10.1016/j.apmr.2010.10.039 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 743VT UT WOS:000289047500018 PM 21367394 ER PT J AU Tosun, D Dabbs, K Caplan, R Siddarth, P Toga, A Seidenberg, M Hermann, B AF Tosun, Duygu Dabbs, Kevin Caplan, Rochelle Siddarth, Prabha Toga, Arthur Seidenberg, Michael Hermann, Bruce TI Deformation-based morphometry of prospective neurodevelopmental changes in new onset paediatric epilepsy SO BRAIN LA English DT Article DE MRI; prospective neurodevelopment changes; deformation-based morphometry; new and recent onset epilepsy; localization-related epilepsy; idiopathic generalized epilepsy ID TEMPORAL-LOBE EPILEPSY; JUVENILE MYOCLONIC EPILEPSY; VOXEL-BASED MORPHOMETRY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; IDIOPATHIC GENERALIZED EPILEPSY; TENSOR-BASED MORPHOMETRY; CEREBELLAR VOLUME REDUCTION; CHILDHOOD ABSENCE EPILEPSY; COMPLEX PARTIAL SEIZURES; BRAIN-DEVELOPMENT AB Epilepsy is a prevalent childhood neurological disorder, but there are few prospective quantitative magnetic resonance imaging studies examining patterns of brain development compared to healthy controls. Controlled prospective investigations initiated at or near epilepsy onset would best characterize the nature, timing and course of neuroimaging abnormalities in paediatric epilepsy. In this study, we report the results of a deformation-based morphometry technique to examine baseline and 2-year prospective neurodevelopmental brain changes in children with new and recent onset localization-related epilepsies (n = 24) and idiopathic generalized epilepsies (n = 20) compared to healthy controls (n = 36). Children with epilepsy demonstrated differences from controls in baseline grey and white matter volumes suggesting antecedent anomalies in brain development, as well as abnormal patterns of prospective brain development that involved not only slowed white matter expansion, but also abnormalities of cortical grey matter development involving both greater and lesser volume changes compared to controls. Furthermore, abnormal neurodevelopmental changes extended outside the cortex affecting several subcortical structures including thalamus, cerebellum, brainstem and pons. Finally, there were significant differences between the epilepsy syndromes (localization-related epilepsies and idiopathic generalized epilepsies) with the idiopathic generalized epilepsies group showing a more disrupted pattern of brain structure both at baseline and over the 2-year interval. C1 [Tosun, Duygu] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. [Dabbs, Kevin; Hermann, Bruce] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Caplan, Rochelle; Siddarth, Prabha] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Toga, Arthur] Univ Calif Los Angeles, David Geffen Sch Med, Lab Neuro Imaging, Dept Neurol, Los Angeles, CA 90095 USA. [Seidenberg, Michael] Rosalind Franklin Univ Med & Sci, Dept Psychol, Madison, WI USA. RP Tosun, D (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, San Francisco, CA USA. EM duygu.tsn@gmail.com FU National Institutes of Health (NIH) through the NIH Roadmap for Medical Research [U54 RR021813]; Center for Computational Biology (CCB); National Institutes of Health (NIH)/National Center for Research Resources [P41 RR013642]; [NS32070]; [MH 67187]; [RO1 44352] FX This work was supported by the National Institutes of Health (NIH) through the NIH Roadmap for Medical Research, Grant No. U54 RR021813, Center for Computational Biology (CCB). Additional support was provided by the National Institutes of Health (NIH)/National Center for Research Resources Grant No. P41 RR013642 and grants NS32070 (RC), MH 67187 (RC), and RO1 44352 (NINDS). NR 97 TC 28 Z9 28 U1 2 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD APR PY 2011 VL 134 BP 1003 EP 1014 DI 10.1093/brain/awr027 PN 4 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 745KC UT WOS:000289163300016 PM 21398377 ER PT J AU Tosun, D Schuff, N Mathis, CA Jagust, W Weiner, MW AF Tosun, Duygu Schuff, Norbert Mathis, Chester A. Jagust, William Weiner, Michael W. CA Alzheimer's Dis NeuroImaging Initi TI Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment SO BRAIN LA English DT Article DE MRI; (11)C-PiB PET; Alzheimer's disease; mild cognitive impairment; amyloid-beta; amyloid; brain atrophy rate; multimodal brain imaging ID PITTSBURGH COMPOUND-B; NEUROIMAGING INITIATIVE ADNI; CEREBROSPINAL-FLUID TAU; VOXEL-BASED ANALYSIS; ALZHEIMERS-DISEASE; HIPPOCAMPAL ATROPHY; ENTORHINAL CORTEX; IN-VIVO; ELDERLY CONTROLS; FUNCTIONAL MRI AB Amyloid-beta accumulation in the brain is thought to be one of the earliest events in Alzheimer's disease, possibly leading to synaptic dysfunction, neurodegeneration and cognitive/functional decline. The earliest detectable changes seen with neuroimaging appear to be amyloid-beta accumulation detected by (11)C-labelled Pittsburgh compound B positron emission tomography imaging. However, some individuals tolerate high brain amyloid-beta loads without developing symptoms, while others progressively decline, suggesting that events in the brain downstream from amyloid-beta deposition, such as regional brain atrophy rates, play an important role. The main purpose of this study was to understand the relationship between the regional distributions of increased amyloid-beta and the regional distribution of increased brain atrophy rates in patients with mild cognitive impairment. To simultaneously capture the spatial distributions of amyloid-beta and brain atrophy rates, we employed the statistical concept of parallel independent component analysis, an effective method for joint analysis of multimodal imaging data. Parallel independent component analysis identified significant relationships between two patterns of amyloid-beta deposition and atrophy rates: (i) increased amyloid-beta burden in the left precuneus/cuneus and medial-temporal regions was associated with increased brain atrophy rates in the left medial-temporal and parietal regions; and (ii) in contrast, increased amyloid-beta burden in bilateral precuneus/cuneus and parietal regions was associated with increased brain atrophy rates in the right medial temporal regions. The spatial distribution of increased amyloid-beta and the associated spatial distribution of increased brain atrophy rates embrace a characteristic pattern of brain structures known for a high vulnerability to Alzheimer's disease pathology, encouraging for the use of (11)C-labelled Pittsburgh compound B positron emission tomography measures as early indicators of Alzheimer's disease. These results may begin to shed light on the mechanisms by which amyloid-beta deposition leads to neurodegeneration and cognitive decline and the development of a more specific Alzheimer's disease-specific imaging signature for diagnosis and use of this knowledge in the development of new anti-therapies for Alzheimer's disease. C1 [Tosun, Duygu] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA. [Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Mathis, Chester A.] Univ Pittsburgh, Dept Radiol, PET Facil, Pittsburgh, PA USA. [Jagust, William] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA. [Jagust, William] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. RP Tosun, D (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, 4150 Clement St,Bldg 13,114 M, San Francisco, CA 94121 USA. EM duygu.tosun@ucsf.edu RI Olde Rikkert, Marcel/D-9773-2012; MOSCATO, PABLO/G-7668-2013; Saykin, Andrew/A-1318-2007; Strittmatter, Stephen/F-5739-2011; Juengling, Freimut/L-8071-2016; OI Looi, Jeffrey/0000-0003-3351-6911; Browndyke, Jeffrey/0000-0002-8573-7073; Saykin, Andrew/0000-0002-1376-8532; Strittmatter, Stephen/0000-0001-8188-3092; Juengling, Freimut/0000-0002-2538-3074; Lemaitre, Herve/0000-0002-5952-076X; Whitcher, Brandon/0000-0002-6452-2399 FU National Institutes of Health (NIH) [P41 RR023953, P30 AG010129, K01 AG030514]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; Abbott; AstraZeneca AB; Bayer Schering Pharma AG; Bristol-Myers Squibb; Eisai Global Clinical Development; Elan Corporation; Genentech; GE Healthcare; GlaxoSmithKline; Innogenetics; Johnson and Johnson; Eli Lilly and Co.; Medpace, Inc.; Merck and Co., Inc.; Novartis AG; Pfizer Inc; F. Hoffman-La Roche; Schering-Plough; Synarc, Inc.; Wyeth; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Dana Foundation FX This work is funded by the National Institutes of Health (NIH) (Grant P41 RR023953). Data collection and sharing for this project were funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc. and Wyeth, as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego, USA. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants (P30 AG010129, K01 AG030514) and the Dana Foundation. NR 96 TC 58 Z9 59 U1 0 U2 28 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-8950 J9 BRAIN JI Brain PD APR PY 2011 VL 134 BP 1077 EP 1088 DI 10.1093/brain/awr044 PN 4 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 745KC UT WOS:000289163300021 PM 21429865 ER PT J AU Wu, IC Zhao, Y Zhai, RH Liu, CY Chen, F Ter-Minassian, M Asomaning, K Su, L Heist, RS Kulke, MH Liu, G Christiani, DC AF Wu, I-Chen Zhao, Yang Zhai, Rihong Liu, Chen-yu Chen, Feng Ter-Minassian, Monica Asomaning, Kofi Su, Li Heist, Rebecca S. Kulke, Matthew H. Liu, Geoffrey Christiani, David C. TI Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk SO CARCINOGENESIS LA English DT Article ID SINGLE-NUCLEOTIDE POLYMORPHISMS; GASTROESOPHAGEAL-REFLUX DISEASE; OVARIAN-CANCER; BARRETTS-ESOPHAGUS; LUNG-CANCER; CELL-LINE; ASSOCIATION; POPULATION; SUSCEPTIBILITY; EPIDEMIOLOGY AB How genetic variations in apoptosis pathway interact with environmental factors to contribute to esophageal adenocarcinoma (EA) risk has not been comprehensively investigated. We conducted a case-only analysis in 335 Caucasian EA patients that were genotyped for 242 single nucleotide polymorphisms (SNPs) in 43 apoptotic genes. Gene-environment interactions were assessed using a two-step approach. First, random forest algorithm was used to screen for the potential interacting markers. Next, we used case-only logistic regression model to estimate the effects of gene-environment interactions on EA risk. Four SNPs (PERP rs648802; PIK3CA rs4855094, rs7644468 and TNFRSF1A rs4149579) had significant interaction with gastroesophageal reflux disease (GERD). The presence of variant alleles in TP53BP1 rs560191, CASP7 rs7907519 or BCL2 rs12454712 enhanced the risk of smoking by 2.08-2.58 times [interaction odds ratio (ORi) = 2.08-2.58, adjusted P-value (P(adj)) = 0.02-0.04]. Compared with patients carrying < 1 risk genotype, the risk of GERD on EA was increased in persons with two (ORi = 1.89, P(adj) = 0.016) or >= 3 (ORi = 4.30, P(adj) < 0.0001) risk genotypes. Compared with cases with < 1 risk genotype, smoking-associated EA risk increased by 3.15 times when >= 2 risk genotypes were present (ORi = 3.15, P(adj) < 0.0001). In conclusion, interactions among apoptotic SNPs and GERD or smoking play an important role in EA development. C1 [Wu, I-Chen; Zhao, Yang; Zhai, Rihong; Liu, Chen-yu; Chen, Feng; Ter-Minassian, Monica; Asomaning, Kofi; Su, Li; Heist, Rebecca S.; Liu, Geoffrey; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, Boston, MA 02115 USA. [Wu, I-Chen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan. [Heist, Rebecca S.; Christiani, David C.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA. [Heist, Rebecca S.; Christiani, David C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA. [Liu, Geoffrey] Princess Margaret Hosp, Dept Med, Div Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada. [Liu, Geoffrey] Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Div Appl Mol Oncol, Toronto, ON M5G 2M9, Canada. RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm & Occupat Med & Epidemiol Program, 665 Huntington Ave,Bldg 1,Room 1401, Boston, MA 02115 USA. EM dchris@hsph.harvard.edu RI Liu, Geoffrey/N-4421-2016; OI LIU, CHEN-YU/0000-0002-4693-5667 FU National Institutes of Health [R01CA109193, R03CA110822, R01CA074386, ES00002]; Canadian Institute of Health; Kevin Jackson Memorial Fund; Alan B. Brown Chair in Molecular Genomics; National Cancer Institute of Canada; Posluns Family Fund Princess Margaret Hospital Foundation; Flight Attendant Medical Research Institute [062459]; National Center for Research Resources [U54 RR020278]; Excellence for cancer research center, Department of Health, Executive Yuan, Taiwan, ROC [DOH100-TD-C-111-002] FX National Institutes of Health (R01CA109193, R03CA110822, R01CA074386 and ES00002); the Canadian Institute of Health Research operating grant; the Kevin Jackson Memorial Fund; Alan B. Brown Chair in Molecular Genomics; National Cancer Institute of Canada Dorothy Lamont Award; Posluns Family Fund Princess Margaret Hospital Foundation; the Flight Attendant Medical Research Institute Award No. 062459. The Broad Institute Center for Genotyping and Analysis is supported by grant U54 RR020278 from the National Center for Research Resources.; The authors thank the physicians and patients from the Massachusetts General Hospital Thoracic Oncology Center and the Dana Farber Cancer Institute GI Oncology Center for their cooperation and participation. The authors also thank researchers from Excellence for cancer research center, Department of Health, Executive Yuan, Taiwan, ROC (grant, DOH100-TD-C-111-002). NR 43 TC 13 Z9 13 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD APR PY 2011 VL 32 IS 4 BP 502 EP 506 DI 10.1093/carcin/bgq287 PG 5 WC Oncology SC Oncology GA 745KM UT WOS:000289164300008 PM 21212151 ER PT J AU Nandakumar, V Vaid, M Katiyar, SK AF Nandakumar, Vijayalakshmi Vaid, Mudit Katiyar, Santosh K. TI (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16(INK4a), by reducing DNA methylation and increasing histones acetylation in human skin cancer cells SO CARCINOGENESIS LA English DT Article ID GREEN TEA POLYPHENOLS; REPAIR; MECHANISMS; PHOTOPROTECTION; ANGIOGENESIS; INHIBITION; GENISTEIN; LINES; MICE AB The anti-skin carcinogenic effects of green tea catechins have been studied extensively in vitro and in vivo models but the precise epigenetic molecular mechanisms are still unclear. Accumulating data suggest that dietary phytochemicals may alter cancer risk by modifications of epigenetic processes in the cells. The present study was designed to investigate whether tea catechins, particularly (-)-epigallocatechin-3-gallate (EGCG), would modify epigenetic events to regulate DNA methylation-silenced tumor suppressor genes in skin cancer cells. DNA methylation, histone modifications and tumor suppressor gene expressions were studied in detail using human epidermoid carcinoma A431 cells as an in vitro model after EGCG treatment using cytostaining, western blotting, dot blot analysis, real-time polymerase chain reaction and enzymatic activity assays. Our study shows that EGCG treatment decreased global DNA methylation levels in A431 cells in a dose-dependent manner. EGCG decreased the levels of 5-methylcytosine, DNA methyltransferase (DNMT) activity, messenger RNA (mRNA) and protein levels of DNMT1, DNMT3a and DNMT3b. EGCG decreased histone deacetylase activity and increased levels of acetylated lysine 9 and 14 on histone H3 (H3-Lys 9 and 14) and acetylated lysine 5, 12 and 16 on histone H4 but decreased levels of methylated H3-Lys 9. Additionally, EGCG treatment resulted in re-expression of the mRNA and proteins of silenced tumor suppressor genes, p16(INK4a) and Cip1/p21. Together, our study provides new insight into the epigenetic mechanism of action of EGCG that may contribute to the chemoprevention of skin cancer and may have important implications for epigenetic therapy. C1 [Nandakumar, Vijayalakshmi; Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama, Dermatol 1Dept, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dermatol 1Dept, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Institutes of Health [CA140832]; Veterans Administration FX National Institutes of Health (CA140832 to S. K. K.); Veterans Administration Merit Review Award (S. K. K.). NR 24 TC 115 Z9 125 U1 0 U2 19 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD APR PY 2011 VL 32 IS 4 BP 537 EP 544 DI 10.1093/carcin/bgq285 PG 8 WC Oncology SC Oncology GA 745KM UT WOS:000289164300013 PM 21209038 ER PT J AU Nandakumar, V Vaid, M Tollefsbol, TO Katiyar, SK AF Nandakumar, Vijayalakshmi Vaid, Mudit Tollefsbol, Trygve O. Katiyar, Santosh K. TI Aberrant DNA hypermethylation patterns lead to transcriptional silencing of tumor suppressor genes in UVB-exposed skin and UVB-induced skin tumors of mice SO CARCINOGENESIS LA English DT Article ID GREEN TEA POLYPHENOLS; CPG BINDING-PROTEIN; ULTRAVIOLET-RADIATION; MELANOMA PATIENTS; METHYLATION; CANCER; CARCINOGENESIS; EPIGENETICS; ACTIVATION; REPRESSION AB Overexposure of the human skin to solar ultraviolet (UV) radiation is the major etiologic factor for development of skin cancers. Here, we report the results of epigenetic modifications in UV-exposed skin and skin tumors in a systematic manner. The skin and tumor samples were collected after chronic exposure of the skin of SKH-1 hairless mice to UVB radiation using a well-established photocarcinogenesis protocol. We found a distinct DNA hypermethylation pattern in the UVB-exposed epidermal skin and UVB-induced skin tumors that was associated with the elevated expression and activity of the DNA methyltransferases (Dnmt) 1, Dnmt3a and Dnmt3b. To explore the role of hypermethylation in skin photocarcinogenesis, we focused on the p16(INK4a) and RASSF1A tumor suppressor genes, which are transcriptionally silenced on methylation. We established that the silencing of these genes in UVB-exposed epidermis and UVB-induced skin tumors is associated with a network of epigenetic modifications, including hypoacetylation of histone H3 and H4 and increased histone deacetylation, as well as recruitment of methyl-binding proteins, including MeCP2 and MBD1, to the methylated CpGs. Higher levels of DNA methylation and DNMT activity in human squamous cell carcinoma specimens than in normal human skin suggest that the data are relevant clinically. Our data indicate for the first time that UVB-induced DNA hypermethylation, enhanced Dnmt activity and histone modifications occur in UVB-exposed skin and UVB-induced skin tumors and suggest that these events are involved in the silencing of tumor suppressor genes and in skin tumor development. C1 [Nandakumar, Vijayalakshmi; Vaid, Mudit; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA. [Tollefsbol, Trygve O.] Univ Alabama, Dept Biol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU National Institutes of Health [CA140832]; Veterans Administration FX National Institutes of Health (CA140832 to S.K.K.); Veterans Administration Merit Review Award (S.K.K.) NR 48 TC 42 Z9 44 U1 1 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0143-3334 J9 CARCINOGENESIS JI Carcinogenesis PD APR PY 2011 VL 32 IS 4 BP 597 EP 604 DI 10.1093/carcin/bgq282 PG 8 WC Oncology SC Oncology GA 745KM UT WOS:000289164300021 PM 21186298 ER PT J AU Lee, BY Wettstein, ZS McGlone, SM Bailey, RR Umscheid, CA Smith, KJ Muder, RR AF Lee, B. Y. Wettstein, Z. S. McGlone, S. M. Bailey, R. R. Umscheid, C. A. Smith, K. J. Muder, R. R. TI Economic value of norovirus outbreak control measures in healthcare settings SO CLINICAL MICROBIOLOGY AND INFECTION LA English DT Article DE Economics; hospital; infection control; interventions; norovirus; outbreak ID NORWALK VIRUS; GASTROENTERITIS; INFECTION; TRANSMISSION; VOLUNTEERS; HYGIENE; ILLNESS; COSTS AB P>Although norovirus is a significant cause of nosocomial viral gastroenteritis, the economic value of hospital outbreak containment measures following identification of a norovirus case is currently unknown. We developed computer simulation models to determine the potential cost-savings from the hospital perspective of implementing the following norovirus outbreak control interventions: (i) increased hand hygiene measures, (ii) enhanced disinfection practices, (iii) patient isolation, (iv) use of protective apparel, (v) staff exclusion policies, and (vi) ward closure. Sensitivity analyses explored the impact of varying intervention efficacy, number of initial norovirus cases, the norovirus reproductive rate (R(0)), and room, ward size, and occupancy. Implementing increased hand hygiene, using protective apparel, staff exclusion policies or increased disinfection separately or in bundles provided net cost-savings, even when the intervention was only 10% effective in preventing further norovirus transmission. Patient isolation or ward closure was cost-saving only when transmission prevention efficacy was very high (>= 90%), and their economic value decreased as the number of beds per room and the number of empty beds per ward increased. Increased hand hygiene, using protective apparel or increased disinfection practices separately or in bundles are the most cost-saving interventions for the control and containment of a norovirus outbreak. C1 [Lee, B. Y.; Wettstein, Z. S.; McGlone, S. M.; Bailey, R. R.; Smith, K. J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Lee, B. Y.; Wettstein, Z. S.; McGlone, S. M.; Bailey, R. R.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA. [Lee, B. Y.; Wettstein, Z. S.; McGlone, S. M.; Bailey, R. R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA. [Umscheid, C. A.] Univ Penn, Philadelphia, PA 19104 USA. [Muder, R. R.] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Lee, BY (reprint author), Univ Pittsburgh, Sch Med, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM BYL1@pitt.edu OI Slayton, Rachel/0000-0003-4699-8040 FU National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [1U54GM088491-0109] FX This study was supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) through grant 1U54GM088491-0109. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 15 Z9 15 U1 1 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1198-743X J9 CLIN MICROBIOL INFEC JI Clin. Microbiol. Infect. PD APR PY 2011 VL 17 IS 4 BP 640 EP 646 DI 10.1111/j.1469-0691.2010.03345.x PG 7 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA 736NP UT WOS:000288501700029 PM 20731684 ER PT J AU Young, AS Niv, N Chinman, M Dixon, L Eisen, SV Fischer, EP Smith, J Valenstein, M Marder, SR Owen, RR AF Young, Alexander S. Niv, Noosha Chinman, Matthew Dixon, Lisa Eisen, Susan V. Fischer, Ellen P. Smith, Jeffrey Valenstein, Marcia Marder, Stephen R. Owen, Richard R. TI Routine Outcomes Monitoring to Support Improving Care for Schizophrenia: Report from the VA Mental Health QUERI SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE Quality improvement; Outcomes assessment; Mental disorders; Community mental health; Evidence-based care ID BRIEF-SYMPTOM-INVENTORY; QUALITY-OF-CARE; IDENTIFICATION TEST AUDIT; ALCOHOL-USE DISORDERS; PSYCHIATRIC RATING-SCALE; SEXUAL EXPERIENCE SCALE; ABUSE SCREENING-TEST; MEDICATION ADHERENCE; ANTIPSYCHOTIC MEDICATION; SCHIZOAFFECTIVE DISORDER AB In schizophrenia, treatments that improve outcomes have not been reliably disseminated. A major barrier to improving care has been a lack of routinely collected outcomes data that identify patients who are failing to improve or not receiving effective treatments. To support high quality care, the VA Mental Health QUERI used literature review, expert interviews, and a national panel process to increase consensus regarding outcomes monitoring instruments and strategies that support quality improvement. There was very good consensus in the domains of psychotic symptoms, side-effects, drugs and alcohol, depression, caregivers, vocational functioning, and community tenure. There are validated instruments and assessment strategies that are feasible for quality improvement in routine practice. C1 [Young, Alexander S.; Niv, Noosha; Marder, Stephen R.] MIRECC, VA Desert Pacific Mental Illness Res, W Los Angeles VA, Los Angeles, CA 90073 USA. [Young, Alexander S.; Niv, Noosha; Marder, Stephen R.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. [Chinman, Matthew] VA Stars & Stripes MIRECC, Pittsburgh, PA 15206 USA. [Chinman, Matthew] RAND Corp, Pittsburgh, PA USA. [Dixon, Lisa] VA Maryland Hlth Care Syst, VA Capitol MIRECC, Baltimore, MD 21201 USA. [Dixon, Lisa] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Eisen, Susan V.] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Eisen, Susan V.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Fischer, Ellen P.; Smith, Jeffrey; Owen, Richard R.] VA Mental Hlth QUERI, Cent Arkansas Vet Healthcare Syst HSR&D NLR 152, N Little Rock, AR 72114 USA. [Fischer, Ellen P.; Smith, Jeffrey; Owen, Richard R.] Univ Arkansas Med Sci, Dept Psychiat & Behav Sci, Little Rock, AR 72205 USA. [Valenstein, Marcia] Ann Arbor VA Med Ctr, Ann Arbor, MI 48113 USA. [Valenstein, Marcia] Univ Michigan, Ann Arbor, MI 48109 USA. RP Young, AS (reprint author), MIRECC, VA Desert Pacific Mental Illness Res, W Los Angeles VA, 11301 Wilshire Blvd,210A, Los Angeles, CA 90073 USA. EM ayoung@ucla.edu RI Young, Alexander/A-1523-2009 OI Young, Alexander/0000-0002-9367-9213 FU NIMH NIH HHS [P30 MH082760, MH082760] NR 100 TC 12 Z9 12 U1 4 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD APR PY 2011 VL 47 IS 2 BP 123 EP 135 DI 10.1007/s10597-010-9328-y PG 13 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 735WQ UT WOS:000288451700001 PM 20658320 ER PT J AU Mather, M Alford, K AF Mather, Mary Alford, Kaye TI Creating a Healthy Work Environment With Civility and Respect SO CRITICAL CARE NURSE LA English DT Meeting Abstract C1 [Mather, Mary; Alford, Kaye] S Texas Vet Hlth Care Syst, San Antonio, TX USA. EM mary.mather@va.gov NR 0 TC 0 Z9 0 U1 0 U2 6 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 J9 CRIT CARE NURSE JI Crit. Care Nurse PD APR PY 2011 VL 31 IS 2 BP E21 EP E22 PG 2 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 744AX UT WOS:000289065500021 ER PT J AU Richardson, J Hendricks-Jensen, J Vann, C AF Richardson, Jeannette Hendricks-Jensen, Jadene Vann, Christina TI Analysis of Practice and Performance Improvement in Patients with Severe Sepsis and Septic Shock SO CRITICAL CARE NURSE LA English DT Meeting Abstract C1 [Richardson, Jeannette; Hendricks-Jensen, Jadene; Vann, Christina] Portland VA Med Ctr, Portland, OR USA. EM jeannette.richardson@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 J9 CRIT CARE NURSE JI Crit. Care Nurse PD APR PY 2011 VL 31 IS 2 BP E15 EP E16 PG 2 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA 744AX UT WOS:000289065500010 ER PT J AU Shimada, T Oda, S Sadahiro, T Nakamura, M Hirayama, Y Watanabe, E Abe, R Nakada, T Tateishi, Y Otani, S Hirasawa, H Tokuhisa, T Uno, H AF Shimada, Tadanaga Oda, Shigeto Sadahiro, Tomohito Nakamura, Masataka Hirayama, Yoh Watanabe, Eizo Abe, Ryuzo Nakada, Taka-aki Tateishi, Yoshihisa Otani, Shunsuke Hirasawa, Hiroyuki Tokuhisa, Takeshi Uno, Hajime TI Outcome prediction in sepsis combined use of genetic polymorphisms - A study in Japanese population SO CYTOKINE LA English DT Article DE Genetics; Interleukin-1; Tumor necrosis factor; Sepsis; Risk factors ID TUMOR-NECROSIS-FACTOR; INTERLEUKIN-6 BLOOD-LEVELS; CRITICAL ILLNESS; CRITICALLY-ILL; MORTALITY; ASSOCIATION; CYTOKINES; SUSCEPTIBILITY; HAPLOTYPE; RELEASE AB Genetic polymorphisms have recently been found to be related to clinical outcome in septic patients. The present study investigated to evaluate the influence of genetic polymorphisms in Japanese septic patients on clinical outcome and whether use of genetic polymorphisms as predictors would enable more accurate prediction of outcome. Effects of 16 genetic polymorphisms related to pro-inflammatory mediators and conventional demographic/clinical parameters (age, sex, past medical history, and APACHE II score) on ICU mortality as well as disease severity during ICU stay were examined in the septic patients (n = 123) admitted to the ICU between October 2001 and November 2007 by multivariable logistic regression analysis. ICU mortality was significantly associated with TNF -308GA, IL1 beta -31CT/TT, and APACHE II score. Receiver-operating characteristics (ROC) analysis demonstrated that, compared with APACHE II score alone (ROC-AUC = 0.68), use of APACHE II score and two genetic parameters (TNF -308 and IL1 beta -31) enabled more accurate prediction of ICU mortality (ROC-AUC = 0.80). Significant association of two genetic polymorphisms, TNF -308 and IL1 beta -31, with ICU mortality was observed in septic patients. In addition, combined use of these genetic parameters with APACHE II score may enable more accurate prediction of outcome in septic patients. (C) 2010 Elsevier Ltd All rights reserved. C1 [Shimada, Tadanaga] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chuo Ku, Chiba 2608677, Japan. [Tokuhisa, Takeshi] Chiba Univ, Grad Sch Med, Dept Dev Genet, Chiba 2608677, Japan. [Uno, Hajime] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Shimada, T (reprint author), Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608677, Japan. EM umitanago@k9.dion.ne.jp NR 35 TC 10 Z9 10 U1 0 U2 2 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD APR PY 2011 VL 54 IS 1 BP 79 EP 84 DI 10.1016/j.cyto.2010.12.001 PG 6 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 743LO UT WOS:000289020000013 PM 21282064 ER PT J AU Keuthen, NJ Rothbaum, BO Falkenstein, MJ Meunier, S Timpano, KR Jenike, MA Welch, SS AF Keuthen, Nancy J. Rothbaum, Barbara O. Falkenstein, Martha J. Meunier, Suzanne Timpano, Kiara R. Jenike, Michael A. Welch, Stacy Shaw TI DBT-ENHANCED HABIT REVERSAL TREATMENT FOR TRICHOTILLOMANIA: 3-AND 6-MONTH FOLLOW-UP RESULTS SO DEPRESSION AND ANXIETY LA English DT Article DE trichotillomania; hair pulling; habit reversal; dialectical behavior therapy ID BEHAVIORAL TREATMENT AB Background: Maintenance of gains with cognitive-behavioral treatment for trichotillomania (TTM) has historically been problematic. Methods: We conducted follow-up assessments 3 and 6 months after completion of a 3-month maintenance phase on 10 individuals with DSM-IV-TR TTM who participated in an open trial of a dialectical behavior therapy (DBT)-enhanced habit reversal treatment (HRT). Results: Significant improvement from baseline was reported at 3- and 6-month follow-up on all measures of hair pulling severity and emotion regulation, although some worsening was reported on some measures from earlier study time points. At 6-month follow-up, five and four participants were full and partial responders, respectively. Significant correlations were reported at both follow-up time points between changes in hair pulling severity and emotion regulation capacity. Conclusions: DBT-enhanced HRT offers promise for improved long-term treatment results in TTM. Changes in TTM severity from baseline to 3- and 6-month follow-up is correlated with changes in emotion regulation capacity. Depression and Anxiety 28:310-313, 2011. (C) 2010 Wiley-Liss, Inc. C1 [Keuthen, Nancy J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Trichotillomania Clin, Boston, MA 02114 USA. [Rothbaum, Barbara O.] Emory Univ, Sch Med, Atlanta, GA USA. [Welch, Stacy Shaw] Anxiety & Stress Reduct Ctr, Seattle, WA USA. [Welch, Stacy Shaw] Univ Washington, Washington, DC USA. RP Keuthen, NJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Trichotillomania Clin, Simches 2,185 Cambridge St, Boston, MA 02114 USA. EM nkeuthen@partners.org RI Citations, TLC SAB/C-4006-2011; Timpano, Kiara/C-8760-2012; OI Falkenstein, Martha/0000-0001-5074-3409; Timpano, Kiara/0000-0002-0665-8722 FU David Judah Fund FX Contract grant sponsor: David Judah Fund. NR 9 TC 26 Z9 26 U1 0 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD APR PY 2011 VL 28 IS 4 BP 310 EP 313 DI 10.1002/da.20778 PG 4 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 744UT UT WOS:000289121000006 PM 21456040 ER PT J AU Steketee, G Siev, J Fama, JM Keshaviah, A Chosak, A Wilhelm, S AF Steketee, Gail Siev, Jedidiah Fama, Jeanne M. Keshaviah, Aparna Chosak, Anne Wilhelm, Sabine TI PREDICTORS OF TREATMENT OUTCOME IN MODULAR COGNITIVE THERAPY FOR OBSESSIVE-COMPULSIVE DISORDER SO DEPRESSION AND ANXIETY LA English DT Article DE cognitive therapy; obsessive-compulsive disorder; treatment; comorbidity; motivation; expectancy ID GENERALIZED ANXIETY DISORDER; BEHAVIOR-THERAPY; PERSONALITY-DISORDERS; SYMPTOM DIMENSIONS; FOLLOW-UP; CONTROLLED TRIAL; PANIC DISORDER; COMORBIDITY; PSYCHOTHERAPY; IMPAIRMENT AB The present study sought to identify predictors of outcome for a comprehensive cognitive therapy (CT) developed for patients with obsessive- compulsive disorder (OCD). Methods: Treatment was delivered over 22 sessions and included standard CT methods, as well as specific strategies designed for subtypes of OCD including religious, sexual, and other obsessions. This study of 39 participants assigned to CT examined predictors of outcomes assessed on the Yale-Brown Obsessive Compulsive Scale. A variety of baseline symptom variables were examined as well as treatment expectancy and motivation. Results: Findings indicated that participants who perceived themselves as having more severe OCD at baseline remained in treatment but more severe symptoms were marginally associated with worse outcome for those who completed therapy. Depressed and anxious mood did not predict post-test outcome, but more Axis I comorbid diagnoses (mainly major depression and anxiety disorders), predicted more improvement, as did the presence of sexual (but not religious) OCD symptoms, and stronger motivation (but not expectancy). A small rebound in OCD symptoms at 1-year follow-up was significantly predicted by higher scores on personality traits, especially for schizotypal (but not obsessive compulsive personality) traits. Conclusions: Longer treatment may be needed for those with more severe symptoms at the outset. CT may have positive effects not only on OCD symptoms but also on comorbid depressive and anxious disorders and associated underlying core beliefs. Findings are discussed in light of study limitations and research on other predictors. Depression and Anxiety 28:333-341, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Steketee, Gail] Boston Univ, Sch Social Work, Boston, MA 02215 USA. [Siev, Jedidiah; Fama, Jeanne M.; Keshaviah, Aparna; Chosak, Anne; Wilhelm, Sabine] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Siev, Jedidiah; Fama, Jeanne M.; Keshaviah, Aparna; Chosak, Anne; Wilhelm, Sabine] Harvard Univ, Sch Med, Boston, MA USA. RP Steketee, G (reprint author), Boston Univ, Sch Social Work, 264 Bay State Rd, Boston, MA 02215 USA. EM steketee@bu.edu FU NIMH [MH58804]; New Harbinger Publications; Obsessive-Compulsive Foundation; FDA; Tourette Syndrome Association; Guilford Publications; Oxford University Press; David Judah Fund; pharmaceutical companies FX We thank Drs. Kimberly Wilson, Bethany Teachman, Ulrike Buhlmann, and Elana Golan for their help with this project. Drs. Wilhelm, Steketee, Chosak, and Fama have received research support from NIMH for this study (NIMH grant MH58804, PI: Wilhelm). Drs. Wilhelm and Steketee received royalties from their CT treatment manual published by New Harbinger Publications. In addition, we have the following disclosures, which are not directly relevant for this project. Drs. Wilhelm, Fama, Chosak, and Siev, and Ms. Keshaviah have received private donor funding from the David Judah Fund. Drs. Wilhelm and Fama have received research support from the Obsessive-Compulsive Foundation. Dr. Wilhelm has also received research support from the FDA and the Tourette Syndrome Association. Forest Laboratories provided her with medication for an NIMH funded study. Drs. Wilhelm, Fama, and Chosak are presenters for the Massachusetts General Hospital Psychiatry Academy in educational programs supported through independent medical education grants from pharmaceutical companies. Drs. Wilhelm and Fama have also received speaking honoraria from various academic institutions. Drs. Wilhelm and Steketee have also received royalties from Guilford Publications and Oxford University Press. NR 59 TC 27 Z9 27 U1 3 U2 12 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1091-4269 J9 DEPRESS ANXIETY JI Depress. Anxiety PD APR PY 2011 VL 28 IS 4 BP 333 EP 341 DI 10.1002/da.20785 PG 9 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 744UT UT WOS:000289121000009 PM 21308884 ER PT J AU Egede, LE Gebregziabher, M Hunt, KJ Axon, RN Echols, C Gilbert, GE Mauldin, PD AF Egede, Leonard E. Gebregziabher, Mulugeta Hunt, Kelly J. Axon, Robert N. Echols, Carrae Gilbert, Gregory E. Mauldin, Patrick D. TI Regional, Geographic, and Racial/Ethnic Variation in Glycemic Control in a National Sample of Veterans With Diabetes SO DIABETES CARE LA English DT Article ID HEMOGLOBIN A(1C); CARE; HEALTH; GLUCOSE; DISPARITIES; BENEFICIARIES; PREVALENCE; OUTCOMES; CLINICS; ADULTS AB OBJECTIVE-We performed a retrospective analysis of a national cohort of veterans with diabetes to better understand regional, geographic, and racial/ethnic variation in diabetes control as measured by HbA(1c). RESEARCH DESIGN AND METHODS-A retrospective cohort study was conducted in a national cohort of 690,968 veterans with diabetes receiving prescriptions for insulin or oral hypoglycemic agents in 2002 that were followed over a 5-year period. The main outcome measures were HbA(1c) levels (as continuous and dichotomized at >= 8.0%). RESULTS-Relative to non-Hispanic whites (NHWs), HbA(1c) levels remained 0.25% higher in non-Hispanic blacks (NHBs), 0.31% higher in Hispanics, and 0.14% higher in individuals with other/unknown/missing racial/ethnic group after controlling for demographics, type of medication used, medication adherence, and comorbidities. Small but statistically significant geographic differences were also noted with HbA(1c) being lowest in the South and highest in the Mid-Atlantic. Rural/urban location of residence was not associated with HbA(1c) levels. For the dichotomous outcome poor control, results were similar with race/ethnic group being strongly associated with poor control (i.e., odds ratios of 1.33 [95% CI 1.31-1.35] and 1.57 [1.54-1.61] for NHBs and Hispanics vs. NHWs, respectively), geographic region being weakly associated with poor control, and rural/urban residence being negligibly associated with poor control. CONCLUSIONS-In a national longitudinal cohort of veterans with diabetes, we found racial/ethnic disparities in HbA(1c) levels and HbA(1c) control; however, these disparities were largely, but not completely, explained by adjustment for demographic characteristics, medication adherence, type of medication used to treat diabetes, and comorbidities. C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Hunt, Kelly J.; Axon, Robert N.; Echols, Carrae; Gilbert, Gregory E.; Mauldin, Patrick D.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Egede, Leonard E.; Axon, Robert N.; Mauldin, Patrick D.] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta; Hunt, Kelly J.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. [Mauldin, Patrick D.] S Carolina Coll Pharm, Dept Clin Pharm & Outcome Sci, Charleston, SC USA. RP Egede, LE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. EM egedel@musc.edu RI Gilbert, Gregory/C-7735-2016; OI Gilbert, Gregory/0000-0003-0879-5496; Gebregziabher, Mulugeta/0000-0002-4826-481X FU VHA Health Services Research and Development [IIR-06-219] FX This study was supported by Grant IIR-06-219 funded by the VHA Health Services Research and Development program. The funding agency did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The article represents the views of the authors and not those of the VA or Health Services Research and Development. NR 23 TC 35 Z9 35 U1 0 U2 3 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2011 VL 34 IS 4 BP 938 EP 943 DI 10.2337/dc10-1504 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 746DE UT WOS:000289221800026 PM 21335370 ER PT J AU Sun, JK Keenan, HA Cavallerano, JD Asztalos, BF Schaefer, EJ Sell, DR Strauch, CM Monnier, VM Doria, A Aiello, LP King, GL AF Sun, Jennifer K. Keenan, Hillary A. Cavallerano, Jerry D. Asztalos, Bela F. Schaefer, Ernst J. Sell, David R. Strauch, Christopher M. Monnier, Vincent M. Doria, Alessandro Aiello, Lloyd Paul King, George L. TI Protection From Retinopathy and Other Complications in Patients With Type 1 Diabetes of Extreme Duration The Joslin 50-Year Medalist Study SO DIABETES CARE LA English DT Article ID ADVANCED GLYCATION ENDPRODUCTS; MICROVASCULAR COMPLICATIONS; PREVALENCE; ASSOCIATION; PROGRESSION; DIAGNOSIS; MELLITUS; DISEASE; UKPDS; RISK AB OBJECTIVE-To assess complication prevalence and identify protective factors in patients with diabetes duration of >= 50 years. Characterization of a complication-free subgroup in this cohort would suggest that some individuals are protected from diabetes complications and allow identification of endogenous protective factors. RESEARCH DESIGN AND METHODS-Cross-sectional, observational study of 351 U.S. residents who have survived with type 1 diabetes for >= 50 years (Medalists). Retinopathy, nephropathy, neuropathy, and cardiovascular disease were assessed in relation to HbA(1c), lipids, and advanced glycation end products (AGEs). Retrospective chart review provided longitudinal ophthalmic data for a subgroup. RESULTS-A high proportion of Medalists remain free from proliferative diabetic retinopathy (PDR) (42.6%), nephropathy (86.9%), neuropathy (39.4%), or cardiovascular disease (51.5%). Current and longitudinal (the past 15 years) glycemic control were unrelated to complications. Subjects with high plasma carboxyethyl-lysine and pentosidine were 7.2-fold more likely to have any complication. Of Medalists without PDR, 96% with no retinopathy progression over the first 17 years of follow-up did not experience retinopathy worsening thereafter. CONCLUSIONS-The Medalist population is likely enriched for protective factors against complications. These factors might prove useful to the general population with diabetes if they can be used to induce protection against long-term complications. Specific AGE combinations were strongly associated with complications, indicating a link between AGE formation or processing with development of diabetic vasculopathy. C1 [Sun, Jennifer K.; Keenan, Hillary A.; Doria, Alessandro; Aiello, Lloyd Paul; King, George L.] Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA. [Sun, Jennifer K.; Cavallerano, Jerry D.; Aiello, Lloyd Paul] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA. [Sun, Jennifer K.; Cavallerano, Jerry D.; Aiello, Lloyd Paul] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Keenan, Hillary A.; King, George L.] Harvard Univ, Sch Med, Dept Internal Med, Boston, MA USA. [Asztalos, Bela F.; Schaefer, Ernst J.] Tufts Univ, Human Nutr Res Ctr Aging, Boston, MA 02111 USA. [Sell, David R.; Strauch, Christopher M.; Monnier, Vincent M.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA. [Sell, David R.; Strauch, Christopher M.; Monnier, Vincent M.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA. RP King, GL (reprint author), Joslin Diabet Ctr, Div Res, 1 Joslin Pl, Boston, MA 02215 USA. EM george.king@joslin.harvard.edu FU Juvenile Diabetes Research Foundation (JDRF) [8-2005-358, 8-2008-363, 25-2008-383]; National Institutes of Health (NIH) [K12 EY16335, T32DK007260, R24 DK083957-01, P30DK036836-23]; Brehm Foundation; Beatson Foundation; Eli Lilly [F3Z-US-X024] FX The following organizations supported this research: the Juvenile Diabetes Research Foundation (JDRF 8-2005-358, 8-2008-363, 25-2008-383); the National Institutes of Health (NIH K12 EY16335, T32DK007260, R24 DK083957-01, P30DK036836-23); the Brehm Foundation; the Beatson Foundation; and Eli Lilly (F3Z-US-X024). No other potential conflicts of interest relevant to this article were reported. NR 25 TC 66 Z9 68 U1 2 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2011 VL 34 IS 4 BP 968 EP 974 DI 10.2337/dc10-1675 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 746DE UT WOS:000289221800031 PM 21447665 ER PT J AU Fitch, KV Stanley, TL Loopy, SE Rope, AM Grinspoon, SK AF Fitch, Kathleen V. Stanley, Takara L. Loopy, Sara E. Rope, Alison M. Grinspoon, Steven K. TI Relationship Between Neck Circumference and Cardiometabolic Parameters in HIV-Infected and Non-HIV-Infected Adults SO DIABETES CARE LA English DT Article ID CARDIOVASCULAR RISK-FACTORS; INTIMA-MEDIA THICKNESS; INSULIN-RESISTANCE; ADIPOSE-TISSUE; COMPUTED-TOMOGRAPHY; DISEASE RISK; MEN; ASSOCIATION; PREDICTION; OBESITY AB OBJECTIVE-Upper body fat is associated with increased cardiometabolic risk. More recently, neck circumference (NC) and/or neck fat have been associated with hyperlipidemia, impaired glucose homeostasis, and hypertension. The objective of this study was to determine whether this relationship is evident in HIV-infected individuals, who often exhibit changes in relative fat distribution, and to determine whether NC is independently associated with carotid intima-media thickness (cIMT) in HIV and non HIV-infected patients. RESEARCH DESIGN AND METHODS-Body composition, including anthropometrics, visceral adipose tissue assessment by CT, and metabolic parameters, including lipids, cIMT, and oral glucose tolerance test, were measured in 174 men and women with HIV infection and 154 non HIV-infected subjects. NC was measured in triplicate inferior to the laryngeal prominence. RESULTS-In univariate analysis, NC was significantly and positively related to blood pressure, hemoglobin A 1 c, glucose, and insulin and significantly and negatively related to HDL cholesterol in HIV-infected individuals and HIV-negative control subjects. NC was significantly associated with cIMT in univariate regression analysis among HIV-infected (r = 0.21, P = 0.006) and non HIV-infected (r = 0.31, P = 0.0001) patients. This relationship remained significant among non HIV-infected patients (R(2) = 0.45, P < 0.001) but not HIV-infected patients in multivariate modeling controlling for age, sex, race, smoking hypertension, glucose, and lipids. CONCLUSIONS-Among both HIV and non HIV-infected patients, increased NC is strongly associated with decreased HDL and impaired glucose homeostasis. Among non-HIV-infected subjects, NC also predicts increased cIMT when controlling for traditional risk factors. C1 [Grinspoon, Steven K.] Massachusetts Gen Hosp, Program Nutr Metab & Neuroendocrine Unit, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Grinspoon, SK (reprint author), Massachusetts Gen Hosp, Program Nutr Metab & Neuroendocrine Unit, Boston, MA 02114 USA. EM sgrinspoon@partners.org FU National Institutes of Health (NIH) [R01-DK-049302, K24-DK-064545, M01-RR-01066, 1-UL1-RR-025758-01, K23-DK-089910-01, K23-NR-011833-01]; Harvard Clinical and Translational Science Center; National Center for Research Resources FX This work was supported by the National Institutes of Health (NIH) grants R01-DK-049302 and K24-DK-064545 (to S.K.G.) and M01-RR-01066 and 1-UL1-RR-025758-01; Harvard Clinical and Translational Science Center; and from the National Center for Research Resources. NIH funding was also provided through K23-DK-089910-01 (to T.L.S.) and K23-NR-011833-01 (to S.E.L.). NR 25 TC 20 Z9 25 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD APR PY 2011 VL 34 IS 4 BP 1026 EP 1031 DI 10.2337/dc10-1983 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 746DE UT WOS:000289221800041 PM 21378212 ER PT J AU Martin, C Balasubramanian, R Dwyer, AA Au, MG Sidis, Y Kaiser, UB Seminara, SB Pitteloud, N Zhou, QY Crowley, WF AF Martin, Cecilia Balasubramanian, Ravikumar Dwyer, Andrew A. Au, Margaret G. Sidis, Yisrael Kaiser, Ursula B. Seminara, Stephanie B. Pitteloud, Nelly Zhou, Qun-Yong Crowley, William F., Jr. TI The Role of the Prokineticin 2 Pathway in Human Reproduction: Evidence from the Study of Human and Murine Gene Mutations SO ENDOCRINE REVIEWS LA English DT Review ID ENDOTHELIAL GROWTH-FACTOR; GONADOTROPIN-RELEASING-HORMONE; IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM; FOLLICLE-STIMULATING-HORMONE; STEROID SULFATASE DEFICIENCY; OLFACTORY-BULB NEUROGENESIS; PROTEIN-COUPLED RECEPTORS; OF-FUNCTION MUTATIONS; BLACK MAMBA VENOM; KALLMANN-SYNDROME AB A widely dispersed network of hypothalamic GnRH neurons controls the reproductive axis in mammals. Genetic investigation of the human disease model of isolated GnRH deficiency has revealed several key genes crucial for GnRHneuronal ontogeny and GnRH secretion. Among these genes, prokineticin 2 (PROK2), and PROK2 receptor (PROKR2) have recently emerged as critical regulators of reproduction in both mice and humans. Both prok2- and prokr2-deficient mice recapitulate the human Kallmann syndrome phenotype. Additionally, PROK2 and PROKR2 mutations are seen in humans with Kallmann syndrome, thus implicating this pathway in GnRH neuronal migration. However, PROK2/PROKR2 mutations are also seen in normosmic GnRH deficiency, suggesting a role for the prokineticin signaling system in GnRH biology that is beyond neuronal migration. This observation is particularly surprising because mature GnRH neurons do not express PROKR2. Moreover, mutations in both PROK2 and PROKR2 are predominantly detected in the heterozygous state with incomplete penetrance or variable expressivity frequently seen within and across pedigrees. In some of these pedigrees, a "second hit" or oligogenicity has been documented. Besides reproduction, a pleiotropic physiological role for PROK2 is now recognized, including regulation of pain perception, circadian rhythms, hematopoiesis, and immune response. Therefore, further detailed clinical studies of patients with PROK2/PROKR2 mutations will help to map the broader biological role of the PROK2/PROKR2 pathway and identify other interacting genes/proteins that mediate its molecular effects in humans. (Endocrine Reviews 32: 225-246, 2011) C1 [Martin, Cecilia; Balasubramanian, Ravikumar; Dwyer, Andrew A.; Au, Margaret G.; Sidis, Yisrael; Kaiser, Ursula B.; Seminara, Stephanie B.; Pitteloud, Nelly; Crowley, William F., Jr.] Massachusetts Gen Hosp, Harvard Ctr Reprod Endocrine Sci, Boston, MA 02114 USA. [Martin, Cecilia; Balasubramanian, Ravikumar; Dwyer, Andrew A.; Au, Margaret G.; Sidis, Yisrael; Seminara, Stephanie B.; Pitteloud, Nelly; Crowley, William F., Jr.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Dept Med, Boston, MA 02114 USA. [Kaiser, Ursula B.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Kaiser, Ursula B.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Zhou, Qun-Yong] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA. RP Crowley, WF (reprint author), Massachusetts Gen Hosp, Harvard Reprod Endocrine Sci Ctr Excellence, 55 Fruit St,Bartlett Hall Extens,5th Floor, Boston, MA 02114 USA. EM wcrowley@partners.org RI Dwyer, Andrew/D-8099-2012; PITTELOUD, Nelly/K-2709-2014 OI Dwyer, Andrew/0000-0002-7023-6794; FU National Institutes of Health [5R01HD015788, 5U54HD028138]; Pew Charitable Trust FX This work was supported by National Institutes of Health Grants 5R01HD015788 and 5U54HD028138, as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research; and C. M. was supported by the Pew Charitable Trust, Latin American Fellows Program in the Biomedical Sciences. NR 164 TC 31 Z9 33 U1 0 U2 7 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0163-769X J9 ENDOCR REV JI Endocr. Rev. PD APR PY 2011 VL 32 IS 2 BP 225 EP 246 DI 10.1210/er.2010-0007 PG 22 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 745DD UT WOS:000289144100002 PM 21037178 ER PT J AU Alexeeff, SE Coull, BA Gryparis, A Suh, H Sparrow, D Vokonas, PS Schwartz, J AF Alexeeff, Stacey E. Coull, Brent A. Gryparis, Alexandros Suh, Helen Sparrow, David Vokonas, Pantel S. Schwartz, Joel TI Medium-Term Exposure to Traffic-Related Air Pollution and Markers of Inflammation and Endothelial Function SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE adhesion molecules; air; cardiovascular; environmental; outdoor air; roadway proximity ID C-REACTIVE PROTEIN; HEALTHY-HUMAN VOLUNTEERS; DIABETIC INDIVIDUALS; CARDIOVASCULAR RISK; PARTICULATE MATTER; DIESEL EXHAUST; PARTICLES; DISEASE; MORTALITY; STATINS AB BACKGROUND: Exposure to traffic-related air pollution (TRAP) contributes to increased cardiovascular risk. Land-use regression models can improve exposure assessment for TRAP. Objectives: We examined the association between medium-term concentrations of black carbon (BC) estimated by land-use regression and levels of soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1), both markers of inflammatory and endothelial response. METHODS: We studied 642 elderly men participating in the Veterans Administration (VA) Normative Aging Study with repeated measurements of sICAM-1 and sVCAM-1 during 1999-2008. Daily estimates of BC exposure at each geocoded participant address were derived using a validated spatio-temporal model and averaged to form 4-, 8-, and 12-week exposures. We used linear mixed models to estimate associations, controlling for confounders. We examined effect modification by statin use, obesity, and diabetes. RESULTS: We found statistically significant positive associations between BC and sICAM-1 for averages of 4, 8, and 12 weeks. An interquartile-range increase in 8-week BC exposure (0.30 mu g/m(3)) was associated with a 1.58% increase in sICAM-1 (95% confidence interval, 0.18-3.00%). Overall associations between sVCAM-1 and BC exposures were suggestive but not statistically significant. We found a significant interaction with diabetes-where diabetics were more susceptible to the effect of BC-for both sICAM-1 and sVCAM-1. We also observed an inter-action with statin use, which was statistically significant for sVCAM-1 and suggestive for sICAM-1. We found no evidence of an interaction with obesity. CONCLUSION: Our results suggest that medium-term exposure to TRAP may induce an increased inflammatory/endothelial response, especially among diabetics and those not using statins. C1 [Alexeeff, Stacey E.; Suh, Helen; Schwartz, Joel] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Coull, Brent A.; Gryparis, Alexandros] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Sparrow, David; Vokonas, Pantel S.] Boston Univ, Sch Med, VA Normat Aging Study, VA Boston Healthcare Syst,Dept Med, Boston, MA 02118 USA. RP Alexeeff, SE (reprint author), Landmark Ctr, 401 Pk Dr,Ste 415 W, Boston, MA 02215 USA. EM salexeeff@fas.harvard.edu FU National Institute of Environmental Health Sciences [ES015172-01, ES00002]; U.S. Environmental Protection Agency [R832416]; U.S. Department of Veterans Affairs, Massachusetts Veterans Epidemiology Research and Information Center (Boston, MA, USA) FX This work was supported by grants ES015172-01 and ES00002 from the National Institute of Environmental Health Sciences, and grant R832416 from the U.S. Environmental Protection Agency. The Normative Aging Study is supported by the Cooperative Studies Program/Epidemiology Research and Information Center of the U.S. Department of Veterans Affairs and is a component of the Massachusetts Veterans Epidemiology Research and Information Center (Boston, MA, USA). NR 38 TC 41 Z9 41 U1 1 U2 16 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD APR PY 2011 VL 119 IS 4 BP 481 EP 486 DI 10.1289/ehp.1002560 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 744BA UT WOS:000289065900028 PM 21349799 ER PT J AU Papakostas, GI Larsen, K AF Papakostas, George I. Larsen, Klaus TI Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram SO EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE LA English DT Article DE Depression; Anxious; Predictor; Moderator; Antidepressant; Unipolar ID SEROTONIN REUPTAKE INHIBITORS; STAR-ASTERISK-D; RANDOMIZED CLINICAL-TRIALS; DOUBLE-BLIND; CONTINUATION TREATMENT; POOLED ANALYSIS; PLACEBO; DULOXETINE; ANXIETY; EFFICACY AB The purpose of this analysis was to explore the potential role of anxious MDD as a treatment predictor and moderator in major depressive disorder (MDD) using a large escitalopram clinical trial dataset. Individual patient-level data from 13 double-blinded, randomized, controlled trials in patients with MDD were pooled. Both univariate, last observation carried forward (LOCF) analyses and repeated measurements analyses without imputation (MMRM) were carried out for change in symptom scores, response and remission rates. Of 3,919 patients, 48.0% were classified as having anxious MDD depression (HAMD) somatization/anxiety subscale score a parts per thousand yen7 at baseline. Patients with anxious MDD were less likely to report symptom improvement on some outcome measures than patients without anxious MDD (predictor analysis). Specifically, the difference in response rates for patients with vs. patients without anxious MDD according to the MADRS (55.6% vs. 57.7%, respectively) was not statistically different. However, the difference in remission rates for patients with versus without anxious MDD according to the MADRS (37.6% vs. 44.1%, respectively) was statistically significant. Escitalopram was more effective than placebo, and as effective as the SSRIs and SNRIs, in the treatment of anxious MDD. The present analysis provides some evidence that the presence of an anxious MDD subtype is a predictor of poor response. There was no difference in the response to treatment of patients with or without anxious MDD to escitalopram, SSRIs, or SNRIs. The present analysis did not support the notion that SNRIs are more effective than escitalopram in the treatment of anxious MDD, nor was there evidence to support treatment moderating effects for anxious MDD. C1 [Papakostas, George I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA. [Larsen, Klaus] H Lundbeck & Co AS, Copenhagen, Denmark. RP Papakostas, GI (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 15 Parkman St,WACC 812, Boston, MA 02114 USA. EM gpapakostas@partners.org RI Papakostas, George/I-6905-2013 OI Papakostas, George/0000-0002-2465-5103 NR 38 TC 12 Z9 13 U1 0 U2 4 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0940-1334 J9 EUR ARCH PSY CLIN N JI Eur. Arch. Psych. Clin. Neurosci. PD APR PY 2011 VL 261 IS 3 BP 147 EP 156 DI 10.1007/s00406-010-0149-3 PG 10 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 746OQ UT WOS:000289257000002 PM 20859636 ER PT J AU Garland, RC Sun, DW Zandi, S Xie, F Faez, S Tayyari, F Frimmel, SAF Schering, A Nakao, S Hafezi-Moghadam, A AF Garland, Rebecca C. Sun, Dawei Zandi, Souska Xie, Fang Faez, Sepideh Tayyari, Faryan Frimmel, Sonja A. F. Schering, Alexander Nakao, Shintaro Hafezi-Moghadam, Ali TI Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury SO FASEB JOURNAL LA English DT Article DE platelet-activating factor; leukocyte recruitment; endotoxin-induced uveitis; P-selectin glycoprotein ligand-1; ginkgolide B; WEB 2086 ID PLATELET-ACTIVATING-FACTOR; ENDOTOXIN-INDUCED UVEITIS; SELECTIN GLYCOPROTEIN LIGAND-1; ROLLING IN-VIVO; P-SELECTIN; FACTOR-ACETYLHYDROLASE; HUMAN NEUTROPHILS; FACTOR RECEPTOR; UP-REGULATION; PLASMA AB Uveitis is a systemic immune disease and a common cause of blindness. The eye is an ideal organ for light-based imaging of molecular events underlying vascular and immune diseases. The phospholipid platelet-activating factor (PAF) is an important mediator of inflammation, the action of which in endothelial and immune cells in vivo is not well understood. The purpose of this study was to investigate the role of PAF in endothelial injury in uveitis. Here, we use our recently introduced in vivo molecular imaging approach in combination with the PAF inhibitors WEB 2086 (WEB) and ginkgolide B (GB). The differential inhibitory effects of WEB and GB in reducing LPS-induced endothelial injury in the choroid indicate an important role for PAF-like lipids, which might not require the PAF receptor for their signaling. P-selectin glycoprotein ligand-1-mediated rolling of mouse leukocytes on immobilized P-selectin in our autoperfused microflow chamber assay revealed a significant reduction in rolling velocity on the cells' contact with PAF. Rolling cells that came in contact with PAF rapidly assumed morphological signs of cell activation, indicating that activation during rolling does not require integrins. Our results show a key role for PAF in mediating endothelial and leukocyte activation in acute ocular inflammation. Our in vivo molecular imaging provides a detailed view of cellular and molecular events in the complex physiological setting.-Garland, R. C., Sun, D., Zandi, S., Xie, F., Faez, S., Tayyari, F., Frimmel, S. A. F., Schering, A., Nakao, S., Hafezi-Moghadam, A. Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury. FASEB J. 25, 1284-1294 (2011). www.fasebj.org C1 [Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Schering, Alexander; Hafezi-Moghadam, Ali] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Funct & Mol Imaging, Boston, MA 02115 USA. [Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Schering, Alexander; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Faez, Sepideh; Tayyari, Faryan; Frimmel, Sonja A. F.; Schering, Alexander; Nakao, Shintaro; Hafezi-Moghadam, Ali] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA. [Garland, Rebecca C.; Sun, Dawei; Zandi, Souska; Xie, Fang; Faez, Sepideh; Tayyari, Faryan; Frimmel, Sonja A. F.; Schering, Alexander; Nakao, Shintaro; Hafezi-Moghadam, Ali] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA. [Sun, Dawei] Harbin Med Coll, Affiliated Hosp 2, Dept Ophthalmol, Harbin, Peoples R China. RP Hafezi-Moghadam, A (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Funct & Mol Imaging, 221 Longwood Ave,3rd Floor, Boston, MA 02115 USA. EM ahm@bwh.harvard.edu OI Hafezi-Moghadam, Ali/0000-0002-5336-0697 FU U.S. National Institutes of Health [AI-050775]; American Health Assistance Foundation; Malaysian Palm Oil Board FX Research-grade YSPSL (recombinant soluble P-selectin glycoprotein ligand IgG fusion protein rPSGL-Ig) was a kind gift of Y's Therapeutics (San Bruno, CA, USA). This work was supported by U.S. National Institutes of Health grant AI-050775, the American Health Assistance Foundation, and the Malaysian Palm Oil Board. NR 36 TC 13 Z9 15 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 J9 FASEB J JI Faseb J. PD APR PY 2011 VL 25 IS 4 BP 1284 EP 1294 DI 10.1096/fj.10-160051 PG 11 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 742ZA UT WOS:000288982800017 PM 21257713 ER PT J AU Chavarro, JE Furtado, J Toth, TL Ford, J Keller, M Campos, H Hauser, R AF Chavarro, Jorge E. Furtado, Jeremy Toth, Thomas L. Ford, Jennifer Keller, Myra Campos, Hannia Hauser, Russ TI Trans-fatty acid levels in sperm are associated with sperm concentration among men from an infertility clinic SO FERTILITY AND STERILITY LA English DT Editorial Material DE Fatty acids; diet; sperm; semen analysis; infertility ID ASTHENOZOOSPERMIC MALES; SEMINAL PLASMA; ADIPOSE-TISSUE; SPERMATOZOA; BIOMARKERS; PARAMETERS; BLOOD; EXPOSURE; HUMANS; LIPIDS AB We measured the sperm fatty acid composition using gas chromatography in anonymized semen samples of 33 men undergoing infertility evaluation at an academic medical center. Trans-fatty acids were present in human sperm and were related inversely to sperm concentration (r = -0.44). (Fertil Steril (R) 2011; 95: 1794-7. (C) 2011 by American Society for Reproductive Medicine.) C1 [Chavarro, Jorge E.; Furtado, Jeremy; Campos, Hannia] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Chavarro, Jorge E.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. [Chavarro, Jorge E.; Toth, Thomas L.; Ford, Jennifer; Keller, Myra; Hauser, Russ] Harvard Univ, Sch Med, Boston, MA USA. [Toth, Thomas L.; Ford, Jennifer; Keller, Myra; Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Boston, MA 02114 USA. [Ford, Jennifer; Keller, Myra; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Chavarro, Jorge E.; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Chavarro, JE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA. EM jchavarr@hsph.harvard.edu FU NIDDK NIH HHS [P30 DK046200, P30 DK046200-18, P30 DK46200-18]; NIEHS NIH HHS [P30 ES000002, ES00002, ES009718, P30 ES000002-46, R01 ES009718, R01 ES009718-12] NR 22 TC 18 Z9 18 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD APR PY 2011 VL 95 IS 5 BP 1794 EP 1797 DI 10.1016/j.fertnstert.2010.10.039 PG 4 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 738OA UT WOS:000288648000067 PM 21071027 ER PT J AU Liu, WJ Liu, F Zhao, W Kim, JM Wang, ZH Vrahas, MS AF Liu, Wanjun Liu, Fang Zhao, Wen Kim, Jaehon M. Wang, Zhenghai Vrahas, Mark S. TI Osteochondral Autograft Transplantation for Acute Osteochondral Fractures Associated with an Ankle Fracture SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE Ankle Fracture; Talar Dome; Osteochondral Fractures; Osteochondral Autograft Transplantation ID AUTOLOGOUS CHONDROCYTE TRANSPLANTATION; TERM FOLLOW-UP; TALAR DOME; TALUS; LESIONS; DEFECTS; MOSAICPLASTY; DISSECANS; CARTILAGE AB Background: Osteochondral fractures of the talar dome (OCFT) are frequently associated with ankle fractures. Controversy exists regarding the treatment of acute Grade III and IV OCFT. Osteochondral autograft transplantation (OAT) is a possible operative solution. Materials and Methods: We performed OAT in 16 patients with acute Grade III or IV OCFT. There were ten males and six females with the average age of 33.9 (range, 18 to 49) years. The average period of followup was 36.3 (range, 21 to 48) months. OCFT was identified, and clinically determined to be Grade III or IV using radiographs and intraoperative assessment. Seven patients were Grade III, nine patients were Grade IV OCFT. The OAT consisted of two sequential procedures: 1) harvesting of osteochondral autograft cylinder from the nonweightbearing surface of the ipsilateral knee, and 2) implanting the donor graft into the talar defect with press-fit technique. Single cylinder transplantation or a mosaicplasty was used. The outcome was determined by the American Orthopaedic Foot and Ankle Society (AOFAS) ankle-hindfoot scale, the simplified symptomatology evaluation, plain radiography and MRI. Results: The mean size of the osteochonral fracture defects was 84.1 (range, 50 to 125) mm(2), and the mean depth was 2.5 (range, I to 5) mm. The mean AOFAS score was 95.4 (range, 86 to 100) points postoperatively. At the latest followup, there was no radiographic evidence of post-traumatic arthritis. Based on the MRI of all patients, 93.7% of the osteochondral grafts showed bony integration and articular congruity of the talar dome. Conclusion: OAT was shown to be an effective treatment with excellent clinical outcome and imaging evidence of graft integration. C1 [Liu, Wanjun; Wang, Zhenghai] Yantai China France Friendship Hosp, Yantaishan Hosp, Yantai 264001, Shandong, Peoples R China. [Liu, Fang; Kim, Jaehon M.; Vrahas, Mark S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Zhao, Wen] Beijing Aerosp Gen Hosp, Beijing, Peoples R China. RP Liu, WJ (reprint author), Yantai China France Friendship Hosp, Yantaishan Hosp, 91 Jiefang Rd, Yantai 264001, Shandong, Peoples R China. EM ytwanjun@gmail.com NR 26 TC 4 Z9 4 U1 1 U2 2 PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC PI SEATTLE PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA SN 1071-1007 J9 FOOT ANKLE INT JI Foot Ankle Int. PD APR PY 2011 VL 32 IS 4 BP 437 EP 442 DI 10.3113/FAI.2011.0437 PG 6 WC Orthopedics SC Orthopedics GA 742XV UT WOS:000288979500020 PM 21733449 ER PT J AU Kwon, JY Campbell, JT Myerson, MS Jeng, CL AF Kwon, John Y. Campbell, John T. Myerson, Mark S. Jeng, Cliff L. TI Effect of a Steel Toe Cap on Forefoot Injury Pattern in a Cadaveric Model SO FOOT & ANKLE INTERNATIONAL LA English DT Article DE Crush; Crush injury; Steel Toe Capped Boot ID TARSOMETATARSAL JOINTS; FOOT AB Background: Crush injuries to the foot are a common workplace injury and a significant source of morbidity, disability and lost wages. Many regulatory bodies including the Occupational Safety and Health Administration (OSHA) recommend the use of safety shoes in certain occupations to help protect against these occupational hazards. However there remains controversy and paucity of published data regarding the protection afforded by a steel toe cap in regards to clinical injury pattern. This study looks to investigates the protective influence of a steel toe cap on crush injuries of the forefoot. Materials and Methods: Five non-osteoporotic paired cadaver lower extremities were appropriately fitted to a standard work boot. One foot of each pair was fitted into a steel toe capped boot (designated "ST" group) while the other foot was fitted into an identical version of the work boot but without the protective steel toe cap (designated "NST" group). Each foot was crushed using a custom designed rig with a load of 150 lb dropped from a calibrated height of 3 feet to the forefoot. X-rays were obtained to assess fracture location & comminution and stress fluoroscopy was used to assess for any ligamentous Lisfranc injury. Results: The NST group averaged 8.2 fractured bones per foot while the ST group averaged 3.6 fractured bones per foot (p = 0.001). The NST group demonstrated significantly more metatarsal fractures (3.2 fractures/foot) versus the ST group (one fracture/foot) (p = 0.020). The NST group demonstrated significantly more proximal phalanx fractures (4.2 fractures/foot) compared to the ST group (2.6 fractures/foot) (p = 0.035). Middle and distal phalanx fractures were not significantly different between the two groups. A higher percentage of the bones fractured were deemed comminuted in the NST group (53.6%) versus the ST group (38.8%) although this did not reach statistical significance. Conclusion: This study demonstrated that the steel toe affords protective advantages in crush injuries to the foot in limiting the number and severity of metatarsal and proximal phalanx fractures. However the steel toe does not fully protect the forefoot from injury. Clinical Relevance: Crush injuries to the foot are a common workplace injury. Strict adherence to workplace safety standards may limit the severity of crush injuries to the foot and additional safety measures such as metatarsal guards should be considered when appropriate. C1 [Kwon, John Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg, Boston, MA 02114 USA. [Campbell, John T.; Myerson, Mark S.; Jeng, Cliff L.] Mercy Hosp, Inst Foot & Ankle Reconstruct, Baltimore, MD USA. RP Kwon, JY (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg, 55 Fruit St, Boston, MA 02114 USA. EM jkwon@partners.org NR 22 TC 2 Z9 3 U1 0 U2 6 PU AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC PI SEATTLE PA 2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA SN 1071-1007 J9 FOOT ANKLE INT JI Foot Ankle Int. PD APR PY 2011 VL 32 IS 4 BP 443 EP 447 DI 10.3113/FAI.2011.0443 PG 5 WC Orthopedics SC Orthopedics GA 742XV UT WOS:000288979500021 PM 21733450 ER PT J AU Brenner, B Cheng, D Clark, S Camargo, CA AF Brenner, Barry Cheng, David Clark, Sunday Camargo, Carlos A., Jr. TI Positive Association between Altitude and Suicide in 2584 U.S. Counties SO HIGH ALTITUDE MEDICINE & BIOLOGY LA English DT Article DE altitude; suicide; firearm; obesity; hypoxia ID MOOD STATES; MORTALITY; DEPRESSION; HYPOXIA; SLEEP; RATES; RISK AB Brenner, Barry, David Cheng, Sunday Clark, and Carlos A. Camargo, Jr. Positive association between altitude and suicide in 2584 U.S. counties. High Alt. Med. Biol. 12:31-35, 2011.-Suicide is an important public health problem worldwide. Recent preliminary studies have reported a positive correlation between mean altitude and the suicide rate of the 48 contiguous U.S. states. Because intrastate altitude may have large variation, we examined all 2584 U.S. counties to evaluate whether an independent relationship between altitude and suicide exists. We hypothesized that counties at higher elevation would have higher suicide rates. This retrospective study examines 20 yr of county-specific mortality data from 1979 to 1998. County altitude was obtained from the U.S. Geologic Survey. Statistical analysis included Pearson correlation, t tests, and multivariable linear and logistic regression. Although there was a negative correlation between county altitude and all-cause mortality (r = -0.31, p < 0.001), there was a strong positive correlation between altitude and suicide rate (r = 0.50, p < 0.001). Mean altitude differed in the 50 counties, with the highest suicide rates compared to those with the lowest rates (4684 vs. 582 ft, p < 0.001). Controlling for percent of age > 50 yr, percent male, percent white, median household income, and population density of each county, the higher-altitude counties had significantly higher suicide rates than the lower-altitude counties. Similar findings were observed for both firearm-related suicides (59% of suicides) and nonfirearm-related suicides. We conclude that altitude may be a novel risk factor for suicide in the contiguous United States. C1 [Brenner, Barry; Cheng, David] Univ Hosp Case Med Ctr, Dept Emergency Med, Cleveland, OH 44106 USA. [Clark, Sunday] Univ Pittsburgh, Med Ctr, Div Gen Internal Med, Pittsburgh, PA USA. [Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Brenner, B (reprint author), Univ Hosp Case Med Ctr, Dept Emergency Med, 11100 Euclid Ave, Cleveland, OH 44106 USA. EM barry.brenner@uhhospitals.org FU NIH (Bethesda, Maryland, USA) [U01 MH-88278] FX Dr. Camargo was supported in part by NIH U01 MH-88278 (Bethesda, Maryland, USA). The authors would like to thank Mr. Lazar Muller for his help with the data collection and entry. NR 32 TC 15 Z9 15 U1 1 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1527-0297 J9 HIGH ALT MED BIOL JI High Alt. Med. Biol. PD APR PY 2011 VL 12 IS 1 BP 31 EP 35 DI 10.1089/ham.2010.1058 PG 5 WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences GA 743CL UT WOS:000288994100007 PM 21214344 ER PT J AU Martinez, EA Shore, A Colantuoni, E Herzer, K Thompson, DA Gurses, AP Marsteller, JA Bauer, L Goeschel, CA Cleary, K Pronovost, PJ Julius, CP AF Martinez, Elizabeth A. Shore, Andrew Colantuoni, Elizabeth Herzer, Kurt Thompson, David A. Gurses, Ayse P. Marsteller, Jill A. Bauer, Laura Goeschel, Christine A. Cleary, Kevin Pronovost, Peter J. Julius Cuong Pham TI Cardiac surgery errors: results from the UK National Reporting and Learning System SO INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE LA English DT Article DE cardiac surgery; surgical errors; perioperative; operating room; medical errors; patient safety; error reporting; incident reporting ID OPERATING-ROOM; ADVERSE EVENTS; MEDICATION ERROR; PATIENT SAFETY; ANESTHESIA; MANAGEMENT; CARE; CLASSIFICATION; FAILURES; LESSONS AB Objective. To describe cardiac surgery-related incidents and compare the types and severity of incidents occurring in the operating room (OR) versus non-OR locations. We hypothesized that the type and severity of incidents in cardiac surgery would differ in the OR compared with non-OR locations. Design. A retrospective cross-sectional study of all incidents categorized as cardiac surgery in the UK National Reporting and Learning System database between January 2003 and February 2007. Differences in proportions were evaluated by chi(2) or Fischer's exact test. The odds ratio of an event occurring in the OR compared with all non-OR settings was calculated using logistic regression. The harm susceptibility ratio ranked locations by the degree of harm. Setting. All trusts performing cardiac surgery. Participants. None. Intervention. None. Main Outcome Measures. Cardiac surgery incidents occurring in the OR versus non-OR. Results. A total of 4828 (< 1%) incidents from 55 trusts were designated as involving cardiac surgery patients during the study period; 21% occurred in the OR. Overall, 32% of incidents resulted in harm: 23% of OR and 34% of non-OR incidents. The distribution of incident type and harmful incidents differed in the OR compared with the non-OR setting (P < 0.05). Conclusions. Our findings offer unique insights into the types of incidents occurring during cardiac surgical care in the UK. In the OR, interventions should focus on reducing errors associated with medical devices/equipment, whereas outside the OR, they may focus on medication errors and patient accidents. C1 [Martinez, Elizabeth A.] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Shore, Andrew; Colantuoni, Elizabeth; Gurses, Ayse P.; Marsteller, Jill A.; Goeschel, Christine A.; Pronovost, Peter J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Herzer, Kurt; Thompson, David A.; Gurses, Ayse P.; Bauer, Laura; Goeschel, Christine A.; Pronovost, Peter J.; Julius Cuong Pham] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Cleary, Kevin] Natl Patient Safety Agcy, London, England. RP Martinez, EA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA. EM emartinez10@partners.org FU Society of Cardiovascular Anesthesiologists Foundation (SCAF), Flawless Operative Cardiovascular Unified Systems Initiative; National Health Service; National Patient Safety Agency in the United Kingdom; Agency for Healthcare Research and Quality [K08HS013904-02, K01HS018762]; SCAF FX This work was supported by the Society of Cardiovascular Anesthesiologists Foundation (SCAF) as part of their Flawless Operative Cardiovascular Unified Systems Initiative (E.A.M., D.A.T., L.B., A.P.G., J.A.M. and P.J.P.); the National Health Service, National Patient Safety Agency in the United Kingdom (A.S. and J.C.P.); and the Agency for Healthcare Research and Quality (K08HS013904-02 to E.A.M., K01HS018762 to A.P.G.). The Flawless Operative Cardiovascular Unified Systems Initiative is a collaborative project of the Society of Cardiovascular Anesthesiologists, the SCAF, and the Johns Hopkins University Quality and Safety Research Group. The Flawless Operative Cardiovascular Unified Systems is funded exclusively by the SCAF. All of the work was completed at Johns Hopkins University. NR 28 TC 13 Z9 13 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1353-4505 J9 INT J QUAL HEALTH C JI Int. J. Qual. Health Care PD APR PY 2011 VL 23 IS 2 BP 151 EP 158 DI 10.1093/intqhc/mzq084 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 733GG UT WOS:000288250600007 PM 21224272 ER PT J AU Goldhaber-Fiebert, JD Jeon, CY Cohen, T Murray, MB AF Goldhaber-Fiebert, Jeremy D. Jeon, Christie Y. Cohen, Ted Murray, Megan B. TI Diabetes mellitus and tuberculosis in countries with high tuberculosis burdens: individual risks and social determinants SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Type 2 diabetes mellitus; Mycobacterium tuberculosis; disease interaction; developing countries; social determinants; observational study ID PULMONARY TUBERCULOSIS; HIV-INFECTION; SELF-REPORTS; HYPERTENSION; PREVALENCE; HEALTH; CARE; PROJECTIONS; AGREEMENT; DIAGNOSIS AB Background A growing body of evidence supports the role of type 2 diabetes as an individual-level risk factor for tuberculosis (TB), though evidence from developing countries with the highest TB burdens is lacking. In developing countries, TB is most common among the poor, in whom diabetes may be less common. We assessed the relationship between individual-level risk, social determinants and population health in these settings. Methods We performed individual-level analyses using the World Health Survey (n = 124 607; 46 countries). We estimated the relationship between TB and diabetes, adjusting for gender, age, body mass index, education, housing quality, crowding and health insurance. We also performed a longitudinal country-level analysis using data on per-capita gross domestic product and TB prevalence and incidence and diabetes prevalence for 1990-95 and 2003-04 (163 countries) to estimate the relationship between increasing diabetes prevalence and TB, identifying countries at risk for disease interactions. Results In lower income countries, individuals with diabetes are more likely than non-diabetics to have TB [univariable odds ratio (OR): 2.39; 95% confidence interval (CI): 1.84-3.10; multivariable OR: 1.81; 95% CI: 1.37-2.39]. Increases in TB prevalence and incidence over time were more likely to occur when diabetes prevalence also increased (OR: 4.7; 95% CI: 1.0-22.5; OR: 8.6; 95% CI: 1.9-40.4). Large populations, prevalent TB and projected increases in diabetes make countries like India, Peru and the Russia Federation areas of particular concern. Conclusions Given the association between diabetes and TB and projected increases in diabetes worldwide, multi-disease health policies should be considered. C1 [Goldhaber-Fiebert, Jeremy D.] Stanford Univ, Dept Med, CHP PCOR, Sch Med, Stanford, CA 94305 USA. [Jeon, Christie Y.] Columbia Univ, Mailman Sch Publ Hlth, Ctr Infect Dis Epidemiol Res, New York, NY USA. [Cohen, Ted; Murray, Megan B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Cohen, Ted; Murray, Megan B.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Murray, Megan B.] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA. RP Goldhaber-Fiebert, JD (reprint author), Stanford Med Sch, CHP PCOR, 117 Encina Commons, Stanford, CA 94305 USA. EM jeremygf@stanford.edu RI Cohen, Ted/G-8101-2011 FU NIA NIH HHS [K01 AG037593] NR 43 TC 43 Z9 50 U1 3 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD APR PY 2011 VL 40 IS 2 BP 417 EP 428 DI 10.1093/ije/dyq238 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 745LB UT WOS:000289165800020 PM 21252210 ER PT J AU Rice, CA Shapiro, EL Shay, J AF Rice, Cecil A. Shapiro, Elizabeth L. Shay, Joseph TI Death of a Group Therapist and the Survival of the Group SO INTERNATIONAL JOURNAL OF GROUP PSYCHOTHERAPY LA English DT Article C1 [Rice, Cecil A.] Boston Inst Psychotherapies Inc, Brookline, MA 02446 USA. [Rice, Cecil A.] Annual No Ireland Grp Psychotherapy Conference, Dublin, Ireland. [Shapiro, Elizabeth L.] Massachusetts Gen Hosp, Ctr Psychoanalyt Studies, Boston, MA 02114 USA. [Shay, Joseph] Harvard Univ, Sch Med, Joint McLean Hosp Massachusetts Gen Hosp Training, Cambridge, MA 02138 USA. [Shay, Joseph] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. RP Rice, CA (reprint author), 23 Briarwood Circle, Needham, MA 02494 USA. EM cecil.rice@comcast.net NR 13 TC 0 Z9 0 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0020-7284 J9 INT J GROUP PSYCHOTH JI Int. J. Group Psychother. PD APR PY 2011 VL 61 IS 2 SI SI BP 177 EP 195 PG 19 WC Psychology, Clinical SC Psychology GA 740FE UT WOS:000288776200002 ER PT J AU Gans, JS AF Gans, Jerome S. TI Unwitting Self-Disclosures in Psychodynamic Psychotherapy: Deciphering Their Meaning and Accessing the Pain Within SO INTERNATIONAL JOURNAL OF GROUP PSYCHOTHERAPY LA English DT Article ID GROUP-THERAPY AB Unwitting self-disclosures (USDs), unconscious yet observable parts of personality, are often behavioral relics of past suffering and, as such, constitute valuable though frequently underutilized clinical information. While ego-syntonic aspects of personality can be commented on with impunity, dealing therapeutically with patients' USDs manifestations of their blind spots requires sensitivity, empathy, and timing. Providing many clinical examples of patient and therapist USDs from individual and group psychotherapy, this report discusses the origins, possible meanings, and the countertransference and empathic challenges encountered in the handling of these blind spots. The importance of establishing a narcissistic alliance and of employing the methods of the existential school of psychotherapy in processing USDs is described. Self-aware therapists can minimize the clinical impasse that may result when therapist-patient blind spots overlap. C1 [Gans, Jerome S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Gans, Jerome S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Gans, JS (reprint author), 55 Cleveland Rd, Wellesley, MA 02481 USA. EM jsgans@comcast.net NR 14 TC 0 Z9 0 U1 0 U2 0 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0020-7284 J9 INT J GROUP PSYCHOTH JI Int. J. Group Psychother. PD APR PY 2011 VL 61 IS 2 SI SI BP 219 EP 237 PG 19 WC Psychology, Clinical SC Psychology GA 740FE UT WOS:000288776200004 ER PT J AU Lennerz, JK Rosenberg, AE AF Lennerz, Jochen K. Rosenberg, Andrew E. TI Ring Around the Roses SO INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY LA English DT Editorial Material C1 [Lennerz, Jochen K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA. RP Lennerz, JK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. EM JLennerz@partners.org NR 8 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1066-8969 J9 INT J SURG PATHOL JI Int. J. Surg. Pathol. PD APR PY 2011 VL 19 IS 2 BP 194 EP 195 DI 10.1177/1066896910397884 PG 2 WC Pathology; Surgery SC Pathology; Surgery GA 746RL UT WOS:000289264300013 PM 21447534 ER PT J AU Kang, MH Oh, DJ Rhee, DJ AF Kang, Min Hyung Oh, Dong-Jin Rhee, Douglas J. TI Effect of Hevin Deletion in Mice and Characterization in Trabecular Meshwork SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article ID MOUSE INTRAOCULAR-PRESSURE; AQUEOUS-HUMOR; NONINVASIVE MEASUREMENT; MATRICELLULAR PROTEINS; SPARC; SC1; EXPRESSION; GLAUCOMA; CELLS; GENE AB PURPOSE. Hevin is a matricellular protein and the result of a gene duplication of SPARC. SPARC-null mice have lower intraocular pressure (IOP). The function of hevin in trabecular meshwork (TM) is unknown. The authors hypothesized that hevin is expressed in TM and has a functional consequence on IOP. METHODS. Reverse transcriptase-polymerase chain reaction (RTPCR) and immunoblotting were performed to identify transcription and protein expression in TM and cultured TM cells. Toluidine blue stain was performed to compare anterior segments in wild-type (WT) and hevin-null mice. Confocal microscopy localized the structural distribution of hevin in human TM and hevin/SPARC in mouse anterior segments. IOP was measured in WT (C57BL6 x 129SvJ) and hevin-null mice using both rebound tonometry and cannulation tonometry. Central corneal thickness (CCT) was measured by ocular coherence tomography. Cultured TM cells were treated with TGF-beta 2 because TGF-beta 2 is associated with primary open-angle glaucoma. RESULTS. Hevin mRNA and protein were expressed in TM tissues but not in cultured TM cells. No structural differences were observed in anterior segments of WT and hevin-null mice. IOP between hevin-null (n = 46) and WT (n = 44) mice was equivalent (15.3 +/- 1.92 mm Hg and 15.9 +/- 2.01 mm Hg, respectively; P = 0.15). CCT was similar between hevin-null and WT mice (107.95 +/- 5.06 mu m and 106.76 +/- 3.46 mu m, respectively; P = 0.11). TGF-beta 2 did not induce hevin, whereas SPARC expression was induced in a dose-dependent manner in human TM cell cultures. CONCLUSIONS. Hevin does not appear to be critical to regulating IOP. Hevin is expressed in TM but, in contrast to SPARC, does not appear to be regulated by TGF-beta 2. (Invest Ophthalmol Vis Sci. 2011;52:2187-2193) DOI:10.1167/iovs.10-5428 C1 [Kang, Min Hyung; Oh, Dong-Jin; Rhee, Douglas J.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Rhee, DJ (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM dougrhee@aol.com FU American Glaucoma Society; National Eye Institute [EY 019654-01, EY14104] FX Supported by an American Glaucoma Society Mid-Career Award and by National Eye Institute Grants EY 019654-01 (DJR) and EY14104 (MEEI Vision-Core Grant). NR 37 TC 12 Z9 12 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 2011 VL 52 IS 5 BP 2187 EP 2193 DI 10.1167/iovs.10-5428 PG 7 WC Ophthalmology SC Ophthalmology GA 746XK UT WOS:000289282600015 PM 21220554 ER PT J AU Shreffler, WG AF Shreffler, Wayne G. TI Microarrayed recombinant allergens for diagnostic testing SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Microarray-based immunoassay; microarray-based allergy testing; component-resolved diagnostics; molecular allergy diagnosis ID COMPONENT-RESOLVED DIAGNOSIS; BASOPHIL-HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; IN-VITRO; SEQUENTIAL EPITOPES; PROTEIN MICROARRAYS; POLLEN ALLERGENS; PEANUT EPITOPES; MILK ALLERGENS; LATEX ALLERGY AB The development of protein microarray-based immunoassays and the availability of recombinant allergens have, to a significant extent, emerged together over the past decade. Their long-anticipated wider application to allergy diagnosis has recently begun to accelerate. This review discusses some of the strengths and weaknesses of molecularly defined allergy testing and the microarray platform. Several recent applications of microarray assays to allergy testing are also summarized. Promising findings, particularly in the context of food and latex allergy, point to the potential for greater resolution between clinical reactivity and asymptomatic sensitization with this platform. (J Allergy Clin Immunol 2011;127:843-9.) C1 [Shreffler, Wayne G.] Harvard Univ, Food Allergy Ctr, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. [Shreffler, Wayne G.] Harvard Univ, Ctr Immunol & Inflammatory Dis, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Shreffler, WG (reprint author), Harvard Univ, Food Allergy Ctr, Sch Med, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM wshreffler@partners.org NR 63 TC 37 Z9 39 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD APR PY 2011 VL 127 IS 4 BP 843 EP 849 DI 10.1016/j.jaci.2011.02.011 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA 743YL UT WOS:000289055800001 PM 21458654 ER PT J AU Mick, E Byrne, D Fried, R Monuteaux, M Faraone, SV Biederman, J AF Mick, Eric Byrne, Deirdre Fried, Ronna Monuteaux, Michael Faraone, Stephen V. Biederman, Joseph TI Predictors of ADHD Persistence in Girls at 5-Year Follow-Up SO JOURNAL OF ATTENTION DISORDERS LA English DT Article DE ADHD; female; follow-up; adolescence ID DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; AGE-DEPENDENT DECLINE; IMPACT; ADOLESCENCE; REMISSION; CHILDREN AB Objective: The main aim of this study was to examine the age-dependent remission from ADHD in girls transitioning through childhood into adolescence and early adulthood. Method: We conducted a 5-year prospective follow-up study of 123 girls with ADHD and 106 non-ADHD control girls aged between 6 and 17 years at ascertainment. ADHD was considered persistent at follow-up if participants met full diagnostic criteria for DSM-IV ADHD or met residual criteria for DSM-IV ADHD with associated impairment (Global Age Forum [GAF] score < 60). Results: By age 16 years, ADHD was persistent in 71% (95% CI = 61-79%) of girls with ADHD. Participants with persistent ADHD at follow-up had more psychiatric comorbidity, behavior problems, and functional impairment than girls with ADHD in remission. Remitted ADHD, however, continued to be associated with functional impairment relative to non-ADHD controls. Persistence at 5 years was predicted by increased behavioral impairment at baseline. Conclusion: This 5-year follow-up suggests that many girls with ADHD experience persistent symptoms and/or functional impairment through late adolescence and into early adulthood. (J. of Att. Dis. 2011; 15(3) 183-192) C1 [Mick, Eric] Massachusetts Gen Hosp, Pediat Psychopharmacol Res Unit, Boston, MA 02114 USA. [Mick, Eric; Byrne, Deirdre; Fried, Ronna; Monuteaux, Michael; Biederman, Joseph] Harvard Univ, Sch Med, Boston, MA USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Syracuse, NY USA. RP Mick, E (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol Res Unit, Warren 705,55 Fruit St, Boston, MA 02114 USA. EM emick1@partners.org OI Mick, Eric/0000-0001-8505-8145; Faraone, Stephen/0000-0002-9217-3982 FU National Institute of Mental Health [R01MH050657]; McNeil Pediatrics; Ortho-McNeil Janssen Scientific Affairs; Pfizer; Shire Pharmaceuticals; Eli Lilly; National Institutes of Health; Shire, Inc.; Alza; AstraZeneca; Bristol Myers Squibb; Eli Lilly and Co.; Janssen Pharmaceuticals Inc.; McNeil; Merck; Organon; Otsuka; Shire; NICHD; Abbott; Celltech; Cephalon; Esai; Forest; Glaxo; Gliatech; NARSAD; NIDA; New River; Novartis; Noven; Neurosearch; Pharmacia; Prechter Foundation; Stanley Foundation; Wyeth FX The authors disclosed receipt of the following financial support for the research and/or authorship of this article: This work was support by grants from the National Institute of Mental Health to Dr Biederman (R01MH050657).; Dr. Eric Mick receives research support from the following sources and is on an advisory board for the following sources: McNeil Pediatrics, Ortho-McNeil Janssen Scientific Affairs, Pfizer, Shire Pharmaceuticals, and the National Institute of Mental Health (NIMH) and has had an advisory or consulting relationship with Pfizer and Shire Pharmaceutical. Dr. Faraone receives research support from and consults to Shire Pharmaceutical Development. He receives grant support from Eli Lilly and the National Institutes of Health. Dr. Ronna Fried has no financial relationships to disclose. Dr. Michael Monuteaux was a speaker in a symposia sponsored by Shire, Inc. Dr. Joseph Biederman is currently receiving research support from the following sources: Alza, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Co., Janssen Pharmaceuticals Inc., McNeil, Merck, Organon, Otsuka, Shire, NIMH, and NICHD. Dr. Biederman is currently a consultant/advisory board member for the following pharmaceutical companies: Janssen, McNeil, Novartis, and Shire. He is currently a speaker for the following speaker's bureaus: Janssen, McNeil, Novartis, Shire, and UCB Pharma, Inc. In previous years, Dr. Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Co., Esai, Forest, Glaxo, Gliatech, NARSAD, NIDA, New River, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, The Stanley Foundation, and Wyeth. NR 31 TC 22 Z9 24 U1 0 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0547 J9 J ATTEN DISORD JI J. Atten. Disord. PD APR PY 2011 VL 15 IS 3 BP 183 EP 192 DI 10.1177/1087054710362217 PG 10 WC Psychology, Developmental; Psychiatry SC Psychology; Psychiatry GA 740LV UT WOS:000288797000001 PM 20332414 ER PT J AU Matlock, DD Kutner, JS Emsermann, CB Al-Khatib, SM Sanders, GD Dickinson, LM Rumsfeld, JS Davidson, AJ Crane, LA Masoudi, FA AF Matlock, Dan D. Kutner, Jean S. Emsermann, Caroline B. Al-Khatib, Sana M. Sanders, Gillian D. Dickinson, L. Miriam Rumsfeld, John S. Davidson, Arthur J. Crane, Lori A. Masoudi, Frederick A. TI Regional Variations in Physicians' Attitudes and Recommendations Surrounding Implantable Cardioverter-Defibrillators SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; frailty; survey ID LIFE TREATMENT INTENSITY; PRIMARY-CARE PHYSICIANS; HEART-FAILURE; HEALTH-CARE; RESOURCE USE; MEDICARE; QUALITY; VALIDATION; PREFERENCES; PERCEPTIONS AB Introduction: This study was designed to determine if physicians' attitudes and recommendations surrounding implantable cardioverter-defibrillators (ICDs) are regionally associated with ICD use. Methods and Results: A national sample of 9969 members of the American College of Cardiology was surveyed electronically. Responses were merged with rates of ICD implantation from the National Cardiovascular Data Registry. Multivariable regression was used to assess trends between regional use and responses. We received 1210 responses (12%) and used 1124 after exclusions. Across regions, physicians were equally likely to recommend ICDs to males or females with ischemic (similar to 99% for both; P = NS) or nonischemic cardiomyopathy (85 vs. 88% P = 0.85). Significant increasing trends in the probability recommending ICD therapy were found when the patient was "frail" (21% to 32%; P = .03) or had a life expectancy < 1 year (5% to 10%; P = .05). These differences were not associated with attitudes toward ICDs. Conclusions: Independent of variations in physicians' attitudes towards ICDs, physicians in regions of low ICD use are not less likely to recommend ICDs in situations clearly supported by guidelines while those in regions of high ICD use are more likely to recommend ICDs to patients who might have limited benefit. (J Cardiac Fail 2011;17:318-324) C1 [Matlock, Dan D.] Univ Colorado, Denver Sch Med, Div Gen Internal Med, Aurora, CO 80045 USA. [Matlock, Dan D.; Rumsfeld, John S.; Masoudi, Frederick A.] Kaiser Permanente, Colorado Inst Hlth Res, Denver, CO USA. [Matlock, Dan D.; Rumsfeld, John S.; Masoudi, Frederick A.] Colorado Cardiovasc Outcomes Res Inst, Denver, CO USA. [Al-Khatib, Sana M.; Sanders, Gillian D.] Duke Cardiovasc Ctr Educ & Res Therapeut, Duke Clin Res Inst, Durham, NC USA. [Al-Khatib, Sana M.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA. [Rumsfeld, John S.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Davidson, Arthur J.; Crane, Lori A.] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. [Masoudi, Frederick A.] Denver Hlth Med Ctr, Denver, CO USA. RP Matlock, DD (reprint author), Univ Colorado, Denver Sch Med, Div Gen Internal Med, Acad Off 1,12631 E 17th Ave, Aurora, CO 80045 USA. EM daniel.matlock@ucdenver.edu FU Medtronic; Biotronik; American College of Cardiology; Oklahoma Foundation for Medical Quality; Agency for Healthcare Research and Quality [U18 HS016964]; The Division of General Internal Medicine at The University of Colorado; [T32HP10006] FX S.M.A.-K. has received research funding and speaking fees from Medtronic and Biotronik. G.D.S. has received research support from Medtronic. F.A.M. has contracts with the American College of Cardiology and the Oklahoma Foundation for Medical Quality; and serves on an advisory board for Amgen. This research was conducted while D.D.M. was supported by an institutional T32HP10006 as well as while he was a Hartford Geriatrics Health Outcomes Scholar. This project was supported in part by cooperative agreement number U18 HS016964 from the Agency for Healthcare Research and Quality. Additional funds were provided by The Division of General Internal Medicine at The University of Colorado. NR 30 TC 5 Z9 5 U1 0 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2011 VL 17 IS 4 BP 318 EP 324 DI 10.1016/j.cardfail.2010.11.009 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 747KK UT WOS:000289318500008 PM 21440870 ER PT J AU Riegel, B Moelter, ST Ratcliffe, SJ Pressler, SJ De Geest, S Potashnik, S Fleck, D Sha, DH Sayers, SL Weintraub, WS Weaver, TE Goldberg, LR AF Riegel, Barbara Moelter, Stephen T. Ratcliffe, Sarah J. Pressler, Susan J. De Geest, Sabina Potashnik, Sheryl Fleck, Desiree Sha, Daohang Sayers, Steven L. Weintraub, William S. Weaver, Terri E. Goldberg, Lee R. TI Excessive Daytime Sleepiness is Associated With Poor Medication Adherence in Adults With Heart Failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Heart failure; sleep; excessive daytime sleepiness; cognition; vigilance; patient compliance; self-care ID GLOBAL PERCEIVED HEALTH; PRIMARY-CARE PATIENTS; OF-THE-LITERATURE; SELF-CARE; IMPACT; APNEA; NONCOMPLIANCE; DEPRIVATION; WAKEFULNESS; PREVALENCE AB Background: A relationship between excessive daytime sleepiness (EDS) and poor treatment adherence has been suspected but not confirmed. We hypothesized that medication adherence would be poorer in adults with heart failure (HF) and EDS and that cognitive status would be the mechanism of effect. Methods and Results: A sample of 280 adults with chronic HF were enrolled into a prospective cohort comparison study. We identified a cohort with EDS and a control group without EDS and further divided both groups into those with and without mild cognitive decline. Data on medication adherence were obtained at baseline and 3 and 6 months by using the Basel Assessment of Adherence Scale. Regression analysis was used to clarify the contribution of EDS and cognition to medication adherence and to assess relationships over 6 months after adjusting for age, enrollment site, gender, race, functional class, depression, and premorbid intellect. At baseline, 62% of subjects were nonadherent to their medication regime. Nonadherence was significantly more common in those with EDS, regardless of cognitive status (P = .035). The odds of nonadherence increased by 11% for each unit increase in EDS (adjusted odds ratio 1.11; 95% confidence interval 1.05-1.19; P = .001). In longitudinal models, there was a 10% increase in the odds of nonadherence for each unit increase in EDS (P = .008). The only cognition measure significantly associated with medication adherence was attention (P = .047). Conclusions: Adults with HF and EDS are more likely to have problems adhering to their medication regimen than those without EDS, regardless of their cognitive status. Identifying and correcting factors that interfere with sleep may improve medication adherence. (J Cardiac Fail 2011;17:340-348) C1 [Riegel, Barbara; Potashnik, Sheryl] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Ratcliffe, Sarah J.; Sha, Daohang; Sayers, Steven L.; Goldberg, Lee R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Moelter, Stephen T.] Univ Sci, Philadelphia, PA USA. [Fleck, Desiree] Hosp Univ Penn, Philadelphia, PA 19104 USA. [Sayers, Steven L.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Pressler, Susan J.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [De Geest, Sabina] Univ Basel, Inst Nursing Sci, Basel, Switzerland. [De Geest, Sabina] Katholieke Univ Leuven, Ctr Hlth Serv & Nursing Res, Louvain, Belgium. [Weintraub, William S.] Christiana Care Hlth Syst, Christiana Care Ctr Outcomes Res, Newark, DE USA. [Weaver, Terri E.] Univ Illinois, Coll Nursing, Chicago, IL USA. RP Riegel, B (reprint author), Univ Penn, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA. EM briegel@nursing.upenn.edu OI Goldberg, Lee/0000-0002-7906-9638; Ratcliffe, Sarah/0000-0002-6644-8284 FU National Heart, Lung, and Blood Institute [RO1 HL084394-01A1]; VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center FX Supported by the National Heart, Lung, and Blood Institute (RO1 HL084394-01A1) and the VISN 4 Mental Illness Research, Education, and Clinical Center, Philadelphia Veterans Affairs Medical Center. NR 66 TC 41 Z9 41 U1 3 U2 5 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD APR PY 2011 VL 17 IS 4 BP 340 EP 348 DI 10.1016/j.cardfail.2010.11.002 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 747KK UT WOS:000289318500011 PM 21440873 ER PT J AU Yaseen, MA Srinivasan, VJ Sakadzic, S Radhakrishnan, H Gorczynska, I Wu, WC Fujimoto, JG Boas, DA AF Yaseen, Mohammad A. Srinivasan, Vivek J. Sakadzic, Sava Radhakrishnan, Harsha Gorczynska, Iwona Wu, Weicheng Fujimoto, James G. Boas, David A. TI Microvascular oxygen tension and flow measurements in rodent cerebral cortex during baseline conditions and functional activation SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE cerebral blood flow; fMRI; microscopy; optical imaging; oxygen ID OPTICAL COHERENCE TOMOGRAPHY; NEAR-INFRARED SPECTROSCOPY; BLOOD-FLOW; BOLD FMRI; SENSORY STIMULATION; PARTIAL-PRESSURE; HUMAN BRAIN; PHOSPHORESCENCE; TISSUE; METABOLISM AB Measuring cerebral oxygen delivery and metabolism microscopically is important for interpreting macroscopic functional magnetic resonance imaging (fMRI) data and identifying pathological changes associated with stroke, Alzheimer's disease, and brain injury. Here, we present simultaneous, microscopic measurements of cerebral blood flow (CBF) and oxygen partial pressure (pO(2)) in cortical microvessels of anesthetized rats under baseline conditions and during somatosensory stimulation. Using a custom-built imaging system, we measured CBF with Fourier-domain optical coherence tomography (OCT), and vascular pO(2) with confocal phosphorescence lifetime microscopy. Cerebral blood flow and pO(2) measurements displayed heterogeneity over distances irresolvable with fMRI and positron emission tomography. Baseline measurements indicate O(2) extraction from pial arterioles and homogeneity of ascending venule pO(2) despite large variation in microvessel flows. Oxygen extraction is linearly related to flow in ascending venules, suggesting that flow in ascending venules closely matches oxygen demand of the drained territory. Oxygen partial pressure and relative CBF transients during somatosensory stimulation further indicate arteriolar O(2) extraction and suggest that arterioles contribute to the fMRI blood oxygen level dependent response. Understanding O(2) supply on a microscopic level will yield better insight into brain function and the underlying mechanisms of various neuropathologies. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1051-1063; doi: 10.1038/jcbfm.2010.227; published online 22 December 2010 C1 [Yaseen, Mohammad A.; Srinivasan, Vivek J.; Sakadzic, Sava; Radhakrishnan, Harsha; Wu, Weicheng; Boas, David A.] Harvard Univ, Sch Med, MGH MIT HMS Athinuola A Martinos Ctr Biomed Imagi, Massachusetts Gen Hosp,Dept Radiol, Charlestown, MA 02129 USA. [Gorczynska, Iwona; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA. [Gorczynska, Iwona; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA. RP Boas, DA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging,Dept Radiol, Charlestown, MA 02129 USA. EM dboas@nmr.mgh.harvard.edu RI Radhakrishnan, Harsha/K-5557-2012; Gorczynska, Iwona/P-9367-2015 OI Gorczynska, Iwona/0000-0002-6120-8791 FU NIH [R01-NS057476, P50-NS010828, K99NS067050, P01-NS055104]; Air Force Office of Scientific Research [FA9550-07-1-0101] FX This study was supported by NIH R01-NS057476, P50-NS010828, K99NS067050, P01-NS055104, and Air Force Office of Scientific Research FA9550-07-1-0101. NR 45 TC 29 Z9 29 U1 2 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD APR PY 2011 VL 31 IS 4 BP 1051 EP 1063 DI 10.1038/jcbfm.2010.227 PG 13 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 744AQ UT WOS:000289064500009 PM 21179069 ER PT J AU Roth, MY Page, ST Lin, K Anawalt, BD Matsumoto, AM Marck, B Bremner, WJ Amory, JK AF Roth, M. Y. Page, S. T. Lin, K. Anawalt, B. D. Matsumoto, A. M. Marck, B. Bremner, W. J. Amory, J. K. TI The Effect of Gonadotropin Withdrawal and Stimulation with Human Chorionic Gonadotropin on Intratesticular Androstenedione and DHEA in Normal Men SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID HUMAN TESTICULAR STEROIDOGENESIS; HORMONE ANTAGONIST; MASS-SPECTROMETRY; STEROID-LEVELS; HUMAN TESTIS; RAT TESTIS; YOUNG MEN; TESTOSTERONE; SPERMATOGENESIS; SECRETION AB Introduction: Concentrations of intratesticular (IT) testosterone (T) are known to be 100-200 times those of serum T; however, the IT concentrations of T's precursors, their testicular to serum gradients, gonadotropin dependence, and response to stimulation with human chorionic gonadotropin (hCG) have not been studied in detail. We hypothesized that serum and IT androstenedione (ADD) and IT dehydroepiandrosterone (DHEA) would be significantly suppressed by the administration of a GnRH antagonist and increased when stimulated by hCG, without a similar suppression of serum DHEA. Methods: We suppressed gonadotropins in 23 normal men with the GnRH antagonist acyline and randomly assigned them to one of four doses of hCG, 0, 15, 60, or 125 IU sc every other day for 10 d. Blood and IT fluid for the measurement of serum and IT hormones were obtained at baseline and after 10 d of treatment. Results: Baseline ITADD[median (25th, 75th percentile)] was 629 (308, 860) nmol/liter, and ITDHEA was 564 (411, 879) nmol/liter, which were 175 and 27 times higher than their respective serum concentrations. IT ADD and IT DHEA were suppressed by 98 and 82%, respectively, by acyline and significantly increased with hCG administration. Likewise, serum ADD was suppressed by 50%, but serum DHEA was unchanged. Discussion: ADD and DHEA are highly concentrated within the human testes compared with serum. Serum and IT ADD and IT DHEA are markedly suppressed with GnRH administration and stimulated by hCG, but serum DHEA is not, suggesting that most circulating DHEA is not of testicular origin. (J Clin Endocrinol Metab 96: 1175-1181, 2011) C1 [Roth, M. Y.; Page, S. T.; Anawalt, B. D.; Matsumoto, A. M.; Bremner, W. J.; Amory, J. K.] Univ Washington, Dept Internal Med, Seattle, WA USA. [Lin, K.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA USA. [Roth, M. Y.; Page, S. T.; Anawalt, B. D.; Matsumoto, A. M.; Bremner, W. J.; Amory, J. K.] Univ Washington, Ctr Res Reprod & Contracept, Seattle, WA USA. [Marck, B.] Vet Affairs Puget Sound Hlth Care Syst, Educ & Clin Ctr, Seattle, WA 98105 USA. RP Roth, MY (reprint author), Univ Washington, Dept Internal Med, 1959 NE Pacific St,Box 357138, Seattle, WA USA. EM mylang@u.washington.edu FU National Institute of Child Health and Human Development [U54 HD-12629, U54 HD-42454]; Cooperative Contraceptive Research Center; Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12 HD053984]; National Institute of Aging, a Division of the National Institutes of Health [K23 AG027238]; Department of Veterans Affairs FX The National Institute of Child Health and Human Development supported this work through cooperative agreements U54 HD-12629 and U54 HD-42454 as part of the specialized Cooperative Centers Program in Reproductive Research and the Cooperative Contraceptive Research Centers Program. M.Y.R. is supported, in part, by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Grant K12 HD053984. S. T. P. is supported by the National Institute of Aging, a Division of the National Institutes of Health, Grant K23 AG027238. A. M. M. is supported by the Department of Veterans Affairs. NR 27 TC 4 Z9 4 U1 0 U2 1 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD APR PY 2011 VL 96 IS 4 BP 1175 EP 1181 DI 10.1210/jc.2010-2518 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 746JO UT WOS:000289242800064 PM 21289266 ER PT J AU Ravikoff, JE Korzenik, JR AF Ravikoff, Jessica E. Korzenik, Joshua R. TI The Role of Fiber in Diverticular Disease SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE fiber; diverticulosis; diverticulitis; colonic microflora ID DIETARY FIBER; LARGE-BOWEL; NATURAL-HISTORY; COLON; JAPAN; TRENDS; RISK; POLYPS; BRAN; RATS AB Diverticular disease is viewed, by most physicians, as a consequence of a diet which consumes inadequate amounts of fiber. Dietary fiber helps form large bulky stool, resulting in a larger radius colon that is less likely to permit segmentation and therefore less likely to develop diverticula. Although as many as two-thirds of individuals in the west have diverticular disease by the age of 85 years, perhaps only 10% to 25% will manifest any related clinical symptoms. What distinguishes individuals who progress to symptomatic disease is still uncertain. Recent studies suggest that the natural history of diverticular disease bears many similarities to that of chronic inflammatory bowel disease. Some of the cellular mechanisms that underlie the development of chronic inflammation and inflammatory complications may be common to both diverticulitis and inflammatory bowel disease. The impact of decreased fiber has been explored largely as having physiological effects in decreasing transit time and increasing intracolonic pressure. Fiber has benefits both as a preventative measure not only by bulking stool but also due to its effects on colonic microflora and also as a treatment for symptomatic diverticular disease. The decrease in soluble fiber in our diets may have altered our gut flora, which may have significant immune consequences central to the pathophysiology of diverticulitis. This study aims to review the potential contribution of different types of fiber to the development of diverticular disease, the relationship between fiber and diverticular disease as both a preventative measure and a treatment as well as its potential influence on colonic flora with speculation on possible neglected areas of importance still left unanswered. C1 [Ravikoff, Jessica E.; Korzenik, Joshua R.] Massachusetts Gen Hosp, Dept Internal Med, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. RP Korzenik, JR (reprint author), Massachusetts Gen Hosp, Dept Internal Med, MGH Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM jkorzenik@partners.org NR 45 TC 2 Z9 2 U1 1 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD APR PY 2011 VL 45 IS 4 SU S BP S7 EP S11 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 742CY UT WOS:000288918200003 ER PT J AU Ravikoff, JE Korzenik, JR AF Ravikoff, Jessica E. Korzenik, Joshua R. TI Case Presentation The Role of Diet-Fiber SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE fiber; diverticulosis; diverticulitis; colonic microflora ID DIVERTICULAR-DISEASE; BRAN AB Diverticular disease is viewed, by most physicians, as a consequence of a diet which consumes inadequate amounts of fiber. Dietary fiber helps form large bulky stool, resulting in a larger radius colon that is less likely to permit segmentation and therefore less likely to develop diverticula. While as many as two-thirds of individuals in the West have diverticular disease by the age of 85, perhaps only 10-25% will manifest any related clinical symptoms. What distinguishes individuals who progress to symptomatic disease is still uncertain. Recent studies suggest that the natural history of diverticular disease bears many similarities to that of chronic inflammatory bowel disease. Some of the cellular mechanisms that underlie the development of chronic inflammation and inflammatory complications may be common to both diverticulitis and inflammatory bowel disease. The impact of decreased fiber has been explored largely as having physiologic effects in decreasing transit time and increasing intra-colonic pressure. Fiber has benefits both as a preventative measure not only by bulking stool but also due to its effects on colonic microflora and also as a treatment for symptomatic diverticular disease. The decrease in soluble fiber in our diets may have altered our gut flora, which may have significant immune consequences central to the pathophysiology of diverticulitis. This study aims to review the potential contribution of different types of fiber to the development of diverticular disease, the relationship between fiber and diverticular disease as both a preventative measure and a treatment as well as its potential influence on colonic flora with speculation on possible neglected areas of importance still left unanswered. C1 [Ravikoff, Jessica E.; Korzenik, Joshua R.] Massachusetts Gen Hosp, Dept Internal Med, MGH Crohns & Colitis Ctr, Boston, MA 02114 USA. RP Korzenik, JR (reprint author), Massachusetts Gen Hosp, Dept Internal Med, MGH Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM jkorzenik@partners.org NR 10 TC 1 Z9 1 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD APR PY 2011 VL 45 IS 4 SU S BP S44 EP S45 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 742CY UT WOS:000288918200010 ER PT J AU Lv, HJ Havari, E Pinto, S Gottumukkala, RVSRK Cornivelli, L Raddassi, K Matsui, T Rosenzweig, A Bronson, RT Smith, R Fletcher, AL Turley, SJ Wucherpfennig, K Kyewski, B Lipes, MA AF Lv, HuiJuan Havari, Evis Pinto, Sheena Gottumukkala, Raju V. S. R. K. Cornivelli, Lizbeth Raddassi, Khadir Matsui, Takashi Rosenzweig, Anthony Bronson, Roderick T. Smith, Ross Fletcher, Anne L. Turley, Shannon J. Wucherpfennig, Kai Kyewski, Bruno Lipes, Myra A. TI Impaired thymic tolerance to alpha-myosin directs autoimmunity to the heart in mice and humans SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID HEAVY-CHAIN GENE; T-CELL TOLERANCE; ANTIGEN-PRESENTING CELLS; CLASS-II MOLECULES; DENDRITIC CELLS; EPITHELIAL-CELLS; PEDIATRIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; CLONAL DELETION; AIRE CONTROL AB Autoimmunity has long been linked to myocarditis and its sequela, dilated cardiomyopathy, the leading causes of heart failure in young patients. However, the underlying mechanisms are poorly defined, with most clinical investigations focused on humoral autoimmunity as the target for intervention. Here, we show that the alpha-isoform of myosin heavy chain (alpha-MyHC, which is encoded by the gene Myh6) is the pathogenic autoantigen for CD4(+) T cells in a spontaneous mouse model of myocarditis. Further, we found that Myh6 transcripts were absent in mouse medullary thymic epithelial cells (mTECs) and peripheral lymphoid stromal cells, which have been implicated in mediating central and peripheral T cell tolerance, respectively. Transgenic expression of alpha-MyHC in thymic epithelium conferred tolerance to cardiac myosin and prevented myocarditis, demonstrating that alpha-MyHC is a primary autoantigen in this disease process. Remarkably, we found that humans also lacked alpha-MyHC in mTECs and had high frequencies of alpha-MyHC-specific T cells in peripheral blood, with markedly augmented T cell responses to alpha-MyHC in patients with myocarditis. Since alpha-MyHC constitutes a small fraction of MyHC in human heart, these findings challenge the longstanding notion that autoimmune targeting of MyHC is due to its cardiac abundance and instead suggest that it is targeted as a result of impaired T cell tolerance mechanisms. These results thus support a role for T cell-specific therapies for myocarditis. C1 [Lv, HuiJuan; Havari, Evis; Gottumukkala, Raju V. S. R. K.; Cornivelli, Lizbeth; Smith, Ross; Lipes, Myra A.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Lv, HuiJuan; Gottumukkala, Raju V. S. R. K.; Lipes, Myra A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Lv, HuiJuan; Gottumukkala, Raju V. S. R. K.; Raddassi, Khadir; Matsui, Takashi; Rosenzweig, Anthony; Bronson, Roderick T.; Fletcher, Anne L.; Turley, Shannon J.; Wucherpfennig, Kai; Lipes, Myra A.] Harvard Univ, Sch Med, Boston, MA USA. [Pinto, Sheena; Kyewski, Bruno] German Canc Res Ctr, D-6900 Heidelberg, Germany. [Raddassi, Khadir] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA. [Matsui, Takashi; Rosenzweig, Anthony] Beth Israel Deaconess Med Ctr, Cardiovasc Inst, Boston, MA 02215 USA. [Fletcher, Anne L.; Turley, Shannon J.; Wucherpfennig, Kai] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Lipes, MA (reprint author), Joslin Diabet Ctr, 1 Joslin Pl,Rm 373, Boston, MA 02215 USA. EM myra.lipes@joslin.harvard.edu FU NIH [R01 DK072090, HL077554, DK074500, P01 AI045757]; JDRF [33-2008-394]; Joslin Diabetes Center Diabetes and Endocrinology Research Center (DERC); German Cancer Research Center; European Union [503410, 14363]; Deutsche Forschungsgemeinschaft [SFB 405] FX We thank Jeffrey Robbins, Mohamed Sayegh, and Diane Mathis for valuable reagents; Mark Anderson, James Gardner, Bechara Mfarrej, Mireia Guerau-de-Arellano, Emily Venanzi, and Aldo Rossini for helpful discussions; John Stockton for microinjections; Heather Thomas for expert technical support; Howard Wolpert and Susan Anello for patient recruitment; Panagiota Stamou for her initial contributions to this project; and the National Disease Research Interchange for human heart and soleus muscle samples. This work was supported by NIH grants R01 DK072090, HL077554 (to M.A. Lipes), DK074500, and P01 AI045757 (to S.J. Turley), JDRF grant 33-2008-394 (to M.A. Lipes), and the Joslin Diabetes Center Diabetes and Endocrinology Research Center (DERC). B. Kyewski and S. Pinto have been supported by the German Cancer Research Center, the European Union-funded Consortia Thymaide (grant 503410) and Immunotherapy (grant 14363), and the Deutsche Forschungsgemeinschaft (SFB 405). NR 68 TC 45 Z9 45 U1 1 U2 4 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2011 VL 121 IS 4 BP 1561 EP + DI 10.1172/JCI44583 PG 13 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 745OK UT WOS:000289174600038 PM 21436590 ER PT J AU Tanner, ACR Mathney, JMJ Kent, RL Chalmers, NI Hughes, CV Loo, CY Pradhan, N Kanasi, E Hwang, J Dahlan, MA Papadopolou, E Dewhirst, FE AF Tanner, A. C. R. Mathney, J. M. J. Kent, R. L., Jr. Chalmers, N. I. Hughes, C. V. Loo, C. Y. Pradhan, N. Kanasi, E. Hwang, J. Dahlan, M. A. Papadopolou, E. Dewhirst, F. E. TI Cultivable Anaerobic Microbiota of Severe Early Childhood Caries SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CARIOUS HUMAN ROOT; HUMAN DENTAL DECAY; STREPTOCOCCUS-MUTANS; PRESCHOOL-CHILDREN; MOLECULAR ANALYSIS; PERMANENT TEETH; NURSING CARIES; ORAL BACTERIA; SP-NOV; RISK AB Severe early childhood caries (ECC), while strongly associated with Streptococcus mutans using selective detection (culture, PCR), has also been associated with a widely diverse microbiota using molecular cloning approaches. The aim of this study was to evaluate the microbiota of severe ECC using anaerobic culture. The microbial composition of dental plaque from 42 severe ECC children was compared with that of 40 caries-free children. Bacterial samples were cultured anaerobically on blood and acid (pH 5) agars. Isolates were purified, and partial sequences for the 16S rRNA gene were obtained from 5,608 isolates. Sequence-based analysis of the 16S rRNA isolate libraries from blood and acid agars of severe ECC and caries-free children had >90% population coverage, with greater diversity occurring in the blood isolate library. Isolate sequences were compared with taxon sequences in the Human Oral Microbiome Database (HOMD), and 198 HOMD taxa were identified, including 45 previously uncultivated taxa, 29 extended HOMD taxa, and 45 potential novel groups. The major species associated with severe ECC included Streptococcus mutans, Scardovia wiggsiae, Veillonella parvula, Streptococcus cristatus, and Actinomyces gerensceriae. S. wiggsiae was significantly associated with severe ECC children in the presence and absence of S. mutans detection. We conclude that anaerobic culture detected as wide a diversity of species in ECC as that observed using cloning approaches. Culture coupled with 16S rRNA identification identified over 74 isolates for human oral taxa without previously cultivated representatives. The major caries-associated species were S. mutans and S. wiggsiae, the latter of which is a candidate as a newly recognized caries pathogen. C1 [Tanner, A. C. R.; Mathney, J. M. J.; Chalmers, N. I.; Kanasi, E.; Papadopolou, E.; Dewhirst, F. E.] Forsyth Inst, Dept Mol Genet, Cambridge, MA 02142 USA. [Kent, R. L., Jr.; Dewhirst, F. E.] Forsyth Inst, Dept Biostat, Cambridge, MA 02142 USA. [Tanner, A. C. R.; Kent, R. L., Jr.; Chalmers, N. I.; Kanasi, E.; Dewhirst, F. E.] Harvard Univ, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. [Hwang, J.] Harvard Univ, Harvard Sch Dent Med, Boston, MA 02115 USA. [Hughes, C. V.; Dahlan, M. A.; Papadopolou, E.] Boston Univ, Goldman Sch Dent Med, Dept Pediat Dent, Boston, MA 02118 USA. [Loo, C. Y.; Pradhan, N.] Tufts Univ, Tufts Sch Dent Med, Dept Pediat Dent, Boston, MA 02111 USA. RP Tanner, ACR (reprint author), Forsyth Inst, Dept Mol Genet, 245 First St, Cambridge, MA 02142 USA. EM annetanner@forsyth.org RI Hughes, Christopher/E-1438-2014 FU National Institute of Dental and Craniofacial Research [DE-014264, DE-015847, DE-016937, DE-007151, DE-007327]; Harvard School of Dental Medicine; Kingdom of Saudi Arabia FX This work was supported by Public Health Service grants DE-014264 (to A. C. R. T.), DE-015847 (to A. C. R. T.), DE-016937 (to F. E. D.), DE-007151 (to E. K.), DE-007327 (to N.I.C. and E. K.) from National Institute of Dental and Craniofacial Research, an intern grant from the Harvard School of Dental Medicine (to J.H.), and a postdoctoral fellowship from the Kingdom of Saudi Arabia (to M.A.D.). NR 55 TC 73 Z9 76 U1 2 U2 22 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD APR PY 2011 VL 49 IS 4 BP 1464 EP 1474 DI 10.1128/JCM.02427-10 PG 11 WC Microbiology SC Microbiology GA 744FP UT WOS:000289080600042 PM 21289150 ER PT J AU Wang, SG Eskandar, EN Kilbride, R Chiappa, KH Curry, WT Williams, Z Simon, MV AF Wang, Sonya G. Eskandar, Emad N. Kilbride, Ronan Chiappa, Keith H. Curry, William T. Williams, Ziv Simon, Mirela V. TI The Variability of Stimulus Thresholds in Electrophysiologic Cortical Language Mapping SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY LA English DT Article DE Stimulus thresholds; Language cortical mapping; Cortical excitability; Lesion location ID BRAIN-TUMORS; MOTOR CORTEX; INTRAOPERATIVE STIMULATION; SURGICAL-MANAGEMENT; BLOOD-VOLUME; GLIOMAS; SURGERY; SUPPRESSION; POTENTIALS; ANESTHESIA AB The aim of this study was to investigate the variability of electrical stimulation threshold in cortical language mapping in relationship to the lobar location of the mapped eloquent cortex and the distance between the latter and the location of the cortical lesion. A multivariate linear regression analysis was performed in a sample of 39 patients who underwent standardized successful language cortical mapping. Estimated stimulus threshold for temporal language cortex was 1.45 times higher than the estimated threshold for frontal language cortex, after adjusting for the other variables (P = 0.017). Stimulation of the mapped cortex in close proximity to the lesion or to the lesional edema increased the estimated threshold 2.6 or 1.8 times, respectively, compared with stimulation in other areas, after adjusting for the other variables (P < 0.0001, P = 0.0017). In concordance with prior findings, our results show that stimulus threshold in cortical language mapping is dependent on the lobar location of the mapped cortex. In addition, stimulus threshold is increased when the mapped cortex is in close proximity to the location of the lesion or perilesional edema. C1 [Wang, Sonya G.; Kilbride, Ronan; Chiappa, Keith H.; Simon, Mirela V.] Massachusetts Gen Hosp, Clin Neurophysiol Div, Dept Neurol, Boston, MA 02114 USA. [Eskandar, Emad N.; Curry, William T.; Williams, Ziv] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Eskandar, Emad N.; Curry, William T.; Williams, Ziv] Harvard Univ, Sch Med, Boston, MA USA. RP Simon, MV (reprint author), Massachusetts Gen Hosp, Clin Neurophysiol Div, Dept Neurol, WACC 739-G,55 Fruit St, Boston, MA 02114 USA. EM mvsimon@partners.org NR 35 TC 1 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0736-0258 J9 J CLIN NEUROPHYSIOL JI J. Clin. Neurophysiol. PD APR PY 2011 VL 28 IS 2 BP 210 EP 216 DI 10.1097/WNP.0b013e3182121827 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 744BP UT WOS:000289068000014 PM 21399523 ER PT J AU Coumans, JV Walcott, BP Redjal, N Kahle, KT Nahed, BV AF Coumans, Jean-Valery Walcott, Brian P. Redjal, Navid Kahle, Kristopher T. Nahed, Brian V. TI En bloc excision of a dermal sinus tract SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Dermal sinus; En bloc excision; Spina bifida occulta; Spinal dysraphism ID ABSCESS; SPINE; MENINGITIS AB Dermal sinus tracts are a form of spinal dysraphism that arises from a failure of dysjunction early in embryogenesis. They are diagnosed in pediatric patients and who present with a dimple, infection, or neurologic deficit. The tract is surgically excised en bloc to avoid contamination from the tract, which harbors bacteria. However, dermal sinus tracts typically terminate intradurally, rendering their en bloc excision difficult. To avoid entering the tract, allowing for an en bloc excision, we modified the usual technique employed for accessing the spinal intradural space. An en bloc excision of the dermal sinus tract was successfully performed. The patient recovered from the procedure neurologically intact and her postoperative course was uncomplicated. We conclude that en bloc excision of a dermal sinus tract down to the intradural space is feasible with modifications to standard operative technique. (c) 2010 Elsevier Ltd. All rights reserved. C1 [Coumans, Jean-Valery] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Coumans, JV (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, WACC 745,15 Parkman St, Boston, MA 02114 USA. EM jcoumans@partners.org NR 21 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD APR PY 2011 VL 18 IS 4 BP 554 EP 558 DI 10.1016/j.jocn.2010.11.008 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 747MY UT WOS:000289325300025 PM 21316971 ER PT J AU Iverson, KM Gradus, JL Resick, PA Suvak, MK Smith, KF Monson, CM AF Iverson, Katherine M. Gradus, Jaimie L. Resick, Patricia A. Suvak, Michael K. Smith, Kamala F. Monson, Candice M. TI Cognitive Behavioral Therapy for PTSD and Depression Symptoms Reduces Risk for Future Intimate Partner Violence Among Interpersonal Trauma Survivors SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE cognitive-behavioral therapy; interpersonal victimization; intimate partner violence; posttraumatic stress disorder; depression ID POSTTRAUMATIC-STRESS-DISORDER; CHILDHOOD SEXUAL-ABUSE; PROCESSING THERAPY; ASSAULT VICTIMS; BATTERED WOMEN; REVICTIMIZATION; VICTIMIZATION; EXPERIENCES; PREVENTION; PROGRAM AB Objective: Women who develop symptoms of posttraumatic stress. disorder (PTSD) and depression subsequent to interpersonal trauma are at heightened risk for future intimate partner violence (IPV) victimization. Cognitive-behavioral therapy (CBT) is effective in reducing PTSD and depression symptoms, yet limited research has investigated the effectiveness of CBT in reducing risk for future IPV among interpersonal. trauma survivors. Method: This study examined the effect of CBT for PTSD and depressive symptoms on the risk of future IPV victimization in a sample of women survivors of interpersonal violence. The current sample included 150 women diagnosed with PTSD secondary to an array of interpersonal traumatic events; they were participating in a randomized clinical trial of different forms of cognitive processing therapy for the treatment of PTSD. Participants were assessed at 9 time points as part of the larger trial: pretreatment, 6 times during treatment, posttreatment, and 6-month follow-up. Results: As hypothesized, reductions in PTSD and in depressive symptoms during treatment were associated with a decreased likelihood of IPV victimization at a 6-month follow-up even after controlling for recent IPV (i.e., IPV from a current partner within the year prior to beginning the study) and prior interpersonal traumas. Conclusions: These findings highlight the importance of identifying and treating PTSD and depressive symptoms among interpersonal trauma survivors as a method for reducing risk for future IPV. C1 [Iverson, Katherine M.; Gradus, Jaimie L.; Resick, Patricia A.; Suvak, Michael K.; Smith, Kamala F.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, W Roxbury, MA USA. [Iverson, Katherine M.; Gradus, Jaimie L.; Resick, Patricia A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Gradus, Jaimie L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Resick, Patricia A.] Boston Univ, Dept Psychol, Boston, MA 02215 USA. [Monson, Candice M.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. RP Iverson, KM (reprint author), WHSD 116B 3 VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA. EM Katherine.Iverson@va.gov OI Gradus, Jaimie/0000-0003-1459-5327 FU NIMH NIH HHS [R01-MH51509, T32 MH019836, T32 MH019836-03, T32MH019836, R01 MH051509, R01 MH051509-05] NR 62 TC 57 Z9 57 U1 7 U2 27 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD APR PY 2011 VL 79 IS 2 BP 193 EP 202 DI 10.1037/a0022512 PG 10 WC Psychology, Clinical SC Psychology GA 742EP UT WOS:000288924400007 PM 21341889 ER PT J AU Mohr, DC Carmody, T Erickson, L Jin, L Leader, J AF Mohr, David C. Carmody, Timothy Erickson, Lauren Jin, Ling Leader, Julie TI Telephone-Administered Cognitive Behavioral Therapy for Veterans Served by Community-Based Outpatient Clinics SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE depression; psychotherapy; telemental health; randomized controlled trial; cognitive behavioral therapy ID POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE; RANDOMIZED-TRIAL; RATING-SCALE; DEPRESSION; PSYCHOTHERAPY; HEALTH; METAANALYSIS; MANAGEMENT; SYMPTOMS AB Objective.. Multiple:trials have found telephone-administered cognitive behavioral therapy (T-CBT) to be effective for the treatment of depression. The aim of this study was to evaluate T-CBT for the treatment of depression among veterans served by community-based outpatient clinics (CBOCs) outside of major urban areas. Method: Eighty-five veterans meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed.; American Psychiatric Association. 1994) criteria for major depressive disorder were randomized to receive 16 sessions of T-CBT over 20 weeks or treatment as usual through the CBOC. Veterans were assessed at baseline, 12 weeks. 20 weeks (posttreatment), and 6-month follow-up using the Hamilton Depression Rating Scale (Hamilton. 1960), the Patient Health Questionnaire-9 (Kroenke, Spitzer. & Williams. 2001). and a standardized psychiatric interview. Results: There were no significant Time X Treatment effects (ps >.20). Patients were compliant, with 38(92.7%) completing at least 12 sessions, and 32(78.0%) having no missed sessions whatsoever. Ratings of audiotaped sessions showed the therapists to be highly competent. Conclusions: This trial yielded negative results for an intervention that has been shown to be effective under other circumstances. We speculate that veterans served within the Veterans Affairs system are more refractory to treatment than other populations, and they may require a more rigorous intervention. Trial Registration: clinicaltrials.gov NCr00223652 C1 [Mohr, David C.; Jin, Ling] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA. [Mohr, David C.] Hines Vet Affairs Med Ctr, Ctr Management Complex Chron Care, Hines, IL USA. [Carmody, Timothy; Erickson, Lauren] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Carmody, Timothy; Leader, Julie] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. RP Mohr, DC (reprint author), Northwestern Univ, Dept Prevent Med, 680 N Lakeshore Dr,Suite 1220, Chicago, IL 60611 USA. EM d-mohr@northwestern.edu NR 25 TC 16 Z9 16 U1 6 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD APR PY 2011 VL 79 IS 2 BP 261 EP 265 DI 10.1037/a0022395 PG 5 WC Psychology, Clinical SC Psychology GA 742EP UT WOS:000288924400014 PM 21299274 ER PT J AU Bourge, RC Tapson, VF Safdar, Z Benza, RL Channick, RN Rosenzweig, EB Shapiro, S McSwain, CS Gotzkowsky, A Nelsen, A Rubin, LJ AF Bourge, R. C. Tapson, V. F. Safdar, Z. Benza, R. L. Channick, R. N. Rosenzweig, E. B. Shapiro, S. McSwain, C. S. Gotzkowsky, A. Nelsen, A. Rubin, L. J. TI Safely Transitioning from Inhaled Iloprost to Inhaled Treprostinil Sodium - Results from a Multicenter Open-Label Study in Patients with Pulmonary Arterial Hypertension SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Meeting Abstract CT 31st Annual Meeting and Scientific Sessions on International-Society-for-Heart-and-Lung-Transplantation CY APR 13-16, 2011 CL San Diego, CA SP Int Soc Heart & Lung Transplantat C1 [Bourge, R. C.] Univ Alabama, Birmingham, AL USA. [Tapson, V. F.] Duke Univ, Med Ctr, Durham, NC USA. [Safdar, Z.] Baylor Coll Med, Houston, TX 77030 USA. [Benza, R. L.] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Channick, R. N.] Massachusetts Gen Hosp, Pulm Hypertens Program, Boston, MA 02114 USA. [Rosenzweig, E. B.] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Shapiro, S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [McSwain, C. S.; Gotzkowsky, A.; Nelsen, A.] United Therapeut Corp, Res Triangle Pk, NC USA. [Rubin, L. J.] Univ Calif San Diego, La Jolla, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD APR PY 2011 VL 30 IS 4 SU S MA 195 BP S71 EP S72 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation GA 742EO UT WOS:000288924300196 ER PT J AU Iturrizaga, J Pamboukian, SV George, J Brown, RN Cadeiras, M Smallfield, M Bourge, RC Kirklin, JK McGiffin, DC Hubbard, M Tallaj, JA AF Iturrizaga, J. Pamboukian, S. V. George, J. Brown, R. N. Cadeiras, M. Smallfield, M. Bourge, R. C. Kirklin, J. K. McGiffin, D. C. Hubbard, M. Tallaj, J. A. TI Post-Transplant Diastolic Dysfunction beyond the First Year: Incidence and Prognostic Significance SO JOURNAL OF HEART AND LUNG TRANSPLANTATION LA English DT Meeting Abstract CT 31st Annual Meeting and Scientific Sessions on International-Society-for-Heart-and-Lung-Transplantation CY APR 13-16, 2011 CL San Diego, CA SP Int Soc Heart & Lung Transplantat C1 [Iturrizaga, J.; Pamboukian, S. V.; George, J.; Brown, R. N.; Cadeiras, M.; Smallfield, M.; Bourge, R. C.; Kirklin, J. K.; McGiffin, D. C.; Hubbard, M.; Tallaj, J. A.] Univ Alabama, Birmingham, AL USA. [Tallaj, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1053-2498 J9 J HEART LUNG TRANSPL JI J. Heart Lung Transplant. PD APR PY 2011 VL 30 IS 4 SU S MA 523 BP S176 EP S177 PG 2 WC Cardiac & Cardiovascular Systems; Respiratory System; Transplantation SC Cardiovascular System & Cardiology; Respiratory System; Transplantation GA 742EO UT WOS:000288924300519 ER PT J AU Chen, S Alcantara, D Josephson, L AF Chen, Suelin Alcantara, David Josephson, Lee TI A Magnetofluorescent Nanoparticle for Ex-Vivo Cell Labeling by Covalently Linking the Drugs Protamine and Feraheme SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY LA English DT Article DE Cell Tracking; Nanoparticle; MRI; Protamine ID SUPERPARAMAGNETIC IRON-OXIDE; LYMPH-NODE METASTASES; STEM-CELLS; IN-VIVO; CLINICAL-TRIAL; GLIOMA MODEL; GENE-THERAPY; MR; FERUMOXIDES; VITRO AB We synthesized a nanoparticle (NP) for ex-vivo cell labeling and MRI tracking by covalently coupling the C-terminus of a rhodamine-labeled protamine (Pro Rho) to Feraheme (FH) in order to yield the nanoparticle denoted ProRho-FH. Since protamine can adsorb to certain charged surfaces, we confirmed a covalent interaction between Pro Rho and FH by heparin affinity chromatography. ProRho-FH lacks a net charge (zeta potential similar to 0) due to the combination of negative FH and positive Pro Rho charges. ProRho-FH was readily internalized by U87 cells and mouse mesenchymal stem cells as determined by FACS and MR relaxometry. Finally, some 4,000 stem cells were implanted in a mouse brain and imaged by MRI. Due to its lack of net surface charge, ProRho-FH relies on the internalizing properties of the surface guanidinium groups present in the arginine-rich protamine to induce NP uptake. ProRho-FH is a unique cell-labeling agent due to its synthesis using two approved drugs, magnetofluorescence, site-specific covalent attachment chemistry, and lack of surface charge. C1 [Chen, Suelin; Alcantara, David; Josephson, Lee] Massachusetts Gen Hosp, Ctr Translat Nucl Med & Mol Imaging, Charlestown, MA 02129 USA. [Chen, Suelin] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA. RP Josephson, L (reprint author), Massachusetts Gen Hosp, Ctr Translat Nucl Med & Mol Imaging, 149 13th St, Charlestown, MA 02129 USA. RI Alcantara, David /A-3357-2014 FU NIH [U54CA119349, P50CA086355, R01EB009691]; postdoctoral Fulbright Fellowship FX This work was supported by NIH grants U54CA119349, P50CA086355 and R01EB009691 from the NIH. DA was supported with a postdoctoral Fulbright Fellowship. NR 46 TC 14 Z9 14 U1 0 U2 21 PU AMER SCIENTIFIC PUBLISHERS PI VALENCIA PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA SN 1533-4880 J9 J NANOSCI NANOTECHNO JI J. Nanosci. Nanotechnol. PD APR PY 2011 VL 11 IS 4 BP 3058 EP 3064 DI 10.1166/jnn.2011.4164 PG 7 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA 745OX UT WOS:000289176100042 PM 21776671 ER PT J AU Slavin-Mulford, J Hilsenroth, M Weinberger, J Gold, J AF Slavin-Mulford, Jenelle Hilsenroth, Mark Weinberger, Joel Gold, Jerold TI Therapeutic Interventions Related to Outcome in Psychodynamic Psychotherapy for Anxiety Disorder Patients SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Psychodynamic psychotherapy; anxiety; technique; STPP; CPPS ID COGNITIVE-BEHAVIORAL THERAPY; OBSESSIVE-COMPULSIVE DISORDER; GENERALIZED ANXIETY; CLINICAL-SIGNIFICANCE; PANIC DISORDER; INTERPERSONAL PSYCHOTHERAPY; SOCIAL PHOBIA; RELIABILITY; ALLIANCE; EXPOSURE AB This is the first study with acceptable inter-rater reliability to examine specific therapeutic techniques related to change in anxiety disorder patients during short-term psychodynamic psychotherapy. The study first examined the effectiveness of short-term psychodynamic psychotherapy and results showed significant and positive pre-/post-treatment changes on both patient and independent clinical ratings for anxiety, global symptomatology, relational, social, and occupational functioning. Likewise, the majority of patients (76%) reported anxiety symptoms within a normal distribution at termination. Importantly, psychodynamic interventions rated early in treatment (third/fourth session) were positively related to changes in anxiety symptoms. Further, results showed that several individual psychodynamic techniques were meaningfully related to outcome including (1) focusing on wishes, fantasies, dreams, and early memories; (2) linking current feelings or perceptions to the past; (3) highlighting patients' typical relational patterns; and (4) helping patients to understand their experiences in new ways. Clinical applications are discussed. C1 [Slavin-Mulford, Jenelle] Massachusetts Gen Hosp, PEaRL, Boston, MA 02114 USA. [Slavin-Mulford, Jenelle] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Hilsenroth, Mark; Weinberger, Joel; Gold, Jerold] Adelphi Univ, Derner Inst Adv Psychol Studies, Garden City, NY 11530 USA. RP Slavin-Mulford, J (reprint author), Massachusetts Gen Hosp, PEaRL, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM jenelle.slavin@gmail.com NR 58 TC 11 Z9 11 U1 3 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD APR PY 2011 VL 199 IS 4 BP 214 EP 221 DI 10.1097/NMD.0b013e3182125d60 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 742ZX UT WOS:000288985400003 PM 21451344 ER PT J AU Jakupcak, M Hoerster, KD Varra, A Vannoy, S Felker, B Hunt, S AF Jakupcak, Matthew Hoerster, Katherine D. Varra, Alethea Vannoy, Steven Felker, Bradford Hunt, Stephen TI Hopelessness and Suicidal Ideation in Iraq and Afghanistan War Veterans Reporting Subthreshold and Threshold Posttraumatic Stress Disorder SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Suicide risk; Iraq and Afghanistan war veterans; subthreshold PTSD ID MENTAL-HEALTH PROBLEMS; PRIMARY-CARE; PREVALENCE; PTSD; IMPAIRMENT; COMBAT; TRAUMA; RISK AB We examined hopelessness and suicidal ideation in association with subthreshold and threshold posttraumatic stress disorder (PTSD) in a sample of Iraq and Afghanistan War Veterans (U.S., N = 275) assessed within a specialty VA postdeployment health clinic. Veterans completed paper-and-pencil questionnaires at intake. The military version of the PTSD Checklist was used to determine PTSD levels (No PTSD; subthreshold PTSD; PTSD), and endorsement of hopelessness or suicidal ideation were used as markers of elevated suicide risk. Veterans were also asked if they received mental health treatment in the prior 6 months. Veterans reporting subthreshold PTSD were 3 times more likely to endorse these markers of elevated suicide risk relative to the Veterans without PTSD. We found no significant differences in likelihood of endorsing hopelessness or suicidal ideation comparing subthreshold and threshold PTSD groups, although the subthreshold PTSD group was less likely to report prior mental health treatment. Clinicians should be attentive to suicide risk in returned Veterans reporting both subthreshold and threshold PTSD. C1 [Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, VISN NW Mental Illness Res Educ & Clin Ctr 20, Seattle, WA 98108 USA. [Jakupcak, Matthew; Hoerster, Katherine D.; Varra, Alethea; Vannoy, Steven] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Jakupcak, M (reprint author), VA Puget Sound Hlth Care Syst, Deployment Hlth Clin, VISN NW Mental Illness Res Educ & Clin Ctr 20, 1660 S Columbian Way, Seattle, WA 98108 USA. EM matthew.jakupcak@va.gov RI Schueter, nicos/A-3625-2014; OI Vannoy, Steven/0000-0003-3029-8306 FU VA Puget Sound Health Care System, Seattle, Washington FX This material is the result of work supported by resources from the VA Puget Sound Health Care System, Seattle, Washington. NR 23 TC 39 Z9 39 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD APR PY 2011 VL 199 IS 4 BP 272 EP 275 DI 10.1097/NMD.0b013e3182124604 PG 4 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 742ZX UT WOS:000288985400012 PM 21451353 ER PT J AU Simeral, JD Kim, SP Black, MJ Donoghue, JP Hochberg, LR AF Simeral, J. D. Kim, S-P Black, M. J. Donoghue, J. P. Hochberg, L. R. TI Neural control of cursor trajectory and click by a human with tetraplegia 1000 days after implant of an intracortical microelectrode array SO JOURNAL OF NEURAL ENGINEERING LA English DT Article; Proceedings Paper CT 4th International Brain-Computer Interface Meeting CY MAY 31-JUN 04, 2010 CL Monterey, CA ID BRAIN-COMPUTER INTERFACE; LOCAL-FIELD POTENTIALS; PRIMARY MOTOR CORTEX; LOCKED-IN SYNDROME; ELECTRODE-ARRAY; CEREBRAL-CORTEX; CORTICAL CONTROL; FITTS LAW; ELECTROCORTICOGRAPHIC SIGNALS; NEUROPROSTHETIC DEVICES AB The ongoing pilot clinical trial of the BrainGate neural interface system aims in part to assess the feasibility of using neural activity obtained from a small-scale, chronically implanted, intracortical microelectrode array to provide control signals for a neural prosthesis system. Critical questions include how long implanted microelectrodes will record useful neural signals, how reliably those signals can be acquired and decoded, and how effectively they can be used to control various assistive technologies such as computers and robotic assistive devices, or to enable functional electrical stimulation of paralyzed muscles. Here we examined these questions by assessing neural cursor control and BrainGate system characteristics on five consecutive days 1000 days after implant of a 4 x 4 mm array of 100 microelectrodes in the motor cortex of a human with longstanding tetraplegia subsequent to a brainstem stroke. On each of five prospectively-selected days we performed time-amplitude sorting of neuronal spiking activity, trained a population-based Kalman velocity decoding filter combined with a linear discriminant click state classifier, and then assessed closed-loop point-and-click cursor control. The participant performed both an eight-target center-out task and a random target Fitts metric task which was adapted from a human-computer interaction ISO standard used to quantify performance of computer input devices. The neural interface system was further characterized by daily measurement of electrode impedances, unit waveforms and local field potentials. Across the five days, spiking signals were obtained from 41 of 96 electrodes and were successfully decoded to provide neural cursor point-and-click control with a mean task performance of 91.3% +/- 0.1% (mean +/- s.d.) correct target acquisition. Results across five consecutive days demonstrate that a neural interface system based on an intracortical microelectrode array can provide repeatable, accurate point-and-click control of a computer interface to an individual with tetraplegia 1000 days after implantation of this sensor. C1 [Simeral, J. D.; Donoghue, J. P.; Hochberg, L. R.] Dept Vet Affairs Med Ctr, Rehabil R&D Serv, Providence, RI 02912 USA. [Simeral, J. D.; Hochberg, L. R.] Brown Univ, Sch Engn, Providence, RI 02912 USA. [Kim, S-P; Black, M. J.] Brown Univ, Dept Comp Sci, Providence, RI 02911 USA. [Donoghue, J. P.] Brown Univ, Dept Neurosci, Providence, RI 02911 USA. [Hochberg, L. R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Stroke Serv,Dept Neurol,Mass Gen Hosp, Boston, MA 02114 USA. [Hochberg, L. R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Neurocrit Care Serv,Dept Neurol,Mass Gen Hosp, Boston, MA 02114 USA. [Hochberg, L. R.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA 02114 USA. RP Simeral, JD (reprint author), Dept Vet Affairs Med Ctr, Rehabil R&D Serv, Providence, RI 02912 USA. EM John_Simeral@brown.edu FU Rehabilitation Research and Development Service, Office of Research and Development, Department of Veterans Affairs FX We thank participant S3 for her dedication to this research. This work is supported by the Rehabilitation Research and Development Service, Office of Research and Development, Department of Veterans Affairs. Additional support is provided by NIH: NICHD-NCMRR (N01HD53403), NINDS/NICHD (RC1HD063931), NIDCD R01DC009899, NIBIB (R01EB007401), NINDS-Javits (NS25074); National Center for Research Resources (NCRR C06-16549-01A1); the Doris Duke Charitable Foundation; the MGH-Deane Institute of Integrated Research on Atrial Fibrillation and Stroke; Katie Samson Foundation. The pilot clinical trial from which these data are derived was sponsored in part by Cyberkinetics Neurotechnology Systems, Inc. The authors thank K Severinson Eklundh for advice about the evaluation of pointing devices. They also wish to thank K Centrella, S Stavisky, G Friehs and J. Stein for their significant contributions to this research. JPD is a former Chief Scientific Officer and director of Cyberkinetics Neurotechnology Systems, Inc. (CKI); he held stocks and received compensation. LRH received research support from Massachusetts General and Spaulding Rehabilitation Hospitals, which in turn received clinical trial support from CKI. JDS received compensation as a consultant for CKI. CKI ceased operations in 2009. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 97 TC 157 Z9 160 U1 1 U2 43 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 EI 1741-2552 J9 J NEURAL ENG JI J. Neural Eng. PD APR PY 2011 VL 8 IS 2 SI SI AR 025027 DI 10.1088/1741-2560/8/2/025027 PG 24 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA 745VS UT WOS:000289199000028 PM 21436513 ER PT J AU Buswell, L AF Buswell, Lori TI Using Electronic Health Records to Transform Care Delivery SO JOURNAL OF NURSING ADMINISTRATION LA English DT Book Review C1 [Buswell, Lori] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Buswell, L (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM Lbuswell@partners.org NR 2 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-0443 EI 1539-0721 J9 J NURS ADMIN JI J. Nurs. Adm. PD APR PY 2011 VL 41 IS 4 BP 159 EP 161 DI 10.1097/NNA.0b013e31821184da PG 3 WC Nursing SC Nursing GA 739TQ UT WOS:000288741400005 ER PT J AU Adams, JM Erickson, JI AF Adams, Jeffrey M. Erickson, Jeanette Ives TI Applying the Adams Influence Model in Nurse Executive Practice SO JOURNAL OF NURSING ADMINISTRATION LA English DT Article AB The ability to influence others is a required competency for nurse executives trying to achieve positive patient/organizational outcomes. The Adams Influence Model (AIM) is a framework for understanding the factors, attributes, and process of influence. The AIM is grounded in nursing and organizational literature and provides nurse leaders with a road map for developing an effective strategy to achieve influence with individuals and/or groups. The authors describe the AIM and present a case study illustrating its application by a chief nurse executive. C1 [Adams, Jeffrey M.] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, Boston, MA 02114 USA. [Erickson, Jeanette Ives] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA. RP Adams, JM (reprint author), Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, 275 Cambridge St,Profess Off Bldg 4th Floor, Boston, MA 02114 USA. EM jadams9@partners.org FU Yvonne L. Munn Center for Nursing Research at Massachusetts General Hospital FX The article was developed and supported, in part, by a postdoctoral fellowship grant from The Yvonne L. Munn Center for Nursing Research at Massachusetts General Hospital. NR 23 TC 7 Z9 7 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0002-0443 EI 1539-0721 J9 J NURS ADMIN JI J. Nurs. Adm. PD APR PY 2011 VL 41 IS 4 BP 186 EP 192 DI 10.1097/NNA.0b013e3182118736 PG 7 WC Nursing SC Nursing GA 739TQ UT WOS:000288741400010 PM 21430468 ER PT J AU Nguyen, DN Zierler, B Nguyen, HQ AF Nguyen, Diane N. Zierler, Brenda Nguyen, Huong Q. TI A Survey of Nursing Faculty Needs for Training in Use of New Technologies for Education and Practice SO JOURNAL OF NURSING EDUCATION LA English DT Article ID STUDENTS EXPERIENCES; DISTANCE EDUCATION; MEDICAL INFORMATICS; ONLINE; COURSES; WEB; NURSES; UNDERGRADUATE; PERSPECTIVES; INSTRUCTION AB This study describes nursing faculty's use, knowledge of, and training needs associated with distance learning, simulation, telehealth, and informatics tools in nursing education and practice. Web-based surveys were completed by 193 faculty members from nursing schools in the western United States. More than half of the respondents were frequent users of distance learning and informatics tools. Approximately 66% of faculty reported they were competent with distance learning and informatics tools. Training and technical support for the use of distance learning was highest, yet 69% of faculty still reported a need for additional training. The availability of training and financial and technical support was associated with greater use of distance learning technologies (p < 0.05 for all). Although a key limitation of this survey was the overlapping definitions across the four technologies, the findings suggest nursing faculty perceive a need for training and support to effectively use educational technologies in nursing education. C1 [Nguyen, Diane N.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Zierler, Brenda; Nguyen, Huong Q.] Univ Washington, Seattle, WA 98195 USA. RP Nguyen, DN (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mail Stop S-118-NOD, Seattle, WA 98108 USA. EM Diane.Nguyen@va.gov FU NCRR NIH HHS [KL2 RR025015] NR 62 TC 13 Z9 15 U1 1 U2 16 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0148-4834 J9 J NURS EDUC JI J. Nurs. Educ. PD APR PY 2011 VL 50 IS 4 BP 181 EP 189 DI 10.3928/01484834-20101130-06 PG 9 WC Nursing SC Nursing GA 742TV UT WOS:000288968300002 PM 21117532 ER PT J AU Fineberg, IC Kawashima, M Asch, SM AF Fineberg, Iris Cohen Kawashima, Michie Asch, Steven M. TI Communication with Families Facing Life-Threatening Illness: A Research-Based Model for Family Conferences SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID INTENSIVE-CARE-UNIT; PALLIATIVE CARE; DECISION-MAKING; SOCIAL SUPPORT; END; CAREGIVERS; SATISFACTION; COLLABORATE; PERCEPTIONS; TRANSITIONS AB Background: Communication is an ongoing challenge for clinicians working with people facing life-threatening illnesses and end of life. Family conferences offer patient-focused, family-oriented care that brings together patients, family members, and health care providers. Objective: The aim of this study was to develop a research-based model for family conferences to help physicians and other health care providers conduct such conferences effectively and improve communication with patients and families. Design: We prospectively studied family conferences for patients facing life-threatening illness in two inpatient medical centers. We videotape and audiotape recorded real-life conferences and postconference interviews with participants. Participants: Twenty-four family conferences were included in the study. Participants consisted of 24 patients, 10 of whom took part in the family conferences, 49 family members, and 85 health care providers. Approach: A multidisciplinary team conducted a qualitative analysis of the videotaped and audiotaped materials using thematic analysis. The team used a multistage approach to independently and collectively analyze and integrate three data sources. Main Results: The resulting theoretical model for family conferences has 4 main components. These include the underlying structural context of conference organization and the key process components of negotiation and personal stance. Emotional engagement by health care providers, emotion work, appears central to the impact of these components on the successful outcome of the conference. In addition to the theoretical model, the authors found that family conference participants place specific value on the "simultaneous presence" of conference attendees that leads to being on the "same page." Conclusions: Physicians and other health care professionals can use the model as a guide for conducting family conferences and strengthening communication with patients, families and colleagues. C1 [Fineberg, Iris Cohen] Univ Lancaster, Int Observ End Life Care, Sch Hlth & Med, Div Hlth Res, Lancaster LA1 4YT, England. [Kawashima, Michie] Japan Soc Promot Sci, Tokyo, Japan. [Kawashima, Michie] Saitama Univ, Saitama 3388570, Japan. [Kawashima, Michie] Tokyo Med & Dent Univ, Tokyo, Japan. [Asch, Steven M.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Fineberg, IC (reprint author), Univ Lancaster, Int Observ End Life Care, Sch Hlth & Med, Div Hlth Res, Bowland Tower E, Lancaster LA1 4YT, England. EM i.fineberg@lancaster.ac.uk FU UniHealth Foundation in Los Angeles, California FX This research was conducted under a grant from the UniHealth Foundation in Los Angeles, California. We appreciate the foundation's support and interest in this work. Thank you to the medical and palliative care teams at the participating medical centers for their crucial collaboration, to Marc Roseboro for his sensitive and skillful videotaping, and to Joya F. Golden for her thoughtful administrative assistance. Most of all, we thank the family conference participants-patients, family members, and staff-who graciously shared their experiences with us and made the research possible. NR 63 TC 17 Z9 17 U1 1 U2 10 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2011 VL 14 IS 4 BP 421 EP 427 DI 10.1089/jpm.2010.0436 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 746HQ UT WOS:000289235100011 PM 21385083 ER PT J AU Smith, KA Goy, ER Harvath, TA Ganzini, L AF Smith, Kathryn A. Goy, Elizabeth R. Harvath, Theresa A. Ganzini, Linda TI Quality of Death and Dying in Patients who Request Physician-Assisted Death SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID FAMILY-MEMBERS; EXPERIENCES; OREGONIANS; SUICIDE AB Background: Physician-assisted death (PAD) was legalized in 1997 by Oregon's Death with Dignity Act (ODDA). Through 2009, 460 Oregonians have died by lethal prescription under the ODDA. Objective: To determine whether there was a difference in the quality of the dying experience, from the perspective of family members, between 52 Oregonians who received lethal prescriptions, 34 who requested but did not receive lethal prescriptions, and 63 who did not pursue PAD. Design: Cross-sectional survey. Measurements: Family members retrospectively rated the dying experience of their loved one with the 33 item Quality of Death and Dying Questionnaire (QODD). Results: There were differences reported in 9 of the 33 quality item indicators. Few significant differences were noted in items that measured domains of connectedness, transcendence, and overall quality of death. Those receiving PAD prescriptions had higher quality ratings on items measuring symptom control (e. g., control over surroundings and control of bowels/bladder) and higher ratings on items related to preparedness for death (saying goodbye to loved ones, and possession of a means to end life if desired) than those who did not pursue PAD or, in some cases, those who requested but did not receive a lethal prescription. Conclusions: The quality of death experienced by those who received lethal prescriptions is no worse than those not pursuing PAD, and in some areas it is rated by family members as better. C1 [Goy, Elizabeth R.; Ganzini, Linda] Portland VA Med Ctr, Div Mental Hlth, Portland, OR 97239 USA. [Smith, Kathryn A.; Harvath, Theresa A.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Goy, Elizabeth R.; Ganzini, Linda] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Ganzini, L (reprint author), Portland VA Med Ctr, Div Mental Hlth, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM Linda.Ganzini@va.gov FU Greenwall Foundation FX Funded by a grant from the Greenwall Foundation. This material is the result of work supported with resources and the use of facilities at the Portland VAMC in Portland, Oregon. NR 19 TC 11 Z9 11 U1 3 U2 21 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2011 VL 14 IS 4 BP 445 EP 450 DI 10.1089/jpm.2010.0425 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 746HQ UT WOS:000289235100014 PM 21417741 ER PT J AU Morss, S Asch, SM Lorenz, KA Weeks, K Sharma, RK Wolff, AC Malin, JL AF Morss, Sydney Asch, Steven M. Lorenz, Karl A. Weeks, Kristina Sharma, Rashmi K. Wolff, Antonio C. Malin, Jennifer L. TI Quality of End-of-Life Care for Patients with Advanced Cancer in an Academic Medical Center SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID HEALTH AB Purpose: We assessed key aspects of the quality of end-of-life care using validated explicit process quality measures in an academic medical center (hospital and cancer center) before expanding to a broader palliative care initiative. Methods: We evaluated 21 indicators most relevant to end-of-life care from the Cancer Quality-ASSIST supportive oncology indicator set for 238 patients with advanced/metastatic solid tumors who died between 2-15 months after diagnosis. These included outpatient and hospital indicators for cancer symptoms and information and care planning that met criteria for feasibility, reliability, and validity. We abstracted detailed information from medical records to specify the necessary data elements. Results: Overall adherence was 53% (95% confidence interval [CI], 50%-56%); this varied widely among indicators. Adherence was highest for pain indicators; in particular, 97% of eligible subjects' hospitalizations had documented screening for pain, and, after an outpatient pain medication was changed, 97% of patients had a pain assessment at the subsequent visit. For other symptoms, adherence ranged from 0% for documentation of life expectancy for patients starting parenteral or enteral nutrition to 87% for assessment of nausea or vomiting on hospital admission. For information and care planning, results ranged from 6% for documentation of ventilation preferences prior to intubation to 68% for documented communication of risks and benefits or prognosis prior to starting chemotherapy. Conclusion: In conclusion, Cancer Quality-ASSIST indicators are useful for practical quality assessment of cancer end-of-life care in an academic medical center. These results will serve as useful data for targeting areas for quality improvement and measuring progress. C1 [Morss, Sydney] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21205 USA. [Weeks, Kristina] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA. [Wolff, Antonio C.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21205 USA. [Asch, Steven M.; Lorenz, Karl A.; Malin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, RAND Hlth, Los Angeles, CA 90095 USA. [Sharma, Rashmi K.] Northwestern Univ, Div Hosp Med, Chicago, IL 60611 USA. RP Morss, S (reprint author), Johns Hopkins Univ, Dept Hlth Policy & Management, Room 609,624 N Broadway, Baltimore, MD 21205 USA. EM sdy@jhsph.edu OI Wolff, Antonio/0000-0003-3734-1063 FU Agency for Healthcare Research and Quality, US Department of Health and Human Services [290-2005-0034I] FX The research reported here was supported under Contract No. 290-2005-0034I from the Agency for Healthcare Research and Quality, US Department of Health and Human Services as part of the Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) program. The authors of this paper are responsible for its content. Statements in this paper should not be construed as endorsement by the Agency for Healthcare Research and Quality. NR 13 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2011 VL 14 IS 4 BP 451 EP 457 DI 10.1089/jpm.2010.0434 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 746HQ UT WOS:000289235100015 ER PT J AU Jacobsen, J Jackson, V Dahlin, C Greer, J Perez-Cruz, P Billings, JA Pirl, W Temel, J AF Jacobsen, Juliet Jackson, Vicki Dahlin, Constance Greer, Joseph Perez-Cruz, Pedro Billings, J. Andrew Pirl, William Temel, Jennifer TI Components of Early Outpatient Palliative Care Consultation in Patients with Metastatic Nonsmall Cell Lung Cancer SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; DISCUSSING PROGNOSIS; CONTROLLED-TRIAL; DEPRESSION; RECOMMENDATIONS; INFORMATION; PREVALENCE; VALIDITY; THERAPY AB Background: Although palliative care consultation is recommended early in the course of oncology treatment, little evidence exists to guide the nature of this intervention. We describe a clinical practice of early palliative care consultation that improved quality of life, mood, and survival in a randomized clinical trial. Methods: As part of a randomized trial of early palliative care versus standard care in patients with newly diagnosed metastatic non-small cell lung cancer (NSCLC), we analyzed documentation of the components of the initial palliative care consultation, self-reported quality of life as measured by the Functional Assessment of Cancer Therapy-Lung Trial Outcome Index (FACT-L TOI), and mood as measured by the Patient Health Questionnaire-9 (PHQ-9). Results: Seven palliative care clinicians provided consultation to 67 patients. The median total time spent with patients for the initial visit was 55 minutes (range, 20-120). Consultations focused on symptom management (median, 20 minutes; range, 0-75), patient and family coping (median, 15 minutes; range, 0-78), and illness understanding and education (median, 10 minutes; range, 0-35). Lower quality of life as measured by the FACTL TOI predicted greater consultation time (odds ratio [OR] 0.95, 95% confidence interval [CI] 0.91-0.99). Additionally, lower quality of life scores on the FACT-L TOI (OR = 0.93, 95% CI = 0.88-0.97) and higher depression scores on the PHQ-9 (OR = 1.15, 95% CI = 1.02-1.31) predicted greater time spent on symptom management. Conclusions: Initial palliative care consultation near the time of diagnosis in patients with metastatic NSCLC in this intervention is nearly an hour in length and largely addresses symptom management, patient and family coping, and illness understanding and education. Lower quality of life predicted longer consultations, with more time dedicated specifically to symptom management. C1 [Jacobsen, Juliet] Massachusetts Gen Hosp, Dept Palliat Care, Palliat Care Serv, Boston, MA 02114 USA. [Greer, Joseph; Pirl, William; Temel, Jennifer] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Jacobsen, J (reprint author), Massachusetts Gen Hosp, Dept Palliat Care, Palliat Care Serv, 55 Fruit St,Founders 600, Boston, MA 02114 USA. EM jjacobsen@partners.org NR 29 TC 58 Z9 58 U1 1 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2011 VL 14 IS 4 BP 459 EP 464 DI 10.1089/jpm.2010.0382 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 746HQ UT WOS:000289235100016 PM 21417739 ER PT J AU Jackson, V Arnold, RM AF Jackson, Vicki Arnold, Robert M. TI The Art of Curriculum Development SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Editorial Material C1 [Jackson, Vicki] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Jackson, V (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. EM VJackson@partners.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 J9 J PALLIAT MED JI J. Palliat. Med. PD APR PY 2011 VL 14 IS 4 BP 501 EP 501 DI 10.1089/jpm.2011.9709 PG 1 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 746HQ UT WOS:000289235100021 ER PT J AU Lee, JK Kwon, YJ AF Lee, Jun-Ki Kwon, Yong-Ju TI What Neural Substrates Trigger the Adept Scientific Pattern Discovery by Biologists? SO JOURNAL OF SCIENCE EDUCATION AND TECHNOLOGY LA English DT Article DE Neural substrates of scientific discovery; Biological pattern discovery; Adept pattern discovery; fMRI; Parieto-temporal network; Brain-based science curriculum ID VISUAL-ATTENTION; EDUCATION; ACTIVATION AB This study investigated the neural correlates of experts and novices during biological object pattern detection using an fMRI approach in order to reveal the neural correlates of a biologist's superior pattern discovery ability. Sixteen healthy male participants (8 biologists and 8 non-biologists) volunteered for the study. Participants were shown fifteen series of organism pictures and asked to detect patterns amid stimulus pictures. Primary findings showed significant activations in the right middle temporal gyrus and inferior parietal lobule amongst participants in the biologist (expert) group. Interestingly, the left superior temporal gyrus was activated in participants from the non-biologist (novice) group. These results suggested that superior pattern discovery ability could be related to a functional facilitation of the parieto-temporal network, which is particularly driven by the right middle temporal gyrus and inferior parietal lobule in addition to the recruitment of additional brain regions. Furthermore, the functional facilitation of the network might actually pertain to high coherent processing skills and visual working memory capacity. Hence, study results suggested that adept scientific thinking ability can be detected by neuronal substrates, which may be used as criteria for developing and evaluating a brain-based science curriculum and test instrument. C1 [Kwon, Yong-Ju] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Lee, Jun-Ki; Kwon, Yong-Ju] Korea Natl Univ Educ, Dept Biol Educ, Cheongwon 363791, Chungbuk, South Korea. RP Kwon, YJ (reprint author), Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM kwonyj@knue.ac.kr FU Korea government (MEST) [NRF 2009-0053595] FX This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (Grant No. NRF 2009-0053595). NR 24 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1059-0145 J9 J SCI EDUC TECHNOL JI J. Sci. Educ. Technol. PD APR PY 2011 VL 20 IS 2 BP 117 EP 122 DI 10.1007/s10956-010-9238-3 PG 6 WC Education & Educational Research; Education, Scientific Disciplines SC Education & Educational Research GA 739YJ UT WOS:000288757800002 ER PT J AU Brill, A AF Brill, A. TI A ride with ferric chloride SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Editorial Material ID HUMAN ATHEROSCLEROTIC PLAQUES; FACTOR PATHWAY INHIBITOR; INTERNAL ELASTIC LAMINA; VON-WILLEBRAND-FACTOR; TISSUE FACTOR; ARTERIAL THROMBOSIS; MICE LACKING; VESSEL WALL; THROMBOGENICITY; TRAPS C1 Harvard Univ, Sch Med, Dept Pathol,Childrens Hosp Boston, Immune Dis Inst,Program Cellular & Mol Med, Boston, MA 02115 USA. RP Brill, A (reprint author), Harvard Univ, Sch Med, Dept Pathol,Childrens Hosp Boston, Immune Dis Inst,Program Cellular & Mol Med, Boston, MA 02115 USA. EM brill@idi.harvard.edu NR 20 TC 7 Z9 7 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1538-7933 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD APR PY 2011 VL 9 IS 4 BP 776 EP 778 DI 10.1111/j.1538-7836.2011.04238.x PG 3 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 745HP UT WOS:000289156800018 PM 21362124 ER PT J AU Steinman, MA Hanlon, JT Sloane, RJ Boscardin, WJ Schmader, KE AF Steinman, Michael A. Hanlon, Joseph T. Sloane, Richard J. Boscardin, W. John Schmader, Kenneth E. TI Do Geriatric Conditions Increase Risk of Adverse Drug Reactions in Ambulatory Elders? Results From the VA GEM Drug Study SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES LA English DT Article DE Adverse drug reactions; Geriatric syndromes; Drug utilization ID OLDER-ADULTS; EVENTS; FRAILTY; AGE; ASSOCIATION; OUTPATIENTS; MANAGEMENT; DISCHARGE; CARE AB Background. Many clinicians prescribe cautiously to older adults with common geriatric conditions for fear of causing adverse drug reactions (ADRs). However, little is known about the association between these conditions and risk of ADRs. Methods. Using data from the VA Geriatric Evaluation and Management Drug Study, we determined any, preventable, and serious ADRs in 808 elders for 12 months after hospital discharge using a validated process involving patient self-report and chart review adjudicated by two health care professionals. Eight common geriatric conditions (activities of daily living, dementia, incontinence, falls, difficulty ambulating, malnourishment, depression, and prolonged bed rest) were evaluated at study baseline through self-report and structured assessments. We used Poisson regression to model the relationship between these geriatric conditions and ADRs. Results. Participants had a mean of 2.9 +/- 1.2 geriatric conditions. Over the 12-month follow-up period, 497 ADRs occurred in 269 participants, including 187 ADRs considered preventable and 127 considered severe. On multivariable analyses, participants with dependency in one or more activities of daily living were less likely to suffer ADRs than those who were fully independent (incidence rate ratio: 0.78, 95% confidence interval = 0.62-1.00). None of the other seven geriatric conditions assessed were associated with ADR risk. Results were similar for preventable and serious ADRs, although participants with a history of falls were more likely to develop serious ADRs (incidence rate ratio: 1.49, 95% confidence interval = 1.00-2.21). Conclusions. Many geriatric conditions were not associated with risk of ADRs. Although it is prudent to prescribe judiciously in patients with these conditions, excessive caution may not be warranted. C1 [Steinman, Michael A.; Boscardin, W. John] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Steinman, Michael A.; Boscardin, W. John] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15260 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Sloane, Richard J.; Schmader, Kenneth E.] Duke Univ, Dept Med, Div Geriatr, Durham, NC USA. [Sloane, Richard J.; Schmader, Kenneth E.] Durham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St, Box 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU National Institute on Aging [R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056]; American Federation for Aging Research [K23 AG030999]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [HS017695, HS018721]; VA Health Services Research [IIR-06-062] FX This work was supported by a grant from the National Institute on Aging and the American Federation for Aging Research (K23 AG030999). Dr Hanlon was supported by National Institute of Aging grants (R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056), a National Institute of Mental Health grant (R34 MH082682), a National Institute of Nursing Research grant (R01 NR010135), Agency for Healthcare Research and Quality grants (HS017695 and HS018721 and a VA Health Services Research grant (IIR-06-062). NR 33 TC 6 Z9 8 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1079-5006 J9 J GERONTOL A-BIOL JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci. PD APR PY 2011 VL 66 IS 4 BP 444 EP 451 DI 10.1093/gerona/glq236 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 741AX UT WOS:000288836600010 PM 21321003 ER PT J AU Mima, A Ohshiro, Y Kitada, M Matsumoto, M Geraldes, P Li, CZ Li, QA White, GS Cahill, C Rask-Madsen, C King, GL AF Mima, Akira Ohshiro, Yuzuru Kitada, Munehiro Matsumoto, Motonobu Geraldes, Pedro Li, Chenzhong Li, Qian White, Gregory S. Cahill, Christopher Rask-Madsen, Christian King, George L. TI Glomerular-specific protein kinase C-beta-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity SO KIDNEY INTERNATIONAL LA English DT Article DE diabetic nephropathy; insulin receptor substrate-1; insulin resistance; obesity; protein kinase C-beta ID NITRIC-OXIDE PRODUCTION; CHRONIC RENAL-DISEASE; ENDOTHELIAL-CELLS; DOWN-REGULATION; NEPHROPATHY; PROGRESSION; ACTIVATION; MECHANISMS; MELLITUS; KIDNEY AB Insulin resistance has been associated with the progression of chronic kidney disease in both diabetes and obesity. In order to determine the cellular mechanisms contributing to this, we characterized insulin signaling in renal tubules and glomeruli during diabetic and insulin-resistant states using streptozotocin-diabetic and Zucker fatty-insulin-resistant rats. Compared with nondiabetic and Zucker lean rats, the insulin-induced phosphorylation of insulin receptor substrate-1 (IRS1), Akt, endothelial nitric oxide synthase, and glycogen synthase kinase 3 alpha were selectively inhibited in the glomeruli but not in the renal tubules of both respective models. Protein, but not mRNA levels of IRS1, was decreased only in the glomeruli of streptozotocin-diabetic rats likely due to increased ubiquitination. Treatment with the protein kinase C-beta inhibitor, ruboxistaurin, enhanced insulin actions and elevated IRS1 expression. In glomerular endothelial cells, high glucose inhibited the phosphorylation of Akt, endothelial nitric oxide synthase, and glycogen synthase kinase 3 alpha; decreased IRS1 protein expression and increased its association with ubiquitin. Overexpression of IRS1 or the addition of ruboxistaurin reversed the inhibitory effects of high glucose. Thus, loss of insulin's effect on endothelial nitric oxide synthase and glycogen synthase kinase 3 alpha activation may contribute to the glomerulopathy observed in diabetes and obesity. Kidney International (2011) 79, 883-896; doi: 10.1038/ki.2010.526; published online 12 January 2011 C1 [Mima, Akira; Ohshiro, Yuzuru; Kitada, Munehiro; Matsumoto, Motonobu; Geraldes, Pedro; Li, Chenzhong; Li, Qian; White, Gregory S.; Rask-Madsen, Christian; King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Vasc Cell Biol, Boston, MA 02115 USA. [Cahill, Christopher] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, Boston, MA 02115 USA. RP King, GL (reprint author), Joslin Diabet Ctr, Dianne Nunnally Hoppes Lab Diabet Complicat, Sect Vasc Cell Biol & Complicat, 1 Joslin Pl, Boston, MA 02215 USA. EM George.king@joslin.harvard.edu FU National Institutes of Health/NIDDK [DK053105]; Manpei Suzuki Diabetes Foundation; Kanzawa Medical Research Foundation; NOVARTIS Foundation, Japan; NIH [K08EY018677]; DERC [P30DK036836] FX This work is supported by a grant from the National Institutes of Health/NIDDK to GLK (DK053105). AM is the recipient of a Research Fellowship (Manpei Suzuki Diabetes Foundation, Kanzawa Medical Research Foundation, NOVARTIS Foundation, Japan). CRM is supported by NIH grant K08EY018677. This project has been supported by DERC P30DK036836. NR 41 TC 52 Z9 55 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD APR PY 2011 VL 79 IS 8 BP 883 EP 896 DI 10.1038/ki.2010.526 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA 742TN UT WOS:000288967500011 PM 21228767 ER PT J AU Juppner, H AF Jueppner, Harald TI Phosphate and FGF-23 SO KIDNEY INTERNATIONAL LA English DT Review DE FGF-23; phosphate and calcium homeostasis; PTH ID CHRONIC KIDNEY-DISEASE; GROWTH-FACTOR 23; HEMODIALYSIS-PATIENTS; PARATHYROID-HORMONE; DIETARY PHOSPHATE; VITAMIN-D; METABOLISM; FGF23; EXPRESSION; FIBROBLAST-GROWTH-FACTOR-23 AB Fibroblast growth factor (FGF)-23 is probably the most important regulator of serum phosphate and calcitriol (1,25(OH)(2)D(3)) levels. It is secreted by osteocytes and osteoblasts in response to oral phosphate loading or increased serum 1,25(OH)(2)D(3) levels. In human chronic kidney disease (CKD), plasma FGF-23 appears to be a sensitive biomarker of abnormal renal phosphate handling, as FGF-23 levels increase during early stages of kidney malfunction. In humans and animals with CKD, elevated FGF-23 levels increase fractional phosphate excretion, reduce serum phosphate levels, and reduce 1 alpha-hydroxylase activity, which reduces 1,25(OH)(2)D(3) formation thereby increasing parathyroid hormone (PTH) secretion. FGF-23 thus has a key adaptive role in maintaining normophosphatemia. Plasma FGF-23 continues to increase as CKD progresses, increasing by orders of magnitude in end-stage renal disease. At the same time, responsiveness to FGF-23 declines as the number of intact nephrons declines, which is associated with reduced expression of Klotho, the co-receptor required for FGF-23 signaling. In late CKD, FGF-23 cannot reduce serum phosphate levels, and abnormally high plasma FGF-23 concentrations appear to exert unwarranted off-target effects, including left ventricular hypertrophy, faster CKD progression, and premature mortality. Lowering serum phosphate levels through the use of oral phosphate binders and/or long-acting PTH agents may reduce FGF-23 levels in early CKD stages, thereby limiting off-target effects, which may improve patient outcomes. Kidney International (2011) 79 (Suppl 121), S24-S27; doi:10.1038/ki.2011.27; published online 23 February 2011 C1 [Jueppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Jueppner, Harald] Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA. [Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA USA. RP Juppner, H (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. EM hjueppner@partners.org NR 26 TC 48 Z9 49 U1 0 U2 15 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD APR PY 2011 VL 79 SU 121 BP S24 EP S27 DI 10.1038/ki.2011.27 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 745TQ UT WOS:000289189800006 ER PT J AU Marty, FM Ljungman, P Papanicolaou, GA Winston, DJ Chemaly, RF Strasfeld, L Young, JAH Rodriguez, T Maertens, J Schmitt, M Einsele, H Ferrant, A Lipton, JH Villano, SA Chen, HZ Boeckh, M AF Marty, Francisco M. Ljungman, Per Papanicolaou, Genovefa A. Winston, Drew J. Chemaly, Roy F. Strasfeld, Lynne Young, Jo-Anne H. Rodriguez, Tulio Maertens, Johan Schmitt, Michael Einsele, Hermann Ferrant, Augustin Lipton, Jeffrey H. Villano, Stephen A. Chen, Hongzi Boeckh, Michael CA Maribavir 1263-300 Clinical Study TI Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial SO LANCET INFECTIOUS DISEASES LA English DT Article ID BONE-MARROW-TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; GANCICLOVIR PROPHYLAXIS; PREEMPTIVE THERAPY; PP65 ANTIGENEMIA; INFECTION; VALACYCLOVIR; REACTIVATION; MULTICENTER; STRATEGIES AB Background Available drugs against cytomegalovirus have adverse effects that compromise their prophylactic use in recipients of allogeneic stem-cell transplants. We assessed the safety, tolerability, and antiviral activity of oral maribavir in such patients. Methods In this placebo-controlled, randomised, double-blind, multicentre phase 3 study, we enrolled adult patients recipient-seropositive or donor-seropositive for cytomegalovirus who had undergone allogeneic stem-cell transplantation. Patients were recruited from 90 centres in Canada, Europe, and the USA. After engraftment, patients were stratified by recipient cytomegalovirus serostatus and conditioning regimen (myeloablative or reduced-intensity) and assigned (2:1) by masked computer-generated randomisation sequence to receive maribavir 100 mg twice daily or placebo for up to 12 weeks, with weekly blood cytomegalovirus surveillance. If the virus was detected, administration of study drug was stopped and pre-emptive anticytomegalovirus treatment started. The primary endpoint was cytomegalovirus disease within 6 months of transplantation. Analysis was by intention-to-treat. This study is registered with ClinicalTrials.gov, NCT00411645. Findings Between December, 2006, and May, 2008,681 patients were enrolled and assigned to receive maribavir (454) or placebo (227). The incidence of cytomegalovirus disease within 6 months was 20 of 454 (4%) for the maribavir group and 11 of 227 (5%) for the placebo group (OR 0.90; 95% CI 0.42-1.92). During the 100 days following transplantation, cytomegalovirus infection rates as measured by pp65 antigenaemia were lower in the maribavir group (26.4%) than in the placebo group (34.8%; OR 0.67; 0.47-0-95), but not when measured by plasma cytomegalovirus DNA PCR (27-8% vs 30.4%; OR 0.88; 0.62-1.25), nor by initiation of treatment against cytomegalovirus (30.6% vs 37.4%; OR 0.73,0.52-1.03). Maribavir was well tolerated: most adverse events, including incident acute graft-versus-host disease and neutropenia, affected both groups equally, except for taste disturbance (15% maribavir, 6% placebo). Interpretation Compared with placebo, maribavir prophylaxis did not prevent cytomegalovirus disease when started after engraftment. Cytomegalovirus disease as a primary endpoint might not be sufficient to show improvements in cytomegalovirus prevention in recipients of allogeneic stem-cell transplants in the setting of pre-emptive antiviral treatment. Clinical and virological composite endpoints should be used in future trials. C1 [Marty, Francisco M.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Marty, Francisco M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ljungman, Per] Karolinska Inst, Stockholm, Sweden. [Papanicolaou, Genovefa A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Winston, Drew J.] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA. [Chemaly, Roy F.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Strasfeld, Lynne] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Young, Jo-Anne H.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Rodriguez, Tulio] Loyola Univ, Med Ctr, Maywood, IL 60153 USA. [Maertens, Johan] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium. [Schmitt, Michael] Univ Ulm, Ulm, Germany. [Einsele, Hermann] Univ Wurzburg, Wurzburg, Germany. [Ferrant, Augustin] Clin Univ St Luc, B-1200 Brussels, Belgium. [Lipton, Jeffrey H.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada. [Villano, Stephen A.; Chen, Hongzi] ViroPharma Inc, Exton, PA USA. [Boeckh, Michael] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. RP Marty, FM (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St,PBB A4, Boston, MA 02115 USA. EM fmarty@partners.org RI 2011, Secribsal/D-9425-2012; mapara, markus/A-2134-2013; Young, Jo-Anne/G-2617-2013; OI Young, Jo-Anne/0000-0003-4182-341X; Papanicolaou, Genovefa/0000-0002-2891-079X FU ViroPharma Incorporated; Chimerix; Vical; AiCuris; Cubist; Pfizer; Merck; Genzyme; Opal; Viral; GlaxoSmithKline; Enzon; Astellas; Schering-Plough; Roche; Genentech; Boehringer Ingelheim; Astellas Pharma Inc; Theraclone Sciences; Novartis FX SAV and HC are employees of ViroPharma Incorporated. All other authors received research funding from ViroPharma Incorporated in association with this clinical trial. FMM, PJ, GAP, DJW, RFC, JM, MS, HE, and MB have served as paid consultants for ViroPharma Incorporated. FM M has received research funding from Chimerix and Vical, and has served as a paid consultant for AiCuris and Cubist. PL has received research funding from Pfizer, Merck, and Genzyme, has served in the data safety monitoring board for studies sponsored by AiCuris and Opal, and has served as a paid consultant for Viral and GlaxoSmithKline. GAP has received research funding from Pfizer and Enzon, and has served as a paid consultant for Astellas, Schering-Plough, and Pfizer. DJW has received research funding from Chimerix. RFC has received research funding from AiCuris. JHY has received research funding front AiCuris and Chimerix. MB has received research funding from Roche, Chimerix, and Vical, and has served as a paid consultant for Chimerix, Vical, Genentech, Boehringer Ingelheim, Astellas Pharma Inc, Theraclone Sciences, and Novartis. NR 31 TC 105 Z9 110 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2011 VL 11 IS 4 BP 284 EP 292 DI 10.1016/S1473-3099(11)70024-X PG 9 WC Infectious Diseases SC Infectious Diseases GA 746VK UT WOS:000289275600016 PM 21414843 ER PT J AU Sun, HY Singh, N AF Sun, Hsin-Yun Singh, Nina TI Mucormycosis: its contemporary face and management strategies SO LANCET INFECTIOUS DISEASES LA English DT Review ID ORGAN TRANSPLANT RECIPIENTS; INVASIVE FUNGAL-INFECTIONS; LIPOSOMAL AMPHOTERICIN-B; COLONY-STIMULATING FACTOR; STEM-CELL TRANSPLANTATION; SURVEILLANCE NETWORK TRANSNET; CALCINEURIN-INHIBITOR AGENTS; VERSUS-HOST-DISEASE; CARE CANCER CENTER; LIPID COMPLEX AB Several countries have seen rising frequencies of mucormycosis among patients with haematological disorders, malignancies, or diabetes mellitus, and among transplant recipients. Growing numbers of immunocompromised hosts, widespread use of antifungal agents inactive against mucormycosis, or other unidentified factors, could be contributing to this situation. The predominant clinical manifestations of mucormycosis vary from host to host. Additionally, risk factors specific to different subgroups have been identified, such as leukaemia, allogeneic haemopoietic stem-cell transplant, voriconazole prophylaxis, diabetes, and malnutrition. We summarise the current state of knowledge of characteristics and risk factors and discuss topical developments in therapeutic methods and strategies in the management of mucormycosis. C1 [Sun, Hsin-Yun; Singh, Nina] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. [Sun, Hsin-Yun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan. [Sun, Hsin-Yun] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan. [Singh, Nina] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA. RP Singh, N (reprint author), VA Med Ctr, Infect Dis Sect, Univ Dr C, Pittsburgh, PA 15240 USA. EM nis5@pitt.edu OI SUN, HSIN-YUN/0000-0003-0074-7721 FU Pfizer FX NS has received support from Pfizer. H-YS declares that she has no conflicts of interest. NR 137 TC 47 Z9 49 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD APR PY 2011 VL 11 IS 4 BP 301 EP 311 PG 11 WC Infectious Diseases SC Infectious Diseases GA 746VK UT WOS:000289275600018 PM 21453871 ER PT J AU Graville, DJ Palmer, AD Andersen, PE Cohen, JI AF Graville, Donna J. Palmer, Andrew D. Andersen, Peter E. Cohen, James I. TI Determining the Efficacy and Cost-Effectiveness of the ActiValve: Results of a Long-Term Prospective Trial SO LARYNGOSCOPE LA English DT Article DE Candidiasis; costs and cost analysis; laryngeal neoplasms; laryngectomy; larynx; artificial prosthesis failure; prosthetic voice rehabilitation; treatment outcome; voice disorders ID SECONDARY TRACHEOESOPHAGEAL PUNCTURE; SALVAGE TOTAL LARYNGECTOMY; VOICE RESTORATION; ALARYNGEAL SPEECH; PROVOX ACTIVALVE; REHABILITATION; PROSTHESIS; COMPLICATIONS; REPLACEMENTS; EXPERIENCE AB Objectives/Hypothesis: To investigate 1) whether the Provox ActiValve results in increased device-life in individuals with below average device-life, 2) whether it is cost-effective, and 3) whether it has any impact on voice-related quality of life. Study Design: Prospective study. Methods: Individuals who experienced below-average tracheoesophageal prosthesis (TEP) life were studied. Results: Individuals with persistent below-average TEP life were enrolled in the study and underwent periodic re-evaluation. The majority (73%) experienced significant improvement as a result of use of the device. Those who continued to wear the device were followed for an average of 30.45 months (range, 14.70-43.49 months) and wore a total of 31 devices over this time. They demonstrated an average increase in device-life of more than 500%, going from an average of 1.93 months with a traditional indwelling device to 10.30 months with the ActiValve. The majority of individuals found that voicing with the ActiValve was either the same or better than with their previous indwelling TEP. Voice-related quality of life was not significantly different from that of a group of controls. Overall satisfaction with the device was high, and the majority would have chosen the ActiValve in the future. Overall, there were estimated to be cost savings to third-party payers through use of the ActiValve in this population. Conclusions: The ActiValve is effective in increasing device-life in selected patients who have failed conservative measures. Our protocol for use of the device requires individuals to meet several usage criteria before initial placement and to return for periodic monitoring. C1 [Graville, Donna J.; Palmer, Andrew D.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, NW Clin Voice & Swallowing, Portland, OR 97239 USA. [Cohen, James I.] Portland VA Med Ctr, Dept Otolaryngol Head & Neck Surg, Portland, OR USA. RP Graville, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, NW Clin Voice & Swallowing, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM graville@ohsu.edu NR 24 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD APR PY 2011 VL 121 IS 4 BP 769 EP 776 DI 10.1002/lary.21380 PG 8 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 740TS UT WOS:000288817900014 PM 21381042 ER PT J AU Shargorodsky, J AF Shargorodsky, Josef TI In Response to A Prospective Study of Cardiovascular Risk Factors and Incident Hearing Loss in Men SO LARYNGOSCOPE LA English DT Letter ID NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH C1 Massachusetts Eye & Ear Infirm, Channing Lab, Brigham & Womens Hosp, Boston, MA 02114 USA. RP Shargorodsky, J (reprint author), Massachusetts Eye & Ear Infirm, Channing Lab, Brigham & Womens Hosp, Boston, MA 02114 USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0023-852X J9 LARYNGOSCOPE JI Laryngoscope PD APR PY 2011 VL 121 IS 4 BP 895 EP 895 DI 10.1002/lary.21440 PG 1 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 740TS UT WOS:000288817900037 ER PT J AU Stone, ME AF Stone, Martha E. TI The Quest for the Cure.: The Science and Stories Behind the Next Generation of Medicines SO LIBRARY JOURNAL LA English DT Book Review C1 [Stone, Martha E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Stone, ME (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU REED BUSINESS INFORMATION PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 USA SN 0363-0277 J9 LIBR J JI Libr. J. PD APR 1 PY 2011 VL 136 IS 6 BP 101 EP 102 PG 2 WC Information Science & Library Science SC Information Science & Library Science GA 746EJ UT WOS:000289225200132 ER PT J AU Maciejewski, ML Weaver, EM Hebert, PL AF Maciejewski, Matthew L. Weaver, Emily M. Hebert, Paul L. TI Synonyms in Health Services Research Methodology SO MEDICAL CARE RESEARCH AND REVIEW LA English DT Article DE explanatory variables; quantitative methods; study design; synonyms; terminology ID SAMPLE SELECTION BIAS; INSTRUMENTAL VARIABLES; PROPENSITY SCORE; RISK-FACTORS; BODY-WEIGHT; OBESITY; MODELS; EXPENDITURES; PREDICTORS; OVERWEIGHT AB There are often multiple discipline-specific terms for a given statistical concept, which can sow confusion in multidisciplinary teams or study sections if researchers are not aware of the synonyms from other disciplines. This article incorporates synonyms and a uniform definition of terminology related to study designs, elements of an equation, and types of bias. Greater multidisciplinary collaboration and exploration of new methods can be facilitated by this methods thesaurus. C1 [Maciejewski, Matthew L.] Durham VA Med Ctr, Durham, NC 27705 USA. [Weaver, Emily M.] Univ N Carolina, Chapel Hill, NC USA. [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Maciejewski, ML (reprint author), Durham VA Med Ctr, 508 Fulton St, Durham, NC 27705 USA. EM mlm34@duke.edu FU AcademyHealth; Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs FX The authors disclosed that they received the following support for their research and/or authorship of this article: Funded by AcademyHealth and supported by the Office of Research and Development, Health Services Research and Development Service, Department of Veterans Affairs. NR 76 TC 2 Z9 2 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5587 EI 1552-6801 J9 MED CARE RES REV JI Med. Care Res. Rev. PD APR PY 2011 VL 68 IS 2 BP 156 EP 176 DI 10.1177/1077558710372809 PG 21 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 738OG UT WOS:000288648900002 PM 20675352 ER PT J AU Wang, TJ Larson, MG Vasan, RS Cheng, S Rhee, EP McCabe, E Lewis, GD Fox, CS Jacques, PF Fernandez, C O'Donnell, CJ Carr, SA Mootha, VK Florez, JC Souza, A Melander, O Clish, CB Gerszten, RE AF Wang, Thomas J. Larson, Martin G. Vasan, Ramachandran S. Cheng, Susan Rhee, Eugene P. McCabe, Elizabeth Lewis, Gregory D. Fox, Caroline S. Jacques, Paul F. Fernandez, Celine O'Donnell, Christopher J. Carr, Stephen A. Mootha, Vamsi K. Florez, Jose C. Souza, Amanda Melander, Olle Clish, Clary B. Gerszten, Robert E. TI Metabolite profiles and the risk of developing diabetes SO NATURE MEDICINE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; AMINO-ACID; INSULIN-RESISTANCE; LIFE-STYLE; SECRETION; PROTEIN; PREDICTION; MIXTURES; MELLITUS; OBESITY AB Emerging technologies allow the high-throughput profiling of metabolic status from a blood specimen (metabolomics). We investigated whether metabolite profiles could predict the development of diabetes. Among 2,422 normoglycemic individuals followed for 12 years, 201 developed diabetes. Amino acids, amines and other polar metabolites were profiled in baseline specimens by liquid chromatography-tandem mass spectrometry (LC-MS). Cases and controls were matched for age, body mass index and fasting glucose. Five branched-chain and aromatic amino acids had highly significant associations with future diabetes: isoleucine, leucine, valine, tyrosine and phenylalanine. A combination of three amino acids predicted future diabetes (with a more than fivefold higher risk for individuals in top quartile). The results were replicated in an independent, prospective cohort. These findings underscore the potential key role of amino acid metabolism early in the pathogenesis of diabetes and suggest that amino acid profiles could aid in diabetes risk assessment. C1 [Wang, Thomas J.; Rhee, Eugene P.; Lewis, Gregory D.; Gerszten, Robert E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02115 USA. [Wang, Thomas J.; Cheng, Susan; McCabe, Elizabeth; Lewis, Gregory D.; O'Donnell, Christopher J.; Gerszten, Robert E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. [Wang, Thomas J.; Larson, Martin G.; Vasan, Ramachandran S.; Cheng, Susan; McCabe, Elizabeth; Fox, Caroline S.; O'Donnell, Christopher J.] Boston Univ, Sch Med, Framingham, MA USA. [Wang, Thomas J.; Larson, Martin G.; Vasan, Ramachandran S.; Cheng, Susan; McCabe, Elizabeth; Fox, Caroline S.; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Boston Med Ctr, Cardiol Sect, Boston, MA 02118 USA. [Cheng, Susan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiol, Boston, MA USA. [Rhee, Eugene P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Renal, Boston, MA USA. [Rhee, Eugene P.; Lewis, Gregory D.; O'Donnell, Christopher J.; Carr, Stephen A.; Mootha, Vamsi K.; Florez, Jose C.; Souza, Amanda; Clish, Clary B.; Gerszten, Robert E.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Fox, Caroline S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Endocrinol, Boston, MA USA. [Fox, Caroline S.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA. [Jacques, Paul F.] Tufts Univ, Jean Mayer US Dept, Agr Human Nutr Res Ctr, Boston, MA 02111 USA. [Fernandez, Celine] Lund Univ, Dept Expt Med Sci, Malmo, Sweden. [Mootha, Vamsi K.; Florez, Jose C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Diabet Unit, Boston, MA USA. [Mootha, Vamsi K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Human Genet Res, Boston, MA USA. [Melander, Olle] Lund Univ, Dept Clin Sci, Malmo, Sweden. RP Wang, TJ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA 02115 USA. EM tjwang@partners.org; rgerszten@partners.org OI Larson, Martin/0000-0002-9631-1254; Ramachandran, Vasan/0000-0001-7357-5970 FU US National Institutes of Health [NO1-HC-25195, R01-DK-HL081572]; Donald W. Reynolds Foundation; Leducq Foundation; American Heart Association; Ellison Foundation; Massachusetts General Hospital; Doris Duke Charitable Foundation FX This work was supported by US National Institutes of Health contract NO1-HC-25195, R01-DK-HL081572, the Donald W. Reynolds Foundation, the Leducq Foundation and the American Heart Association. S. C. is also supported by an award from the Ellison Foundation. J.C.F. is also supported by the Massachusetts General Hospital and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. NR 31 TC 801 Z9 827 U1 49 U2 274 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1078-8956 J9 NAT MED JI Nat. Med. PD APR PY 2011 VL 17 IS 4 BP 448 EP U83 DI 10.1038/nm.2307 PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA 746KI UT WOS:000289245100035 PM 21423183 ER PT J AU Milbradt, AG Kulkarni, M Yi, TF Takeuchi, K Sun, ZYJ Luna, RE Selenko, P Naar, AM Wagner, G AF Milbradt, Alexander G. Kulkarni, Madhura Yi, Tingfang Takeuchi, Koh Sun, Zhen-Yu J. Luna, Rafael E. Selenko, Philipp Naeaer, Anders M. Wagner, Gerhard TI Structure of the VP16 transactivator target in the Mediator SO NATURE STRUCTURAL & MOLECULAR BIOLOGY LA English DT Article ID ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; MACROMOLECULAR STRUCTURE; NOESY SPECTRA; NMR STRUCTURE; PROTEIN; COMPLEX; COACTIVATOR; INTERACTS; HOMOLOGY AB The human Mediator coactivator complex interacts with many transcriptional activators and facilitates recruitment of RNA polymerase II to promote target gene transcription. The MED25 subunit is a critical target of the potent herpes simplex 1 viral transcriptional activator VP16. Here we determine the solution structure of the MED25 VP16-binding domain (VBD) and define its binding site for the N-terminal portion of the VP16 transactivation domain (TADn). A hydrophobic furrow, formed by a beta-barrel and two alpha-helices in MED25 VBD, interacts tightly with VP16 TADn. Mutations in this furrow prevent binding of VP16 TAD to MED25 VBD and interfere with the ability of overexpressed MED25 VBD to inhibit VP16-dependent transcriptional activation in vivo. This detailed molecular understanding of transactivation by the benchmark activator VP16 could provide important insights into viral and cellular gene activation mechanisms. C1 [Kulkarni, Madhura; Naeaer, Anders M.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA. [Milbradt, Alexander G.; Yi, Tingfang; Takeuchi, Koh; Sun, Zhen-Yu J.; Luna, Rafael E.; Selenko, Philipp; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Kulkarni, Madhura; Naeaer, Anders M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA. RP Naar, AM (reprint author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA. EM naar@helix.mgh.harvard.edu; gerhard_wagner@hms.harvard.edu FU Deutscher Akademischer Austausch Dienst; Human Frontier Science Program Organization [LT00686/2004-C]; US National Institutes of Health [CA127990, GM47467, EB002026, GM071449] FX We thank M. Oberer for initial NMR data collection, R. Rodriguez for critical advice on designing biochemical experiments, K. Edmonds for critical reading and Python script writing, S. Hiller and V. Orekhov for advice and assistance with nonlinear-sampling NMR data collection and processing, and H. Arthanari for advice on NMR data collection and manuscript editing. We are very grateful to M. Sattler and E. Vojnic of the Technical University of Munich for critical discussion of unpublished data. We are also thankful for H. C. Seou's assistance with DNA cloning procedures and A. Koglin for help with CNS calculations. A. G. M. was partially supported by a Deutscher Akademischer Austausch Dienst postdoctoral fellowship. P. S. was funded by the Human Frontier Science Program Organization long-term fellowship LT00686/2004-C. The work was supported by US National Institutes of Health grants CA127990 (G. W. and A.M.N.), GM47467 and EB002026 (G. W.) and GM071449 (A.M.N.). NR 46 TC 38 Z9 39 U1 0 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1545-9993 J9 NAT STRUCT MOL BIOL JI Nat. Struct. Mol. Biol. PD APR PY 2011 VL 18 IS 4 BP 410 EP U36 DI 10.1038/nsmb.1999 PG 7 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 745UZ UT WOS:000289195000003 PM 21378963 ER PT J AU Doupis, J Rahangdale, S Gnardellis, C Pena, SE Malhotra, A Veves, A AF Doupis, John Rahangdale, Shilpa Gnardellis, Charalambos Pena, Salvador E. Malhotra, Atul Veves, Aristidis TI Effects of Diabetes and Obesity on Vascular Reactivity, Inflammatory Cytokines, and Growth Factors SO OBESITY LA English DT Article ID ENDOTHELIAL FUNCTION; ADIPOSE-TISSUE; INSULIN-RESISTANCE; WOMEN; RISK; FLOW; OSTEOPROTEGERIN; VASODILATION; DYSFUNCTION; ACTIVATION AB We examined the influences of obesity and diabetes on endothelium-dependent and -independent vasodilation, inflammatory cytokines, and growth factors. We included 258 subjects, age 21-80 years in four groups matched for age and gender: 40 healthy nonobese (BMI < 30 kg.m(-2)) nondiabetic subjects, 76 nonobese diabetic patients, 37 obese (BMI > 30) nondiabetic subjects, and 105 obese (BMI > 30) diabetic patients. The flow-mediated dilation (FMD, endothelium-dependent) and nitroglycerin-induced dilation (NID, endothelium-independent) in the brachial artery, the vascular reactivity at the forearm skin and serum growth factors and inflammatory cytokines were measured. FMD was reduced in the nonobese diabetic patients, obese nondiabetic controls, and obese diabetic patients (P < 0.0001). NID was different among all four groups, being highest in the obese nondiabetic subjects and lowest in the obese diabetic patients (P < 0.0001). The resting skin forearm blood flow was reduced in the obese nondiabetic subjects (P < 0.01). Vascular endothelial growth factor (VEGF) was higher in the obese nondiabetic subjects (P < 0.05), tumor necrosis factor-a was higher in the obese diabetic patients (P < 0.0001) and C-reactive protein was higher in both the obese nondiabetic and diabetic subjects (P < 0.0001). Soluble intercellular adhesion molecule-1 was elevated in the two diabetic groups and the obese nondiabetic subjects (P < 0.05). We conclude that diabetes and obesity affect equally the endothelial cell function but the smooth muscle cell function is affected only by diabetes. In addition, the above findings may be related to differences that were observed in the growth factors and inflammatory cytokines. C1 [Doupis, John; Pena, Salvador E.; Veves, Aristidis] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Joslin Beth Israel Deaconess Foot Ctr,Microcircul, Boston, MA 02215 USA. [Rahangdale, Shilpa; Malhotra, Atul] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Gnardellis, Charalambos] Technol Educ Inst Messolonghi, Mesolongion, Greece. RP Veves, A (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Joslin Beth Israel Deaconess Foot Ctr,Microcircul, Boston, MA 02215 USA. EM aveves@caregroup.harvard.edu FU National Institutes of Health [R01-HL075678, R01 DK076937, R01-HL73146] FX This work was supported by National Institutes of Health Grants R01-HL075678, R01 DK076937, R01 DK076937 to A.V. and R01-HL73146 to A.M. NR 29 TC 27 Z9 28 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD APR PY 2011 VL 19 IS 4 BP 729 EP 735 DI 10.1038/oby.2010.193 PG 7 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 741XV UT WOS:000288901400011 PM 20829804 ER PT J AU Ramirez-Schrempp, D Vinci, RJ Liteplo, AS AF Ramirez-Schrempp, Daniela Vinci, Robert J. Liteplo, Andrew S. TI Bedside Ultrasound in the Diagnosis of Skull Fractures in the Pediatric Emergency Department SO PEDIATRIC EMERGENCY CARE LA English DT Article DE head trauma; bedside ultrasound; skull fracture ID HEAD-INJURED INFANTS; INTRACRANIAL INJURY; CHILDREN YOUNGER; REDUCTION; CANCER; TRAUMA; RISKS; CT AB Bedside ultrasound has become a diagnostic tool that is commonly used in the emergency department. In trained hands, it can be used to diagnose multiple pathologies. In this case series, we describe the utility of ultrasound in diagnosing skull fractures in pediatric patients with scalp hematomas. C1 [Ramirez-Schrempp, Daniela; Vinci, Robert J.] Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat,Div Pediat Emergency Med, Boston, MA 02118 USA. [Liteplo, Andrew S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med,Div Emergency Ultrasound, Boston, MA USA. RP Ramirez-Schrempp, D (reprint author), Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat,Div Pediat Emergency Med, 88 E Newton St,Vose 5, Boston, MA 02118 USA. EM daniela.ramirez-schrempp@bmc.org OI Vinci, Robert/0000-0002-2616-1879 NR 17 TC 8 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0749-5161 J9 PEDIATR EMERG CARE JI Pediatr. Emerg. Care PD APR PY 2011 VL 27 IS 4 BP 312 EP 314 DI 10.1097/PEC.0b013e3182131579 PG 3 WC Emergency Medicine; Pediatrics SC Emergency Medicine; Pediatrics GA 745UB UT WOS:000289191100014 PM 21467882 ER PT J AU Sittig, DF Singh, H AF Sittig, Dean F. Singh, Hardeep TI Legal, Ethical, and Financial Dilemmas in Electronic Health Record Adoption and Use SO PEDIATRICS LA English DT Article DE electronic health records; ethics; medical; confidentiality ID ORDER ENTRY SYSTEMS; INFORMATION-TECHNOLOGY; MISSED OPPORTUNITIES; CANCER DIAGNOSIS; MEDICAL-RECORD; PATIENT; CARE; LIABILITY; PRIVACY; ERRORS AB Electronic health records (EHRs) facilitate several innovations capable of reforming health care. Despite their promise, many currently unanswered legal, ethical, and financial questions threaten the widespread adoption and use of EHRs. Key legal dilemmas that must be addressed in the near-term pertain to the extent of clinicians' responsibilities for reviewing the entire computer-accessible clinical synopsis from multiple clinicians and institutions, the liabilities posed by overriding clinical decision support warnings and alerts, and mechanisms for clinicians to publically report potential EHR safety issues. Ethical dilemmas that need additional discussion relate to opt-out provisions that exclude patients from electronic record storage, sale of deidentified patient data by EHR vendors, adolescent control of access to their data, and use of electronic data repositories to redesign the nation's health care delivery and payment mechanisms on the basis of statistical analyses. Finally, one overwhelming financial question is who should pay for EHR implementation because most users and current owners of these systems will not receive the majority of benefits. The authors recommend that key stakeholders begin discussing these issues in a national forum. These actions can help identify and prioritize solutions to the key legal, ethical, and financial dilemmas discussed, so that widespread, safe, effective, interoperable EHRs can help transform health care. Pediatrics 2011; 127: e1042-e1047 C1 [Sittig, Dean F.] Univ Texas Houston, Sch Biomed Informat, Mem Hermann Ctr Healthcare Qual & Safety, Hlth Sci Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Houston Vet Affairs Hlth Serv Res & Dev, Ctr Excellence, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Ctr Inquiry Improve Outpatient Safety Effect Elec, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Sect Hlth Serv Res, Dept Med, Houston, TX 77030 USA. RP Sittig, DF (reprint author), Univ Texas Houston, Sch Biomed Informat, Mem Hermann Ctr Healthcare Qual & Safety, Hlth Sci Ctr, 6410 Fannin St,UTPB 1100-43, Houston, TX 77030 USA. EM dean.f.sittig@uth.tmc.edu FU National Institutes of Health (NIH) [K23CA125585]; National Library of Medicine [R01-LM006942]; Veterans Affairs National Center for Patient Safety; Agency for Healthcare Research and Quality; Houston Veterans Affairs Health Services Research and Development Center of Excellence [HFP90-020]; Office of the National Coordinator for Health Information Technology [10510592] FX Funded by the National Institutes of Health (NIH).; Dr Sittig is supported in part by National Library of Medicine grant R01-LM006942; Dr Singh is supported by a National Institutes of Health K23 career development award (K23CA125585), the Veterans Affairs National Center for Patient Safety, Agency for Healthcare Research and Quality, and in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020); and Drs Sittig and Singh are supported by a SHARP (Strategic Health IT Advanced Research Projects) contract from the Office of the National Coordinator for Health Information Technology (ONC #10510592). NR 64 TC 21 Z9 21 U1 0 U2 30 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD APR PY 2011 VL 127 IS 4 BP E1042 EP E1047 DI 10.1542/peds.2010-2184 PG 6 WC Pediatrics SC Pediatrics GA 744DQ UT WOS:000289074800025 PM 21422090 ER PT J AU Kasckow, J Ingram, E Brown, C Tew, JD Conner, KO Morse, JQ Haas, GL Reynolds, CF Oslin, DW AF Kasckow, John Ingram, Erin Brown, Charlotte Tew, James D. Conner, Kyaien O. Morse, Jennifer Q. Haas, Gretchen L. Reynolds, Charles F. Oslin, David W. TI Differences in Treatment Attitudes Between Depressed African-American and Caucasian Veterans in Primary Care SO PSYCHIATRIC SERVICES LA English DT Article ID MINOR DEPRESSION; SERVICE USE; ETHNICITY; RACE; SYMPTOMS; TRIAL AB Objectives: Depressive disorders are common, and it is important to understand the factors that contribute to racial disparities in depression treatment. This primary care study of veterans with subsyndromal depression examined two hypotheses: that African Americans would be less likely than Caucasians to believe that medication is beneficial in depression treatment and would be more likely to believe that counseling or psychotherapy is beneficial. Methods: Primary care patients with subsyndromal depression were referred to the Philadelphia Department of Veterans Affairs Behavioral Health Laboratory and asked about past experiences and attitudes toward depression treatment. Results: Among 111 African-American and 95 Caucasian participants, logistic regression analyses determined that African Americans were less likely to view medication as beneficial (odds ratio=.44). No racial differences were found in participants' attitude toward counseling or psychotherapy. Conclusions: The findings support the premise that clinicians treating patients with subsyndromal depressive syndromes should take into account racial differences in attitudes toward treatment. (Psychiatric Services 62: 426-429, 2011) C1 [Kasckow, John; Tew, James D.] Dept Vet Affairs VA Pittsburgh Hlth Care Syst, Behav Hlth Div, Pittsburgh, PA 15206 USA. [Kasckow, John; Tew, James D.] Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA 15260 USA. [Brown, Charlotte; Conner, Kyaien O.; Morse, Jennifer Q.; Haas, Gretchen L.; Reynolds, Charles F.] VA Pittsburgh Hlth Care Syst, MIRECC, Pittsburgh, PA USA. [Ingram, Erin; Oslin, David W.] Philadelphia VA Med Ctr, MIRECC, Philadelphia, PA USA. [Oslin, David W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Kasckow, J (reprint author), Dept Vet Affairs VA Pittsburgh Hlth Care Syst, Behav Hlth Div, Pittsburgh, PA 15206 USA. EM kasckowjw@upmc.edu RI Schueter, nicos/A-3625-2014 FU Mental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4, National Institutes of Health [P30-MH-71944, P60-MD00107]; University of Pittsburgh Medical Center Endowment in Geriatric Psychiatry; Robert Wood Johnson Foundation FX This research was supported by the Mental Illness Research, Education and Clinical Center, Veterans Integrated Service Network 4; grants P30-MH-71944 and P60-MD00107 to Dr. Reynolds from the National Institutes of Health; the University of Pittsburgh Medical Center Endowment in Geriatric Psychiatry (Dr. Reynolds); and the Robert Wood Johnson Foundation. The authors thank Steven Sayers, Ph.D., for letting them use the "perceived barriers" portion of the "watchful waiting medical care questions." NR 12 TC 8 Z9 8 U1 0 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR PY 2011 VL 62 IS 4 BP 426 EP 429 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 743ZM UT WOS:000289060200016 PM 21459996 ER PT J AU Harner, HM Hentz, PM Evangelista, MC AF Harner, Holly M. Hentz, Patricia M. Evangelista, Maria Carmela TI Grief Interrupted: The Experience of Loss Among Incarcerated Women SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE bereavement / grief; phenomenology; prisons, prisoners; women's health ID BEREAVEMENT AB Incarcerated women face a number of stressors apart from the actual incarceration. Nearly half of all women in prison experience the death of a loved one during their incarceration. Our purpose for this study was to explore the experience of grief and loss among incarcerated women using a phenomenological method. Our study approach followed van Manen's method of phenomenology and Munhall's description of existential lifeworlds. Our analysis revealed four existential lifeworlds: temporality: frozen in time; spatiality: no place, no space to grieve; corporeality: buried emotions; and relationality: never alone, yet feeling so lonely. The findings generated from this study can help mental health providers as well as correctional professionals develop policies and programs that facilitate the grief process of incarcerated women within the confines of imprisonment. C1 [Harner, Holly M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. [Hentz, Patricia M.] Univ Penn, Sch Nursing, Adv Practice Psychiat Mental Hlth Nursing Program, Philadelphia, PA 19104 USA. [Evangelista, Maria Carmela] Columbia Univ, Sch Nursing, New York, NY USA. RP Harner, HM (reprint author), Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Philadelphia, PA 19104 USA. EM harnerh@nursing.upenn.edu FU NINR NIH HHS [T32 NR007100] NR 35 TC 5 Z9 5 U1 1 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 J9 QUAL HEALTH RES JI Qual. Health Res. PD APR PY 2011 VL 21 IS 4 BP 454 EP 464 DI 10.1177/1049732310373257 PG 11 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA 738OY UT WOS:000288651900002 PM 20581074 ER PT J AU Chen, LLK Haneef, Z Dorsch, A Keselman, I Stern, JM AF Chen, Leo L. K. Haneef, Zulfi Dorsch, Andrew Keselman, Inna Stern, John M. TI Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam SO SEIZURE-EUROPEAN JOURNAL OF EPILEPSY LA English DT Article DE Lacosamide; Levetiracetam; Focal status epilepticus; Simple partial status epilepticus; Refractory status epilepticus; Epilepsia partialis continua AB Lacosamide has been reported to have been successfully used for non-convulsive status epilepticus after benzodiazepine failure, and convulsive status epilepticus after benzodiazepine and levetiracetam failure. We report a case of simple motor status epilepticus refractory to benzodiazepines and multiple anti-epileptic medications (AEDs) over 4 days. The addition of lacosamide in combination with existing levetiracetam aborted the continuous seizure with maintenance of seizure freedom through the most recent follow-up at 4 weeks. Published by Elsevier Ireland Ltd on behalf of British Epilepsy Association. C1 [Chen, Leo L. K.; Haneef, Zulfi; Dorsch, Andrew; Keselman, Inna; Stern, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Chen, Leo L. K.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. RP Chen, LLK (reprint author), 710 Westwood Plz Rm 1-240 Box 951769, Los Angeles, CA 90095 USA. EM llchen@mednet.ucla.edu FU UCB, Sepracor, Lundbeck; Cyberonics FX Dr. Stern has received support or served as a consultant for UCB, Sepracor, Lundbeck, and Cyberonics. The remaining authors report no conflicts of interest. NR 6 TC 17 Z9 17 U1 0 U2 3 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1059-1311 J9 SEIZURE-EUR J EPILEP JI Seizure PD APR PY 2011 VL 20 IS 3 BP 263 EP 265 DI 10.1016/j.seizure.2010.11.004 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 742GL UT WOS:000288929200014 PM 21109468 ER PT J AU Calvi, L Daniels, GH AF Calvi, Laura Daniels, Gilbert H. TI Acute Thyrotoxicosis Secondary to Destructive Thyroiditis Associated with Cardiac Catheterization Contrast Dye SO THYROID LA English DT Article ID IODINE-INDUCED THYROTOXICOSIS; AMIODARONE-INDUCED THYROTOXICOSIS; GRAVES-DISEASE; SUBACUTE THYROIDITIS; SUPPURATIVE THYROIDITIS; INDUCED HYPERTHYROIDISM; POSTPARTUM THYROIDITIS; SILENT THYROIDITIS; PAINFUL; ANGIOGRAPHY AB Background: Thyrotoxicosis caused by destructive thyroiditis is self-limited and results from the subacute release of preformed thyroid hormone. Common etiologies include painful subacute thyroiditis and silent (painless) subacute thyroiditis (including postpartum thyroiditis, amiodarone-associated destructive thyroiditis, and lithium-associated thyroiditis). Thyrotoxicosis commonly evolves slowly over a matter of weeks. Patient Findings: We report a unique case of severe thyrotoxicosis caused by acute-onset painful destructive thyroiditis in a patient who received large amounts of nonionic contrast dye Hexabrix (R) for cardiac catheterization. The results of thyroid function and physical examination were normal before the catheterization. Summary: The acute onset of severe thyroid pain, rapid increase in serum Free Thyroxine Index, and thyroglobulin concentrations with a triiodothyronine to free thyroxine index ratio of <20 to 1 were compatible with an acute onset destructive thyroiditis, likely related to direct toxicity from the iodinated contrast material. Conclusions: In light of the large number of patients who receive these contrast agents during cardiac catheterization, clinicians should be advised of this potentially serious complication, particularly in the setting of unstable cardiac disease. C1 [Daniels, Gilbert H.] Massachusetts Gen Hosp, Dept Med, Thyroid Unit, Boston, MA 02114 USA. [Calvi, Laura] Massachusetts Gen Hosp, Dept Med, Div Endocrine, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Daniels, GH (reprint author), Massachusetts Gen Hosp, Thyroid Unit ACC 730, Boston, MA 02114 USA. EM gdaniels@partners.org OI Calvi, Laura Maria/0000-0001-6969-239X NR 63 TC 7 Z9 7 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1050-7256 EI 1557-9077 J9 THYROID JI Thyroid PD APR PY 2011 VL 21 IS 4 BP 443 EP 449 DI 10.1089/thy.2010.0300 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 745TV UT WOS:000289190400015 PM 21385076 ER PT J AU Kontos, N AF Kontos, Nicholas TI Biomedicine-Menace or Straw Man? Reexamining the Biopsychosocial Argument SO ACADEMIC MEDICINE LA English DT Article ID PRIMARY-CARE-PHYSICIANS; MEDICAL-EDUCATION; MODEL; PATIENT; SCIENCE; HUMANISM; VIEW; PERSPECTIVE; PROFESSION; STRATEGIES AB Medical educators are responsible for training current and future generations of physicians; this includes the early and accurate identification of "struggling" medical trainees, which has implications for future training, practice, and success. The authors propose a theory-based framework, Self-Regulated Learning-Microanalytic Assessment and Training (SRL-MAT), that is specifically designed to foster individual medical trainee self-regulatory beliefs and behaviors, and thus provide a distinct method to assist medical trainees who struggle. The SRL-MAT is grounded in social-cognitive theory and research and makes a variety of important assumptions about learning and the essential techniques needed to evaluate trainee functioning. Two critical assumptions are that (1) self-efficacy beliefs are a key personal process affecting trainee behavior, and (2) trainee beliefs and behaviors are dynamic and fluid in nature and thus will often vary across educational contexts, as well as for specific tasks within those contexts. To address these assumptions, the SRL-MAT uses an emergent assessment approach called self-regulated learning microanalysis, a procedure that involves asking a series of temporally sequenced questions about specific regulatory processes as trainees engage in an authentic task or activity. The framework, which is grounded in a foundation of established educational research, is adaptable to practically any task that has a clear beginning and end. The authors believe this framework could make important contributions to traditional medical training assessment frameworks that have been used to identify and remediate strugglers. C1 [Kontos, Nicholas] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kontos, Nicholas] Harvard Univ, Sch Med, Boston, MA USA. RP Kontos, N (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Warren 605, Boston, MA 02114 USA. EM nkontos@partners.org FU Harvard Medical School; Cambridge Health Alliance FX This work was supported by the Eleanor and Miles Shore 50th Anniversary Fellowship Program for Scholars in Medicine via Harvard Medical School and Cambridge Health Alliance. NR 94 TC 11 Z9 11 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD APR PY 2011 VL 86 IS 4 BP 509 EP 515 DI 10.1097/ACM.0b013e31820e0d16 PG 7 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 742TA UT WOS:000288966200025 PM 21346496 ER PT J AU Johnson, BA Messing, RO Charness, ME Crabbe, JC Goldman, MS Harris, RA Kranzler, HR Mitchell, MC Nixon, SJ Riley, EP Schuckit, MA Sher, KJ Thomas, JD AF Johnson, Bankole A. Messing, Robert O. Charness, Michael E. Crabbe, John C. Goldman, Mark S. Harris, R. Adron Kranzler, Henry R. Mitchell, Mack C., Jr. Nixon, Sara Jo Riley, Edward P. Schuckit, Marc A. Sher, Kenneth J. Thomas, Jennifer D. TI Should the Reorganization of Addiction-Related Research Across All the National Institutes of Health Be Structural?-The Devil Is Truly in the Details SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Editorial Material DE National Institutes of Health ID USE DISORDERS; ALCOHOL; PREVALENCE; DEPENDENCE; BURDEN; ABUSE AB The recent proposal to dissolve the National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse and create a new institute for substance use, abuse, and addiction will require significant effort by the staff of both institutes, the Advisory Councils, and outside experts to overcome complex challenges that could threaten its success. Although integration of the grants portfolios can be achieved, harmonization of goals and policies related to legal use of alcohol versus illegal consumption of drugs will present serious challenges. Consolidating the infrastructure of the 2 existing institutes would entail avoiding encroachment on grant funding. A new institute for substance use, abuse, and addiction would require an enormous amount of cooperation from other institutes as the portfolios of research on alcohol, tobacco, and other drug abuse should logically be transferred to the new institute. In the near term, a structural reorganization would be less efficient and more costly than the individual institutes are currently. Increasing efficiency and reducing costs over time will necessitate careful strategic planning. Success in this difficult task would be made easier and less costly by first implementing carefully placed building blocks of increasing functional reorganization. The newly created institute should increase opportunities for specialization within disorders of addiction, attract new leadership, and build a novel strategic plan that will energize scientists and staff and incorporate ideas of stakeholders to advance the public good in preventing and treating alcohol, tobacco, and all addictions. Attention must be paid to the devil in the details. C1 [Johnson, Bankole A.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22908 USA. [Messing, Robert O.] Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, San Francisco, CA 94143 USA. [Charness, Michael E.] Boston Univ, Sch Med, Harvard Univ, Dept Neurol,VA Boston Healthcare Syst, Boston, MA 02118 USA. [Crabbe, John C.] Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97201 USA. [Crabbe, John C.] VA Med Ctr, Portland, OR USA. [Goldman, Mark S.] Univ S Florida, Dept Psychol, Alcohol & Subst Use Res Inst, Tampa, FL 33620 USA. [Harris, R. Adron] Univ Texas Austin, Sch Biol Sci, Waggoner Ctr Alcohol & Addict Res, Neurobiol Sect, Austin, TX 78712 USA. [Kranzler, Henry R.] Univ Penn, Dept Psychiat, Treatment Res Ctr, Philadelphia, PA 19104 USA. [Mitchell, Mack C., Jr.] Johns Hopkins Univ, Sch Med, Johns Hopkins Bayview Med Ctr, Dept Internal Med, Baltimore, MD USA. [Nixon, Sara Jo] Univ Florida, Dept Psychiat, Div Addict Res, Gainesville, FL 32611 USA. [Riley, Edward P.; Thomas, Jennifer D.] San Diego State Univ, Dept Psychol, Ctr Behav Teratol, San Diego, CA 92182 USA. [Schuckit, Marc A.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Sher, Kenneth J.] Univ Missouri, Dept Psychol Sci, Columbia, MO USA. [Sher, Kenneth J.] Midwest Alcoholism Res Ctr, Columbia, MO USA. RP Johnson, BA (reprint author), Univ Virginia, Dept Psychiat & Neurobehav Sci, POB 800623, Charlottesville, VA 22908 USA. EM bankolejohnson@virginia.edu RI Riley, Edward/E-6369-2013; Nixon, Sara/L-1369-2014; OI Riley, Edward/0000-0001-8747-891X; Nixon, Sara/0000-0003-1179-2851; Charness, Michael/0000-0002-3301-8966 FU NIAAA NIH HHS [U10 AA011776-10, R01 AA010522, R01 AA010522-16, R01 AA012964, R01 AA012964-06, R01 AA013964-05, R01 AA010522-12, R01 AA014628, U10 AA011776, R01 AA014628-04, K05 AA017242, P60 AA010760, R01 AA013964]; NIDA NIH HHS [R01 DA012191, R01 DA013002-04, R01 DA012969-04, R01 DA017296-04, R01 DA019804, R01 DA012191-09, R01 DA012969, R01 DA013002, R01 DA019804-04, R01 DA017296] NR 22 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD APR PY 2011 VL 35 IS 4 BP 572 EP 580 DI 10.1111/j.1530-0277.2011.01493.x PG 9 WC Substance Abuse SC Substance Abuse GA 741MF UT WOS:000288867100002 PM 21443646 ER PT J AU Fujitani, S George, WL Morgan, MA Nichols, S Murthy, AR AF Fujitani, Shigeki George, W. Lance Morgan, Margie A. Nichols, Stephen Murthy, A. Rekha TI Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Clostridium difficile; vancomycin-resistant Enterococcus; multidrug-resistant pathogens ID LIVER-TRANSPLANT CANDIDATES; INTENSIVE-CARE-UNIT; LONG-TERM-CARE; STAPHYLOCOCCUS-AUREUS; RISK-FACTORS; SURVEILLANCE; RECIPIENTS; DISEASE; COSTS AB Background: Vancomycin-resistant Enterococcus (VRE) colonization of the gastrointestinal tract shares similar risk factors with Clostridium difficile infection. We sought to elucidate the prevalence and risk factors of VRE colonization associated with C difficile infection. Methods: All adult inpatients with C difficile infection from July 2006 to October 2006 were prospectively evaluated. All C difficile toxin-positive stool samples were screened for detection of VRE. Risk factors for VRE colonization were compared in patients with C difficile infection with and without VRE colonization. Results: Of the 158 cases of C difficile infection evaluated, 88 (55.7%) involved VRE colonization. Independent risk factors for VRE colonization were admission from long-term care facilities (P = .013), dementia (P = .017), and hospitalization in the previous 2 months (P = .014). No statistically significant difference between C difficile infection cases with and without VRE colonization in terms of previous receipt (within 1 month) of antibiotics, including metronidazole and vancomycin, was found on multivariate analysis. C difficile infection cases with VRE colonization had a higher prevalence of coinfection with methicillin-resistant Staphylococcus aureus (P = .002) and Acinetobacter spp (P = .006). Conclusion: VRE colonization was associated with >50% of C difficile infection cases and with a higher rate of coinfection with multidrug-resistant pathogens. Given the high rate of C difficile infection associated with VRE colonization, active surveillance of VRE in patients with C difficile infection is reasonable in high-risk settings. C1 [Fujitani, Shigeki] St Marianna Univ Hosp, Dept Emergency & Crit Care Med, Miyamae Ku, Kanagawa, Japan. [Fujitani, Shigeki] Cedars Sinai Med Ctr, Div Infect Dis, Los Angeles, CA 90048 USA. [George, W. Lance] VA Greater Los Angeles Healthcare Syst, Infect Dis Sect, Los Angeles, CA USA. [Morgan, Margie A.; Nichols, Stephen; Murthy, A. Rekha] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Murthy, A. Rekha] Cedars Sinai Med Ctr, Dept Hosp Epidemiol, Los Angeles, CA 90048 USA. RP Fujitani, S (reprint author), St Marianna Univ Hosp, Dept Emergency & Crit Care Med, Miyamae Ku, 2-16-1 Sugao, Kanagawa, Japan. EM shigekifujitani@marianna-u.ac.jp FU Society's Young Fellow Award FX This study was presented at the 26th annual Infectious Diseases Society of America meeting, San Diego, California, October 5, 2007, and was awarded the Society's Young Fellow Award in 2007. NR 25 TC 11 Z9 11 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD APR PY 2011 VL 39 IS 3 BP 188 EP 193 DI 10.1016/j.ajic.2010.10.024 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 743ZQ UT WOS:000289060600004 PM 21458682 ER PT J AU Fitzgibbons, LN Puls, DL Mackay, K Forrest, GN AF Fitzgibbons, Lynn N. Puls, Darcy L. Mackay, Kimberly Forrest, Graeme N. TI Management of Gram-Positive Coccal Bacteremia and Hemodialysis SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Staphylococcus aureus; hemodialysis; Enterococcus; catheter-related bacteremia; dialysis access-related infection ID STAPHYLOCOCCUS-AUREUS BACTEREMIA; CATHETER-RELATED BACTEREMIA; BLOOD-STREAM INFECTIONS; COAGULASE-NEGATIVE STAPHYLOCOCCI; RANDOMIZED CONTROLLED-TRIAL; VANCOMYCIN-RESISTANT ENTEROCOCCI; RENAL REPLACEMENT THERAPY; ANTIBIOTIC-LOCK THERAPY; ENDOCARDITIS MERGED DATABASE; SINGLE-CENTER EXPERIENCE AB Gram-positive cocci are the most common cause of bloodstream infections in hemodialysis patients, with Staphylococcus aureus and coagulase-negative staphylococci causing most infections. Management of these infections often is complicated by limited vascular access options, as well as an increasing prevalence of drug-resistant bacteria in hemodialysis centers, including the emergence of strains of methicillin-resistant S aureus with vancomycin heteroresistance and increasing rates of vancomycin-resistant enterococci, both of which have limited antibiotic treatment options. This article describes the management of these infections based on the organism and its susceptibility profile, including catheter management, antibiotic lock therapies, and systemic antibiotic choices. Although coagulase-negative staphylococci bacteremia often may be managed with preservation of the catheter, antibiotic lock therapy, and intravenous antibiotics, this is rarely the case with S aureus bacteremia because of frequent relapse and the risk of complications, including endocarditis. Enterococcal bacteremia requires more individualization of care, but catheters are less likely to be salvaged, especially when vancomycin-resistant Enterococcus is the causative organism. Finally, strong infection control policies in the hemodialysis unit, conversion from catheter to arteriovenous access when possible, and appropriate use of antibiotics are essential factors in the prevention of these bloodstream infections. Am J Kidney Dis. 57(4):624-640. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Forrest, Graeme N.] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Fitzgibbons, Lynn N.; Puls, Darcy L.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Mackay, Kimberly] Portland VA Med Ctr, Dept Pharm, Portland, OR 97239 USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3701 SW US Vet Hosp Rd,P3-ID, Portland, OR 97239 USA. EM forrestg@ohsu.edu FU Cubist Pharmaceuticals Inc.; Pfizer Inc; Astellas Pharmaceuticals Inc FX Financial Disclosure: Dr Forrest had previously received research support and honoraria from Astellas Pharmaceuticals Inc (manufacturer of telavancin), Cubist Pharmaceuticals Inc (manufacturer of daptomycin), and Pfizer Inc (manufacturer of cefazolin and linezolid) between 2004 and 2007. He also had consulted for AdvanDx Inc (develops and markets PNA FISH tests) and Cepheid, which markets PCR-based in vitro diagnostic tests for S aureus. Currently, he receives research support from Cubist Pharmaceuticals Inc. The remaining authors report that they have no relevant financial interests. NR 173 TC 15 Z9 15 U1 0 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2011 VL 57 IS 4 BP 624 EP 640 DI 10.1053/j.ajkd.2010.12.013 PG 17 WC Urology & Nephrology SC Urology & Nephrology GA 738QN UT WOS:000288657100387 PM 21333430 ER PT J AU Jasti, S Quddus, A Sandhu, GS Garg, J Goldfarb-Rumyantzev, AS Williams, M AF Jasti, Sravan Quddus, Abdullah Sandhu, Gurprataap Singh Garg, Jalaj Goldfarb-Rumyantzev, Alexander S. Williams, Mark TI RACIAL DISPARITIES IN MORTALITY OF ESRD ON HEMODIALYSIS PATIENTS FROM USRDS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT 2011 Spring Clinical Meeting on National Kidney Foundation CY APR 26-30, 2011 CL Las Vegas, NV SP Natl Kidney Fdn C1 [Jasti, Sravan; Quddus, Abdullah] Joslin Diabet Ctr, Boston, MA 02215 USA. [Sandhu, Gurprataap Singh; Garg, Jalaj; Goldfarb-Rumyantzev, Alexander S.; Williams, Mark] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2011 VL 57 IS 4 MA 356 BP A105 EP A105 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 738QN UT WOS:000288657100357 ER PT J AU McMahon, GM Gibbons, FK Christopher, KB AF McMahon, Gearoid M. Gibbons, Fiona K. Christopher, Kenneth B. TI ASSOCIATION OF HYPERKALEMIA AT CRITICAL CARE INITIATION AND MORTALITY SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT 2011 Spring Clinical Meeting on National Kidney Foundation CY APR 26-30, 2011 CL Las Vegas, NV SP Natl Kidney Fdn C1 [McMahon, Gearoid M.; Gibbons, Fiona K.; Christopher, Kenneth B.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2011 VL 57 IS 4 MA 201 BP A67 EP A67 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 738QN UT WOS:000288657100202 ER PT J AU Provenzano, LF Piraino, B Steenkiste, A Sevick, MA AF Provenzano, Laura Ferreira Piraino, Beth Steenkiste, Ann Sevick, Mary Ann TI SODIUM INTAKE IN TYPE 2 DM IS HIGH SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT 2011 Spring Clinical Meeting on National Kidney Foundation CY APR 26-30, 2011 CL Las Vegas, NV SP Natl Kidney Fdn C1 [Provenzano, Laura Ferreira; Piraino, Beth; Sevick, Mary Ann] Univ Pittsburgh, Pittsburgh, PA USA. [Steenkiste, Ann; Sevick, Mary Ann] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2011 VL 57 IS 4 MA 91 BP A39 EP A39 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 738QN UT WOS:000288657100092 ER PT J AU Quddus, A Jasti, S Sandhu, GS Garg, J Goldfarb-Rumyantzev, AS Williams, M AF Quddus, Abdullah Jasti, Sravan Sandhu, Gurprataap Singh Garg, Jalaj Goldfarb-Rumyantzev, Alexander S. Williams, Mark TI GERIATRIC ESRD: COMPARISON BY AGE GROUP AND DEMOGRAPHICS SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Meeting Abstract CT 2011 Spring Clinical Meeting on National Kidney Foundation CY APR 26-30, 2011 CL Las Vegas, NV SP Natl Kidney Fdn C1 [Quddus, Abdullah; Jasti, Sravan] Joslin Diabet Ctr, Boston, MA 02215 USA. [Sandhu, Gurprataap Singh; Garg, Jalaj; Goldfarb-Rumyantzev, Alexander S.; Williams, Mark] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD APR PY 2011 VL 57 IS 4 MA 355 BP A105 EP A105 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 738QN UT WOS:000288657100356 ER PT J AU Baloul, SS Gerstenfeld, LC Morgan, EF Carvalho, RS Van Dyke, TE Kantarci, A AF Baloul, S. Susan Gerstenfeld, Louis C. Morgan, Elise F. Carvalho, Roberto S. Van Dyke, Thomas E. Kantarci, Alpdogan TI Mechanism of action and morphologic changes in the alveolar bone in response to selective alveolar decortication-facilitated tooth movement SO AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS LA English DT Article ID PERIODONTAL-LIGAMENT CELLS; ORTHODONTIC TREATMENT; RECEPTOR ACTIVATOR; TRABECULAR BONE; KAPPA-B; OSTEOPONTIN; RAT; EXPRESSION; SIALOPROTEIN; RESORPTION AB Background and Purpose: The aim of this study was to test if corticotomy-induced osteoclastogenesis and bone remodeling underlie orthodontic tooth movement and how selective alveolar decortication enhances the rate of tooth movement. Materials and Methods: A total of 114 Sprague-Dawley rats were included in 3 treatment groups: selective alveolar decortication alone (SADc); tooth movement alone (TM); and "combined" therapy (SADc + TM). Surgery was performed around the buccal and palatal aspects of the left maxillary first molar tooth and included 5 decortication dots on each side. Tooth movement was performed on the first molar using a 25-g Sentalloy spring. Measurements were done at baseline (day 0: no treatment rendered) and on days 3, 7, 14, 21, 28 and 42. Microcomputed tomography, Faxitron analyses, and quantitative real-time polymerase chain reaction (q-PCR) of expressed mRNAs were used to assess changes. Results: The combined group showed increased tooth movement (P = 0.04) at 7 days compared with the tooth movement group with significantly decreased bone volume (62%; P = 0.016) and bone mineral content (63%; P = 0.015). RNA markers of osteoclastic cells and key osteoclastic regulators (M-CSF [macrophage colony-stimulating factor], RANKL [receptor activator of nuclear factor kappa-B ligand], OPG [osteoprotegerin], calcitonin receptor [CTR], TRACP-5b [tartrate-resistant acid phosphatase 5b], cathepsin K [Ctsk]) all showed expression indicating increased osteoclastogenesis in the combined group. RNA markers of osteoblastic cells (OPN [osteopontin], BSP [bone sialoprotein], OCN [osteocalcin]) also showed increased anabolic activity in response to the combination of alveolar decortication and tooth movement. Conclusions: The data suggest that the alveolar decortication enhances the rate of tooth movement during the initial tooth displacement phase; this results in a coupled mechanism of bone resorption and bone formation during the earlier stages of treatment, and this mechanism underlies the rapid orthodontic tooth movement. (Am J Orthod Dentofacial Orthop 2011; 139:S83-101) C1 [Baloul, S. Susan; Carvalho, Roberto S.] Boston Univ, Goldman Sch Dent Med, Dept Orthodont & Dentofacial Orthoped, Boston, MA 02215 USA. [Gerstenfeld, Louis C.] Boston Univ, Sch Med, Boston, MA 02215 USA. [Van Dyke, Thomas E.; Kantarci, Alpdogan] Boston Univ, Goldman Sch Dent Med, Dept Periodontol & Oral Biol, Boston, MA 02215 USA. RP Kantarci, A (reprint author), Forsyth Inst, Dept Periodontol, 245 1st St, Cambridge, MA 02142 USA. EM AKantarci@forsyth.org RI Morgan, Elise/L-1706-2013; OI /0000-0002-0477-1211 NR 61 TC 42 Z9 45 U1 0 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0889-5406 J9 AM J ORTHOD DENTOFAC JI Am. J. Orthod. Dentofac. Orthop. PD APR PY 2011 VL 139 IS 4 SU 1 BP S83 EP S101 DI 10.1016/j.ajodo.2010.09.026 PG 19 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 739GG UT WOS:000288701900021 PM 21435543 ER PT J AU Hopson, KP Truelove, J Chun, J Wang, YM Waeber, C AF Hopson, Kristen Park Truelove, Jessica Chun, Jerold Wang, Yumei Waeber, Christian TI S1P activates store-operated calcium entry via receptor- and non-receptor-mediated pathways in vascular smooth muscle cells SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY LA English DT Article DE sphingosine-1-phosphate; STIM1; sphingosine-1-phosphate receptor; blood vessels ID SPHINGOSINE 1-PHOSPHATE; CA2+ INFLUX; SIGNALING PATHWAYS; CEREBRAL-ARTERIES; NULL MICE; IN-VIVO; SPHINGOSINE-1-PHOSPHATE; STIM1; CONSTRICTION; CHANNELS AB Hopson KP, Truelove J, Chun J, Wang Y, Waeber C. S1P activates store-operated calcium entry via receptor- and non-receptor-mediated pathways in vascular smooth muscle cells. Am J Physiol Cell Physiol 300: C919-C926, 2011. First published January 26, 2011; doi:10.1152/ajpcell.00350.2010.-Sphingosine-1-phosphate (S1P) has been shown to modulate intracellular Ca(2+) through both G protein-coupled receptors and intracellular second messenger pathways. The precise mechanism by which S1P activates store-operated calcium entry (SOCE) in vascular smooth muscle cells (VSMCs) has not been fully characterized. Because sphingolipids and Ca(2+) modulate proliferation and constriction in VSMCs, characterizing the connection between S1P and SOCE may provide novel therapeutic targets for vascular diseases. We found that S1P triggered STIM1 puncta formation and SOCE in VSMCs. S1P-activated SOCE was inhibited by 2-aminoethoxydiphenyl borate (2-APB), diethylstilbestrol (DES), and gadolinium (Gd(3+)). SOCE was observed in VSMCs lacking either S1P(2) or S1P(3) receptors, suggesting that S1P acts via multiple signaling pathways. Indeed, both extracellular and intracellular S1P application increased the total internal reflection fluorescence signal in VSMCs cells transfected with STIM1-yellow fluorescent protein in a 2-APB-sensitive manner. These data, and the fact that 2-APB, DES, and Gd(3+) all inhibited S1P-induced cerebral artery constriction, suggest that SOCE modulates S1P-induced vasoconstriction in vivo. Finally, S1P-induced SOCE was larger in proliferative than in contractile VSMCs, correlating with increases in STIM1, Orai1, S1P(1), and S1P(3) receptor mRNA. These data demonstrate that S1P can act through both receptors and a novel intracellular pathway to activate SOCE. Because S1P-induced SOCE contributes to vessel constriction and is increased in proliferative VSMCs, it is likely that S1P/SOCE signaling in proliferative VSMCs may play a role in vascular dysfunction such as atherosclerosis and diabetes. C1 [Hopson, Kristen Park; Truelove, Jessica; Wang, Yumei; Waeber, Christian] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA. [Chun, Jerold] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA. RP Waeber, C (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Stroke & Neurovasc Regulat Lab, CNY149 Rm 6403,149 13th St, Charlestown, MA 02129 USA. EM waeber@helix.mgh.harvard.edu RI Waeber, Christian/A-8333-2009 OI Waeber, Christian/0000-0001-6078-0027 FU National Institutes of Health [R01NS049263, P01NS055104, 5T32AG00277, DA019674, DC009505] FX This study was supported by National Institutes of Health Grants R01NS049263 and P01NS055104 (to C. Waeber), 5T32AG00277 (to K. P. Hopson), and DA019674 and DC009505 (to J. Chun). NR 59 TC 17 Z9 17 U1 1 U2 4 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6143 J9 AM J PHYSIOL-CELL PH JI Am. J. Physiol.-Cell Physiol. PD APR PY 2011 VL 300 IS 4 BP C919 EP C926 DI 10.1152/ajpcell.00350.2010 PG 8 WC Cell Biology; Physiology SC Cell Biology; Physiology GA 741VS UT WOS:000288894200020 PM 21270296 ER PT J AU Ge, RL Mo, VY Januzzi, JL Jin, GA Yang, YZ Han, SF Wood, MJ Levine, BD AF Ge, Ri-Li Mo, Vivian Y. Januzzi, James L. Jin, Guan Yang, Yinzhong Han, Shufen Wood, Malissa J. Levine, Benjamin D. TI B-type natriuretic peptide, vascular endothelial growth factor, endothelin-1, and nitric oxide synthase in chronic mountain sickness SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE altitude; pulmonary hypertension; echocardiography ID PULMONARY ARTERIAL-HYPERTENSION; HIGH-ALTITUDE NATIVES; HEMOGLOBIN CONCENTRATION; ADAPTATION; HIGHLANDERS; EXPOSURE; TIBETANS; HYPOXIA; DISEASE; HEART AB Ge RL, Mo VY, Januzzi JL, Jin G, Yang Y, Han S, Wood MJ, Levine BD. B-type natriuretic peptide, vascular endothelial growth factor, endothelin-1, and nitric oxide synthase in chronic mountain sickness. Am J Physiol Heart Circ Physiol 300: H1427-H1433, 2011. First published January 7, 2011; doi:10.1152/ajpheart.00366.2010.-The pathogenesis of chronic mountain sickness (CMS) may involve vasoactive peptides. The aim of this study was to investigate associations between CMS and levels of B-type natriuretic peptide (BNP), vascular endothelial growth factor (VEGF), endothelin-1 (ET-1), and endothelial nitric oxide synthase (eNOS). A total of 24 patients with CMS and 50 control subjects residing at 4,300 m participated in this study. Mean pulmonary arterial pressure (mPAP) was measured by echocardiography. Serum BNP, VEGF, ET-1, and eNOS were measured. Receiver operator characteristic curves to assess the balance of sensitivity and specificity for CMS were constructed. As a result, patients with CMS had significantly greater mPAP compared with controls and had lower arterial O(2) saturation (Sa(O2)). Both BNP and ET-1 correlated positively with mPAP and negatively with Sa(O2), whereas serum VEGF levels were inversely correlated with Sa(O2); eNOS correlated negatively with mPAP and positively with Sa(O2). Median concentrations of BNP were greater in patients with CMS compared with those without CMS: 369 pg/ml [interquartile range (IQR) = 336-431] vs. 243 pg/ml (IQR = 216-279); P < 0.001. Similarly, concentrations of VEGF [543 pg/ml (IQR = 446-546) vs. 243 pg/ml (IQR = 216-279); P < 0.001] and ET-1 [14.7 pg/ml (IQR = 12.5-17.9) vs. 11.1 pg/ml (IQR = 8.7-13.9); P = 0.05] were higher in those with CMS compared with those without, whereas eNOS levels were lower in those with CMS [8.90 pg/ml (IQR 7.59-10.8) vs. 11.2 pg/ml (9.13-13.1); P < 0.001]. The areas under the receiver operator characteristic curves for diagnosis of CMS were 0.91, 0.93, 0.77, and 0.74 for BNP, VEGF, ET-1, and eNOS, respectively. In age-and biomarker-adjusted logistic regression, BNP and VEGF were positively predictive of CMS, whereas eNOS was inversely predictive. In conclusion, severe chronic hypoxemia and consequent pulmonary hypertension in patients with CMS may stimulate release of natriuretic peptides and angiogenic cytokines. These vasoactive peptides may play an important role in the pathogenesis and clinical expression of CMS and may indicate potential prognostic factors in CMS that could serve as targets for therapeutic trials or clinical decision making. C1 [Ge, Ri-Li; Jin, Guan; Yang, Yinzhong; Han, Shufen] Qinghai Univ, Res Ctr High Altitude Med, Xining, Qinghai, Peoples R China. [Mo, Vivian Y.; Levine, Benjamin D.] Univ Texas SW Med Ctr Dallas, Inst Exercise & Environm Med, Dallas, TX 75390 USA. [Mo, Vivian Y.; Levine, Benjamin D.] Univ Texas SW Med Ctr Dallas, Div Cardiol, Dallas, TX 75390 USA. [Januzzi, James L.; Wood, Malissa J.] Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Div Cardiol, Boston, MA 02114 USA. RP Ge, RL (reprint author), Qinghai Univ, Res Ctr High Altitude Med, 16 Rd, Xining, Qinghai, Peoples R China. EM geriligao@hotmail.com FU National Basic Research Program of China [2006CB504100]; National Natural Science Foundation of China [30393133]; Balson Scholar Fund FX This work supported by National Basic Research Program of China Grant 2006CB504100 and National Natural Science Foundation of China Grant 30393133. J. L. Januzzi is supported in part by the Balson Scholar Fund. NR 30 TC 16 Z9 18 U1 3 U2 13 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD APR PY 2011 VL 300 IS 4 BP H1427 EP H1433 DI 10.1152/ajpheart.00366.2010 PG 7 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 742KR UT WOS:000288942300031 PM 21217075 ER PT J AU Nagasaka, Y Buys, ES Spagnolli, E Steinbicker, AU Hayton, SR Rauwerdink, KM Brouckaert, P Zapol, WM Bloch, KD AF Nagasaka, Yasuko Buys, Emmanuel S. Spagnolli, Ester Steinbicker, Andrea U. Hayton, Sarah R. Rauwerdink, Kristen M. Brouckaert, Peter Zapol, Warren M. Bloch, Kenneth D. TI Soluble guanylate cyclase-alpha(1) is required for the cardioprotective effects of inhaled nitric oxide SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE guanosine 3 ',5 '-cyclic monophosphate; cardiac ischemia-reperfusion injury ID ISCHEMIA-REPERFUSION INJURY; DEPENDENT PROTEIN-KINASE; MYOCARDIAL-ISCHEMIA; CYCLIC-GMP; ALPHA(1) SUBUNIT; S-NITROSYLATION; KNOCKOUT MICE; MURINE MODEL; IN-VITRO; CYCLASE AB Nagasaka Y, Buys ES, Spagnolli E, Steinbicker AU, Hayton SR, Rauwerdink KM, Brouckaert P, Zapol WM, Bloch KD. Soluble guanylate cyclase-alpha(1) is required for the cardioprotective effects of inhaled nitric oxide. Am J Physiol Heart Circ Physiol 300: H1477-H1483, 2011. First published January 21, 2011; doi:10.1152/ajpheart.00948.2010.-Reperfusion injury limits the benefits of revascularization in the treatment of myocardial infarction (MI). Breathing nitric oxide (NO) reduces cardiac ischemia-reperfusion injury in animal models; however, the signaling pathways by which inhaled NO confers cardioprotection remain uncertain. The objective of this study was to learn whether inhaled NO reduces cardiac ischemia-reperfusion injury by activating the cGMP-generating enzyme, soluble guanylate cyclase (sGC), and to investigate whether bone marrow (BM)derived cells participate in the sGC-mediated cardioprotective effects of inhaled NO. Wild-type (WT) mice and mice deficient in the sGC alpha(1)-subunit (sGC alpha(-/-)(1) mice) were subjected to cardiac ischemia for 1 h, followed by 24 h of reperfusion. During ischemia and for the first 10 min of reperfusion, mice were ventilated with oxygen or with oxygen supplemented with NO (80 parts per million). The ratio of MI size to area at risk (MI/AAR) did not differ in WT and sGC alpha(-/-)(1) mice that did not breathe NO. Breathing NO decreased MI/AAR in WT mice (41%, P = 0.002) but not in sGC alpha(-/-)(1) mice (7%, P = not significant). BM transplantation was performed to restore WT BM-derived cells to sGC alpha(-/-)(1) mice. Breathing NO decreased MI/AAR in sGC alpha(-/-)(1) mice carrying WT BM (39%, P = 0.031). In conclusion, these results demonstrate that a global deficiency of sGC alpha(1) does not alter the degree of cardiac ischemia-reperfusion injury in mice. The cardioprotective effects of inhaled NO require the presence of sGC alpha(1). Moreover, our studies suggest that BM-derived cells are key mediators of the ability of NO to reduce cardiac ischemia-reperfusion injury. C1 [Nagasaka, Yasuko; Buys, Emmanuel S.; Spagnolli, Ester; Steinbicker, Andrea U.; Hayton, Sarah R.; Rauwerdink, Kristen M.; Zapol, Warren M.; Bloch, Kenneth D.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, Boston, MA 02114 USA. [Nagasaka, Yasuko; Buys, Emmanuel S.; Spagnolli, Ester; Steinbicker, Andrea U.; Hayton, Sarah R.; Rauwerdink, Kristen M.; Zapol, Warren M.; Bloch, Kenneth D.] Harvard Univ, Sch Med, Boston, MA USA. [Brouckaert, Peter] Univ Ghent, Dept Mol Biomed Res, Flanders Inst Biotechnol, B-9000 Ghent, Belgium. [Brouckaert, Peter] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium. RP Nagasaka, Y (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, 55 Fruit St, Boston, MA 02114 USA. EM ynagasaka@partners.org FU Harvard Medical School; American Heart Association; Fonds Wetenschappelijk Onderzoek-Vlaanderen; University of Gent; Ikaria FX This study was supported by Eleanor & Miles Shore Fellowship grants from Harvard Medical School (to Y. Nagasaka and E. S. Buys) and a Scientist Development Grant from the American Heart Association (to E. S. Buys). Research of P. Brouckaert was supported by grants from the Fonds Wetenschappelijk Onderzoek-Vlaanderen and the University of Gent Special Research Fund (Bijzonder Onderzoeksfonds-Geconcerteerde Onderzoeksacties).; W. M. Zapol and K. D. Bloch have obtained patents relating to the use of inhaled nitric oxide. These patents are assigned to Massachusetts General Hospital, which has licensed them to Ikaria and Linde Gas Therapeutics (Lidingo, Sweden). W. M. Zapol receives royalties, and K. D. Bloch has received research grants from Ikaria. NR 56 TC 13 Z9 13 U1 0 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD APR PY 2011 VL 300 IS 4 BP H1477 EP H1483 DI 10.1152/ajpheart.00948.2010 PG 7 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 742KR UT WOS:000288942300037 PM 21257915 ER PT J AU Figlewicz, DP Bennett-Jay, JL Kittleson, S Sipols, AJ Zavosh, A AF Figlewicz, Dianne P. Bennett-Jay, Jennifer L. Kittleson, Sepideh Sipols, Alfred J. Zavosh, Aryana TI Sucrose self-administration and CNS activation in the rat SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE food reward; c-Fos; hypothalamus ID VENTRAL TEGMENTAL AREA; BETA-ENDORPHIN LEVELS; NUCLEUS-ACCUMBENS; FOOD-INTAKE; PARAVENTRICULAR NUCLEUS; LATERAL HYPOTHALAMUS; STRIA TERMINALIS; REWARD CIRCUITRY; CHRONIC STRESS; BED NUCLEUS AB We have previously reported that administration of insulin into the arcuate nucleus of the hypothalamus decreases motivation for sucrose, assessed by a self-administration task, in rats. Because the pattern of central nervous system (CNS) activation in association with sucrose self-administration has not been evaluated, in the present study, we measured expression of c-Fos as an index of neuronal activation. We trained rats to bar-press for sucrose, according to a fixed-ratio (FR) or progressive-ratio (PR) schedule and mapped expression of c-Fos immunoreactivity in the CNS, compared with c-Fos expression in handled controls. We observed a unique expression of c-Fos in the medial hypothalamus (the arcuate, paraventricular, retrochiasmatic, dorsomedial, and ventromedial nuclei) in association with the onset of PR performance, and expression of c-Fos in the lateral hypothalamus and the bed nucleus of stria terminalis in association with the onset of FR performance. c-Fos expression was increased in the nucleus accumbens of both FR and PR rats. Our study emphasizes the importance of both hypothalamic energy homeostasis circuitry and limbic circuitry in the performance of a food reward task. Given the role of the medial hypothalamus in regulation of energy balance, our study suggests that this circuitry may contribute to reward regulation within the larger context of energy homeostasis. C1 [Figlewicz, Dianne P.; Kittleson, Sepideh] VA Puget Sound Hlth Care Syst 151, Seattle, WA USA. [Figlewicz, Dianne P.; Bennett-Jay, Jennifer L.; Zavosh, Aryana] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Sipols, Alfred J.] Univ Latvia, Fac Med, Riga, Latvia. [Sipols, Alfred J.] Univ Latvia, Inst Expt & Clin Med, Riga, Latvia. RP Figlewicz, DP (reprint author), VA Puget Sound Hlth Care Syst, Metab Endocrinol 151, 1660 So Columbian Way, Seattle, WA 98108 USA. EM latte@u.washington.edu FU National Institutes of Health [DK40963]; Latvian Council of Science [04.1116] FX This research was supported by National Institutes of Health Grant DK40963. Dr. Dianne Figlewicz Lattemann is a Senior Research Career Scientist, Biomedical Laboratory Research Program, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington. Dr. Sipols is supported by Latvian Council of Science Grant 04.1116. NR 50 TC 14 Z9 14 U1 1 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD APR PY 2011 VL 300 IS 4 BP R876 EP R884 DI 10.1152/ajpregu.00655.2010 PG 9 WC Physiology SC Physiology GA 744GH UT WOS:000289082400011 PM 21307361 ER PT J AU Gvilia, I Suntsova, N Angara, B McGinty, D Szymusiak, R AF Gvilia, Irma Suntsova, Natalia Angara, Bryan McGinty, Dennis Szymusiak, Ronald TI Maturation of sleep homeostasis in developing rats: a role for preoptic area neurons SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY LA English DT Article DE postnatal development; sleep-promoting systems; sleep homeostasis; preoptic hypothalamus ID C-FOS EXPRESSION; WAKING DISCHARGE PATTERNS; SLOW-WAVE SLEEP; SUPRACHIASMATIC NUCLEUS; INFANT RATS; PARAVENTRICULAR NUCLEUS; GALANINERGIC NEURONS; HYPOTHALAMUS; DEPRIVATION; INNERVATION AB The present study evaluated the hypothesis that developmental changes in hypothalamic sleep-regulatory neuronal circuits contribute to the maturation of sleep homeostasis in rats during the fourth postnatal week. In a longitudinal study, we quantified electrographic measures of sleep during baseline and in response to sleep deprivation (SD) on postnatal days 21/29 (P21/29) and P22/30 (experiment 1). During 24-h baseline recordings on P21, total sleep time (TST) during the light and dark phases did not differ significantly. On P29, TST during the light phase was significantly higher than during the dark phase. Mean duration of non-rapid-eye-movement (NREM) sleep bouts was significantly longer on P29 vs. P21, indicating improved sleep consolidation. On both P22 and P30, rats exhibited increased NREM sleep amounts and NREM electroencephalogram delta power during recovery sleep (RS) compared with baseline. Increased NREM sleep bout length during RS was observed only on P30. In experiment 2, we quantified activity of GABAergic neurons in median preoptic nucleus (MnPN) and ventrolateral preoptic area (VLPO) during SD and RS in separate groups of P22 and P30 rats using c-Fos and glutamic acid decarboxylase (GAD) immunohistochemistry. In P22 rats, numbers of Fos(+)GAD(+) neurons in VLPO did not differ among experimental conditions. In P30 rats, Fos(+)GAD(+) counts in VLPO were elevated during RS. MnPN neuronal activity was state-dependent in P22 rats, but Fos(+)GAD(+) cell counts were higher in P30 rats. These findings support the hypothesis that functional emergence of preoptic sleep-regulatory neurons contributes to the maturation of sleep homeostasis in the developing rat brain. C1 Vet Affairs Greater Los Angeles, Healthcare system, Res Serv 151A3, North Hills, CA 91344 USA. [Gvilia, Irma; Szymusiak, Ronald] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Suntsova, Natalia; McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Gvilia, Irma] Ilia State Univ, Tbilisi, Rep of Georgia. RP Gvilia, I (reprint author), Vet Affairs Greater Los Angeles, Healthcare system, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91344 USA. EM magvilia@hotmail.com FU Department of Veterans Affairs, National Institute of Mental Health [MH-63323, GNSF/ST09-722-6-274] FX This work was supported by the Department of Veterans Affairs, National Institute of Mental Health Grant MH-63323, and GNSF/ST09-722-6-274. NR 50 TC 9 Z9 9 U1 1 U2 8 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6119 J9 AM J PHYSIOL-REG I JI Am. J. Physiol.-Regul. Integr. Comp. Physiol. PD APR PY 2011 VL 300 IS 4 BP R885 EP R894 DI 10.1152/ajpregu.00727.2010 PG 10 WC Physiology SC Physiology GA 744GH UT WOS:000289082400012 PM 21325650 ER PT J AU Subramanya, AR Welling, PA AF Subramanya, Arohan R. Welling, Paul A. TI Toward an understanding of hypertension resistance SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article ID BLOOD-PRESSURE; ASSOCIATION; MECHANISMS C1 [Subramanya, Arohan R.] Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Sch Med, Pittsburgh, PA 15261 USA. [Subramanya, Arohan R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Welling, Paul A.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA. RP Subramanya, AR (reprint author), Univ Pittsburgh, Dept Med, Renal Electrolyte Div, Sch Med, S828A Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM ars129@pitt.edu FU NIDDK NIH HHS [R01DK63049, RC1DK086817, R01 DK054231, DK084566, R01DK54231] NR 11 TC 3 Z9 3 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2011 VL 300 IS 4 BP F838 EP F839 DI 10.1152/ajprenal.00078.2011 PG 2 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 744LF UT WOS:000289095300004 PM 21325498 ER PT J AU Flanagan, J Gray, PK Hahn, N Hayes, J Myers, LJ Carney-Doebbeling, C Sweeney, CJ AF Flanagan, J. Gray, P. Kathryn Hahn, N. Hayes, J. Myers, L. J. Carney-Doebbeling, C. Sweeney, C. J. TI Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer SO ANNALS OF ONCOLOGY LA English DT Article DE hormonal therapy; metabolic syndrome; prostate cancer; resistance ID CARDIOVASCULAR-DISEASE; RISK; METFORMIN; OBESITY; MEN; TESTOSTERONE; INFLAMMATION; LEPTIN; COHORT; ADULTS AB Background: Metabolic syndrome (MS) is a set of risk factors that includes obesity and insulin resistance and has been implicated in the development of prostate cancer. Its impact on androgen deprivation therapy (ADT) efficacy has not been studied. Patients and methods: Retrospective study of prostate cancer patients seen from 1998 to 2005 in a medical oncology clinic. MS, as defined by modified Adult Treatment Panel III criteria, was assessed at the time of initiation of ADT. The study end points were time to prostate-specific antigen (PSA) progression and overall survival (OS) from time of starting ADT. Results: Eighty-two patients treated with ADT and data to assess for presence of MS were identified. Median age in men with and without MS was 70 years and 49% of the patients evaluated met criteria for MS. Median time to PSA progression for patients with MS was 16 versus 36 months without MS (P = 0.003). The median OS for patients with MS was 36.5 months after commencing ADT compared with 46.7 months for those patients without MS (P = 0.061). Conclusions: This preliminary data suggest that MS is a risk factor for earlier development of castration-resistant prostate cancer and support the need for a prospective evaluation of this finding. C1 [Hayes, J.; Sweeney, C. J.] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA. [Flanagan, J.; Hahn, N.; Carney-Doebbeling, C.; Sweeney, C. J.] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN USA. [Flanagan, J.] Kansas City Canc Ctr, US Oncol, Kansas City, MO USA. [Gray, P. Kathryn] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Myers, L. J.] Indiana Univ Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN USA. [Myers, L. J.] Roudebush VA Med Ctr, Ctr Excellence Implementing Evidence Based Practi, Hlth Serv Res & Dev, Indianapolis, IN USA. [Carney-Doebbeling, C.] Regenstrief Inst Inc, Indianapolis, IN USA. RP Sweeney, CJ (reprint author), Dana Farber Canc Inst, Dept Med, 44 Binney St,Suite D1230, Boston, MA 02115 USA. EM christopher_sweeney@dfci.harvard.edu NR 40 TC 22 Z9 23 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD APR PY 2011 VL 22 IS 4 BP 801 EP 807 DI 10.1093/annonc/mdq443 PG 7 WC Oncology SC Oncology GA 745JH UT WOS:000289161200008 PM 20880998 ER PT J AU Barnes, JA LaCasce, AS Zukotynski, K Israel, D Feng, Y Neuberg, D Toomey, CE Hochberg, EP Canellos, GP Abramson, JS AF Barnes, J. A. LaCasce, A. S. Zukotynski, K. Israel, D. Feng, Y. Neuberg, D. Toomey, C. E. Hochberg, E. P. Canellos, G. P. Abramson, J. S. TI End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma SO ANNALS OF ONCOLOGY LA English DT Article DE FDG-PET; HL; Hodgkin's disease; interim; prognosis; staging ID POSITRON-EMISSION-TOMOGRAPHY; RADIATION-THERAPY; FDG-PET; CHEMOTHERAPY; DISEASE; ABVD; PROGRESSION; RELAPSE; CYCLES; TRIALS AB Background: Early interim positron emission tomography (PET) scans appear powerfully predictive of outcome in Hodgkin's lymphoma (HL), particularly in advanced-stage disease where it has been predominantly studied. The prognostic value of interim PET in limited-stage patients with nonbulky disease has not been well established. Patients and methods: Ninety-six patients with nonbulky limited-stage HL were identified who had interim and end-of-treatment PET scans. Response rate, overall survival (OS), and progression-free survival (PFS) were calculated. Results: Four-year PFS and OS for the entire cohort were 88% and 97%, respectively. Interim PET did not predict outcome, with PFS in positive and negative patients 87% versus 91% (P = 0.57), respectively. End-of-treatment PET result was predictive of outcome, with PFS of 94% in end PET-negative patients versus 54% in end PET-positive patients (P < 0.0001). Four-year OS was 100% in end PET-negative patients and 84% in end PET-positive patients (P < 0.0001). Conclusions: Interim PET scans were not predictive of outcome, compared with scans carried out at completion of therapy. End-of-treatment PET was highly predictive of PFS and OS, regardless of interim PET result. In this low-risk patient population, even patients with interim positive PET scans show a favorable prognosis. C1 [Barnes, J. A.; Toomey, C. E.; Hochberg, E. P.; Abramson, J. S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA 02114 USA. [Barnes, J. A.; LaCasce, A. S.; Hochberg, E. P.; Canellos, G. P.; Abramson, J. S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [LaCasce, A. S.; Canellos, G. P.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Zukotynski, K.; Israel, D.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA. [Zukotynski, K.; Israel, D.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Feng, Y.; Neuberg, D.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Neuberg, D.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Abramson, JS (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Yawkey 7B,55 Fruit St, Boston, MA 02114 USA. EM jabramson@partners.org NR 19 TC 42 Z9 44 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD APR PY 2011 VL 22 IS 4 BP 910 EP 915 DI 10.1093/annonc/mdq549 PG 6 WC Oncology SC Oncology GA 745JH UT WOS:000289161200024 PM 20952598 ER PT J AU Khimani, NB Ng, AK Chen, YH Catalano, P Silver, B Mauch, PM AF Khimani, N. B. Ng, A. K. Chen, Y. H. Catalano, P. Silver, B. Mauch, P. M. TI Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy SO ANNALS OF ONCOLOGY LA English DT Article DE CNS; high-dose methotrexate; lymphoma; radiotherapy; salvage ID PRIMARY CNS LYMPHOMA; WHOLE-BRAIN RADIOTHERAPY; NON-HODGKINS-LYMPHOMA; DEFERRED RADIOTHERAPY; ONCOLOGY-GROUP; FOLLOW-UP; PHASE-II; RADIATION; THERAPY; SURVIVAL AB Background: To assess the efficacy of salvage radiation therapy (RT) in patients with recurrent/refractory primary or secondary central nervous system lymphoma (CNSL) after initial methotrexate (MTX)-based chemotherapy and to identify factors associated with treatment outcome. Patients and methods: We reviewed 36 patients with primary or secondary CNSL who relapsed after MTX therapy and received salvage RT. Primary end points were radiographic response and overall survival (OS). Results: After salvage RT, 18 patients (50%) achieved a complete radiographic response and 6 (17%) achieved a partial response, for an overall response rate of 67% [95% confidence interval (CI) 49% to 81%]. The median OS from start of salvage RT was 11.7 months (range: 0.6-94.7). Patients treated with less than five cycles of MTX before failure had a significantly shorter OS than patients who received five or more cycles (9.2 months versus not reached, P = 0.04). Patients with CNSL limited to brain only had a significantly longer OS than patients with disease in the brain and other central nervous system locations (16.5 versus 4.5 months, P = 0.01). Conclusion: Salvage RT is effective for patients with recurrent/refractory primary or secondary CNSL after initial MTX therapy. Having received five or more cycles of MTX before failure and CNSL limited to the brain at relapse are associated with longer OS. C1 [Khimani, N. B.; Ng, A. K.; Silver, B.; Mauch, P. M.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Chen, Y. H.; Catalano, P.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Khimani, N. B.] Harvard Univ, Sch Med, Boston, MA USA. RP Ng, AK (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St,ASB1-L2, Boston, MA 02115 USA. EM ang@lroc.harvard.edu NR 16 TC 5 Z9 5 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 J9 ANN ONCOL JI Ann. Oncol. PD APR PY 2011 VL 22 IS 4 BP 979 EP 984 DI 10.1093/annonc/mdq548 PG 6 WC Oncology SC Oncology GA 745JH UT WOS:000289161200034 PM 20935059 ER PT J AU Lanuti, M DeDelva, P Morse, CR Wright, CD Wain, JC Gaissert, HA Donahue, DM Mathisen, DJ AF Lanuti, Michael DeDelva, Pierre Morse, Christopher R. Wright, Cameron D. Wain, John C. Gaissert, Henning A. Donahue, Dean M. Mathisen, Douglas J. TI Management of Delayed Gastric Emptying After Esophagectomy With Endoscopic Balloon Dilatation of the Pylorus SO ANNALS OF THORACIC SURGERY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; INTRATHORACIC STOMACH; NO DRAINAGE; PYLOROPLASTY; REPLACEMENT; ESOPHAGUS; PYLOROMYOTOMY; CANCER AB Background. This study seeks to evaluate the use of postoperative pyloric balloon dilatation for delayed gastric emptying after esophageal substitution with gastric conduit. Methods. A total of 436 patients underwent esophagectomy with gastric conduit from 2002 to 2009. All approaches to esophagectomy were included except patients with alternative reconstruction or emergent esophagectomy. Gastric conduit diameter, anastomotic location, and mediastinal route were variable. Gastric outlet obstruction (GOO) was strictly defined to include patients with clinical and radiographic delayed gastric emptying requiring intervention. Results. Gastric outlet obstruction was found in 22% (98 of 436) of patients who underwent esophagectomy. Pyloromytomy was performed on 52% (51 of 98) of these patients and employed in 41% (179 of 436) of patients in the entire cohort. GOO was present in 28% (51 of 179) of patients who underwent a pyloric drainage procedure compared with 18% (47 of 257) of patients with no pyloric intervention (p = 0.01). Endoscopic balloon dilatation of the pylorus was used to treat 39% (38 of 98) of patients with delayed gastric emptying yielding a 95% (36 of 98) success rate. Pyloric dilatations were performed with controlled radial expansion esophageal balloon dilators (range, 10 to 20 mm). The remaining patients were treated conservatively with prokinetics, nasogastric drainage, or observation. Nasogastric drainage was employed for 7.4 +/- 4.4 days in patients with GOO and 6.8 +/- 4.0 days in asymptomatic patients (p = 0.15). Neoadjuvant chemoradiotherapy did not contribute to increased incidence of GOO. There was a significant difference in postoperative pneumonia (18.4% vs 10.6%, p = 0.05) and median length of hospital stay (12 +/- 16 vs 10 +/- 9 days, p < 0.0001) in patients with GOO versus normal emptying. Conclusions. Delayed gastric emptying after esophageal substitution with gastric conduit can be adequately treated with balloon dilatation of the pylorus despite an operative drainage procedure. (Ann Thorac Surg 2011;91:1019-24) (C) 2011 by The Society of Thoracic Surgeons C1 [Lanuti, Michael] Harvard Univ, Massachusetts Gen Hosp, Div Thorac Surg, Sch Med, Boston, MA 01748 USA. RP Lanuti, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Thorac Surg, Sch Med, 55 Fruit St,Blake 1570, Boston, MA 01748 USA. EM mlanuti@partners.org FU Division of Thoracic Surgery at the Massachusetts General Hospital FX Financial support for this study was provided by the Division of Thoracic Surgery at the Massachusetts General Hospital. We would like to acknowledge our data manager and research coordinator, Sheila Cann and Diane Davies, respectively, for their diligence and dedication toward compiling and maintaining the Thoracic Surgery Database. NR 20 TC 9 Z9 11 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD APR PY 2011 VL 91 IS 4 BP 1019 EP 1024 DI 10.1016/j.athoracsur.2010.12.055 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 740IL UT WOS:000288785800015 PM 21292237 ER PT J AU Stappenbeck, TS Rioux, JD Mizoguchi, A Saitoh, T Huett, A Darfeuille-Michaud, A Wileman, T Mizushima, N Carding, S Akira, S Parkes, M Xavier, RJ AF Stappenbeck, Thaddeus S. Rioux, John D. Mizoguchi, Atsushi Saitoh, Tatsuya Huett, Alan Darfeuille-Michaud, Arlette Wileman, Tom Mizushima, Noboru Carding, Simon Akira, Shizuo Parkes, Miles Xavier, Ramnik J. TI Crohn disease A current perspective on genetics, autophagy and immunity SO AUTOPHAGY LA English DT Review DE Atg16L1; dendritic cells; gastrointestinal; genome-wide association; gut microbiota; inflammatory bowel diseases; IRGM; Paneth cell; ulcerative colitis ID INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; INTESTINAL EPITHELIAL-CELLS; INVASIVE ESCHERICHIA-COLI; AVIUM SUBSPECIES PARATUBERCULOSIS; PROTEIN CONJUGATION SYSTEM; ALPHA-DEFENSIN EXPRESSION; TNBS-INDUCED COLITIS; TOLL-LIKE RECEPTORS; HUMAN FECAL SAMPLES AB Crohn disease (CD) is a chronic and debilitating inflammatory condition of the gastrointestinal tract. 1 Prevalence in western populations is 100-150/100,000 and somewhat higher in Ashkenazi Jews. Peak incidence is in early adult life, although any age can be affected and a majority of affected individuals progress to relapsing and chronic disease. Medical treatments rely significantly on empirical corticosteroid therapy and immunosuppression, and intestinal resectional surgery is frequently required. Thus, 80% of patients with CD come to surgery for refractory disease or complications. It is hoped that an improved understanding of pathogenic mechanisms, for example by studying the genetic basis of CD and other forms of inflammatory bowel diseases (IBD), will lead to improved therapies and possibly preventative strategies in individuals identified as being at risk. C1 [Stappenbeck, Thaddeus S.] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA. [Stappenbeck, Thaddeus S.] Washington Univ, Sch Med, Dept Immunol, St Louis, MO 63110 USA. [Rioux, John D.] Univ Montreal, Montreal, PQ H3C 3J7, Canada. [Rioux, John D.] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada. [Mizoguchi, Atsushi] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Mizoguchi, Atsushi] Harvard Univ, Sch Med, Boston, MA USA. [Saitoh, Tatsuya; Akira, Shizuo] Osaka Univ, Host Def Lab, WPI Immunol Frontier Res Ctr, Suita, Osaka, Japan. [Saitoh, Tatsuya; Akira, Shizuo] Dept Host Def Osaka, Osaka, Japan. [Darfeuille-Michaud, Arlette] Univ Auvergne, Auvergne, France. [Wileman, Tom] Univ E Anglia, Sch Med, Fac Hlth, E Anglia, Norfolk, England. [Mizushima, Noboru] Tokyo Med & Dent Univ, Dept Physiol & Cell Biol, Bunkyo Ku, Tokyo, Japan. [Carding, Simon] Inst Food Res, Norwich NR4 7UA, Norfolk, England. [Parkes, Miles] Univ Cambridge, Addenbrookes Hosp, IBD Res Grp, Cambridge CB2 2QQ, England. RP Stappenbeck, TS (reprint author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA. EM stappenb@wustl.edu; john.rioux@inflammgen.org; amizoguchi@partners.org; tatsuya@biken.osaka-u.ac.jp; a.huett@ccib.mgh.harvard.edu; darfeuille-michaud@u-clermont1.fr; T.Wileman@uea.ac.uk; nmizu.phy2@tmd.ac.jp; simon.carding@bbsrc.ac.uk; akira@biken.osaka-u.ac.jp; miles.parkes@addenbrookes.nhs.uk; xavier@molbio.mgh.harvard.edu RI Akira, Shizuo/C-3134-2009; Mizushima, Noboru/C-3635-2009; Rioux, John/A-9599-2015 OI Mizushima, Noboru/0000-0002-6258-6444; Rioux, John/0000-0001-7560-8326 FU Biotechnology and Biological Sciences Research Council [BB/E018521/1, BB/F012861/1] NR 252 TC 44 Z9 46 U1 0 U2 9 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8627 J9 AUTOPHAGY JI Autophagy PD APR PY 2011 VL 7 IS 4 BP 355 EP 374 DI 10.4161/auto.7.4.13074 PG 20 WC Cell Biology SC Cell Biology GA 744DW UT WOS:000289075600002 PM 20729636 ER PT J AU Bishop, MR Alyea, EP Cairo, MS Falkenburg, JHF June, CH Kroger, N Little, RF Miller, JS Pavletic, SZ Porter, DL Riddell, SR van Besien, K Wayne, AS Weisdorf, DJ Wu, RS Giralt, S AF Bishop, Michael R. Alyea, Edwin P., III Cairo, Mitchell S. Falkenburg, J. H. Frederik June, Carl H. Kroeger, Nicolaus Little, Richard F. Miller, Jeffrey S. Pavletic, Steven Z. Porter, David L. Riddell, Stanley R. van Besien, Koen Wayne, Alan S. Weisdorf, Daniel J. Wu, Roy S. Giralt, Sergio TI National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Graft-versus-tumor; Minimal residual disease; Donor lymphocyte infusion ID BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; DONOR LEUKOCYTE TRANSFUSIONS; CHRONIC MYELOID-LEUKEMIA; DISEASE-SPECIFIC METHODS; GRAFT-VERSUS-LEUKEMIA; HOST DISEASE; IMMUNOTHERAPY; CYCLOPHOSPHAMIDE; CHEMOTHERAPY AB The National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation was organized and convened to identify, prioritize, and coordinate future research activities related to relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Each of the Workshop's 6 Working Committees has published individual reports of ongoing basic, translational, and clinical research and recommended areas for future research related to the areas of relapse biology, epidemiology, prevention, and treatment. This document summarizes each committee's recommendations and suggests 3 major initiatives for a coordinated research effort to address the problem of relapse after allo-HSCT: (1) to establish multicenter correlative and clinical trial networks for basic/translational, epidemiologic, and clinical research; (2) to establish a network of biorepositories for the collection of samples before and after allo-HSCT to aid in laboratory and clinical studies; and (3) to further refine, implement, and study the Workshop-proposed definitions for disease-specific response and relapse and recommendations for monitoring of minimal residual disease. These recommendations, in coordination with ongoing research initiatives and transplantation organizations, provide a research framework to rapidly and efficiently address the significant problem of relapse after allo-HSCT. Biol Blood Marrow Transplant 17: 443-454 (2011) Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation C1 [Bishop, Michael R.; Pavletic, Steven Z.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA. [Bishop, Michael R.; Alyea, Edwin P., III; Cairo, Mitchell S.; Falkenburg, J. H. Frederik; June, Carl H.; Kroeger, Nicolaus; Little, Richard F.; Miller, Jeffrey S.; Pavletic, Steven Z.; Porter, David L.; Riddell, Stanley R.; van Besien, Koen; Wayne, Alan S.; Weisdorf, Daniel J.; Wu, Roy S.; Giralt, Sergio] NCI, Organizing Comm, Bethesda, MD 20892 USA. [Alyea, Edwin P., III] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Cairo, Mitchell S.] Columbia Univ, Dept Pediat, Morgan Stanley Childrens Hosp New York Presbyteri, New York, NY 10027 USA. [Falkenburg, J. H. Frederik] Leiden Univ, Dept Hematol, Med Ctr, Leiden, Netherlands. [June, Carl H.; Porter, David L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Kroeger, Nicolaus] Univ Hosp Hamburg Eppendorf, Ctr Stem Cell Transplantat, D-52425 Hamburg, Germany. [Little, Richard F.; Wu, Roy S.] NCI, Canc Therapy Evaluat Program, NIH, Bethesda, MD 20892 USA. [Miller, Jeffrey S.; Weisdorf, Daniel J.] Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA. [Riddell, Stanley R.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [van Besien, Koen] Univ Chicago, Sch Med, Dept Med, Chicago, IL 60637 USA. [Wayne, Alan S.] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA. [Giralt, Sergio] Mem Sloan Kettering Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapies, New York, NY 10021 USA. RP Bishop, MR (reprint author), NCI, Expt Transplantat & Immunol Branch, NIH, 10 Ctr Dr,CRC Room 4-3152, Bethesda, MD 20892 USA. EM mbishop@mail.nih.gov RI van Besien, Koen/G-4221-2012; OI van Besien, Koen/0000-0002-8164-6211; Miller, Jeffrey S/0000-0002-0339-4944 FU Center for Cancer Research, National Cancer Institute FX This work was supported by the Center for Cancer Research, National Cancer Institute, Intramural Research Program. NR 34 TC 27 Z9 28 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD APR PY 2011 VL 17 IS 4 BP 443 EP 454 DI 10.1016/j.bbmt.2010.12.713 PG 12 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 742DJ UT WOS:000288920000001 PM 21224011 ER PT J AU Espinosa-Aguilar, L Green, JS Forrest, GN Ball, ED Maziarz, RT Strasfeld, L Taplitz, RA AF Espinosa-Aguilar, Luis Green, Jaime S. Forrest, Graeme N. Ball, Edward D. Maziarz, Richard T. Strasfeld, Lynne Taplitz, Randy Allison TI Novel H1N1 Influenza in Hematopoietic Stem Cell Transplantation Recipients: Two Centers' Experiences SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE 2009 Influenza virus; Immunocompromised; Lower respiratory tract infection ID RESPIRATORY VIRUS-INFECTIONS; CRITICALLY-ILL PATIENTS; NEW-YORK-CITY; A H1N1; HEMATOLOGIC MALIGNANCIES; MARROW-TRANSPLANTATION; HOSPITALIZED-PATIENTS; CLINICAL-FEATURES; ANTIVIRAL THERAPY; ADULT RECIPIENTS AB Respiratory virus infections, such as influenza A, cause significant morbidity in hematopoietic stem cell transplantation (HSCT) recipients. The clinical characteristics and impact of infection with the novel H1N1 virus in this patient population is not yet well defined, however. HSCT recipients diagnosed with proven or probable H1N1 during the 2009 pandemic were identified and charts were retrospectively reviewed with analysis of clinical descriptions, risk factors, diagnosis, treatments, and outcomes. Twenty-seven patients from two medical centers were identified. Fever and cough were the most common presenting symptoms. The incidence of influenza lower respiratory tract infection (LRTI) was 52% (14/27). Compared with patients with LRTI, those with influenza upper respiratory tract infection (URTI) were more likely to have a classic influenza-like syndrome. Compared to patients with URTI, those with LRTI were started on antiviral therapy significantly later after symptom onset (3.0 days vs 6.58 days after onset of symptoms; P = .03; 95% confidence interval [CI], 0.29-6.8). Overall influenza-related 30-day mortality was 22% (6/27), and that in patients with LRTI was 43% (6/14). Chronic steroid use (>= 20 mg/day of prednisone equivalent) at the time of presentation was associated with LRTI (P = .006) and mortality (P = .003) on univariate analysis. Five cases were hospital-acquired. In this first season of the novel H1N1 pandemic, infection in HSCT often presented as an atypical severe illness with a high incidence of LRTI and high mortality. Biol Blood Marrow Transplant 17: 566-573 (2011) (C) 2011 American Society for Blood and Marrow Transplantation C1 [Green, Jaime S.; Ball, Edward D.; Taplitz, Randy Allison] Univ Calif San Diego, La Jolla, CA 92093 USA. [Espinosa-Aguilar, Luis; Maziarz, Richard T.; Strasfeld, Lynne] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Forrest, Graeme N.] Portland VA Med Ctr, Portland, OR USA. RP Taplitz, RA (reprint author), Univ Calif San Diego, 3855 Hlth Sci Dr,0960, La Jolla, CA 92093 USA. EM rtaplitz@ucsd.edu NR 41 TC 16 Z9 16 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD APR PY 2011 VL 17 IS 4 BP 566 EP 573 DI 10.1016/j.bbmt.2010.07.018 PG 8 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 742DJ UT WOS:000288920000014 PM 20708084 ER PT J AU Baron, R Ferrari, S Russell, RGG AF Baron, Roland Ferrari, Serge Russell, R. Graham G. TI Denosumab and bisphosphonates: Different mechanisms of action and effects SO BONE LA English DT Review DE Bisphosphonates; Denosumab; Osteoclast; Osteoporosis; RANK ligand ID COLONY-STIMULATING FACTOR; SUPPRESSED BONE TURNOVER; FRACTURE INTERVENTION TRIAL; CALCIUM PHOSPHATE CRYSTALS; HUMAN MONOCLONAL-ANTIBODY; OSTEOBLAST-LIKE CELLS; KAPPA-B LIGAND; POSTMENOPAUSAL WOMEN; IN-VIVO; TRABECULAR BONE AB To treat systemic bone loss as in osteoporosis and/or focal osteolysis as in rheumatoid arthritis or periodontal disease, most approaches target the osteoclasts, the cells that resorb bone. Bisphosphonates are currently the most widely used antiresorptive therapies. They act by binding the mineral component of bone and interfere with the action of osteoclasts. The nitrogen-containing bisphosphonates, such as alendronate, act as inhibitors of farnesyl-pyrophosphate synthase, which leads to inhibition of the prenylation of many intracellular signaling proteins. The discovery of RANKL and the essential role of RANK signaling in osteoclast differentiation, activity and survival have led to the development of denosumab, a fully human monoclonal antibody. Denosumab acts by binding to and inhibiting RANKL, leading to the loss of osteoclasts from bone surfaces. In phase 3 clinical studies, denosumab was shown to significantly reduce vertebral, nonvertebral and hip fractures compared with placebo and increase areal BMD compared with alendronate. In this review, we suggest that the key pharmacological differences between denosumab and the bisphosphonates reside in the distribution of the drugs within bone and their effects on precursors and mature osteoclasts. This may explain differences in the degree and rapidity of reduction of bone resorption, their potential differential effects on trabecular and cortical bone, and the reversibility of their actions. (C) 2010 Elsevier Inc. All rights reserved. C1 [Russell, R. Graham G.] Univ Oxford, Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Nuffield Orthopaed Ctr,Botnar Res Ctr, Oxford OX3 7LD, England. [Baron, Roland] Harvard Univ, Dept Med, Sch Med, Endocrine Unit,Massachusetts Gen Hosp, Boston, MA 02115 USA. [Baron, Roland] Harvard Univ, Dept Oral Med Infect & Immun, Sch Dent Med, Boston, MA 02115 USA. [Ferrari, Serge] Hop Univ, Serv Malad Osseuses, Dept Rehabil & Geriatrie, CH-1211 Geneva 14, Switzerland. [Ferrari, Serge] Fac Med Geneva, CH-1211 Geneva 14, Switzerland. [Russell, R. Graham G.] Univ Sheffield, Mellanby Ctr Bone Res, Dept Human Metab, Sch Med, Sheffield S10 2RX, S Yorkshire, England. RP Russell, RGG (reprint author), Univ Oxford, Inst Musculoskeletal Sci, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Nuffield Orthopaed Ctr,Botnar Res Ctr, Oxford OX3 7LD, England. EM Roland_Baron@hsdm.harvard.edu; Serge.Ferrari@unige.ch; graham.russell@ndorms.ox.ac.uk FU Amgen (Europe) GmbH; GlaxoSmithKline FX The authors drafted and wrote this review article. Writing/editing assistance was also provided by Reza Sayeed (Bioscript Stirling Ltd.) funded by Amgen (Europe) GmbH and GlaxoSmithKline. Graphics support was provided by Jennifer Keysor (Surfmedia). Thanks also to Antonia Panayi, Robert Stad, and Nathalie Franchimont of Amgen (Europe) GmbH and Paul Kostenuik and Cesar Libanati of Amgen Inc for providing many helpful discussions and comments during the preparation of this review. NR 196 TC 164 Z9 170 U1 5 U2 43 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD APR 1 PY 2011 VL 48 IS 4 BP 677 EP 692 DI 10.1016/j.bone.2010.11.020 PG 16 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 742DQ UT WOS:000288920900001 PM 21145999 ER PT J AU Yu, EW Neer, RM Lee, H Wyland, JJ de la Paz, AV Davis, MC Okazaki, M Finkelstein, JS AF Yu, Elaine W. Neer, Robert M. Lee, Hang Wyland, Jason J. de la Paz, Amanda V. Davis, Melissa C. Okazaki, Makoto Finkelstein, Joel S. TI Time-dependent changes in skeletal response to teriparatide: Escalating vs. constant dose teriparatide (PTH 1-34) in osteoporotic women SO BONE LA English DT Article DE Teriparatide; Parathyroid hormone; Osteoporosis; Bone turnover markers; Bone densitometry ID BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED-TRIAL; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; PARATHYROID-HORMONE (1-34); POSTMENOPAUSAL WOMEN; ESTROGEN-DEFICIENCY; TURNOVER MARKERS; ALENDRONATE; MEN; FRACTURES AB Once-daily injections of teriparatide initially increase biochemical markers of bone formation and resorption, but markers peak after 6-12 months and then decline despite continued treatment. We sought to determine whether increasing teriparatide doses in a stepwise fashion could prolong skeletal responsiveness. We randomized 52 postmenopausal women with low spine and/or hip bone mineral density (BMD) to either a constant or an escalating subcutaneous teriparatide dose (30 mu g daily for 18 months or 20 mu g daily for 6 months, then 30 mu g daily for 6 months, and then 40 mu g daily for 6 months). Serum procollagen I N-terminal propeptide, osteocalcin, and C-terminal telopeptide of type I collagen were assessed frequently. BMD of the spine, hip, radius, and total body was measured every 6 months. Acute changes in urinary cyclic AMP in response to teriparatide were examined in a subset of women in the constant dose group. All bone markers differed significantly between the two treatment groups. During the final six months, bone markers declined in the constant dose group but remained stable or increased in the escalating dose group (all markers, p < 0.017). Nonetheless, mean area under the curve did not differ between treatments for any bone marker, and BMD increases were equivalent in both treatment groups. Acute renal response to teriparatide, as assessed by urinary cyclic AMP, did not change over 18 months of teriparatide administration. In conclusion, stepwise increases in teriparatide prevented the decline in bone turnover markers that is observed with chronic administration without altering BMD increases. The time-dependent waning of the response to teriparatide appears to be bone-specific. (C) 2010 Elsevier Inc. All rights reserved. C1 [Yu, Elaine W.; Neer, Robert M.; Wyland, Jason J.; de la Paz, Amanda V.; Davis, Melissa C.; Okazaki, Makoto; Finkelstein, Joel S.] Massachusetts Gen Hosp, Dept Med, Endocrine Unit, Boston, MA 02114 USA. [Lee, Hang] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. RP Yu, EW (reprint author), Massachusetts Gen Hosp, Dept Med, Endocrine Unit, 50 Blossom St,Thier 1051, Boston, MA 02114 USA. EM ewyu@partners.org; rneer@partners.org; hlee5@partners.org; jwyland@partners.org; amandadelapaz@gmail.com; davismelissac@gmail.com; okazakiMKT@chugai-pharm.co.jp; jfinkelstein@partners.org FU National Institutes of Health [5 P50 AR44855, K24 DK02759, 1 UL1 RR025758-03, RR-1066] FX This work was supported by National Institutes of Health grants 5 P50 AR44855, K24 DK02759, 1 UL1 RR025758-03, and RR-1066. NR 34 TC 9 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD APR 1 PY 2011 VL 48 IS 4 BP 713 EP 719 DI 10.1016/j.bone.2010.11.012 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 742DQ UT WOS:000288920900004 PM 21111078 ER PT J AU Bredella, MA Torriani, M Ghomi, RH Thomas, BJ Brick, DJ Gerweck, AV Harrington, LM Breggia, A Rosen, CJ Miller, KK AF Bredella, Miriam A. Torriani, Martin Ghomi, Reza Hosseini Thomas, Bijoy J. Brick, Danielle J. Gerweck, Anu V. Harrington, Lindsey M. Breggia, Anne Rosen, Clifford J. Miller, Karen K. TI Determinants of bone mineral density in obese premenopausal women SO BONE LA English DT Article DE Bone mineral density; Obesity; Visceral adipose tissue; IGF-1; Quantitative computed tomography (QCT) ID GROWTH-HORMONE DEFICIENCY; 1,25-DIHYDROXY VITAMIN-D; BODY-MASS INDEX; FAT MASS; POSTMENOPAUSAL WOMEN; PERIMENOPAUSAL WOMEN; CARDIOVASCULAR RISK; METABOLIC SYNDROME; ADIPOSE-TISSUE; SEX STEROIDS AB Despite being a risk factor for cardiovascular disease and diabetes mellitus, obesity has been thought to protect against osteoporosis. However, recent studies have demonstrated a differential impact of specific fat compartments on bone mineral density (BMD) with visceral adipose tissue (VAT) having potential detrimental effects on BMD. Visceral obesity is also associated with dysregulation of the GH/IGF-1 axis, an important regulator of bone homeostasis. The purpose of our study was to evaluate the differential effects of abdominal fat depots and muscle, vitamin D, and hormonal determinants, including insulin-like growth factor-1 (IGF-1), testosterone, and estradiol, on trabecular BMD of the lumbar spine. We studied 68 healthy obese premenopausal women (mean BMI, 36.7 +/- 4.2 kg/m(2)). Quantitative computed tomography (QCT) was used to assess body composition and lumbar trabecular BMD. There was an inverse association between BMD and VAT, independent of age and BMI (p = 0.003). IGF-1 correlated positively with BMD and negatively with VAT and, in stepwise multivariate regression modeling, was the strongest predictor of BMD and procollagen type 1 amino-terminal propeptide (P1NP). Thigh muscle cross sectional area (CSA) and thigh muscle density were also associated with BMD (p < 0.05), but 25-hydroxyvitamin D [25(OH)D], testosterone, free testosterone, and estradiol levels were not. 25(OH)D was associated inversely with BMI, total, and subcutaneous abdominal adipose tissue (p < 0.05). These findings support the hypothesis that VAT exerts detrimental effects, whereas muscle mass exerts positive effects on BMD in premenopausal obese women. Moreover, our findings suggest that IGF-1 may be a mediator of the deleterious effects of VAT on bone health through effects on bone formation. (C) 2010 Elsevier Inc. All rights reserved. C1 [Bredella, Miriam A.; Torriani, Martin; Ghomi, Reza Hosseini; Thomas, Bijoy J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Bredella, Miriam A.; Torriani, Martin; Ghomi, Reza Hosseini; Thomas, Bijoy J.; Brick, Danielle J.; Gerweck, Anu V.; Harrington, Lindsey M.; Miller, Karen K.] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Brick, Danielle J.; Gerweck, Anu V.; Harrington, Lindsey M.; Miller, Karen K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Breggia, Anne; Rosen, Clifford J.] Maine Med Ctr, Res Inst, Scarborough, ME 04074 USA. RP Bredella, MA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Yawkey 6E,55 Fruit St, Boston, MA 02114 USA. EM mbredella@partners.org OI Hosseini Ghomi, Reza/0000-0003-4369-8237 FU National Institutes of Health [RO1 HL-077674, UL1 RR-025758, K23 RR-23090] FX This work was supported in part by National Institutes of Health Grants RO1 HL-077674, UL1 RR-025758, and K23 RR-23090. NR 46 TC 59 Z9 62 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 8756-3282 J9 BONE JI Bone PD APR 1 PY 2011 VL 48 IS 4 BP 748 EP 754 DI 10.1016/j.bone.2010.12.011 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 742DQ UT WOS:000288920900009 PM 21195217 ER PT J AU Richardson, P Schlag, R Khuageva, N Dimopoulos, M Shpilberg, O Kropff, M Vekemans, MC Petrucci, MT Rossiev, V Hou, JA Robak, T Mateos, MV Anderson, K Esseltine, DL Cakana, A Liu, K Deraedt, W van de Velde, H San Miguel, JF AF Richardson, Paul Schlag, Rudolf Khuageva, Nuriet Dimopoulos, Meletios Shpilberg, Ofer Kropff, Martin Vekemans, Marie-Christiane Petrucci, Maria Teresa Rossiev, Viktor Hou, Jian Robak, Tadeusz Mateos, Maria-Victoria Anderson, Kenneth Esseltine, Dixie-Lee Cakana, Andrew Liu, Kevin Deraedt, William van de Velde, Helgi San Miguel, Jesus F. TI Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE bortezomib; erythropoiesis-stimulating agents; melphalan; prednisone; myeloma ID REFRACTORY MULTIPLE-MYELOMA; CANCER ANEMIA SURVEY; DOUBLE-BLIND; LENALIDOMIDE; SURVIVAL; EPOETIN; DEXAMETHASONE; CHEMOTHERAPY; MALIGNANCIES; COMBINATION AB P>Although haematological toxicities, such as anaemia, are common in multiple myeloma (MM), no clear consensus exists on the use and impact of erythropoiesis-stimulating agents (ESA) on outcomes in MM. This analysis characterizes haematological toxicities and associated interventions in the phase III VISTA (Velcade (R) as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone) study of bortezomib plus melphalan/prednisone (VMP, n = 344) versus MP (n = 338) in previously untreated MM patients ineligible for high-dose therapy, and evaluates the impact of ESA use or red-blood-cell (RBC) transfusions on outcomes and thromboembolic risk. Incidence of haematological toxicities was similar with VMP and MP; similar rates of interventions and associated complications (e.g. bleeding, febrile neutropenia) were observed. Two hundred thirty three patients received ESA; 204 had RBC transfusions. Frequency of thromboembolic events was low and not affected by ESA use. Median time-to progression (TTP) was similar between ESA/non-ESA [hazard ratio: 1 center dot 03 (95% confidence interval 0 center dot 76-1 center dot 39); P = 0 center dot 8478] in both arms (VMP: 19 center dot 9/not reached; MP: 15 center dot 0/17 center dot 5 months). Three-year overall survival (OS) rates were similar between ESA/non-ESA in each arm. Patients receiving RBC transfusions had significantly shorter OS (P < 0 center dot 0001) versus non-RBC-transfusion patients. In conclusion, bortezomib did not add to melphalan haematological toxicity. Concomitant ESA use with VMP/MP in previously untreated MM patients did not adversely affect TTP or OS, or increase thromboembolic risk. However, RBC transfusion was associated with significantly shorter survival. C1 [Richardson, Paul; Anderson, Kenneth] Dana Farber Canc Inst, Boston, MA 02115 USA. [Schlag, Rudolf] Praxisklin Dr Schlag, Wurzburg, Germany. [Khuageva, Nuriet] SP Botkin Moscow City Clin Hosp, Moscow, Russia. [Dimopoulos, Meletios] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Shpilberg, Ofer] Rabin Med Ctr, Petah Tiqwa, Israel. [Kropff, Martin] Univ Munster, Munster, Germany. [Vekemans, Marie-Christiane] St Luc Univ Hosp, Belgian Multiple Myeloma Study Grp, Brussels, Belgium. [Petrucci, Maria Teresa] Univ Roma La Sapienza, Rome, Italy. [Rossiev, Viktor] Samara Reg Clin Hosp, Samara, Russia. [Hou, Jian] Shanghai Changzheng Hosp, Shanghai, Peoples R China. [Robak, Tadeusz] Med Univ Lodz, Lodz, Poland. [Mateos, Maria-Victoria; San Miguel, Jesus F.] Hosp Univ Salamanca CIC, IBMCC USAL CSIC, Salamanca, Spain. [Esseltine, Dixie-Lee] Millennium Pharmaceut Inc, Cambridge, MA USA. [Cakana, Andrew; Deraedt, William; van de Velde, Helgi] Johnson & Johnson Pharmaceut Res & Dev, Beerse, Belgium. [Liu, Kevin] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA. RP Richardson, P (reprint author), Dana Farber Canc Inst, 44 Binney St,Dana 1B02, Boston, MA 02115 USA. EM paul_richardson@dfci.harvard.edu RI 2011, Secribsal/D-9425-2012 FU Millennium Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research Development FX The authors gratefully acknowledge the administrative support of Katherine Redman of the Dana-Farber Cancer Institute, and the writing assistance of Sarah Maloney and Catherine Crookes of FireKite (funded by Millennium Pharmaceuticals, Inc.), during the development of this publication. Research support for this study was provided by Johnson & Johnson Pharmaceutical Research & Development, L. L. C. and Millennium Pharmaceuticals, Inc. NR 47 TC 4 Z9 5 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD APR PY 2011 VL 153 IS 2 BP 212 EP 221 DI 10.1111/j.1365-2141.2011.08569.x PG 10 WC Hematology SC Hematology GA 741ZI UT WOS:000288907100006 PM 21375521 ER PT J AU Schwartz, BE Hofer, MD Lemieux, ME Bauer, DE Cameron, MJ West, NH Agoston, ES Reynoird, N Khochbin, S Ince, TA Christie, A Janeway, KA Vargas, SO Perez-Atayde, AR Aster, JC Sallan, SE Kung, AL Bradner, JE French, CA AF Schwartz, Brian E. Hofer, Matthias D. Lemieux, Madeleine E. Bauer, Daniel E. Cameron, Michael J. West, Nathan H. Agoston, Elin S. Reynoird, Nicolas Khochbin, Saadi Ince, Tan A. Christie, Amanda Janeway, Katherine A. Vargas, Sara O. Perez-Atayde, Antonio R. Aster, Jon C. Sallan, Stephen E. Kung, Andrew L. Bradner, James E. French, Christopher A. TI Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming SO CANCER RESEARCH LA English DT Article ID BROMODOMAIN PROTEIN BRD4; SUBEROYLANILIDE HYDROXAMIC ACID; ACUTE PROMYELOCYTIC LEUKEMIA; CELL LUNG-CANCER; MYELODYSPLASTIC SYNDROMES; AGGRESSIVE CARCINOMA; TRANSCRIPTION FACTOR; THYMIC CARCINOMA; TYROSINE KINASE; IN-VIVO AB NUT midline carcinoma (NMC) is a lethal pediatric tumor defined by the presence of BRD-NUT fusion proteins that arrest differentiation. Here we explore the mechanisms underlying the ability of BRD4-NUT to prevent squamous differentiation. In both gain-of and loss-of-expression assays, we find that expression of BRD4-NUT is associated with globally decreased histone acetylation and transcriptional repression. Bulk chromatin acetylation can be restored by treatment of NMC cells with histone deacetylase inhibitors (HDACi), engaging a program of squamous differentiation and arrested growth in vitro that closely mimics the effects of siRNA-mediated attenuation of BRD4-NUT expression. The potential therapeutic utility of HDACi differentiation therapy was established in three different NMC xenograft models, where it produced significant growth inhibition and a survival benefit. Based on these results and translational studies performed with patient-derived primary tumor cells, a child with NMC was treated with the FDA-approved HDAC inhibitor, vorinostat. An objective response was obtained after five weeks of therapy, as determined by positron emission tomography. These findings provide preclinical support for trials of HDACi in patients with NMC. Cancer Res; 71(7); 2686-96. (C)2011 AACR. C1 [French, Christopher A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Ince, Tan A.] Brigham & Womens Hosp, Div Womens & Perinatal Pathol, Dept Pathol, Boston, MA 02115 USA. [Lemieux, Madeleine E.; Kung, Andrew L.; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bauer, Daniel E.; Janeway, Katherine A.; Sallan, Stephen E.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Christie, Amanda; Kung, Andrew L.] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02115 USA. [Vargas, Sara O.; Perez-Atayde, Antonio R.] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Reynoird, Nicolas; Khochbin, Saadi] Univ Grenoble 1, INSERM, U823, Inst Albert Bonniot, Grenoble, France. RP French, CA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. EM james_bradner@dfci.harvard.edu; cfrench@partners.org RI Khochbin, Saadi/M-8090-2013; OI Lemieux, Madeleine/0000-0001-6355-8691; Kung, Andrew/0000-0002-9091-488X FU Dana Farber/Harvard Cancer Center [5P30CA06516-44]; US National Institutes of Health [1R01CA124633]; Stanley L. Robbins Memorial Award; National Institutes of Health [1K08CA128972]; Burroughs-Wellcome Foundation; National Cancer Institute's Initiative for Chemical Genetics [N01-CO-12400] FX This work was supported by a Dana Farber/Harvard Cancer Center Nodal Award 5P30CA06516-44 (C.A. French and J.E. Bradner), US National Institutes of Health grant 1R01CA124633 (C.A. French), the Stanley L. Robbins Memorial Award (M.D. Hofer), the National Institutes of Health grant 1K08CA128972 (J.E. Bradner), the Burroughs-Wellcome Foundation (J.E. Bradner), and funds from the National Cancer Institute's Initiative for Chemical Genetics (Contract No. N01-CO-12400). NR 43 TC 68 Z9 70 U1 1 U2 9 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 1 PY 2011 VL 71 IS 7 BP 2686 EP 2696 DI 10.1158/0008-5472.CAN-10-3513 PG 11 WC Oncology SC Oncology GA 743YW UT WOS:000289057600029 PM 21447744 ER PT J AU Haber, DA Gray, NS Baselga, J AF Haber, Daniel A. Gray, Nathanael S. Baselga, Jose TI The Evolving War on Cancer SO CELL LA English DT Article ID CELL LUNG-CANCER; KINASE INHIBITORS; MUTATIONS; GEFITINIB; EGFR; IMATINIB; GENE; DRUG; IDENTIFICATION; CHROMOSOME AB Building on years of basic scientific discovery, recent advances in the fields of cancer genetics and medicinal chemistry are now converging to revolutionize the treatment of cancer. Starting with serendipitous observations in rare subsets of cancer, a paradigm shift in clinical research is poised to ensure that new molecular insights are rapidly applied to shape emerging cancer therapies. Could this mark a turning point in the "War on Cancer''? C1 [Haber, Daniel A.; Baselga, Jose] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. [Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Haber, Daniel A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. RP Haber, DA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. EM haber@helix.mgh.harvard.edu FU Howard Hughes Medical Institute NR 39 TC 101 Z9 101 U1 1 U2 19 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 J9 CELL JI Cell PD APR 1 PY 2011 VL 145 IS 1 BP 19 EP 24 DI 10.1016/j.cell.2011.03.026 PG 6 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 743XW UT WOS:000289053900005 PM 21458664 ER PT J AU Hoffmann, U Dilekoz, E Kudo, C Ayata, C AF Hoffmann, Ulrike Dilekoez, Ergin Kudo, Chiho Ayata, Cenk TI Oxcarbazepine does not suppress cortical spreading depression SO CEPHALALGIA LA English DT Article DE Cortical spreading depression; migraine; oxcarbazepine; valproate ID MIGRAINE PROPHYLAXIS; NEUROPATHIC PAIN; RAT; CARBAMAZEPINE; VALPROATE; DAMAGE; MODEL AB Background: Cortical spreading depression is the electrophysiological substrate of migraine aura, and may trigger headache. Recently, chronic treatment with five migraine prophylactic drugs was shown to suppress cortical spreading depression, implicating spreading depression as a common therapeutic target in migraine prophylaxis. Materials and methods: In order to assess the negative predictive value of spreading depression susceptibility as a preclinical drug screening tool, we tested oxcarbazepine, an anti-epileptic ineffective in migraine prophylaxis. Valproate served as the positive control. Cortical spreading depression susceptibility was measured in rats using topical KCl or electrical stimulation. Results: Oxcarbazepine did not suppress spreading depression either after a single dose or after daily treatment for 5 weeks. As previously shown, valproate suppressed spreading depression susceptibility after chronic dosing, while a single dose was ineffective. Conclusions: These data provide further support for spreading depression as a relevant target in migraine prophylaxis, and demonstrate the predictive utility of employed spreading depression models. C1 [Ayata, Cenk] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA. RP Ayata, C (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Stroke & Neurovasc Regulat Lab, 149 13th St,Room 6408, Charlestown, MA 02129 USA. EM cayata@partners.org FU National Institute of Health [NS061505]; Deutsche Forschungsgemeinschaft [HO 4211/1-1] FX This work was supported by the National Institute of Health (NS061505, CA) and Deutsche Forschungsgemeinschaft (HO 4211/1-1, UH). NR 14 TC 9 Z9 9 U1 1 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0333-1024 J9 CEPHALALGIA JI Cephalalgia PD APR PY 2011 VL 31 IS 5 BP 537 EP 542 DI 10.1177/0333102410388433 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 741OT UT WOS:000288873700005 PM 21059627 ER PT J AU Storch, EA Muroff, J Lewin, AB Geller, D Ross, A McCarthy, K Morgan, J Murphy, TK Frost, R Steketee, G AF Storch, Eric A. Muroff, Jordana Lewin, Adam B. Geller, Daniel Ross, Abigail McCarthy, Katherine Morgan, Jessica Murphy, Tanya K. Frost, Randy Steketee, Gail TI Development and Preliminary Psychometric Evaluation of the Children's Saving Inventory SO CHILD PSYCHIATRY & HUMAN DEVELOPMENT LA English DT Article DE Hoarding; Children's saving inventory; Assessment; Reliability; Validity ID OBSESSIVE-COMPULSIVE DISORDER; MULTIDIMENSIONAL ANXIETY SCALE; COGNITIVE-BEHAVIORAL THERAPY; PRADER-WILLI-SYNDROME; FUNCTIONAL IMPAIRMENT; FAMILY ACCOMMODATION; CLINICAL-FEATURES; PARALLEL ANALYSIS; ADOLESCENTS; OCD AB This study reports on the development and initial psychometric properties of the Children's Saving Inventory (CSI), a parent-rated measure designed to assess child hoarding behaviors. Subjects included 123 children and adolescents diagnosed with primary Obsessive-Compulsive Disorder (OCD) and their parents. Trained clinicians administered the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS), items assessing Family Accommodation and the Clinical Global Impressions-Severity index. Parents completed the CSI, Child Obsessive-Compulsive Impact Scale (COIS)-Parent Version and Child Behavior Checklist. Youth completed the COIS-Child Version, Obsessive-Compulsive Inventory Child Version (OCI-CV), Multidimensional Anxiety Scale for Children, and Children's Depression Inventory-Short Form. A four factor solution was identified; factors were named Discarding, Clutter, Acquisition, and Distress/Impairment. Internal consistency for the CSI Total and factor scores were good. One-week test-retest reliability (n = 31) from a random subsample was excellent. Known groups validity was supported vis-A -vis higher CSI scores for those endorsing hoarding on the CY-BOCS Symptom Checklist. Convergent and discriminant validity was evidenced by weak relationships with OCI-CV Checking and Contamination factors but strong relationships with the OCI-CV Hoarding factor and with hoarding obsession/compulsions on the CY-BOCS. These findings provide initial support for the reliability and validity of the CSI for the assessment of hoarding behaviors among youth with OCD. Future studies are needed to extend these findings to non-OCD samples of youth. C1 [Storch, Eric A.; Lewin, Adam B.; Morgan, Jessica; Murphy, Tanya K.] Univ S Florida, Dept Pediat, St Petersburg, FL 33701 USA. [Storch, Eric A.; Lewin, Adam B.; Morgan, Jessica; Murphy, Tanya K.] Univ S Florida, Dept Psychiat, St Petersburg, FL 33701 USA. [Muroff, Jordana; Ross, Abigail; Steketee, Gail] Boston Univ, Sch Social Work, Boston, MA 02215 USA. [Geller, Daniel; McCarthy, Katherine] Massachusetts Gen Hosp, Dept Psychiat, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA. [Frost, Randy] Smith Coll, Dept Psychol, Northampton, MA 01063 USA. RP Storch, EA (reprint author), Univ S Florida, Dept Pediat, 800 6th St S 4th Floor, St Petersburg, FL 33701 USA. EM estorch@health.usf.edu RI Storch, Eric/I-4935-2012; Lewin, Adam/A-9832-2013 FU NIMH NIH HHS [L40 MH081950-02] NR 71 TC 21 Z9 23 U1 5 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0009-398X J9 CHILD PSYCHIAT HUM D JI Child Psychiat. Hum. Dev. PD APR PY 2011 VL 42 IS 2 BP 166 EP 182 DI 10.1007/s10578-010-0207-0 PG 17 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 741XO UT WOS:000288900500004 PM 20886284 ER PT J AU Yan, BP Moran, D Hynes, BG Kiernan, TJ Yu, CM AF Yan, Bryan P. Moran, Darragh Hynes, Brian G. Kiernan, Thomas J. Yu, Cheuk-Man TI Advances in Endovascular Treatment of Critical Limb Ischemia SO CIRCULATION JOURNAL LA English DT Review DE Angioplasty; Peripheral arterial disease; Stents ID PERIPHERAL ARTERIAL-DISEASE; LOWER-EXTREMITY; BALLOON-ANGIOPLASTY; SUBINTIMAL ANGIOPLASTY; OCCLUSIVE DISEASE; DIABETIC-PATIENTS; BYPASS-SURGERY; FOLLOW-UP; TASC-II; REVASCULARIZATION AB Critical limb ischemia (CLI) represents the most severe clinical manifestation of peripheral, arterial disease. In the absence of timely revascularization, CLI carries high risk-of mortality and amputation. Over the past-decade, endovascular revascularization has rapidly become the preferred primary treatment strategy for CLI, especially for the treatment of below-the-knee disease. Advances in percutaneous devices and techniques have expanded the spectrum of patients with CLI who are deemed candidates for revascularization. This review will focus on advances in endovascular options for the treatment of CLI, in particular for below-the-knee disease. (Circ J 2011;75: 756-765) C1 [Yan, Bryan P.; Yu, Cheuk-Man] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Div Cardiol, Hong Kong, Hong Kong, Peoples R China. [Yan, Bryan P.; Yu, Cheuk-Man] Chinese Univ Hong Kong, Inst Vasc Med, Hong Kong, Hong Kong, Peoples R China. [Moran, Darragh; Kiernan, Thomas J.] Natl Univ Ireland Univ Coll Cork, Cork Univ Hosp, Sch Med, Dept Cardiol, Cork, Ireland. [Hynes, Brian G.] Massachusetts Gen Hosp, Sect Intervent Cardiol & Vasc Med, Boston, MA 02114 USA. RP Yan, BP (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Div Cardiol, Hong Kong, Hong Kong, Peoples R China. RI Yu, Cheuk-man/P-3747-2015; Yan, Bryan/P-5928-2015 NR 50 TC 13 Z9 16 U1 2 U2 5 PU JAPANESE CIRCULATION SOC PI KYOTO PA KINKI INVENTION CENTER, 14 YOSHIDA KAWAHARACHO, SAKYO-KU, KYOTO, 606-8305, JAPAN SN 1346-9843 J9 CIRC J JI Circ. J. PD APR PY 2011 VL 75 IS 4 BP 756 EP 765 DI 10.1253/circj.CJ-11-0103 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 743NI UT WOS:000289024600002 PM 21422665 ER PT J AU Weber, J Atkins, M Hwu, P Radvanyi, L Sznol, M Yee, C AF Weber, Jeffrey Atkins, Michael Hwu, Patrick Radvanyi, Laszlo Sznol, Mario Yee, Cassian CA Immunotherapy Task Force NCI TI White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy SO CLINICAL CANCER RESEARCH LA English DT Article ID MINOR HISTOCOMPATIBILITY ANTIGEN; CD8(+) T-CELLS; CHRONIC MYELOID-LEUKEMIA; IN-VIVO PERSISTENCE; METASTATIC MELANOMA; PERIPHERAL-BLOOD; ANTITUMOR LYMPHOCYTES; NEUTROPHIL ELASTASE; TELOMERE LENGTH; GENE-TRANSFER AB Adoptive T-cell therapy (ACT) using expanded autologous tumor-infiltrating lymphocytes (TIL) and tumor antigen-specific T cell expanded from peripheral blood are complex but powerful immunotherapies directed against metastatic melanoma. A number of nonrandomized clinical trials using TIL combined with high-dose interleukin-2 (IL-2) have consistently found clinical response rates of 50% or more in metastatic melanoma patients accompanied by long progression-free survival. Recent studies have also established practical methods for the expansion of TIL from melanoma tumors with high success rates. These results have set the stage for randomized phase II/III clinical trials to determine whether ACT provides benefit in stage IV melanoma. Here, we provide an overview of the current state-of-the art in T-cell-based therapies for melanoma focusing on ACT using expanded TIL and address some of the key unanswered biological and clinical questions in the field. Different phase II/III randomized clinical trial scenarios comparing the efficacy of TIL therapy to high-dose IL-2 alone are described. Finally, we provide a roadmap describing the critical steps required to test TIL therapy in a randomized multicenter setting. We suggest an approach using centralized cell expansion facilities that will receive specimens and ship expanded TIL infusion products to participating centers to ensure maximal yield and product consistency. If successful, this approach will definitively answer the question of whether ACT can enter mainstream treatment for cancer. Clin Cancer Res; 17(7); 1664-73. (C) 2011 AACR. C1 [Weber, Jeffrey] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Atkins, Michael] Dana Farber Harvard Canc Ctr, Boston, MA USA. [Hwu, Patrick; Radvanyi, Laszlo] MD Anderson Canc Ctr, Houston, TX USA. [Sznol, Mario] Yale Univ, New Haven, CT 06520 USA. [Yee, Cassian] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. RP Weber, J (reprint author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA. EM jeffrey.weber@moffitt.org NR 73 TC 49 Z9 52 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 1 PY 2011 VL 17 IS 7 BP 1664 EP 1673 DI 10.1158/1078-0432.CCR-10-2272 PG 10 WC Oncology SC Oncology GA 743XY UT WOS:000289054100004 PM 21325070 ER PT J AU Kong, Y Si, L Zhu, YY Xu, XW Corless, CL Flaherty, KT Li, L Li, HF Sheng, XA Cui, CL Chi, ZH Li, SM Han, M Mao, LL Lu, AP Guo, J AF Kong, Yan Si, Lu Zhu, Yanyan Xu, Xiaowei Corless, Christopher L. Flaherty, Keith T. Li, Li Li, Haifu Sheng, Xinan Cui, Chuanliang Chi, Zhihong Li, Siming Han, Mei Mao, Lili Lu, Aiping Guo, Jun TI Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma SO CLINICAL CANCER RESEARCH LA English DT Article ID GASTROINTESTINAL STROMAL TUMORS; AMERICAN JOINT COMMITTEE; ACUTE MYELOID-LEUKEMIA; PHASE-II TRIAL; C-KIT; IMATINIB MESYLATE; METASTATIC MELANOMA; PROTEIN EXPRESSION; PROGNOSTIC FACTORS; MUTATIONS AB Purpose: KIT aberrations were described in acral and mucosal melanomas in largely Caucasian populations. Asian populations are more prone to develop acral and mucosal than cutaneous melanomas, and may harbor a high frequency of KIT aberrations. Experimental Design: Melanoma subtypes (n = 502) were analyzed histologically to determine melanoma subtype. Tissue samples were analyzed for mutations in exons 9, 11, 13, 17, and 18 of KIT gene in genomic DNA by PCR amplification and Sanger sequencing. The copy numbers of the KIT gene were analyzed by quantitative PCR, and protein expression levels of KIT (CD117) were determined by immunohistochemistry. Results: The most common melanoma subtypes were acral (38.4%) and mucosal (33.3%) melanomas in this population. The overall incidence of somatic mutations within the KIT gene was 10.8% (54/502), and all subtypes of melanoma contained KIT mutations. Increases in KIT gene copy numbers were correlated to CD117 overexpression. The genetic mutations of KIT were unrelated to the age, gender, stage, thickness, and ulceration of primary melanomas. Importantly, the overall survival of melanoma patients with KIT mutations (P = 0.001) or with KIT aberrations (mutation plus amplification, P = 0.0002) was significantly shorter than that of patients without such alterations. Conclusion: In China, the prevalent melanomas are acral and mucosal melanomas. KIT mutations are detected in all melanoma subtypes. Our study suggests that increases in KIT gene copy numbers, but not KIT mutations, may be correlated to CD117 overexpression. For the first time, our study suggests that genetic KIT aberration is an adverse prognostic factor for melanoma. Clin Cancer Res; 17(7); 1684-91. (C) 2011 AACR. C1 [Kong, Yan; Si, Lu; Zhu, Yanyan; Li, Li; Li, Haifu; Sheng, Xinan; Cui, Chuanliang; Chi, Zhihong; Li, Siming; Han, Mei; Mao, Lili; Lu, Aiping; Guo, Jun] Peking Univ, Dept Renal Canc & Melanoma, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China. [Xu, Xiaowei] Univ Penn, Dept Pathol & Lab Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Corless, Christopher L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. RP Guo, J (reprint author), Peking Univ, Dept Renal Canc & Melanoma, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China. EM guoj307@126.com FU Novartis Pharma; Pfizer; Program for New Century Excellent Talents in University [985-2-085-113]; National Natural Science Foundation of China [30973483]; Novartis Oncology in China FX Drs J. Guo and C.L. Corless have received consulting fees and research funding from Novartis Pharma, and consulting fees from Pfizer.; Program for New Century Excellent Talents in University (985-2-085-113), the National Natural Science Foundation of China (30973483), and Novartis Oncology in China. NR 34 TC 83 Z9 92 U1 1 U2 10 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 1 PY 2011 VL 17 IS 7 BP 1684 EP 1691 DI 10.1158/1078-0432.CCR-10-2346 PG 8 WC Oncology SC Oncology GA 743XY UT WOS:000289054100006 PM 21325067 ER PT J AU Sacco, A Aujay, M Morgan, B Azab, AK Maiso, P Liu, Y Zhang, Y Azab, F Ngo, HT Issa, GC Quang, P Roccaro, AM Ghobrial, IM AF Sacco, Antonio Aujay, Monette Morgan, Brittany Azab, Abdel Kareem Maiso, Patricia Liu, Yang Zhang, Yong Azab, Feda Ngo, Hai T. Issa, Ghayas C. Quang, Phong Roccaro, Aldo M. ghobrial, Irene M. TI Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia SO CLINICAL CANCER RESEARCH LA English DT Article ID MULTIPLE-MYELOMA; IRREVERSIBLE INHIBITOR; BORTEZOMIB; IMMUNOPROTEASOME; COMBINATION; STRATEGY; PATHWAY; STRESS; PR-171; MODELS AB Purpose: Primary Waldenstrom's Macroglobulinemia (WM) cells present with a significantly higher level of the immunoproteasome compared with the constitutive proteasome. It has been demonstrated that selective inhibition of the chymotrypsin-like (CT-L) activity of constitutive-(c20S) and immuno-(i20S) proteasome represents a valid strategy to induce antineoplastic effect in hematologic tumors. We therefore evaluated carfilzomib, a potent selective, irreversible inhibitor of the CT-L activity of the i20S and c20S in WM cells. Experimental Design: We tested the effect of carfilzomib on survival and proliferation of primary WM cells, as well as of other IgM-secreting lymphoma cell lines. Carfilzomib-dependent mechanisms of induced apoptosis in WM cells, and its effect on WM cells in the context of bone marrow (BM) microenvironment have been also evaluated. Moreover, the combinatory effect of carfilzomib and bortezomib has been investigated. In vivo studies have been performed. Results: We demonstrated that carfilzomib targeted the CT-L activity of both i20S and c20S, which led to the induction of toxicity in primary WM cells, as well as in other IgM-secreting lymphoma cells. Importantly, carfilzomib targeted WM cells even in the context of BM milieu. In addition, carfilzomib induced apoptosis through c-jun-N-terminal-kinase activation, caspase cleavage, and initiation of unfolded protein response. Importantly, the combination of carfilzomib and bortezomib synergistically inhibited CT-L activity, as well as caspase-, PARP-cleavage and GRP94 expression. Antitumor activity of carfilzomib has been validated in vivo. Conclusions: These findings suggest that targeting i20S and c20S CT-L activity by carfilzomib represents a valid antitumor strategy in WM and other IgM-secreting lymphomas. Clin Cancer Res; 17(7); 1753-64. (C) 2011 AACR. C1 [Sacco, Antonio; Morgan, Brittany; Azab, Abdel Kareem; Maiso, Patricia; Liu, Yang; Zhang, Yong; Azab, Feda; Ngo, Hai T.; Issa, Ghayas C.; Quang, Phong; Roccaro, Aldo M.; ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sacco, Antonio; Morgan, Brittany; Azab, Abdel Kareem; Maiso, Patricia; Liu, Yang; Zhang, Yong; Azab, Feda; Ngo, Hai T.; Issa, Ghayas C.; Quang, Phong; Roccaro, Aldo M.; ghobrial, Irene M.] Harvard Univ, Sch Med, Boston, MA USA. [Aujay, Monette] Onyx Pharmaceut, Emeryville, CA USA. RP Roccaro, AM (reprint author), Dana Farber Canc Inst, 44 Binney St,Mayer 548A, Boston, MA 02115 USA. EM aldo_roccaro@dfci.harvard.edu RI Sacco, Antonio/K-4681-2016; OI Sacco, Antonio/0000-0003-2945-9416; Maiso, Patricia/0000-0003-3745-1924; Roccaro, Aldo/0000-0002-1872-5128 FU International Waldenstrom's Macroglobulinemia Foundation (IWMF); Michelle and Steven Kirsch lab for Waldenstrom; Heje fellowship for Waldenstrom FX Supported in part by the International Waldenstrom's Macroglobulinemia Foundation (IWMF). This work was supported by the Michelle and Steven Kirsch lab for Waldenstrom and the Heje fellowship for Waldenstrom. NR 25 TC 28 Z9 28 U1 0 U2 6 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 1 PY 2011 VL 17 IS 7 BP 1753 EP 1764 DI 10.1158/1078-0432.CCR-10-2130 PG 12 WC Oncology SC Oncology GA 743XY UT WOS:000289054100013 PM 21355079 ER PT J AU Wilkin, TJ Goetz, MB Leduc, R Skowron, G Su, ZH Chan, ES Heera, J Chapman, D Spritzler, J Reeves, JD Gulick, RM Coakley, E AF Wilkin, Timothy J. Goetz, Mathew Bidwell Leduc, Robert Skowron, Gail Su, Zhaohui Chan, Ellen S. Heera, Jayyant Chapman, Doug Spritzler, John Reeves, Jacqueline D. Gulick, Roy M. Coakley, Eoin TI Reanalysis of Coreceptor Tropism in HIV-1-Infected Adults Using a Phenotypic Assay with Enhanced Sensitivity SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID TREATMENT-EXPERIENCED PATIENTS; HIV-1 INFECTION; NAIVE SUBJECTS; PROGRESSION; MARAVIROC; AIDS; CCR5 AB The enhanced-sensitivity Trofile assay (TF-ES; Monogram Biosciences) was used to retest coreceptor tropism samples from 4 different cohorts of HIV-1-infected patients. Nine percent to 26% of patients with CCR5-tropic virus by the original Trofile assay had CXCR4-using virus by TF-ES. Lower CD4 cell counts were associated with CXCR4-using virus in all cohorts. C1 [Wilkin, Timothy J.; Gulick, Roy M.] Weill Cornell Med Coll, Div Infect Dis, New York, NY 10011 USA. [Chapman, Doug] Pfizer, New York, NY USA. [Goetz, Mathew Bidwell] Univ Calif Los Angeles, Vet Adm Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Mathew Bidwell] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Reeves, Jacqueline D.; Coakley, Eoin] Monogram Biosci, San Francisco, CA USA. [Leduc, Robert] Univ Minnesota, Div Biostat, Minneapolis, MN USA. [Skowron, Gail] Roger Williams Med Ctr, Div Infect Dis, Providence, RI USA. [Reeves, Jacqueline D.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Chan, Ellen S.; Spritzler, John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Su, Zhaohui] Outcome Sci, Cambridge, MA USA. [Heera, Jayyant] Pfizer Global Res & Dev, New London, CT USA. RP Wilkin, TJ (reprint author), Weill Cornell Med Coll, Div Infect Dis, New York, NY 10011 USA. EM tiw2001@med.cornell.edu RI Reeves, Jacqueline/I-5379-2012 FU NCRR NIH HHS [UL1 RR024996, RR024996]; NIAID NIH HHS [AI-46381, AI-68634, AI-69419, K23 AI055038, K23 AI55038, K24 AI051966, K24 AI51966, R44 AI050321, R44AI050321, U01 AI-42170, U01 AI-46362, U01 AI-68636, U01 AI-68641, U01 AI042170, U01 AI046362, U01 AI046381, U01 AI068634, U01 AI068636, U01 AI068641, U01 AI069419, UM1 AI068634, UM1 AI069419] NR 13 TC 32 Z9 32 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2011 VL 52 IS 7 BP 925 EP 928 DI 10.1093/cid/cir072 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 740NW UT WOS:000288802600018 PM 21427401 ER PT J AU Choi, AI Lo, JC Mulligan, K Schnell, A Kalapus, SC Li, YM Hunt, PW Martin, JN Deeks, SG Hsue, PY AF Choi, Andy I. Lo, Joan C. Mulligan, Kathleen Schnell, Amanda Kalapus, S. Craig Li, Yongmei Hunt, Peter W. Martin, Jeffrey N. Deeks, Steven G. Hsue, Priscilla Y. TI Association of Vitamin D Insufficiency with Carotid Intima-Media Thickness in HIV-Infected Persons SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID POPULATION; RISK AB We observed an independent association between vitamin D insufficiency and higher carotid intima-media thickness in a cross-sectional analysis of 139 HIV-infected persons. If confirmed, these findings support a clinical trial of vitamin D supplementation to reduce cardiovascular events in HIV-infected persons. C1 [Choi, Andy I.; Lo, Joan C.; Mulligan, Kathleen; Li, Yongmei; Hunt, Peter W.; Deeks, Steven G.; Hsue, Priscilla Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Choi, Andy I.; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Choi, Andy I.; Li, Yongmei] San Francisco VA Med Ctr, San Francisco, CA USA. [Mulligan, Kathleen; Schnell, Amanda; Kalapus, S. Craig; Hsue, Priscilla Y.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Hunt, Peter W.; Deeks, Steven G.] San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94110 USA. [Lo, Joan C.] Kaiser Permanente Div Res, Oakland, CA USA. RP Hsue, PY (reprint author), San Francisco Gen Hosp, Dept Cardiol, Rm 5G1,1001 Potrero Ave, San Francisco, CA 94110 USA. EM phsue@medsfgh.ucsf.edu FU NCRR NIH HHS [UL1 RR024131, KL2 RR024130, UL1 RR024131-01]; NHLBI NIH HHS [R01 HL095130, R01HL095130]; NIAID NIH HHS [K23 AI065244, K23 AI066885, K23AI066885, K23AI65244, K24 AI069994, K24AI069994, P30 AI027763]; NIDDK NIH HHS [K23 DK080645, K23DK080645-01A1] NR 13 TC 32 Z9 33 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD APR 1 PY 2011 VL 52 IS 7 BP 941 EP 944 DI 10.1093/cid/ciq239 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 740NW UT WOS:000288802600020 PM 21273298 ER PT J AU Merlo-Pich, E Alexander, RC Fava, M Gomeni, R AF Merlo-Pich, E. Alexander, R. C. Fava, M. Gomeni, R. TI Response to "Clinical Trials of Antidepressants: 'Enrichment Strategies'" and "The Placebo Response Is Part of Good Medicine" SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Letter C1 [Gomeni, R.] GlaxoSmithKline R&D, Pharmacometr, Upper Merion, PA USA. [Merlo-Pich, E.] GlaxoSmithKline R&D, rCEDD, Neuronal Target DPU, Upper Merion, PA USA. [Alexander, R. C.] AstraZeneca, Neurosci, Innovat Med, Wilmington, DE USA. [Fava, M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Gomeni, R (reprint author), GlaxoSmithKline R&D, Pharmacometr, Upper Merion, PA USA. EM roberto.a.gomeni@gsk.com NR 8 TC 0 Z9 0 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0009-9236 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD APR PY 2011 VL 89 IS 4 BP 486 EP 487 DI 10.1038/clpt.2010.339 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 738OK UT WOS:000288649600011 ER PT J AU Flood, KL Brown, CJ Carroll, MB Locher, JL AF Flood, Kellie L. Brown, Cynthia J. Carroll, Maria B. Locher, Julie L. TI Nutritional processes of care for older adults admitted to an oncology-acute care for elders unit SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY LA English DT Review DE Cancer; Hospital nutritional support; OACE unit; Older adults ID PROTEIN-ENERGY UNDERNUTRITION; HOSPITALIZED MEDICAL PATIENTS; INCREASED LENGTH; MALNUTRITION; STAY; ADMISSION; CANCER; IMPACT; MASS AB Background: Acute care for elders (ACE) units have been established in the United States to prevent functional decline in older hospitalized patients. Purpose: We sought to examine whether an ace unit that focused specifically on care of older oncology patients (OACE) compared with a usual care cancer ward (UCCW) demonstrated improved nutritional processes of care in patients who had documentation of nutritional deficits. Methods: We conducted a retrospective chart review to examine whether orders had been placed for a nutritional consult or use of nutritional supplements. Logistic regression analyses, controlling for confounding variables, were conducted to evaluate differences between the wards. Results: OACE unit patients were 2.1 times more likely than UCCW patients to have a nutrition consult placed and 2.5 times more likely to have nutritional supplements ordered. Conclusions: An OACE unit model of care resulted in increased nutritional interventions. Future work is warranted to evaluate outcomes of care. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Locher, Julie L.] Univ Alabama Birmingham, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham, AL USA. [Flood, Kellie L.; Brown, Cynthia J.; Locher, Julie L.] UAB Ctr Aging, Birmingham, AL USA. [Brown, Cynthia J.] Birmingham Vet Affairs Med Ctr, Fall Prevent & Mobil Clin, Birmingham, AL USA. [Carroll, Maria B.] Barnes Jewish Hosp, St Louis, MO 63110 USA. [Locher, Julie L.] UAB Dept Hlth Care Org & Policy, Birmingham, AL USA. [Locher, Julie L.] UAB Lister Hill Ctr Hlth Policy, Birmingham, AL USA. RP Locher, JL (reprint author), CH19,Room 218F,1530 3rd Ave S, Birmingham, AL 35294 USA. EM jlocher@uab.edu FU Barnes-Jewish Hospital Foundation; Division of State, Community, and Public Health, Bureau of Health Professions, Health Resources and Services Administration, Department of Health and Human Services [K01HP00079]; VA Research Career Development Award [E6329W] FX This work was supported by grants from the Barnes-Jewish Hospital Foundation and the Division of State, Community, and Public Health, Bureau of Health Professions, Health Resources and Services Administration, Department of Health and Human Services under Grant No. K01HP00079 to Dr. Flood. Dr. Brown is a recipient of a VA Research Career Development Award (E6329W). The study sponsors had no role in the study design, collection, analysis, and interpretation of data; writing of manuscript; or decision to submit the manuscript for publication. NR 28 TC 2 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1040-8428 J9 CRIT REV ONCOL HEMAT JI Crit. Rev. Oncol./Hematol. PD APR PY 2011 VL 78 IS 1 BP 73 EP 78 DI 10.1016/j.critrevonc.2010.02.011 PG 6 WC Oncology; Hematology SC Oncology; Hematology GA 745CB UT WOS:000289140400007 PM 20299236 ER PT J AU Herman, J Chavalitdhamrong, D Jensen, DM Cortina, G Manuyakorn, A Jutabha, R AF Herman, J. Chavalitdhamrong, D. Jensen, D. M. Cortina, G. Manuyakorn, A. Jutabha, R. TI The significance of gastric and duodenal histological ischemia reported on endoscopic biopsy SO ENDOSCOPY LA English DT Article ID CHRONIC MESENTERIC ISCHEMIA; ABDOMINAL-PAIN; REVASCULARIZATION; GASTROPATHY; ULCERATION; INSUFFICIENCY; DISSECTION; INFARCTION; DISEASE; ARTERY AB Although frequently reported, it is unknown whether pathological reports of ischemia obtained from gastroduodenal biopsies suggest a diagnosis, prognosis or a requirement for additional evaluation. The aim of this study was to review the natural history, clinical presentation, endoscopic appearance, treatments, and major clinical outcomes of patients with gastroduodenal ischemia. A case series of 14 patients with variable etiologies (seven gastric and seven duodenal) was obtained from a search of our endoscopic pathological database for reports of histological ischemia. The results were as follows. The most common presentation was upper gastrointestinal bleeding (71%). Half of the endoscopic lesions appeared very severe (large or circumferential lesions, exudative, pseudomembranous, black or pale mucosa). There were six cases of rebleeding (43%) and four deaths (29%). Computed tomography scanning was frequently used (12 cases, 86%), but led to an underlying diagnosis in only three cases. In our series, patients with underlying vascular pathology have substantial 6-month mortality (29%). C1 [Herman, J.; Chavalitdhamrong, D.; Jensen, D. M.; Jutabha, R.] Digest Dis Res Ctr, CURE, Los Angeles, CA USA. [Jensen, D. M.; Jutabha, R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Jensen, D. M.; Jutabha, R.] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Cortina, G.; Manuyakorn, A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA. RP Jutabha, R (reprint author), 100 UCLA Med Plaza,Suite 310, Los Angeles, CA 90095 USA. EM rjutabha@ucla.edu FU NIH-NIDDK Human Studies Core of NIH-NIDDK [AM41301]; CURE Digestive Diseases Research Center; NIH [02650] FX Dr. Jensen's contribution was partially supported by NIH-NIDDK Human Studies Core of NIH-NIDDK AM41301 CURE Digestive Diseases Research Center and an NIH K24 grant (02650). NR 30 TC 4 Z9 4 U1 0 U2 1 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0013-726X EI 1438-8812 J9 ENDOSCOPY JI Endoscopy PD APR PY 2011 VL 43 IS 4 BP 365 EP 368 DI 10.1055/s-0030-1256040 PG 4 WC Gastroenterology & Hepatology; Surgery SC Gastroenterology & Hepatology; Surgery GA 743YP UT WOS:000289056300014 PM 21360426 ER PT J AU Reeves, RK Evans, TI Fultz, PN Johnson, RP AF Reeves, R. Keith Evans, Tristan I. Fultz, Patricia N. Johnson, R. Paul TI Potential confusion of contaminating CD16(+) myeloid DCs with anergic CD16(+) NK cells in chimpanzees SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE Animal models; DCs; HIV; NK cells ID HEPATITIS-C VIRUS; DENDRITIC CELLS; PERIPHERAL-BLOOD; SIV INFECTION; SUBSETS AB Precise identification of NK-cell populations in humans and nonhuman primates has been confounded by imprecise phenotypic definitions. A common definition used in nonhuman primates, including chimpanzees, is CD3(-)CD8(alpha)(+)CD16(+), and this is the dominant NK-cell phenotype in peripheral blood. However, recent data suggest that in chimpanzees a rare CD8 alpha(-)CD16(+) population also exists. Herein, we present evidence validating the existence of this rare subset in chimpanzee peripheral blood, but also demonstrating that gating on CD3(-)CD8(alpha)(-)CD16(+) cells can inadvertently include a large number of CD16(+) myeloid DCs (mDCs). We confirmed the inclusion of mDCs in CD3(-)CD8(alpha)(-)CD16(+) gated cells by demonstrating high expression of CD11c, BDCA-1 and HLA-DR, and by the lack of expression of NKp46 and intracellular perforin. We also functionally validated the CD8(alpha)(-) NK-cell and mDC populations by mutually exclusive responsiveness to a classical NK-cell stimulus, MHC class I-deficient cells, and a prototypic mDC stimulus, poly I:C, respectively. Overall, these data demonstrate common problems with gating of NK cells that can lead to erroneous conclusions and highlight a critical need for consensus protocols for NK-cell phenotyping. C1 [Reeves, R. Keith; Evans, Tristan I.; Johnson, R. Paul] Harvard Univ, Sch Med, New England Primate Res Ctr, Div Immunol, Southborough, MA 01772 USA. [Fultz, Patricia N.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Johnson, R. Paul] Massachusetts Gen Hosp MIT & Harvard, Ragon Inst, Boston, MA 02114 USA. [Johnson, R. Paul] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA. RP Johnson, RP (reprint author), Harvard Univ, Sch Med, New England Primate Res Ctr, Div Immunol, Southborough Campus,Pine Hill Dr, Southborough, MA 01772 USA. EM paul_johnson@hms.harvard.edu FU French National AIDS Research Agency (ANRS), NIH [U19 AI028147, AI062412, AI071306, AI090735, RR00168]; CHAVI/HVTN Early Career Investigator award [U19 AI 067854-04] FX The authors thank Michelle Connole, Jackie Gillis, Yi Yu, and Jacqueline Stallworth for expert technical assistance; as well as Kay Lee Summerville and the staff of the Yerkes National Primate Center, Emory University for chimpanzee blood samples. This research was supported by the French National AIDS Research Agency (ANRS), NIH grants U19 AI028147, AI062412, AI071306, AI090735, and RR00168 as well as a CHAVI/HVTN Early Career Investigator award, grant number U19 AI 067854-04, to R.K.R. NR 12 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD APR PY 2011 VL 41 IS 4 BP 1070 EP 1074 DI 10.1002/eji.201040832 PG 5 WC Immunology SC Immunology GA 740UX UT WOS:000288821000020 PM 21360701 ER PT J AU Bodhankar, S Wang, CH Vandenbark, AA Offner, H AF Bodhankar, Sheetal Wang, Chunhe Vandenbark, Arthur A. Offner, Halina TI Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells SO EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE EAE; Estrogen; MS; Regulatory B cells ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; REGULATORY T-CELLS; PROGRAMMED DEATH 1; MULTIPLE-SCLEROSIS; MICE; DISEASE; ACTIVATION; PREGNANCY; PROTEIN; INTERLEUKIN-17 AB Increased remissions in multiple sclerosis (MS) during pregnancy suggest that elevated levels of sex steroids exert immunoregulatory activity. Estrogen (E2=17 beta-estradiol) protects against experimental autoimmune encephalomyelitis (EAE), but the cellular basis for E2-induced protection remains unclear. Studies demonstrate that depletion of B cells prior to induction of EAE exacerbates disease severity, implicating regulatory B cells. We thus evaluated pathogenic and E2-induced protective mechanisms in B-cell-deficient (mu MT-/-) mice. EAE-protective effects of E2 were abrogated in mu MT-/- mice, with no reduction in disease severity, cellular infiltration or pro-inflammatory factors in the central nervous system compared to untreated controls. E2 treatment of WT mice selectively upregulated expression of PD-L1 on B cells and increased the percentage of IL-10-producing CD1d(high)CD5(+) regulatory B cells. Upregulation of PD-L1 was critical for E2-mediated protection since E2 did not inhibit EAE in PD-L1(-/-) mice. Direct treatment of B cells with E2 significantly reduced proliferation of MOG(35-55)-specific T cells that required estrogen receptor-alpha (ER alpha). These results demonstrate, for the first time, a requirement for B cells in E2-mediated protection against EAE involving direct E2 effects on regulatory B cells mediated through ER alpha and the PD-1/PD-L1 negative co-stimulatory pathway. E2-primed B cells may represent an important regulatory mechanism in MS and have strong implications for women receiving current MS therapies that cause B-cell depletion. C1 [Offner, Halina] Portland VA Med Ctr, R&D 31, Portland, OR 97239 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. [Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH [NS45445, NS49210]; National Multiple Sclerosis Society [RG3405-C-6]; Biomedical Laboratory R&D Service, Department of Veterans' Affairs FX The authors thank Dr Sushmita Sinha and Ms Sandhya Subramanian for helpful discussions and Ms Eva Niehaus for assistance with manuscript preparation. This work was supported by NIH grants NS45445 and NS49210; National Multiple Sclerosis Society grant RG3405-C-6; and the Biomedical Laboratory R&D Service, Department of Veterans' Affairs. NR 41 TC 32 Z9 38 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0014-2980 EI 1521-4141 J9 EUR J IMMUNOL JI Eur. J. Immunol. PD APR PY 2011 VL 41 IS 4 BP 1165 EP 1175 DI 10.1002/eji.201040992 PG 11 WC Immunology SC Immunology GA 740UX UT WOS:000288821000029 PM 21413005 ER PT J AU Rader, AA Oman, CM Merfeld, DM AF Rader, Andrew A. Oman, Charles M. Merfeld, Daniel M. TI Perceived tilt and translation during variable-radius swing motion with congruent or conflicting visual and vestibular cues SO EXPERIMENTAL BRAIN RESEARCH LA English DT Article DE Visual; Vestibular; Perception; Human; Swing; Null ID SPATIAL ORIENTATION; VERTICAL AXIS; INERTIAL MOTION; SELF-MOTION; PERCEPTION; HUMANS; RESPONSES; MOVEMENT; ROTATION; INFORMATION AB We examined the influence of dynamic visual scenes on the motion perception of subjects undergoing sinusoidal (0.45 Hz) roll swing motion at different radii. The visual scenes were presented on a flatscreen monitor with a monocular 40A degrees field of view. There were three categories of trials: (1) trials in the dark; (2) trials where the visual scene matched the actual motion; and (3) trials where the visual scene showed swing motion at a different radius. Subjects verbally reported perceptions of head tilt and translation. When the visual and vestibular cues differed, subjects reported perceptions that were geometrically consistent with a radius between the radii of the visual scene and the actual motion. Even when sensations did not match either the visual or vestibular stimuli, reported motion perceptions were consistent with swing motions combining elements of each. Subjects were generally unable to detect cue conflicts or judge their own visual-vestibular biases, which suggests that the visual and vestibular self-motion cues are not independently accessible. C1 [Merfeld, Daniel M.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Res Lab, Boston, MA 02114 USA. [Rader, Andrew A.; Oman, Charles M.] MIT, Dept Aeronaut & Astronaut, Man Vehicle Lab, Cambridge, MA 02139 USA. RP Merfeld, DM (reprint author), Massachusetts Eye & Ear Infirm, Jenks Vestibular Res Lab, Boston, MA 02114 USA. EM dan_merfeld@meei.harvard.edu FU NASA [NNJ04HF79G]; NIH [NIDCD R01 DC04158] FX Funding for this experiment was generously provided by NASA (NNJ04HF79G) and NIH (NIDCD R01 DC04158). The authors would also like to thank the subjects who participated. This experiment protocol was approved by the MEEI and MIT IRBs. NR 47 TC 5 Z9 5 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0014-4819 J9 EXP BRAIN RES JI Exp. Brain Res. PD APR PY 2011 VL 210 IS 2 BP 173 EP 184 DI 10.1007/s00221-011-2612-4 PG 12 WC Neurosciences SC Neurosciences & Neurology GA 742QJ UT WOS:000288959200002 PM 21424258 ER PT J AU Batista, A Barata, JT Raderschall, E Sallan, SE Carlesso, N Nadler, LM Cardoso, AA AF Batista, Ana Barata, Joao T. Raderschall, Elke Sallan, Stephen E. Carlesso, Nadia Nadler, Lee M. Cardoso, Angelo A. TI Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors SO EXPERIMENTAL HEMATOLOGY LA English DT Article ID ACUTE LYMPHOBLASTIC-LEUKEMIA; MULTIPLE-MYELOMA CELLS; MAMMALIAN TARGET; BONE-MARROW; CANCER-CELLS; IN-VIVO; TREATMENT STRATEGY; CYCLE PROGRESSION; INDUCED APOPTOSIS; MESSENGER-RNA AB Objective. Rationally designed therapies aim at the specific disruption of critical signaling pathways activated by malignant transformation or signals from the tumor microenvironment. Because mammalian target of rapamycin (mTOR) is an important signal integrator and a key translational regulator, we evaluated its potential involvement in T-cell acute lymphoblastic leukemia (T-ALL) and whether mTOR blockade synergizes with chemotherapeutic agents or other signaling antagonists to inhibit primary leukemia T cells. Materials and Methods. mTOR signaling status was assessed using biochemical, immunostaining, and molecular regulation studies and functional assays performed to assess the impact of mTOR blockade on T-ALL proliferation, survival, and cell cycle. Results. We observed that mTOR signaling is highly activated in all T-ALL patients tested, with phosphorylation of its downstream substrates eIF4G and Sfi ribosomal protein. mTOR activation was detected in vivo and was further increased in vitro by stimulation with interleukin-7, a potentially leukemogenic cytokine normally produced by the bone marrow microenvironment. In T-ALL cells, mTOR blockade was associated with accumulation of the cyclin-dependent kinase inhibitor p27(kip1), which preferentially adopted a nuclear localization. Functional studies using rapamycin or CCI-779 showed a dominant inhibitory effect of mTOR blockade on interleukin-7 induced proliferation, survival, and cell-cycle progression of T-ALL cells. Furthermore, mTOR blockade markedly potentiated the antileukemia effects of dexamethasone and doxorubicin, and showed highly synergistic interactions in combination with specific inhibitors of phosphatidylinositol 3-kinase/Akt and Janus kinase 3 signaling. Conclusions. This study shows activation of mTOR signaling in primary T-ALL cells evolving in the leukemic bone marrow, and supports the inclusion of mTOR antagonists in current therapeutic regimens for this cancer. (C) 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. C1 [Batista, Ana; Cardoso, Angelo A.] Indiana Univ Sch Med, Div Hematol Oncol, Indianapolis, IN 46202 USA. [Batista, Ana; Cardoso, Angelo A.] Indiana Univ Sch Med, Div Hematol Oncol, Indiana Univ Simon Canc Ctr, Indianapolis, IN 46202 USA. [Batista, Ana; Raderschall, Elke; Nadler, Lee M.; Cardoso, Angelo A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Barata, Joao T.] Inst Mol Med, Lisbon, Portugal. [Carlesso, Nadia] Indiana Univ Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA. RP Cardoso, AA (reprint author), Indiana Univ Sch Med, Div Hematol Oncol, 980 W Walnut St,Room R3-C321J, Indianapolis, IN 46202 USA. EM aacardos@iupui.edu RI Barata, Joao/D-9181-2015 OI Barata, Joao/0000-0002-4826-8976 FU National Institutes of Health [P01-CA68484]; Fundacao para Ciencia e Tecnologia, Portugal (FCT) [SAU/13240, CBO/34914] FX We thank Dr. Sabina Signoretti and the Pathology Core for their assistance on the immunohistochemistry studies. Supported by grants from the National Institutes of Health (P01-CA68484) and from the Fundacao para Ciencia e Tecnologia, Portugal (FCT; SAU/13240 and CBO/34914). A.B. was supported by a scholarship FCT-Portugal. NR 60 TC 19 Z9 19 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X J9 EXP HEMATOL JI Exp. Hematol. PD APR PY 2011 VL 39 IS 4 BP 457 EP 472 DI 10.1016/j.exphem.2011.01.005 PG 16 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 742WG UT WOS:000288975400008 PM 21277936 ER PT J AU Berzin, TM Sanaka, S Barnett, SR Sundar, E Sepe, PS Jakubowski, M Pleskow, DK Chuttani, R Sawhney, MS AF Berzin, Tyler M. Sanaka, Sirish Barnett, Sheila R. Sundar, Eswar Sepe, Paul S. Jakubowski, Moshe Pleskow, Douglas K. Chuttani, Ram Sawhney, Mandeep S. TI A prospective assessment of sedation-related adverse events and patient and endoscopist satisfaction in ERCP with anesthesiologist-administered sedation SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID CONSCIOUS SEDATION; RETROGRADE CHOLANGIOPANCREATOGRAPHY; PROPOFOL; MIDAZOLAM; RISK; MEPERIDINE; REVERSAL AB Background: Despite the increasing use of anesthesiologist-administered sedation for monitored anesthesia care (MAC) or general anesthesia in patients undergoing ERCP, limited prospective data exist on the effectiveness, safety, and cost of this approach. Objective: To prospectively assess sedation-related adverse events (SRAEs), patient- and procedure-related risk factors associated with SRAEs, and endoscopist and patient satisfaction with anesthesiologist-administered sedation. Design: Single-center, prospective cohort study. Setting: Tertiary-care referral center. Patients: A total of 528 consecutive patients undergoing ERCP. Interventions: Anesthesiologist-administered MAC or general anesthesia. Main Outcome Measurements: SRAEs, endoscopist and patient satisfaction. Results: There were 120 intraprocedure SRAEs during 109 of the 528 ERCPs (21% of cases). Intraprocedure SRAEs included hypotension (38 events), arrhythmia (20 events), O(2) desaturation to less than 85% (66 events), unplanned intubation (16 events), and procedure termination (1 event). Thirty postprocedure SRAEs occurred in a total of 22 patients (4% of cases), including hypotension (5 events), endotracheal intubation (2 events), and arrhythmia (12 events). Patient-related variables associated with adverse intraprocedure events were American Society of Anesthesiologists class (P = .004) and body mass index (kg/m(2)) (P = .02). On a 10-point scale, mean endoscopist satisfaction with sedation was 9.2 (standard deviation 1.8) and patient satisfaction with sedation was 9.9 (standard deviation 0.7). Limitations: The approach to sedation was not randomized. Conclusions: Higher American Society of Anesthesiologists class and body mass index are associated with an increased rate of cardiac and respiratory events during ERCP. Cardiac and respiratory events are generally minor, and MAC can be considered a safe option for most ERCP patients. Despite the frequency of minor sedation-related events, procedure interruption or premature termination was rare in the setting of anesthesiologist-administered sedation. (Gastrointest Endosc 2011;73:710-7.) C1 Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA. Beth Israel Deaconess Med Ctr, Dept Anesthesia Pain & Palliat Med, Boston, MA 02215 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Sawhney, MS (reprint author), Beth Israel Deaconess Med Ctr E, Div Gastroenterol, Rabb Rose 101,330 Brookline Ave, Boston, MA 02215 USA. OI Berzin, Tyler/0000-0002-4364-6210; Pleskow, Douglas/0000-0003-0092-9496 NR 16 TC 29 Z9 29 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2011 VL 73 IS 4 BP 710 EP 717 DI 10.1016/j.gie.2010.12.011 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 744YP UT WOS:000289131400012 PM 21316669 ER PT J AU Turner, BG Kim, MC Gee, DW Dursun, A Mino-Kenudson, M Huang, ES Sylla, P Rattner, DW Brugge, WR AF Turner, Brian G. Kim, Min-Chan Gee, Denise W. Dursun, Abdulmetin Mino-Kenudson, Mari Huang, Edward S. Sylla, Patricia Rattner, David W. Brugge, William R. TI A prospective, randomized trial of esophageal submucosal tunnel closure with a stent versus no closure to secure a transesophageal natural orifice transluminal endoscopic surgery access site SO GASTROINTESTINAL ENDOSCOPY LA English DT Article ID HERNIA REPAIR; MEDIASTINOSCOPY; SURVIVAL; THORACOSCOPY; SALIVA AB Background: Secure esophagotomy closure methods are a critical element in the advancement of transesophageal natural orifice transluminal endoscopic surgery (NOTES) procedures. Objective: To compare the clinical outcomes in swine receiving an esophageal stent or no stent after a submucosal tunnel NOTES access procedure. Design: Prospective, randomized, controlled trial in 10 Yorkshire swine. Setting: Academic center. Intervention: An endoscopic mucosectomy device was used to create an esophageal mucosal defect. An endoscope was advanced through a submucosal tunnel into the mediastinum and thorax, and diagnostic mediastinoscopy and thoracoscopy were performed. Ten animals were randomized to no stenting (n = 5) or stenting (n = 5) with a prototype small-intestine submucosa-covered stent. Main Outcome Measurements: Gross and histologic appearance of the mucosectomy and esophagotomy sites as well as clinical outcomes. Results: There was a significant difference in the overall procedure time between the animals that received a stent (35.0 min, range 27-46.0 min) and those with no closure (19.0 min, range 17-32 min) (P value = .018). The unstented group achieved endoscopic and histologic evidence of complete re-epithelialization and healing (100%) at the mucosectomy site compared with the stented group (20%, P = .048). Stem: migration into the stomach occurred in two swine. Both groups had complete closure of the submucosal tunnel and well-healed esophagotomy sites. Limitations: Animal study, small number of subjects. Conclusion: The placement of a covered esophageal stem significantly interferes with mucosectomy site healing. (Gastrointest Enclose 201173:785-90.) C1 [Turner, Brian G.; Huang, Edward S.; Brugge, William R.] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA. [Kim, Min-Chan; Gee, Denise W.; Dursun, Abdulmetin; Sylla, Patricia; Rattner, David W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Kim, Min-Chan] Dong A Univ, Coll Med, Minimally Invas & Robot Ctr, Dept Surg, Pusan, South Korea. RP Brugge, WR (reprint author), Massachusetts Gen Hosp, Gastroenterol Unit, 55 Fruit St, Boston, MA 02114 USA. FU Center for Integrative Medicine and Technology FX DISCLOSURE: Funding fir this project was provided by a grant from the Center for Integrative Medicine and Technology. D. Rattner disclosed a speaker relationship with Olympus and receipt of an honorarium. W Brugge is a consultant for Boston Scientific. Cook Medical, Inc donated the prototype stent and additional endoscopic supplies essential for completing this Mal. Mother financial relationships relevant to this publication were disclosed. NR 16 TC 6 Z9 7 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0016-5107 J9 GASTROINTEST ENDOSC JI Gastrointest. Endosc. PD APR PY 2011 VL 73 IS 4 BP 785 EP 790 DI 10.1016/j.gie.2010.11.025 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 744YP UT WOS:000289131400023 PM 21288511 ER PT J AU Hyde, R Corkins, ME Somers, GA Hart, AC AF Hyde, R. Corkins, M. E. Somers, G. A. Hart, A. C. TI PKC-1 acts with the ERK MAPK signaling pathway to regulate Caenorhabditis elegans mechanosensory response SO GENES BRAIN AND BEHAVIOR LA English DT Article DE Behavior; Caenorhabditis elegans; MAPK; mechanosensation; nose touch; PKC-1; protein kinase C ID PROTEIN-KINASE-C; GLR-1 GLUTAMATE-RECEPTOR; DORSAL-HORN NEURONS; NERVOUS-SYSTEM; PHOSPHORYLATION SITE; CHEMICAL REPELLENTS; SENSORY STIMULI; AMPA RECEPTORS; INTEGRATES PKA; NEURAL CIRCUIT AB In most animals, multiple genes encode protein kinase C (PKC) proteins. Pharmacological studies have revealed numerous roles for this protein family, yet the in vivo roles of specific PKC proteins and the functional targets of PKC activation are poorly understood. We find that in Caenorhabditis elegans, two PKC genes, pkc-1 and tpa-1, are required for mechanosensory response; the role of the nPKC epsilon/eta ortholog, pkc-1, was examined in detail. pkc-1 function is required for response to nose touch in adult C. elegans and pkc-1 likely acts in the interneurons that regulate locomotion which are direct synaptic targets of mechanosensory neurons. Previous studies have suggested numerous possible targets of pkc-1; our analysis indicates that pkc-1 may act via the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway. We find that ERK/MAPK pathway function is required for mechanosensory response in C. elegans and that at least one component of this pathway, lin-45 Raf, acts in interneurons of the mechanosensory circuit. Genetic analysis indicates that lin-45 and pkc-1 act together to regulate nose touch response. Thus, these results functionally link two conserved signaling pathways in adult C. elegans neurons and define distinct roles for PKC genes in vivo. C1 [Corkins, M. E.; Hart, A. C.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Hyde, R.; Somers, G. A.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA. [Hyde, R.; Somers, G. A.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Hart, AC (reprint author), Brown Univ, Dept Neurosci, 185 Meeting St,SFH458,Mailbox GL-N, Providence, RI 02912 USA. EM anne_hart@brown.edu FU NIH National Center for Research Resources (NCRR); National Institutes of Health [NIGMS GM57918, NINDS NS55813]; American Psychological Association FX We are grateful to Marianne Land, Charles Rubin, Derek Sieburth, Lars Dreier, Josh Kaplan, Yoshifumi Okochi, Ikue Mori, Tim Schedl, X.Z. Shawn Xu and Mike Boxem for reagents and advice. Some nematode strains used in this work were provided by the Caenorhabditis Genetics Center, which is funded by the NIH National Center for Research Resources (NCRR). We thank Komudi Singh for technical assistance and members of the Hart, van den Heuvel and Whetstine laboratories for helpful comments and discussions. This work was supported by the National Institutes of Health (NIGMS GM57918 and NINDS NS55813 to A. C. H.) and the American Psychological Association Diversity Program in Neuroscience (R.H.). NR 78 TC 10 Z9 16 U1 0 U2 3 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1601-1848 J9 GENES BRAIN BEHAV JI Genes Brain Behav. PD APR PY 2011 VL 10 IS 3 BP 286 EP 298 DI 10.1111/j.1601-183X.2010.00667.x PG 13 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 745FV UT WOS:000289152200004 PM 21143768 ER PT J AU Hu, YD Scully, R Sobhian, B Xie, AY Shestakova, E Livingston, DM AF Hu, Yiduo Scully, Ralph Sobhian, Bijan Xie, Anyong Shestakova, Elena Livingston, David M. TI RAP80-directed tuning of BRCA1 homologous recombination function at ionizing radiation-induced nuclear foci SO GENES & DEVELOPMENT LA English DT Article DE BRCA1; RAP80; homologous recombination; ionizing radiation-induced foci ID DOUBLE-STRAND-BREAK; DNA-DAMAGE-RESPONSE; SISTER-CHROMATID RECOMBINATION; BLOOMS-SYNDROME HELICASE; INACTIVE X-CHROMOSOME; MAMMALIAN-CELLS; BINDING-PROTEIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; TUMOR-SUPPRESSOR AB In response to DNA double-strand breaks (DSBs), BRCA1 forms biochemically distinct complexes with certain other DNA damage response proteins. These structures, some of which are required for homologous recombination (HR)-type DSB repair, concentrate at distinct nuclear foci that demarcate sites of genome breakage. Polyubiquitin binding by one of these structures, the RAP80/BRCA1 complex, is required for efficient BRCA1 focal recruitment, but the relationship of this process to the execution of HR has been unclear. We found that this complex actively suppresses otherwise exaggerated, BRCA1-driven HR. By controlling the kinetics by which other BRCA1-interacting proteins that promote HR concentrate together with BRCA1 in nuclear foci, RAP80/BRCA1 complexes suppress excessive DSB end processing, HR-type DSB repair, and overt chromosomal instability. Since chromosomal instability emerges when BRCA1 HR function is either unbridled or absent, active tuning of BRCA1 activity, executed in nuclear foci, is important to genome integrity maintenance. C1 [Hu, Yiduo; Sobhian, Bijan; Shestakova, Elena; Livingston, David M.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. [Hu, Yiduo; Sobhian, Bijan; Shestakova, Elena; Livingston, David M.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Scully, Ralph; Xie, Anyong] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Scully, Ralph; Xie, Anyong] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Livingston, DM (reprint author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. EM david_livingston@dfci.harvard.edu RI Scully, Ralph/F-5008-2013 FU National Cancer Institute; Breast Cancer Research Foundation; SPORE in breast cancer research; U.S. Department of Defense [W81XWH-09-1-0632] FX We thank all of our laboratory colleagues for many helpful discussions. We are also grateful to Dr. Steve Elledge and Brittany Adamson for a critical discussion of our results, and we thank Dr. Junjie Chen for providing an Abraxas/CCDC98 expression vector, Dr. Richard Baer for providing anti-CtIP antibody, Dr. Sharon Cantor for providing anti-BACH1 antibodies, Dr. Maria Jasin for providing the HomAlu ES cell line, and Dr. Peter Sicinski for providing MEFs for feeder cell preparations. This work was supported by grants from the National Cancer Institute and the Breast Cancer Research Foundation to D.M.L. and by a SPORE in breast cancer research to Dana-Farber/Harvard Cancer Center. Y.H. was supported by a U.S. Department of Defense postdoctoral fellowship award (W81XWH-09-1-0632). NR 108 TC 95 Z9 97 U1 0 U2 4 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 0890-9369 J9 GENE DEV JI Genes Dev. PD APR 1 PY 2011 VL 25 IS 7 BP 685 EP 700 DI 10.1101/gad.2011011 PG 16 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA 744AD UT WOS:000289062700004 PM 21406551 ER PT J AU Yang, SH Wang, XX Contino, G Liesa, M Sahin, E Ying, HQ Bause, A Li, YH Stommel, JM Dell'Antonio, G Mautner, J Tonon, G Haigis, M Shirihai, OS Doglioni, C Bardeesy, N Kimmelman, AC AF Yang, Shenghong Wang, Xiaoxu Contino, Gianmarco Liesa, Marc Sahin, Ergun Ying, Haoqiang Bause, Alexandra Li, Yinghua Stommel, Jayne M. Dell'Antonio, Giacomo Mautner, Josef Tonon, Giovanni Haigis, Marcia Shirihai, Orian S. Doglioni, Claudio Bardeesy, Nabeel Kimmelman, Alec C. TI Pancreatic cancers require autophagy for tumor growth SO GENES & DEVELOPMENT LA English DT Article DE pancreatic cancer; autophagy; Kras; chloroquine; DNA damage; metabolism ID CELL-DEATH; MOUSE MODEL; INHIBITION; DISEASE; ADENOCARCINOMA; TUMORIGENESIS; PROGRESSION; ELIMINATION; RESISTANCE; INDUCTION AB Macroautophagy (autophagy) is a regulated catabolic pathway to degrade cellular organelles and macromolecules. The role of autophagy in cancer is complex and may differ depending on tumor type or context. Here we show that pancreatic cancers have a distinct dependence on autophagy. Pancreatic cancer primary tumors and cell lines show elevated autophagy under basal conditions. Genetic or pharmacologic inhibition of autophagy leads to increased reactive oxygen species, elevated DNA damage, and a metabolic defect leading to decreased mitochondrial oxidative phosphorylation. Together, these ultimately result in significant growth suppression of pancreatic cancer cells in vitro. Most importantly, inhibition of autophagy by genetic means or chloroquine treatment leads to robust tumor regression and prolonged survival in pancreatic cancer xenografts and genetic mouse models. These results suggest that, unlike in other cancers where autophagy inhibition may synergize with chemotherapy or targeted agents by preventing the up-regulation of autophagy as a reactive survival mechanism, autophagy is actually required for tumorigenic growth of pancreatic cancers de novo, and drugs that inactivate this process may have a unique clinical utility in treating pancreatic cancers and other malignancies with a similar dependence on autophagy. As chloroquine and its derivatives are potent inhibitors of autophagy and have been used safely in human patients for decades for a variety of purposes, these results are immediately translatable to the treatment of pancreatic cancer patients, and provide a much needed, novel vantage point of attack. C1 [Yang, Shenghong; Wang, Xiaoxu; Li, Yinghua; Kimmelman, Alec C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Genom Stabil & DNA Repair,Dept Radiat Oncol, Boston, MA 02115 USA. [Contino, Gianmarco; Bardeesy, Nabeel] Harvard Univ, Sch Med, Ctr Canc, Massachusetts Gen Hosp,Dept Med, Boston, MA 02114 USA. [Contino, Gianmarco] Univ Milan, European Inst Oncol, Div Gen Surg, I-20141 Milan, Italy. [Liesa, Marc; Shirihai, Orian S.] Boston Univ, Sch Med, Obes Res Ctr, Dept Med, Boston, MA 02118 USA. [Sahin, Ergun; Ying, Haoqiang; Stommel, Jayne M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bause, Alexandra; Haigis, Marcia] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02114 USA. [Bause, Alexandra; Haigis, Marcia] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02114 USA. [Dell'Antonio, Giacomo; Doglioni, Claudio] San Raffaele Monte Tabor Sci Inst, Dept Pathol, I-20132 Milan, Italy. [Mautner, Josef] Univ Munich, Helmholtz Zentrum & Tech, D-81377 Munich, Germany. [Tonon, Giovanni] San Raffaele Monte Tabor Sci Inst, Div Mol Oncol, I-20132 Milan, Italy. RP Kimmelman, AC (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Genom Stabil & DNA Repair,Dept Radiat Oncol, Boston, MA 02115 USA. EM alec_kimmelman@dfci.harvard.edu OI Contino, Gianmarco/0000-0001-5874-0405; Liesa Roig, Marc/0000-0002-5909-8570; DOGLIONI, Claudio/0000-0002-4969-5216; Yang, Shusen/0000-0002-4495-6237 FU Dana-Farber Cancer Institute; National Cancer Institute [5P50CA127003-03]; Kimmel Scholar Award; AACR-PanCAN; American-Italian Cancer Foundation; Fondazione Umberto Veronesi; Fundacion Ramon Areces FX We thank Drs. Alan Wang and David Sabatini for critical reading of the manuscript. We thank Drs. Florian Muller, Dipanjan Chowdhury, Kwok Wong, Brian Alexander, and Ron DePinho for insightful discussion. We thank Dr. Xiao-Feng Zhu for shRNAs to ATG5 and Dr. Randall King for the GFP-53BP1 fusion protein. We thank Dr. Ming Tsao for the HPDE cells. We thank Dr. Andrew Thorburn for the Rab7 dominant-negative. A.C.K., S.Y., and Y.L. are supported by the Dana-Farber Cancer Institute. Funding was also provided by the National Cancer Institute Grants (5P50CA127003-03; developmental project grant to A.C.K.), Kimmel Scholar Award (to A.C.K.), and AACR-PanCAN Career Development Award (to A.C.K.). G.C. is supported by an American-Italian Cancer Foundation post-doctoral fellowship and a grant from Fondazione Umberto Veronesi. M.L. is a recipient of a post-doctoral fellowship from Fundacion Ramon Areces. NR 53 TC 424 Z9 445 U1 6 U2 76 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 0890-9369 J9 GENE DEV JI Genes Dev. PD APR 1 PY 2011 VL 25 IS 7 BP 717 EP 729 DI 10.1101/gad.2016111 PG 13 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA 744AD UT WOS:000289062700006 PM 21406549 ER PT J AU Levy, DE Byfield, SD Comstock, CB Garber, JE Syngal, S Crown, WH Shields, AE AF Levy, Douglas E. Byfield, Stacey D. Comstock, Catherine B. Garber, Judy E. Syngal, Sapna Crown, William H. Shields, Alexandra E. TI Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk SO GENETICS IN MEDICINE LA English DT Article DE breast cancer; BRCA1/2; race; ethnicity ID PRIMARY-CARE PHYSICIANS; AFRICAN-AMERICAN WOMEN; OVARIAN-CANCER; HEREDITARY BREAST; MUTATION CARRIERS; UNITED-STATES; DISPARITIES; SUSCEPTIBILITY; POPULATION; DECISIONS AB Purpose: Women with early-onset (age <= 40 years) breast cancer are at high risk of carrying deleterious mutations in the BRCA1/2 genes; genetic assessment is thus recommended. Knowledge of BRCA1/2 mutation status is useful in guiding treatment decisions. To date, there has been no national study of BRCA1/2 testing among newly diagnosed women. Methods: We used administrative data (2004-2007) from a national sample of 14.4 million commercially insured patients to identify newly diagnosed, early-onset breast cancer cases among women aged 20-40 years (n = 1474). Cox models assessed BRCA1/2 testing, adjusting for covariates and differential lengths of follow-up. Results: Overall, 30% of women aged 40 years or younger received BRCA1/2 testing. In adjusted analyses, women of Jewish ethnicity were significantly more likely to be tested (hazard ratio = 2.83, 95% confidence interval: 1.52-5.28), whereas black women (hazard ratio = 0.34, 95% 0.18-0.64) and Hispanic women (hazard ratio = 0.52, 95% confidence interval: 0.33-0.81) were significantly less likely to be tested than non-Jewish white women. Those enrolled in a health maintenance organization (hazard ratio = 0.73, 95% confidence interval: 0.54-0.99) were significantly less likely to receive BRCA1/2 testing than those point of service insurance plans. Testing rates increased sharply for women diagnosed in 2007 compared with 2004. Conclusions: In this national sample of patients with newly diagnosed breast cancer at high risk for BRCA1/2 mutations, genetic assessment was low, with marked racial differences in testing. Genet Med 2011:13(4):349-355. C1 [Levy, Douglas E.; Shields, Alexandra E.] Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, Boston, MA 02114 USA. [Levy, Douglas E.; Shields, Alexandra E.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Levy, Douglas E.; Garber, Judy E.; Syngal, Sapna; Shields, Alexandra E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Byfield, Stacey D.; Crown, William H.] I3 Innovus, Medford, MA USA. [Garber, Judy E.; Syngal, Sapna] Dana Farber Canc Inst, Div Populat Sci, Brookline, MA USA. [Syngal, Sapna] Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA. I3 Innovus, Ann Arbor, MI USA. RP Shields, AE (reprint author), Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM ashields@partners.org FU Dana-Farber/Harvard Cancer Center as part of National Institutes of Health [P30 CA06516-43]; NCI [R25 CA92203-04] FX This work was supported by a Nodal Award Grant (A. E. S., PI) from the Dana-Farber/Harvard Cancer Center as part of the Center's Grant from the National Institutes of Health (P30 CA06516-43) and by a training Grant from NCI (R25 CA92203-04) (S. D. B.). The authors thank Anna Boonin Schachter, MPH, and Nicole D. Colucci, BA, for research assistance. They gratefully acknowledge Wylie Burke, MD, and John Z. Ayanian, MD, MPP, for their comments on an earlier draft of this article. NR 44 TC 58 Z9 58 U1 2 U2 10 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD APR PY 2011 VL 13 IS 4 BP 349 EP 355 DI 10.1097/GIM.0b013e3182091ba4 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 742ZD UT WOS:000288983200012 PM 21358336 ER PT J AU Serandour, AA Avner, S Percevault, F Demay, F Bizot, M Lucchetti-Miganeh, C Barloy-Hubler, F Brown, M Lupien, M Metivier, R Salbert, G Eeckhoute, J AF Serandour, Aurelien A. Avner, Stephane Percevault, Frederic Demay, Florence Bizot, Maud Lucchetti-Miganeh, Celine Barloy-Hubler, Frederique Brown, Myles Lupien, Mathieu Metivier, Raphael Salbert, Gilles Eeckhoute, Jerome TI Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers SO GENOME RESEARCH LA English DT Article ID EMBRYONAL CARCINOMA-CELLS; FORKHEAD BOX A1; DNA METHYLATION; TRANSCRIPTION FACTORS; BREAST-CANCER; HUMAN GENOME; ANDROGEN RECEPTOR; NEURAL DIFFERENTIATION; HISTONE MODIFICATIONS; PROSTATE-CANCER AB Transcription factors (TFs) bind specifically to discrete regions of mammalian genomes called cis-regulatory elements. Among those are enhancers, which play key roles in regulation of gene expression during development and differentiation. Despite the recognized central regulatory role exerted by chromatin in control of TF functions, much remains to be learned regarding the chromatin structure of enhancers and how it is established. Here, we have analyzed on a genomic-scale enhancers that recruit FOXA1, a pioneer transcription factor that triggers transcriptional competency of these cis-regulatory sites. Importantly, we found that FOXA1 binds to genomic regions showing local DNA hypomethylation and that its cell-type-specific recruitment to chromatin is linked to differential DNA methylation levels of its binding sites. Using neural differentiation as a model, we showed that induction of FOXA1 expression and its subsequent recruitment to enhancers is associated with DNA demethylation. Concomitantly, histone H3 lysine 4 methylation is induced at these enhancers. These epigenetic changes may both stabilize FOXA1 binding and allow for subsequent recruitment of transcriptional regulatory effectors. Interestingly, when cloned into reporter constructs, FOXA1-dependent enhancers were able to recapitulate their cell type specificity. However, their activities were inhibited by DNA methylation. Hence, these enhancers are intrinsic cell-type-specific regulatory regions of which activities have to be potentiated by FOXA1 through induction of an epigenetic switch that includes notably DNA demethylation. C1 [Serandour, Aurelien A.; Avner, Stephane; Percevault, Frederic; Demay, Florence; Bizot, Maud; Lucchetti-Miganeh, Celine; Barloy-Hubler, Frederique; Metivier, Raphael; Salbert, Gilles; Eeckhoute, Jerome] Univ Rennes 1, F-35065 Rennes, France. [Serandour, Aurelien A.; Avner, Stephane; Percevault, Frederic; Bizot, Maud; Lucchetti-Miganeh, Celine; Barloy-Hubler, Frederique; Metivier, Raphael; Salbert, Gilles; Eeckhoute, Jerome] CNRS, Equipe SPARTE Labellise Ligue Natl Canc, UMR 6026, F-35042 Rennes, France. [Serandour, Aurelien A.; Avner, Stephane; Percevault, Frederic; Demay, Florence; Bizot, Maud; Lucchetti-Miganeh, Celine; Barloy-Hubler, Frederique; Metivier, Raphael; Salbert, Gilles; Eeckhoute, Jerome] Univ Europeenne Bretagne, F-35000 Rennes, France. [Demay, Florence] CNRS, Equipe RED, UMR 6026, F-35042 Rennes, France. [Brown, Myles] Dana Farber Canc Inst, Div Mol & Cellular Oncol, Dept Med Oncol, Boston, MA 02115 USA. [Lupien, Mathieu] Dartmouth Med Sch, Dept Genet, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA. RP Salbert, G (reprint author), Univ Rennes 1, F-35065 Rennes, France. EM gilles.salbert@univ-rennes1.fr; jerome.eeckhoute@inserm.fr RI percevault, frederic/K-1836-2015; demay, florence/K-1881-2015; Serandour, Aurelien/C-1390-2010; OI Serandour, Aurelien/0000-0001-5253-9567; Brown, Myles/0000-0002-8213-1658; Eeckhoute, Jerome/0000-0002-7222-9264 FU Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1; Region Bretagne [SAD 08HC315-02]; Rennes metropole [08.503]; Ligue nationale contre le cancer; Agence Nationale de la Recherche; French Ministerede l'enseignement superieur et de la recherche FX We are indebted to G. Palierne and C. Brigand for technical assistance and to Dr. C. Meyer and Dr. X. S. Liu (Dana-Farber Cancer Institute, Boston, MA) for advice regarding analyses of tiling array data. We also thank Dr. Patrick Descombes (University of Geneva, Switzerland) and Dr. Catherine Chevalier (OUEST-Genopole Microarray Core Facility, Nantes, France) for their advice and help with the DNA labeling and array hybridization protocols. We acknowledge Dr. M. Klug and Dr. M. Rehli (University Hospital, Regensburg, Germany) for their generous gift of the pCpGLCMV/EF1 vector and Dr. Z. Culig (Innsbruck Medical University, Austria) for providing us with the LNCaP-abl cells. This work was supported by funds from the Centre National de la Recherche Scientifique (CNRS), Universite de Rennes 1, Region Bretagne (SAD 08HC315-02), Rennes metropole (Allocation 08.503), Ligue nationale contre le cancer, and Agence Nationale de la Recherche. A. A. S. is a recipient of a fellowship from the French Ministerede l'enseignement superieur et de la recherche. NR 69 TC 103 Z9 105 U1 3 U2 19 PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT PI COLD SPRING HARBOR PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA SN 1088-9051 J9 GENOME RES JI Genome Res. PD APR PY 2011 VL 21 IS 4 BP 555 EP 565 DI 10.1101/gr.111534.110 PG 11 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 744BN UT WOS:000289067800006 PM 21233399 ER PT J AU Wang, XF Laurie, JD Liu, T Wentz, J Liu, XS AF Wang, Xiangfeng Laurie, John D. Liu, Tao Wentz, Jacqueline Liu, X. Shirley TI Computational dissection of Arabidopsis smRNAome leads to discovery of novel microRNAs and short interfering RNAs associated with transcription start sites SO GENOMICS LA English DT Article DE High-throughput sequencing; Small RNAs; Principal component analysis; TSS-associated RNAs ID DEEP SEQUENCING DATA; DNA METHYLATION; POLYMERASE-IV; PLANT MICRORNAS; GENE-EXPRESSION; GENOME-WIDE; HUMAN-CELLS; TINY RNAS; SIRNAS; THALIANA AB The profiling of small RNAs by high-throughput sequencing (smRNA-Seq) has revealed the complexity of the RNA world. Here, we describe a computational scheme for dissecting the plant smRNAome by integrating smRNA-Seq datasets in Arabidopsis thaliana. Our analytical approach first defines ab initio the genomic loci that produce smRNAs as basic units, then utilizes principal component analysis (PCA) to predict novel miRNAs. Secondary structure prediction of candidates' putative precursors discovered a group of long hairpin double-stranded RNAs (Ih-dsRNAs) formed by inverted duplications of decayed coding genes. These gene remnants produce miRNA-like small RNAs which are predominantly 21- and 22-nt long, dependent of DCL1 but independent of RDR2 and DCL2/3/4, and associated with AGO1. Additionally, we found two classes of transcription start site associated (TSSa) RNAs located at sense (+) and antisense (-) approximately 100200 bp downstream of TSSs, but are differentially incorporated into AGO1 and AG04, respectively. Published by Elsevier Inc. C1 [Wang, Xiangfeng; Laurie, John D.] Univ Arizona, Sch Plant Sci, Tucson, AZ 85721 USA. [Wang, Xiangfeng; Liu, Tao; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Wang, Xiangfeng; Liu, Tao; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Wentz, Jacqueline] MIT, Dept Bioengn, Cambridge, MA 02139 USA. RP Wang, XF (reprint author), Univ Arizona, Sch Plant Sci, 1140 E S Campus Dr, Tucson, AZ 85721 USA. EM xwang1@cals.arizona.edu; xsliu@jimmy.harvard.edu RI Liu, Tao/G-3585-2010; OI Liu, Tao/0000-0002-8818-8313; Liu, Tao/0000-0003-0446-9001 FU Sloan Research Fellowship; NIH [HG004069] FX We thank Dr. Yijun Qi of the National Institute of Biological Sciences at Beijing for generously providing the processed AGO1/2/4/5 associated smRNA-Seq data. We are grateful to Scott Taing for proofreading the manuscript. Dr. Xiangfeng Wang is a research fellow supported by Sloan Research Fellowship and NIH grant HG004069. NR 46 TC 4 Z9 5 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0888-7543 EI 1089-8646 J9 GENOMICS JI Genomics PD APR PY 2011 VL 97 IS 4 BP 235 EP 243 DI 10.1016/j.ygeno.2011.01.006 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 743VP UT WOS:000289047100006 PM 21295131 ER PT J AU Growdon, WB Roussel, BN Scialabba, VL Foster, R Dias-Santagata, D Iafrate, AJ Ellisen, LW Tambouret, RH Rueda, BR Borger, DR AF Growdon, Whitfield B. Roussel, Breton N. Scialabba, Vanessa L. Foster, Rosemary Dias-Santagata, Dora Iafrate, A. John Ellisen, Leif W. Tambouret, Rosemary H. Rueda, Bo R. Borger, Darrell R. TI Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin SO GYNECOLOGIC ONCOLOGY LA English DT Article DE Carcinosarcoma; Metaplastic carcinoma; Genotyping; Mutation; PIK3CA; KRAS ID MIXED MULLERIAN TUMORS; PHASE-II TRIAL; ONCOLOGY-GROUP; UTERINE CARCINOSARCOMAS; ENDOMETRIAL CARCINOMA; MESODERMAL TUMORS; C-KIT; METAPLASTIC CARCINOMAS; MESENCHYMAL COMPONENTS; STAGE-I AB Objectives. Gynecologic carcinosarcoma is an aggressive malignancy that requires more effective treatment approaches. However, therapeutic implications regarding the specific gynecologic site of origin and the admixture of carcinomatous and sarcomatous elements that define this tumor remain uncertain. Therefore, broad genotyping was performed to identify tissue-specific somatic mutational profiles that may help direct targeted therapies in this complex neoplasia. Methods. Genotyping was conducted on primary gynecologic carcinosarcomas arising from various disease sites (uterus, ovary, fallopian tube, vagina) and within isolated histological subcomponents. Nucleic acids extracted from diagnostic tissue were used in a genotyping platform that simultaneously queried >120 common mutations across 14 cancer genes. Mutational status was correlated with clinical variables using logistic regression and Kaplan-Meier survival estimates. Results. Cancer gene mutations were identified in 46% of the 52 patient cohort and include TP53 (23%), PIK3CA (19%), KRAS (15%), CTNNB1 (4%) and NRAS (2%). Mutation in a single gene was observed in 31% of patient samples, while synchronous mutations involving 2 and 3 genes were noted in 13% and 2% of samples, respectively. Comparative evaluation of the carcinomatous and sarcomatous elements within a tumor demonstrated a similar mutation signature. Mutations in PIK3CA, KRAS and NRAS were exclusive to tumors of uterine origin and age-adjusted Cox proportional hazards modeling associated advanced age, stage and TP53 mutations with decreased survival in the uterine subset. Conclusion. While carcinosarcomas across gynecologic disease sites are histologically similar, therapeutically relevant mutations in the mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways predominated in carcinosarcomas arising in the uterus. (C) 2010 Elsevier Inc. All rights reserved. C1 [Roussel, Breton N.; Scialabba, Vanessa L.; Ellisen, Leif W.; Borger, Darrell R.] Massachusetts Gen Hosp, Translat Res Lab, Ctr Canc, Div Hematol Oncol, Boston, MA 02114 USA. [Growdon, Whitfield B.; Foster, Rosemary; Rueda, Bo R.] Massachusetts Gen Hosp, MGH Vincent Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. [Dias-Santagata, Dora; Iafrate, A. John; Tambouret, Rosemary H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Growdon, Whitfield B.] Massachusetts Gen Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Growdon, Whitfield B.; Foster, Rosemary; Dias-Santagata, Dora; Iafrate, A. John; Ellisen, Leif W.; Tambouret, Rosemary H.; Rueda, Bo R.; Borger, Darrell R.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Borger, DR (reprint author), Massachusetts Gen Hosp, Translat Res Lab, Ctr Canc, Div Hematol Oncol, GRJ 1008A,55 Fruit St, Boston, MA 02114 USA. EM dborger@partners.org FU Advanced Medical Research Foundation; Vincent Memorial Research Funds; Belkin family fund FX We would like to thank Susan Boisvert, Kenneth Fan and Serena David for their technical assistance. We would also like to thank Dr. Robert H. Young for providing his expert knowledge in carcinosarcoma diagnosis. These investigations were supported by generous grants from the Advanced Medical Research Foundation, Vincent Memorial Research Funds and the Belkin family fund. NR 50 TC 25 Z9 25 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD APR PY 2011 VL 121 IS 1 BP 212 EP 217 DI 10.1016/j.ygyno.2010.11.039 PG 6 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA 742DO UT WOS:000288920700037 PM 21168197 ER PT J AU Singer, SJ Hayes, J Cooper, JB Vogt, JW Sales, M Aristidou, A Gray, GC Kiang, MV Meyer, GS AF Singer, Sara J. Hayes, Jennifer Cooper, Jeffrey B. Vogt, Jay W. Sales, Michael Aristidou, Angela Gray, Garry C. Kiang, Mathew V. Meyer, Gregg S. TI A case for safety leadership team training of hospital managers SO HEALTH CARE MANAGEMENT REVIEW LA English DT Article DE collective learning; leadership training; multidisciplinary teams; patient safety ID HEALTH-CARE; PATIENT SAFETY; TECHNOLOGY IMPLEMENTATION; PSYCHOLOGICAL SAFETY; LEARNING ORIENTATION; PERFORMANCE; WORK; IMPROVEMENT; BEHAVIOR; ERROR AB Background: Delivering safe patient care remains an elusive goal. Resolving problems in complex organizations like hospitals requires managers to work together. Safety leadership training that encourages managers to exercise learning-oriented, team-based leadership behaviors could promote systemic problem solving and enhance patient safety. Despite the need for such training, few programs teach multidisciplinary groups of managers about specific behaviors that can enhance their role as leadership teams in the realm of patient safety. Purpose: The aims of this study were to describe a learning-oriented, team-based, safety leadership training program composed of reinforcing exercises and to provide evidence confirming the need for such training and demonstrating behavior change among management groups after training. Methods: Twelve groups of managers from an academic medical center based in the Northeast United States were randomly selected to participate in the program and exposed to its customized, experience-based, integrated, multimodal curriculum. We extracted data from transcripts of four training sessions over 15 months with groups of managers about the need for the training in these groups and change in participants' awareness, professional behaviors, and group activity. Findings: Training transcripts confirmed the need for safety leadership team training and provided evidence of the potential for training to increase targeted behaviors. The training increased awareness and use of leadership behaviors among many managers and led to new routines and coordinated effort among most management groups. Enhanced learning-oriented leadership often helped promote a learning orientation in managers' work areas. Practice Implications: Team-based training that promotes specific learning-oriented leader behaviors can promote behavioral change among multidisciplinary groups of hospital managers. C1 [Singer, Sara J.; Gray, Garry C.; Kiang, Mathew V.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Singer, Sara J.; Cooper, Jeffrey B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Cooper, Jeffrey B.] Ctr Med Simulat, Cambridge, MA USA. [Vogt, Jay W.] Peoplesworth, Concord, MA USA. [Sales, Michael] Art Future, Newburyport, MA USA. [Aristidou, Angela] Univ Cambridge, Judge Business Sch, Cambdridge, England. [Meyer, Gregg S.] Massachusetts Gen Hosp, Massachusetts Gen Phys Org, Ctr Qual & Safety, Boston, MA 02114 USA. RP Singer, SJ (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. EM ssinger@hsph.harvard.edu NR 49 TC 8 Z9 8 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0361-6274 J9 HEALTH CARE MANAGE R JI Health Care Manage. Rev. PD APR-JUN PY 2011 VL 36 IS 2 BP 188 EP 200 DI 10.1097/HMR.0b013e318208cd1d PG 13 WC Health Policy & Services SC Health Care Sciences & Services GA 730BC UT WOS:000288002700010 PM 21317660 ER PT J AU Weinick, RM Elliott, MN Volandes, AE Lopez, L Burkhart, Q Schlesinger, M AF Weinick, Robin M. Elliott, Marc N. Volandes, Angelo E. Lopez, Lenny Burkhart, Q. Schlesinger, Mark TI Using Standardized Encounters to Understand Reported Racial/Ethnic Disparities in Patient Experiences with Care SO HEALTH SERVICES RESEARCH LA English DT Article DE Racial; ethnic disparities; CAHPS; patient experiences with care; measurement ID MEDICAID MANAGED CARE; HEALTH-CARE; ETHNIC-DIFFERENCES; ASSESSMENTS; SATISFACTION; RESPONSES; RATINGS AB Objective To assess the extent to which racial/ethnic differences in ratings of patient experiences with health care represent true differences versus differences in expectations, how scales are used, or how identical physician-patient interactions are perceived by members of different groups. Study Setting Primary data collection from a nationally representative online panel (n=567), including white, African American, and Latino respondents. Study Design We administered questions on expectations of care, a series of written vignettes, a video-depicted doctor-patient interaction, and modified CAHPS Clinician and Group Doctor Communication items. Principal Findings Different groups reported generally similar expectations regarding physicians' behaviors and provided similar mean responses to CAHPS communication items in response to standardized encounters. Conclusions Preliminary evidence suggests that unlike more subjective global ratings, reported disparities in more specific and objective CAHPS composites may primarily reflect differences in experiences, rather than differences in expectations and scale use, adding to our confidence in using the latter to assess disparities. C1 [Weinick, Robin M.] RAND Corp, Arlington, VA 22202 USA. [Elliott, Marc N.; Burkhart, Q.] RAND Corp, Santa Monica, CA USA. [Volandes, Angelo E.] Massachusetts Gen Hosp, Sect Gen Med, Boston, MA 02114 USA. [Lopez, Lenny] Mongan Inst Hlth Policy, Boston, MA USA. [Schlesinger, Mark] Yale Univ, Sch Publ Hlth, New Haven, CT USA. RP Weinick, RM (reprint author), RAND Corp, 1200 S Hayes St, Arlington, VA 22202 USA. EM rweinick@rand.org OI Weinick, Robin/0000-0002-7188-1162 FU Robert Wood Johnson Foundation [63843] FX This work was funded by a grant from the Robert Wood Johnson Foundation (grant #63843). The authors would like to thank Steffanie Bristol for her research assistance, Poom Nukulkij for his assistance with data collection for this project, and the anonymous reviewers for their helpful comments. An earlier version of this work was presented at the 2009 Annual Meeting of AcademyHealth. NR 30 TC 24 Z9 24 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2011 VL 46 IS 2 BP 491 EP 509 DI 10.1111/j.1475-6773.2010.01214.x PG 19 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 729QL UT WOS:000287965600009 PM 21143475 ER PT J AU Park, J Konetzka, RT Werner, RM AF Park, Jeongyoung Konetzka, R. Tamara Werner, Rachel M. TI Performing Well on Nursing Home Report Cards: Does It Pay Off? SO HEALTH SERVICES RESEARCH LA English DT Article DE Public reporting; quality of care; nursing homes; financial performance ID COMPARE REPORT CARD; QUALITY-OF-CARE; LONG-TERM-CARE; UNINTENDED CONSEQUENCES; DISPARITIES; PUBLICATION; TRENDS AB Objective To examine whether high performance or improvement on quality measures leads to economic rewards for nursing homes in the presence of public reporting. Data Sources Data from 6,286 freestanding Medicare-certified nursing homes between 1999 and 2005 were identified in Medicare Cost Reports, Minimum Data Set, and Online Survey and Certification Reporting System. Study Design Using a facility-level fixed-effects model, the effect of public reporting on financial performance was measured by comparing each of four financial outcomes (revenues, expenses, operating, and total profit margins) before (1999-2002) to after (2003-2005) public reporting was initiated. The effects were estimated separately by level of performance and improvement over time. Principal Findings Facilities that improved on publicly reported performance had increased revenues and higher profit margins after public reporting, mainly through increased Medicare admissions. High-scoring facilities showed similar patterns, though differences were not statistically significant. Conclusions Providers that improve their performance under public reporting may receive a return on their investment in quality improvement. This supports the business case for public reporting. C1 [Park, Jeongyoung] Amer Board Internal Med, Philadelphia, PA 19106 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Philadelphia VAMC, Ctr Hlth Equ Res & Promot, Philadelphia, PA 19104 USA. RP Park, J (reprint author), Amer Board Internal Med, 510 Walnut St,Suite 1700, Philadelphia, PA 19106 USA. EM jpark@abim.org FU Agency for Healthcare Research and Quality [R01 HS016478-01]; VA HSRD FX This research was funded by a grant from the Agency for Healthcare Research and Quality (R01 HS016478-01). Rachel M. Werner is supported in part by a VA HSR&D Career Development Award. An earlier version of the study was presented at the 2009 AcademyHealth Annual Research Meeting. NR 27 TC 6 Z9 6 U1 1 U2 7 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2011 VL 46 IS 2 BP 531 EP 554 DI 10.1111/j.1475-6773.2010.01197.x PG 24 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 729QL UT WOS:000287965600011 PM 21029093 ER PT J AU Werner, RM Konetzka, RT Stuart, EA Polsky, D AF Werner, Rachel M. Konetzka, R. Tamara Stuart, Elizabeth A. Polsky, Daniel TI Changes in Patient Sorting to Nursing Homes under Public Reporting: Improved Patient Matching or Provider Gaming? SO HEALTH SERVICES RESEARCH LA English DT Article DE Public reporting; quality of care; nursing home quality ID REPORT CARDS; PERFORMANCE DATA; QUALITY MEASURES; ASSESSMENTS; SURGERY; COMPARE; IMPACT; PAIN AB Objective To test whether public reporting in the setting of postacute care in nursing homes results in changes in patient sorting. Data Sources/Study Setting All postacute care admissions from 2001 to 2003 in the nursing home Minimum Data Set. Study Design We test changes in patient sorting (or the changes in the illness severity of patients going to high- versus low-scoring facilities) when public reporting was initiated in nursing homes in 2002. We test for changes in sorting with respect to pain, delirium, and walking and then examine the potential roles of cream skimming and downcoding in changes in patient sorting. We use a difference-in-differences framework, taking advantage of the variation in the launch of public reporting in pilot and nonpilot states, to control for underlying trends in patient sorting. Principal Findings There was a significant change in patient sorting with respect to pain after public reporting was initiated, with high-risk patients being more likely to go to high-scoring facilities and low-risk patients more likely to go to low-scoring facilities. There was also an overall decrease in patient risk of pain with the launch of public reporting, which may be consistent with changes in documentation of pain levels (or downcoding). There was no significant change in sorting for delirium or walking. Conclusions Public reporting of nursing home quality improves matching of high-risk patients to high-quality facilities. However, efforts should be made to reduce the incentives for downcoding by nursing facilities. C1 [Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Sch Med, Ctr Hlth Equ Res & Promot,Philadelphia VAMC, Philadelphia, PA 19104 USA. [Konetzka, R. Tamara] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Stuart, Elizabeth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA. [Polsky, Daniel] Univ Penn, Div Gen Internal Med, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Werner, RM (reprint author), Univ Penn, Div Gen Internal Med, Sch Med, Ctr Hlth Equ Res & Promot,Philadelphia VAMC, 1230 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM rwerner@upenn.edu OI Stuart, Elizabeth/0000-0002-9042-8611 FU Agency for Healthcare Research and Quality [R01 HS016478-01]; VA HSRD FX This research was funded by a grant from the Agency for Healthcare Research and Quality (R01 HS016478-01). Rachel M. Werner is supported in part by a VA HSR&D Career Development Award. NR 21 TC 9 Z9 9 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2011 VL 46 IS 2 BP 555 EP 571 DI 10.1111/j.1475-6773.2010.01205.x PG 17 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 729QL UT WOS:000287965600012 PM 21105869 ER PT J AU Yi, YS Emanuel, KM Chuang, SK AF Yi, Young S. Emanuel, Kim M. Chuang, Sung-Kiang TI Short (5.0 x 5.0 mm) Implant Placements and Restoration With Integrated Abutment Crowns SO IMPLANT DENTISTRY LA English DT Article DE short implant; dentistry; edentulism; complication ID SHORT DENTAL IMPLANTS; FOLLOW-UP; SURVIVAL; MAXILLAE AB The average length of dental implants has decreased over the years. The rationale behind shorter dental implants includes an expansion of the patient pool that can benefit from dental implants, decreased procedural invasiveness, and subsequent shorter osseointegration and healing periods. While the stability and efficacy of shorter implants have been criticized, research about short implants has continued and led to numerous clinical studies that have demonstrated a comparable clinical effectiveness between short and long implants. This study validates the clinical feasibility of the shortest dental implant available. This article reports on the success of using four 5.0 x 5.0 mm implants in a 56-year-old patient with partial edentulism. The entire treatment was accomplished in 3 clinical visits, concluding with insertion of an Integrated Abutment Crown in each implant site. The success of this case study suggests a potential for decreasing the frequency of complications, such as inferior alveolar canal perforation, and of being able to provide dental implants to individuals who have inadequate alveolar bone levels for conventionally longer implants. (Implant Dent 2011; 20:125-130) C1 [Chuang, Sung-Kiang] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yi, Young S.; Chuang, Sung-Kiang] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA. [Emanuel, Kim M.] Implant Dent Ctr, Boston, MA USA. RP Chuang, SK (reprint author), Chestnut Hill Stn, POB 67376, Chestnut Hill, MA 02467 USA. EM sungkiangchuang@gmail.com NR 19 TC 7 Z9 7 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1056-6163 J9 IMPLANT DENT JI Implant Dent. PD APR PY 2011 VL 20 IS 2 BP 125 EP 130 DI 10.1097/ID.0b013e31820fb67e PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 742KS UT WOS:000288942400008 PM 21448021 ER PT J AU Nguyen, PL Chen, MH Choueiri, TK Hoffman, KE Hu, JC Martin, NE Beard, CJ Dosoretz, DE Moran, BJ Katin, MJ Braccioforte, MH Ross, R Salenius, SA Kantoff, PW D'Amico, AV AF Nguyen, Paul L. Chen, Ming H. Choueiri, Toni K. Hoffman, Karen E. Hu, Jim C. Martin, Neil E. Beard, Claw J. Dosoretz, Daniel E. Moran, Brian J. Katin, Michael J. Braccioforte, Michelle H. Ross, Rud Salenius, Sharon A. Kantoff, Philip W. D'Amico, Anthony V. TI RISK OF ALL-CAUSE AND PROSTATE CANCER-SPECIFIC MORTALITY AFTER BRACHYTHERAPY IN MEN WITH SMALL PROSTATE SIZE SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Prostate cancer; Brachytherapy; Small volume; All-cause mortality; Prostate volume ID THERAPY AB Background: Brachytherapy for prostate cancer can be technically challenging in men with small prostates (<= 20 cc), but it is unknown whether their outcomes are different than those of men with larger prostates. Methods and Materials: We studied 6,416 men treated with brachytherapy in one of 21 community-based practices. Cox regression and Fine and Gray's regression were used to determine whether volume <= 20 cc was associated with a higher risk of all-cause mortality (ACM) or prostate cancer specific mortality (PCSM), respectively, after adjustment for other known prognostic factors. Results: 443 patients (6.9%) had a prostate volume <= 20 cc. After a median follow-up of 2.91 years (interquartile range, 1.06-4.79), volume <= 20 cc was associated with a significantly higher risk of ACM (adjusted hazard ratio = 1.33 [95% CI 1.08-1.65], p = 0.0085) with 3-year estimates of ACM for <= 20 cc vs. > 20 cc of 13.0% vs. 6.9% (p = 0.028). Only 23 men (0.36%) have died of prostate cancer, and no difference was seen in PCSM by volume (p = 0.4). Conclusion: Men with small prostates at the time of implant had a 33% higher risk of ACM, and the underlying cause of this remains uncertain. No increase in PCSM was observed in men with volume <= 20cc, suggesting that a small prostate should not in itself be a contraindication for brachytherapy, but inasmuch as absolute rates of PCSM were small, further follow-up will be needed to confirm this finding. (C) 2011 Elsevier Inc. C1 [Nguyen, Paul L.; D'Amico, Anthony V.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Nguyen, Paul L.; D'Amico, Anthony V.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. [Choueiri, Toni K.; Kantoff, Philip W.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hu, Jim C.] Brigham & Womens Hosp, Dept Urol, Boston, MA 02115 USA. [Nguyen, Paul L.; Choueiri, Toni K.; Hu, Jim C.; Martin, Neil E.; Beard, Claw J.; Kantoff, Philip W.; D'Amico, Anthony V.] Harvard Univ, Sch Med, Boston, MA USA. [Chen, Ming H.] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA. [Hoffman, Karen E.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Dosoretz, Daniel E.; Katin, Michael J.; Ross, Rud; Salenius, Sharon A.] 21st Century Oncol, Ft Myers, FL USA. [Moran, Brian J.; Braccioforte, Michelle H.] Chicago Prostate Ctr, Westmont, IL USA. RP Nguyen, PL (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM E-pnguyen@LROC.harvard.edu RI Martin, Neil/E-2193-2014 OI Martin, Neil/0000-0002-8164-8516 NR 11 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD APR 1 PY 2011 VL 79 IS 5 BP 1318 EP 1322 DI 10.1016/j.ijrobp.2010.01.023 PG 5 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 742YB UT WOS:000288980100006 PM 20605366 ER PT J AU Valicenti, RK Bae, K Michalski, J Sandler, H Shipley, W Lin, A Cox, J AF Valicenti, Richard K. Bae, Kwounghwa Michalski, Jeff Sandler, Howard Shipley, William Lin, Alex Cox, James TI DOES HORMONE THERAPY REDUCE DISEASE RECURRENCE IN PROSTATE CANCER PATIENTS RECEIVING DOSE-ESCALATED RADIATION THERAPY? AN ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP 94-06 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Prostate cancer; Hormone therapy; Radiation therapy; Dose escalation; Biochemical failure ID RANDOMIZED CONTROLLED-TRIAL; PHASE-III TRIAL; ANDROGEN SUPPRESSION; CONFORMAL RADIOTHERAPY; TERM; NEOADJUVANT; DEPRIVATION; CARCINOMA; TOXICITY; ADJUVANT AB Purpose: The purpose of this study was to evaluate the effect on freedom from biochemical failure (bNED) or disease-free survival (DFS) by adding hormone therapy (HT) to dose-escalated radiation therapy (HDRT). Methods and Materials: We used 883 analyzable prostate cancer patients who enrolled on Radiation Therapy Oncology Group (RTOG) 94-06, a Phase I/II dose escalation trial, and whose mean planning target volume dose exceeded 73.8 Gy (mean, 78.5 Gy; maximum, 84.3 Gy). We defined biochemical failure according to the Phoenix definition. Results: A total of 259 men started HT 2 to 3 months before HDRT, but not longer than 6 months, and 66 men with high-risk prostate cancer received HT for a longer duration. At 5 years, the biochemical failure rates after HDRT alone were 12%, 18%, and 29% for low-, intermediate-, and high-risk patients, respectively (p < 0.0001). Cox proportional hazards regression analysis adjusted for covariates revealed that pretreatment PSA level was a significant factor, whereas risk group, Gleason score, T-stage, and age were not. When the patients were stratified by risk groups, the Cox proportion hazards regression model (after adjusting for pretreatment PSA, biopsy Gleason score, and T stage) did not reveal a significant effect on bNED or DES by adding HT to HDRT. Conclusion: The addition of HT did not significantly improve bNED survival or DES in all prostate cancer patients receiving HDRT, but did approach significance in high-risk patient subgroup. The result of this study is hypothesis generating and requires testing in a prospective randomized trial. (C) 2011 Elsevier Inc. C1 [Valicenti, Richard K.] Univ Calif Davis, Sch Med, Dept Radiat Oncol, Sacramento, CA 95817 USA. [Bae, Kwounghwa] Dept Stat, Radiat Therapy Oncol Grp, Philadelphia, PA USA. [Michalski, Jeff] Washington Univ, Dept Radiat Oncol, St Louis, MO USA. [Sandler, Howard] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA. [Shipley, William] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Lin, Alex] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA. [Cox, James] Univ Texas Houston, MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA. RP Valicenti, RK (reprint author), Univ Calif Davis, Sch Med, Dept Radiat Oncol, 4501 X St,G140, Sacramento, CA 95817 USA. EM richard.valicenti@ucdmc.ucdavis.edu FU National Cancer Institute (NCI) [RTOG U10 CA21661, CCOP U10 CA37422, Stat U10 CA32115] FX Supported by RTOG U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115 grants from the National Cancer Institute (NCI). This manuscript's contents are the sole responsibility of the authors and do not necessarily represent the official views of the NCI. NR 29 TC 33 Z9 33 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD APR 1 PY 2011 VL 79 IS 5 BP 1323 EP 1329 DI 10.1016/j.ijrobp.2010.01.009 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 742YB UT WOS:000288980100007 PM 21414514 ER PT J AU Alexander, BM Othus, M Caglar, HB Allen, AM AF Alexander, Brian M. Othus, Megan Caglar, Hale B. Allen, Aaron M. TI TUMOR VOLUME IS A PROGNOSTIC FACTOR IN NON-SMALL-CELL LUNG CANCER TREATED WITH CHEMORADIOTHERAPY SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Chemoradiotherapy; Non-small-cell lung cancer; Prognosis ID RADIATION-THERAPY; STAGE; CHEMOTHERAPY; SURVIVAL; SURGERY AB Purpose: To investigate whether primary tumor and nodal volumes defined on radiotherapy planning scans are correlated with outcome (survival and recurrence) after combined-modality treatment. Methods and Materials: A retrospective review of patients with Stage III non-small-cell lung cancer treated with chemoradiation at Brigham and Women's Hospital/Dana-Farber Cancer Institute from 2000 to 2006 was performed. Tumor and nodal volume measurements, as computed by Eclipse (Varian, Palo Alto, CA), were used as independent variables, along with existing clinical factors, in univariate and multivariate analyses for association with outcomes. Results: For patients treated with definitive chemoradiotherapy, both nodal volume (hazard ratio [HR], 1.09; p < 0.01) and tumor volume (HR, 1.03; p < 0.01) were associated with overall survival on multivariate analysis. Both nodal volume (HR, 1.10; p < 0.01) and tumor volume (HR, 1.04; p < 0.01) were also associated with local control but not distant metastases. Conclusions: In addition to traditional surgical staging variables, disease burden, measured by primary tumor and nodal metastases volume, provides information that may be helpful in determining prognosis and identifying groups of patients for which more aggressive local therapy is warranted. (C) 2011 Elsevier Inc. C1 [Alexander, Brian M.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA. [Caglar, Hale B.; Allen, Aaron M.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Allen, AM (reprint author), Rabin Med Ctr, Davidoff Ctr, Dept Radiat Oncol, Petah Tiqwa, Israel. EM aallen@lroc.harvard.edu NR 21 TC 33 Z9 40 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD APR 1 PY 2011 VL 79 IS 5 BP 1381 EP 1387 DI 10.1016/j.ijrobp.2009.12.060 PG 7 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 742YB UT WOS:000288980100015 PM 20605346 ER PT J AU Ancukiewicz, M Russell, TA Otoole, J Specht, M Singer, M Kelada, A Murphy, CD Pogachar, J Gioioso, V Patel, M Skolny, M Smith, BL Taghian, AG AF Ancukiewicz, Marek Russell, Tara A. Otoole, Jean Specht, Michelle Singer, Marybeth Kelada, Alexandra Murphy, Colleen D. Pogachar, Jessica Gioioso, Valeria Patel, Megha Skolny, Melissa Smith, Barbara L. Taghian, Alphonse G. TI STANDARDIZED METHOD FOR QUANTIFICATION OF DEVELOPING LYMPHEDEMA IN PATIENTS TREATED FOR BREAST CANCER SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE Lymphedema; Quantification; Standardized method; Perometer; Breast cancer ID LIMB VOLUME; ARM EDEMA; IMPACT; RISK AB Purpose: To develop a simple and practical formula for quantifying breast cancer-related lymphedema, accounting for both the asymmetry of upper extremities' volumes and their temporal changes. Methods and Materials: We analyzed bilateral perometer measurements of the upper extremity in a series of 677 women who prospectively underwent lymphedema screening during treatment for unilateral breast cancer at Massachusetts General Hospital between August 2005 and November 2008. Four sources of variation were analyzed: between repeated measurements on the same arm at the same session; between both arms at baseline (pre-operative) visit; in follow-up measurements; and between patients. Effects of hand dominance, time since diagnosis and surgery, age, weight, and body mass index were also analyzed. Results: The statistical distribution of variation of measurements suggests that the ratio of volume ratios is most appropriate for quantification of both asymmetry and temporal changes. Therefore, we present the formula for relative volume change (RVC): RVC = (A(2)U(1))/(U(2)A(1)) - 1, where A(1), A(2) are arm volumes on the side of the treated breast at two different time points, and U(1), U(2) are volumes on the contralateral side. Relative volume change is not significantly associated with hand dominance, age, or time since diagnosis. Baseline weight correlates (p = 0.0074) with higher RVC; however, baseline body mass index or weight changes over time do not. Conclusions: We propose the use of the RVC formula to assess the presence and course of breast cancer related lymphedema in clinical practice and research. (C) 2011 Elsevier Inc. C1 [Ancukiewicz, Marek; Russell, Tara A.; Kelada, Alexandra; Pogachar, Jessica; Gioioso, Valeria; Patel, Megha; Skolny, Melissa; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Otoole, Jean; Murphy, Colleen D.] Massachusetts Gen Hosp, Dept Phys & Occupat Therapy, Boston, MA 02114 USA. [Specht, Michelle; Smith, Barbara L.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA. [Singer, Marybeth] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA. RP Taghian, AG (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St, Boston, MA 02114 USA. EM ataghian@partners.org FU National Cancer Institute [R01CA139118, P50CA089393]; Tim Levy Fund for Breast Cancer Research; Jane Mail-loux Fund; Blanche Montesi Fund FX This project was supported by National Cancer Institute Grants R01CA139118 and P50CA089393 (both to A.G.T.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. This study was also partially supported by the Tim Levy Fund for Breast Cancer Research, the Jane Mail-loux Fund, and the Blanche Montesi Fund. NR 23 TC 34 Z9 35 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD APR 1 PY 2011 VL 79 IS 5 BP 1436 EP 1443 DI 10.1016/j.ijrobp.2010.01.001 PG 8 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 742YB UT WOS:000288980100023 PM 20605339 ER PT J AU Miller, MA Ivkovic, A Porter, R Harris, MB Estok, DM Smith, RM Evans, CH Vrahas, MS AF Miller, Micah A. Ivkovic, Alan Porter, Ryan Harris, Mitchel B. Estok, Daniel M., II Smith, R. Malcolm Evans, Christopher H. Vrahas, Mark S. TI Autologous bone grafting on steroids: preliminary clinical results. A novel treatment for nonunions and segmental bone defects SO INTERNATIONAL ORTHOPAEDICS LA English DT Article ID ECHOCARDIOGRAPHY; FRACTURES AB Clinical management of delayed healing or nonunion of long bone fractures and segmental bone defects poses a substantial orthopaedic challenge. Surgical advances and bone tissue engineering are providing new avenues to stimulate bone growth in cases of bone loss and nonunion. The reamer-irrigator-aspirator (RIA) device allows surgeons to aspirate the medullary contents of long bones and use the progenitor-rich "flow-through" fraction in autologous bone grafting. Dexamethasone (DEX) is a synthetic steroid that has been shown to induce osteoblastic differentiation. A series of 13 patients treated with RIA bone grafting enhanced with DEX for nonunion or segmental defect was examined retrospectively to assess the quality of bony union and clinical outcomes. Despite the initial poor prognoses, promising results were achieved using this technique; and given the complexity of these cases the observed success is of great value and warrants controlled study into both standardisation of the procedure and concentration of the grafting material. C1 [Miller, Micah A.; Smith, R. Malcolm; Vrahas, Mark S.] Massachusetts Gen Hosp, Dept Orthopaed Trauma, Boston, MA 02114 USA. [Ivkovic, Alan] Univ Hosp Ctr, Clin Inst Rehabil & Orthopaed Aids, Zagreb, Croatia. [Porter, Ryan; Evans, Christopher H.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped, Boston, MA USA. [Harris, Mitchel B.; Estok, Daniel M., II] Brigham & Womens Hosp, Dept Orthopaed Trauma, Boston, MA 02115 USA. RP Miller, MA (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Trauma, Boston, MA 02114 USA. EM mmiller17@partners.org OI Ivkovic, Alan/0000-0003-0236-6244 NR 23 TC 19 Z9 20 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0341-2695 J9 INT ORTHOP JI Int. Orthop. PD APR PY 2011 VL 35 IS 4 BP 599 EP 605 DI 10.1007/s00264-010-1013-9 PG 7 WC Orthopedics SC Orthopedics GA 742QU UT WOS:000288960300021 PM 20414656 ER PT J AU Alsanafi, S Kovarik, C Mermelstein, AL Werth, VP AF Alsanafi, Shamael Kovarik, Carrie Mermelstein, Andrew L. Werth, Victoria P. TI Rituximab in the Treatment of Bullous Systemic Lupus Erythematosus SO JCR-JOURNAL OF CLINICAL RHEUMATOLOGY LA English DT Article DE bullous systemic lupus erythematosus; rituximab; CD20 antibody ID DEPLETION; LYMPHOMA; DISEASES; TRIAL AB Rituximab is a CD20 chimeric monoclonal antibody. It was approved by the US Food and Drug Administration for the treatment of relapsed or refractory low-grade or follicular non-Hodgkin lymphoma and for the treatment of moderate to severely active rheumatoid arthritis. It has been used as an off-label treatment in many autoimmune diseases, where B cells play a major role in the pathogenesis. We report a case of successful use of rituximab in the treatment of refractory bullous systemic lupus erythematosus in an African American patient. C1 [Alsanafi, Shamael; Kovarik, Carrie; Werth, Victoria P.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Alsanafi, Shamael; Kovarik, Carrie; Werth, Victoria P.] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Mermelstein, Andrew L.] Rheumatol Associates Ltd, E Norriton, PA USA. RP Alsanafi, S (reprint author), Hosp Univ Penn, Dept Dermatol, PCAM Suite 1-330S,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM dr_shamael@yahoo.com FU National Institutes of Health [K24-AR 02207]; Kuwaiti Government FX This study was supported in part by the National Institutes of Health (K24-AR 02207) to Dr Werth. It was also supported by a grant from the Kuwaiti Government (S.A.). NR 13 TC 10 Z9 14 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-1608 J9 JCR-J CLIN RHEUMATOL JI JCR-J. Clin. Rheumatol. PD APR PY 2011 VL 17 IS 3 BP 142 EP 144 DI 10.1097/RHU.0b013e318214f30c PG 3 WC Rheumatology SC Rheumatology GA 745EM UT WOS:000289148500007 PM 21441817 ER PT J AU Potter, CM Vujanovic, AA Marshall-Berenz, EC Bernstein, A Bonn-Miller, MO AF Potter, Carrie M. Vujanovic, Anka A. Marshall-Berenz, Erin C. Bernstein, Amit Bonn-Miller, Marcel O. TI Posttraumatic stress and marijuana use coping motives: The mediating role of distress tolerance SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Trauma; Posttraumatic stress; Distress tolerance; Marijuana; Coping ID VIETNAM COMBAT VETERANS; PTSD SYMPTOM SEVERITY; SELF-REPORT MEASURE; EMPIRICAL LITERATURE; ANXIETY SENSITIVITY; SUBSTANCE-ABUSE; CANNABIS USE; ALCOHOL-USE; SMOKING; DISORDER AB The present investigation examined the explanatory (i.e,. mediating) role of distress tolerance (DT) in the relation between posttraumatic stress (PTS) symptom severity and marijuana use coping motives. The sample consisted of 142 adults (46.5% women; M(age) =22.18, SD = 7.22, range = 18-55), who endorsed exposure to at least one Criterion A traumatic life event (DSM-IV-TR, 2000) and reported marijuana use within the past 30 days. As predicted, results demonstrated that DT partially mediated the relation between PTS symptom severity and coping-oriented marijuana use. These preliminary results suggest that DT may be an important cognitive-affective mechanism underlying the PTS-marijuana use coping motives association. Theoretically, trauma-exposed marijuana users with greater PTS symptom severity may use marijuana to cope with negative mood states, at least partially because of a lower perceived capacity to withstand emotional distress. Published by Elsevier Ltd. C1 [Potter, Carrie M.; Vujanovic, Anka A.] VA Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, Boston, MA 02130 USA. [Vujanovic, Anka A.] Boston Univ, Sch Med, Boston, MA 02130 USA. [Marshall-Berenz, Erin C.] Univ Mississippi, Med Ctr, Burlington, VT 05405 USA. [Marshall-Berenz, Erin C.] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Bernstein, Amit] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel. [Bonn-Miller, Marcel O.] VA Palo Alto Healthcare Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] VA Palo Alto Healthcare Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. RP Vujanovic, AA (reprint author), VA Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, 150 S Huntington Ave,116B-2, Boston, MA 02130 USA. EM carrie.potter@va.gov; anka.vujanovic@va.gov; erin.berenz@gmail.com; abernstein@psy.haifa.ac.il; marcel.bonn-miller@va.gov FU NIDA NIH HHS [1 R03 DA016566-01A2, 1F31DA21006-02, F31 DA021006, F31 DA021006-02, R03 DA016566, R03 DA016566-01A2]; NIMH NIH HHS [1F31 MH080453-01A1, F31 MH073205, F31 MH073205-01, F31 MH080453, F31 MH080453-01A1, F31MH073205-01] NR 55 TC 29 Z9 29 U1 2 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD APR PY 2011 VL 25 IS 3 BP 437 EP 443 DI 10.1016/j.janxdis.2010.11.007 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 736VL UT WOS:000288523000018 PM 21146357 ER PT J AU Mandal, CC Ghosh-Choudhury, N Yoneda, T Choudhury, GG Ghosh-Choudhury, N AF Mandal, Chandi Charan Ghosh-Choudhury, Nayana Yoneda, Toshi Choudhury, Goutam Ghosh Ghosh-Choudhury, Nandini TI Simvastatin Prevents Skeletal Metastasis of Breast Cancer by an Antagonistic Interplay between p53 and CD44 SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NF-KAPPA-B; CELL-LINES; STEM-CELLS; LUNG METASTASIS; ANTICANCER AGENTS; BINDING PROTEIN; BONE METASTASES; MUTANT P53; EXPRESSION; GROWTH AB Substantial data from clinical trials and epidemiological studies show promising results for use of statins in many cancers, including mammary carcinoma. Breast tumor primarily metastasizes to bone to form osteolytic lesions, causing severe pain and pathological fracture. Here, we report that simvastatin acts as an inhibitor of osteolysis in a mouse model of breast cancer skeletal metastasis of human mammary cancer cell MDA-MB-231, which expresses the mutant p53R280K. Simvastatin and lovastatin attenuated migration and invasion of MDA-MB- 231 and BT-20 breast tumor cells in culture. Acquisition of phenotype to express the cancer stem cell marker, CD44, leads to invasive potential of the tumor cells. Interestingly, statins significantly decreased the expression of CD44 protein via a transcriptional mechanism. shRNA-mediated down-regulation of CD44 markedly reduced the migration and invasion of breast cancer cells in culture. We identified that in the MDA-MB-231 cells, simvastatin elevated the levels of mutated p53R280K, which was remarkably active as a transcription factor. shRNA-derived inhibition of mutant p53R280K augmented the expression of CD44, leading to increased migration and invasion. Finally, we demonstrate an inverse correlation between expression of p53 and CD44 in the tumors of mice that received simvastatin. Our results reveal a unique function of statins, which foster enhanced expression of mutant p53R280K to prevent breast cancer cell metastasis to bone. C1 [Yoneda, Toshi; Choudhury, Goutam Ghosh; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Mandal, Chandi Charan; Ghosh-Choudhury, Nayana; Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA. [Choudhury, Goutam Ghosh] S Texas Vet Hlth Care Syst, Vet Affairs Res, San Antonio, TX 78229 USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhury@uthscsa.edu; choudhuryg@uthscsa.edu; choudhury@uthscsa.edu FU National Institutes of Health [RO1 AR52425, ROI DK50190]; Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grants RO1 AR52425 (to N.G.-C.) and ROI DK50190 (to G.G.C.) This work was also supported by Veterans Affairs merit review grants (to N.G.-C. and G.G.C.). NR 71 TC 44 Z9 45 U1 1 U2 5 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 1 PY 2011 VL 286 IS 13 BP 11314 EP 11327 DI 10.1074/jbc.M110.193714 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 740LW UT WOS:000288797100044 PM 21199873 ER PT J AU Kim, TH Shivdasani, RA AF Kim, Tae-Hee Shivdasani, Ramesh A. TI Genetic Evidence That Intestinal Notch Functions Vary Regionally and Operate through a Common Mechanism of Math1 Repression SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID ATONAL HOMOLOG 1; STEM-CELLS; SECRETASE INHIBITORS; PROGENITOR CELLS; TRANSGENIC MICE; SELF-RENEWAL; DIFFERENTIATION; FATE; HES-1; RECOMBINATION AB Notch signaling is active in many sites, and its diverse activities must require tissue-specific intermediaries, which are largely unknown. In the intestinal epithelium, Notch promotes crypt cell proliferation and inhibits goblet cell differentiation. Pharmacologic studies suggest that the latter effect occurs through the transcription factor Math1/Atoh1, which specifies all intestinal secretory cells. We tested this hypothesis using mouse mutants. Genetic loss of the Notch effector RBP-J kappa alone increases all intestinal secretory lineages, with variation between proximal and distal gut segments. This secretory cell excess observed with RBP-J kappa loss was blocked in the absence of Math1 in RBP-J kappa(Fl/Fl); Math1(Fl/Fl); Villin-Cre((ER-T2)) mice. Loss of both factors also restored progenitor replication, proving that Math1 is epistatic to Notch signaling in both secretory cell differentiation and crypt cell proliferation. Investigating mechanisms downstream of Math1, we found that expression of the known Notch effector protein Hes1 was predictably lost in RBP-J kappa(-/-) mice but surprisingly recovered in RBP-J kappa;Math1 compound conditional mutants. Furthermore, the cell cycle inhibitors p27(Kip1) and p57(Kip2) were selectively overexpressed in duodenal and ileal crypts, respectively, in RBP-J kappa-deficient mice. Regional activation of these products was completely abrogated in the absence of Math1. Thus, all intestinal Notch effects channel through the tissue-restricted factor Math1, which promotes secretory differentiation and cell cycle exit by regionally distinct mechanisms. Our data further suggest that, besides transmitting Notch signals, the transcription factor Hes1 acts downstream of Math1 to regulate expression of cell cycle inhibitors and intestinal crypt cell replication. C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Shivdasani, RA (reprint author), 44 Binney St, Boston, MA 02215 USA. EM ramesh_shivdasani@dfci.harvard.edu FU National Institutes of Health [R01DK081113]; Caring for Carcinoid Foundation FX This work was supported, in whole or in part, by National Institutes of Health Grant R01DK081113 (to R. A. S.). This work was also supported by a gift from the Caring for Carcinoid Foundation. NR 30 TC 35 Z9 36 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 1 PY 2011 VL 286 IS 13 BP 11427 EP 11433 DI 10.1074/jbc.M110.188797 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 740LW UT WOS:000288797100054 PM 21282114 ER PT J AU Nishi, M Akutsu, H Masui, S Kondo, A Nagashima, Y Kimura, H Perrem, K Shigeri, Y Toyoda, M Okayama, A Hirano, H Umezawa, A Yamamoto, N Lee, SW Ryo, A AF Nishi, Mayuko Akutsu, Hidenori Masui, Shinji Kondo, Asami Nagashima, Yoji Kimura, Hirokazu Perrem, Kilian Shigeri, Yasushi Toyoda, Masashi Okayama, Akiko Hirano, Hisashi Umezawa, Akihiro Yamamoto, Naoki Lee, Sam W. Ryo, Akihide TI A Distinct Role for Pin1 in the Induction and Maintenance of Pluripotency SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID EMBRYONIC STEM-CELLS; PROLYL ISOMERASE PIN1; SELF-RENEWAL; PHOSPHORYLATION; EXPRESSION; DIFFERENTIATION; ISOMERIZATION; SURVIVAL; MICE AB The prominent characteristics of pluripotent stem cells are their unique capacity to self-renew and pluripotency. Although pluripotent stem cell proliferation is maintained by specific intracellular phosphorylation signaling events, it has not been well characterized how the resulting phosphorylated proteins are subsequently regulated. We here report that the peptidylprolyl isomerase Pin1 is indispensable for the self-renewal and maintenance of pluripotent stem cells via the regulation of phosphorylated Oct4 and other substrates. Pin1 expression was found to be up-regulated upon the induction of induced pluripotent stem (iPS) cells, and the forced expression of Pin1 with defined reprogramming factors was observed to further enhance the frequency of iPS cell generation. The inhibition of Pin1 activity significantly suppressed colony formation and induced the aberrant differentiation of human iPS cells as well as murine ES cells. We further found that Pin1 interacts with the phosphorylated Ser(12)-Pro motif of Oct4 and that this in turn facilitates the stability and transcriptional activity functions of Oct4. Our current findings thus uncover an atypical role for Pin1 as a putative regulator of the induction and maintenance of pluripotency via the control of phosphorylation signaling. These data suggest that the manipulation of Pin1 function could be a potential strategy for the stable induction and proliferation of human iPS cells. C1 [Ryo, Akihide] Yokohama City Univ, Sch Med, Dept Microbiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan. [Nagashima, Yoji] Yokohama City Univ, Sch Med, Dept Pathol, Yokohama, Kanagawa 2360004, Japan. [Okayama, Akiko; Hirano, Hisashi] Yokohama City Univ, Sch Med, Dept Supramol Biol, Yokohama, Kanagawa 2360004, Japan. [Akutsu, Hidenori; Toyoda, Masashi; Umezawa, Akihiro] Natl Res Inst Child Hlth & Dev, Dept Reprod Biol, Tokyo 1578535, Japan. [Masui, Shinji] Int Med Ctr Japan, Res Inst, Dept Regenerat Med, Tokyo 1628655, Japan. [Kimura, Hirokazu] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo 2080011, Japan. [Perrem, Kilian] Commonwealth Sci & Ind Res Org, Dickson, ACT 2602, Australia. [Shigeri, Yasushi] Natl Inst Adv Ind Sci & Technol, Osaka 5638577, Japan. [Yamamoto, Naoki] Natl Univ Singapore, Dept Microbiol, Singapore 117597, Singapore. [Lee, Sam W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA. [Lee, Sam W.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Ryo, A (reprint author), Yokohama City Univ, Sch Med, Dept Microbiol, Kanazawa Ku, 3-9 Fuku Ura, Yokohama, Kanagawa 2360004, Japan. EM aryo@yokohama-cu.ac.jp FU Takeda Science Foundation; Uehara Memorial Foundation; Kanagawa Nanbyo Foundation FX This work was supported in part by grants from the Takeda Science Foundation, Uehara Memorial Foundation, and Kanagawa Nanbyo Foundation (to A. R.). NR 35 TC 21 Z9 23 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 1 PY 2011 VL 286 IS 13 BP 11593 EP 11603 DI 10.1074/jbc.M110.187989 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 740LW UT WOS:000288797100069 PM 21296877 ER PT J AU Pathak, N Austin, CA Drummond, IA AF Pathak, Narendra Austin, Christina A. Drummond, Iain A. TI Tubulin Tyrosine Ligase-like Genes ttll3 and ttll6 Maintain Zebrafish Cilia Structure and Motility SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID BETA-TUBULIN; POSTTRANSLATIONAL MODIFICATIONS; TETRAHYMENA-THERMOPHILA; ALPHA-TUBULIN; INTRAFLAGELLAR TRANSPORT; EPITHELIAL-CELLS; POLYGLYCYLATION; MICROTUBULES; POLYGLUTAMYLATION; GLYCYLATION AB Tubulin post-translational modifications generate microtubule heterogeneity and modulate microtubule function, and are catalyzed by tubulin tyrosine ligase-like (TTLL) proteins. Using antibodies specific to monoglycylated, polyglycylated, and glutamylated tubulin in whole mount immunostaining of zebrafish embryos, we observed distinct, tissue-specific patterns of tubulin modifications. Tubulin modification patterns in cilia correlated with the expression of ttll3 and ttll6 in ciliated cells. Expression screening of all zebrafish tubulin tyrosine ligase-like genes revealed additional tissue-specific expression of ttll1 in brain neurons, ttll4 in muscle, and ttll7 in otic placodes. Knockdown of ttll3 eliminated cilia tubulin glycylation but had surprisingly mild effects on cilia structure and motility. Similarly, knockdown of ttll6 strongly reduced cilia tubulin glutamylation but only partially affected cilia structure and motility. Combined loss of function of ttll3 and ttll6 caused near complete loss of cilia motility and induced a variety of axonemal ultrastructural defects similar to defects previously observed in zebrafish fleer mutants, which were shown to lack tubulin glutamylation. Consistently, we find that fleer mutants also lack tubulin glycylation. These results indicate that tubulin glycylation and glutamylation have overlapping functions in maintaining cilia structure and motility and that the fleer/dyf-1 TPR protein is required for both types of tubulin post-translational modification. C1 [Pathak, Narendra; Drummond, Iain A.] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA 02129 USA. [Austin, Christina A.; Drummond, Iain A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA. RP Drummond, IA (reprint author), 149 13th St, Charlestown, MA 02129 USA. EM idrummon@receptor.mgh.harvard.edu FU National Institutes of Health [K01DK078741, RO1DK053093] FX This work was supported, in whole or in part, by National Institutes of Health Grants K01DK078741 (to N. P.) and RO1DK053093 (to I. A. D.). NR 52 TC 32 Z9 33 U1 1 U2 14 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD APR 1 PY 2011 VL 286 IS 13 BP 11685 EP 11695 DI 10.1074/jbc.M110.209817 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 740LW UT WOS:000288797100076 PM 21262966 ER PT J AU Leissner, KB Srinivasa, V Beutler, S Matyal, R Badr, R Haime, M Mahmood, FU AF Leissner, Kay B. Srinivasa, Venkatesh Beutler, Sascha Matyal, Robina Badr, Rana Haime, Miguel Mahmood, Feroze U. TI Left Atrial Dissection and Intramural Hematoma After Aortic Valve Replacement SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA LA English DT Article DE transesophageal echocardiography; left atrium; left atrial dissection; left atrial hematoma; aortic valve replacement C1 [Leissner, Kay B.; Srinivasa, Venkatesh; Beutler, Sascha] Harvard Univ, Sch Med, Dept Anesthesia & Crit Care, VA Boston Healthcare Serv, Boston, MA USA. [Leissner, Kay B.; Srinivasa, Venkatesh; Beutler, Sascha] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Matyal, Robina; Mahmood, Feroze U.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Anesthesiol & Crit Care, Boston, MA 02215 USA. [Badr, Rana] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol, Boston, MA USA. [Haime, Miguel] Boston Univ, Sch Med, Dept Cardiothorac Surg, VA Boston Healthcare Serv, Boston, MA 02118 USA. RP Leissner, KB (reprint author), VA Boston Healthcare Serv, Anesthesiol Serv, 1400 VFW Pkwy, W Roxbury, MA 02132 USA. EM kbleissner@yahoo.com RI Mahmood, Feroze/B-1383-2008 OI Mahmood, Feroze/0000-0002-7071-0476 NR 7 TC 4 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1053-0770 J9 J CARDIOTHOR VASC AN JI J. Cardiothorac. Vasc. Anesth. PD APR PY 2011 VL 25 IS 2 BP 309 EP 310 DI 10.1053/j.jvca.2010.03.011 PG 2 WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System GA 743UI UT WOS:000289043800018 PM 20584618 ER PT J AU Wei, WY Kaelin, WG AF Wei, Wenyi Kaelin, William G., Jr. TI Good COP1 or bad COP1? In vivo veritas SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Editorial Material ID UBIQUITIN LIGASE COP1; C-JUN; E3 LIGASE; DEGRADATION; INHIBITION; REGULATOR; STABILITY; P53 AB The evolutionarily conserved protein COP1 has been shown to operate as an E3 ubiquitin ligase complex, and a number of putative substrates have been identified, including the c-JUN oncoprotein and p53 tumor suppressor protein. New work by Migliorini and colleagues described in the current issue of JCI demonstrates that COP1 acts as a tumor suppressor in vivo and does so, at least in part, by promoting the destruction of c-JUN. These findings challenge the view that COP1 regulates p53 stability and call into question the wisdom of developing COP1 inhibitors as potential anticancer agents. C1 [Kaelin, William G., Jr.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Wei, Wenyi] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02115 USA. [Kaelin, William G., Jr.] Howard Hughes Med Inst, Chevy Chase, MD USA. RP Kaelin, WG (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Mayer 457, Boston, MA 02115 USA. EM William_Kaelin@dfci.harvard.edu FU Howard Hughes Medical Institute; NCI NIH HHS [CA068490, P50 CA101942, CA101942, R01 CA068490]; NIGMS NIH HHS [R01 GM089763, GM089763] NR 20 TC 13 Z9 13 U1 0 U2 2 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2011 VL 121 IS 4 BP 1263 EP 1265 DI 10.1172/JCI57080 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 745OK UT WOS:000289174600012 PM 21403396 ER PT J AU Rhee, EP Cheng, S Larson, MG Walford, GA Lewis, GD McCabe, E Yang, E Farrell, L Fox, CS O'Donnell, CJ Carr, SA Vasan, RS Florez, JC Clish, CB Wang, TJ Gerszten, RE AF Rhee, Eugene P. Cheng, Susan Larson, Martin G. Walford, Geoffrey A. Lewis, Gregory D. McCabe, Elizabeth Yang, Elaine Farrell, Laurie Fox, Caroline S. O'Donnell, Christopher J. Carr, Steven A. Vasan, Ramachandran S. Florez, Jose C. Clish, Clary B. Wang, Thomas J. Gerszten, Robert E. TI Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID FATTY-ACID-COMPOSITION; CORONARY-HEART-DISEASE; MIDDLE-AGED ADULTS; RISK; DESATURASES; MELLITUS; GLUCOSE; ATHEROSCLEROSIS; EXERCISE; DELTA-5 AB Dyslipidemia is an independent risk factor for type 2 diabetes, although exactly which of the many plasma lipids contribute to this remains unclear. We therefore investigated whether lipid profiling can inform diabetes prediction by performing liquid chromatography/mass spectrometry-based lipid profiling in 189 individuals who developed type 2 diabetes and 189 matched disease-free individuals, with over 12 years of follow up in the Framingham Heart Study. We found that lipids of lower carbon number and double bond content were associated with an increased risk of diabetes, whereas lipids of higher carbon number and double bond content were associated with decreased risk. This pattern was strongest for triacylglycerols (TAGs) and persisted after multivariable adjustment for age, sex, BMI, fasting glucose, fasting insulin, total triglycerides, and HDL cholesterol. A combination of 2 TAGs further improved diabetes prediction. To explore potential mechanisms that modulate the distribution of plasma lipids, we performed lipid profiling during oral glucose tolerance testing, pharmacologic interventions, and acute exercise testing. Levels of TAGs associated with increased risk for diabetes decreased in response to insulin action and were elevated in the setting of insulin resistance. Conversely, levels of TAGs associated with decreased diabetes risk rose in response to insulin and were poorly correlated with insulin resistance. These studies identify a relationship between lipid acyl chain content and diabetes risk and demonstrate how lipid profiling could aid in clinical risk assessment. C1 [Rhee, Eugene P.] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. [Rhee, Eugene P.; Lewis, Gregory D.; Yang, Elaine; Carr, Steven A.; Florez, Jose C.; Clish, Clary B.; Gerszten, Robert E.] Broad Inst, Cambridge, MA 02142 USA. [Cheng, Susan; Larson, Martin G.; McCabe, Elizabeth; Fox, Caroline S.; O'Donnell, Christopher J.; Vasan, Ramachandran S.; Wang, Thomas J.] Framingham Heart Study Natl Heart Lung & Blood In, Framingham, MA USA. [Cheng, Susan; Larson, Martin G.; McCabe, Elizabeth; Fox, Caroline S.; O'Donnell, Christopher J.; Vasan, Ramachandran S.; Wang, Thomas J.] Boston Univ, Sch Med, Framingham, MA USA. [Cheng, Susan] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Cheng, Susan; Lewis, Gregory D.; McCabe, Elizabeth; Farrell, Laurie; O'Donnell, Christopher J.; Wang, Thomas J.; Gerszten, Robert E.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA. [Walford, Geoffrey A.; Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. [Walford, Geoffrey A.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Fox, Caroline S.] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA. [Fox, Caroline S.; O'Donnell, Christopher J.] Boston Univ, Sch Med, Boston Med Ctr, NHLBI Div Intramural Res, Boston, MA 02118 USA. [Vasan, Ramachandran S.] Boston Univ, Sch Med, Boston Med Ctr, Cardiol Sect, Boston, MA 02118 USA. [Wang, Thomas J.; Gerszten, Robert E.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Gerszten, Robert E.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA. RP Gerszten, RE (reprint author), Massachusetts Gen Hosp E, Div Cardiol, 149 13th St,8th Floor, Charlestown, MA 02129 USA. EM clary@broadinstitute.org; tjwang@partners.org; rgerszten@partners.org OI Larson, Martin/0000-0002-9631-1254; Ramachandran, Vasan/0000-0001-7357-5970 FU NIH [N01-HC-25195, R01-DK-HL081572, T32-DK-00754023]; Donald W. Reynolds Foundation; Leducq Foundation; American Heart Association; Endocrine Fellows Foundation; MGH; Doris Duke Charitable Foundation FX This work was supported by NIH contracts N01-HC-25195 and R01-DK-HL081572, the Donald W. Reynolds Foundation, the Leducq Foundation, and the American Heart Association. E.P. Rhee received support from the NIH grant T32-DK-00754023. G.A. Walford is supported by the Endocrine Fellows Foundation. J.C. Florez is also supported by the MGH and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. We also acknowledge David Altshuler for his support. NR 31 TC 160 Z9 161 U1 5 U2 27 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2011 VL 121 IS 4 BP 1402 EP 1411 DI 10.1172/JCI44442 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 745OK UT WOS:000289174600024 PM 21403394 ER PT J AU Chen, HB Li, C Huang, JH Cung, T Seiss, K Beamon, J Carrington, MF Porter, LC Burke, PS Yang, Y Ryan, BJ Liu, RW Weiss, RH Pereyra, F Cress, WD Brass, AL Rosenberg, ES Walker, BD Yu, XG Lichterfeld, M AF Chen, Huabiao Li, Chun Huang, Jinghe Cung, Thai Seiss, Katherine Beamon, Jill Carrington, Mary F. Porter, Lindsay C. Burke, Patrick S. Yang, Yue Ryan, Bethany J. Liu, Ruiwu Weiss, Robert H. Pereyra, Florencia Cress, William D. Brass, Abraham L. Rosenberg, Eric S. Walker, Bruce D. Yu, Xu G. Lichterfeld, Mathias TI CD4(+) T cells from elite controllers resist HIV-1 infection by selective upregulation of p21 SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; CYCLIN-DEPENDENT KINASES; ANTIVIRAL DRUGS; IN-VIVO; PROLIFERATION; TRANSCRIPTION; ACTIVATION; REPLICATION; NONPROGRESSORS; IDENTIFICATION AB Elite controllers represent a unique group of HIV-1-infected persons with undetectable HIV-1 replication in the absence of antiretroviral therapy. However, the mechanisms contributing to effective viral immune defense in these patients remain unclear. Here, we show that compared with HIV-1 progressors and HIV-1-negative persons, CD4(+) T cells from elite controllers are less susceptible to HIV-1 infection. This partial resistance to HIV-1 infection involved less effective reverse transcription and mRNA transcription from proviral DNA and was associated with strong and selective upregulation of the cyclin-dependent kinase inhibitor p21 (also known as cip-1 and waf-1). Experimental blockade of p21 in CD4(+) T cells from elite controllers resulted in a marked increase of viral reverse transcripts and mRNA production and led to higher enzymatic activities of cyclin-dependent kinase 9 (CDK9), which serves as a transcriptional coactivator of HIV-1 gene expression. This suggests that p21 acts as a barrier against HIV-1 infection in CD4(+) T cells from elite controllers by inhibiting a cyclin-dependent kinase required for effective HIV-1 replication. These data demonstrate a mechanism of host resistance to HIV-1 in elite controllers and may open novel perspectives for clinical strategies to prevent or treat HIV-1 infection. C1 [Rosenberg, Eric S.; Lichterfeld, Mathias] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Chen, Huabiao; Li, Chun; Huang, Jinghe; Cung, Thai; Seiss, Katherine; Beamon, Jill; Carrington, Mary F.; Porter, Lindsay C.; Burke, Patrick S.; Yang, Yue; Ryan, Bethany J.; Pereyra, Florencia; Brass, Abraham L.; Walker, Bruce D.; Yu, Xu G.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA. [Chen, Huabiao; Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA. [Li, Chun] Harvard Univ, Program Biol Sci Dent Med, Cambridge, MA 02138 USA. [Liu, Ruiwu] UCD, Dept Biochem & Mol Med, Davis, CA USA. [Weiss, Robert H.] UCD, Dept Med, Div Nephrol, Davis, CA USA. [Cress, William D.] Lee Moffitt Canc Ctr, Dept Mol Oncol, Tampa, FL USA. RP Lichterfeld, M (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. EM mlichterfeld@partners.org RI Huang, Jinghe/O-1986-2015 FU Doris Duke Clinical Scientist Development Award; NIH [AI078799, AI089339, AI093203, CA135401, DK082690]; Medical Service of the US Department of Veterans' Affairs; National Cancer Institute [P50 CA119997]; Florida Department of Health [FDH 08BB-05] FX X.G. Yu and M. Lichterfeld are both recipients of the Doris Duke Clinical Scientist Development Award. This study was supported by the NIH (grants AI078799 and AI089339 to X.G. Yu and AI093203 to M. Lichterfeld). Work in the laboratory of R.H. Weiss was supported by the NIH (grants CA135401 and DK082690) and by the Medical Service of the US Department of Veterans' Affairs. W.D. Cress is supported by the National Cancer Institute (grant P50 CA119997) and the Florida Department of Health (grant FDH 08BB-05). Elite controller patient recruitment was supported by the Mark and Lisa Schwartz Foundation and the Bill and Melinda Gates Foundation. The authors would like to thank Frederic Bushman (University of Pennsylvania) for sharing the HIV-1 infected cell line 293T, Nicholas Chomont (VGTI Florida) for sharing a detailed protocol for assessment of integrated HIV-1 DNA, Nicholas Manel and Dan R. Littman (New York University) for sharing GFP-encoding X4- and RS-tropic HIV-1 viruses, and Daniel Kavanagh and Sylvie Le Gall (Ragon Institute) for helpful discussion. NR 45 TC 87 Z9 87 U1 1 U2 5 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2011 VL 121 IS 4 BP 1549 EP 1560 DI 10.1172/JCI44539 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 745OK UT WOS:000289174600037 PM 21403397 ER PT J AU Lin, Y Zhang, L Cai, AX Lee, M Zhang, WD Neuberg, D Canning, CM Soiffer, RJ Alyea, EP Ritz, J Hacohen, N Means, TK Wu, CJ AF Lin, Yun Zhang, Li Cai, Ann X. Lee, Mark Zhang, Wandi Neuberg, Donna Canning, Christine M. Soiffer, Robert J. Alyea, Edwin P. Ritz, Jerome Hacohen, Nir Means, Terry K. Wu, Catherine J. TI Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID CHRONIC MYELOGENOUS LEUKEMIA; TOLL-LIKE RECEPTORS; T-CELL RESPONSES; DENDRITIC CELLS; B-CELLS; CPG-DNA; CROSS-PRESENTATION; MARROW TRANSPLANT; PROGENITOR CELLS; CANCER-PATIENTS AB Donor lymphocyte infusion (DLI), whereby donor mononuclear cells are infused into patients, is one of the few effective immunotherapeutic strategies that generate long-lasting tumor remissions. We previously demonstrated that chronic myelogenous leukemia (CML) patients treated with DLI develop high-titer plasma antibodies specific for CML-associated antigens, the majority of which have been reported to bind nucleic acids These observations led us to predict that circulating antibody-antigen complexes in DLI-responsive patients carry nucleic acids that can engage innate immune sensors. Consistent with this, we report here that post-DLI plasma from 5 CML patients that responded to DLI treatment induced massive upregulation of MIP-1 alpha, IP-10, and IFN-alpha in normal blood mononuclear cells. Importantly, this was not observed with plasma obtained before DLI and from DLI nonresponders and imatinib-treated patients. This endogenous immunostimulatory activity required nucleic acid and protein for its adjuvant effect and activated antigen-presenting cells through the RNA and DNA sensors TLR8 and TLR9. Presence of the immunoglobulin Fc receptor CD32 enhanced cellular responses, suggesting that immunoglobulins associate with this activity. Finally, a TLR-induced expression signature was detectable in post-DLI but not pre-DLI blood, consistent with an active circulating TLR8/9-stimulating factor. We have therefore demonstrated that effective tumor immunity correlates with the presence of endogenous nucleic acid-immunoglobulin complexes in patient plasma, thus providing a putative mechanism for the induction of potent antigen-specific immunity against malignant cells. C1 [Wu, Catherine J.] Dana Farber Canc Inst, Harvard Inst Med, Dept Med Oncol, Boston, MA 02115 USA. [Lin, Yun; Zhang, Li; Cai, Ann X.; Zhang, Wandi; Canning, Christine M.; Ritz, Jerome; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA. [Zhang, Li] Sichuan Univ, W China Hosp, Minist Hlth, Key Lab Transplant Engn & Immunol, Chengdu 610064, Peoples R China. [Lee, Mark; Hacohen, Nir; Means, Terry K.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA. [Canning, Christine M.; Soiffer, Robert J.; Alyea, Edwin P.; Ritz, Jerome; Wu, Catherine J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA. RP Wu, CJ (reprint author), Dana Farber Canc Inst, Harvard Inst Med, Dept Med Oncol, Room 416,77 Ave Louis Pasteur, Boston, MA 02115 USA. EM cwu@partners.org OI Ritz, Jerome/0000-0001-5526-4669 FU Department of Defense [W81XWH-07-1-0080]; Miles and Eleanor Shore Award; National Cancer Institute [5R21CA115043-2]; Claudia Adams Barr Program in Cancer Research; Howard Hughes Medical Institute; Damon-Runyon Cancer Research Foundation [CI-38-07] FX We acknowledge expert technical assistance from Naa Lokko and Sean McDonough, and helpful suggestions from Joosang Park and Jonathan Duke-Cohan. We are also appreciative of the generous support from the Dana-Farber Cancer Institute (DFCI) Pasquarello Tissue Bank and from the DFCI clinical transplant teams. C.J. Wu acknowledges support from the Department of Defense (W81XWH-07-1-0080), the Miles and Eleanor Shore Award, the National Cancer Institute (5R21CA115043-2), and the Claudia Adams Barr Program in Cancer Research. C.J. Wu also received the Early Career Physician-Scientist Award of the Howard Hughes Medical Institute and is a Damon-Runyon Clinical Investigator supported (in part) by the Damon-Runyon Cancer Research Foundation (CI-38-07). NR 56 TC 10 Z9 11 U1 1 U2 5 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2011 VL 121 IS 4 BP 1574 EP 1584 DI 10.1172/JCI44581 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 745OK UT WOS:000289174600039 PM 21403403 ER PT J AU Alef, MJ Vallabhaneni, R Carchman, E Morris, SM Shiva, S Wang, YN Kelley, EE Tarpey, MM Gladwin, MT Tzeng, E Zuckerbraun, BS AF Alef, Matthew J. Vallabhaneni, Raghuveer Carchman, Evie Morris, Sidney M., Jr. Shiva, Sruti Wang, Yinna Kelley, Eric E. Tarpey, Margaret M. Gladwin, Mark T. Tzeng, Edith Zuckerbraun, Brian S. TI Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID MUSCLE-CELL-PROLIFERATION; OXIDE SYNTHASE GENE; SELECTIVE PULMONARY VASODILATOR; ORAL L-ARGININE; DIETARY NITRATE; IN-VIVO; NEOINTIMA FORMATION; ISCHEMIA/REPERFUSION INJURY; XANTHINE OXIDOREDUCTASE; ISCHEMIA-REPERFUSION AB Vascular disease, a significant cause of morbidity and mortality in the developed world, results from vascular injury. Following vascular injury, damaged or dysfunctional endothelial cells and activated SMCs engage in vasoproliferative remodeling and the formation of flow-limiting intimal hyperplasia (IH). We hypothesized that vascular injury results in decreased bioavailability of NO secondary to dysregulated arginine-dependent NO generation. Furthermore, we postulated that nitrite-dependent NO generation is augmented as an adaptive response to limit vascular injury/proliferation and can be harnessed for its protective effects. Here we report that sodium nitrite (intraperitoneal, inhaled, or oral) limited the development of IH in a rat model of vascular injury. Additionally, nitrite led to the generation of NO in vessels and SMCs, as well as limited SMC proliferation via p21(Waf1/Cip1) signaling. These data demonstrate that IH is associated with increased arginase-1 levels, which leads to decreased NO production and bioavailability. Vascular injury also was associated with increased levels of xanthine oxidoreductase (XOR), a known nitrite reductase. Chronic inhibition of XOR and a diet deficient in nitrate/nitrite each exacerbated vascular injury. Moreover, established IH was reversed by dietary supplementation of nitrite. The vasoprotective effects of nitrite were counteracted by inhibition of XOR. These data illustrate the importance of nitrite-generated NO as an endogenous adaptive response and as a pathway that can be harnessed for therapeutic benefit. C1 [Alef, Matthew J.; Vallabhaneni, Raghuveer; Carchman, Evie; Tzeng, Edith; Zuckerbraun, Brian S.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Morris, Sidney M., Jr.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA. [Shiva, Sruti; Wang, Yinna; Kelley, Eric E.] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA. [Tarpey, Margaret M.] Univ Pittsburgh, Sch Med, Dept Anesthesia, Dept Med, Pittsburgh, PA 15261 USA. [Tarpey, Margaret M.; Tzeng, Edith; Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gladwin, Mark T.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. RP Tzeng, E (reprint author), A1010 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM tzenge@upmc.edu; zuckerbraunbs@upmc.edu RI Morris, Sidney/I-3440-2015 FU American Heart Association [09GRNT2050220]; NIH [R01HL098032, RO1HL096973, RC1DK085852, R01GM57384]; Institute for Transfusion Medicine; Hemophilia Center of Western Pennsylvania FX We are appreciative of the excellent technical assistance of Diane Kepka-Lenhart. This work was supported in part by the American Heart Association, Great Rivers Affiliate grant 09GRNT2050220 (to B.S. Zuckerbraun); NIH grants R01HL098032, RO1HL096973, and RC1DK085852 (to M.T. Gladwin) and R01GM57384 (to S.M. Morris); and the Institute for Transfusion Medicine and the Hemophilia Center of Western Pennsylvania (to M.T. Gladwin). NR 63 TC 55 Z9 59 U1 0 U2 5 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 2011 VL 121 IS 4 BP 1646 EP 1656 DI 10.1172/JCI44079 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 745OK UT WOS:000289174600045 PM 21436585 ER PT J AU Flaherty, KT AF Flaherty, Keith T. TI Is It Good or Bad to Find a BRAF Mutation? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID CANCER; MELANOMA C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. RP Flaherty, KT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. NR 13 TC 6 Z9 6 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR 1 PY 2011 VL 29 IS 10 BP 1229 EP 1230 DI 10.1200/JCO.2010.34.0497 PG 2 WC Oncology SC Oncology GA 743BI UT WOS:000288990100015 PM 21343552 ER PT J AU Burstein, HJ AF Burstein, Harold J. TI Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID 1ST-LINE TREATMENT; PHASE-III; PACLITAXEL C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Burstein, HJ (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. NR 15 TC 32 Z9 33 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR 1 PY 2011 VL 29 IS 10 BP 1232 EP 1235 DI 10.1200/JCO.2010.33.2684 PG 5 WC Oncology SC Oncology GA 743BI UT WOS:000288990100017 PM 21383305 ER PT J AU Hurria, A Cirrincione, CT Muss, HB Kornblith, AB Barry, W Artz, AS Schmieder, L Ansari, R Tew, WP Weckstein, D Kirshner, J Togawa, K Hansen, K Katheria, V Stone, R Galinsky, I Postiglione, J Cohen, HJ AF Hurria, Arti Cirrincione, Constance T. Muss, Hyman B. Kornblith, Alice B. Barry, William Artz, Andrew S. Schmieder, Linda Ansari, Rafat Tew, William P. Weckstein, Douglas Kirshner, Jeffrey Togawa, Kayo Hansen, Kurt Katheria, Vani Stone, Richard Galinsky, Ilene Postiglione, John Cohen, Harvey Jay TI Implementing a Geriatric Assessment in Cooperative Group Clinical Cancer Trials: CALGB 360401 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID MEMORY-CONCENTRATION TEST; POSITIVE BREAST-CANCER; BODY-MASS INDEX; ELDERLY-PATIENTS; ADJUVANT CHEMOTHERAPY; FUNCTIONAL STATUS; COGNITIVE IMPAIRMENT; SOCIAL SUPPORT; OLDER PERSONS; COLON-CANCER AB Purpose Factors captured in a geriatric assessment can predict morbidity and mortality in older adults, but are not routinely measured in cancer clinical trials. This study evaluated the implementation of a geriatric assessment tool in the cooperative group setting. Patients and Methods Patients age >= 65 with cancer, who enrolled on cooperative group cancer trials, were eligible to enroll on Cancer and Leukemia Group B (CALGB) 360401. They completed a geriatric assessment tool before initiation of protocol therapy, consisting of valid and reliable geriatric assessment measures which are primarily self-administered and require minimal resources and time by healthcare providers. The assessment measures functional status, comorbidity, cognitive function, psychological state, social support, and nutritional status. The protocol specified criteria for incorporation of the tool in future cooperative group trials was based on the time to completion and percent of patients who could complete their portion without assistance. Patient satisfaction with the tool was captured. Results Of the 93 patients who enrolled in this study, five (5%) met criteria for cognitive impairment and three did not complete the cognitive screen, leaving 85 assessable patients (median age, 72 years). The median time to complete the geriatric assessment tool was 22 minutes, 87% of patients (n = 74) completed their portion without assistance, 92% (n = 78) were satisfied with the questionnaire length, 95% (n = 81) reported no difficult questions, and 96% (n = 82) reported no upsetting questions. One hundred percent of health care professionals completed their portion. Conclusion This brief, primarily self-administered geriatric assessment tool met the protocol specified criteria for inclusion in future cooperative group clinical trials. C1 [Hurria, Arti] City Hope Natl Med Ctr, Duarte, CA 91010 USA. Duke Univ, Med Ctr, Canc & Leukemia Grp Stat Ctr B, Durham, NC USA. Univ Vermont, Burlington, VT USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Chicago, Chicago, IL 60637 USA. Roswell Pk Canc Inst, Buffalo, NY 14263 USA. Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. Cent New York Community Clin Oncol Program, Hematology Oncol Associates, Syracuse, NY USA. No Indiana Canc Res Consortium Community Clin Onc, South Bend, IN USA. New Hampshire Oncol Hematol PA, Concord, NH USA. RP Hurria, A (reprint author), City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM ahurria@coh.org FU National Cancer Institute [CA31946, CA33601, CA77406, CA32291, CA41287, CA59518, CA86726, CA77651, CA45389, CA47577, K23 AG026749-01]; American Society of Clinical Oncology-Association of Specialty Professors-Junior Development Award in Geriatric Oncology FX Supported in part by Grant No. CA31946 from the National Cancer Institute to the Cancer and Leukemia Group B and by Grant No. CA33601 to the CALGB Statistical Center; by Grants No. CA33601, CA77406, CA32291, CA41287, CA59518, CA86726, CA77651, CA45389, CA47577 from the National Cancer Institute; and by K23 AG026749-01 (Paul Beeson Career Development Award in Aging Research), and American Society of Clinical Oncology-Association of Specialty Professors-Junior Development Award in Geriatric Oncology (A. H.). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. NR 49 TC 103 Z9 104 U1 2 U2 3 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR 1 PY 2011 VL 29 IS 10 BP 1290 EP 1296 DI 10.1200/JCO.2010.30.6985 PG 7 WC Oncology SC Oncology GA 743BI UT WOS:000288990100025 PM 21357782 ER PT J AU Giardino, AA O'Regan, K Jagannathan, JP Elco, C Ramaiya, N Lacasce, A AF Giardino, Angela A. O'Regan, Kevin Jagannathan, Jyothipriya P. Elco, Chrisopher Ramaiya, Nikhil Lacasce, Ann TI Richter's Transformation of Chronic Lymphocytic Leukemia SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article C1 [Giardino, Angela A.; O'Regan, Kevin; Jagannathan, Jyothipriya P.; Elco, Chrisopher; Ramaiya, Nikhil; Lacasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Giardino, AA (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA. NR 3 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR 1 PY 2011 VL 29 IS 10 BP E274 EP E276 DI 10.1200/JCO.2010.32.6579 PG 3 WC Oncology SC Oncology GA 743BI UT WOS:000288990100008 PM 21220587 ER PT J AU Cordasco, KM Ponce, NA Gatchell, MS Traudt, B Escarce, JJ AF Cordasco, Kristina M. Ponce, Ninez A. Gatchell, Melissa S. Traudt, Brandon Escarce, Jose J. TI English Language Proficiency and Geographical Proximity to a Safety Net Clinic as a Predictor of Health Care Access SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article; Proceedings Paper CT Academy Health Annual Research Meeting CY JUN 08-10, 2008 CL Washington, DC SP Acad Hlth DE Linguistic disparities; Access to care; Uninsured; Health care safety net; Geographic analysis; Secondary analysis ID INSURANCE-COVERAGE; UNINSURED ADULTS; UNITED-STATES; MEDICAL-CARE; DISPARITIES; CHILDREN; CONTINUITY; SERVICES; LATINOS; NEEDS AB Studies suggest that proximity to a safety net clinic (SNC) promotes access to care among the uninsured. Distance-based barriers to care may be greater for people with limited English proficiency (LEP), compared to those who are English proficient (EP), but this has not been explored. We assessed the relationship between distance to the nearest SNC and access in non-rural uninsured adults in California, and examined whether this relationship differs by language proficiency. Using the 2005 California Health Interview Survey and a list we compiled of California's SNCs, we calculated distance between uninsured interviewee residence and the exact address of the nearest SNC. Using multivariate regression to adjust for other relevant characteristics, we examined associations between this distance and interviewee's probability of having a usual source of health care (USOC) and having visited a physician in the prior 12 months. To examine differences by language proficiency, we included interactions between distance and language proficiency. Uninsured LEP adults living within 2 miles of a SNC were 9.3% less likely than their EP counterparts to have a USOC (P = 0.046). Further, distance to the nearest SNC was inversely associated with the probability of having a USOC among LEP, but not among EP; consequently, the difference between LEP and EP in the probability of having a USOC widened with increasing distance to the nearest SNC. There was no difference between LEP and EP adults living within 2 miles of a SNC in likelihood of having a physician visit; however, as with USOC, distance to the nearest SNC was inversely associated with the probability of having a physician visit among LEP but not EP. The effect sizes diminished, but remained significant, when we included county fixed effects in the models. Having LEP is a barrier to health care access, which compounds when combined with increased distance to the nearest SNC, among uninsured adults. Future studies should explore potential mechanisms so that appropriate interventions can be implemented. C1 [Cordasco, Kristina M.] Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, Los Angeles, CA 90073 USA. [Cordasco, Kristina M.; Escarce, Jose J.] Univ Calif Los Angeles, Dept Med, Sch Med, Los Angeles, CA 90073 USA. [Ponce, Ninez A.; Gatchell, Melissa S.; Traudt, Brandon] Univ Calif Los Angeles, Sch Publ Hlth, Ctr Hlth Policy Res, Los Angeles, CA 90095 USA. [Cordasco, Kristina M.; Escarce, Jose J.] RAND Corp, Santa Monica, CA USA. [Traudt, Brandon] So Calif Permanente Med Grp, Dept Clin Anal, Pasadena, CA 91188 USA. [Escarce, Jose J.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. RP Cordasco, KM (reprint author), Univ Calif Los Angeles, Greater Los Angeles VA Healthcare Syst, 11301 Wilshire Blvd 111G, Los Angeles, CA 90073 USA. EM kcordasco@mednet.ucla.edu; nponce@ucla.edu; gatchell@ucla.edu; Brandon.C.Traudt@kp.org; jescarce@mednet.ucla.edu OI Ponce, Ninez/0000-0001-5151-6718 FU NCI NIH HHS [K07 CA100097-01A2, K07 CA100097] NR 35 TC 18 Z9 18 U1 2 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD APR PY 2011 VL 13 IS 2 BP 260 EP 267 DI 10.1007/s10903-010-9425-6 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 733IQ UT WOS:000288256800010 PM 21170588 ER PT J AU Giugliano, RP Pollack, CV Brogan, GX Cohen, M Diercks, DB Grines, CL Henry, TD Kleiman, NS AF Giugliano, Robert P. Pollack, Charles V., Jr. Brogan, Gerard X., Jr. Cohen, Marc Diercks, Deborah B. Grines, Cindy L. Henry, Timothy D. Kleiman, Neal S. TI Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discussion SO JOURNAL OF INTERVENTIONAL CARDIOLOGY LA English DT Review ID ELEVATION MYOCARDIAL-INFARCTION; PLATELET GLYCOPROTEIN IIB/IIIA; AMERICAN-HEART-ASSOCIATION; ANTITHROMBOTIC THERAPY; RANDOMIZED-TRIAL; STENT THROMBOSIS; GLOBAL REGISTRY; UNSTABLE ANGINA; POOLED ANALYSIS; CLOPIDOGREL AB Over the past 2 years, multiple clinical trials have reported results that will influence the treatment of patients with non-ST-segment elevation acute coronary syndromes (ACS) for many years to come. However, large-scale clinical trials take years to complete, during which time the underlying landscape may shift. Thus, while clinical trials provide baseline information to help physicians make evidence-based decisions regarding patient care, trials must be interpreted in the context of current treatment guidelines and practices. In addition, regulatory and advisory board decisions, case reports, clinician experience, and patient factors have a clear but difficult-to-measure impact on practice patterns. In recognition of the wide range of information affecting physicians' decision-making processes in patients with ACS, a roundtable was convened on June 5, 2009, in New York City to discuss the implications of recent data for clinical practice. Eight clinicians from the disciplines of cardiology and emergency medicine shared information and opinions on recent advances in antiplatelet treatment, clinical trial results, guidelines, and other issues related to patient care. This article is derived from transcripts of their presentations and the surrounding discussions at this meeting, with the intent of reporting both quantitative information on recent advances in the management of ACS and qualitative information and opinions from participants. Each author held primary responsibility for the writing and editing of his or her section, and participated in the editing of the entire manuscript. (J Interven Cardiol 2011;24:119-136). C1 [Giugliano, Robert P.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA. [Giugliano, Robert P.] Harvard Univ, Sch Med, Boston, MA USA. [Pollack, Charles V., Jr.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Pollack, Charles V., Jr.] Penn Hosp, Philadelphia, PA 19107 USA. [Brogan, Gerard X., Jr.] Forest Hills Hosp, Forest Hills, NY USA. [Brogan, Gerard X., Jr.] NYU, Sch Med, New York, NY 10003 USA. [Cohen, Marc] Newark Beth Israel Med Ctr, Div Cardiol, Newark, NJ USA. [Cohen, Marc] Mt Sinai Sch Med, New York, NY USA. [Diercks, Deborah B.] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. [Grines, Cindy L.] William Beaumont Hosp, Royal Oak, MI 48072 USA. [Henry, Timothy D.] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA. [Kleiman, Neal S.] Methodist DeBakey Heart & Vasc Ctr, Cardiac Catheterizat Lab, Houston, TX USA. [Kleiman, Neal S.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. RP Giugliano, RP (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 350 Longwood Ave,1st F1 Off, Boston, MA 02115 USA. EM rgiugliano@partners.org FU Schering Corp.; Merck Co. FX Editorial assistance was provided by Rina Kleege, MS, and Rob Coover, MPH, of AdelphiEden Health Communications. This assistance and the roundtable on which this manuscript is based were funded by Schering Corp., now Merck & Co. NR 48 TC 1 Z9 1 U1 0 U2 2 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0896-4327 J9 J INTERV CARDIOL JI J. Interv. Cardiol. PD APR PY 2011 VL 24 IS 2 BP 119 EP 136 DI 10.1111/j.1540-8183.2010.00607.x PG 18 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 745JV UT WOS:000289162600003 PM 21114529 ER PT J AU Plotkin, SR O'Donnell, CC Curry, WT Bove, CM MacCollin, M Nunes, FP AF Plotkin, Scott R. O'Donnell, Caroline C. Curry, William T., Jr. Bove, Catherine M. MacCollin, Mia Nunes, Fabio P. TI Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients Clinical article SO JOURNAL OF NEUROSURGERY-SPINE LA English DT Article DE ependymoma; natural history; neurofibromatosis Type 2; spinal cord ID TANYCYTIC EPENDYMOMA; MRI FEATURES; TUMORS; INTRAMEDULLARY; GENOTYPE; PROGNOSIS; GENE AB Object. The aim of this paper was to define the clinical characteristics of spinal ependymomas associated with neurofibromatosis Type 2 (NF2). Methods. The authors retrospectively reviewed the clinical records of patients with NF2 who had imaging findings consistent with ependymomas and were seen at Massachusetts General Hospital between 1994 and 2007. Clinical characteristics of these patients were obtained from hospital records, imaging studies, surgical reports, and pathology reports. Mutational analysis of the NF2 gene was performed in 37 of 44 unrelated patients. Results. Fifty-five patients met inclusion criteria for the study. The median age at diagnosis of NF2 was 21 years; the median time after diagnosis until identification of ependymomas was 5 years. Multiple ependymomas were present in 58% of patients. The most common site of involvement was the cervical cord or cervicomedullary junction (86% of imaging studies), followed by the thoracic and lumbar cords (62% and 8%, respectively). The majority of patients had no symptoms related to their tumors (42 patients [76%]). After a median follow-up of 50 months, surgery was performed in 11 patients (20%) for symptomatic progression (indications for surgery). Mutational analysis of the NF2 gene detected alterations in 28 (76%) of 37 unrelated patients, with nonsense and frameshift mutations accounting for 64% of detected mutations. The high rate of truncating mutations may help explain the high tumor burden in these patients. Conclusions. Neurofibromatosis Type 2 related ependymomas exhibit an indolent growth pattern with tumor progression limited to a minority of patients. The authors believe that surveillance is reasonable for asymptomatic ependymomas, including those with cystic areas that expand the cord. For symptomatic tumors, resection may be warranted depending on age, overall clinical status, and ease of resectability. (DOI: 10.3171/2010.11.SPINE10350) C1 [Plotkin, Scott R.; O'Donnell, Caroline C.; Bove, Catherine M.; MacCollin, Mia; Nunes, Fabio P.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Plotkin, Scott R.; O'Donnell, Caroline C.; Bove, Catherine M.; MacCollin, Mia; Nunes, Fabio P.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Curry, William T., Jr.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Plotkin, Scott R.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. RP Plotkin, SR (reprint author), Massachusetts Gen Hosp, Dept Neurol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA. EM splotkin@partners.org FU Massachusetts General Hospital; Department of Defense [NF050202]; NIH [5-T32-GM007748-32] FX This work was supported in part by the Brian D. Silber Memorial Fund for spine tumor research at Massachusetts General Hospital (S.R.P.) and Department of Defense Grant No. NF050202 (to S.R.P.) and NIH Grant No. 5-T32-GM007748-32 (to F.P.N.). NR 17 TC 25 Z9 26 U1 0 U2 1 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 1547-5654 J9 J NEUROSURG-SPINE JI J. Neurosurg.-Spine PD APR PY 2011 VL 14 IS 4 BP 543 EP 547 DI 10.3171/2010.11.SPINE10350 PG 5 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 739NZ UT WOS:000288726200020 PM 21294614 ER PT J AU Gurm, GS Tawakol, A AF Gurm, Gagandeep S. Tawakol, Ahmed TI Beyond stenosis: Further progress in multi-modal evaluation of carotid disease SO JOURNAL OF NUCLEAR CARDIOLOGY LA English DT Editorial Material ID POSITRON-EMISSION-TOMOGRAPHY; ATHEROSCLEROTIC PLAQUE INFLAMMATION; ARTERY PLAQUES; RISK-FACTORS; FDG-PET; FLUORODEOXYGLUCOSE; STROKE; EVENTS; ECHOLUCENCY C1 [Tawakol, Ahmed] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Tawakol, A (reprint author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. EM atawakol@partners.org NR 30 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1071-3581 J9 J NUCL CARDIOL JI J. Nucl. Cardiol. PD APR PY 2011 VL 18 IS 2 BP 204 EP 206 DI 10.1007/s12350-011-9341-8 PG 3 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 744RF UT WOS:000289111400003 PM 21290206 ER PT J AU Gavrieli, A Yannakoulia, M Fragopoulou, E Margaritopoulos, D Chamberland, JP Kaisari, P Kavouras, SA Mantzoros, CS AF Gavrieli, Anna Yannakoulia, Mary Fragopoulou, Elizabeth Margaritopoulos, Dimitris Chamberland, John P. Kaisari, Panagiota Kavouras, Stavros A. Mantzoros, Christos S. TI Caffeinated Coffee Does Not Acutely Affect Energy Intake, Appetite, or Inflammation but Prevents Serum Cortisol Concentrations from Falling in Healthy Men SO JOURNAL OF NUTRITION LA English DT Article ID GLUCOSE-TOLERANCE TEST; BLOOD-GLUCOSE; WEIGHT-LOSS; FOOD-INTAKE; CONSUMPTION; INGESTION; WOMEN; HUMANS; SECRETION; MARKERS AB Our aim in this crossover study was to investigate the acute effects of caffeinated and decaffeinated coffee consumption on appetite feelings, energy intake, and appetite-, inflammation-, stress-, and glucose metabolism-related markers. Sixteen healthy men (age range, 21-39 y; BMI range, 19.7-28.6 kg/m(2)) received in a random order on 3 separate occasions a standard breakfast snack with 200 mL of either caffeinated coffee (3 mg caffeine/kg body weight), decaffeinated coffee, or water (control). Before intervention (-15 min) and at standard time points following breakfast consumption (0, 15, 30, 60, 90, 120, 150, and 180 min), participants recorded their appetite feelings and we collected blood samples for measurements of circulating glucose, insulin, cortisol, and appetite- and inflammation-related markers. At 180 min, participants consumed a meal ad libitum. The appetite-related ratings, the appetite plasma hormonal responses as well as the plasma glucose, serum insulin, and plasma and serum inflammatory marker responses did not show an overall intervention effect or a time x intervention interaction. Ad libitum energy intake did not differ among the 3 interventions. However, a significant intervention effect (P = 0.04) and a time x intervention interaction (P-interaction = 0.02) were found for serum cortisol; cortisol concentrations were significantly higher following the caffeinated coffee intervention, compared to control, at 60 mm and thereafter. In conclusion, the usually consumed amount of caffeinated coffee does not have short-term effects on appetite, energy intake, glucose metabolism, and inflammatory markers, but it increases circulating cortisol concentrations in healthy men. J. Nutr. 141: 703-707, 2011. C1 [Gavrieli, Anna; Yannakoulia, Mary; Fragopoulou, Elizabeth; Margaritopoulos, Dimitris; Kaisari, Panagiota; Kavouras, Stavros A.] Harokopio Univ, Dept Nutr & Dietet, Athens 17671, Greece. [Chamberland, John P.; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol, Boston, MA 02215 USA. [Mantzoros, Christos S.] VA Boston Healthcare Syst, Boston, MA 02130 USA. RP Yannakoulia, M (reprint author), Harokopio Univ, Dept Nutr & Dietet, El Venizelou 70, Athens 17671, Greece. EM myiannak@hua.gr OI Chamberland, John/0000-0002-7862-1371; Kavouras, Stavros/0000-0001-7485-8112 FU Department of Nutrition and Dietetics, Harokopio University; Beth Israel Deaconess Medical Center FX Supported by the Graduate Program of the Department of Nutrition and Dietetics, Harokopio University and a discretionary grant from Beth Israel Deaconess Medical Center. NR 29 TC 28 Z9 28 U1 0 U2 9 PU AMER SOC NUTRITIONAL SCIENCE PI BETHESDA PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD APR PY 2011 VL 141 IS 4 BP 703 EP 707 DI 10.3945/jn.110.137323 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 741PU UT WOS:000288876800025 PM 21346100 ER PT J AU Brudvig, TJ Fletcher, M AF Brudvig, Tracy J. Fletcher, Mary TI Differential Diagnosis in a Patient With Dizziness SO JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY LA English DT Editorial Material C1 [Brudvig, Tracy J.] Massachusetts Gen Hosp, Dept Phys Therapy, Inst Hlth Profess, Boston, MA 02114 USA. [Fletcher, Mary] Mahoning Phys Therapy, Clymer, PA USA. RP Brudvig, TJ (reprint author), Massachusetts Gen Hosp, Dept Phys Therapy, Inst Hlth Profess, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU J O S P T, PI ALEXANDRIA PA 1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA SN 0190-6011 J9 J ORTHOP SPORT PHYS JI J. Orthop. Sports Phys. Ther. PD APR PY 2011 VL 41 IS 4 BP 281 EP 281 DI 10.2519/jospt.2011.0407 PG 1 WC Orthopedics; Rehabilitation; Sport Sciences SC Orthopedics; Rehabilitation; Sport Sciences GA 743RR UT WOS:000289036900010 PM 21460459 ER PT J AU Mendez, M Shapira, JS AF Mendez, Mario Shapira, Jill S. TI Pedophilic Behavior from Brain Disease SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Pedophilia; Hypersexuality; Brain Disorders; Child Molestation ID VISUAL SEXUAL STIMULI; TEMPORAL-LOBE EPILEPSY; KLUVER-BUCY SYNDROME; FRONTOTEMPORAL DEMENTIA; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; PREFRONTAL CORTEX; ACTIVATION; HYPERSEXUALITY; AMYGDALA AB Introduction. Child molestation or other pedophilic behavior may result as a consequence of a brain disorder. Aim. To characterize the mechanisms of pedophilic behavior associated with neurological diseases. Methods. We report eight patients with pedophilic behavior as a manifestation of their brain disorder and review the literature. Main Outcome Measures. The sexual, neuropsychiatric, and neurological aspects of a series of patients. Results. All eight developed sexual behavior toward prepubescent children in mid- to late-life coincident with the development of a neurological disorder. Five had limited insight, anxiety, or concern for their behavior and tended to have frontal lobe executive deficits. Most of this group had frontally predominant disorders. Two others retained insight and concern in the context of marked hypersexuality. This second group had treated Parkinson's disease and resembled reports of pedophilic behavior from subcortical lesions. The further presence of right temporal lobe-amygdala involvement may have predisposed to specific sexual preoccupation in some patients. Conclusions. Brain disorders may release a predisposition to sexual attraction for children through disinhibition with frontal disease, sexual preoccupation with right temporal disease, or hypersexuality with subcortical disease in non-motor basal ganglia, hypothalamus, or septal nuclei. Differentiating these mechanisms of pedophilic behavior from brain disease could facilitate targeted interventions. Mendez M and Shapira JS. Pedophilic behavior from brain disease. J Sex Med 2011;8:1092-1100. C1 [Mendez, Mario] UCLA Neurol & Psychiat, Neurol Clin, Los Angeles, CA 90095 USA. [Mendez, Mario] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Shapira, Jill S.] UCLA Neurol, Los Angeles, CA USA. RP Mendez, M (reprint author), UCLA Neurol & Psychiat, Neurol Clin, 300 UCLA Med Plaza, Los Angeles, CA 90095 USA. EM mmendez@ucla.edu NR 72 TC 19 Z9 19 U1 2 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 J9 J SEX MED JI J. Sex. Med. PD APR PY 2011 VL 8 IS 4 BP 1092 EP 1100 DI 10.1111/j.1743-6109.2010.02172.x PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 744SS UT WOS:000289115400016 PM 21235721 ER PT J AU Ayer, L Danielson, CK Amstadter, AB Ruggiero, K Saunders, B Kilpatrick, D AF Ayer, Lynsay Danielson, Carla Kmett Amstadter, Ananda B. Ruggiero, Ken Saunders, Ben Kilpatrick, Dean TI Latent Classes of Adolescent Posttraumatic Stress Disorder Predict Functioning and Disorder After 1 Year SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE posttraumatic stress disorder; functional impairment; latent class analysis ID NATIONAL COMORBIDITY SURVEY; CONFIRMATORY FACTOR-ANALYSIS; SURVEY REPLICATION; MENTAL-HEALTH; PTSD; PREVALENCE; SYMPTOMS; SAMPLES; INSTRUMENTS; IMPAIRMENT AB Objective: To identify latent classes of posttraumatic stress disorder (PTSD) symptoms in a national sample of adolescents, and to test their associations with PTSD and functional impairment 1 year later. Method: A total of 1,119 trauma-exposed youth aged 12 through 17 years (mean = 14.99 years, 51% female and 49% male) participating in the National Survey of Adolescents Replication were included in this study. Telephone interviews were conducted to assess PTSD symptoms and functional impairment at Waves 1 and 2. Results: Latent Class Analysis revealed three classes of adolescent PTSD at each time point: pervasive disturbance, intermediate disturbance, and no disturbance. Three numbing and two hyperarousal symptoms best distinguished the pervasive and intermediate disturbance classes at Wave 1. Three re-experiencing, one avoidance, and one hyperarousal symptom best distinguished these classes at Wave 2. The Wave 1 intermediate disturbance class was less likely to have a PTSD diagnosis, belong to the Wave 2 pervasive disturbance class, and report functional impairment 1 year later compared with the Wave 1 pervasive disturbance class. The Wave 1 no disturbance class was least likely to have PTSD, belong to the pervasive disturbance class, and report functional impairment at Wave 2. Conclusions: This study suggests that PTSD severity distinguishing symptoms change substantially in adolescence and are not characterized by the numbing cluster, contrary to studies in adult samples. These results may help to explain inconsistent factor analytic findings on the structure and diagnosis of PTSD, and emphasize that developmental context is critical to consider in both research and clinical work in PTSD assessment and diagnosis. J. Am. Acad. Child Adolesc. Psychiatry, 2011;50(4):364-375. C1 [Ayer, Lynsay] Univ Vermont, Dept Psychiat, Vermont Ctr Children Youth & Families, Burlington, VT 05401 USA. [Danielson, Carla Kmett; Ruggiero, Ken; Saunders, Ben; Kilpatrick, Dean] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA. [Ruggiero, Ken] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA. RP Ayer, L (reprint author), Univ Vermont, Dept Psychiat, Vermont Ctr Children Youth & Families, Room 3213,1 S Prospect St, Burlington, VT 05401 USA. EM Lynsay.Ayer@uvm.edu OI Ayer, Lynsay/0000-0003-1111-8197 FU National Institute of Child Health and Human Development [1R01 HD046830-01]; [K23DA018686]; [R21MH086313]; [R01 MH81056]; [5RC2MH089995-02] FX This research was supported by National Institute of Child Health and Human Development Grant 1R01 HD046830-01 (PI: D.G.K.). The preparation of this article was partially supported by Grant K23DA018686 (C.K.D.), Grant R21MH086313 (C.K.D.), grant R01 MH81056 (KR.), and Grant 5RC2MH089995-02 (PI: James J. Hudziak). NR 45 TC 21 Z9 22 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD APR PY 2011 VL 50 IS 4 BP 364 EP 375 DI 10.1016/j.jaac.2011.01.004 PG 12 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 742EV UT WOS:000288925000008 PM 21421176 ER PT J AU Robinson, EB Munir, K Munafo, MR Hughes, M McCormick, MC Koenen, KC AF Robinson, Elise B. Munir, Kerim Munafo, Marcus R. Hughes, Michael McCormick, Marie C. Koenen, Karestan C. TI Stability of Autistic Traits in the General Population: Further Evidence for a Continuum of Impairment SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE autism spectrum disorders; autistic traits; longitudinal analysis; Avon Longitudinal Study of Parents and Children ID PERVASIVE DEVELOPMENTAL DISORDERS; SPECTRUM DISORDERS; EARLY-CHILDHOOD; CHILDREN; ADOLESCENCE; VALIDITY; ADULTS; TWIN; AGE AB Objective: This study investigated the developmental course of autistic traits in a nationally representative sample of subjects 7 to 13 years of age. Method: The parents of 6,539 children in the Avon Longitudinal Study of Parents and Children completed the Social and Communication Disorders Checklist at ages 7, 10, and 13. The phenotypic progression of autistic traits was assessed in the full sample and in high-scoring individuals (e.g., top 10%, 5%). Gender, IQ, and overall behavior difficulties were examined as potentially relevant influences on autistic trait trajectories. Results: Autistic traits were highly stable in the general population overall and in the high-scoring groups. In the full sample, there was no change in mean Social and Communication Disorders Checklist scores for female subjects ages 7 to 13 (p = .43). Scores for male subjects decreased slightly, but significantly, on the order of 0.1 standard deviations (p < .001). There was no mean change in parent-rated autistic traits within any of the high-scoring groups. IQ was not related to phenotypic progression; high parent-rated behavior problems predicted slight improvement in Social and Communication Disorders Checklist scores over the course of the study period in high-scoring individuals (p < .01). Conclusions: These findings suggest that autistic traits are highly stable in the general population, even in individuals with the highest concentrations of autism-like behaviors. Phenotypic stability is consistent with expectations for individuals with autism spectrum disorders, providing further support for a phenomenologic continuum across the clinical threshold. Moreover, the gap between female and male risk for autistic symptomology is consistent over time. J. Am. Acad. Child Adolesc. Psychiatry, 2011;50(4):376-384. C1 [Robinson, Elise B.; Hughes, Michael; McCormick, Marie C.; Koenen, Karestan C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Robinson, Elise B.; Munir, Kerim] Harvard Univ, Sch Med, Childrens Hosp Boston, Mental Hlth & Dev Disabil Program,Div Dev Med, Boston, MA 02115 USA. [Robinson, Elise B.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02114 USA. [Koenen, Karestan C.] Harvard Univ, Harvard Ctr Developing Child, Cambridge, MA 02138 USA. [Munafo, Marcus R.] Univ Bristol, Sch Expt Psychol, Bristol, Avon, England. RP Robinson, EB (reprint author), 185 Cambridge St,6th Floor, Boston, MA 02114 USA. EM erobinso@hsph.harvard.edu RI Munir, Kerim/D-6910-2015; Koenen, Karestan/K-5402-2014; OI Munir, Kerim/0000-0002-2404-1806; Robinson, Elise/0000-0003-2314-2792; McCormmick, Marie/0000-0002-3938-1707; Koenen, Karestan/0000-0003-3293-4281; Munafo, Marcus/0000-0002-4049-993X FU UK Medical Research Council [74882]; Wellcome Trust [076467]; University of Bristol; National Institute of Mental Health/National Institute of Health [MH71286]; Harvard School of Public Health [T32MH017119] FX The UK Medical Research Council (74882), the Wellcome Trust (076467), and the University of Bristol provide core support for Avon Longitudinal Study of Parents and Children (ALSPAC). The research was specifically funded by a National Institute of Mental Health/National Institute of Health Research Fellowship in Mental Health and Developmental Disabilities at The Children's Hospital Boston, Harvard Medical School (MH71286) and the Training Program in Psychiatric Genetics and Translational Research at the Harvard School of Public Health (T32MH017119). NR 24 TC 37 Z9 37 U1 2 U2 20 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0890-8567 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD APR PY 2011 VL 50 IS 4 BP 376 EP 384 DI 10.1016/j.jaac.2011.01.005 PG 9 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA 742EV UT WOS:000288925000009 PM 21421177 ER PT J AU Burstein, HJ AF Burstein, Harold J. TI Mind the Gap SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Editorial Material C1 [Burstein, Harold J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Burstein, Harold J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Burstein, Harold J.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Burstein, HJ (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD APR PY 2011 VL 9 IS 4 BP 343 EP 343 PG 1 WC Oncology SC Oncology GA 744VA UT WOS:000289121700001 PM 21464142 ER PT J AU Brem, SS Bierman, PJ Brem, H Butowski, N Chamberlain, MC Chiocca, EA DeAngelis, LM Fenstermaker, RA Friedman, A Gilbert, MR Hesser, D Junck, L Linette, GP Loeffler, JS Maor, MH Michael, M Moots, PL Morrison, T Mrugala, M Nabors, LB Newton, HB Portnow, J Raizer, JJ Recht, L Shrieve, DC Sills, AK Vrionis, FD Wen, PY AF Brem, Steven S. Bierman, Philip J. Brem, Henry Butowski, Nicholas Chamberlain, Marc C. Chiocca, Ennio A. DeAngelis, Lisa M. Fenstermaker, Robert A. Friedman, Allan Gilbert, Mark R. Hesser, Deneen Junck, Larry Linette, Gerald P. Loeffler, Jay S. Maor, Moshe H. Michael, Madison Moots, Paul L. Morrison, Tara Mrugala, Maciej Nabors, Louis Burt Newton, Herbert B. Portnow, Jana Raizer, Jeffrey J. Recht, Lawrence Shrieve, Dennis C. Sills, Allen K., Jr. Vrionis, Frank D. Wen, Patrick Y. TI Central Nervous System Cancers SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK LA English DT Review DE NCCN Clinical Practice Guidelines; NCCN Guidelines; angiogenesis; astrocytoma; bevacizumab; brain metastases; brain tumor; chemotherapy; glioblastoma; irinotecan; temozolomide; spinal tumors; medulloblastoma; PTEN (JNCCN 2011;9:352-400) ID SPINAL-CORD COMPRESSION; PHASE-II TRIAL; RECURRENT MALIGNANT GLIOMA; AVERAGE-RISK MEDULLOBLASTOMA; BRAIN RADIATION-THERAPY; REFRACTORY ANAPLASTIC ASTROCYTOMA; RADIOTHERAPY PLUS CONCOMITANT; HIGH-DOSE DEXAMETHASONE; GAMMA-KNIFE SURGERY; CELL LUNG-CARCINOMA C1 [Brem, Steven S.; Vrionis, Frank D.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Bierman, Philip J.] Nebraska Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA. [Brem, Henry] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Sidney, BC, Canada. [Butowski, Nicholas] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Chamberlain, Marc C.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Chiocca, Ennio A.; Newton, Herbert B.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA. [DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Fenstermaker, Robert A.] Roswell Pk Canc Inst, Buffalo, NY USA. [Friedman, Allan] Duke Canc Inst, Durham, NC USA. [Gilbert, Mark R.; Maor, Moshe H.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Junck, Larry] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [Linette, Gerald P.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA. [Linette, Gerald P.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Loeffler, Jay S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Michael, Madison] Univ Tennessee, Inst Canc, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA. [Moots, Paul L.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Morrison, Tara] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Mrugala, Maciej] Univ Washington, Seattle, WA 98195 USA. [Nabors, Louis Burt] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Portnow, Jana] City Hope Comprehens Canc Ctr, Duarte, CA USA. [Raizer, Jeffrey J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA. [Recht, Lawrence] Stanford Comprehens Canc Ctr, Stanford, CA USA. [Shrieve, Dennis C.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA. RP Brem, SS (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. RI Gilbert, Mark/J-7494-2016 OI Gilbert, Mark/0000-0003-2556-9722 NR 190 TC 43 Z9 43 U1 0 U2 8 PU HARBORSIDE PRESS PI COLD SPRING HARBOR PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA SN 1540-1405 J9 J NATL COMPR CANC NE JI J. Natl. Compr. Cancer Netw. PD APR PY 2011 VL 9 IS 4 BP 352 EP 400 PG 49 WC Oncology SC Oncology GA 744VA UT WOS:000289121700003 PM 21464144 ER PT J AU Abularrage, CJ Conrad, MF Haurani, MJ Crawford, RS Hackney, LA Lee, H LaMuraglia, GM Cambria, RP AF Abularrage, Christopher J. Conrad, Mark F. Haurani, M. Joseph Crawford, Robert S. Hackney, Lauren A. Lee, Hang LaMuraglia, Glenn M. Cambria, Richard P. TI Long-term outcomes of patients undergoing endovascular infrainguinal interventions with single-vessel peroneal artery runoff SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID LOWER-EXTREMITY; LIMB SALVAGE; BYPASS-SURGERY; PERCUTANEOUS INTERVENTIONS; OCCLUSIVE DISEASE; VEIN GRAFTS; TISSUE LOSS; ANGIOPLASTY; REVASCULARIZATION; ISCHEMIA AB Objectives: Recent reports have shown promising early results after endovascular revascularization (percutaneous transluminal angioplasty [PTA]/stent) of patients with peroneal artery-only runoff (PAOR), although the long-term durability is unclear. This study evaluated long-term primary patency and limb salvage of PTA/stent in patients with single-vessel runoff and critical limb ischemia to determine if the peroneal artery yields inferior results. Methods: From January 2002 to December 2007, 1075 infrainguinal PTA/stent procedures were performed in 920 patients. The study cohort comprised 201 limbs in 187 patients with single-vessel runoff and critical limb ischemia. End points included primary patency, assisted patency, limb salvage, and survival. Long-term outcomes were determined by Kaplan-Meier life-table and multivariate Cox regression analyses. Results: There were 104 PAOR and 97 limbs with single-vessel posterior or anterior tibial artery runoff (non-PAOR). Median follow-up was 25 months (range, 0-75 months). PAOR patients tended to be older (77.36 +/- 0.92 vs 72.65 +/- 1.18 years, P = .002) and were more likely to be taking clopidogrel at presentation (88% vs 76%; P = .04). There were no statistically significant differences in 5-year primary pulley (26% +/- 6.8% vs 30% +/- 7.6%; P = .79), assisted patency (75% +/- 8.8% vs 81% +/- 7.0%; P = .77), limb salvage (74% +/- 8.0% vs 75% +/- 7.1%; P = .47), and survival (38% +/- 7.7% vs 47% +/- 6.6%; P = .99) between the PAOR and the non-PAOR groups, respectively. On Cox regression multivariate analysis, total occlusions predicted decreased assisted patency (hazard ratio, 2.99 ; 95% confidence interval, 1.21-7.41; P = .02), whereas younger age predicted poor limb salvage (hazard ratio, 0.97; 95% confidence interval, 0.94-0.99; P = .04). PAOR was not an independent predictor of any outcome on multivariate analysis. Conclusions: Patients with PAOR have similar long-term outcomes to patients with non-PAOR. Thus, infrainguinal endovascular revascularization can be considered a first-line therapy for patients with PAOR and critical limb ischemia. (J Vasc Surg 2011;53:1007-13.) C1 [Abularrage, Christopher J.; Conrad, Mark F.; Haurani, M. Joseph; Crawford, Robert S.; Hackney, Lauren A.; LaMuraglia, Glenn M.; Cambria, Richard P.] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. [Lee, Hang] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Conrad, MF (reprint author), Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, WAC440,15 Parkman St, Boston, MA 02114 USA. EM mconrad@partners.org RI Haurani, Mounir/F-5802-2012; OI Goldman, Lauren/0000-0002-8469-2416; Haurani, Mounir/0000-0003-3984-3366 NR 33 TC 6 Z9 6 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD APR PY 2011 VL 53 IS 4 BP 1007 EP 1013 DI 10.1016/j.jvs.2010.10.057 PG 7 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 743IS UT WOS:000289012600017 PM 21215565 ER PT J AU Conrad, MF Crawford, RS Hackney, LA Paruchuri, V Abularrage, CJ Patel, VI Lamuraglia, GM Cambria, RP AF Conrad, Mark F. Crawford, Robert S. Hackney, Lauren A. Paruchuri, Vikram Abularrage, Christopher J. Patel, Virendra I. Lamuraglia, Glenn M. Cambria, Richard P. TI Endovascular management of patients with critical limb ischemia SO JOURNAL OF VASCULAR SURGERY LA English DT Article ID LOWER-EXTREMITY REVASCULARIZATION; LONG-TERM PATENCY; INFRAPOPLITEAL ANGIOPLASTY; OCCLUSIVE DISEASE; BYPASS; SALVAGE; INTERVENTION; SURGERY; CONSENSUS; ARTERY AB Background: Although percutaneous intervention (PTA) is considered first-line therapy for peripheral vascular disease in many scenarios, its role in critical limb ischemia (CLI), wherein anatomic disease is more extensive, remains unclear. In the present study, late (5-year) clinical and patency data for PTA in CLI are defined. Methods: From January 2002 to December 2007, 409 patients underwent infrainguinal PTA +/- stent for CLI (Rutherford IV-VI) of 447 limbs. Primary patency, assisted patency, limb salvage, and survival were assessed using Kaplan-Meier. Predictors of patency, limb salvage, and death were determined using multivariate models. Results: Demographics included age (70 +/- 12 years old), diabetes (65.8%), and dialysis dependence (13%). The superficial femoral artery was treated in 58% of the patients, 16% were limited to the crural vessels, 38% had multilevel treatment, and stents were placed in 26%. Eighty percent of patients received postprocedure clopidogrel. Mean follow-up was 28 months (0-83). Five-year primary and assisted patency were 31% +/- 0.04 and 75% +/- 0.04, respectively. Limb salvage at 5 years was 74% +/- 0.038. Sixty-three patients had major amputations. Survival at 5 years was 39% +/- 0.03. Multivariate analysis identified dialysis dependence (P = .0005; 2.7 [1.6-4.8]), <= 1 vessel runoff (P = .02; 1.5 [1.1-2.0]), and warfarin use (P = .001; 1.7 [1.25-2.3]) as negative predictors of primary patency, but none of these were negative predictors of assisted patency. Dialysis dependence (P = .006; 2.5 [1.3-4.8]), female gender (P = .02; 2.0 [1.1-3.7]), and <= 1 vessel run-off (P = .04; 1.8 [1.0-3.2]) predicted limb loss. Dialysis dependence (P = .0003; 2.3 [1.5-3.5]), diabetes (P = .04; 1.5 [0.5-2.1]), and poor run-off (P = .04; 1.6 [1.2-2.1]) were predictors of mortality. Conclusion: Although primary patency is low, excellent limb salvage rates can be achieved in patients with CLI through close follow-up and secondary interventions. These data, and the 12% annual death rate, validate PTA as first-line therapy in patients with CLI. (J Vasc Surg 2011;53:1020-5.) C1 [Conrad, Mark F.; Crawford, Robert S.; Hackney, Lauren A.; Paruchuri, Vikram; Abularrage, Christopher J.; Patel, Virendra I.; Lamuraglia, Glenn M.; Cambria, Richard P.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. RP Conrad, MF (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, 15 Parkman St,WAC 440, Boston, MA 02114 USA. EM mconrad@partners.org OI Goldman, Lauren/0000-0002-8469-2416 NR 26 TC 63 Z9 66 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD APR PY 2011 VL 53 IS 4 BP 1020 EP 1025 DI 10.1016/j.jvs.2010.10.088 PG 6 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 743IS UT WOS:000289012600019 PM 21211929 ER PT J AU LeWitt, PA Rezai, AR Leehey, MA Ojemann, SG Flaherty, AW Eskandar, EN Kostyk, SK Thomas, K Sarkar, A Siddiqui, MS Tatter, SB Schwalb, JM Poston, KL Henderson, JM Kurlan, RM Richard, IH Van Meter, L Sapan, CV During, MJ Kaplitt, MG Feigin, A AF LeWitt, Peter A. Rezai, Ali R. Leehey, Maureen A. Ojemann, Steven G. Flaherty, Alice W. Eskandar, Emad N. Kostyk, Sandra K. Thomas, Karen Sarkar, Atom Siddiqui, Mustafa S. Tatter, Stephen B. Schwalb, Jason M. Poston, Kathleen L. Henderson, Jaimie M. Kurlan, Roger M. Richard, Irene H. Van Meter, Lori Sapan, Christine V. During, Matthew J. Kaplitt, Michael G. Feigin, Andrew TI AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial SO LANCET NEUROLOGY LA English DT Article ID DEEP-BRAIN-STIMULATION; PHASE-I TRIAL; SUBTHALAMIC NUCLEUS; RATING-SCALE; OPEN-LABEL; GAD GENE; TOLERABILITY; RELIABILITY; DEMENTIA; DELIVERY AB Background Gene transfer of glutamic acid decarboxylase (GAD) and other methods that modulate production of GABA in the subthalamic nucleus improve basal ganglia function in parkinsonism in animal models. We aimed to assess the effect of bilateral delivery of AAV2-GAD in the subthalamic nucleus compared with sham surgery in patients with advanced Parkinson's disease. Methods Patients aged 30-75 years who had progressive levodopa-responsive Parkinson's disease and an overnight off-medication unified Parkinson's disease rating scale (UPDRS) motor score of 25 or more were enrolled into this double-blind, phase 2, randomised controlled trial, which took place at seven centres in the USA between Nov 17, 2008, and May 11, 2010. Infusion failure or catheter tip location beyond a predefined target zone led to exclusion of patients before unmasking for the efficacy analysis. The primary outcome measure was the 6-month change from baseline in double-blind assessment of off-medication UPDRS motor scores. This trial is registered with ClinicalTrials.gov, NCT00643890. Findings Of 66 patients assessed for eligibility, 23 were randomly assigned to sham surgery and 22 to AAV2-GAD infusions; of those, 21 and 16, respectively, were analysed. At the 6-month endpoint, UPDRS score for the AAV2-GAD group decreased by 8.1 points (SD 1.7, 23.1%; p < 0.0001) and by 4.7 points in the sham group (1.5, 12-7%; p=0.003). The AAV2-GAD group showed a significantly greater improvement from baseline in UPDRS scores compared with the sham group over the 6-month course of the study (RMANOVA, p=0.04). One serious adverse event occurred within 6 months of surgery; this case of bowel obstruction occurred in the AAV2-GAD group, was not attributed to treatment or the surgical procedure, and fully resolved. Other adverse events were mild or moderate, likely related to surgery and resolved; the most common were headache (seven patients in the AAV2-GAD group vs two in the sham group) and nausea (six vs two). Interpretation The efficacy and safety of bilateral infusion of AAV2-GAD in the subthalamic nucleus supports its further development for Parkinson's disease and shows the promise for gene therapy for neurological disorders. C1 [Feigin, Andrew] N Shore LIJ Hlth Syst, Feinstein Inst Med Res, Manhasset, NY 11030 USA. [LeWitt, Peter A.] Wayne State Univ, Sch Med, Parkinsons Dis & Movement Disorders Program, Henry Ford W Bloomfield Hosp, Detroit, MI 48202 USA. [Rezai, Ali R.; Kostyk, Sandra K.; Thomas, Karen; Sarkar, Atom; During, Matthew J.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Leehey, Maureen A.; Ojemann, Steven G.] Univ Colorado, Sch Med, Aurora, CO USA. [Flaherty, Alice W.; Eskandar, Emad N.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Siddiqui, Mustafa S.; Tatter, Stephen B.] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Schwalb, Jason M.] Henry Ford Hlth Syst, W Bloomfield Charter Township, Detroit, MI USA. [Poston, Kathleen L.; Henderson, Jaimie M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Kurlan, Roger M.; Richard, Irene H.] Univ Rochester, Sch Med, Rochester, NY USA. [Van Meter, Lori] PharmaNet Dev Grp, Princeton, NJ USA. [Sapan, Christine V.] Neurologix Inc, Ft Lee, NJ USA. [Kaplitt, Michael G.] Weill Cornell Med Coll, New York, NY USA. RP Feigin, A (reprint author), N Shore LIJ Hlth Syst, Feinstein Inst Med Res, 350 Community Dr, Manhasset, NY 11030 USA. EM afeigin@nshs.edu RI Siddiqui, Mustafa/L-5495-2013; OI Siddiqui, Mustafa/0000-0003-4794-5119; Henderson, Jaimie/0000-0002-3276-2267 FU Neurologix; Allergan; Boehringer-Ingelheim; Chelsea Therapeutics; The Michael J Fox Foundation for Parkinson's Research; Merz; Novartis; Santhera; UCB; Medtronic Neurological; Schwartz Biosciences; Molecular Biometrics; IMPAX Pharmaceuticals; Ohio State University; Chalmers P Wiley VA Medical Center; National Institute of Health; Huntington's Disease Society of America; Teva; Acadia; Ipsen; Impair; Chelsea Pharmaceuticals; US Department of Defense, National Institutes of Health; National Institutes of Health Neurological Disorders and Stroke; Kyowa; Boehringer Ingelheim; Eli Lilly; Ceregene; Genzyme; National Institutes of Health; The Dana Foundation; Thomas Hartman Foundation for Parkinson's Research FX PAL served as a paid speaker for Allergan, Boehringer-Ingelheim, Chelsea Therapeutics, Lundbeck, Novartis, and Ipsen, served as a paid consultant for Boehringer-Ingelheim. GlaxoSmithKline, Impax, Itec, Ipsen, NeuroDerm, Merck, Schering-Plough, and XenoPort; he receives grant funding (grants pending) from Allergan, Boehringer-Ingelheim, Chelsea Therapeutics, The Michael J Fox Foundation for Parkinson's Research, Merz, Novartis, Santhera, and UCB. ARR served as a paid consultant for Autonomic Technologies and Neurologix, received grant funding (grants pending) from Medtronic Neurological, served as a paid speaker for Medtronic Neurological, patents with money to institution from Autonomic Technologies and Intelect Medical, and holds stock options in Surgivision and Autonomic Technologies. MAL received grant funding (grants pending) from Schwartz Biosciences, Molecular Biometrics, IMPAX Pharmaceuticals; served as a paid speaker for Athena Diagnostics, Teva Neurosciences, American Federation of Research, The Movement Disorders Society; and received meeting expenses from Parkinson Study Group. SGO served as a paid consultant for Medtronic. SKK receives salary support from Ohio State University and Chalmers P Wiley VA Medical Center and receives grant funding (grants pending) from National Institute of Health and Huntington's Disease Society of America. KT receives grant funding (grants pending) from Teva, Acadia, UCB, Ipsen, Impair and Chelsea Pharmaceuticals. MSS received travel expenses for research-related meetings, and provisions of writing assistance, medicines, equipment, or administrative support to Wake Forest University School of Medicine from Neurologix. SBT reports grant funding (grants pending) to Wake Forest University School of Medicine from the US Department of Defense, National Institutes of Health and from the National Institutes of Health Neurological Disorders and Stroke. JMH has served on the speakers' bureau for Medtronic. RMK served as a paid consultant for Boehringer-Ingelheim and receives grant funding (grants pending) from Kyowa and Boehringer Ingelheim. IHR reports grant funding (grants pending) to University of Rochester School of Medicine from Eli Lilly and Novartis, and served as a paid speaker for Teva Pharmaceuticals. LVM, an employee of PharmaNet Development Group, Princeton, NJ, USA, served as the study biostatistician under contract from Neurologix. CVS is a paid employee of and holds stock options in Neurologix. MJD is co-founder of, paid consultant for, and holds stock options in Neurologix, and is a co-author on issued patent related to the AAV-GAD product. MGK is cofounder of, paid consultant for, receives grant funding (grants pending) from and holds stock options in Neurologix, patents with financial gain to Rockefeller University and Weill Cornell Medical College, royalties to Weill Cornell Medical College from Neurologix, Ceregene and Genzyme. AF served as a paid consultant for Rexahn and Alnylam Pharmaceuticals, provided expert testimony for medico-legal cases; receives grant funding (grants pending) from National Institutes of Health, The Dana Foundation, Thomas Hartman Foundation for Parkinson's Research, Huntington's Disease Society of America; and has served on the speakers' bureau for Teva Pharmaceuticals and Allergan. The other authors declare that they have no conflicts of interest. NR 37 TC 229 Z9 238 U1 11 U2 64 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 J9 LANCET NEUROL JI Lancet Neurol. PD APR PY 2011 VL 10 IS 4 BP 309 EP 319 DI 10.1016/S1474-4422(11)70039-4 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA 745SB UT WOS:000289185000014 PM 21419704 ER PT J AU Furman, RR Grossbard, ML Johnson, JL Pecora, AL Cassileth, PA Jung, SH Peterson, BA Nadler, LM Freedman, A Bayer, RL Bartlett, NL Hurd, DD Cheson, BD AF Furman, Richard R. Grossbard, Michael L. Johnson, Jeffrey L. Pecora, Andrew L. Cassileth, Peter A. Jung, Sin-Ho Peterson, Bruce A. Nadler, Lee M. Freedman, Arnold Bayer, Ruthee-Lu Bartlett, Nancy L. Hurd, David D. Cheson, Bruce D. CA Canc Leukemia Grp B Eastern Cooperative Oncology Grp TI A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254 SO LEUKEMIA & LYMPHOMA LA English DT Article DE Lymphoma; anti-B4-blocked ricin; autologous transplant; adjuvant therapy ID NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; DETUDE-DES-LYMPHOMES; HIGH-DOSE THERAPY; ELDERLY-PATIENTS; BLOCKED RICIN; I TRIAL; MULTIDRUG-RESISTANT AB Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively (p aEuroS== aEuroS0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively (p aEuroS== aEuroS0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma.